key: cord-0033730-pt9q4s8l
authors: nan
title: Physicians Poster Sessions
date: 2013-04-03
journal: Bone Marrow Transplant
DOI: 10.1038/bmt.2013.23
sha: 6d05e7dfa72bc903c5ffefe83bdef661a1e4cc6c
doc_id: 33730
cord_uid: pt9q4s8l

nan

Γ/δ T cells are innate immune cells with strong anti-tumor activity and provide anti-tumor receptors that are interesting tools in immune therapy against cancer. The introduction of γ/δ TCR genes into α/β T-cells allows the adoptive transfer of T cells that are not limited by HLA-restriction, in any patient with any cancer. Combinatorial γ/δ TCR-exchange (CTE) has been applied to design a gamm9δ2 TCR with strong and broad anti-tumor reactivity, referred to as TCR γ9-G115/δ2-cl5. Here, we prepare this attractive candidate γ/δ TCR for clinical application. First, we introduced both γ and δ chains into the retroviral vector pMP71, separated by a 2A peptide sequence. Gene-engineered human α/β T-cells expressed the γ/δ TCR and recognized tumors of diff erent hematological origin as well as solid tumors. Second, we tested expression and function of the γ/δ TCR after addition of suicide genes which will enable in vivo elimination of therapeutic T cells. Following the introduction of either CD20 or EGFR separated with another 2A sequence from the TCR transgene cassette in pMP71, TCR expression and function was greatly impaired and as such this approach is not suitable for clinical application. Third, we tested the infl uence of the γ/δ TCR transgene cassette and the particular 2A peptide sequence. Interestingly, the orientation of the γ and δ chains and the 2A peptide sequence infl uenced TCR expression as well as anti-tumor function as previously demonstrated for α/ β TCR genes. All together, our results demonstrate that currently available suicide genes severely impair expression of introduced TCRs and functional avidity of engineered T-cells, thus are not useful for clinical application. In addition, modulating 2A sequences and the sequence of receptor chains allowed a deliberate choice for the most potent clinical γ/δ TCR receptor cassette that will be used in our next TCR gene therapy trial.

Sleeping Beauty system-mediated expression of chimeric antigen receptors (CARs) in CIK cells: a novel tool towards the cure of childhood leukaemia C. Magnani (1) , G. Giordano Attianese (1) , S. Tettamanti (1) , N. Turazzi (1) , V. Marin (1) , L. Cooper (2) , A. Biondi (1) , E. Biagi (1) (

Stable gene transfer of chimeric antigen receptors (CAR) is a powerful tool to redirect antigen specifi city of eff ector T cells for adoptive immunotherapy of tumours. The development of effi cient and safe nonviral vectors would rescue the safety and manufacture concerns that limit so far their clinical application. The ex-vivo use of the latest generation Sleeping Beauty (SB) Transposon-mediated gene transfer off ers a valid alternative to viral vectors for human gene therapy. Here we used nucleofection of SB system and an optimized clinical-grade stimulation protocol to generate and propagate cytokine-induced killer (CIK) cells genetically modifi ed to express CD123-specifi c 3rd generation chimeric antigen receptor (CAR) to redirect antigen specifi city towards the acute myelogenous leukaemia (AML) CD123+ blasts. Indeed, CD123 overexpression is well known to be a poor prognosis marker in AML. With this system, the average transfection at 24hours was 68.9% (±1.0, n=6) and mean survival percentage was 34.8% (±5. 6, n=5) . Electroporation with the optimized stimulation protocol did not aff ect the phenotype of CIK cells, preserved their naïve and stem cell memory populations, and resulted in a fold increase of 15.7±3.3 at the end of the CIK culture at day 21. Transposed CIK cells displayed stable expression of Tr scFvCD123.3rdCAR (39.4%±8.6), effi cient lysis of AML target cells, and CAR-specifi c cytokine secretion. Finally, long-term expansion (fold increase 423.8±301.4, n=2 at day 40) upon stimulation with AML cells in vitro promoted effi cient selection of CAR+ CIK cells with potent cytotoxic activity towards AML target (92.9±1, n=2), suggesting long-term persistence of functional CIK cells in vivo. Effi cient transfection of CARs together with a feasible manufacturing practice (GMP) strategy to select and propagate CAR-expressing CIK cells will be instrumental in defi ning novel therapeutic approaches to target childhood acute myeloid leukaemia.

J.E. Griffi n, B. Carpenter, E. Nicholson, S. Ghorashian, A. Holler, P. Velica, J. Sivakumaran, M. Pule, H. Stauss, S. Xue, R. Chakraverty UCL (London, GB) Adoptive immunotherapy with TCR-redirected T cells has potential to treat Cytomegalovirus infection or Epstein-Barr virus-related post-transplant lymphoproliferative disorder. Immune suppressive drugs used to prevent rejection, or graft-versus-host disease, may inhibit adoptively transferred cells. We have evaluated the potential for gene transfer to T cells of mutated inosine-5'-monophosphate dehydrogenase (IMPDH2R; T333I, S351Y) which confers resistance to the immune suppressive drug mycophenolate mofetil (MMF). IMPDH2R and IMPDH2 catalytic site mutant (IMPDH2CS; C331A) were cloned into SFG retroviral vectors fused to eGFP reporter sequences. Cells were transduced with each vector, their phenotype and function evaluated in the presence or absence of mycophenolic acid (MPA), the active metabolite of MMF. IMPDH2R-transduced murine thymoma (BW5147) cells exhibited less apoptosis in response to MPA than IMPDH2CS-transduced cells (ratio % Annexin V+ MPA:no MPA IMPDH2R =1.2; IMPDH2CS =2.9, p=0.01). IMPDH2R-transduced cells overcame MPA induced cell-cycle arrest (Ratio % in S-G2/M phases MPA: no MPA-IMPDH2R = 1.0; IMPDH2CS = 0.3, p=0.03). Human peripheral blood mononuclear cells transduced with LMP2 TCR and either IMPDH2R or IMPDH2CS were stimulated with cognate peptide-loaded T2 cells. MPA exposure selected IMPDH2R but not IMPDH2CS-transduced cells. Selection persisted following subsequent stimulation without MPA. To assess in vivo selection, sub-lethally irradiated B6.PL (Thy1.1) mice were injected with a 1:1 mix of OT1 TCR transgenic CD8 T cells transduced with IMPDH2R or IMPDH2CS diff erentiated from each other and the host by congenic markers. Transferred cells were stimulated by cognate or irrelevant peptide in adjuvant and MMF or dextrose was given by daily ip injection. IMPDH2R-transduced Current therapeutic regimens for AML are still associated with high rates of relapse. Immunotherapy with T-cells genetically modifi ed to express chimeric antigen receptors (CARs) represents a valid and innovative cell therapy approach for haematological malignancies. In this study we developed a new CAR molecule specifi c for the IL-3Rα (CD123) target antigen, which is overexpressed on AML blasts, CD34+ leukaemic progenitors, and leukaemic stem cells (LSCs) compared to normal haematopoietic stem/progenitor cells (HSPCs), and whose overexpression is associated with poor prognosis. CIK cells were transduced with an SFG-retroviral vector encoding an anti-CD123.CAR. The effi cacy and safety profi les of transduced cells were characterized in vitro by short and long-term cytotoxicity assays. Their potential reactivity against HSPCs was evaluated by colony-forming unit assay after 4-hours co-incubation. Anti-CD123.CAR+CIK cells strongly killed CD123+ THP-1 cell line (60%±5.4%, Eff ector:Target -E:T-ratio of 5:1, n=3), as well as primary AML blasts (59%±5.4%, E:T ratio of 3:1, n=4) in 4-hours citotoxicity assays. In long-term cytotoxicity assay we observed a leukaemic cell recovery for THP-1 of 3.5%±1.5% (n=5) and for primary AML cells of 2.4%±1.4% (n=3) when co-cultured with anti-CD123.CAR+CIK cells, compared to an average survival of up to 80%, when co-cultured with unmanipulated (NT) CIK cells. Interestingly, secondary colonies experiments after co-culture of cord blood-derived HSPCs with anti-CD123.CAR+CIK cells demonstrated that anti-CD123. CAR better preserved the normal haematopoietic reconstitution in contrast to a previously generated anti-CD33.CAR (total number of colonies of 146.8±6. 6, 66.4±5.1, 117 .6±4.6, after co-culture with NT CIK cells, anti-CD33.CAR+CIK cells, anti-CD123.CAR+CIK cells respectively, n=4). Furthermore, a limited killing of normal CD123+monocytes and CD123-low expressing endothelial cells was measured. Taken together, our results indicate that anti-CD123.CAR strongly enhances antileukaemic CIK functions towards AML, while sparing HSPCs and normal CD123-expressing tissues, paving the way for the development of novel immunotherapy approaches for the treatment of resistant forms of AML. T. Erkers, S. Nava, J. Yosef, O. Ringdén, H. Kaipe Karolinska Institutet (Stockholm, SE) Bone marrow-derived mesenchymal stromal cells (BM-MSCs) have been used to treat GvHD, but maternal stromal cells from term fetal membrane (FMCs) have many advantages compared to BM-MSCs, including an increased allosuppression, unlimited supply, great expansion potential and high expression of integrins. We introduced the use of FMCs in patients with steroid refractory aGvHD and the overall response was 75%. In this study, we are elucidating factors of importance in the reduction of alloreactivity by FMCs. We found that FMCs need to have cell-cell contact in order to mediate suppression in mixed lymphocyte reactions (MLR) (p=0.01, n=11). This distinguishes FMCs from BM-MSCs, which can suppress the MLR without contact to the MLR. The frequency of CD4+CD25highFOXP3+ regulatory T cells (Treg) was increased (median 2.3-fold), whereas the proportion of total CD25+ T cells was decreased (median 1.4-fold) when the FMCs were added to the MLR cultures (p=0.03, n=10 and p=0.03, n=6, respectively). This was only observed when cell-cell contact was allowed between the MLR and FMCs. Blocking the activity of indoleamine-2,3-dioxygenase (IDO) (median 2.6-fold increase in proliferation compared to MLR+FMC-control, p=0.01, n=8), IFN-γ (median 2.0fold increase, p<0.01, n=11), Prostaglandin E2 (median 1.26-fold increase, p=0.01, n=12) and PD-L1 (median 1.23-fold increase, p=0.03, n=7), signifi cantly impaired the anti-proliferative ability of the FMCs in MLRs. Neutralization of molecules such as IL-10, IL-17, TGF-β and HLA-G had no eff ect on proliferation in MLRs. Inactivation of IDO also reduced the frequency of Tregs. In contrast to BM-MSC, pre-treatment of the FMCs with high concentrations of IFN-γ (100 U/ml) decreased their function to suppress alloreactivity (p<0.01, n=16), but stimulation of FMCs with MLR supernatants containing low levels of IFN-γ had no eff ect on the suppressive capacity in the MLR. To conclude, FMCs diff ers in several aspects from BM-MSCs and needs proximity to allo-reactive lymphocytes to mediate a suppressive eff ect and increase the frequency of Tregs. Thus, FMCs may not only use paracrine factors for systemic immunosuppression, but more specifi cally target T cells locally in aff ected tissues.

It has been previously shown that treatment of diff erent leukemias by allogenic hematopoetic stem cell transplantation (HSCT) followed by the administration of donor lymphocyte infusions (DLI) can induce remissions in patients with residual leukemic cells or relapse. The graft versus leukemia (GVL) activity mediated by DLI could be increased by genetic modifi cation of the DLI with T cell receptors (TCR) recognizing epitopes naturally presented on primary leukemia cells. We used an immunoproteomic approach to identify such epitopes, expanded peptide specifi c T cells with the selected candidates and isolated TCR recognizing those epitopes. Cells of patients with chronic and acute myelogenous leukemia were lysed in detergent containing buff er and human leukocyte class I (HLA I) molecules were subsequently immunoprecipitated by the W6/32 antibody. HLA I associated peptides were eluted by acid treatment followed by sequencing via mass spectrometry (MS). Peptide lists were established selecting epitopes originating from genes with expression restricted to hematopoietic cells or cancer testis like expression profi le according to database and literature research.

Results were validated by real time polymerase chain reaction. Amongst the candidate peptides were several epitopes from the myeloblastosis viral oncogene homolog (c-myb) and the myeloperoxidase (MPO) which are both known to be highly expressed in many cases of myeloid leukemia. Candidate peptides were synthesized and naïve cytotoxic T lymphocytes were stimulated with semi-allogenic dendritic cells pulsed with the respective peptide for expansion of epitope-specifi c T cells. By sorting with HLA I multimers we could so far isolate a high avidity TCR specifi c for a HLA-B*0702 restricted epitope of MPO. The TCR shows reactivity against peptide pulsed target cells and leukemia cell lines endogenously expressing MPO.

In conclusion, the analysis of peptides directly eluted from HLA molecules on the surface of myeloid leukemia cells resulted in the identifi cation of attractive target candidates for the development of novel cellular immunotherapies in leukemias. A high avidity TCR specifi c for an HLA-B*0702 restricted epitope of MPO could be isolated that shows tumor reactivity in vitro. This TCR could serve as a therapeutic tool in a HLA-B*0702 mismatch transplantation setting and is further tested in a preclinical mouse model to show tumor reactivity in vivo.

Effi cacy of platelet-rich plasma for the treatment of chronic wounds V.N. Obolenskiy (1) , D.A. Ermolova (2) , L.A. Laberko (2) (1)Municipal Hospital #13 (Moscow, RU); (2) RRMU (Moscow, RU) Objective: to assess the effi cacy of platelet-rich plasma (PRP) for the treatment of patients with chronic wounds (CW) of various etiologies. Materials and methods: Analysis of the treatment outcomesof 81 patients with CW of various etiologies was performed: trophic venous ulcers (TVU) -8, ulcers of combined etiology (CEU) -20, related to diabetic foot syndrome (DFS) -20, post-traumatic and post-surgical scar-trophic ulcer (STU) -19 and bedsores (BU) -14.

After the bacteriological investigation all patientsreceived treatment of the underlyingdisease and the topical treatment, aimed at the wound cleaning and decontamination. For the treatment of the 44 patients (experimental group: 17 males, 27 females, the mean age -56.0 ± 3.1; VTU -3, CCEU -8, DFS -12, STU -14 BU -7, the mean CW area was 90.2 ± 14.1 cm 2 ), we used PRP fl at clot therapy starting from phase II of wound healing process. Flat clots were obtained by one-step centrifugation using special BTI equipment (Spain). The volume of collected blood depends on the size of the wound and should be between 5 ml and 40 ml at a time. Platelet growth factors were activated with 10% CaCl2. The time from blood collection to ligation was 20-30 minutes on the average. PRP is placed on the top of atraumatic mesh bandage and covered with secondary dressing. Frequency of dressing changeis once in seven days, which allows patient transfers to outpatient care. For the treatment of the 37 patients (control group: 17 males, 20 females, mean age was 69.5 ± 2.2; VTU -5, CEU -12, DFS -8, STU -5, BU -7, the mean CW area was 79.6 ± 12.3 cm 2 ), traditional topical agents were used starting from phase II of wound healing process. Evaluation of the treatment outcomeswas performed within 3 months. Results: Mean number of PRP applications was 6.0 ± 0.6 per patient in the experimental group. In 3 patients following 3-4 applications autodermoplastics of wound was performeddue to a large area of the wound defect; 35 patients (85.4%) achieved complete CW epithelialization within 46.4 ± 4.3 days; and for 6 patients this treatment method was not eff ective. In the control group autodermoplastics of wound was performed in 3 patients, and only 4 patients (11.8%) achieved wound epithelialization within 3 months. Mean duration of hospital stay was 11.0 ± 2.5 days in the experimental group and 23.1 ± 1.5 daysin the control group. Conclusions: Treatment of patients with CW using PRP is safe, clinically benefi cial and cost eff ective.

Experimental justifi cation for clinical use of platelet rich plasma V.N. Obolenskiy (1) , N.V. Borovkova (2) , M.S. Makarov (2) , D. A. Ermolova (3) , L.A. Laberko (3) (1)Municipal Hospital #13 (Moscow, RU); (2) 

Objective: to asses in vitro the effi ciency of platelet rich plasma (PRP) for clinical use. Materials and methods: Blood collected from a peripheral vein of the patients with chronic wounds of various etiologies was usedas a biological material. PRP was obtained by separating blood with the use of BTI equipment (Spain). Whole blood platelets were stained with vital fl uorochrome dye for further morpho-functional analysison a fl uorescence microscope. Concentration of plateletderived growth factor (PDGF) in blood serum was determined by enzyme-linked immunosorbent assay (ELISA) using reagents «Qantikine, Human PDGF-BB Immunoassay» (R & D Systems) and system «Multiskan ascent» (Thermo). Proliferative activity of human fi broblast culture (M-22) was assessed in the wells containing diff erent amount of serum PDGF and also using fl uorochrome vital dyes. Results: A direct correlation between concentration and morphofunctional parameters of whole blood platelets and concentration of PDGF in the serum has been observed. Degranulation of platelets is associated with the massive release of PDGF. The study fi nding was that the content of PDGF in one well equal to 150 pg is associated with the maximum gain of proliferative activity of fi broblastswith their viability being preserved; at the higher PDGF concentrations fi broblasts viability decreased and cells death was observed. Conclusions: These data allow recommending the clinical use of PRP for stimulation of the regenerative-reparative processes.

Cytokine-induced killer cell derivates with reduced risk for graft-versus-host disease eradicate acute leukaemia and soft tissue sarcoma cells in vitro and in vivo in immunodefi cient mice E. Rettinger (1) , V. Meyer (1) , H. Kreyenberg (1) , S. Kuci (1) , A. Willasch (1) , G. Bug (2) , W.S. Wels (3) , H. Bonig (4) , T. Klingebiel (1) , P. Bader (1) (1)University Children´s Hospital (Frankfurt, DE) ; (2) Internal Medicine II (Frankfurt, DE) ; (3) Chemotherapeutisches Forschungsinstitut Georg Speyer Haus (Frankfurt, DE) ; (4) Institute for Transfusion Medicine and Immunohematology (Frankfurt, DE) Objectives: Pre-emptive immunotherapy using unmanipulated cytokine induced killer (CIK) cells or CIK cell products with reduced risk of graft versus host disease (GvHD), i.e. CD56-enriched (CD56+) or irradiated CIK cells derived from IL-15-expanded CIK cells may off er a novel therapeutic approach for patients with high risk acute leukemia and soft tissue sarcoma relapsing after haploidentical stem cell transplantation (haplo-SCT). Methods: This study was performed to evaluate the cytotoxic impact of CIK cell derivates in vitro and in vivo. Mice injected with malignant cells, either received a single dose of unmanipulated CIK cells or serial injections of unmanipulated CIK cells or CIK cell products, and were randomly assigned for analysis of CIK cell treatment in terms of disease free survival (DFS) and engraftment of malignant cells compared to untreated controls. Results: CIK cell products showed reduced proliferative capacity in vitro compared to unmanipulated CIK cells. But, in vitro cytotoxicity of CD56+ CIK cells was signifi cantly improved against soft tissue sarcomas compared to unmanipulated and irradiated CIK cells, whereas no diff erences occurred against acute leukemias. In vivo analysis demonstrated that inoculated leukemias responded to infusions of unmanipulated CIK cells but not to administered CIK cell products (CD33+ primary AML cells [%] , w/o 91.0±2.0; w unmanipulated 26.3±22.9 (once) and 0±0 (repetitive); w CD56+ 43.7±40.7; w irradiated 89.3±0.6). Sequential infusions of unmanipulated CIK cells resulted in an eradication of leukemia cells. In addition, treated mice showed an increased DSF (median survival [days] , w/o 182; w unmanipulated 337 (once) and >340 (repetitive); w CD56+ 220; w irradiated 200). In contrast, in rhabdomyosarcoma-bearing mice, one infusion of unmanipulated CIK cells was suffi cient for eradication of malignant cells (engraftment [RFU] , w/o 77.3±27.0; w unmanipulated 1.2±2.9; w CD56+ 41.9±11.4; w irradiated 30.4±13.8) which resulted in an increased DFS (median survival [days] , w/o 59; w unmanipulated >100; w CD56+ 84; w irradiated 92). Further analysis confi rmed that unmanipulated CIK cells were detectable in signifi cant numbers compared to CD56+ or irradiated CIK cells. Conclusion: The non-restricted anti-tumoral cytotoxicity and the limited risk for GvHD may suggest serial infusions of high numbers of unmanipulated CIK cells as a promising immunotherapeutic approach for high risk patients even in the context of haplo-SCT.

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib diff erently aff ect γδ T-cell reactivity in a long-term induction ex-vivo environment K. Wu, Y. He, H. Fu, Y. Hu, L. Sheng, H. Huang School of Medicine, Zhejiang University (Hang Zhou, CN) Objectives: As γδ (gd) T cell immunotherapy is still poorly successful, combinations with drugs enhancing its reactivity are of major interest.Mustjoki et al. recently found dasatinib, but not imatinib or nilotinib had a rapid mobilization of lymphocytes including gd T in blood peaking 1-2h after an oral intake. Here we explore how clinically relevant doses of these 3 BCR/ABL-inhibitors aff ect gd T cell reactivity in a long-term induction ex-vivo environment. Methods: gd T cells were expanded in the presence of 2uM zoledronate and IL-2. The study was divided into seven groups:; imatinib (5uM and 0.6uM), nilotinib (3. 6uM and 30nM) and dasatinib (200nM and 10nM) separately corresponding to plasma peak and

S77 IC50 concentrations and DMSO as control were added every 3 days. gdT cells cultured after 12 days were used for function analysis including proliferation, activation, degranulation, intracellular IFN-γ production, antitumor eff ect and phenotype alteration. Results: gd T cell proliferation were not signifi cantly aff ected in IC50 groups of 3 drugs compared with control. In plasma peak groups, both imatinib and dasatinib obviously decreased gd T cells proliferation, only nilotinib had a role in promoting (Figure1A). The expression of activation markers CD25 and HLA-DR were both obviously up-regulated in dasatinib IC50 group(Figure1B). CD107a mobilization were all decreased or not signifi cantly aff ected in experiment groups (Figure1C) . Of note, intracellular IFN-γ introduction was only obviously increased in dasatinib IC50 group, whether by PMA or K562 cells 1:1 stimulation (Figure1D) . Also Antitumor eff ect of dasatinib IC50 group was observed to be superior to control cells. To fi nd the possible reasons, we further analysed phenotype of gd T cells using CD27 and CD45RA. The results showed only dasatinib IC50 group induced a population shift to CD27-, which represented immediate eff ector functions (Figure1E) . Preferentially cytotoxicity CD27-CD45RA+ subset decreased in all the experiment groups, while preferentially IFN γ-secreting CD27-CD45RA-subset obviously increased in dasatinib IC50 group, which may at least in part explain our previous fi ndings. Conclusion: Dasatinib IC50 concentration not the other BCR/ABLinhibitors enhanced gd T cell antitumor eff ect through a shift to CD27-diff erentiation and IFN γ-secreting responses without aff ected gd T cell proliferation. These data represents a promising way to optimize gd T cell-based immunotherapies.

I. Turin (1) , E. Montini (1) , F. Ferulli (1) , M. Tanzi (1) , P. Merli (1) , R. Maccario (1) , M. Zecca (1) , D. Montagna (2) (

Important pre-requisites for anti-tumor adoptive cell therapy (ACT) include the possibility of obtaining CTLs able to reach tumor sites and effi ciently kill neoplastic cells. We have previously developed a methodological approach to ex-vivo expand anti-tumor CTLs by stimulation of eff ector cells with dendritic cells (DC) pulsed with either apoptotic malignant cells (anti-leukemia CTL) or WT1-peptides as tumor antigens. Recently, it has been described the potential antitumor activity of IFN-alfa and its capacity to induce the diff erentiation of monocytes into DC highly effi cient in mediating cross-priming of CD8+ T cells. The aim of the present study was to evaluate if the induction of either anti-leukemia or WT1-specifi c CTLs, using IFN-alfa during the maturation of DC and/or the priming of eff ector cells, lead to an improvement of their specifi c anti-tumor cytotoxic activity. Four WT1-specifi c and 8 anti-leukemia CTL lines were generated from 5 donor of HSCT. DC were generated culturing CD14+ cells in the presence of GM-CSF and IL-4 (IL4-DC) or IFN-alfa (IFN-DC). During the priming, PBMC or CD8+ T cells were stimulated with IL4-DC or IFN-DC pulsed with irradiated tumor cells or WT1 peptides in the presence of IL-7 and IL-12, with or without IFN-alfa. IFN-DC displayed a set of membrane molecules involved in antigen presentation even though their morphologic aspect was more monocyte-like than DC-like. In all CTL lines we observed that cytotoxic activity against leukemia blasts was higher when IFN-DC were used as APC instead of IL4-DC (mean lysis: 48%, range 32-61 and 31%, range 17-39, respectively at E:T ratio of 25:1). Specifi c lysis was further enhanced by the addition of IFN-alfa during the priming of CTLs. In spite of an increase percentage of NK cells in IFN-CTLs, we did not documented a loss of their specifi city, in that the reactivity against non-malignant cells was less than 15% at the E/T ratio of 25:1, and the addition of cold K562 in cytotoxicity assay did not cause sizeable reduction of anti-leukemia cytotoxic activity.

These data confi rm the possibility of effi ciently generating antileukemia CTL lines using IFN-alfa in order (i) to improve DC's ability to act as APCs and (ii) to stimulate T-cells to recognise, during the priming, either leukemic associated antigens on the surface of apoptotic leukemic blasts or specifi c peptides. This approach will be useful to improve ACT strategies to control or prevent leukemia relapse after HSCT. A. Chauchet, R. Vallion, F. Bonnefoy, A. Daoui, S. Kaminski, B. Lamarthee, P. Saas, S. Perruche INSERM UMR 1098 (Besancon, FR) Introduction: Allogeneic hematopoietic cell transplantation (AHCT) is a curative therapy for hematological malignancies. However, such a therapeutic is limited by graft-versus-host-disease (GvHD) occurrence. New strategies are therefore needed and our laboratory showed that the use of apoptotic cell has immunomodulatory properties to favor engraftment and limit GvHD. These eff ects are TGF-B and regulatory T cell dependent. However, since apoptotic cell injection favors tolerance, the infl uence of apoptotic cell injection on leukemia development has never been evaluated. Methods: To examine whether graft-versus-leukemia (GvL) activity of T cells was maintained after AHCT in the presence of apoptotic cells, we developed an experimental mouse model of T celldepleted bone marrow (TCD BM) transplantation. Leukemic A20 luciferase+ cells were also injected the day of TCD BM transplantation (d0). A delayed allogeneic donor T cell infusion was given on day 6 to induce GvHD and GvL. Apoptotic cells were injected either on d0 or d6. Results: Eradication of leukemic cells was observed in all animals receiving delayed T cells injection. Indeed, all mice not receiving T cells died from leukemia before day 27 post-graft, as attested by tumor growth evaluation by luminescence (NightOwl technology). Then, we observed that T cell injection prevents tumor growth as attested by absence of luminescence, however all mice developed GvHD (according to Ferrara's score) and died before day 27 . In sharp contrast, 60% of mice receiving apoptotic cells on d0 survived at day 27. In addition, such mice receiving apoptotic cells that prevent GvHD occurrence, did not present leukemic growth as attested by the absence of luminescence at day 27 post-graft. No diff erence was observed for infl ammatory lymphocyte. Proliferation of CD3 (BRDU) and cytotoxicity of LT CD8+ vs receipt cells was decreased contrary to cytoxicity of CD8 vs A20 which was preserved with apoptotic cell on day 0. Conclusion: Our data clearly demonstrated that GvHD suppression by apoptotic cell injection does not abrogate GvL activity of adoptively transferred donor T cells. Thus, apoptotic cell injection should be considered in clinic to favor engraftment, prevent GvHD, conserving high GvL therapeutic activity.

I. Bigalke (1) , M. Lundby (1) , J. Kasten (2) , S. Saeboe-Larssen (1) , H. Haakenstad (1) , D.J. Schendel (2) , G. Kvalheim (1) (1)Oslo University Hospital (Oslo, NO) ; (2) Helmholtz Zentrum (Munich, DE) We have previously shown that a new generation of fast DCs, using a maturation cocktail containing IL-1β, TNFα, IFNγ, PGE2 and the TLR7/8 ligand R848 was more effi cient than the standard 7 days DCs. To establish this DC method in our GMP-facility, we cultivated monocytes from 2 volunteer healthy donors. On day 3, the maturation cocktail was added. mDCs were harvested and electroporated on day 4 and frozen after a recovery period. The following parameters were investigated: expression of the S78 surface markers CD14, CD80, CD83, CD86, CD40 HLA-DR, CCR7, CD274 using FACS analysis, the capability to secrete IL-10 and IL-12p70 during co-culture with CD40L-mouse fi broblasts and the migratory capacity using a CCL19 gradient. In both preparations CD14 showed a complete negative shift in mean fl uorescence intensity after maturation while all other markers showed a complete positive shift. All tested cells produced IL-12p70 in the range from 138 pg/ml to 216 pg/ml. The IL-10 production ranged from 14 pg/ml to 60 pg/ml. All mDCs showed increased migration towards CCL19 compared to controls. Thereafter, two autologous DC vaccines transfected with mRNA hTERT and Survivin were produced for "compassionate use". DC phenotype, IL-12 /IL-10 production and migration capacity was similar compared to mDCs from healthy donors. Of the two patients vaccinated, one suff ered from metastatic lung cancer with a brain metastasis. Following diagnosis in June 2011 she was treated with chemotherapy and radiotherapy. Since December 2011 she has been vaccinated and CT/MRI examination in November 2012 showed a partial response in the lung and no further disease development in the brain. The second patient receiving DC vaccination has a hormone resistant prostate cancer, but he is still too early to evaluate. Altogether, our results show that our new generation of DC vaccines can be a potentially useful immunotherapy for cancer patients.

Human platelet lysate and exosomes improve the in vitro osteogenic pre-diff erentiation of bone marrow-derived stem cells T. Lener, M. Oeller, D. Peckl-Schmid, D. Streif, M. Gimona, F. Rivera, L. Aigner, E. Rohde Paracelsus Medical University (Salzburg, AT) Rationale: Bone marrow-derived mesenchymal stem and progenitor cells (BM-MSPCs) are attractive candidates for cell therapy. Replacing bovine serum with human platelet lysate (HPL) for in vitro culture has been established as a safe procedure to maintain the multi-lineage potential of BM-MSPCs, and HPL has been shown to promote osteogenic diff erentiation in vitro and in vivo. Pre-diff erentiation of BM-MSPCs in vitro can improve bone regeneration when used for critical-sized bone defects. Thus we tested the hypothesis that progenitor cell-derived exosomes further enhance osteogenic diff erentiation. Methods: We employed cell counting, colony formation assays and the xCELLigence impedance assay (ROCHE) for determination of the proliferative capacity of BM-MSPCs in the presence or absence of exosomes derived from either MSPCs or Endothelial Colony Forming Cells (ECFCs). Osteogenic diff erentiation of BM-MSPCs was induced by dexamethasone, ascorbic acid and β-glycerophosphate in HPL-supplemented media. Flow cytometric analysis was used to monitor stem cell and osteogenic lineage marker expression. Fluorescence and phase contrast microscopy was performed to visualize exosome uptake and osteogenic diff erentiation, respectively. Results: Here we show that exosomes derived from BM-MSPCs, but not from ECFCs further potentiate the HPL-supported osteogenic diff erentiation of BM-MSPCs. In contrast, the proliferative potential of BM-MSPCs was increased by ECFC-derived exosomes only. In the presence of homotypic exosomes BM-MSPCs can be replated after ostogenic diff erentiation without osteo-inductive supplements, and maintain the secretion and deposition of mineralizing matrix. To our knowledge this is the fi rst description of enhanced osteogenic diff erentiation of BM-MSPCs by stem cellderived exosomes. Conclusions: Various procedures have been developed to promote osteogenic diff erentiation of mesenchymal cells in vitro, including growth factor and medium supplements, genetic manipulation or mechanical stimulation. Our results show that in the presence of HPL and exosomes BM-MSPCs can be diff erentiated in vitro towards osteoprogenitors that maintain deposition of calcifying matrix material. Establishing future protocols for the in vitro pre-diff erentiation of BM-MSPCs may contribute to improved stem cell therapy, specifi cally for critical size bone defects.

T.S. Lam, M. van de Meent, J.H.F. Falkenburg, I. Jedema Leiden University Medical Center (Leiden, NL) Although profound graft versus leukemia (GvL) responses can be induced after donor lymphocyte infusion (DLI) and allogeneic stem cell transplantation (alloSCT) in some patients, the therapeutic eff ectivity in other patients is limited by inadequate induction of GvL reactivity due to limited numbers and/or inferior immunogenicity of (malignant) antigen-presenting cells of patient origin. Moreover, due to the broad repertoire of specifi cities within unselected donor T cells GvL reactivity often coincides with induction of graft versus host disease (GvHD). Adoptive transfer of selected populations of donor T cells directed against minor histocompatibility antigens (MiHA) that are specifi cally expressed on only hematopoietic cells of the patient may be an elegant strategy to induce therapeutic GvL reactivity without GvHD. In this study, we used an 'in-vitro vaccin' of hematopoiesis-specifi c MiHA peptides loaded on monocyte-derived dendritic cells of donor origin for in-vitro generation of MiHAspecifi c donor T cells. Naïve CD8+ donor T cells enriched from peripheral blood by magnetic bead separation were stimulated with peptide-loaded (10-7M ) autologous DCs. To enrich for T cells with suffi cient functional avidity, the immune responses were restimulated at day 10 with peptide loaded (10-7M ) autologous monocytes, followed by isolation of reactive T cells 36 hours later based on the expression of the activation marker CD137. MiHAspecifi c T cells were further enriched using peptide/MHC multimers and magnetic bead isolation. Clonal analysis of the isolated MiHA-specifi c T cells demonstrated the generation of MiHA-specifi c T cells showing signifi cant reactivity (cytokine production and/or cytotoxicity) against pepide-loaded target cells, but also against EBV-LCL, and normal and malignant hematopoietic cells of patient origin and no reactivity against cells of donor origin. This illustrates their specifi city for MiHA specifi cally expressed on cells of the patient and their relevant functional avidity allowing reactivity against target cells presenting physiological amounts of endogenously processed antigens. In conclusion, we here present a strategy to generate donor T cells directed against MiHA specifically expressed on (malignant) hematopoietic cells of the patient using an 'in-vitro vaccination' strategy. These T cells may be used to specifi cally induce GvL reactivity without coinciding GvHD in patients with relapsing or recurrent disease early after alloSCT.

In vitro generation of therapeutic haematopoiesis-directed donor T-cell products allowing broad clinical application in patients with diff erent haematological malignancies I. Jedema, C. Hoogstraten, M. van de Meent, T.S. Lam, J.H.F. Falkenburg Leiden University Medical Center (Leiden, NL) The induction of adequate anti-tumor responses after donor lymphocyte infusion (DLI) and allogeneic stem cell transplantation (alloSCT) is limited by inadequate induction of primary immune responses from the naïve donor repertoire, most likely due to the unavailability of suffi cient professional antigen presenting cells (APCs) of patient origin and the time required for immune responses to be induced and amplifi ed in-vivo. In this study, we developed a universal strategy for the in-vitro generation of donor T cells recognizing minor histocompatibility antigens (MiHA) specifi cally expressed on hematopoietic cells of patients with diff erent hematological malignancies. For this purpose, monocyte-derived dendritic cells (DCs) were generated from CD14 positive monocytes of patient origin and used as APCs for priming of naïve T cells from the HLA matched stem cell donor. Naive donor T cells were enriched by depletion of CD25+ regulatory T cells and memory T cells and stimulated with patient-derived DCs. After 10 days of co-culture the immune responses were restimulated with unmodifi ed monocytes of patient origin and patient hematopoiesis-reactive T cells were enriched 36 hours later using clinical grade CD137-biotin and anti-biotin beads (Miltenyi) . Clonal analysis of multiple T cell products demonstrated that the products contained oligoclonal populations of both CD4 and CD8 T cells that showed reactivity (cytokine production and/or cytotoxicity) against both myeloid cells and EBV-LCL of patient origin and no reactivity against cells of donor origin, illustrating their specifi city for MiHA expressed on patient hematopoietic cells of diff erent lineages. Although the repertoire of antigens expressed by monocyte-derived DCs was skewed towards antigens specifi cally expressed on hematopoietic cells, they will also include antigens with a more broad expression profi le on both hematopoietic and non-hematopoietic tissues. Therefore, potentially GvHD-inducing reactive T cells in the generated T cell products will be removed by stimulation of the T cells with patient-derived primary skin fi broblasts followed by depletion based on CD137 expression after stimulation. In conclusion, we here present a universal strategy for the generation of therapeutic hematopoiesis-directed donor T cell products allowing broad clinical application for the treatment of patients with diff erent hematological malignancies showing recurrence or persistence of their disease early after alloSCT.

Umbilical cord blood derived T-cells exhibit a higher degree of polyfunctionality and a higher proliferation potential after the addition of IL-7 to in vitro cultures S. Berglund, J. Gertow, I. Magalhaes, J. Mattsson, M. Uhlin Karolinska Institute/Karolinska Univ. Hospital (Stockholm, SE) Background: Umbilical cord blood transplantation (UCBT) is an increasingly used stem cell source for allogeneic stem cell transplantation. One disadvantage to UCBT is that treatment with donor lymphocyte infusion (DLI) is not possible. We wanted to explore if cultured lymphocytes from the UCB graft could off er an alternative to DLI in this setting, with focus on adding IL-7 to the protocol. Methods: T cells were positively selected with CD3+/CD28+ magnetic beads and cultured with IL-2 at escalating concentrations. In addition, IL-7 (20 ng/ml) was added to half of the cultures. After 7 days expansion the T cells were analyzed by fl ow cytometry to determine phenotype, and assess apoptosis and cytokine production. The statistical analysis was performed with Wilcoxon's matched pairs signed rank test. Results: There was a strong trend (p=0.063, n = 5) toward greater proliferation in cultures to which IL-7 had been added. The greatest proliferation was seen in T cells cultured with 100 IU IL-2/ml and IL-7. The CD4+/CD8+ T cell ratio was higher with IL-7 and high dose IL-2 (p = 0.031) compared to only high dose IL-2. A lower percentage of central memory T cells (CD45RO+ CCR7+) was seen in conditions with IL-7 and high dose IU IL-2 compared to only IL-2 (p = 0.016). In CD4+ T cells, this was the case for both high dose IL-2 (p = 0.008) and low dose IL-2 (p = 0.019). There was a trend towards less cell death (defined as % of AnnexinV+ 7-AAD+) with IL-7 and low dose IL-2 (p = 0.079). We assessed the intracellular production of IL-2, TNF-α, IFN-γ and CD107a after culture. There was more polyfunctional T cells (positive for three or four factors) in cells cultured with IL-7 (p = 0.049). In CD4+ cells the percentage of cells producing TNF-α was significantly higher in cultures with only IL-2, and there were significantly more cells producing IFN-γ in the culture conditions containing IL-7. Conclusion: There seem to be a proliferation advantage in adding IL-7 to a lower dose of IL-2. Addition of IL-7 might also have an impact on the diff erentiation status of the cells. T cells cultured in IL-7 had more polyfunctional traits, possibly increasing the activity of a putative future DLI.

Signifi cance of T-regulatory cells CD4+CD25+CD127low for the monitoring and treatment of graft-versus-host disease in paediatric patients after allogeneic stem cell transplantation E. Pristanskova (1) , K. Kirgizov (1) , S. Bykovskaya (2) , V. Muhin (2) , E. Skorobogatova (1) (1) The Russian Children's Research Hospital (Moscow, RU) ; (2) The Russian National Research Medical University named after N.I. Pirogov (Moscow, RU) Treatment of severe steroid-refractory "Graft versus host" disease (GvHD) is one of the signifi cant problems now. T-regulatory cells CD4+CD25+CD127low (T-regs) play the signifi cant role in the maintenance of the immunological tolerance. Purpose: To evaluate the role and signifi cance of T-regs for the recipients of Allogenic hematopoietic stem cell transplantation (Allo-HSCT). Patients and methods: Method of the native T-regs cultivation, invented by our group, allows to growth cells ex-vivo. Number of T-regs can be increased in more than 100 times in 7-10 days. This survey includes 22 patients after Allo-HSCT. Subpopulation of the lymphocytes was assessed in transplant source (TS) and in peripheral blood (PB) on days +30, +60, +90. Ex-vivo cultivated T-regs subcutaneous (SC) injection was performed for 5 patients with steroid-refractory GvHD in dose 5-7 X 106/kg 1-2 times per months. Mean number of SC injections -3 (2) (3) (4) . Results: T-regs level assessment in the TS showed the absence of the correlation between the number of T-regs and the risk of GvHD. Investigation of the number T-regs and CD4/CD8 ration in the PB at the moment of engraftment and the T-regs level in PB on days +30, +60, +90 showed the absence of correlation of the Tregs level and clinical signifi cance of GvHD. Possibly, the reason of absence of this correlation can be corresponded with prolonged immunosuppression. Signifi cant clinical improvement in GvHD and subpopulation characteristics (increasing of T-regs level (%) and CD4/CD8 ratio) was achieved at the patients who received ex-vivo cultivated T-regs. Some of the patients showed decreasing of absolute lymphocytes count connected with the corresponding immunosuppression, transplant hypofunction and CMV-associated therapy. There were no any side eff ects after the T-regs SC injection. Four patients are alive now (one patient died, cause of death -CMV disease). Observation period: 3-55 months. Patients with oncological diseases (n=2) is free from relapse now. Conclusion: T-regs level monitoring in TS and in the PB during the early post-transplant period with aim of GvHD risk assessment isn't informative and reasonable. Including of the injections of exvivo cultivated cells to the scheme of the steroid-refractory GvHD treatment is the perspective way of improvement of the GvHD therapy. T-regs infusions didn't show any side eff ects.

Donor lymphocyte infusions (DLI) are applied after allogeneic stem cell transplantation (HSCT) of hematological malignancies against an impending relapse. DLI of haploidentical natural killer (NK) cells represent a novel strategy to enhance the graft-versustumor eff ect of HSCT in the treatment of acute myeloid leukemia (AML) and multiple myeloma (MM). Initial clinical studies by our institution and others indicated that cell dose and resting state of freshly isolated NK cells may limit the anti-tumor eff ect of NK-DLI in vivo. Here we describe the in vitro expansion of NK cells under good manufacturing practice (GMP) conditions for preemptive mega dose NK cell infusions and follow-up of cytokine-activated NK cells in vivo. NK cells were purifi ed from unstimulated leukaphereses (mean: 12.5L, n=4) by T cell depletion and subsequent NK cell selection using CliniMACS. Starting from 180 x 10e8 total nucleated cells, 7.2 x 10e8 NK cells were obtained with a purity of 95.8% and a residual T cell contamination of 1.8 x 10e5 cells corresponding to a T cell depletion effi cacy of 5.22 log. Purifi ed NK cells were expanded for 19 days in air-permeable bags in up to 13.4L medium containing human serum, IL-2, IL-15, anti-CD3 monoclonal antibody and irradiated autologous feeder cells. After 19 days NK cell numbers increased 50. 3-fold (range 22 to 75-fold) to 197 x 10e8 cells with a viability of 72% and with a minimal T cell contamination of 0.023%. The NK cell products were divided and cryopreserved as 3-8 (mean: 5.25 ) escalating doses ranging from 1.3 x 10e6 to 1.0 x 10e8 cells/kg body weight. Of GMP-expanded NK cells we determined the phenotype, size of alloreactive cell subsets and cytolytic activity of against K562 cells. Fourteen NK-DLIs were given to two patients and well tolerated without any acute adverse eff ects. The faith of infused NK cells was monitored by FACS analysis of discriminative donor-specifi c HLA molecules and by quantitative real-time PCR of donor-specifi c DNA loci in one MM patient treated with autologous HSCT and haploidentical NK cells. After all NK-DLIs with maximal cell dose, we detected NK cells of donor origin at one and 20 hours post infusion (1.87% and 0.12% of purifi ed NK cells, respectively) indicating prolonged survival of cytokine-activated NK cells in the recipient's blood circulation. These results demonstrate the feasibility of large-scale expansion under GMP conditions and multiple mega dose infusions of human NK cells as immunotherapy after HSCT for malignant disease.

Mesenchymal Stromal Cells (MSC) can be expanded in vitro to facilitate cellular therapies utilising the immunosuppressive activity of MSC when exposed to an acute infl ammatory environment. Extensive data has accrued in acute graft versus host disease (GvHD) where effi cacy in the acute setting is clearly demonstrated in a sub-set of patients, but to date a large scale clinical trial has yet to be reported. MSC are also reported to have effi cacy in applications such as infl ammatory bowel disease and solid organ transplant rejection. We have been manufacturing MSC since 2006 under ever more stringent good manufacturing practice (GMP) and regulatory requirements. MSC are Advanced Therapeutic Medicinal Products and we hold both a relevant Investigational Medicinal Products license and a Specials license to permit manufacture of MSC for clinical trials or as an unlicensed drug under prescription for individual need. We have given MSC mainly in acute GvHD and an abstract detailing the clinical outcomes has been submitted, but we have also provided cells for Crohn's Disease, hyperimmunity, acquired immune haemolytic anaemia and organ transplant rejection. Production of MSC utilises multi-level tissue culture stacks (636cm2/level). Foetal bovine serum (FBS) has been replaced by human platelet lysate (PL). In adult donors, PL (n=33) did not signifi cantly increase yield (4.8 ± 3 .9 x 10 6 /level vs 8.9 ± 9.7 x 10 6 /level, p=0.35) compared with FBS (n=10) but decreased time to harvest (44.1 ± 10days vs 23.9 ± 10.9 days (p=0.001)). Yield varies widely between individuals and declines with donor age, most marked in donors <10y.o or >50y.o. We cryopreserve pooled seed stocks from primary cultures and establish multiple identical fi rst passage (P1) cultures for clinical use. P1 culture yield is donor dependent (mean yield for two 5 years old donors is 15.2 vs 37.0 x 10 6 /level, n=23 vs 24, p=0.001) but the range of yields per pooled stock (representative donor 13.8-53.8 x 10 6 /level, mean 37.0) indicates that multiple factors are involved. It is likely that MSC manufacture will ultimately reach industrial scale. Until such time, we expect production effi ciency in small centres to continue to evolve with small scale automated systems, hypoxia and commercially-driven introduction of serum-free medias and recombinant growth factors all key factors. S82 6 of the 10 patients treated with fresh MSC also received freezethawed MSC at another time. Because of this, response has been evaluated per individual infusion, and we have refrained from comparing survival. 108 tissue samples from 15 of the patients have been analysed for engraftment using PCR for MSC donor DNA. A total of 72 MSC infusions, 10 from fresh MSC and 62 freezethawed, were evaluated regarding clinical response. 22 infusions, of which 6 were of fresh MSC, were evaluated regarding engraftment. Results: The clinical response to fresh MSC was 70% responders, similar to freeze-thawed MSC (66%). MSC used fresh were to a higher degree HLA-matched (70% vs 15% partial or total HLAmatch) and of a lower average passage (median passage 2 vs 3), which could potentially infl uence the outcome in favour of the fresh MSC. For engraftment, no diff erence could be seen. Of fresh MSC, 50% (3/6) could be found in one or more sampled tissue, in comparison to 54% (7/13) of frozen MSC. Distribution was about the same with exception of the lungs, where only frozen MSC could be found. Discussion: In evaluating clinical response and engraftment of MSC, no diff erence could be found between fresh or frozen MSC. This analysis is limited by the small number of infusions of fresh MSC, a power calculation shows that we would only detect a difference in eff ect size of about 50% and we might miss a clinically signifi cant diff erence. As other factors possibly associated with better clinical response were more common in the fresh infusions we can at least conclude that no dramatic diff erence in favour of fresh MSC was evident from our data.

Epstein-Barr virus-specifi c cytotoxic T-lymphocyte production for adoptive cellular immunotherapy Y. Wang, L. Aissi-Rothe, J. Stoltz, V. Decot, D. Bensoussan CHU de Nancy (Nancy, FR) Objectives: Epstein-Barr virus (EBV) infection represents one of the major causes of morbidity following haematopoietic stem cell transplantation (HSCT) and can turn into post transplantation lymphoproliferative disorder (PTLD) associated with a high mortality rate although the use of targeted therapy, Rituximab. Adoptive cellular Immunotherapy using EBV-Lymphoblastoid Cell Lines (LCL) as stimulating antigen has proven effi ciency as it restored specifi c immunity. However, EBV presents a lot of immunodominant antigens and the challenge to develop a fast, clinical grade immunotherapy relies on the defi nition of a GMP universal stimulating antigen. Methods: Peripheral blood mononuclear cells (PBMC) from 6 donors presenting a cellular immune response against EBV were stimulated with an optimal EBV antigen association including an EBNA-3 peptide pool for 9 hours and the immunomagnetic selection based on IFN-γ secretion was performed. After selection, cells were expanded within 14 days and functional assays were carried out with the expanded cells. Results: After immunoselection, a mean of 0.53 ± 0.25×10 6 cells were recovered consisting in a mean of 24.77 ± 18.01% CD4+ secreting IFN-γ and 51.42 ± 26.92% of CD8+ secreting IFN-γ. The ability of expanded EBV-specifi c T cells to secrete IFN-γ and to proliferate after restimulation with EBV antigen was confi rmed. A specifi c lysis was observed against autologous target cells pulsed with EBV peptide pools (57.6 ± 11 .5%) and interestingly against autologous EBV-LCL (18.3 ± 7.3%). A decrease of 94.7 % in allogeneic reaction against third-party donor mononuclear cells with EBV-specifi c T cells compared with the PBMC before selection was observed. Conclusions: Our results brought out that an association of peptide pools including EBNA-3 is mandatory to generate EBVspecifi c T cells harboring a good specifi c cytotoxicity and a lack of alloreactivity.

Generation of bi-specifi c cytotoxic T-lymphocytes (CTL) against Epstein-Barr virus and adenovirus Y. Wang, L. Fievet, J.-F. Stoltz, V. Decot, D. Bensoussan CHU de Nancy (Nancy, FR) Objectives: Human Adenovirus (ADV) and Epstein Barr Virus (EBV) infections or associated diseases are serious complications following allogeneic hematopoietic stem cell transplantations which are responsible for signifi cant morbidity and mortality. Although available anti-viral drugs as cidofovir (ADV) and Rituximab (EBV), their effi ciency is impaired in absence of specifi c immune reconstitution and toxicity remains a concern. Furthermore, adoptive cellular immunotherapy with ADV or EBV cytotoxic T cells (CTL) has proven safety of use and effi ciency as it restored specifi c immunity. The concern is now to develop such an immunotherapy against the 2 viruses simultaneously. We focused on the generation of anti-ADV/ EBV bi-specifi c T cells and the comparison with the mono-specifi c T cells in respect of enrichment, effi ciency and toxicity. Such a comparative study was only reported once (Khanna et al, 2011) . Methods: Peripheral blood mononuclear cells (PBMC) from 3 donors presenting a cellular immune response against ADV and EBV were stimulated with ADV or EBV antigens or both. Immunomagnetic selection based on IFN-γ secretion was performed and functional assays were carried out with the expanded cells. Results: After immunoselection, a mean of 62.3±18.08%, 39.9 ± 25.54% and 60.6 ± 20.25% CD4+ secreting IFN-γ and 33. 1 ± 20.46%; 26.3 ± 32.29% and 60.7 ± 20 .55% of CD8+ secreting IFN-γ were recovered for ADV-CTL, EBV-CTL and ADV/EBV-CTL, respectively. Virus-specifi c T cells were expanded in vitro and their ability to secrete IFN-γ and to proliferate after restimulation with virus antigens was confi rmed. A specifi c lysis for EBV-CTL and ADV/ EBV-CTL was observed against autologous target cells pulsed with EBV peptide pools (59. 3 ± 22.5% and 43.7 ± 32.6, respectively) and a lower lysis for ADV-CTL and ADV/EBV-CTL against autologous target cells loaded with PepT-ADV (31.0 ± 4.0% and 14.0 ± 6.1, respectively). A reduced alloreactivity of bispecifi c and monospecifi c T cells against third-party donor mononuclear cells, compared to the PBMC before selection was observed. Conclusion: Despite a good enrichment in CD4 IFN-γ and CD8 IFN-γ T cells, bi-specifi c CTL showed a loss of cytotoxicity against ADV presenting targets compared with ADV mono-specifi c CTL. Although we cannot exclude antigenic competition during multispecifi c CTL stimulation, our data seem to incriminate the amplification step required to perform functional assays.

Aim and Methods: The aim of our study was to generate DC/DCleu ex vivo from AML-pts in active stages of the disease from mononuclear cells ('MNC-DC' , n=42), heparinised whole blood samples ('WB-DC' , n=12) using standardized DC-generating protocols (MCM-MIMIC ('MCM'), Picibanil ('Pici'), Calciumionophore ('Ca') or IFNα ('IFN' , containing IFNα, GM-CSF and TNFα) or using combinations of 1-3 selected cytokines, antibiotics, bacterial lysates, or other clinically approved response-modifi ers in 9 minimalized DC-cocktails ('WB-mini-cock-DC' , n=11) and to study the role of IFNα. Moreover the infl uence of 'IFN'-DC' on the antileukemic functionality of T-cells was studied and data correlated with the clinical response to immunotherapy (SCT/DLI). Results: 1.Generation of DC:a) From 'MNC-DC' DC/DCleu could be successfully generated (>10%DC and >5% DCleu in the total cell fraction) with MCM-mimic (MCM, 31% of cases), Picibanil (Pici, 34%), Calcium-ionophore (Ca, 21%) and IFNα (IFN, 26%). b) From 'WB-DC' DC/DCleu could be successfully generated with 'MCM' (33% of cases), 'Pici' (20%), 'Ca' (25%) and 'IFN' (38%). c) Using 'WBmini-cock-DC' DC/DCleu could be successfully generated with cocktails containing diff erent combinations of response-modifi ers (20-50% of cases), but never, if IFNα was added to the cultures. None of the used DC-methods or cocktails induced blast proliferation. 2. Antileukemic functionality: T-cells stimulated with 'MNC-DC' using 'IFN' compared to 'Pici' or 'MCM' in 4 cases showed comparable lytic activity in the two settings (3 of 4 cases lytic activity achieved). Detailed data of DC-proportions in the context of functionality, response to immunotherapy and in the context of cytokine release will be presented. Conclusion: DC/DCleu can be generated regularily from blastcontaining MNC ('MNC-DC)' , from whole blood ('WB-DC') using standard DC-methods -including 'IFN'-methods. However, DCgeneration is only possible, if IFNα, GM-CSF and TNFα, are added to cultures and not with minimalized combinations of IFNα. In a clinical context this could mean, that IFN is eff ective only in a special context with other response modifi ers -resulting in antileukemic T-cells or not.

Centralized production and distribution of CMV-specifi c cytotoxic T cell lymphocytes ready for commercialization K. Newton (1) , A. Skulte (1) , A. Mitra (1) , K. Hodgkin (1) , K.S. Peggs (2) , A. Friedetzky (1) , R. Knaus (1) (1)Cell Medica Ltd. (London, GB) ; (2) UCL Cancer Institute (London, GB) Objective: Investigator-led Phase I/II studies have shown that adoptive transfer of donor virus-specifi c cytotoxic T cell lymphocytes (CTL) can reconstitute immunity on a long-lasting basis in patients at risk for viral reactivation following allogeneic hematopoietic stem cell transplantation (allo HSCT). In order to support routine clinical use for virus-specifi c CTL, it is critical to establish a reliable and convenient approach for supply of the cell product to transplant centers across Europe. Methods: Requests for Cytomegalovirus-specifi c (CMV) CTL are accepted for specifi c patients from transplant physicians under a service level agreement with Cell Medica, employing standard forms for donor and patient consent. Eligibility is confi rmed, including HLA-type and presence of CMV-specifi c cells, in donor samples. A proprietary technology is utilized for direct selection of CTL based on MHC-multimer technology (STAGE Cell Therapeutics GmbH). After fi nal testing the CMV-specifi c CTL are released as Cytovir TM CMV and shipped to the hospital in a temperature controlled manner for direct infusion. Results: The centralized production reliably results in a product that after microbiological clearance can be delivered in 10-14 days from receipt of starting material. Based on the provision of over 50 cell products to support clinical trials to 13 centers, no logistics failures have occurred. The table shows data from the last 24 products manufactured after process optimization. Conclusion: Cell Medica have developed a model for centralized production and delivery of virus-specifi c CTL for transplant IL-12p70, TNF-α in 'MNC-DC'-or 'WB-DC'-stimulated T-cell supernatants. Conclusion: In sum high concentrations of IL-8, MCP1, INF-γ and low concentrations of IL-10, IL-12, TNF-α in serum,'DC'-or MLCsupernatants correlate with antileukemic T-cell functionality or clinical response to immunotherapy. These data could contribute to develop strategies to shift the cytokine profi le/immuneresponse -e.g by application of responsemodifi ers to patients.

Evaluation of the Amicus Separator for extracorporeal photochemotherapy F. Heshmati Cochin Hospital (Paris, FR) Background: Cochin is a public University Hospital (AP-HP, Paris) with a therapeutic apheresis activity focused on extracorporeal photo-chemotherapy (ECP); 428 in 2011, and 438 other therapeutic apheresis procedures. 3 Cobe Spectra and 1 Optia devices (Terumo BCT) are currently used. We evaluated the Amicus Separator (Fenwal) as an alternate platform to collect lymphocytes for off line ECP. The objective was to assess procedure performance and safety. Methods: A total of 16 Amicus procedures (SW 4.3) were evaluated in patients with GVHD (5), bronchiolitis obliterans syndrome (8), oral lichen planus (3) . Two whole blood volumes were targeted to process. The illumination procedure post collection was performed after addition of 8-MOP using a Macogenic 2 device (Macopharma). A lymphocyte proliferation inhibition test was performed post treatment. The performance was evaluated based on 1) lymphocyte collection yield and purity; 2) patient PLT depletion; 3) procedure time (reinfusion included); 4) adverse events during the collection procedure. Results: 16 patients with a weight of 59 ± 9 kg, platelet (PLT) pre count of 245 ± 58 x 10E3/μl (N=14) and white blood cells (WBC) pre count of 7.6 ± 7.3 per μL (N=14) were collected. PLT post count was 227 ± 51 x 10E3/μl (N=13) corresponding to a PLT depletion of 10.8 ± 5.9% (N=13). WBC post count was 6.9 ± 6.0 per μl (N=13). Whole blood volume processed was 8516 ± 1500 ml in 198 ± 33 minutes including reinfusion time (N=16). Collected product volume was 312 ± 13 ml (N=15). WBC yield was 10.8 ± 6.4 x 10E9 with 14 ± 11% monocytes, 77 ± 14% lymphocytes and 8 ± 9% granulocytes (N=16). Hematocrit of the product was 1.6 ± 0.3 % and PLT content 7.6 ± 3.4 x 10E10 (N=14). The lymphocyte proliferation inhibition was superior to 95%. There were no recorded adverse events. The graph below shows MNC enrichment with Amicus compared to historical data from Cochin and Montpellier University Hospitals with other platforms. Conclusion: Collection on the Amicus Separator yielded satisfactory lymphocyte count and purity to perform a successful

S85 ECP procedure with inhibition of proliferation greater than 95%. Hematocrit of the product to be irradiated is low as well as platelet content. Consequently platelet loss in the patient is limited. The operator found the device easy to operate thanks to the fully automated procedure and troubleshooting aids. The Amicus Separator is a suitable alternate collection platform for ECP.

The eff ectiveness of darbepoetin alfa in patients undergoing autologous stem cell transplantation. Single institution experience P. González Sierra (1), F. Almagro Torres (1) , M.J. Martínez Quesada (1) , M.M. Trujillo Pérez (2) , J.A. López López (1) , P. Luque Ortega (2) , S. Durán Nieto (1) , A. Carrero González (2) , A. Alcala Muñoz (1) (1)University Hospital of Jaen (Jaen, ES); (2) Blood Transfusion Center of Jaen (Jaen, ES) Introduction: Darbepoetin alfa (Aranesp ®) is an erithropoyesis stimulating agent (ESA) approved for the treatment of anaemia asocciated with chemotherapy in cancer patients.

Patients diagnosed of hematologic malignancy undergoing Autologous Stem cell Transplant (ASCT) show an anaemic syndrome due to conditioning treatment prior to infusion of hematopoietic progenitors. In our centre, we have administered through stipulated protocols ESA agents from day +1, dosing 300 μ g once every two weeks, regardless of the individual characteristics of each patient, to 14 months ago. Since then, we have not used this universal strategy, reserving this drug for specifi c cases. Objective: Compare transfusional requirements between two cohorts of patients undergoing ASCT, those who have received ESA agents versus Non-ESA agents and check the eff ectiveness of their use. Patients and method: 86 consecutive patients under ASCT have been performed in our center, 62 patients have received ESA agents (from Jan 2008 to Oct 2011), and 34 belong to Non-ESA group (from Nov 2011 to Jul 2012 . The characteristics of both groups are shown in Table 1 . There are no signifi cant diff erences between both groups according to sex, age, diagnosis and number of cells infused. Transfusion criteria was given by the discretion of Consultant Haematologist managing the patient. We have analyzed the period from day +1 to day +100.

S86 Results: For statistical analysis we used the test U of Mann-Whitney. There are no signifi cant diff erences (p = 0.065) in the number of transfusions received between the group who has received ESA on day +1 and those who have not received throughout the whole study period. It has also been analyzed platelet concentrates that have required in both groups, with no signifi cant diff erences (p = 0.387) between them. Conclusions: If we use the number of transfusions as a direct parameter of the use of ESA over red cell engraftment in patients undergoing ASCT, we can confi rm that its use does not provide any advantage as it does not decrease the number of transfusions. We also analyzed platelet transfusion as possible indirect parameter of the ESA eff ect over another series and bone marrow microenviroment. According to our analysis, its administration is not benefi cial as there are no diff erences between both groups. Therefore, we believe that the use of ESA in patients undergoing ASCT, may have a role in selected patients with poor quality of life or poor tolerance to anemic syndrome, but this should not be used universally.

The 'Swiss Army Knife' of leukoapheresis: granulocyte collection and leukodepletion with the electronic-interfacecontrolled Spectra Optia IDL apheresis device M. Schulz, H. Bialleck, K. Thorausch, B. Luxembourg, E. Seifried, H. Bonig German Red Cross Blood Service Baden-Württemberg-Hessen (Frankfurt, DE) Introduction: The apheresis device Spectra Optia (SO) which features continuous electronic interface monitoring was introduced to replace COBE Spectra (CS). Successively, protocols were released for plasma/erythrocyte exchange followed by a mononuclear cell (MNC) protocol for autologous/allogeneic "stem cell" apheresis and unstimulated MNC collections (e.g. donor lymphocyte infusions, extracorporeal photopheresis). Safety/effi cacy of the device for these indications were reported. Most recently, by introducing the SO-IDL platform, the portfolio was extended to leukocyte depletions and granulocyte collections. Performance data for these protocols are reported. Methods: SO-IDL diff ers from SO-MNC by use of a diff erent (exchangeable) fi ller, to accommodate the more voluminous IDL tubing set, and by depositing the product directly in the collection bag. For leukodepletions, we retrospectively analyzed data from 23 procedures in de-novo AML patients with symptomatic hyperleukocytosis performed between 6/2011 and 7/2012, 8 with SO-IDL and 15 with CS-MNC. For granulocyte collections, we compared outcomes from 70 aphereses, performed between 10/2011 and 9/2012, 35 each with CS-PMN and SO-IDL. Results: Epidemiology and blood counts of leukodepletion patients were typical for AML patients with hyperleukocytosis. Aphereses were tolerated without complications with both systems. Blasts were depleted with a mean collection effi ciency (CE2) of ca. 50% with both systems. An inverse correlation between blast count and CE2 was noted. Platelet attrition was modest (30%), erythrocyte loss minimal. Leukodepletion outcomes did not diff er in any relevant manner between the two technologies. Volunteer granulocyte donors received a single dose of G-CSF to achieve a neutrophilia of 26/nL (mean) and were randomly assigned to apheresis with SO-IDL or CS-PMN. High molecular weight hydroxyl ethyl starch was used as sedimentation enhancer. The procedure was well tolerated. Apheresis processing of 6.5-7 L of blood yielded a dose of 1x10E10 granulocytes (one therapeutic dose as per German transfusion guidelines) in 69/70 donors, granulocyte dose/product by the two apheresis systems was indistinguishable (3.4 vs. 3 .6x10E10, mean for SO-IDL and CS-PMN, respectively); some minor, clinically likely irrelevant diff erences in apheresis outcomes were observed. Conclusion: Our data indicate the suitability of the IDL-based apheresis protocols "leukodepletion" and "PMN" for clinical usage.

Mesenchymal stromal cells protect from complement activation in graft-versus-host disease A. J. Innes, B. Uttenthal, S. Marley, A. Hall, M. Botto, M. Pickering, F. Dazzi Imperial College London (London, GB) Mesenchymal stromal cells (MSC) have shown promise as a therapeutic strategy in patients with severe refractory graft-versushost disease (GvHD) although their exact mechanism remains elusive. The role of complement activation in GvHD has previously been described, and recent in vitro data suggests that MSC may be capable of inhibiting complement activation by constitutively secreting complement inhibitors (such as factor H). Our aim was to investigate the eff ects of infused MSC on complement activation in patients receiving allogeneic MSC for steroidresistant GvHD. We investigated complement levels in 14 consecutive patients receiving allogeneic MSC for steroid-resistant acute (n=7) or chronic (n=7) GvHD. Serum C3, C4, factor H and factor I levels were measured immediately before and 30 minutes, 7 days and 28 days after the infusion. MSC were derived from third-party healthy donors and were expanded in human platelet lysate. Grading of GvHD was measured according to established Glucksberg and NCI criteria, and response was defi ned as a reduction by one grade or more of GvHD in at least 1 involved organ. All patients gave informed consent and the study was approved by the local ethics committee. Serum C3 and C4 levels 30 minutes after infusion of MSC remained unchanged (median C3 before infusion = 1.01 g/l, post infusion = 0.90 g/l, p=0.60; median C4 before infusion = 0.23 g/l, post-infusion = 0.24 g/l, p=0.89), suggesting no signifi cant complement activation. At day 7 following infusion both C3 and C4 levels had increased, to 1.24 g/l (p=0.07) and 0.28 g/l (p=0.03) respectively. This protection from complement activation was sustained until at least day 28, when C3 levels reached 1.26 g/l (p=0.007) and C4 0.27 g/l (p=0.03). In patients responding to MSCs (n=7) a significant rise in factor I levels was observed 30 minutes after infusion of MSCs (median rise of 16 units (p=0.04)) compared to a fall in non-responders (median fall of 47 units (p=0.09). This pattern persisted at day 7, although was less marked and did not achieve signifi cance. A similar pattern of rising levels in responders and falling in non-responders was observed in factor H, but this did not attain statistical signifi cance. Our data supports the notion that allogeneic MSC suppress complement activation by secreting complement inhibiting factors. Patients exhibiting such a profi le are more likely to respond to MSC. S87 been shown, little is known about the safety of DLI from such donors. Increasingly sensitive methods of minimal residual disease detection leading to earlier identifi cation of relapse and registry data suggesting that 16-40% of HSCT recipients subsequently require DLI makes the safety of DLI from HLA-mismatched donors is an increasingly pertinent question. To address this issue we retrospectively performed high resolution HLA typing (HLA-A, B, C, DR and DQ) on stored genomic DNA samples of 58 consecutive patients receiving DLI for the management of relapse or mixed chimerism at our institution between December 1995 and August 2010. All patients received unrelated donor transplants following uniform alemtuzumab-based myeloablative, conditioning for leukaemia (CML n=56, AML n=1, ALL n=2). DLI was administered using an established escalating-dose regimen. The primary endpoint was acute Graft-versus-Host Disease (GvHD) within 100 days of DLI. Secondary endpoints were incidence of chronic GvHD, probability of remission and overall survival (OS). Thirty patients were fully matched at all 10 loci (MUD), while mismatches (MMUD) were identifi ed in 28 patients (HLA-A n=3, HLA-B n=4, HLA-C n=15, HLA-DR n= 8, HLA-DQ n=12). Mismatches were present at 1, 2 or 3 loci in 18, 6 and 4 patients respectively. The groups were comparable with regard to baseline and transplant demographics. The rates of grade II-IV aGvHD following DLI were low and comparable in both groups (17.2% in MUD and 23.1% in MMUD, p=0.59) . Similarly we found no signifi cant diff erences in the incidence of cGvHD (34% in MUD vs 42% in MMUD, p=0.51), although there was a trend towards more severe cGvHD in the MMUD recipients (27% MMUD vs 10% MUD, p=0.09). The probability of remission at 3 years was similar in both groups (62.1% vs 63.9% in MUD and MMUD respectively, p=0.89), as was the 5 year OS (89.8% vs 77.7% in MUD and MMUD respectively (p=0.22) ). The only identifi ed predictor of inferior survival was time from HSCT to DLI of less than 9 months (3yr OS, 33.3% vs 93.3%, p<0.01). Our data suggests that escalating-dose DLI can safely be given to mismatched transplant recipients following alemtuzumab-based myeloablative allogeneic stem cell transplantation without a signifi cant impact on GvHD, disease response or OS.

High rate of false-positive CMV screening results in healthy donors: implications for adequate stem cell donor selection B. Eiz-Vesper, C. Sukdolak, L. Goudeva, W. Puppe, R. Blasczyk, H. Heuft Hannover Medical School (Hannover, DE) Herpesviruses such as cytomegalovirus (CMV) are common and associated with increased morbidity and mortality after hematopoietic stem cell transplantation (HSCT) . CMV serostatus of donor and recipient infl uence the risk of recurrent CMV reactivation post HSCT. For CMV screening of stem cell donors and recipients the Abbott Architect chemiluminescent microparticle CMV-IgG immunoassay (Abbott Diagnostic Division, London, UK) is used. To get more insight into the CMV-specifi c memory T-cell repertoire, we analyzed CMV-specifi c T-cell responses using an IFN-γ ELISpot assay in 204 healthy donors. According to the initial CMV screening, 143 (71%) of the enrolled donors were considered CMV-seropositive and 61 (29%) CMV-seronegative. None of the samples of CMV-seronegative donors yielded positive ELISpot results after short overnight stimulation; but also 19/143 seropositive samples were found not reacting to either pp65 or IE-1 peptides. To validate the ELISpot and exclude false-positive CMV screening results, we performed confi rmatory serology testing by Western Blot (WB; recomBlot CMV IgG/IgM). WB testing was prospectively performed at the time of the baseline T-cell assay and at 4 weeks and 3 months of follow-up. The 19/143 ELISpot nonresponders were also non-reactive in the WB indicating a 13% rate of false-positive screening results. Additional confi rmatory WB testing was done retrospectively using 191 look back samples with a positive CMV screening result from whole blood or apheresis donations between 2006 and 2010. All donors without CMV WB-confi rmation were reevaluated with follow-up samples from further donations. For 128/191 (67%) donors the initial CMV screening result was confi rmed, 7 were indeterminate, 11 remained unclear because of missing follow-up donations, and 45 (23.6%) were defi nitely CMV seronegative. Conventional CMV screening is associated with a signifi cant rate (13-23% depending on the confi rmation strategy) of false positive results. If the CMV status of a specifi c HSC donor is decisive for adequate donor selection, confi rmatory serological testing or evaluation of T-cell reactivity to virus-specifi c antigens is required.

The HistoCheck score for assessment of HLA-disparities does not predict clinical outcome of haematopoietic stem cell transplantation D. Fuerst (1) , C. Zollikofer (1) , C.H. Mueller (2) , H. Schrezenmeier (1) , J. Mytilineos (1) (1)University of Ulm (Ulm, DE) ; (2) ZKRD -Zentrales Knochenmarkspender-Register für Deutschland (Ulm, DE) Hematopoietic stem cell transplantation (HSCT) has been established as a potentially curative therapy for hematologic malignancies or non-malignant immunologic disorders. Matching for HLA class I and II alleles is an important criterion for outcome of HSCT, in particular regarding non-related allogeneic transplantation. For patients with rare HLA-haplotypes mismatched donors often need to be taken into consideration. The HistoCheck (HS) algorithm provides a scoring value for comparison of HLA-disparities. This score is based on structural and functional diff erences between two mismatched HLA alleles. We validated the prognostic signifi cance of this algorithm by assigning HS-scores to 800 patients with single HLA-mismatched donors (based on high resolution HLA-A,-B,-C,-DRB1,-DQB1 typing). Assigned score values showed a bipolar clustering and therefore the patients were grouped into those with low and high scores, separated by the median value for the entire cohort (11.98, range 1.03-35.77). Overall survival (OS), disease free survival (DFS), relapse incidence (RI), and treatment related mortality (TRM) were assessed using Kaplan-Meier analysis, competing risks regression and extended Cox regression models. For any mismatch (i) and in subanalyses for HLA-Class I (ii) or HLA-Class II (iii) mismatches only, univariate analysis showed no eff ect of HS on OS ((i) p=0.396, (ii) p=0.964, (iii) p=0.186), DFS ((i) p=0.502, (ii) p=0.926, (iii) p=0.218), TRM ((i) 30.9% vs. 27.5%, p=0.402, (ii) 32.1% vs. 28.6%, p=0.401, (iii) 27.6% vs. 14.7%, p=0.303), and RI ((i) 31.7% vs. 32.4%, p=0.553, (ii) 29.2% vs. 32.0%, p=0.420. (iii) 39.7% vs. 37.0%, p=0.660). Multivariate Analysis also did not reveal any signifi cant eff ect of HS assignment on OS ((i) CI 0.90-1.32, p=0.390, (ii) CI 0.82-1.25, p=0.931, (iii) 0.81-2.48, P=0.217), DFS ((i) CI 0. p=0.477, p=0.923, p=0.129) , TRM ((i) CI 0.66-1.14, p=0.310, (ii) CI 0. p=0.290, p=0.489) , and RI ((i) 0.91-1.30, p=0.340, (ii) CI 0.97-1.66, p=0.420, (iii) CI 0.67- 1.87, p=0.660) . No diff erences in engraftment rates were seen for transplantations with low or high HS values (p=0.115). Furthermore, consideration of the HS value as a continuous variable in multivariate analysis also did not have any impact on survival outcomes. We conclude that HS did not provide any clinically relevant prognostic value and therefore its use in the HSCT donor selection process is questionable. S89 was AML for 88 (35%) patients, ALL for 29 (11.5%) , MDS/MPS for 55 (22%), multiple myeloma for 32 (12.5%), and 47 patients (19%) had CML, CLL, HL and NHL. For conditioning, 120 (48%) received MAC and 131 (52%) received RIC. At transplantation, 140 patients (58%) were in CR, 111 (42%) were in less than CR; 121 (48%) patients received PBSC and 130 (52%) BM. Fourteen (5.5%) patients received HSCT from 10/10 unrelated donor had a mismatched DRB4 donor, 23 (9.5%) patients had a mismatched DRB3 donor and 214 (85%) had a fully matched unrelated donor (10/10) without DRB3 or DRB4 mismatched donor. We compared the outcome of the 37 patients with a DRB3 or DRB4 mismatch to the rest of the population. After a median follow-up of 60 months (range, , 241 patients (96%) engrafted. For the whole cohort, the cumulative incidence of aGvHD≥2 at 3 months was 15% (95%CI, 13-18) and the cumulative incidence of cGvHD at one year was 13% (95%CI, 10.5-16) . The median survival for patient without DRB3,4 mismatch was 18 months (95%CI, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) , for DRB3 mismatched patients 32 months (95%CI, 13-NR), and for DRB4 mismatched patients 7 months (95%CI, . The probability of survival at 24 months, without mismatch DRB3, 4 was 40% (95%CI, 31-51) , with DRB3 mismatch 51% (95%CI, 12-33) and with DRB4 mismatch 24% (95%CI, . The PFS and the TRM incidence at 24 months without DRB3,4 mismatch was 34% (95%CI, (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) and 22% (95%CI, respectively, with DRB3 mismatch 49 (95%CI, 30-78) and 13% (95%CI, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] respectively and with DRB4 mismatch 25 (95%CI, and 50% (95%CI , . (Figure ) . In univariate analysis, we found no impact of the DRB3 mismatch while the DRB4 mismatch have a negative impact on TRM (p=0.04) and on acute GvHD (p=0.085). The multivariate analysis showed no impact of the DRB3 mismatching on survival, GvHD, PFS and TRM but a signifi cant impact of DRB4 mismatching on survival (HR= 2.1 [95%CI, ], p=0.045), aGvHD (HR=2.66 (95%CI, 0.99-7.09) p=0.05) and on TRM (HR= 2.8; [95%CI, ] p= 0.024). In view of the important impact of DRB4 locus mismatch on clinical outcome, it seems to be important to be considered in the unrelated donor selection.

Donor characteristics as pre-transplant predictive factors of long-term outcomes after allogeneic peripheral blood stem cell transplantation from HLA-matched related and unrelated donors in patients with haematologic malignancies S. Servais, R. Porcher, A. Xhaard, M. Robin, E. Masson, J. Larghero, P. Ribaud, S. Abbes, N. Dhedin, G. Socie, R. Peff ault de Latour Saint-Louis Hospital (Paris, FR) Optimal strategy for donor selection is still controversial. We evaluated the impact of donor type vs. matched related (MRD)) and other donor traits on long term outcomes of patients with hematologic malignancies after peripheral blood stem cell transplantation (PBSCT). Methods: We analyzed outcome of 442 consecutive patients with hematologic malignancies who were treated with PBSCT either from MUD (n= 164) or MRD (n=278) from 01/2000 to 12/2010 at our center. Two-third of patients underwent PBSCT following reduced intensity conditioning. Antithymocyte globulin was used for 19% of patients. MUD and MRD PBSCT were balanced for patient age, disease risk and conditioning. Median donor age was 40 years. We assessed the impact of donor type, age, gender, CMV and ABO status on outcomes. As the upper age limit for voluntary stem cells donation was 60 years, we completed our analysis by performing 3 groups according to donor type and age (MUD, MRD<60y and MRD≥60y). Thirty-six patients were transplanted with MRD≥60y. Results: Median follow up was 36 months and 25% of patients had a follow up of at least 60 months. The cumulative incidence at 5 years (5y-CIf ) of chronic graft-versus-host disease (cGVHD) was 58%. In multivariate analysis, sex mismatch (female donor for male recipient) increased risk of cGVHD (hazard ratio (HR): 1.41, P=.02). The 5y-CIf of relapse was 34% and was higher with MRD than MUD (39% vs. 24%, P=.038). In multivariate analysis, only MRD≥60y resulted in signifi cant higher risk of relapse than MUD (HR: 2.46, P=.006) while MRD<60y had similar risk. The 5 year non relapse mortality (NRM) was 26%. MUD vs. MRD was associated with higher NRM (HR: 1.84, P=.005). The 5 year overall survival (OS) was 46% and was similar with MUD and MRD. MRD≥60y appeared to have notable low 5y-OS (6%, ±6%). In multivariate analysis, transplantation from MRD≥60y was associated with higher risk of late (≥18 months) mortality (HR: 4.36, P=.007) than MUD (Fig. 1) . Conclusion: Donor/recipient gender parity, donor type and age appeared as signifi cant predictive factors of long term outcomes after HLA-matched PBSCT. Female donor for male recipient was associated with higher risk of cGVHD. MUD provided higher NRM but better disease control and similar OS than MRD. We observed notable poor outcome for patients transplanted with MRD≥60y. One may thus question PBSCT with old MRD when a younger MUD is available.

High impact of matching score on diff erent HSCT outcomes after single and double umbilical cord blood transplantation for haematological malignancies M. Michallet (1) , M. Sobh (1) , S. Morisset (1) , H. Labussière (1) , V. Dubois (2) , J. Bourgeot (2) , M. Detrait (1) , S. Ducastelle (1) , F. Barraco (1) , Y. Chelghoum (1) , V. Milaou (3) , V. Chapelle (1) , S. Sar (1) , O. Hequet (4) , X. Thomas (1) , F. Nicolini (1) , Y. Bertrand (3) (1)Centre Hospitalier Lyon-Sud (Pierre Benite, FR) ; (2) 

We evaluated the impact of the diff erent matching variables in addition to cellularity and other disease and patient characteristics on single(s) and double (d) umbilical cord blood transplantation (UCBT) outcomes in pediatric and adult patients between 1998 and 2011. There were 53 adults (37 dUCBT and 16 sUCBT) with a median age of 36 years (18-64) and 48 children (3 dUCBT and 45 sUCBT) with a median age of 2 years (0-14) and a median follow-up of surviving patients of 24 months . The median number of pre-freezing and post-thawing cells was for 1) TNC: 3.3x10 7 /kg (1.9-5.1) and 2.6x10 7 (1.5-4.6) in adults; 1.6x10 7 (0.5-4) and 1.18x10 7 (0.5-3) in children; 2) CD34: 1.89x10 5 (0.57-4.2 ) and 1.55x10 5 (0.5-4.1) in adults; 4x10 5 (0. 6-19.3 ) and 2.8x10 5 (0.26-19) in children with a respective cells viability of 54% and 58%. We built a scoring scale that took into account the matching variables (sex, ABO and HLA) between UCB units and recipient and between UCB units each other in case of dUCBT. The median score was 3.8 (1) (2) (3) (4) (5) (6) (7) in adults and 3 (1) (2) (3) (4) (5) (6) in children; the detailed score calculation method will be communicated later. The multivariate analysis done separately in adults and children found a positive impact of infused CD34 ≥1.55x10 5 on neutrophiles recovery in adults [HR=2. 1 (1.16-3.8) , p=0.015] and infused CD34 ≥2.8x10 5 on neutrophiles and platelets recovery [HR=2. 5 (1.2-5) , p=0.007 and HR= 4.4 (1.6-11.6 ), p=0.002 respectively] in children; no signifi cant factor was observed on the cumulative incidence of acute GVHD≥ grade II. In addition, we showed a signifi cant negative impact of matching score > 3.8 on adults overall survival (OS) with a 3 years probability of 19% vs. 57% (38-84) for those with score ≤3.8 [HR=3.9 (1.5-9.8), p=0.003]. Similarly, score >3.8 had a signifi cant negative impact also on progression-free survival (PFS) only in adults with a 3 years probability of 13% vs. 21% for patients with a score p=0.04] . No signifi cant factor was found to infl uence transplant related mortality. In conclusion, cell dose remains a signifi cant impacting factor on short term transplantation outcome while the matching score appears to have a strong impact on adult long term outcomes mainly OS and PFS. These very promising results lead us to evaluate this score in larger number of patients for its validation and in order to include it in the UCB unit choice either in simple or double UCBT.

Bone marrow donor recruitment in students at Poitiers University: results of a survey and perspectives for development of bone marrow donation by young people L. Turcan (1) , J. Tourenne (1) , S. Rousseau (2) , E. Delannoy (3) , I. Jollet (4) , , F. Audat (5) , S. Thevenot (1) , C. Giraud (1) (1)University Hospital (Poitiers, FR) ; (2) Icomtec (Poitiers, FR) ; (3) Adot (Poitiers, FR) ; (4)Blood Center (Poitiers, FR) ; (5) Agence Biomedicine (Paris, FR) Aim: Young bone marrow donors are to be recruited for two main reasons: to promote allogenic bone marrow transplantation and to increase the number of potential donors; young donors are more likely than older donors to be signed up for a longer period of time. Method: In order to register a maximum number of young donors, University student groups decided to pool their eff orts with those provided by hospital and university institutions, donor and patient associations, and blood transfusion centers. A student developed a questionnaire designed to evaluate young people's perceptions of bone marrow donation and to educate them on the subject. To answer this questionnaire, 4000 fi rst-year students were recruited within diff erent University faculties. Analysis was carried out by an optical reading system. Following distribution of the questionnaire, fi ve students in communication techniques were tasked will developing strategies specifi cally targeting young people (cf.Facebook) Young donors were informed on the subject by the pharmacy and medical students associations now functioning in all the faculties of Poitiers University. The topic was: How and why could young people become bone marrow or blood stem cell donors? Results: Analysis of the 3561 returned and completed questionnaires showed that the participating students had only limited knowledge of bone marrow donation. All of them required more information on the conditions of bone marrow donation (47%) and its possible consequences for them (78%). Many of them confused bone marrow and spinal cord (46%), some knew nothing about donation procedures (25%), and a sizable number were not interested (26%). Only a limited proportion (21%) showed interest in the procedures and expressed willingness to become bone marrow donors. A written document will be elaborated as a response to the students' concerns. Medical and pharmacy students have been organizing presentation sessions in the diff erent faculties. Since these initiatives have been favorably welcomed, the students are planning to continue the sessions Additionally, the NCC, CD34 counts and CD34/NC ratio were compared between donors ≤16 years and >16 years of age. Median age was 14,3 y (1,5y-54 y). M/F:42/50. Median NCC and CD34 count were 0,22 x 10 8 /ml (0,09 x 10 8 /ml-0,72 x 10 8 /ml) and 0,34 x 10 6 /ml (0,03 x 106/ml-1,47 x 10 6 /ml) respectively. CD34/NC was median 1,43 (0,3-4,8) . A negative correlation was found between the donor age and NC count (r=-0,229, p<0,05) , CD34 count (r=-0,563, p<0,01) and 664, p<0, 01) . This negative correlation persisted in female donors with increasing age 356, p<0, 05) , CD34 count (r=-0,583, p<0,01), CD34/NC ratio (r=-0,645, p<0,01)] but for male donors the negative correlation was signifi cant only for CD34 count (r=-0,550, p<0,01) and CD34/ NC ratio (r=-0,670, p<0,01) . For the donors >16 y (n=29) and ≤16 y (n=63), the median NC count [0,17 x10 8 /ml (0,09 x10 8 /ml -0,72 x10 8 /ml)vs 0,23 x10 8 /ml (0,12 x10 8 /ml -0,51 x10 8 /ml); p<0,05)], CD34 count [0,14 x10 6 /ml (0,03 x10 6 /ml-1,01 x10 6 /ml) vs 0,40 x10 6 / ml (0,09 x10 6 /ml-1,46 x10 6 /ml);p<0,01] and CD34/NC [0,74(0, 34-4,19) vs 1,68(0,54-4,81) ; (p<0,01)] were signifi cantly lower in the older donor group. With increasing age, the NC and CD34 counts per ml of BM and CD34 cells per NC decrease signifi cantly. The age of the donor should be taken into consideration while planning the volume of the BM collection for the targeted CD34 count. This might prevent the unnecessary high volume collection from the younger donors, while higher volumes might be necessary from older donors.

The single nucleotide polymorphisms of SDF-1 and CXCR4 and the outcome of haematopoietic stem cells mobilization in healthy donors T. Wang (1) , L. Wu (2) , K. Yang (3) , S. Chen (1) , S. Yang (1) , S. Chu (1) , Y. Wu (1) , R. Kao (1) (

Introduction: Recently, mobilized peripheral blood stem cell (PBSC) had replaced bone marrow aspiration as the main source of hematopoietic stem cell transplantation (HSCT). Infusion of suffi cient stem cells is the most important factor for reconstruction of hematopoietic system next to HLA matching. Granulocyte colony-stimulating factor (G-CSF) is now the predominant mobilizing agent used for HSCT. However, the number of CD34+ stem cells mobilized in response to G-CSF varies signifi cantly. The aim of this study was focus on the impact of genetic variation in hematopoietic stem cell mobilization by G-CSF. We compared the single-nucleotide polymorphisms of SDF1 and CXCR4 in healthy volunteer stem cell donors. Materials and Methods: This study was nested within a longitudinal cohort of 976 healthy donors who had mobilized by G-CSF for allogeneic PBSC donation via Buddhist Tzu-Chi Stem Cell Center from September 2006 to the end of December 2010. The G-CSF was given subcutaneously on the basis of 10ug/kg per day for 5 consecutive days. The outcome of mobilization was defi ned as the circulating CD34+ cells in peripheral blood after 5 days infection of G-CSF. A retrospective review of clinical records of donors, including donor gender, age, body height/weight, blood tests and circulating CD34+ cells in peripheral blood post GCSF injection was performed. The allele frequencies of the SNPs for SDF-1 and CXCR4, were compared between donors had high and low circulating CD34+ cells in peripheral blood. Results: Totally, 134 pairs of good and poor mobilized donors were included from this longitudinal cohort. The good and poor mobilized donors were selected from the top and bottom 10% CD34+ cell counts in each groups stratifi ed by donor age, body weight and gender. The allele frequencies of 6 SNPs in SDF1 (rs754618, rs2839693, rs266085, rs2297630, rs1801157, rs1065297) and 2 SNPs in CXCR4 (rs16832740, rs12691874) were tested. None of these SNPs showed signifi cant diff erence in allele frequency between good and poor mobilized groups. Conclusion: We did not fi nd any signifi cant SNPs by comparing the allele frequencies of the SNPs of CXCR4 and SDF1 in paired good and poor mobilized HSC donors. There are still many candidate genes need to be investigated. Further study to clarify the mechanism of moblization would be necessary to improve the effi cacy of hematopoietic stem cell mobilization and outcome of transplantation.

Introduction: The Italian Bone Marrow Donor Registry (IBMDR) was established in Italy in 1989 with the role of providing an unrelated volunteer haemopoietic stem cell (HSC) donor for haematological patients waiting for a transplant. The HSC potential donors are adults, who meet the minimum eligibility criteria for peripheral blood donor, according to Italian low, HLA typed and listed in the IBMDR. Donors and Methods: Peripheral Stem Cell collections are performed in the Peripheral Collection Centers (CCs-P) that are are located within public hospitals, authorized to perform aphaeretic procedures. Donor receives G-CSF (not biosimilar G-CSF), subcutaneously, at a maximum of 10 μg/Kg donor body weight. The characteristics of the collected PBSC (unit identifi cation code, nucleated cells parameters, volume) are certifi ed by the CC-P with Form CP201-p that must accompany the PBSC bags, and qualifi ed with serological and NAT tests for communicable diseases, according to Italian low. Results: From1989 to 2011 a total of 2.686 Haemopoietic Stem Cell Donations has been performed: 2.039 Bone Marrow Donations, and 647 Peripheral Stem Cell Donation, that are authorized as a fi rst stem cell donation from 2005. HSC units are been donated respectivelly for Italian and non Italian patients on 60% and 40% of cases. We compared the compliance of the CCs-P to Transplant Center (TC) prescription of Peripheral Stem Cells: TC required units with an average of CD34 5,2+1,1 x10e6/Kg, corresponding to 377+115 x10e6 CD34 and CCs-P distributed HSC units with an average of CD34 7,3+4,9 x10e6/Kg, corresponding to 491+203 x10e6 CD34 (Table I) . TC required units with CD34 >5x10e6/kg for 33% of patients, obtaining more than 72% of units with CD34 >5 x10e6/Kg; 97% of units contained CD34 >3x10e6/Kg, as show in Table II . Conclusions: This study show a good performance of CCs-P of IBMDR and a good compliance with the CD34 prescripted by national and international TCs, collecting more CD34 than requested in 40% of donations.

Impact of ethnicity on umbilical cord blood banking and outcomes following transplantation: a systematic review C. Akyurekli (1) , J. Chan (1) , H. Elmoazzen (2) , J. Tay (1) , D. Allan (1) (1)University of Ottawa (Ottawa, CA); (2) Canadian Blood Services (Ottawa, CA) Background: Umbilical cord blood (UCB) is used increasingly as a source of hematopoietic stem cells for transplantation to address shortages in matched donors, particularly in patients of non-Caucasian ethnicity. The role of ethnicity, however, on characteristics of units collected by cord blood banks and the impact of ethnicity on outcomes following transplantation remain unclear. Methods: A systematic search of published literature was performed using electronic databases (MEDLINE, EMBASE) . Studies that considered donor and/or patient ethnicity and included data concerning transplant outcomes or characteristics of collected UCB units were included. Results: A total of 403 published articles were identifi ed in our literature search of electronic databases and from experts' fi les. After removing duplicates, screening for relevance and reviewing in detail with regards to inclusion and exclusion criteria, a total of 21 studies underwent comprehensive review and data extraction. 11 studies addressed the impact of ethnicity on characteristics of collected units. Non-Caucasian ethnicity (African American, Asian, or non-Caucasian compared with Caucasian) was associated with a higher risk of rejecting the collected unit (4/4 studies), reduced total volume (3/9 studies), lower total nucleated cell count (5/9 studies), fewer CD34+ cells (4/9 studies) , and reduced colonyforming units (3/9 studies). Metanalysis was not possible due to lack of raw data reported in the studies. 9 studies reported worse outcome following transplant for non-Caucasian patients compared with Caucasians with respect to time to platelet engraftment (3/7 studies) , graft versus host disease (1/6 studies), overall survival (3/8 studies) and disease-free survival (1/4 studies) . The degree of HLA-matching, total nucleated cells infused, time to neutrophil engraftment and rates of relapse were not diff erent in any of the studies reporting on these outcomes. 1 of 3 studies that addressed the impact of mismatched donor/recipient ethnicity reported reduced overall survival for non-matched transplants. Conclusions: Non-Caucasian ethnicity may be associated with reductions in quality indicators of collected cord blood units. Transplant outcomes in patients of non-Caucasian ethnicity may be associated with delayed platelet engraftment and reduced overall survival. More research is needed to understand and optimize cord blood banking and transplantation to improve outcomes for non-Caucasians.

Allogeneic stem cell transplantation from unrelatedmismatched/familial-mismatched donors, which would be better? X.W. Liao (1) , C.T. Lin (1) , M. Yao (2) , C.C. Li (1) , B.S. Ko (2) , M.Y. Lu (2) , K.H. Lin (2) , S.T. Jou (2) , S.J. Wu (2) , D.T. Lin (2) , Y.L. Yang (2) , S.Y. Huang (2) , H.A. Hou (2) , J.H. Liu (1) , J.L. Tang (1) (1) National Taiwan University (Taipei, TW); (2) National Taiwan University Hospital (Taipei, TW) Objective: Allogeneic stem cell transplantation (Allo-HSCT) has been used to treat malignancies and immune and hematologic diseases for more than 50 years. According to a report by Buddhist Tzu Chi Stem Cells Center suggests that, only 25% of patients were able to fi nd an HLA-identical sibling as donors, while less than 50% of patients were able to fi nd an HLA -matched unrelated donor. For those patients who did not have matched donors, the question remains whether a partially matched unrelated donor or a familial mismatched/haplo-identical donor would be a better option. Methods: 151 patients who received Allo-HSCT between 1987 and October 2012 were analyzed, with 80 undergoing HLA≤3 mismatched unrelated donor transplantation (HLA≤3 UDT), 51 receiving HLA≤3 mismatched related donor transplantation (HLA≤3 RDT), and 20 having HLA>3 mismatched related donor transplantation (HLA>3 RDT). Time-to-event was assessed starting on the day of transplantation, and overall survival (OS) rates, cumulative incidences of relapse rates and treatment related mortality (TRM) rates for the 3 groups were compared. Results: Table 1 shows the patient demographics, indicating a strong similarity between the 3 groups in terms of age, gender, disease and pre-HSCT disease status, with the exception of a higher proportion of peripheral blood stem cell and ABO mismatch in the HLA≤3 UDT group. The 5-year OS rate after HL≤3 UDT was 53.9%, followed by 23.6% after HLA≤3 RDT and 13% after HLA>3 RDT (Fig 1) , showing a signifi cant diff erence (P=0.009). Comparison of cumulative incidence of relapse rates between the 3 groups indicated that the number for patients with HLA≤3 RDT was 74.1%, signifi cantly higher than those for HLA>3 RDT (69%) and HLA≤3 UDT (37.2%)(P=0.045). The TRM rates after HLA≤3 UDT, HLA≤ 3 RDT and HLA>3 RDT were 20.3%, 49% and 62%, respectively. Conclusions: Our study fi nds a relatively higher 5-year overall survival rate (53.9%) and a lower relapse rate after HLA≤3 UDT, signifi cantly better than the patients after HLA mismatched related donor transplantation. This could become a clinical reference for physicians when they choose donors for patients who have no suitable candidates.

Introduction: Since 2005, we used a reduced conditioning regimen associating fl udarabine, intravenous (iv) busulfan and anti-thymocyte globulin (ATG) before allogeneic stem cell transplantation to treat hematological malignancies. We report here the comparison of patients consecutively grafted with an unrelated or related donor after FBA RIC. Patients and methods: From July 2005 to December 2010, 109 patients with hematological malignancies were allografted using FBA RIC: for 51, stem cells from an unrelated donor stem cells (alloUD) were used while 58 patients received a HLA sibling (allo-SIB). FBA consisted of fl udarabine (30 mg/m2 5 days), iv busulfan (3.2 mg/kg 2 days), and intermediate dose of ATG (2.5 mg/kg 2 days). Peripheral blood stem cells were used in all but 4 patients, receiving marrow stem cells (alloUD group). Cyclosporine alone was used as GVHD prophylaxis. The two cohorts received an identical supportive care. Results: Patient characteristics were not statistically diff erent ( Table 1 ). The median follow-up of alive patients was 43 months S98 (range 19-76) . For alloUD and alloSIB grade 2-4 aGVHD incidence was 17% (CI 7-28) and 27% and cGVHD incidence was 39% (CI 25-53) and 28% , respectively (p= ns). For the whole population (n= 109), the 4-year PFS, OS and relapse incidence were 40%, 52%, and 47%; 1-year and 4-year non relapse mortality (NRM) were 12% and 20%, without signifi cantly differences between the 2 groups. Infectious complications were reported in Table 2 . Results were similar, except for bacterial infections, CMV infections and multiple reactivations which seemed more frequent in alloUD cohort. Conclusions: This retrospective study comparing unrelated to HLA identical sibling after a homogenous ATG-based RIC showed that acute and chronic GVHD incidence as well as PFS, OS, RR, and NRM were not diff erent. Infectious complications, mainly bacterial and viral, were more frequent after alloUD. Based on patient characteristics, this RIC regimen including "middle" doses of ATG, achieved a good balance between effi cacy and tolerance, and can be used as common platform before allogeneic transplantation from different kind of donors.

Does the 18 month survival rate following a haploidentical bone marrow transplant diff er from the 18 month survival rate following a mismatched unrelated donor transplant? O Fasan, T. Klumpp, R. Patel, P. Kropf, M. Martin, J. Ulicny, K. Mangan, M. Sharma Temple University (Philadelphia, US) Background: Allogeneic hematopoietic stem cell transplantation remains a curative option for adult patients with hematologic malignancies. About 30% of patients will have matched sibling donors. For the remainder of patients an unrelated donor will be found for 50% of Caucasians and for ethnic minorities the chances are much less. Alternative donor transplantation using related haploidentical donors and cord blood is an option for patients without a sibling or unrelated donor. Cord blood transplantation is not widely accessible and is resource intensive making haploidentical transplants the logical alternative donor source. However there are concerns about the survival following a haploidentical transplant. Goal: To compare the published 18 month survival following a myeloablative conditioned (MAC) haploidentical transplantation to the 18 month survival of mismatched unrelated donor transplants at our center. Subjects and methods: We retrospectively analyzed data on consecutive matched unrelated donor transplants for which we had molecular typing results at HLA -A, B, C, DRB1 and DQ. Subjects had a 10/10 or 9/10 unrelated donor and were undergoing their fi rst transplant. The data was extracted from our in house developed quality management database and analyzed using SAS software. Results: One hundred twenty two (122) patients met our inclusion criteria, including 77 males and 45 females. The median age on day of transplant was 50.5 years. The diagnoses were: ALL = 22, AML = 50, CLL = 7, CML = 13, MDS = 8, NHL = 10, others = 12. Ninety two patients had a 10/10 allele match and 30 patients had a 9/10 allele match. Forty eight percent received MAC regimens and 52% received RIC regimens. The 18 month OS for the 9/10 matched transplant was 43% and the published actuarial 18 month OS for MAC haploidentical bone marrow transplant is 62% (Railoa et al, BBMT, Article in Press) (p = 0.174). Survival for 10/10 matched transplant was 46% not signifi cantly diff erent from 9/10 matched transplants (p = 0.687). Conclusions: The 18 month OS for MAC haploidentical bone marrow transplant is not inferior to the 18 month OS for mismatched unrelated donor transplants at our center. We will be adopting MAC haploidentical bone marrow transplant as an option for our patients.

DRB1*11 alleles distribution in the Croatian population and implications for donor matching in haematopoietic stem cell transplantation Z. Grubic, K. Stingl, R. Serventi-Seiwerth, M. Mikulic, B. Labar, R. Zunec Clinical Hospital Centre Zagreb (Zagreb, HR) Hematopoietic stem cell transplantation (HSCT) has been established as a method of therapy for hematologic malignancies and other hematologic or immune disorders. Donor selection has been almost exclusively based on selecting a human leukocyte antigen (HLA) identical donor. The diff erences among populations arising from the HLA polymorphism also play a role and should be considered in establishing the matched unrelated donor (MUD) search protocol. The aim of this study was to address this question with respect to the Croatian population. In the period 2009-2012 (July), a successful search for MUD/CBU in the Bone Marrow Donors Worldwide (BMDW) was performed at our centre for 105 patients for whom a matched donor could not be previously found among family members. The donor was an unrelated individual in 103 cases, while for the remaining two patients CBU was chosen as a source of HSCT, double CBU transplantation in one case. The HLA typing criteria in our transplantation centre is high resolution typing for HLA-A, -B, -C, -DRB1 and -DQB1 loci. However, the 10/10 matching level was not achieved for 67 patients. For thirty-one patient 9/10 matched donor was found and for fi ve patients 8/10 donor was found. The highest number of mismatches was found at the HLA-C and -DRB1 loci (14 patients each). However, the most interesting fi nding regarding HLA matching was observed among our patients positive for the HLA-DRB1*11 gene. Namely, patients with HLA-DRB1*11:04 allele were more diffi cult to match than those with HLA-DRB1*11:01 allele. This was the case for fi ve patients in the group of patients mismatched for one DRB1 allele (N=13), and one patient who received an 8/10 matched transplant and in addition to uncommon DRB1 allele (DRB1*11:28) also had the HLA-DRB1*11:04 allele. All those patients ultimately received a DRB1*11:01 positive transplant. The explanation for this fi nding lies in the almost equal frequency of DRB1*11:01 (7.9%) and DRB1*11:04 (7.7%) alleles among Croats as opposed to the predominance of DRB1*11:01 in registries with largest representation in BMDW. In conclusion, this study revealed some specifi c characteristics of the Croatian population which should be taken into account while performing the donor search. The fi nding regarding the HLA-DRB1*11 alleles is an important example of how the diff erences in allele distribution between Croats and populations with potential donors can infl uence the search outcome.

It is generally accepted that HLA-C mismatched (mm) donors should be avoided for allogeneic HSCT. In the present retrospective study we analysed 382 patients undergoing HSCT between 1995 and 2011. Of these 115 patients received an HLA-C mm HSCT and 266 received an HLA-C matched graft. Only patients with malignant disease were included in the analysis with no signifi cant diff erences between patients with HLA-C matched or mm donors. Median age was 42 (<1-68) versus 41 (<1-65) years in the matched and mm groups respectively. Early/late disease was 119/147 and 51/64, respectively (ns). Reduced intensity conditioning was given to 100 patients (38%) among HLA-C matched patients compared to 42 (37%) in the HLA-C mm group. Myeloablative conditioning was similar in both groups. Female donor to male recipient was given to 20 (8%) in the matched group versus 19 (17%) in the mm group. Bone marrow was used as stem cell source in 74 (28%) patients in the HLA-C matched group compared to 45 (39%) in the mm group (ns). The remaining patients received PBSC in each group. Median CD34 cell dose (x106/kg) was 7.2 (0. 2-56.4) versus 7.1 (0.3-28.7) , respectively. GVHD prophylaxis consisted of CsA + MTX in 84% versus 85% of the patients in each group. ATG was given to all patients before HSCT. An HLA-C mm between donor and recipient has previously been associated with an increased risk of graft failure (GF). In the present material GF occurred in 9 (3.4%) in HLA-C matched group compared to 7 (6.1%) in the mm group (ns). In multivariate analysis for GF, major AB0 mismatch (p=0.03), RIC (p=0.01) and female donor to male recipient (p=0.002) were signifi cant risk factors. HLA-C mm was not found to be signifi cant (p=0.71). Neither had HLA-C mm any impact on mortality. Signifi cant factors associated to mortality in multivariate analysis were: disease stage (p<0.001), year of HSCT (p=0.015) and donor age (p<0.001). For acute GVHD grades II-IV CsA+MTX (p<0.001) and RIC (p<0.001) decreased the risk whereas the use of PBSC (p=0.016) increased the risk. HLA-C matched patients compared to HLA-C mm showed no statistical diff erence regarding TRM, RFS, mortality, acute GVHD grades II-IV and relapse incidence. In conclusion, in the present study we fi nd no negative impact of HLA-C mismatch on outcome after HSCT. The use of ATG in the conditioning could be one important explanation for this diff ering

S100 data compared to other centers. According to this our center will continue to use HLA-C mm donors.

The impact of high resolution hla and Kir-ligand mismatches on clinical outcome in unrelated cord blood transplantation L.E. Creary (1) , C.J. BRown (2) , S. Davey (2) , G. Miqueles (2) , I. Ionescu (3) , A. Ruggeri (4) , E. Gluckman (4) , V. Rocha (5) , C. navarrete (6) (1)NHS Blood and Transplant/UCL (London, GB) ; (2) NHS Blood and Transplant (London, GB) ; (3) Agence de la Biomedicine/Eurocord Registry (Saint-Denis La Plaine/Paris, FR); (4) Eurocord Registry (Paris, FR) ; (5) NHS Cord Blood Bank, NHS Blood and Transplant/University of Oxford (London/Oxford, GB) ; (6) NHS Cord Blood Bank, NHS Blood and Transplant/UCL (London, GB) Background: HLA incompatibility between patients and donors is one of the most important factors infl uencing the outcome of haematopoietic stem cell transplantation (HSCT). Although a less stringent level of HLA matching is acceptable in umbilical cord blood transplantation (UCBT), when compared to bone marrow, data on the HLA loci and the degree of resolution tolerated for good outcome is limited. Alloreactive donor derived natural killer (NK) cells, regulated in part by KIR genes, have also been shown to infl uence UCBT outcome. Our aim was to examine the eff ect of high-resolution (HR) HLA and donor KIR-patient HLA ligand mismatches (MM), and other prognostics factors on the clinical outcome of 86 patients transplanted with unrelated single cord blood units (CBUs) issued from the NHS Cord Blood Bank (NHS-CBB). Methods: Patients (n=86) of whom 61 were aged <15 yrs and with various clinical conditions including 47 patients with acute leukaemia were studied. Twenty-nine patients had received TBI with or without cyclophosphamide plus other drugs. DNA from patients and CBUs was whole genome amplifi ed when required and retrospectively sequenced at HR for HLA-A,-B,-C,-DRB1, and -DQB1 loci. Samples were also genotyped by PCR-SSOP/Luminex for the presence or absence of 16 KIR genes. Clinical outcome data was provided by the Eurocord registry and the NHS-CBB. Results: HR typing revealed additional HLA MMs previously not observed by low-resolution (LR) typing methods. Univariate analyses showed that both LR and HR MM in HLA-DRB1, and LR MM in the DQB1 loci were signifi cantly associated with increased risk of mortality (RR 2.3, 95% CI 1.1-5.0, P=0.042; RR 3.2, 95% CI 1.5-6.6, P=0.002 and RR 2.4, 95% CI 1.2-5.1, P=0.021 respectively). A single MM at the HLA-A gene typed at LR was associated with decreased rate of neutrophil engraftment (RR 0.6, 95% CI 0.4-1.0, P=0.05). We found no signifi cant associations between any HLA single gene MM with acute GvHD II-IV, TRM, and relapse. Donor iKIR 2DL1 and patient ligand HLA-C2 MM were signifi cantly associated with acute GvHD II-IV (RR 3.5, 95% CI 1. 6-7.7, P=0 .006) and relapse (RR 0.03, 95% CI 0.0-13.4, P=0.020) Conclusions: Our data suggests that matching patients and CBUs at LR for HLA-A,-B and HR -DRB1 loci appears to be adequate for successful UCBT outcome but additional MM for donor iKIR gene-patient HLA ligand should be considered. A larger series of recipients and donors of UCBT will need to be studied to draw defi nitive conclusions.

The impact of HLA-DPB1 matching in unrelated donor haematopoietic stem cell transplantation: a single centre study R. Beattie (1) , R. Sergeant (1) , A. Innes (2) , J. Apperley (2) , R. Szydlo (2) , K. Rezvani (2) (1)Imperial College Healthcare NHS Trust, Hammersmith Hospital (London, GB) ; (2)Imperial College London (London, GB) Unrelated donor (URD) haematopoietic stem cell transplantation (HSCT) is a curative therapy for a variety of haematological disorders. It is well established that allelic HLA matching between recipient and donor at HLA-A, -B, -C and -DR improves success of URD HSCT. The role of HLA-DPB1 disparity is not well defi ned, with matching not currently performed at our centre. We examined the impact of HLA-DPB1 matching on overall survival (OS) and development of Graft-Versus-Host Disease (GvHD). Allelic HLA typing was performed retrospectively on stored DNA from 114 recipients and their donors who underwent URD HSCT following myeloablative conditioning. 89 (78%) of donor and recipient pairs were mismatched at HLA-DPB1, with 18 mismatched at both alleles. Of the 89 HLA-DPB1 mismatched recipients, 49 (55%) were matched at all other loci, while additional mismatches were identifi ed at class I (n=20; 22%), class II (n=8; 9%) or both class I and II (n=12; 13%). Of the 25 recipients matched at HLA-DPB1, 11 (44%) were fully matched at all loci, while additional mismatches were identifi ed at class I (n=5; 20%), class II (n=5; 20%) or both class I and II (n=4; 16%). Recipients were stratifi ed according to the presence or absence of an HLA-DPB1 mismatch and outcomes (GvHD and OS) examined. Recipients mismatched at HLA-DPB1 had superior survival at fi ve years (74.8% vs. 56.8%; p=0.023) than recipients who were matched at HLA-DPB1 but mismatched at other loci or 12/12 matched recipients (fi gure 1). In contrast, incidence of grade II-IV acute GvHD was not signifi cantly diff erent between the two groups (45% vs. 48% in matched and mismatched respectively, p=0.77). The median time to onset of acute GvHD was 27. 5 (range 8-74) and 20 (range 11-122) days respectively. Similarly, there was no signifi cant diff erence in rates of chronic GVHD between HLA-DPB1 matched and mismatched recipients (61% in matched vs. 50% in mismatched, p=0.37, median time to onset 256 days and 212 days respectively). As linkage disequilibrium does not extend to HLA-DPB1, it was considered possible to assess HLA-DPB1 matching as an independent risk factor. The inferior survival of patients matched at HLA-DPB1 supports the current approach which does not restrict donor selection based on this locus. Furthermore it raises important questions about the loci's role in the Graft-Versus-Leukaemia eff ect, given the superior survival of mismatched recipients without evidence of increased acute or chronic GvHD. S101 at St.Bartholomew's Hospital, London. A clinical audit was performed on adult patients removed from the list without having received an allograft to analyse the HLA testing performed during the process of donor identifi cation. Methods: 166 testing episodes from 156 patients removed from the list without having received an allograft between the years 2009-2011 who had received HLA testing for either siblings, volunteer unrelated donor (VUD) search or both were analysed by year, ethnicity and diagnosis. 10 patients were present more than once due to discrete testing episodes for sibling/VUD workup. Results : 64.5% of the patients were male and 35.5% female (107/59). Median age was 46.5 years (range 18. 1-69.8 ). The main ethnic groups were N.European Caucasoid 74.7% (124), Asian 9.6% (16) and Black 9% (15) . The most frequent diagnoses were AML 27.7% (46), NHL 12% (20) and myeloma 10.2% (17) . Median number of days on the list was 109. 5 (range 8-847) . 24.1% of patients (40) had an HLA-matched sibling, with a median of 28.5 days to identify (range 0-106). 47.6% (79) patients were considered for VUD allograft for which 76% (59) had an HLA-matched donor identifi ed. 24.7% (41) patients were removed from the list because a donor was not identifi ed in suffi cient time. A total of 244 siblings and 236 VUD were tested. 11 patients with a donor identifi ed (11.3%) received an allogeneic transplant at a later date, of which 9 were with the donor identifi ed at the time; 2 patients used a diff erent donor identifi ed at a later date. Conclusion: Substantial HLA testing was performed for this patient cohort, of which only a small proportion eventually received an allograft. In the current fi nancial climate, this audit will help identify for which patients, if any, it may be possible to postpone donor testing -specifi cally the more expensive VUDs -until dates when the patient is clinically closer to allogeneic transplantation. Any fi nancial saving must be balanced against the need for adequate time to identify a donor. This audit will be extended to analyse patients who received an allograft over the same time period to assess any diff erences present in time taken to identify a donor.

A rare but severe complication of G-CSF in healthy donor; splenic rupture G. Akyol, C. Pala, A. Yildirim, K. Demir, S. Dortdudak, L. Kaynar, A. Unal, M. Cetin Erciyes University (Kayseri, TR) Granulocyte-colony stimulating factor (G-CSF) is widely administered to donors who provide peripheral blood stem cells (PBSC) for individuals who undergo hematopoietic stem cell transplants. G-CSF administration is associated with a small but defi nite risks of serious adverse events like splenic rupture. The donor, healthy individual with a body weight of 66 kg and height of 149 cm, had no remarkable previous history except a 10 year history of smoking (10 cigarettes/day) and any physical examination abnormality. Her complete blood count, biochemistry and chest x-ray were normal. Serologic tests for hepatitis B, C and HIV were all negative. We started G-CSF (fi lgrastim) therapy at a dose of 11μ/kg/day (twice daily administration) for 5 days. At forth day of mobilisation after 2 hours later of administration of G-CSF at 06 PM, she suff ered from a pain at chest bones. EKG fi ndings were normal. At 10:30 PM her pain began severe sharp and radiating to all abdominal regions. On physical assessment, she had left upper tenderness and rigidity. Tachycardia (110/min) and tachypnea (30/min) was present while signifi cant hypotension was not measured. An abdominal computed tomography (CT) scan showed splenic rupture and perisplenic fl uid. Contrast-enhanced CT scan of the upper abdomen reveals irregular intrasplenic low-attenuation areas (arrows) consistent with ruptured spleen and perisplenic high density fl uid (asterix) compatible with blood (50 HU). HU: Hounsfi eld unit ( Figure 1 ). There was no sudden decrease in hematocrit and haemoglobin (Hgb) levels according to the blood count, so that at fi rst, splenectomy was not planned and she was followed up closely. We could not collect stem cell from our donor as expected risk of extra bleeding with citrate usage during aferesis and she refused collecting stem cell from bone marrow. When a Hgb decrease of 2 gr/dl and hematocrit decrased of 28.4% aschieved, we replaced one unit of eritrosit suspension. We should take care of splenic rupture in patients, previously administrated G-CSF and suff er from sharp and sudden abdominal pain.

has been approved by the European Medicines Agency for autologous and allogeneic PBSC mobilization. However, this authorization was based on comparable safety and effi cacy to the reference fi lgastrim, (Neupogen ®, Amgen) in the management of chemotherapy-induced neutropenia, with no data available regarding PBPC mobilization in healthy donors. We present our experience with 9 HLA-identical sibling donors mobilized with Bio-fi lgastrim that were compared with the previous 9 donors mobilized with fi lgastrim. Both drugs were given at a dose of 5μg/kg/day for 4 or 5 days with the fi rst apheresis performed on day 5. The target CD34+ cell dose was 5 x 10 6 /kg recipient body weight. Donor median age was 48 years (range 17 -77) . Median duration of G-CSF treatment was 5 days (5) (6) and the median number of apheresis was 1 (1) (2) in both groups. Side eff ects included mild bone/muscle pain all patients with no diff erences between the 2 groups. No immediate serious adverse eff ects were detected in either group. Bio-fi lgastrim seemed to have been well tolerated with no long-term adverse events reported. There were no signifi cant diff erences in mobilization outcomes between groups receiving the biosimilar or reference fi lgastrim. The median number of circulating CD34+ cells at day 5 was 70.2 x 10 9 /L (24-114) and 86.3 x 10 9 /L (42. 3-146.4) respectively. No mobilization failure was observed in either group. The median number of CD34+ cells/kg harvested was 7.2 x 10 6 (4-9.2) and 9.0 x 10 6 (6-14.3) respectively (p=0.12). So far seven patients have undergone allogeneic SCT with PBPC mobilized with bio-fi lgastrim with no signifi cant side-eff ects during the infusion. All patients engrafted at a median of 23 days (18 -28) for the bio-fi lgastrim group compared with 19 days (12-28) for the reference fi lgastrim group (p=0.11). Platelets engraftment occurred at 25 and 24 days respectively.

Our fi ndings suggest that Zarzio ® is well tolerated and safe as compared with Neupogen ® for PBPC mobilization of HLA-Identical siblings before allogeneic SCT. Given the similar eff ectiveness and their reduced costs, G-CSF biosimilars may represent a costeff ective alternative for PBPC mobilization. However, further studies are required to assess longer-term safety of G-CSF biosimilars.

N. Bazuaye (1) , B. Nwogoh (2) , K. Atoe (2) (1)University of Benin Teaching Hospital (Benin, NG) ; (2) UBTH (Benin, NG) Objective: The fi rst Hematopoetic stem cell transplantation in Nigeria was performed in September 2011. There are documented several Challenges in HSCT in developing centres like Nigeria. Blood donation is mainly commercial and medical students were encouraged to voluntarily donate blood components. This study is to assess the suitability of these voluntary donors. Method: A total of 67 students were randomly selected and samples assessed for full blood count(autoanalyser), Hepatitis B and C(rapid kit), Syphilis(rapid kit), HIV 1 and 11(rapid kit), Blood Group, Hemaglobin Genotype and Cytomegalovirus(rapid kit IgG). Results: 94% were age range 19-30 years, 2.6% Jehovah's Witnesses, 13.2% and 22.4% do not know their blood group and Hb genotype respectively. 67% have never donated blood and 5.3% are not aware of HSCT. Only 53.9% are willing to donate stem cells of which 12.5% want to be paid to donate stem cells. 26.3% have Hb genotype AS, 62% Blood Group O and 6% Rhesus Negative. 95.5% are CMV (IgG) positive, HbsAs 1.3% positive and 100% HCV negative.4(6%) was HIV 1 and 11 positive and 100% negative for Syphilis.Total mean White cells was 5500/ul ±1.3(range 3700-9100/ul),Mean Hb of 13.2g/dl ± 1.7 (range 9.6 -16.9g/dl with 38.8% < 12.5g/dl),Mean Platelet count 285000/ul ±76.8(range 108000 -528000/ul with 7.5<200,000/ul). Conclusions: There is a very high prevalence of exposure to CMV, and a rather high prevalence of HIV that will require ELISA confi rmation of all blood used for HSCT.There is signifi cant donors that may not be fi t to donate red cell concentrate and these fi ndings may be worse for commercial donors.

Allogeneic and autologous haematopoietic peripheral blood stem cell collection: 11 years' experience R. Grubovic (1) , B. Georgievski (2) , R. Dukovski (1) , L. Cevreska (2) , A. Hristova-Dimceva (1) , S. Genadieva-Stavric (2) , S. Useini (1) , Z. Stojanoski (2) , A. Pivkova (2) , M. Grubovic (1) (1)Institute for Transfusion Medicine of RM (Skopje, MK); (2) University Hematology Hospital (Skopje, MK) Properly mobilized and harvested hematopoietic peripheral blood stem cells from (PBSC) at the appropriate time before stem cell transplantation (SCT) is prerequisite for a successful transplantation. Mobilized PBSC have become the preferred cell source for 99% autologous and 75% of allogeneic hematopoietic SCT. The aim of this study is to present our experience in apheresis of autologous and allogeneic PBSC in hematological patients and healthy donors in the last 11 years. Material and Method: This is a retrospective study performed in the Institute for Transfusion Medicine of Republic of Macedonia and University Hematology Hospital between 2001 and 2012 in patients and healthy donors. PBSC harvesting was performed with continuous flow cell separator Baxter C53000 and COBE Spectra using conventional-volume apheresis processing. Mobilization regimens included granulocyte colony-stimulating factor (G-CSF) alone in healthy donors, and G-CSF alone or combination of G-CSF and disease-specific chemotherapy in patients. Minimum dose required to ensure successful and sustained engraftment was 2x10 6 /kg CD34+ cells and 2x10 8 /kg mono-nucleated cells (MNC) . Results: There were 403 apheresis procedures in total, of which 317 performed (78.7%) in 141 hematologic patients (88 S103 males and 53 females, aged 18-63), and 86 procedures (21.3%) in 50 healthy sibling donors (32 males and 18 females, aged 20-54). Sufficient number of PBSC was collected with 2.2 apheresis in patients (range [1] [2] [3] [4] [5] , and 1.72 apheresis in donors (range [1] [2] [3] . The single procedure usually took 3-4 hours and the volume of collected stem cells was 50-220 ml. The tolerance of apheresis procedure in our patients and donors was good. The only adverse effects of the apheresis procedure were bone pain as reaction of G-CSF and numbness of the extremities as reaction of anticoagulant (hypocalcemia), which occur rarely and were very mild. The main indications for autologous SCT in our patients were: acute myeloid leukemia (28.4%), multiple myeloma (26.2%), Hodgkin disease (21.2%), non-Hodgkin lymphoma (12.7%) and acute lymphoblastic leukemia (7.8%); and acute myeloid leukemia (60%), acute lymphoblastic leukemia (14%) and chronic myeloid leukemia (7%) in allogeneic SCT. Conclusion: Autologous collection and transplantations of PBSC makes nearly 80% versus allogeneic (20%). All allogeneic donations are done by sibling donors. We should work on developing unrelated donation, National Stem Cell Donors Registry and become a part of Bone Marrow Donors Worldwide.

T-cell analysis via next-generation sequencing before allogeneic stem cell transplantation: a closer look at fi ngerprints J. Ritter (1) , V. Seitz (1) , A. Seegebarth (1) , R. Gary (2) , M. Wurdack (2) , S. Moi (2) , A. Mackensen (2) , S. Hennig (3) , A. Gerbitz (2) , M. Hummel (1) (

T-cells recognise antigenic peptides presented by class I and II molecules of major histocompatibility complex (MHC) via their specifi c T-cell receptors (TCRs). The enormous diversity of TCRs is in large part determined by the sequence in their hypervariable complementarity-determining region 3 (CDR3) which is generated by somatic recombination of the Variable (V), Diversity (D), and Joining (J) segments of the TCR-β gene and by insertion of random non-template bases at recombination junctions. Each single CDR3 region is unique and can be referred as the fi ngerprint of a T-cell. To determine the entire diversity of T-cells in the course of allogeneic hematopoietic stem cell transplantation (aHSCT) based on their unique TCR-β rearrangements, we utilized a multiplex TCR-β PCR-assay in combination with next generation sequencing (NGS, Illumina HiSeq 2000) . For this purpose, we isolated DNA from 60 samples of sorted CD4-and CD8-positive T-cell preparations derived from peripheral blood of donors before and after G-CSF mobilisation. Our TCR-β NGS-PCR revealed approximately 2 million sequence reads per sample which were intensively analysed by newly developed bioinformatics tools. After their alignment to germline segments (IMGT), we found a very similar Vβ-and Jβ-segment usage in CD4-and CD8-positive T-cells which was not signifi cantly aff ected by G-CSF administration. Despite this similar segment usage, two signifi cant and consistent diff erences between CD4and CD8-positive T-cells were detectable: (i) the CDR3 diversity is more restricted in the CD8-positive T-cells and (ii) the dominance of certain T-cell populations is much more prominent in the CD8positive T-cells. Our data provide a remarkable deep insight in the T-cell repertoire of CD4-and CD8-positive T-cells and in the development of T-cell composition of donors undergoing G-CSF induced stem cell mobilisation. In addition, our TCR-β NGS-PCR approach is an innovative tool to track single T-cells based on their individual TCR-β rearrangements.

Plerixafor 'on demand' after chemotherapy + granulocytecolony-stimulating factor: results of a strategy based on peripheral blood CD34+ cells and an algorithm for preemptive use L. Farina, F. Spina, A. Guidetti, P. Longoni, F. Ravagnani, A. Dodero, V. Montefusco, C. Carlo-Stella, P. Corradini Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, IT) Backgroud: Plerixafor is a CXCR4-inhibitor that improves peripheral-blood-stem-cell (PBSC) mobilization when combined with granulocyte-colony-stimulating factor (G-CSF). Plerixafor 'on demand' after chemotherapy + G-CSF may be effi cient and costeff ective, but timing of administration and criteria for patient selection are under investigation. Objectives: Our study was aimed to assess the feasibility and efficacy of plerixafor 'on demand' with chemotherapy + G-CSF and to design an algorithm for the 'on demand' use after high-dose cyclophosphamide + G-CSF. Patients and methods. Twenty-seven lymphoma (n=24) and myeloma (n=3) patients were treated with chemotherapy + G-CSF and plerixafor: 19 patients had failed a previous mobilization with chemotherapy + G-CSF, 8 received plerixafor as fi rst-line mobilizing therapy. The decision of adding plerixafor was based on circulating CD34+ cells at hematopoietic recovery. To devise an algorithm for the 'on demand' use of plerixafor after a fi rst mobilization attempt we reviewed the data of 107 patients treated with cyclophosphamide + G-CSF: 51 myeloma patients received 3-4 gr/ms and 56 lymphoma patients received 6-7 gr/ms. Leukocytes and CD34+ cells were analyzed by a multivariate logistic regression model. Results: Twenty-six patients treated with plerixafor 'on demand' collected a median of 4,45 x 10 6 /kg CD34+ cells (range, 0,8-13) after a median of one plerixafor injection and one leukapheresis (range, [1] [2] [3] . Nineteen patients collected ≥ 4 x 10 6 CD34+/kg. The median fold increase of CD34+ cells after plerixafor was 4,8 (range, 1-52) . The median time from chemotherapy to plerixafor administration was 15 days (range, 12-25) . In our retrospective analysis on 107 patients treated with cyclophosphamide + G-CSF, having a CD34+ cell count < 10/μl on the day of leukocyte recovery (>1000/μl) or leukocyte count < 1000/μl after day +12 in myeloma and day +14 in lymphoma patients predicted the risk of failing PBSC collection by 2.7 and 2.8 times (p=0.001 and p=0.02) with a sensitivity of 89% and specifi city of 88%, respectively. Conclusions: Our results show that plerixafor 'on demand' can induce the collection of PBSC in > 90% of patients treated with chemotherapy + G-CSF. The retrospective analysis on 107 patients treated with cyclophosphamide + G-CSF showed that those with delayed hematopoietic recovery and CD34+ cells < 10/μl at recovery may deserve plerixafor 'on demand' , as fi rst-line mobilization therapy. A. Olivieri, B. Bruno, R. Lemoli, G. Meloni, W. Arcese, M. Falda, G. Milone, A. Cortelezzi, F. Ciceri, E.P. Alessandrino, G. Specchia, R. Scimè, R. Raimondi, G. Leone, I. Attolico, F. Saraceni, D. Capelli, A. Bosi, A. Rambaldi on behalf of GITMO (Gruppo Italiano Trapianto di Midollo Osseo) PBSC for ASCT have completely replaced BM also in AML; this policy did not change, although some recent studies suggest that PBSC source was associated with increased Relapse Incidence (RI) and reduced Overall Survival (OS). In a previous GITMO survey on 2333 AML patients PBSC were associated as well with an increased Relapse Incidence (RI) and reduced OS, but this analysis suff ered S104 S105 from some biases, consequent to missing data such as the interval between achievement of CR and ASCT and the cytogenetics and molecular characteristics of the patients undergoing ASCT. Now we have selected 970 AML non-M3 patients in whom the interval between CR achievement and ASCT and molecular/cytogenetics marker were available. According to cytogenetics/molecular markers, AML patients have been categorized in 4 groups (Foran JM Hematology 2010, 47-55 Educational Book) : group A including 154 patients with favourable molecular/cytogenetics; group B including 165 patients with adverse kariotype (K) or adverse molecular markers; group C including 354 patients with intermediate K; group D including 297 patients with normal K and unknown molecular markers. Median age was 47 (range 2-78); 511 were male and 459 female; 648 received ASCT with PBSC and 322 with BM;. 528 received conditioning with Busulfan, 304with chemotherapy not including Busulfan and 85 Received TBI; in 53 conditioning regimen was unknown. With a median follow-up of 911days (range 0-7543) the 5 years OS and LFS, in patients receiving BM ,were 46% and 39% respectively. In patients transplanted with PBSC (median follow up: 850 days, range 0-6065) 5 years OS and LFS were 46% and 38% respectively; one year non relapse mortality (NRM) was 6% for PBSC and 7% for BM ( Fig.1  a, b,c) . Multivariate analysis, including the main factors for the outcome (age, disease status, interval between diagnosis and ASCT, kind of conditioning, cytogenetics/molecular risk category and transplant era), showed that OS and LFS were signifi cantly aff ected by disease status at ASCT (CR2 or >CR2 vs CR1), age>60 years and cytogenetics/molecular category; factors infl uencing NRM were age (>30 years), disease status and interval between diagnosis and ASCT (Tab. 1). These data suggest that PBSC are similar to BM, while the main factors negatively aff ecting the outcome remain advanced age, biological characteristics and disease status at ASCT.

Y. Chen, X.S. Zhao, L.P. Xu, D.H. Liu, X.H. Zhang, H. Chen, Y.H. Chen, W. Han, Y. Wang, K.Y. Liu, X.J. Huang Peking University People's Hospital (Beijing, CN) Objectives: Until now, very few studies compared the clinical outcomes of transplant using granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood (G-PB) and a combination of G-CSF mobilized bone marrow (G-BM) with G-PB (G-BM&PB). The aim of this study was to fi nd a more suitable cell preparation for each patient based on a risk-stratifi cation system. Methods: This retrospective study compared transplantation outcomes in 98 consecutive patients with standard-risk acute leukemia. Allogeneic hematopoietic stem cells transplantation was used G-CSF mobilized bone marrow and blood (G-BM&PB, n=65) or G-CSF mobilized blood (G-PB, n=33) from HLA-identical sibling donors. Results: The G-BM&PB and G-PB groups had significantly different speed of neutrophil recovery (medians 15 vs 14 days, respectively; P=0.009), but similar rate of platelet recovery. Cumulative incidences of grades II-IV acute graft-versus-host disease (aGVHD) in the G-BM&PB and G-PB cohorts were similar (18.0% vs 21.8%, respectively; P = 0.697), but significantly different for grades III-IV aGVHD (5.5% vs 18.9%, respectively; P = 0.04). The G-BM&PB and G-PB cohorts showed similar cumulative incidences of chronic GVHD (cGVHD, 49.1% vs 42.7%, P = 0.467), 1-year cumulative incidences of treatment related mortality (16.2% vs 24.4%, P = 0.222), and 5-year cumulative incidences of relapse (13.8% and 26.8%, P = 0.115). The G-BM&PB group showed significantly higher 5-year probability of leukemia free survival (LFS) compared to G-PB group (77.8% vs 57.6%, P = 0.023). Multivariate analysis identified G-PB as an independent risk factor for III-IV aGVHD and LFS.

Conclusions: Our results suggested that HLA-identical transplant with G-BM&PB provided superior clinical outcomes compared to G-PB for patients in standard-risk acute leukemia.

Intrabone cord blood transplant (IB.CBT): preliminary results from a prospective phase II study F. Bonifazi (1) , M. Labopin (2) , E. Dan (1) , M. Ferioli (1) , S. Rizzi (1) , A. Bontadini (2) , B. Sinigaglia (1) , M.R. Motta (1) , M. Cavo (1) , G. Bandini (1) (1)University of Bologna, S. Orsola-Malpighi Hospital (Bologna, IT) ; (2) Hopital Saint Antoine (Paris, FR); (2) S. Orsola-Malpighi Hospital (Bologna, IT) IB transplantation has been described as an effi cient way to infuse CB. Here we report on 23 patients undergoing IB-CBT for advanced haematological malignancies. The study was a phase II prospective monocentric study approved by local EC and registered at http://clinicaltrials.gov/; the primary endpoint was engraftment rate. Conditioning regimen was myeloablative (Bus or TBI based); prophylaxis of GVHD was CsA, MMF 15 mg/kg/ bid and ATG-F (15-30 mg/kg, td) .CB processing was as described by Frassoni et al. Infusion on both iliac crests was performed in OR with monitored care sedation.Median age was 36 yrs, median recipients weight 63 kg (52-93); 17 were AML, 4 ALL, 1 MM and 1 CML. Phase at transplant was mainly advanced (for AL: 10 primary refr. or res. relapse, 6 beyond fi rst CR,5 fi rst CR; 1 progression for MM and 1 CB for CML). 3 pts had a previous allotransplant and 4 an autotransplant. All CB units were 4/6 except for 3 (5/6) . Median total cell infused was 2.06x10e7/kg and median CD34+ cells 0.53x10e5/kg. The CI of neutrophils recovery (>0.5x10e9/L) was 82+9% at day+60. The CI of platelet recovery (>20 or 50x10e9/L) was 82+9% and 70+10% at day+90 respectively. 2pts died before engraftment, due to CNS bleeding and myocarditis. 2 pts didn't engraft and a second unit, again via IB, was given. 1-year OS and NRM were 66+11% and NRM 20+9%, respectively. aGVHD was 39% with only 1 pt with grade III. We recorded 3 limited cGVHD and 1 extensive. All the evaluable pts achieved a CR, except for the MM pt, who obtain a nCR and a resistant AL pt who remained cytopenic due to persistence of blasts. CMV reactivation occurred in 13/23 pts (median onset day+38);1 pt reactivated EBV and developed an EBV-related encephalitis, successfully treated with anti-CD20 MAb. 6 pts had a hemorrhagic cystitis (median onset day+23,4/6 pos. for BK-virus). We recorded 3 possible/probable IFI. To our knowledge this is the fi rst prospective study confi rming the feasibility and the impressive platelet recovery of a new route of CB transplant, fi rstly reported by Frassoni et al. Even if these data need to be confi rmed on a larger population, plt recovery and the low amount of cell needed using IB route are important challenges able to propose CBT as a real alternative option when a matched donor isn't available much more rapidly than currently is. In addition, IB-CBT represents an ideal in vivo model to study and understand the biological phenomena regulating the function of stem cell niche.

Effi cacy of G-CSF mobilization is not associated with the CXCL12 801 G/A-polymorphism: a study in 463 healthy volunteer donors M. Bornhauser, J. Lenk, M. Kramer, K. Poppe-Thiede, H. Schmidt, H. Kristina, M. Wiesneth, K. Schäfer-Eckhart, P. Schlenke, M. Punzel, S. Martin, F. Kroschinsky, A. Schmidt, G. Ehninger, C 

Objectives: A common polymorphism in the 3' untranslated region of the gene encoding for stromal cell-derived factor-1 (CXCL12-3'UTR-801 G-A) has been associated with the progression of HIV and cancer risk. Analyses of relatively small cohorts have suggested that individuals harbouring the CXCL12-A allele are able to mobilize grafts with a higher content of CD34+ hematopoietic stem and progenitor cells (HSPC.

Methods: In order to verify this hypothesis, we typed 463 healthy unrelated donors (376m/87f, median ager 33) for CXCL12 801 G/A using a real-time PCR assay who had received daily subcutaneous injections of a mean dose of 7.36 ± 1.71 μg/kg glycosylated G-CSF for 5 days.Effi cacy of CD34+ mobilization was associated with the allelic status and donor characteristics. Results: The allelic distribution in our cohort was representative with 133 (29%) and 15 (3%) donors heterozygous and homozygous for the A-allele, respectively. Median age and the sex distribution of the G/G-group and donors with the A allele were identical. The same was true for leukocyte counts at baseline and on day 5. Interestingly, the median concentration of mobilized CD34+ cells on day 5 was almost identical in donors with the A-allele (76/μl, range, 11-249) and G/G-group (71/μl, range . In addition, the allelic distribution was not diff erent in donors (n=11) who mobilized less than 20/μl CD34+ cells. No diff erence in the overall yield of CD34+ HSPC in the apheresis product and in the number of CD34+ HSPC/kg recipient could be detected between both groups. In a multivariate regression model for the prediction of CD34+ cells/μl at day 5, only male sex (Regression coeffi cient (RC) 11.2 , 95% CI 1. 5-21.1, p=0 .023) and BMI as continuous variable (RC 3.5, p=0 .0001) but not age, smoking status and CXCL12 allelic status represented independent variables. Conclusion: Our data derived from a large well controlled cohort contradict previous analyses suggesting an association between CXCL12 allelic status and yield of CD34+ HSPC. Concentration of CD34+ HSPC in the peripheral blood, the most objective parameter, could not be predicted by CXCL12 genotype. As the content of CD34+ HSPC in the graft is an important parameter for transplant outcome and novel drugs have been developed to boost CD34+ cell counts in the peripheral blood, more comprehensive, genome wide association studies in larger donor cohorts are warranted to identify other potential genetic predictors.

Cyclophosphamide and G-CSF are not superior to G-CSF in mobilization of haematopoietic stem cells in donors without prior cytostatic exposure E. Snarski (1) , K. Halaburda (1) , M. Król (1) , M. Król (1) , E. Urbanowska (1) , A. Milczarczyk (2) , K. Jedynasty (2) , E. Franek (2) , W. Wiktor Jedrzejczak (1) (1)Medical University of Warsaw (Warsaw, PL); (2) Central Hospital, Ministry of Interior Aff airs and Administration (Warsaw, PL) The effi cacy of cyclophosphamide (CY) plus granulocyte colony stimulating factor (G-CSF) mobilization regimen has not been evaluated in healthy hematopoietic stem cell (HSC) donors for ethical reasons. Experimental autologous hematopoietic stem cell transplantation (AHSCT) program in early type 1 diabetes mellitus (T1DM), which was conducted at our institution enabled us to study the infl uence of CY on mobilization in this otherwise healthy population and compare it with healthy hematopoietic stem cell donors mobilized with G-CSF alone. This population of patients with T1DM is naïve to cytotoxic drugs, and mobilization is their fi rst contact with cytotoxic drugs (such as CY). The group of T1DM consisted of 25 patients aged 18 to 35 (mean 25). There were 16 males and 9 females. The matched unrelated donor group consisted of 40 donors aged 19 to 40 (mean 27) group adjusted for demographic characteristics to reach similar distribution of sex, age and weight. There were 25 males and 15 females. For the purpose of this comparison we evaluated only the fi rst collection day data. White blood cell count (WBC) on the collection day ranged from 1.5 G/L to 33.3G/L (mean 15.7 G/L) in T1DM patients. The values for URD were 22,8 G/L to 63.43 G/L (mean 40.72) (p<0.00000001, t-test). CD34+ cells accounted for 0.21% to 4.2% WBC in T1DM (mean 0.99%) and 0.04 to 0.59% WBC (mean 0.19%) in URD (p<0.0001, . In absolute numbers of circulating CD34+ cells, the data comprised of 26 to 477 per microliter in T1DM patients (mean 127 cells/ microliter) while in URD population the numbers ranged from 23 to 265 (mean 76) (p=0.028, t-test). In terms of collection effi cacy, the average yield of CD34+ cells during the fi rst leukapheresis was 332 x 106 (range 150 to 814 x 106) in T1DM group. For the URD group the average yield during the fi rst leukapheresis was 294 x 106 (range 42 to 873 x 106) CD34+ cells (p=0.35 , t-test) .

In conclusion, the CY + G-CSF mobilization is the standard protocol used in hematologic and non-hematologic patients. Our results show that CY+ G-CSF used for HSC mobilization in chemotherapy naïve individuals results in very similar numbers of circulating CD34+ cells, as well as collection effi cacy as compared to G-CSF only mobilization.

Prospective comparison of three diff erent donor groups -matched siblings, matched unrelated donors and haploidentical families -in allogeneic haematopoietic cell transplantation for acute myelogenous leukaemia in remission: a preliminary analysis K. Lee, J. Lee, J. Lee, D. Kim, Y. Lee, Y. Kang, M. Jeon, M. Seol University of Ulsan (Seoul, KR) HLA-haploidentical hematopoietic cell transplantation (HCT) without ex vivo-T cell depletion using conditioning with reduced-dose busulfan, fl udarabine, and ATG achieved consistent engraftment with low graft-versus-host disease (GVHD) and transplantationrelated mortality (TRM; Lee K-H, Blood 2011; 118:2609 -2617 . Therefore, we initiated a prospective study, where patients with intermediate-high risk acute myelogenous leukemia in complete remission (CR) underwent allogeneic HCT according to the donor priority of matched sibling (MS), matched unrelated (MU), then haploidentical familial donors (HF). Conditioning regimens for MS-HCT were busufan (3.2 mg/kg x 4 days)-cyclophosphamide (60 mg/kg x 2 days) or, for patients >55 years or with co-morbidity, busulfan (3.2 mg/kg x 2 days)-fl udarabine (30 mg/m 2 x 6 days)-ATG (Thymoglobulin 1.5 mg/kg x 3 days). Patients undergoing MU-or HF-HCT received busulfan (3.2 mg/kg x 2 days)-fl udarabine (30 mg/m 2 x 6 days)-ATG (Thymoglobulin 3 mg/kg x 3 days). GVHD prophylaxis included cyclosporine plus a short course of methotrexate, with cyclosporine taper initiated on days 30 (for ATG containing conditioning) or 60 (for BuCy conditioning). Between January 2010 and June 2012, 123 patients were enrolled. Of those, 6 patients experienced recurrence of their leukemia at the time HCT and, therefore, excluded from the analysis. The characteristics of remaining 117 patient-donor pairs were summarized in Table 1 . The median follow-up duration of survivors was 17.5 months (range, 4.2-34.4 months) . The donor-group eff ect on the HCT outcomes was described in Table 2 . In this preliminary analysis, patients undergoing HF-HCT showed higher frequency of grade 2-4 acute GVHD when compared to those undergoing MS-or MU-HCT. However, there was no signifi cant diff erence in terms of chronic GVHD, leukemia recurrence, TRM, event-free survival, and overall survival. These results corroborated our previous observations showing the feasibility of HF-HCT using a common reducedintensity conditioning regimen of busulfan, fl udarabine, and ATG. This study is ongoing with further patient enrollment and longer follow-up period.

The role of LTB4 receptor on progenitor cell mobilization by rh-GCSF in C57BL/6 mice C. Seong, Y. Mun, K. Lee, E. Yoo, S. Lee, J. Kong, J. Ahn, Y. Bae, S. Lee Ewha Womans University (Seoul, KR) Background: The mechanism on HSC seem to be complex including the role of SDF gradient between BM and PB, and the role of protease pathway. We previously had reported that LT(Leukotriene)B4 was able to mobilize HSC in the murine model within 4 hours without signifi cant side eff ects. Since there are possibilities of similar mechanisms during HSC mobilization, which are shared by rhG-CSF or LTB4, in this study, we investigate the role of LTB4 receptor by rhG-CSF during HSC mobilization. Methods: Peripheral blood samples were obtained via cardiac puncture. Samples were analyzed for TNC using trypan blue staining and FACS analysis using Sca-1, Lin, CD45R(B220), CD116, Gr-1, TER119 were performed. LTB4APA and U75302, which are LTB4 receptor antagonists were given to C57BL/6 mice at diff erent dose levels(0.5μg, 1μg, 2μg or PBS with equal volume in control arm) followed by rhG-CSF (5μg, IV). Results: The number of WBC and HSC were decreased in rhG-CSF mobilized mice, in which LTB4 receptor antagonists were given. Up to 1μg of LTB4APA or U75302, there were tendencies of blocking of mobilization in dose dependent manner. However, beyond 1μg of LTB4 receptor antagonists, the blocking eff ects were in plateau. Interestingly, the blocking eff ects on mobilization by LTB4 receptor antagonists were more dramatic by rh-GCSF than that of LTB4. Conclusions: LTB4 receptor is involved not only in the downstream pathway of rh-GCSF mobilization, but LTB4 mobilization pathway in C57BL/6 mice. The eff ect of rh-GCSF on LTB4 K/O mice should be studied further to elucidate the cellular and molecular mechanisms of progenitor cell mobilization. It is necessary to have the insights understanding more precise mechanisms on rhG-CSF and LTB4 mobilization for developing effi cient protocols in the clinic.

Alternative source of multipotent mesenchymal stromal cells: discarded bone marrow fraction M. Mantelli, M. A Avanzini, E. Lenta, D.M Ingo, A. Rimella, L. Catenacci, G. Quartuccio, G. Acquafredda, I. Nardiello, C. Gagliardone, A. Moretta, M. Zecca IRCCS Policlinico S. Matteo (Pavia, IT) Mesenchymal stromal cells (MSC) are a very promising source for cell therapy. They can be isolated from various adult human tissues, but procurement is diffi cult. Therefore, research has focused on fi nding new, more convenient sources. A number of bone marrow (BM) processing and manipulation techniques have been developed to improve outcome of hematopoietic stem cell transplantation. BM erythrocyte depletion is used to circumvent donor/recipient incompatibility for ABO blood group antigens. The erythrocyte portion, containing a viable number of stem cells, is subsequently discarded. We report on the feasibility of expanding MSC from this material. For this purpose, after obtaining patient written informed consent, we sampled BM from four HLA-identical sibling donors, RBC depleted for ABO blood group antigen incompatibility. ER-MSC preparations were in vitro expanded and compared to counterpart MSC obtained from the same units before manipulation (BM-MSCs) . We evaluated CFU-F, growth rate, morphology, antigen surface expression, capability to diff erentiate and reach senescence. The median volume of the four erythrocyte portions was 300 ml (range: 800-100 ml) with a median MNC recovery of 484x106. This yield, which we consider an adequate quantity for MSC preparation, is comparable to that obtained from the processing of 50 ml starting BM suspension, the typical starting material for BM-MSC expansion. After plating MNC from the two sources at the same density (160.000 cm2), we observed a comparable number of CFU-F (ER-MSC: 4.4±1.1, BM-MSC:6±2.12) after 7-days culture. ER-MSC were comparable with BM-MSC for morphology and proliferative capacity, expressed as calculated cumulative cell count, with an hypothetical average cell recovery of 129x109 and 143x109, respectively. ER-MSC as well as BM-MSC expressed high levels (>95%) of CD90, CD73, CD105, CD13 and HLA A-B-C surface antigens, whereas they were negative for CD34, CD45, CD14, CD80, HLA-DR and CD31 molecules. ER-and BM-MSC were similarly able to diff erentiate into either adipocytes or osteoblasts. MSC from both sources reached senescence at the same number of passages (median P18) and they did not show chromosome instability. Our data indicate that the erythrocyte fraction obtained after BM erythrocyte depletion, a material that would be otherwise discarded, may be considered a good source of MSCs. The elevated number of cells that could be obtained make it suitable for clinical grade MSC expansion.

A quality control score for cord blood unit selection A. Picardi (1) Background: Quality of selected Cord Blood Unit (CBU) strongly aff ects patient outcome after Cord Blood Transplant (CBT). Although the fi nal quality assessments (QA) are performed at infusion, QA are carried out during the whole process. Recently, the Cord Blood APGAR score based on the QA pre-freezing and at infusion has been identifi ed with promising results in order to optimize CBU selection. However, the role of QA at pre-releasing check remains undefi ned. Objectives: Aims of this study consisted of 1) comparing the QA in terms of cell dose and viability between pre-freezing, pre-releasing and at infusion and 2) defi ning a Quality Control Score System based on the CBU pre-releasing checks, performed on the attached segment before transplant, as predictive factor for CBT outcome. Methods: Our study includes 104 patients transplanted at 3 Italian Centres (Rome Transplant Network, Florence-Careggi and Bergamo-Ospedale Riuniti). Most of them (76/104) were aff ected by Acute Leukemia with median age and body weight of 28 years (0.6-66) and 54.5 kg (4-96), respectively. Pre-freezing and prereleasing data were collected from Cord Blood Banks and data at infusion from Transplant Centres. The Quality Control Score (QCS) was calculated as a sum of points related to the number of NC, CD34+ cells, CFU-GM and viability. Each variable has been classifi ed by quartiles. Each subset was weighted based on the value of correlation's coeffi cient. The degree of correlation between the variables was evaluated by the Spearman correlation coeffi cient. Results: Overall, our analysis has shown a signifi cant linear relationship between pre-freezing, pre-releasing and at infusion QA as number of NC (p<0.0001), CD34+ (p<0.0001) and CFU-GM ( < 0.01). Independently by the method used for the test, a significant correlation between pre-releasing and at infusion viability (p< 0.05) was found. Furthermore, 72 out of 104 patients were evaluable for the attribution of the QCS (ranged between 3 and 12) allowing the identifi cation of a cut-off of 9 as 3rd quartile. The patients who received CBU with a score > 9 showed a signifi cantly faster PMN engraftment (p=0.03), while the risk of acute GVHD (grade II-IV) was signifi cantly lower (p=0.02) for a QCS <9. Conclusions: The pre-releasing QA are predictive of cell dose at infusion and can be alternative to missing pre-freezing data. Finally, the pre-releasing QCS may represent a useful tool for optimizing CBU selection.

Impact of cell dose in BM and PBSC on outcome after allo-HSCT M. Remberger (1) , O. Ringden (2) , M. Uhlin (2) , J. Mattsson (2) (1)Therapeutic Immunology (Stockholm, SE); (2)TIM (Stockholm, SE) We studied the eff ect of the transplanted cell-dose on the outcome in 855 HSCT patients transplanted between 2000 and 2012 in a single center study. Most patients had a haematological malignancy. A sibling donor was used in 377 cases and a matched unrelated donor in 478 cases. Most patients (n=553) were treated with conventional myeloablative conditioning while 302 received reduced intensity conditioning. Bone marrow (BM)(n=366) and PBSC grafts (n=489) were analysed separately as the cell-dose are very diff erent. Median nucleated (NC) and CD34+ cell dose was 2.9x108/kg vs. 11.3x108/kg and 3.8x106/kg vs. 7.9x106/kg in BM and PBSC grafts, respectively. First the BM and PBSC groups were divided into four equally sized groups depending on the nucleated or CD34+ cell dose. Then the diff erent outcome variables (survival, TRM, GVHD and engraftment) were studied in these groups. Corrections were made for diff erences in characteristics between the groups. In the BM group we found that a NC dose <2.0x108/kg were associated to more chronic GVHD (p<0.01), a slower platelet engraftment (p<0.01) and a trend for higher TRM (p=0.12). A low CD34+ cell dose (<2.3x106/kg) were correlated to slower neutrophil and platelet engraftment (p=0.037 and p<0.01) and a trend for more chronic GVHD (p=0.12). The fastest engraftment and lowest cGVHD was seen in patients receiving a BM graft containing both >2.0x108/kg NC and >2.3.0x106/kg (n=182). In the PBSC group we found that patients given a NC dose <8.3x108/kg had less acute GVHD II-IV (p<0.01), a trend for inferior overall survival and relapse-free survival (RFS)(p=0.08 and p=0.12). A CD34+ cell dose >11x106/kg was associated to inferior survival (p=0.02), more relapse (p=0.02) and inferior RFS (p<0.01) but quicker platelet engraftment (p=0.02).

In conclusion, when using bone marrow as stem cell source a NC dose of >2.0x108/kg and a CD34+ cell dose >2.3x106/kg is needed to achieve a faster platelet engraftment and less chronic GVHD. When using PBSC as stem cell source a NC dose >8.3x108/kg or a CD34+ cell dose <11.0x106/kg were associated to superior survival and RFS, less relapse but more acute GVHD grades II-IV. A high CD34+ cell dose resulted in faster platelet engraftment.

Unrelated donor peripheral blood stem cell versus bone marrow transplantation for haematological diseases A. González, C. Pardo, C. Alarcón, C. Martínez-Múgica, A.-P. González, P. Palomo, R. Fernández, A. Fonseca, E. Arija, C. Vallejo University Central Hospital of Asturias (Oviedo, ES) Background: previous studies have suggested that allogeneic stem cell transplantation (allo-SCT) from HLA-identical sibling using peripheral-blood stem cells (PBSC) accelerates the engraftment and decreases the relapse rate of high-risk malignancies, but increases the risk of acute and/or chronic graft-versus-host disease (GVHD) compared to bone marrow (BM). In the unrelated donor (URD) setting, a recently published randomized study did not detect signifi cant survival diff erences between PBSC and BM transplants. In addition, the use of low-dose anti-thymocyte (ATG) might modify the pattern of events when comparing between both HSC sources.

[P506] S109 Objective: we aimed to restrospectively compare the URD-HSCT performed with BM and PBSC in a single center. Methods and patients: we report the outcome of 56 consecutive patients (pts) who underwent allo-HSCT from URD during the last four years in our institution. Pts receiving BM were older than those transplanted with PBSC. As expected, the number of CD34+ and CD3+ cells infused were substantially higher in the BM arm. The characteristics of the series of pts is showed in the table. Results: as is shown in the table, early acute GVHD and gr. II-IV acute GVHD were higher in the PBSC group. On the other hand, graft failure (GF) and overall survival were higher in the BM group. The 3 pts who had GF were rescued with autologous backup (2) and with a second transplant (1) , and are alive at the last follow-up. Conclusion: in our experience, BM exhibits better long-term outcome than PBSC URD transplant, and continues to be the preferred source of SC for the majority of patients.

Clinical outcome of single and double cord blood transplants performed using NHS-CBB units M. Guttridge (1), S. Watt (2) , R. Hough (3) , C. Brown (4) , G. Miqueles (4), B. Cash (1) , J. James (4) , I. Ionescu (5) , E. Gluckman (6) , R. Pawson (2) , V. Rocha (2) , C. Navarrete (4) (1)NHS Blood and Transplant (Bristol, GB) ; (2) Objective: The NHS-CBB was established in 1996 and has over 19,500 unrelated cord blood units (CBUs) stored of which around 40% are from ethnic minority donors. We have issued over 400 CBUs for transplantation to patients worldwide. The aim of this study was to assess the quality of CBUs stored from the clinical outcome of the transplants performed. Methods: In collaboration with Eurocord registry, we performed a retrospective analysis of the outcome of 190 single and 104 double cord blood transplants (CBT) from 1998 to December 2011. The clinical end points analysed were platelet and neutrophil engraftment, acute and chronic GVHD, overall survival (OS) and disease free survival (DFS). Median follow up (FU) for single CBTs was 33.8 months (3.1-144.4 ) and for double CBT was 17.6 months (1.2-85.1) . Results: Two different analysis were performed by graft type (single or double UCBT). The majority, 155 (81%) of the single CBTs were in children and 125 (66%) had malignant disease (MD). Median time to neutrophil and platelet recovery was 23 and 40 days, respectively. The K-M estimate of aGVHD (II-IV) incidence was 33±4% and 14±3% (grade III and IV). cGVHD was seen in 28 patients,10 (43%) extensive and 13 (57%) limited. OS was 61% in children and 30% in adults; 63% for HLA matched 6/6 or 5/6 and 43% in the 4/6 or less matched transplants; 64% in transplants with TNC >4.1x10 7 /kg and 42% in those with <4.1x10 7 /Kg, and 61% in those with >1.8 x10 5 /kg CD34+ cells and 46% in those with <1.8x10 5 /Kg. At 3 years, DFS in patients with MD was 44±5%. Cause of death evaluated in 81 patients showed 23 were due to relapse, 57 were transplant related and 1 was secondary malignancy. Of the double CBTs 93 (89%) were in adults and of these 90 (98%) had MD. Myeloablative conditioning was used in 39 (41%) patients and RIC in 57 (59%). Median time to neutrophil and platelet recovery was 21 and 40 days, respectively. The K-M estimate of aGVHD incidence was 29±5%. At 18 months, OS was 51±5% and DFS was 44±6%. Cause of death in 51 patients with data were relapse (31%) or transplant related (69%). Conclusions: The clinical outcome of CBTs performed using NHS-CBB units compares favourably with published studies indicating that the procedures in place at the NHS CBB contribute to safe and high quality products for transplantation.

Detection of microparticles in cord blood units A. Xagorari (1), M. Samalidou (1), D. Bougiouklis (1), D. Zacharaki (1), N. Leventopoulou (1), A. Siogna (2) , L. Economou (2) , D. Sotiropoulos (1) , A. Anagnostopoulos (1) (1)G.H. "G.Papanicolaou" (Thessaloniki, GR); (2) Aristotle University of Thessaloniki (Thessaloniki, GR) Objectives: The microparticles (MPs) are small membrane vesicles (sized around 0.1mm) relased from diff erent cell types after activation or apoptosis. MPs are considered markers of cell activation and apoptosis. Recently MPs were shown to participate in important biological functions and pathological processes, such as angiogenesis in tumor metastasis, infl ammation, thrombosis and haemostasis. The aim of this study is to quantify the MPs in cord blood units and to investigate their relationship with diff erent parameters. Methods: Collected cord blood units (CBUs) (n=30) were processed with SEPAX apparatus (BIOSAFE) and analysed based on their net volume, the absolute number of CD34+cells/unit and their viability by fl ow cytometry, the number of total nucleated cells (TNC) and the absolute number of nucleated red cells by microscope after Giemsa staining. Mononuclear cells were seeded in semisolid culture in the presence of growth factors (SCF, IL-3, GM-CSF, EPO) for CFU-GM, BFUe and CFU-GEMM colony growth. MPs were isolated after plasma centrifugation. The number of MPs was determined after incubation with annexin-V and anti-CD34 by fl ow-cytometry. Electron microscope photographs were obtained. For the statistical analysis used t-test, Pearson's and Spearman's depending on the normality of the distribution of variables. Results: The mean (± SD) number of annexin-V+/CD34+MPs was 73±22/ μl. Univariate analysis showed that the number of MPs had signifi cant negative correlation to the number of BFU-E (p<0,019; r=-0,426), CFU-GEMM (p<0,016;r=-0.435) and CFCs (p<0,015; r=-0,440). There was no signifi cant correlation between the number of MPs and each of the following: TNC, CD34+, CFU-GM the net units volume. CBUs were frozen and thawed and the numbers of annexin-V+/ CD34+MPs and colonies were determined. Univariate analysis showed that the number of MPs has strong negative correlation to the post-thaw number of BFU-E (p<0,0012; r=-0,988) and CFU-GM (p<0,038;r= -0.962). The number of MPs has strong positive correlation to the number of CFU-GEMM (p<0,0; r=1,0) after thawing. Concusion: MPs from haematopoietic progenitor cells were identifi ed in cord blood units. The number of annexin-V+/CD34+MPs showed a signifi cant negative correlation with the number of colonies (total CFUs, CFU-GEMM, BFU-E) as well as the post-thaw number of CFU-GM and BFU-E colonies. The role of MPs in CBUs and possible correlation with transplantation remains to be investigated.

Stem cell viability in umbilical cord banking; how good are our quality controls? R.C. Duggleby (1) Objectives: Umbilical cord blood (CB) is increasingly being used as a viable alternative to peripheral blood or bone marrow aspirates as a stem cell source in hematopoietic stem cell transplantation (HSCT). Practically, however, it requires cryopreservation in large (25ml) volumes and establishment of an accredited CB Bank. Recently, we published (Transfusion 2012) that the standard flow cytometer assessments of viability, utilizing 7-Aminoactynomicin D (7AAD), do not detect early apoptotic cells. Significant numbers can be present following thawing, detected by labelling with annexin V (AnnV). In CB banking, the tubing used to fill the storage bag is sealed into segments and frozen with the rest of the unit (25 ml bag). These segments can then be thawed as quality controls. However, these more sensitive assessments raise the possibility that differences might arise between segment and bag, compromising their value as quality controls. Methods: Control thaws (n=18) of CB units were performed to reassess the effi cacy of using the segments as quality controls for the unit. Assessed were stem cell dose (ISHAGE guidelines), nonapoptotic dose by AnnV labelling, and functional cell dose (n=12) by 14-day, colony forming unit assay (CFU). Results: The paired bag and segments showed extensive evidence of loss of CD34+ cell viability with high proportions of AnnV (~ 65% in both) and 7AAD+ (10%) and morphology (30%). Despite this, viability and cell dose correlated in the bag and the segment, and there was no signifi cant diff erence in the median proportion of CD34+ cells present or absolute counts of viable CD34+ cells. In addition, the correlation between function dose (by CFU) and viable CD34+ dose (by AnnV) was very similar in the bag and the segment (R2= 0.546 and 0.549). Conclusion: These data indicate that, as observed previously, extensive apoptosis occurs post-thaw. However, the data also suggests that the segment still appears to behave similar to the bag, despite the diff erence in volume (~0.1ml to 25 mls). Reassuringly, this indicates that the segments remained a valid quality control for the remaining unit. It should be noted that the majority of these units were cryopreserved for less than 1.5 years, thus the stability of this relationship with time remains to be seen. Also this is an on-going process, larger sample sizes may detect diff erences. However, Our ability to assess the units that are banked is essential if we are to be able to guarantee the viable/functional cell dose delivered to a patient.

Outcomes of haematopoietic stem cell transplantation in primary immunodefi ciency: a single centre experience K. Humala Barbier, M. Gasior Kabat, R. Guerrero Camacho, R. De Paz, I. Galindo, A. Marcos, P. García De Miguel, M. Díaz Almirón, R. Arrieta Gallastegui La Paz University Hospital (Madrid, ES) Objective: To analyze outcomes of 19 patients with primary immunodefi ciency treated by hematopoietic stem cell transplantation (HSCT) from haploidentical donors (HD), unrelated cord blood donors (UCBD) and bone marrow donors (BMD) related and unrelated, at six months from transplant. Methods: We performed a retrospective analysis on the outcome of 19 patients transplanted for primary immunodefi ciency who received HSCT between 2001 and 2011 at our center (Hospital Universitario La Paz, Madrid, Spain). Data was analyzed using SAS 9.1 Statistical Program. A p value less than 0.05 was considered signifi cant. Person chi-square test used for comparative analysis. Results: 19 patients with primary immunodefi ciency were treated with HSCT, 7 received HD from peripheral blood, 5 UCBD and 7 BMD (3 related and 4 unrelated). The median patient age at transplant was 22,2 months (range, 2-99 months). The most common condition transplanted was severe combined immunodefi ciency (68% of patients). Survival rate at six months was 71% in HD, 85% in BMD and 100% in HD. Only 3 patients did not develop post transplant infections, out of which 2 belonged to group treated with BMD and 1 to HD. The main cause of infection was infection by gram negative. Cytomegalovirus reactivation after HSCT was observed in 50% of patients treated with HD and in 50% with BMD. 7 patients developed acute graft-versus-host-disease (aGVHD), out of which 66.7% belonged to BMD and 33.3% to UCBD. Also, 7 patients presented GvHD of the skin, out of which 66.7% belonged to BMD and 33.3% to UCBD. Hematopoietic reconstitution was observed in 17 patients. Only 2 patients, treated with HD,

[P510] S111 presented graft failure. Univariate analysis showed that the occurrence of aGvHD and skin GvHD have signifi cant correlation with the source of transplant (P = 0.007, in both cases) (Table1). Conclusions: Our study suggests that other sources as haploidentical and cord blood donors are curative therapy for primary immunodefi ciency syndromes and they should be consider in the absence of a relative with identical HLA.

CD34+ cells concentration kinetics after plerixafor in poor mobilizers: is time to change the schedule? Z. Koristek (1) , J. Novák (2) , I. Skoumalova (3) (1)University Hospital Brno (Brno, CZ); (2)University Hospital Kralovske Vinohrady (Prague, CZ); (3)University Hospital Olomouc (Olomouc, CZ) Introduction: Combination of plerixafor + G-CSF is approved for mobilization of hematopoietic stem cells for autologous transplantation (ASCT) in patients with lymphoma and myeloma whose cells mobilize poorly. The recommended schedule is to administer plerixafor approximately 10 hours before apheresis to collect the cells during the estimated peak mobilization. This recommendation arises from the fi rst studies phase I and II, in which the CD34+ cells peripheral blood concentrations after plerixafor were monitored. However, the data considering CD34+ cells concentration kinetics after plerixafor administration were studied in healthy subjects and patients who were not proven poor mobilizers. Our aim was to check whether the mobilization kinetics is similar also in poor mobilizers. Patients and methods: Nine patients (5 males, 4 females) of median age 53 years (19-63), treated for lymphoma (n=5) and myeloma (n=4), were given plerixafor for proven (n=7) or estimated (n=2, both after previous high dose chemotherapies) mobilization failure. Plerixafor was used in a standard schedule in 7 patients (G-CSF 10 ug/kg day 1-5/+6, plerixafor 240 ug/kg day 4/+5, apheresis day 5/+6), and on-demand in two patients during failing chemomobilization (plerixafor 240 ug/kg day before apheresis during WBC increase after chemotherapy + G-CSF). CD34+ cells count was measured in peripheral blood just before plerixafor administration and subsequently every 2 hours for next 16 hours after 11 plerixafor injections (2 patients received 2 doses of plerixafor). All patients signed informed consent with the study. Results: Seven out of 9 patients (78%) yielded at least 2x10e6 CD34+ cells/kg (median 4,81; range 2,01-6,71). The CD34+ cells concentrations in blood peaked between 2 and 10 hours after plerixafor administrations. If we consider the CD34+ cell count in the blood in the morning before the fi rst plerixafor injection as 100%, the percentage of CD34+ cell concentration increase was in mean between 399% and 426% during 2 and 10 hours after plerixafor injection and then started to quickly drop. Conclusions: The standard recommended schedule for plerixafor administration is derived from data obtained in healthy subjects and normally mobilizing patients. The late evening plerixafor administration is not very practical and, moreover, the peak mobilization could be missed in poor mobilizers. We can conclude, that plerixafor administration 2 hours before apheresis in poor mobilizers could be more effi cient and practical as well.

The number of mesenchymal cells from Wharton jelly is not aff ected by the fragment of the umbilical cord from which the cells were isolated M. Murzyn (1) Introduction: At present , the mesenchymal stem cells (MSC) are new and giving new opportunities for therapies of various inherited and acquired disorders. Wharton Jelly (WJ) as a source of MSC has all the advantages of cord blood and it is reachable in MSC. In the present publication we describe the results of the collection, culture, investigation, and cryopreservation of cells derived from the umbilical cord (UC) collected by the companies from the group controlled by The Polish Stem Cell Bank confi rmed by clinical application. Materials and methods: UC were collected after natural deliveries as well as caesarian sections. UC samples were packed in a special transport container. In the laboratory, plastic-adherent cells were isolated cultured, and enumerated, and their viability was evaluated. Then the cells were cryopreserved and placed in the vapour phase of liquid nitrogen. The repeated cell counting, viability tests, fl ow cytometric immunophenotyping, and functional in vitro diff erentiation assays were performed from thawed reference samples. Results: We reported a low contamination level . The fi rst adherent cells with fi broblast-like morphology were well distinguishable within a week after the initiation of the cell culture. We haven't noticed any diff erences in growth, cell number and morphology in primary culture between tissue fragments from placental, central and baby side. The average number of p0 cells from the 6-well plate dish was between 1,5 x 10 6 ± 0,2 x 10 6 . The fi rst adherent cells with fi broblast-like morphology were well distinguishable within a week after the initiation of the cell culture. The post-thaw viability was not lower than 85% and thawed cells give rise the new culture in less than 4 hours. The immunophenotype (CD45-/CD34-/CD19-/HLA-DR-/CD73+/CD90+/CD105+) was stable during the whole period of culture (15 passages) . Cells were capable for diff erentiation into adipogenic, chondrogenic and osteogenic cells. Conclusion: The results described above demonstrate a quick, repeatable and effi cient method for WJ-derived MSC isolation and propagation to get MSC units contained cells in a number hypothetically suitable for clinical use. Moreover, we have found that the effi ciency of the isolation and the number of received cells is not aff ected by the origin of the fragment of the tissue from which the cells were isolated.

Additional haematopoietic stem cells from placenta perfusion J. Placzkowska, M. Murzyn, I. Marszalek, K. Zagorska, K. Poteralska, J. Piskula, A. Orczykowska, I. Czaplicka, A. Olkowicz, D. Boruczkowski, T. Oldak, J. Baran Polish Stem Cells Bank SA (Warsaw, PL) Introduction: Today cord blood (CB) is widely recognized as a source of hematopoietic stem cells (HSC). For potential transplantations the major key is the number of CD34+ cells derived. The number of CD34+ cells derived from single umbilical CB is often not enough for eff ective transplantation in adults. The human placenta is a possible source of additional progenitor cells and/or stem cells. Some CB banks try to increase the CB volume collected by the additional puncture of the cord's vessels with a needle & syringe. The results of these attempts are not satisfactory, which is why we developed the new strategy of obtaining an additional pool of cells by fl ushing placenta vessels. Materials and methods: CB and placenta blood was obtained using specially constructed separate kits during natural deliveries. CB was obtained in accordance with standard procedures. After birth, the placenta was rinsed by the injection of a solution into placenta vessels and we got an extra portion of blood. The number of CD34+ cells, viability, total nucleic cells (TNC) and contamination in placenta blood and CB was determined. Results: Flow cytometry showed that HSC were in the placental perfusion blood. A signifi cant increase in CD34+ was observed. Additionally we received on average signifi cantly more TNC and CD34+ cells, whereas the averaged viability of the high level remained, and the percentage of contaminated units stayed unchanged. Conclusion: Based on our results we suggest that the CB collection with placental blood might off er an increase in the CD34+ number. Of course further studies are necessary, but in the case of allogeneic or autologous CB transplantations, today we can predict the increase of the recipient's body weight by about 15% -20%. These double portions may be used in a higher number of adult lifesaving transplantation therapies. We also showed that the method of collecting placenta blood is quick and easy for potential clinical use and safe for both, newborn and mother.

Post-transplant treatment for patients with unfavourable acute leukaemia after haploidentical stem cell transplantation.Single centre experience O. Paina, N. Stancheva, S. Bondarenko, O. Slesarchuk, V. Vavilov, E. Babenko, N. Ivanova, A. Alyanskiy, D. Bagge, E. Semenova, L. Zubarovskaya, B. Afanasyev R.Gorbacheva Memorial Institute of children hematology and transplantation (St. Petersburg, RU) Introduction: Hematopoietic stem cell transplantation (HSCT) may be the only curative option for patients with unfavorable acute leukemia's. Improvements over the last 15 years in conditioning regimens, graft engineering and pharmacological immunoprophylaxis of GVHD have substantially reduced the morbidity and mortality of HLA-haploidentical HSCT (haplo-HSCT). However the main reason of mortality after haplo-HSCT in this group of patients is recurrence of the primary disease. Aim: Evaluate diff erent post transplant strategy in patients with unfavorable acute leukemias after haplo-HSCT. Methods: Fifty seven patients (range from 1-56 y.o.) with unfavorable acute leukemias were included in the study. ALL-29pts, AML-25pts, acute biphenotype leukemia-3pts. The RIC regimen based on Flu received 34 pts, MAC based on GIAC protocol*-24 pts. G-CSF-primed BM was used as a graft source. Median CD34+ cell were for children 10,9x10 6 /kg b.w., for adults 4,78x10 6 /kg b.w. Prophylaxis of aGVHD: CsA-based -36 pts, Tacro-based -21 pts. Children and adults with engraftment survived > 90 days from haplo-HSCT without signs of severe aGVHD or infection complications were evaluated for post transplant strategy. Post transplant therapy received 19 pts (maintenance-6MP+MTX 2pts, immunoadoptive chemotherapy-RIST 5pts, DLI 12pts). Results: One-year and two-year overall survival (OS) was higher in patients who received post transplant therapy compared patients without post transplant treatment 73,7% vs 23,7% and 47,4% vs 13,2% respectively (p=0,001). In multivariate analyses predicted cumulative incidence for bone marrow relapse was 8% and 92% respectively (95% CI, 0,62-1, p=0,001). Conclusions: Haplo-HSCT is eff ective therapy for achievement remission in patients with unfavorable acute leukemia. Because of lack of treatment due to relapse which is the main reason of mortality it's necessary to use post transplant treatment for patients with unfavorable acute leukemia after haplo-HSCT. It's necessary to further investigation for study optimal types post transplant therapy.

Safety and effi cacy of a G-CSF biosimilar (Zarzio ® ) for haematopoietic progenitor cell mobilization in patients with haematological malignancies A. Zabalza, M.P. Sanchez Anton, M. Antelo, S. Zalba, M. Aznar, E. Vicente, I. Aoiz, E. Olavarria Complejo Hospitalario de Navarra (Pamplona, ES) Recently, a new G-CSF biosimilar (Bio-fi lgastrim, Zarzio ® , Sandoz) has been approved by the European Medicines Agency for autologous PBSC mobilization. However, this authorization was based on comparable safety and effi cacy to the reference product (Neupogen ® ) in the management of chemotherapy-induced neutropenia, with no data available regarding PBPC mobilization in patients with Hematological Malignancies.

Since 2011, Zarzio ® has been approved in our institution for all authorized indications including PBPC mobilization in autologous SCT. A total of 36 patients mobilized with bio-fi lgastrim were included in this retrospective study, and were compared with the previous 36 patients mobilized with reference fi lgastrim. Neupogen ® was given at a dose of 10 μg/kg/day while Zarzio® was given at a dose of 5 or 10 μg/kg/day (depending on the CD34 target). Both were given during 5 or 6 days with the fi rst apheresis scheduled for day 5. The target CD34+ cell dose was 2 x 10 6 /kg recipient body weight in Lymphomas and 4 x 10 6 /Kg in Myelomas. Median age was 53 years (range 19 -72). The median duration of G-CSF treatment was 5 days (5) (6) and the median number of apheresis was 1 (1) (2) (3) in both groups equally. Zarzio ® seemed to have been well tolerated with no long-term adverse events reported in our series. Side eff ects included mild bone/muscle pain in both groups. There were no signifi cant diff erences in mobilization outcomes between groups receiving the bio-fi lgastrim or reference fi lgastrim. The median number of circulating CD34+/L at day 5 was 58.8 x 10 9 (range 3.2 -256.5) and 31.3 x 10 9 (range 1.8 -119.1) respectively (p=0.01). The median number of CD34+/kg was 4.76 x 10 6 (2.04 -13.42) and 4.36 x 10 6 (1.04 -10.98) in both groups (p=ns). All 36 patients (100%) in the bio-fi lgastrim group achieved the target CD34 cell dose compared to 28/36 (78%) patients in the control group (p<0.001) To date, 26 patients mobilized with bio-fi lgastrim and 27 with reference fi lgastrim, have undergone autologous SCT. All patients engrafted within a median of 13 days (10 -19) for the bio-fi lgastrim group and 11 days (10) (11) (12) (13) (14) (15) (16) (17) for the control group. Platelet engraftment was at 21 and 20 days respectively.

In our group of patients, our fi ndings suggest that Zarzio ® is well tolerated and safe when compared with Neupogen ® for PBPC mobilization before autologous SCT in patients with Hematological Malignancies. However, further studies are required to assess longer-term safety of G-CSF biosimilars.

Use of plerixafor to rescue absolute and predicted mobilization failures: a UK and Ireland consensus K.W. Douglas (1) , P. Hayden (2) , H. Hunter (3) , P. Johnson (4), R. Malladi (5) , S. Paneesha (6) , R. Pawson (7), M. Quinn (8), K. Raj (9), D. Richardson (10), S. Robinson (11), N. Russell (12) , J. Snowden (13), A. Sureda (14) , E. Tholouli (15) Background: Granulocyte colony-stimulating factor (G-CSF) is often used, alone or in combination with chemotherapy, to mobilise peripheral blood (PB) stem cells (PBSCs) from the bone marrow for use in stem cell transplantation. Despite established mobilisation strategies, many patients fail to mobilise suffi cient PBSCs to proceed to transplant. Plerixafor has been shown to increase the number of CD34+ cells in PB and can be used to salvage absolute or probable mobilisation failures in patients who mobilise poorly. While there is evidence to support use in poor mobilisers, there is no consensus on the most appropriate and cost-eff ective way to use plerixafor. Actions and Objectives: Working Group meetings were held with representatives from around the UK, to facilitate discussion on the use of plerixafor in bone marrow transplantation. The meetings aimed to review data and gain consensus on the most suitable method to identify poor mobilisers who should receive plerixafor. Results: The Working Group agreed that 15-20% of patients primed with G-CSF or G-CSF plus chemotherapy fail to mobilise suffi cient CD34+ cells, necessitating repeated mobilisation attempts, increased resource utilisation and a delayed time to transplant. Patients who fail mobilisation generally go on to receive plerixafor. Pre-emptive use of plerixafor in patients who are predicted to fail mobilisation can lead to fi nancial and effi ciency savings (vs requiring a patient to fail mobilisation and restart the process prior to plerixafor) so it is important to defi ne criteria to identify predicted poor mobilisers prior to failure. A patient is eligible for pre-emptive rescue with plerixafor when an established mobilisation protocol has been followed and on the predicted day of mobilisation the patient has a PB CD34+ count below 15/ μ L and a white cell count of at least 4x10 9 /L. This is not anticipated to increase the amount of plerixafor use as the same patients who would go on to fail mobilisation will simply receive plerixafor earlier in their treatment. Conclusion: The use of plerixafor to rescue absolute or probable mobilisation failures can improve resource utilisation and patient experience but an evidence-based protocol is needed to defi ne eligible patients. Following further discussion among the Working Group members, a consensus publication should be produced to provide information on plerixafor use and guide the use of plerixafor in absolute and probable mobilisation failures.

Dynamics of CD34 peripheral cells are predictive of stem cell mobilization success in patients with low count on the day before collection A.C. Gac (1) , J.J. Parienti (1), S. Chantepie (2) , C. Fruchart (3) , V. Lefevre (4) , O. Reman (2) (1)Université de Caen (Caen, FR); (2) Centre hospitalo-universitaire (Caen, FR); (3)Centre François Baclesse (Caen, FR); (4)Etablissement Français du Sang (Caen, FR) Autologous hematopoietic stem cell (HSC) transplantation is an eff ective treatment for patients with lymphoma. Unfortunately,

[P517] S114 15-30% of patients fail to mobilize a suffi cient number of HSC for the transplant. With the availability of plerixafor for stem cell mobilization, most patients are now able to yield stem cells successfully; however, because of its high cost, we have to select patients who might benefi t of its early introduction. Objectives: We identifi ed poor mobilizers in a homogenous cohort of patients with lymphoma and we analysed predictive factors before collection which can help us to determine the plerixafor's best indication. Methods: We report here 174 lymphoma patients who underwent cytapheresis between 2007 and 2011. None patient received plerixafor. 52 (29%) patients having less than 2.106 CD34/kg after the fi rst cytapheresis were considered as failure. Among these, 8 did not have cytapheresis because of peripheral CD34 positive cells count the day before cytapheresis was less than 6/mm 3 . The optimal count of CD34 positive cells allowing a successful mobilization was in our study 30 /mm 3 . Results: We fi rst analysed pre-collection characteristics of the 52 patients who failed to have more than 2.106 CD34/kg in order to predict the HSC mobilisation failure after the fi rst cytapheresis. Unfortunately, as it was described in the literature, only peripheral CD34 count the day before cytapheresis was the strong predictive factor of fi rst cytapheresis failure and any other predictive factors were found. Then, we selected 56 patients from the cohort who had less than 30 CD34/mm 3 the day before the fi rst cytapharesis. Of these patients, 41 (74%) had less than 2.106 CD34/kg after the fi rst cytapheresis. We showed that if the peripheral CD34 count the day before cytapheresis and more interestingly, dynamics of CD34 peripheral cells between the day before and the day of cytapheresis are predictive of a fi rst cytapheresis failure (respectively p=0.0133 and p=0.0108) (fi gure1 and fi gure2) and these factors are independent (p<0.01). Inversely, we can identify among these patients with less than 30 CD34 positive cells day before collection who had successful mobilization and for whom, plerixafor can be avoided. Conclusion: For patients having a count less than 30 CD34/mm 3 the day before the fi rst cytapharesis, dynamics of CD34 peripheral cells between the day before and the day of cytapheresis can select patients for who plerixafor is needed or not.

Assessing the HLA diversity of cord blood units collected from a birth clinic caring for pregnant women in an ethnically diverse metropolitan area J. Magalon (1) One advantage over registries of unrelated donors (UD) is that Cord blood banks (CBB) may off er more HLA diversity, and thus that suitable Cord Blood Units (CBU) may be identifi ed for a higher proportion of diff erent geographic origin individuals that are candidates for allogeneic transplantation. Thus, one of the goals of the Marseilles CBB that operates within the French network of CBB (RFSP) is to take advantage of the genetically diverse population that lives in the Marseilles metropolitan area due to its location on the Mediterranean shore and a long history of immigration. The Marseilles CBB principally works with one of the Marseilles University birth clinic that cares for an ethically, culturally, sociologically and ethnically diverse population of pregnant women. The aim of our study was to measure to which extent collecting CBU in these conditions would contribute to an increase in HLA diversity. Generic resolution HLA-A, -B, and allelic resolution -DRB1 genotyping was performed by SSO molecular techniques (oneλ) on 328 mothers and CBU collected between October 2010 and May 2012, as per standard SOPs. Observed HLA frequencies were compared with those from UD registered in southeastern France. Identifi cation of putative HLA haplotypes CBU was deduced using the maternal HLA typing and data published by Maïers et al in 2007. Finally, the enrichment of international UD and UCB registries in new HLA phenotypes was assessed: a CBU was considered as enriching the registry when no 6/6 matched CBU or UD was identifi ed in the respective registries. When compared to southeastern France UD characteristics, Marseilles CBUs display an increased frequency of HLA antigens that are frequent in populations of African origin, whereas antigens highly expressed in populations of European origin are proportionally less represented. Two putative HLA haplotypes were identifi ed as "European" for 129 CBUs (39,3%) while at least one putative haplotype was not present in Maïers' database for 142 CBUs (43, 29%) . This latter group enriched the CBUs registry in 93% of cases, and adds new possibilities to identify a suitable unrelated graft with 68% of HLA diversity enrichment in the BMDR. CBU with two putative "European" haplotypes contributed more modestly to increasing enrichment: 42% for CBUs registry and 7% for BMDR. We conclude that the activity of the Marseilles CBB increases the genetic diversity of banked CBU. In total, the clinical relevance of such HLA diversity CBU will only be confi rmed by their recruitment.

Experiences of autologous peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with "biosimilar" fi lgrastim (Zarzio ®, Sandoz, granulocyte colony-stimulating factor) L. Gopcsa (1), P. Remenyi (1) , N. Adamkovich (2) Introduction: Biosimilar version of fi lgrastim (Zarzio ®, Sandoz, granulocyte colony-stimulating factor, G-CSF) is now widely available. Biosimilar G-CSF has very similar features to the original recombinant G-CSF and has comparable quality, safety and eff ectivity profi le. Methods: In our study, 70 patients with diff erent hematological malignancies scheduled to receive biosimilar G-CSF after autologous haematopoietic stem cell transplantatation (AHSCT) for facilitating engraftment. Furthermore, 21 additional patients with lymphoid malignancies scheduled to receive biosimilar G-CSF following chemotherapy for autologous peripheral blood stem cell (PBSC) mobilization were included. Results: Among 70 patients who recieved AHSCT the median age was 56 years, including 42 male and 28 female. The diseases were: 41 multiple myeloma (MM), 19 Non-Hodgkin's lymphoma (NHL), 10 Hodgkin's lymphoma (HL). The conditioning regimen was mainly high-dose Melphalan (N=41) or BEAM (N=21). At time of AHSCT, the median number of reinfused CD34+ cells was 6,33x10 6 /kg (range 2-17,4x10 6 /kg). Median time of > 0,5 G/l absolute neutrophyl leukocyte engraftment were 9 days (range 8-11 days). Median time of 20 G/l platelet engraftment was 10,5 days (range 7-19 days). Twenty one patients with planned AHSCT received chemotherapy followed by administration of biosimilar G-CSF after the last day of chemotherapy for PBSC mobilization. The median age of patients was 55 years, including 13 female and 8 male. According to diagnosis, the diseases were: 11 MM, 8 NHL, 2 HL. Mobilization regimen was following: 10 patients with Cyclophosphamide+biosimilar G-CSF, 11 patients with salvage regimens+biosimilar G-CSF. 19/21 patients were harvested successfully. Median time interval between day 1 of the cycle of mobilization-chemotherapy and fi rst leukapheresis was 12 days (range 9-27). The median yield of CD34+ cells was 3,0x10 6 /kg (range 0,81-24,7 x 10 6 /kg) in one leukapheresis collection. In the autologous PBSC grafts, the median number of the CD34+ cells was 5,83 x 10 6 /kg (range 2,22-24,7 x 10 6 /kg). Conclusion: Biosimilar G-CSF after AHSCT showed as eff ective as our earlier results with G-CSF in the engraftment setting. Biosimilar S115 G-CSF is comparable to G-CSF for kinetics of PBSC mobilzation and yield of stem cells collected.We emphasize that use of biosimilar G-CSF is eff ective in PBSC mobilization and facilitating engraftment after AHSCT as well.

Predicted parameters of CD 34+ harvest during early-phase stem cell mobilization in patients with multiple myeloma and lymphoma. single centre experience M. Bonferroni, A. Ghiglia, R. Sorasio, L. Bertolotti, C. Di Marco, C. Castellino, M. Grasso, D. Mattei, N. Mordini, D. Rapezzi, I. Celeghini, G. Strola, D. Marenchino, A. Gallamini Santa Croce-Carle Hospital (Cuneo, IT) Introduction. High dose chemotherapy followed by autologous stem cell transplant is a standard treatment in patients (pts) with

[P520] S116 multiple myeloma (MM) and relapsed/refractory lymphoma. Granulocyte colony-stimulating factor with or without chemotherapy is the most commonly used mobilization treatment. The target CD34+ harvest for a single transplant is 4 x 10 6 /Kg, but current mobilization regimens yield inadequate CD34+ cell doses in 5-40% of pts (To L. Bik et al., Blood 2011) . Despite known prognostic factors negatively aff ecting successful stem cell collection (i.e. age, underlying disease, previous alkylating therapy, prior irradiation), predicting poor mobilization is current challenge. Objectives: To defi ne predictive parameters of inadequate stem cell mobilization. Material and Methods: A total of 438 mobilization procedures (170 MM and 268 lymphoma pts) performed at our institution in the last 17 years were retrospectively analyzed. The following parameters were considered: CD34+/ul and CD34+% (ISHAGE protocol) from the fi rst day of WBC≥1x10 3 /ul (day 1) until procedure end or failure. The overall CD34+ yield for each collection was calculated as the sum of all the apheresis. Less than 2x10 6 CD34+/Kg was considered a collection failure. Linear regression (R test) for correlations, Mann-Whitney test for diff erences between medians and ROC curve analysis for identifi cation of cut-off levels were used. Overall 438 procedures were done: 69 (16%) failed, while 78% reached the target of CD34+/kg>4x10 6 . There was a linear correlation between CD34+ harvest and levels of both CD34+/ul (R 0,58, p<0,0001) and CD34+% at day 1 (R 0,65, p<0,0001), with lower median levels of CD34+/ul and CD34+% in patients who failed mobilization (4 vs 42/ul and 0,06 vs 0,83%, respectively, p<0,0001). Ninety-eight percent of pts with CD34+/ul>20 at day 1 harvested more than 4x10 6 CD34+/kg. For pts with CD34+/ul<20 at day 1, CD34+%>0.5 predicted an adequate mobilization in 97% of the cases and CD43 less than 0.05% an inadequate mobilization in more than 80% of the cases. For CD34+/ul<20 and CD34+%<0,1 at day 2, NPV was 88%. Conclusions: Our results indicate that CD34+/ul<20 and CD34%<0,05% at day 1 are predictive of failure. When CD34+/ ul<20 and CD34+%<0,1 at day 2, the use of alternative strategies (i.e. plerixafor) could represent a way to actively mobilize in an otherwise diffi cult setting.

Prediction of poor mobilizers allows for early plerixafor administration: the Pamplona protocol M.P. Sanchez Anton, M. Antelo, A. Zabalza, S. Zalba, M. Aznar, E. Vicente, I. Aoiz, E. Olavarria Complejo Hospitalario de Navarra (Pamplona, ES) The role of Plerixafor in routine peripheral blood progenitor cells (PBPC) mobilization in Myeloma or Lymphoma patients remains to be established. In our institution we have developed a mobilization guideline (The Pamplona Protocol) to assess the safety and effi cacy of Plerixafor + G-CSF in patients predicted to be poor mobilizers (PM). The Pamplona protocol classifi es patients according to PM risk factors including: a) previous mobilization failure; b) advanced disease; c) prior extensive radiotherapy; d) prior Hyper-CVAD, Fludarabine, Lenalidomide or alkylating agents; e) extensive BM involvement; f ) >2 lines of chemotherapy; and g) age > 65. Patients with ≥3 risk factors classify as PM and a PB CD34+ cell count is taken on day 4 of mobilization. All other patients have a CD34+ cell count on day 5 immediately before the apheresis procedure. Plerixafor is administered at 6pm subcutaneously (0.24 mg/Kg) to: a) patients with a circulating CD34+ cell count < 10/uL (on either day 4 or 5) and b) patients with a fi rst apheresis yield < 1.0 x 10 6 CD34+/kg. G-CSF continues at the same dose (5-10 ug/Kg) and an apheresis is scheduled for the following morning. Since October 2009, a total of 146 patients were managed according to the Pamplona Protocol. 11 out of the 13 patients (85%) who were classifi ed as PM before mobilization (9%) had a circulating CD34+ cell count < 10/uL on day 4 and received Plerixafor as planned, demonstrating the high positive predictive value of the protocol. In addition, 9 patients (6%) failed to mobilize on day 5 despite having a median of 0.77 risk factors and also received Plerixafor. The diagnosis for the 20 patients that received Plerixafor was MM (n= 7), NHL (n=11), HL and Amyloidosis (n=1 each). We observed a median of 3 fold increase in the number of CD34 circulating cells. The median CD34+ cell dose harvested was 2.86 x 10 6 /Kg (range 0.32-5.69). There were no diff erences between the CD34+ cell dose in patients receiving Plerixafor on day 4 (median 2.6 x 10 6 /Kg) and day 5 (median 3.1 x 10 6 /Kg). The median number of apheresis was 1 (1) (2) (3) . Only one patient failed to mobilize suffi cient CD34+ cells. G-CSF and Plerixafor treatment was well tolerated. Adverse events were grade 1 in severity and were mostly gastrointestinal. The Pamplona Protocol was able to predict PM before G-CSF administration allowing for early Plerixafor administration. Despite a 13.7% of PM in our series, 145/146 (99%) patients were able to harvest suffi cient CD34+ cells for autologous SCT.

Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies: a systematic Cochrane analysis U. Holtick, M. Müller, J. Chemnitz, S. Theurich, N. Skoetz, C. Scheid, M. von-Bergwelt-Baildon University Hospital Cologne (Cologne, DE) Background: Allogeneic hematopoietic stem cell transplantation is an established treatment option for haematological malignancies. In the last two decades peripheral blood stem cells (PBSC) predominantly replaced bone marrow (BM) as stem cell source due to faster engraftment and immune reconstitution as well as practicability issues. As transplant indications and conditioning regimens have changed, it is still under debate whether the choice of the stem cell source may have impact on the transplant outcome. Objectives: To assess the effect of BM versus PBSC transplantation in haematological malignancies with regard to overall survival, incidence of relapse and non-relapse mortality (NRM), disease free survival (DFS), incidence of GvHD and time to engraftment. Search methods/ Selction criteria: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1948 to present), trials registries and conference proceedings. The search was conducted in 10/2011 (update 11/2012) for randomised controlled trials comparing BM and PBSC transplantation in haematological malignancies. Data collection and analysis: Two review authors independently screened abstracts, extracted data and analysed the data. We contacted study authors for additional information. Results: In this meta-analysis we included eight randomised controlled trials involving a total of 995 participants. The primary outcome overall survival was not signifi cantly diff erent between the study groups (HR 1.21 Conclusion: Overall and disease-free survival as well as NRM are not aff ected by the stem cell source although there was significantly more chronic GvHD with PBSC used. This Cochrane analysis confi rms older analyses with a longer follow-up and a larger patient cohort.

Skeletal disease in myeloma patients is yet another independent risk factor to predict poor mobilization in myeloma patients: need for upfront plerixafor? P. Lokireddy, A. Hunter, S. Gribbin, S. Ward University Hospitals of Leicester NHS Trust (Leicester, GB) There is increasing use of Plerixafor, a novel CXCR4 inhibitor in mobilizing Peripheral Blood Stem Cells (PBSC) particularly in patients who failed with conventional methods. The safety and preliminary effi cacy of Plerixafor in combination with chemotherapy and G-CSF has been established. (1) There are many known factors, which infl uence poor mobilisation including bone marrow disease, multiple treatments, age and certain chemotherapy. (2) There is some data to suggest Plerixafor delays platelet engraftment. We are authorized to use Plerixafor only in failed harvests, as per our local guidelines. We have performed retrospective analysis of patients who underwent PBSC collections from July 2009 to April 2012. We specifi cally analysed data for reviewing neutrophil and platelet engraftment times. We also examined characteristics of the Plerixafor group in terms of risk factors for failed mobilisation. Out of 134 autografts, 113 received conventional mobilisation and 21 Plerixafor mobilisations (15% of total autografts) and Only one patient failed to harvest with Plerixafor. Neutrophil engraftment is established when the neutrophil count reaches 0.5x 109/l, Platelet engraftment is achieved with a platelet count of 50 x 109/l and above. Neutrophil engraftment time for Plerixafor is comparable to the non Plerixafor group (median time to engraftment is 16 days in both groups), 75% of patients have shown neutrophil engraftment within 20 days in both groups. Fifty fi ve percent of patients had platelet engraftment in the non Plerixafor group compared to forty six percent in the Plerixafor group with in thirty-day period. The median platelet engraftment was 33 days in the Plerixafor group compared to 37 days in the non Plerixafor group. There were no reported side eff ects noted in Plerixafor group. We specifi cally looked at the Myeloma group who required Plerixafor and analyzed known parameters to look for the cause of failed mobilisation. Out of twenty-one there were only two patients with multiple treatments and only one patient in the cohort had cytopaenia. There was no documented evidence of sepsis and none had prior exposure of Lenolidamide or Melphalan. Not all patients had a bone marrow aspirate prior to harvest or at the end of treatment, hence we could not correlate marrow hypoplasia with failed mobilisation. The striking parameters were patients with extensive disease at presentation and with skeletal disease and Plasmacytoma seems to correlate with poor mobilization. Sixty four percent of plerixafor group had extensive skeletal disease compared to forty percent in non plerixafor mobilised group. Risk adapted strategies for pre-emptive (3), salvage use or upfront use of Plerixafor as a fi rst line PBSC mobiliser for high risk patients like high tumour burden, skeletal disease, multiple treatments, patients with poor marrow reserve will prevent delays and unnecessary anxiety to patients. Reference: 1. M J Dugan, Bone marrow Transplantation (2010) Background: In order to provide information for cord blood (CB) bank to adopt optimal collection strategy and to make CB banks operate effi ciently, we investigate the reasons of exclusion of CB units in a 3-year period of recruitment. Materials and methods: We analyzed the reasons of exclusion of potential CB donation records from 2004 to 2006 in Tzu-Chi Cord Blood Bank and compared the results in a 3-year period. We grouped these reasons of exclusion into 5 phases according to the time sequence: before collection, during delivery, before

[P524] S118 processing, during processing and after freezing, and analyzed the reasons at each phase. Donors were recruited at 36 weeks of gestation. Education was provided and comprehensive history screen was performed. Consenting, CB collection and transportation, testing, processing, cryopreservation and long-term storage were subsequently performed if banking criteria were met. Results: Between 2004 and 2006, there were 10,685 deliveries with intention of cord blood donation to our Institute. There were 6,280 donations excluded and the number of fi nal eligible CB units was 4405 during this 3-years period. Overall exclusion rates were 93. 1%, 48.4% and 54.1% in 2004, 2005 and 2006 , respectively. We excluded 612 pregnant women before delivery, 133 CB units during delivery, 80 units before processing, 5,010 units during processing and 421 units after freezing. There were 24 CB units with unknown reason of ineligibility. Totally, 41.2% of the CB units were considered eligible and entered the search registry. Overall, low CB weight and low cell count were the fi rst 2 leading causes of exclusion (48.6% and 30.9%, respectively). The incidences of artificial error, holiday/transportation problem, low weight and infant problems decreased year by year. Conclusion: The exclusion rate was high at the beginning in our study as was in previous literatures. Effi cient work is necessary to decrease the expenditure of a public CB bank. Understanding the exclusion reason of CB may help in improving the effi ciency of CB banking programs in the future.

Optimizing plerixafor use in poor mobilizers. Should remobilization or 'on demand' use be preferred? A single-centre experience I. Marton, Á. Báthori, Á. Bereczki, D. Földeák, N. Adamkovich, S. Modok, T. Gurbity -Pálfi , A. Szoke, K. Piukovics, É. Trucza, É. Pósfai, Z. Borbényi University of Szeged Albert Szent-Györgyi Medical Center (Szeged, HU) Objective: The most common stem cell source of autologous stem cell tranplantation is the mobilized peripheral blood. To assess plerixafor use in poor mobilizers to survey the incidence of patients with poor mobilization and to evaluate the eff ectiveness of remobilization strategy, and "pre-emptive use". Methods: In our retrospective analysis (2009) (2010) (2011) (2012) , 86 patients' mobilization procedure was analyzed, 45 female, 41 male with median age of 57 years (range: 19-69 years). 53 myeloma multiplex; 19 non-Hodgkin lymphoma, and 14 Hodgkin lymphoma patients. 11 patients (13%) required plerixafor for the successful completion [P524] S119 of mobilization. Remobilization group (group 1) and a pre-emptive group (group 2) were created. Group 1 contained 5 patients, who had previously one or more unsuccessful mobilization attempts. Group 2 contained 6 patients, who had never been mobilized before in which 3 patients were defi ned as predicted poor mobilizers and 3 patients were diffi cult to mobilize due to poor stem cell mobilization kinetics. The target yield was > 4 x 10 6 CD34+ cells/kg body weight. All patients received plerixafor plus G-CSF with or without chemotherapy. Plerixafor was administered depending on the kinetics of CD34+ cells and white blood cell recovery. Results: In group 1 the median of circulating CD34+ cells after plerixafor administration was 36 cell/microl (range: 9-150) versus group 2 in which 45 cell/microl (range: 25-63) could be observed. The median of collected CD34+/kg cells was 7.11x10 6 /kg (range: 4.38 -13.2) in group 1, whereas in group 2 the median was 5.02x10 6 / kg (range: 3.08-6.34). Median apheresis number was 4 (range: [1] [2] [3] [4] in group 1,in group 2 the median was 3 (range: [2] [3] [4] . Two patients in group 1 required 2 remobilization. The average plerixafor dose in group1 was 2.5 vials, in group 2 it was 1.66 vials by which the required target cell number could be achieved. From 11 patients 9 underwent stem cell transplantation and were engrafted. Conclusions: All detailed patients achieved the required target cell number for ASCT. Plerixafor could be combined with G-CSF only or chemomobilization strategy. Our experience confi rmed the view that pre-emptive administration of plerixafor may rescue the mobilization process, and enable the patient to proceed to ASCT without delay. The kinetics of hematopoietic recovery after chemotherapy may allow for early (just in time) intervention with plerixafor and may help reduce the risk of the mobilization failure.

Evaluation of the Amicus Separator for mononuclear cell collection T. Kanouni, P. Latry, S. Bouhya CHU Montpellier (Montpellier, FR) Purpose: Montpellier University Hospital performs therapeutic apheresis since 1978. In 2011, 1217 procedures were performed with 2 Spectra, 1 Optia (Terumo BCT) and 1 Com.Tec (Fresenius).

We evaluated in 2012 the Amicus Separator (Fenwal) as an alternate platform to collect mononuclear cells (MNC). The objective was to assess procedure performance and safety. Methods: A total of 17 Amicus (SW 4.3) autologous stem cell collections were compared with 17 Spectra procedures matched from the database (N=2427) for similar patient characteristics, mobilization regimen, blood counts and processed volumes. Data was also compared with previously performed procedures on Com.Tec and Optia. The Amicus Separator (software V.4.3) was set up with: 12:1 WB: ACD-A ratio, number of cycles (10 cycles ± 3), blood volume per cycle (1000ml if WBC > 35/μl or 1400ml if WBC < 35/μl), MNC off set (2.3 ml to 1.5 ml) and RBC off set (6.0 ml). The performance was evaluated based on 1) CD 34+ effi ciency; 2) CD34+ yield; 3) Procedure time; 4) Patient PLT depletion; 5) Overall cell content of the collected product; 6) Adverse events. Results: CD34+ collection effi ciency (N=16) was 44.4± 14.8% for Amicus vs 50.2 ± 20.5% for Spectra. CD34+ yield (N=17) was 6.3 ± 11.0 x 10E6 /kg for Amicus vs 4.4 ± 4.7 x 10E6 /kg for Spectra. Collection time (N=17) was 295 ± 42 min for Amicus and 248 ± 31 min for Spectra. Harvested platelets (N=16) were 4.8 ± 1.2 % for Amicus vs 26.5 ± 18.7 % for Spectra corresponding to a patient platelet loss of respectively 11.4 ± 11.0% (N=17) vs 40.8 ± 21.1% (N=15). The overall cell content for Amicus and Spectra is shown in graph 1. The key performance indicators for the four tested apheresis platforms are presented in table 1. Adverse events with Amicus were mild. No citrate related reactions were observed. Conclusion: CD34+ collection effi ciency with Amicus was satisfactory and comparable to Spectra with signifi cantly lower platelet depletion from the patient. Yield and purity of the collected product are predictable. Performance of the four tested separators is overall comparable with the exception of the lower platelet loss with Amicus. The full automated control of the cell separation and collection frees up operators from manual monitoring, while he still have the possibility to adjust parameters during the procedure.

Preemptive use of plerixafor in patients with lymphoproliferative diseases undergoing haematopoietic stem cell mobilization V. Telonis, T. Vassilakopoulos, E. Lalou, G. Boutsikas, Z. Galani, M. Moschogiannis, A. Dimitrakopoulou, C. Kalpadaki, A. Meletiou, K. Anargyrou, S. Sachanas, P. Flevari, G. Gainaru, A. Koutsi, L. Papageorgiou, A. Zannou, M. Dimou, N. Vyniou, P. Panayiotidis, M.-C. Kyrtsonis, P. Tsaftaridis, J. Meletis, M. Angelopoulou National and Kapodistrian University of Athens (Athens, GR) Plerixafor is a CXCR4 inhibitor that disrupts the adhesion of hematopoietic stem cells (HSC) to bone marrow stroma resulting in the mobilization of HSC to peripheral blood. It is indicated in combination with G-CSF in poor mobilizers. Using Plerixafor, patients in whom HSC collection has failed succeed in collecting suffi cient numbers of CD34+ HSC and may undergo subsequent autologous [P526] S120 stem cell transplantation. Aim: To evaluate the preemptive use of plerixafor in lymphoma and myeloma patients undergoing HSC collection. Methods: We retrospectively evaluated all patients from a single Hematology Unit in whom plerixafor was used preemptively: Patients were mobilized with chemotherapy or G-CSF and were not intended to receive plerixafor, unless absolute peripheral blood CD34 counts at the expected peak day were either below <20/μL or suboptimal for the desired HSC target. Results: Rescue plerixafor was used in 32 patients and 38 mobilization attempts; 6 patients underwent 2 mobilization procedures. Their median age at mobilization was 54 years, there were 18 females and 14 males, 12 had multiple myeloma, 1 Hodgkin and 19 non-Hodgkin lymphoma, 22 had received 1-2 prior chemotherapy regimens, whereas 16 patients ≥3 and 84% were chemosensitive. Mobilizing regimens included platinum-based chemotherapy in 6 (16%), ifosfamide-based in 6 (16%), cyclophosphamide in 13 (34%) and G-CSF in 13 (34%). Plerixafor was administered once, twice or thrice in 20, 11 and 7 cases respectively. One collection was performed in 16 patients, two in 14 and 3 in 8 patients. The median absolute CD34 counts after plerixafor (CD34-post) were signifi cantly higher compared to those before Plerixafor (CD34pre), i.e. 37.5/μL (4-208) vs 19.2/μL (2.6-67) , respectively, p<0.001. The median total number of CD34+cells/kg collected was 4.025 x 106/kg (0.49-16.77) and the median number of CD34+cells/kg per collection was 2.415 x 106/kg. Univariate prognostic factor analysis is shown in the table. Conclusion: Preemptive use of plerixafor according to circulating absolute CD34 counts at the expected days of peak results in suffi cient HSC collections, and might prove more cost-eff ective.

'Platelet gel from cord blood' national project: preliminary data on internal validation at the Pavia cord blood bank I. Sbarsi (1) , P. Bergamaschi (1) 

Cord blood (CB) represents an alternative stem cell source for transplantation in patients aff ected by haematological diseases. An accurate evaluation of all CB characteristics and maternal medical history ensures that only those units suitable for clinical use according to FACT-Netcord standards are banked. This leads to discard a huge amount of collected CB units. Recently the Milano CB Bank launched the idea to produce platelet gel (PG) from CB not eligible for unrelated transplantation and is coordinating a national project for applying CBPG to wounds repair in diabetic patients. At the Pavia CB Bank we modifi ed the protocol by Mazzucco at al. to verify its feasibility in producing CBPG in our setting. Only CB units with total nucleated cells <1x10 9 and platelet >200 x10 6 /ml were enrolled in this study. CB was collected, with mother's informed consent, in collection kit containing 22 ml CPDA (JMS) and was processed within 48 hours. After addition of 10 ml ACD and saline to a fi nal volume of 150 ml, CBPG was obtained with a three-step procedure: fi rst, a soft spin centrifugation (180 g x 10 min) to obtain platelet-rich plasma (PRP); second, an additional soft spin centrifugation (100g x 10min) to remove leukocytes as much as possible; third, an high-spin centrifugation (1000g x 10min) to pellet the platelets. Then platelet concentrate (PC) was resuspended in 8 ml of platelet poor plasma (PPP) and frozen at -80°C. A 6 mL plastic bag was used to ensure storage and transport conditions appropriate for clinical purposes (SIAD Healthcare). After thawing, CB-PCs were pooled according to ABO compatibility to reach 1.5-2 x10 9 platelets/ml and batroxobin (Plateltex-Act ®) was added according to the manufacturer instructions. 25 CB units with a mean platelet concentration of 255 x10 6 /ml were processed to obtain PCs with a mean platelet content of 835 x10 6 /ml and 35% of platelet recovery on average. Leukocyte contamination was always < 1 x 10 6 . Sterility testing performed at the end of processing resulted negative in all CB-PCs except of one. The addiction of batroxobin to pooled CB-PCs was able to obtain gelation demonstrating that this adapted protocol is feasible in producing CBPG in our hands. In future this strategy will rescue unsuitable CB to a new diff erent clinical use and reduce the discard rate in CB Banks. This will favorably impact on both donor's mothers' and collection site personnel's expectations: to be helpful for patients.

Zarzio plus chemotherapy as peripheral blood stem cell mobilization strategy in patients with haematological diseases candidated to autologous stem cell transplantation A. Ostuni, M.R. Morciano, A. Mele, M. Fina, D. Carlino, G. Greco, S. Sibilla, R. De Francesco, B. Rossini, C. Derisi, V. Pavone Hospital G Panico (Tricase, IT) Introduction: Biosimilar granulocyte colony-stimulating factor (G-CSF) has been recently approved for mobilization of peripheral blood stem cell (PBSC). Various recent reports describe a comparable effi cacy as original G-CSF with a signifi cant reduction of costs. In this study we assessed safety and effi cacy of Zarzio (Zarzio ® Sandoz Biopharmaceuticals) in order to mobilize PBSC in patients (pts) with hematological malignancies and to ensure an optimal engrafment capability. Methods: From June 2011 to December 2012, a cohort of 44 pts was studied. All pts received disease specifi c chemotherapy plus Zarzio at a dose of 5μg/kg body weight twice daily. Programmed CD34+ cells target dose was 4x10 6 /kg for pts with non-Hodgkin and Hodgkin Lymphomas, Leukemia and 6x10 6 /kg for Multiple Myeloma. Plerixafor was used in predicted poor mobilizer pts. Amicus Fenwal separator was used in all leukapheresis procedures. Results: Patients' demographic characteristics are listed in table 1. Median time of Zarzio administration was 8.2 days; 38 pts (86%) reached the target dose to perform autologous stem cell transplantation with an average number of apheresis of 1.45. Collection data are in table 2. Poor mobilization was documented in 13 pts (29%), mainly of them received more than 3 chemotherapy regimens previously. Six pts failed mobilization, two of them even after the administration of Plerixafor. Among pts who have mobilized, 21 (55.3%) were submitted to high-dose chemotherapy followed by autologous (18) or allogenic (3) PBSC infusion. Median of CD34x10 6 /kg infuse and viability were 4.3 x10 6 /kg (0.8-6.2) and 75. 3% (51.4-88.2) , respectively. Engraftment occurred in all pts. The median time to absolute nucleated cells >500 and to platelets >20000 was 12 days (10-23) and 14 (10-33) after CD34+ infusion, respectively. Conclusion: Biosimilar G-CSF, such as Zarzio, may represent an eff ective strategy for PBSC mobilization and collection after chemotherapy in terms of CD34+ cell dose and timing of collection. A study of comparison will be necessary to establish advantages in terms of cost.

Comparison of 'plerixafor rescue' with standard use of plerixafor in autologous donors who fail mobilization following G-CSF with or without prior chemotherapy K. Wilson, D. Powell, S. Thompson, S. Phillips, W 

Background: Autologous haematopoietic progenitor cell transplantation (HPCT) is an established treatment for selected patients with lymphoma or multiple myeloma. However 15-30% of patients fail mobilisation making them ineligible for HPCT. Plerixafor is a selective reversible CXCR4 antagonist which, when used in combination with granulocyte colony stimulating factor (G-CSF), results in successful mobilisation in 60-85% of patients who previously failed mobilisation. Rationale: Plerixafor was approved for use in Wales for lymphoma and myeloma patients who failed mobilisation, precluding use in patients predicted to fail mobilisation. The ability to rescue a failed mobilisation attempt would minimise the under-utilisation of apheresis slots and prevent the need to re-book patients for harvest making the collection programme more effi cient and potentially reducing cost. Methods: To comply with use only in failed mobilisers, plerixafor rescue was limited to patients whose peripheral blood (PB) CD34 count after four consecutive days of G-CSF at a dose of 10 mcg/ kg (without prior chemotherapy) was insuffi cient to proceed to apheresis. These patients were given a fi fth dose of G-CSF followed by plerixafor 240 mcg/kg at 2200 h. On day 6 a further dose of G-CSF was given at 0800h followed by apheresis. Further plerixafor and G-CSF were given as required up to a maximum of 4 plerixafor doses. Patients failing mobilisation following G-CSF and chemotherapy were re-mobilised with the standard plerixafor protocol consisting of G-CSF 10 mcg/kg days 1-4, plerixafor 240 mcg/kg at 2200 h on d4 followed by G-CSF on d5 at 0800h followed by apheresis. Up to 4 doses of plerixafor were allowed. Results: Between May 2011 and October 2012, 120 collections were performed using G-CSF with (n = 70) or without (n = 50) prior chemotherapy. G-CSF alone was limited to myeloma patients attaining at least a very good partial response (VGPR). All other patients were mobilised with cyclophosphamide (myeloma patients without VGPR)or salvage chemotherapy (lymphoma patients) + G-CSF (chemo-G). Priming failure was higher with G-CSF (13/50 = 26%) than with chemo-G (4/70 = 6%) and with cyclophosphamide (25%) than salvage chemotherapy (4%). Nine of 11(82%) plerixafor rescue attempts were successful compared with 13/15 (87%) standard plerixafor for an overall plerixafor success rate of 22/26 (85%). Conclusion: Plerixafor rescue used after G-CSF mobilisation failure is as eff ective as re-mobilisation and prevents wastage of apheresis slots. van der Veeken, E.H.C.M. Römers, A. Kelder, F. Kessler, A. Dräger, J.J.W.M. Janssen, G.J. Schuurhuis VU University Medical Center (Amsterdam, NL) Introduction: In an allogeneic MUD transplantation, a transplant centre requires a minimum number of CD34 positive cells. If not reached the time to engraftment, the critical clinical care period for the patient and the duration of hospital stay may be aff ected. Sometimes the number of CD34+ cells determined by the collection centre is diff erent from that determined by the transplant centre. The most critical situation emerges when, according to the collection centre, the minimum number of CD34+ cells was harvested while according to the transplant centre the required minimum number has not been reached. These discrepancies were also seen in the grafts with large CD34+ amounts. We investigated whether these discrepancies are related to the time period between collection and transplantation or the white blood cell (WBC) concentration of the graft. Method: In a retrospective analysis in 132 MUD transplantations performed from September 2008 until October 2012, the total number of CD34+ in the graft was determined both by the collection centre and the transplant centre. From these data, the recovery of CD34+ cells was determined and the two factors of possible infl uence were assessed. Results: In the 132 MUD transplantations, the CD34 yield measured in the transplant centre was median of 97% (range 56 to 147%) of values in collection centre. The transplant centre found 24 cases that did not contain the requested minimal amount of CD34+ cells. A graft failure occurred in 5 of these 24 transplantations (21%) compared to only 9 of 108 other transplants (8%). In 9/24 cases only the collection centre reported enough CD34 yield, but these contained 2/5 graft failures. In transplants with a time period between collection and transplantation less than 40 hrs the median CD34 recovery was 93% (78%-129%); with a time period > 40 hrs 98% (56%-147)(no signifi cant: p=0.60). Regression analysis shows no correlation between the WBC concentration and the CD34 recovery; r 2 =0.012. When divided in 3 groups (WBC in millions per ml), ie <200, in between 200 and 300 and >300, CD34 recoveries were median 94% (62%-129%), 97% (63%-130%) and 97% (56%-147%). Conclusion: In roughly 10% of the transplants, graft failure was observed; this occurred in grafts with too low CD34 content according to both collection centre and transplant centre but also according to transplant centre alone. Discrepancies between collection and transplant centre CD34+ are not related to time period between collection and transplantation or WBC concentration.

J. Oberink, Y.F.C.M.

Collection of peripheral blood stem cells in patients and donors using the Amicus ® Separator and the Spectra Optia®

A. Sputtek (1) , C. Schubert (1), S. Peine (1) , A. Rowe (2) (1)University Medical Center Hamburg-Eppendorf (Hamburg, DE) ; (2) New York University School of Medicine (New York, US) Because technical support of the Cobe ® Spectra Apheresis System after 2014 is uncertain, we therefore compared the eff ectiveness of two alternative blood cell separators, i.e. the Spectra Optia ® Apheresis System and the Amicus ® Separator. After mobilization using G-CSF alone or G-CSF plus Plerixafor, 36 PBSC components were collected with each machine from patients and healthy donors, with 15 persons undergoing procedures with both machines. We tried to adjust the process time to 4 h (Amicus: 250 ±15 min, Optia 244 ± 15 min, mean ± standard deviation), irrespective of the processed blood volumes. As a consequence the volumes diff ered signifi cantly (P = 0.006, two-tailed Mann-Whitney-U-test): 10.9 ± 1.9 L for the Amicus and 9.8 ± 1.6 L for the Optia. But the volumes of the anticoagulant ACD-A used (942 ± 166 ml for the Amicus and 924 ± 138 ml for the Optia, respectively) did not diff er significantly. The numbers of collected CD34+ cells, CD34+ collection effi ciencies, and CD34+ collection rates amounted to 386 ± 413 x 10 6 , 64.6 ±14.6%, 1.55 ±1.65 x 10 6 /min (Amicus) and 378 ± 404 x 10 6 , 71.1 ± 12.0%, 1.56 ±1.69 /min (Optia), respectively. However, these diff erences were not signifi cant (P > 0.05). The components collected with the Amicus contained 21.3 ± 8.5 x 10 9 mononuclear cells compared with 18.4 ± 8.7 x 10 9 , for the Optia, however, this diff erence was not signifi cant as well. Whereas the Optia products showed a slightly higher contamination with granulocytes (11.0 ± 6,9 x 10 9 ) vs. 9.2 ± 4.8 for the Amicus, this diff erence was not signifi cant. Product hematocrits due to contaminating red cells were twice as high for the Amicus (0.029 ± 0.016 l/l) in comparison to the Optia (0.013 ± 0.019 l/l), and this was a signifi cant diff erence (P < 0.0001). On the other hand, the number of platelets contained in the Optia products was almost 4 times higher than in the case of the Amicus products (2.6 ± 1.5 x 10 11 vs. 0.7 ± 0.3 x 10 11 , P < 0.0001 ). We observed typical moderate citrate related reactions (perioral discomfort, paresthesia, nausea) in 4 out of the 72 runs, all of them could be stopped by either oral or intravenous Ca 2+ administration. In conclusion, both blood cell separators showed a good performance for peripheral blood stem cell collections in patients and donors and are suitable to replace the Cobe ® Spectra Apheresis System.

Modelling improvements in cell yield of banked umbilical cord blood and the impact on availability of donor units for transplantation into adults N. Kekre (1) , J. Philippe (2) , R. Mallick (1), S. Smith (2) , D. Allan (1) (1)University of Ottawa (Ottawa, CA); (2)Canadian Blood Services (Ottawa, CA) Background: Umbilical cord blood (UCB) is used increasingly as an alternative source of hematopoietic stem cells for allogeneic transplantation. Thresholds of pre-storage cell numbers associated with timely engraftment are well established yet availability of adequate donor units continues to be lacking for many patients and especially adults. We postulate that even modest improvements in the yield of cells following storage and thawing will allow more patients to fi nd suitable units with suffi cient cell numbers and proceed to transplant. Methods: We utilized 21 consecutive anonymous umbilical cord blood searches performed by Canadian Blood Services to simulate the impact of improved cell yield. Published criteria were used for selecting UCB units from the anonymized searches based on total nucleated cells (TNC) per kg recipient weight and in accordance with the degree of HLA matching. The number of donors available per patient was calculated based on hypothetical recipient weight of 50 kg, 70 kg and 90 kg. The analysis was repeated by increasing the fraction of cells surviving storage and thawing by 10%, 20% and 30%. Results: Increasing the percentage of cells that survive storage by 30% lowered the TNC threshold used to select UCB units and demonstrated an increase in UCB units available for patients weighing 50 (p=0.011), 70, (p=0.014) and 90 kg (p=0.003), controlling for diff erences in HLA compatibility using a mixed eff ects analysis. Moreover, if recipients were 90 kg, 12 out of 21 patients had access to at least one UCB unit that met standard criteria, and this increased to 19 out of 21 patients (p=0.035) when the fraction of cells surviving storage and thawing increased by 30%. Conclusion: We conclude that a modest increase in the yield of cells in banked UCB units can signifi cantly increase donor options for adult patients undergoing HSCT. Improved processing, cryopreservation and storage techniques could allow substantially more patients to undergo HSCT using UCB.

One step can make a diff erence in the optimization of stem cell collection S.M. Tan, S. Bai Renganathan, M.Z. Zakaria, T.C. Ong, Y.K. Guan, F. Kassim, A.S. Nordin, J. Tan, J.S. Rajasuriar, A.N. Kori, X. Sim, K.M. Chang Hospital Ampang (Ampang, MY) Introduction: Peripheral blood stem cell (PBSC) harvesting and storage incur signifi cant cost and resources. For the last thirteen years since we started our autologous stem cell transplantation (ASCT) service, the cases have been increased tremendously. We implemented mobilizing patients based on peripheral blood CD34 count (PB-CD34) cutoff points at least 10/uL as one of our optimization of PBSC collection measures since June 2011. Method and results: We compared the outcome of PBSC collection in 18 months before (pre) and after (post) the implementation of mobilizing patients based on PB-CD34 cutoff points at least 10/uL. A total of 499 patients (215 pre and 284 post implementation) have been subjected for PBSC mobilization using G-CSF alone or in combination with chemotherapy mainly consists of high dose cyclophosphamide or etoposide since November 2009. Only 394 patients (78.96%) (182 pre and 212 post implementation) managed to undergo apheresis. Majority were lymphoma patients (Non-Hodgkin's lymphoma (NHL) 189; 47.97% and Hodgkin's disease (HD) 92; 23.35%), followed by multiple myeloma (MM) 70; 17.77% and acute leukaemia (acute myeloid leukaemia (AML) 36; 9.14% and acute lymphoblastic leukaemia (ALL) 7; 1.78%). There was no statistic difference in disease, age and gender distribution in between both groups. Among the 182 patients who underwent apheresis in pre implementation cohort, only 133 patients (73.07%) were successfully mobilized >2x10 6 /kg of CD34 as compared to 195 patients (91.98%) among the 212 patients in post implementation cohort. 96 cases were mobilized with PB-CD34 below 10/uL among pre implementation cohort as compared to 21 cases in post implementation cohort retrospectively. Furthermore, there were more patients underwent inappropriate PBSC collection (97.87% versus 40%) among the pre implementation cohort when mobilized with PB-CD34 below 10/uL. By using one step measure of deciding PBSC mobilization based on PB-CD34 cutoff points at least 10/uL, we have improved the successfulness of PBSC collection more than 18% and reduced the wastage of more than 57%. The cost effectiveness after implementation of this measure will be presented later.

Background: The Amicus Separator (Fenwal) can be used to collect mononuclear cells (MNC). The procedure is automated and doesn't require operator intervention for controlling the separation. This allows limiting the variation of the collection performance. Another benefi t is the low platelet contamination of the MNC product avoiding signifi cant platelet loss in patients. Amicus Separator is also characterized by high MNC collection effi cacy. Mont-Godinne BTC uses both Amicus (Fenwal) and Spectra (Terumo BCT). We report on the comparison of Amicus and Spectra in our institution during one year. Methods: We compared routine procedures performed in 2011: 68 MNC collections with Amicus (SW 3.2) and 36 MNC collections with Spectra (SW 7.2). Amicus settings are adjusted based on the patient's white blood cells (WBC) pre-count. For WBC <25K/μl, the whole blood (WB) collected per cycle is 1200 ml , the maximum fl ow rate 65 ml/min and the RBC off set 7.0 ml while for WBC >25K/μl, the WB per cycle is 800-1000 ml, the maximum fl ow rate 80 ml/min and the RBC off set 8.0 ml. MNC off set is 2.3 ml and MNC set point 0.6 in both cases. The evaluated parameters were WBC yield, CD 34+ yield, CD34+ collection effi cacy and platelet depletion. The CD34+ collection effi cacy is defi ned as CD34+ yield / ((pre + post /2) * WB processed). The adverse reactions due to citrate intolerance were recorded We also studied a subset of 13 patients collected on both Amicus and Spectra on two consecutive days Results: Total blood volume processed and whole blood fl ow rate were signifi cantly higher on SPECTRA. Platelet depletion was signifi cantly lower on AMICUS (22 ± 20% vs 38 ± 13%) . No signifi cant diff erences were observed for WBC yield (176 ± 72.108 vs 204 ± 116.108), CD34 yield (252 ± 212.106 vs 208 ± 140.106), CD34 collection effi cacy (63 ± 14% vs 59 ± 15%) or CD34 yield per minute of collection (1.04 ± 0.97.106/min vs 1,11 ± 0,82.106/min). The number of cases of citrate intolerance was 17 (25%) for Amicus and 7 (19%) for Spectra. 6 procedures (8.8%) required IV calcium for Amicus and 4 (11.1%) for Spectra. No procedure was stopped. Data from the subset of 13 patients collected on both machines will be presented during the fi nal communication. Conclusion: The CD34 + collection effi cacy with Amicus is equivalent to Spectra but platelet depletion in patients is signifi cantly lower. The Spectra procedure is manually controlled. The Amicus MNC procedure is automatically controlled, not requiring significant operator interventions.

Autologous peripheral blood stem cell collection and transplantation in patients with multiple myeloma previously treated with thalidomide and/or lenalidomide using a cyclophosphamide-based mobilization regimen R.M. Grubovic, A. Alavi, G.J. Schiller University of California Los Angeles (Los Angeles, US) Background: High-dose chemotherapy followed by autologous transplantation of peripheral blood stem cells (PBSC) plays an important role in the management of multiple myeloma. In order for successful engraftment to occur, adequate numbers of high quality PBSC must be harvested prior to transplantation.

Mobilization of PBSC in heavily pretreated patients is often associated with unsuccessful harvests. The aim of this study is to present our experience utilizing an intermediate-dose cyclophosphamidebased mobilization regimen in multiple myeloma patients previously treated with Thalidomide and/or its analog Lenalidomide. Material and Method: This is a retrospective study performed at the Department of Medicine/Hematological Malignancy/Stem Cell Transplant Unit at UCLA between 2006 and 2011. All patients underwent a single mobilization regimen that included, Cyclophosphamide 2.5gm/m 2 iv once, Granulocyte Colony-Stimulating Factor (G-CSF) 10mcg/kg/day sc until collection day 1, and Prednisone 2mg/kg po daily x 5 in all multiple myeloma patients. Minimum dose required to ensure successful and sustained engraftment was 2x10 6 /kg CD34+cells, whereas the optimal dose was 5x10 6 /kg CD34+cells. PBSC harvesting was performed with COBE Spectra processing 2-2.5 total blood volume/per apheresis session. Results: Autologous PBSC transplantation was performed in 103 multiple myeloma patients with high-dose Melphalan. 212 autologous PSBC apheresis procedures were done, with median number of apheresis per patient of 1.0 (range1-12). Median age was 55.7y (range 32. 6-75.1) . 70 patients (68.9%) required just one collection to achieve the requisite number of cells, 15 patients required 2 collections (14.5%), and 14 patients (17.4%) had more than two collection procedures. There was only one patient with fewer than 2x10 6 /kg CD34+cells (0.9%) collected and he underwent bone marrow harvesting. Median CD34+cells collected were 6.7 x10 6 /kg, range (1.4-33.5x10 6 /kg CD34+cells). Median CD34+cells infused were 5.8 x10 6 /kg, range . Most patients achieved neutrophil recovery in 10 days (range 1-18). Conclusion: Despite pre-transplant use of Thalidomide and/or Lenalidomide, combination of G-CSF, Cyclophosphamide and Prednisone happened to be an excellent mobilization strategy which permits adequate collection with the majority of patients requiring only one apheresis procedure with mobilization failure in fewer than 1%.

The eff ect of diabetes mellitus and end-stage renal disease on the number of CD34+ cells in the blood C. Pala (1) The aim of this study was to investigate the eff ect of end-stage renal disease (ESRD) and diabetes mellitus (DM) on the number of stem cells in the peripheral blood. Sixty-two patients diagnosed with ESRD who had not received dialysis previously, 25 patients with a diagnosis of DM without nephropathy, and 21 healthy volunteers were included in the study. The group diagnosed with ESRD was divided into two groups. First group (DM-CRD) consisted of 28 patients with DM who had developed chronic renal disease (CRD). Second group (NON-DM-CRD) consisted of 34 patients without DM who had CRD by etiology. The routine complete blood count, renal function, and number of CD34+ cells were determined for all of those involved in the study. The microalbumin/creatinine levels were measured, and glomerular fi ltration rates were calculated in all patients. The number of CD34+ cells was found to be signifi cantly lower in the DM control group and DM-CRD group compared with the healthy group. No statistically signifi cant diff erence was found between the NON-DM-CRD and the healthy control group. There was a moderate negative correlation between the ratio of microalbumin/creatinine and the number of CD34+ cells. A signifi cant reduction in the number of CD34+ cells was shown in subjects with DM and ESRD caused by diabetic nephropathy.

Outcome of stem cell mobilization following G-CSF versus G-CSF plus chemotherapy in adult patients with haematological malignancies W. Ingram (1), D. Powell (1) , S. Thompson (1) , D. Davies (1) , H. Bass (1) , J. Thomas (2) , S. Al-Ismail (2) , H. Sati (2) , S. Phillips (1), K. Wilson (1) (1)University Hospital of Wales (Cardiff , GB); (2)Singleton Hospital (Swansea, GB) The ability to mobilise adequate number of CD34+ stem cells is a pre-requisite for autologous stem cell transplantation (ASCT). Selection of the optimal priming regimen is vital to maximise the CD34+ cell yield. Furthermore, adherence to priming protocols minimises adverse events such as prescribing errors and enhances effi ciency of the service through the use of predicted dates of mobilisation. The stem cell collection (SCC) facility at the University Hospital of Wales (UHW) provides aphaeresis services for the South Wales Blood and Marrow Transplant (SWBMT) Programme. A prospective data collection exercise of 124 adult referrals who underwent SCC using pre-defi ned priming protocols from May 2011 to October 2012 inclusive was conducted. The underlying diagnoses were Non-Hodgkin Lymphoma (NHL) n=48, Hodgkin Lymphoma (HL) n=21, Multiple Myeloma (MM) n=53 and Plasmacytoma (PC) n=2. A summary of outcomes is shown in the attached table. Priming failure was defi ned as a predicted CD34+ cell dose of < 0.8 x 10 6 /kg. The dose of cyclophosphamide (cyclo) was at the discretion of the referring clinician (1.5g/m 2 n=3, 3g/m 2 n=15 and 4g/m 2 n=2). Other chemotherapy regimens encompassed a variety of salvage protocols commonly used for HL and NHL, with only miniBEAM resulting in priming failure. The minimum CD34+ cell dose acceptable for ASCT was 2 x 10 6 /kg. With regard to MM, a CD34+ cell dose suffi cient for two transplants was achieved in 46% v 64% of patients receiving G-CSF alone v G-CSF + cyclo. In summary, with the exception of mini-BEAM, G-CSF + chemotherapy successfully mobilised stem cells in a high proportion of lymphoma patients (84%) with a low rate of infectious complications. Although priming failures in MM were lower following G-CSF + cyclo than with G-CSF alone, the high rate of infections resulted in an overall lower rate of successful SCC (61% v 70%). Whether 1.5g/m 2 cyclo will result in lower rates of infection and improved outcomes is the subject of further evaluation.

Infl uence of plerixafor on viability of peripheral blood stem cells collected by apheresis M. Postorino (1) F. Marchesi (2) , D. Renzi (2) , G. Adorno (1) , M. Cantonetti (1) (1)Policlinico Tor Vergata (Rome, IT); IT) Background: Plerixafor is a CXCR-4 receptor antagonist capable to mobilize stem cells (SCs) in peripheral blood. Diff erent studies showed that circulating CD34+ cells can be increased by several folds with the use of Plerixafor associated to G-CSF and that this mobilization regimen can be a valid option for myeloma or lymphoma patients defi ned "poor mobilizer". It is now not clear if the combination of Plerixafor to G-CSF has a role in viability of stem cells collected from peripheral blood. We report analysis of data relative to viability of CD34+ cells collected after mobilization with Plerixafor and G-CSF in two diff erent patients. Methods: Two patients (one Multiple Myeloma and one Non-Hodgkin Lymphoma) both underwent to a second harvest of CD34+ cells after mobilization with Plerixafor plus G-CSF as a consequence of low rate of viability observed at the moment of cryopreservation of the fi rst harvest collected after mobilization with chemotherapy plus G-CSF. Patient #1 underwent a fi rst attempt of mobilization with high-dose Cyclophosphamide, resulting in a CD34+ cells/Kg harvest of 4,2 x 10 6 with a viability of only 22,5%. Patient #2 underwent two attempts of mobilization with highdose Cyclophosphamide and high-dose Cytarabine, resulting in two subsequent CD34+ cells/Kg harvests of 7,3 x 10 6 and 4,5 x 10 6 with a viability of only 5% and 45% respectively. In all cases CFU-GM assays confi rm the low percentage of viable cells. Results: In patient 1, after mobilization with Plerixafor 0,24 mg/Kg and G-CSF 10 μg/Kg/day, we obtain a number of CD34+ cells/Kg of 6 x 10 6 with a higher level of viability (93 and 89% in two different units),CFU-GM 41,5 and 55,5 respectively. In patient 2, after mobilization with Plerixafor 0,24 mg/Kg and G-CSF 10 μg/Kg/day, we obtain a number of CD34+ cells/Kg of (4,8 x 10 6 ) with a higher level of viability (99 and 83% in two diff erent units),CFU-GM 46 and 34,25 respectively. Conclusions: Our data seem to suggest that combination of Plerixafor to G-CSF determine an increase of CD34+ cells viability rate observed before cryopreservation in patients in which we obtained a low viability rate of CD34+ cells collected after mobilization with chemotherapy and G-CSF. Further studies are necessary to defi ne the cause of reduced viability of SCs before cryopreservation and to confi rm our observation about the mobilization of viable SCs with Plerixafor in these particular conditions.

When can we safely talk about healing in chronic myeloid leukaemia patients after allogeneic haematopoietic stem cell transplant? A.P. Iori, D. Diverio, S. Perrone, A. Ferretti, E. Scalzulli, W. Barberi, F. Natalino, M.G. Loglisci, A. Di Lascio, M. Breccia, G.F. Torelli, R. Foà Sapienza University (Rome, IT) Objectives: Studies on long-term results in chronic myeloid leukemia (CML) patients who underwent an allogeneic hemato poietic stem cell transplant (HCT) have shown very rare relapses even after 10 years. However, long-term molecular assessment of the disease has never been closely evaluated. Aim of this study was to verify whether patients who survive for many years after an HCT, apparently free of leukemia, may have residual leukemia cells by quantitative real-time polymerase chain reaction (RQ-PCR) analysis. Patients & Methods: Since January 2010, we performed a single center, prospective evaluation of the persistence of the Bcr/Abl transcript, by qRT-PCR, in 61 patients with CML who underwent a myeloablative HCT from an identical sibling between 1984 and 2001, and surviving in continuous complete hematological remission (CCR) for at least 10 years after transplant. Of these 61 patients, 8 refused to participate in the study and 7 were not traceable. The qRT-PCR analysis was therefore performed on 46 patients. Results: Of the 46 patients analyzed, with a median follow-up from transplant of 17 years (range 12-30) and in CCR for over 10 years, qRT-PCR resulted positive in 6 (13%). A patient with 62 copiesIS, at 23 years after HCT, presented a previously undetected hematological relapse. A patient with 33 copiesIS showed a cytogenetic relapse. Four patients with a median number of copiesIS of 0.3 (range 0.2-0.7), negative cytogenetics for the Ph chromosome and normal blood cell counts were monitored by qRT-PCR every 3 months: molecular evidence of disease persisted in 2 cases, evolved into an hematological relapse in 1 patient and disappeared in the other. Conclusions: Our study shows that residual leukemia stem cells identifi able by qRT-PCR may persist in CML patients long after HCT. It is therefore necessary to indefi nitely monitor allografted CML patients. However, the prognostic signifi cance of residual leukemic cells at low molecular levels and the defi nition of "low molecular level" after an allo-SCT remains undefi ned: we observed disappearance of the rearrangement in some patients and the persistence or the evolution into an overt hematological relapse phase in others. The uncertain clinical signifi cance of these molecular fi ndings raises ethical and clinical concerns regarding disclosing adequate information to the patients and in terms of therapeutic decisions. Prospective studies on long-term molecular assessments are required to monitor late relapse patterns and to answer the above-mentioned questions.

Long-term outcome of allogeneic stem cell transplantation for chronic myeloid leukaemia: a 30-year single centre experience S. Perrone (1) (1), A.P. Iori (1) (1)Sapienza University (Rome, IT); (2)"Tor Vergata" (Rome, IT) Purpose: For decades allogeneic hematopoietic stem cell transplantation (HCT) has been considered the curative approach for patients with chronic myeloid leukemia (CML. In the era of tyrosine kinase inhibitors (TKIs), HCT represents a second line treatment, due to the high risk of transplant-related mortality (TRM). Over the years, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcome of transplanted CML patients over a prolonged follow-up period. Patients and Methods: We retrospectively analysed the overall survival (OS), TRM and haematological relapse among 163 consecutive patients with CML in chronic phase or accelerated phase who received their fi rst HCT at our centre between 1984 and 1990 (group A, 62 patients), between 1991 and 2000 (group B, 75 patients) and between 2001 and 2011 (group C, 26 patients) . Results: At a median follow-up of 7 years (range 1-28years), the 10 year OS for the entire case series was 37%, 60% and 92% for groups A, B and C, respectively (p=0.0005) (Fig. 1 ). The 10 year cumulative incidence of TRM was 30%, 28% and 3% for each group, respectively (p=0.04). Patients in group A, B and C showed a cumulative incidence of haematological relapse of 72%, 27% and 2.7% respectively (p <0.001). Conclusions: We observed a substantial reduction in the hazard of death related to HCT, as well as a reduction in haematological relapse and an increased OS over the years. The reduction in TRM is probably due to advances in the care of patients undergoing transplantation; moreover, the more recent strategy of a close monitoring of minimal residual disease, with a prompt use of TKI or donor lymphocyte infusion strategies have reduced the risk of haematological relapse. These improved transplant policies have translated into a signifi cantly better OS. Nowadays, allogeneic transplantation is therefore a safer therapeutic procedure for CML patients that should be timely employed in TKI resistant patients.

Transplantation for primary myelofi brosis using bone marrow, peripheral blood and umbilical cord blood: a retrospective analysis of the Japan Society for Hematopoietic Cell Transplantation M. Murata (1) , T. Nishida (1), S. Taniguchi (2) , K. Ohashi (3), H. Ogawa (4) , T. Fukuda (5) , Y. Morishima (6) , T. Nagamura-Inoue (7), The only known curative therapy for primary myelofi brosis (PMF) is allogeneic hematopoietic stem cell transplantation (HSCT). The issues of the choice of stem cell source, the choice of conditioning regimen, and the timing of transplantation are currently under debate. To determine whether a diff erence in stem cell sources aff ects the outcome of HSCT, a retrospective study was conducted using the national registry data on PMF patients who received fi rst allogeneic HSCT in Japan. A total of 83 PMF patients, with a median age of 53 years (range, 21-79 years), were treated with a variety of preconditioning regimens and prophylaxis for GVHD. Stem cell sources were related bone marrow (BM) in 19 patients, related peripheral blood stem cells (PBSC) in 25 patients, unrelated BM in 28 patients, and unrelated umbilical cord blood (UCB) in 11 patients. This study included the most UCB transplantation among the previous reports. Neutrophil recovery on day 60 occurred in 92% of related BM, 92% of related PBSC, 79% of unrelated BM, and 82% of unrelated UCB transplantation. Unrelated BM and unrelated UCB transplantation (vs. related BM) were signifi cantly associated with a lower probability of neutrophil recovery (P = 0.015 and P = 0.016, respectively). Non-relapse mortality (NRM) at 2 years after transplantation were 33% in related BM, 45% in related PBSC, 61% in unrelated BM, and 64% in unrelated UCB transplantation. Multivariate analysis demonstrated that PS ≥ 2 and unrelated BM were predictive factors for higher NRM. Overall survival (OS) rates at 5 years after transplantation were 63% in related BM, 43% in related PBSC, and 41% in unrelated BM transplantation. OS rate at 2 years after unrelated UCB transplantation was 36%, and OS rate at 5 years after UCB transplantation was not evaluable due to lack of patient who was alive beyond 5 years after transplantation (the longest follow-up term, 48 months). Multivariate analysis demonstrated that donor source was not a signifi cant factor to predict OS rate. Instead, PS ≥ 2 predicted lower OS rate and the 20 times or more RBC transfusion prior to transplantation had a trend toward lower OS rate. The present study could not fi nd an advantage of non-myeloablative preconditioning regimens in terms of decreasing NRM and increasing OS rate. Our results suggest that allogeneic HSCT, even unrelated BM and UCB transplantation, provide a curative treatment for PMF patients.

Allogeneic stem cell transplantation for advanced phase chronic myeloid leukaemia: experience from the imatinib era A. Holroyd (1) , R. Pearce (2) , A.L Latif (3), J. Byrne (4) , B. Roomallah (5) , R.E. Clark (6) , D.I. Marks (7) St. James' University Hospital (Leeds, GB) Patients with advanced phase chronic myeloid leukaemia (AP-CML) fare badly with tyrosine kinase inhibitors (TKI), the current "gold standard" therapy for treatment of chronic phase (CP) disease. The only long-term curative option for AP-CML is allogeneic stem cell transplantation (HSCT) but there are limited data on its effi cacy, especially since the introduction of TKI. We have performed preliminary analysis for 238 patients transplanted from 1st January 2000 to 30th September 2011 using British Society for Blood and Marrow Transplantation registry data. Inclusion criteria were: BCR-ABL1-positive CML, patients receiving fi rst HSCT and HSCT performed for CML not in 1st CP. Median age at HSCT was 41.4 years and 68 patients received reduced intensity conditioning (29%); 169 (71%) had myeloablative HSCT. The stem cell source was bone marrow for 60 (25%), peripheral blood for 173 (73%) and umbilical cord for 5 (2%) patients. At the time of HSCT, disease stage was CP>1 in 122 (51%), accelerated phase in 80 (34%) and blastic phase (BP) in 36 (15%) patients. Eighty-seven (37%) patients had an HLA-identical sibling donor, 140 (59%) had an unrelated donor and 11 (4%) patients had other donors. Median time from CML diagnosis to HSCT was 13 months, and median follow-up post-HSCT was 4.25 years. Outcome estimates are in table 1. The management of patients with AP-CML remains problematic, in particular regarding the relative effi cacy of 1st, 2nd and 3rd generation TKI alone or in combination with conventional chemotherapy, and whether the outcome is aff ected according to whether patients present in AP or progress from 1st CP. In order to study these questions we have returned to the transplant centres with more detailed questions regarding treatment prior to HSCT. We have further data on 83 patients: median age at HSCT was 40.8 years with disease stage at HSCT determined as CP>1 in 46 (55%), accelerated phase in 35 (42%) and BP in 2 (2%) patients. Median disease duration pre-HSCT was 18 months, progression time to AP-CML was a median of 5.6 months and median HSCT followup was 6.75 years. Prior to HSCT 66 patients received imatinib, 21 had dasatinib, 4 had nilotinib, and 32 patients had chemotherapy, some with additional TKI. Outcome estimates show no signifi cant diff erence from those for the group of 238 patients (table 2) . Data collection and analysis are ongoing and outcome by disease phase at presentation and at HSCT, donor type and conditioning will be presented.

Timing of immunosuppression tapering, chronic GVHD, and minimal residual disease (MRD) eradication in patients allografted for poor-risk chronic lymphocytic leukaemia (CLL) as defi ned by the EBMT consensus criteria: a single centre experience M. Hahn (1), S. Böttcher (2) , M. Ritgen (2) , S. Dietrich (1) , I. Herth (1) (2), P. Dreger (1) (1)University of Heidelberg (Heidelberg, DE); (2)University of Schleswig-Holstein (Kiel, DE) Study Design and Patients: In a single centre retrospective descriptive analysis, timing and dynamics of immune modulation, cGVHD, MRD (MRD-fl ow), and clinical outcome of all patients allografted for CLL between June 2005 and September 2012 were recorded. Results: Altogether 66 patients with a median age of 52 (37-67) years were allografted in the 7-year period. Indications according to EBMT criteria (hierarchical) were: (1) 17p-/TP53mut 24, (2) fl udarabine resistant 26, (3) early relapse 13, and Richter's syndrome 3. While 10 patients (15%) were allografted in 1st remission, 14 patients (21%) had refractory CLL (<PR) at SCT. An unrelated donor (UD) was used in 49 patients (74%). Disregarding 16 patients who were too early or had no MRD monitoring performed, the probability to live relapse-free and MRD-at 12 months after SCT was 58%, whereas the remainder had TRM (14%), relapse (10%), or lived relapse-free but MRD+ (18%). With a median follow-up of 33 months, all 29 +12mo MRD-patients are in continuing clinical remission with only a single patient re-converting to MRD+. In contrast, the relapse rate was 50% at 3 years in the 9 +12mo MRD+ patients (p<0.0001). +12mo MRD-could not be predicted by any pretransplant variable, but was strongly associated with GVL response patterns 1-2 (Leukemia 22:1377) (82% probability to achieve +12mo MRD-) and cGVHD (86% probability to achieve +12mo MRD-). The median time to immunosuppression taper (IST) was 86d and tended to be slower in patients with UD, those in CR/PR at SCT, and those MRD-immediately after SCT. The median time from IST to cGVHD was 63d, and the median time from cGHVD to MRD-was 49d. The cumulative incidence of cGVHD at 12mo was 67%; however, the +12mo prevalence of cGVHD was only 52% in living patients, and only 39% of these were still on IS. TRM, relapse incidence, PFS and OS at 3 years were 17%, 25%, 67% and 79% with <PR at SCT as the only factor signifi cantly aff ecting outcome. Conclusions: Patients with poor-risk CLL who survive relapse-free and are MRD-12mo after SCT have an extremely favourable outcome. With timely IST, the probability to achieve this status can be >50% and is signifi cantly improved by cGVHD. In GVL-sensitive patients, MRD-is immediately reached upon cGVHD onset.

Prevalence and severity of cGVHD decrease over time, resulting in need for IS in <40% of patients alive 12mo after SCT.

Allogeneic haematopoietic stem cell transplantation for T-prolymphocytic leukaemia: a retrospective analysis from the Société Française de Greff e de Moelle et de Thérapie Cellulaire T. Guillaume (1) , Y. Beguin (2) , R. Tabrizi (3) , V. Leblond (4) , D. Blaise (5) , E. Deconinck (6) , R. Redjoul (7) , J. Cornillon (8), N. Contentin (9) , G. Guillerm (10) , N. Fegueux (11), P. Turlure (12), A. Salmon (13), T. de Revel (14) , M. Mohty (15) (1)CHU Nantes (Nantes, FR); (2) T prolymphocytic (T-PLL) is a rare aggressive mature T cell disorder with distinctive clinical, morphologic, immunophenotypic and cytogenetic characteristics. The median OS is approximately 7 m with conventional chemotherapy. The anti-CD52 mAb allowed for an improved overall response rate around 75% with a CR rate of 60% and a median OS of 10 m. Allo-HSCT is currently the only potentially active option to consolidate response to initial chemoimmunotherapy in those eligible pts. We retrospectively studied all pts fulfi lling the requirements for P-TLL diagnosis and who underwent allo-HSCT reported to the SFGM-TC registry. Twenty pts (age 54 (36-65)) were identifi ed from 14 SFGM-TC ctrs from 2000 to 2010 (median y, 2009). Prior to allo-HSCT, 9 pts were in CR, 8 in PR, 3 refractory or in progression. Conditioning regimen was myeloablative for 8 pts and reduced for 12 pts. TBI was used in the conditioning regimen for 13 pts with 6 pts receiving ≥ 8 grays and 7 pts receiving 2 grays. Stem cells source was BM for 2, PBSCs for 14 and CB for 4 pts. Donor was HLA-matched sibling in 7 cases. Following transplantation, as best response, 17 pts were in CR while 1 progressive pt became partial responder. For 2 pts, response could not be determined due to early TRM. Eleven pts developed acute GVHD (gr I, n=1; gr II, n=7; gr III, n=2; and gr IV, n=1). The cumulative incidence of gr II to IV GVHD was 52% (95%CI:29-70%). Chronic GVHD was observed in 45% of the pts (4 limited form, 5 extensive form). With a median follow-up of 28.8 m (6.8-103) for surviving pts, 10 pts are alive with 7 of them being in CR. The KM estimates of OS and progression-free survival (PFS) at 3 y were 41.7 (95%CI: 18-62%) and 29% (95%CI: 14-50%), respectively. The cause of death among the 10 pts was transplant related in 6 and due to disease progression in 4. The relapse incidence was 51%. Relapse was observed at a median of 14 m (2-24) after allo-HSCT. Among the 8 relapses, 4 occurred during the second year. TRM incidence was 38% at 3 years. Though not statistically signifi cant due to the relatively low number of pts, the use of TBI in the conditioning regimen was associated with a better PFS. We conclude that allo-HSCT may allow long term survival in some pts with T-PLL following induction treatment. Given the rarity of this disease, national and international collaborations (e.g. registry) are needed to further clarify the role of allo-HSCT and natural history of this rare and fatal disease.

A single centre experience of allogeneic stem cell transplantation for chronic lymphocytic leukaemia V. Murthy, B. Bailiff , K. Holder, M. Nikolousis, S. Paneesha, R. Lovell, D. Milligan, B. Kishore, A. Rekhi Heart of Engalnd NHS Foundation Trust (Birmingham, GB) Chronic lymphocytic leukaemia [CLL] is incurable with conventional chemo immune therapy. Allogeneic stem cell transplantation (SCT) is a treatment option for patients with poor-risk CLL. Role of T-cell depletion with alemtuzumab in the transplant conditioning is controversial. We report here the single centre experience of SCT for CLL with both T deplete and T replete protocols. Methods: This is a retrospective study of 33 allografts for CLL between September 1999 and December 2011. Median age at diagnosis was 48yrs and median age at transplantation was 52yrs . Median number of previous therapies prior to SCT was 3 [range: 1 to 6] . 33% were in complete remission (CR), 48 % in partial remission (PR) and 12% with progressive disease (PD) at SCT. 67% received matched related donor (MRD) where as 27% received matched unrelated donor (MUD) and 6% mismatched unrelated donor (mMUD). Conditioning regimen was either fl udarabine, melphalan and alemtuzumab or fl udarabine and cyclophosphamide. Dose of alemtuzumab was 100 mg until 2001 which was changed to 60 mg for MRD and 100mg for MUD from 2002 to 2004 where as from 2006 onwards it is 50 mg for MUD and 30 mg for MRD. Results: Mean overall survival (OS) was 67 months [MRD 67, MUD 64 & mMUD 22] Median OS has not reached in our cohort. 55% achieved CR, 18% VGPR and 6% PR following SCT. 75% patients following T replete transplants and 72% patients with T deplete transplants are alive. 15% had relapse post SCT and are still alive. 33% patients received donor lymphocyte infusions. 9 patients died [3 due to infections, 1 grade IV graft versus host disease, 1 disease progression and 4 others]. All 3 infective deaths were in group receiving higher dose of alemtuzumab. Grade IV GvHD was in patient undergoing T replete allograft. There were 5 deaths in CR. Grade 3 or 4 acuteGvHD and extensive chroinc GVHD was seen in 18% which was observed in T replete transplants and in who received lower alemtuzumab dose. 15 patients had chronic GVHD and are alive. Transplant related mortality at 1 year is 15%. Survival postSCT at 1, 3 and 5 years is 76%, 65% and 65% respectively. Conclusion: Our data suggests allogeneic stem cell transplantation off er longer lasting remissions with less toxicity in patients with CLL. T cell depletion does not adversely impact transplant outcomes. Outcome in patients undergoing matched unrelated donor transplants is good and number of prior therapies does not have an adverse impact on the overall survival.

RIC-SCT in 68 consecutive CLL patients from two centres: equivalent outcome between siblings and unrelated donors and ability of SCT to eliminate eff ect of adverse cytogenetics P. Jindra (1) , L. Raida (2) , M. Karas (1), A. Jungová (1), R. Urbanová (2) , T. Svoboda (1) , V. Vozobulová (1), K. Indrák (2) , D. Lysák (1) (1)University Hospital Pilsen (Pilsen, CZ); (2)University Hospital Olomouc (Olomouc, CZ) Background: Despite innovative treatments CLL remains essentially incurable disease. Alternative approach is particularly needed for pts with an accumulation of adverse prognostic factors (del17p, purine resistance). AlloSCT with reduced conditioning (RIC) is promising therapeutic alternative because it reduces toxicity whilst preserving GVL. This prompted us to perform retrospective study to address the role of RIC-SCT in high-risk CLL pts and to identify the independent factors associated with transplant outcomes. Patients&Methods: Retrospective analysis of 68 consecutive pts with CLL from 2 centres (median 58 y, range 31-71) transplanted between 2002-12 by RIC protocols either with sibling (SIB group, n=22;32%) or unrelated donor (MUD,n=46;68%). Cytogenetics was available in 63 (93%) pts with unfavorable in 39 (57%). Del17p was detected in 20 (32%) of evaluable pts. Pts received a median of 3 lines of therapy (1) (2) (3) (4) (5) (6) before SCT, all were refractory to purines, 33 (49%) were transplanted in advanced stage (>CR/PR3 or rel/refractory) There were no signifi cant diff erences between SIB and URD group with respect to relevant parameter (age, cytogenetics, disease status). MUDs were signifi cantly younger than the SIBs (median 31vs.56; p<0,0001). Results: For all patients (median follow of surviving 21 months, range 1-108) the median OS was 26 months and the 3-y Kaplan-Meier OS/DFS probabilities were 39% and 28%, respectively. The 3-y cumulative incidences of NRM and relapse were 49% and 37%. In multivariate analyses MUD recipients had similar OS and DFS compared to SIB recipients (hazard ratio [HR] 0, 72; p=0, 29 and 0, 649; p=0, 143) . The presence of del17p and/or adverse cytogenetics has no impact on survival (HR 1,49; p=0,2526 and 1,30; p=0,4066) . Similarly, advanced disease status (HR 1,63; p=0,1172) , no. of lines of therapy, interval from dg. to SCT, donor age, sex, no. of CD34+ cells transplanted have no impact on OS and DFS . Conclusion: RIC-SCT is an eff ective treatment of poor prognosis CLL and has capacity to overcome negative impact of cytogenetics. The data suggest equivalence of outcome using either SIB or MUD and supports the recommendation to consider RIC-SCT for poor risk CLL patient regardless of cytogenetic risk and the absence of related donor.

Non-myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia: a single institution experience G. Chakupurakal, P. Langerbeins, S. Leitzke, J. Schiller, U. Holtick, S. Theurich, R. James, P. Schneider, M. Hallek, M. von Bergwelt-Baildon, C. Scheid University of Cologne (Cologne, DE) Allogeneic stem cell transplantation is a treatment option for CLL patients who are refractory to therapy with purine analogues and/or those with a p53 mutation/deletion. We conducted a retrospective analysis of all CLL patients allografted at our institution University of Koln, Germany. Data was collected on 40 patients over a period of 8 years 2004-2012. The mean age was 54 (range 33-75) and the majority were male (male: female 30:10). On average the patients were diagnosed 6 years (range 2-12 years) prior to transplant with an average of 4 years (range 1-8 years) from time of fi rst line therapy to transplant. The remission status at the time of transplant were complete remission (CR) (n=3), stable disease (SD) (n=12), partial remission (PR) (n= 18) and progressive disease (PD) (n=7). On average the patients had received 4 (range 1-8) lines of treatment prior to transplant including autograft (n=4), Fludarabine (n=35) and Campath (n=21). 13 patients had matched sibling donors, 26 matched unrelated donors and one patient received stem cells from a Haplo-identical sibling. The conditioning regimens were reduced intensity such as Fludarabine, Cyclophosphamide and 4Gy TBI (n=3), Fludarabine, Busulphan and Cyclophosphamide (n=5), Fludarabine and Busulphan (n=6), Fludarabine and Treosulfan (n=18), Fludarabine and 2Gy TBI (n=4) as well as Fludarabine and Cyclophosphamide (n=4). Unrelated and haploidentical transplant recipients recieved ATG (n=16) or Campath (n=2) in addition to CsA and MMF as GvHD prophylaxis. The average CD34+ cell dose was 4.16x106/kg (range 2.24-19.9). Neutrophil engraftment was seen on day +17(range 10-23) and 93% (37/40) achieved 100% donor chimerism by day 100. 35% (14/40) were in CR post transplant at day 100. 75% of patients are currently alive while 8 patients (20%) died of transplant related complications whilst 2 (5%) died of disease progression. Whereas time since fi rst diagnosis or number of lines of treatment prior to transplant had no infl uence on outcome, we found that use of ATG and CMV infection negatively infl uenced overall survival. Our single centre experience confi rms that nommyeloablative allogeneic stem cell transplantation is a valuable treatment option in CLL patients refractory to Fludarabine or Campath with promising long term survival and acceptable transplant related mortality. Our preliminary fi ndings regarding ATG and CMV infection should prompt further research to improve immune recovery after allograft in CLL patients.

A retrospective long-term study from allogeneic haematopoietic stem cell transplantation (HSCT) in chronic myeloid leukaemia (CML) M. Benakli, R. Ahmed Nacer, A. Talbi, N. Rahmoune, F. Mehdid, R. Belhadj, M. Baazizi, D. Ait Ouali, F. Harieche, F. Zerhouni, R.M. Hamladji Pierre and Marie Curie Center (Algiers, DZ) Background: Allogeneic HSCT is recognized as being the only curative treatment in the CML, despite its complications and high mortality rates. We report a single center retrospective study involving in 278 pts receiving HSCT for CML with myéloablative or reduced intensity conditioning regimen (RIC). Material and methods: From April 1998 to November 2011, 278 patients (pts) with CML underwent allogeneic HSCT with HLA identical sibling donors. The median age of the pts at transplant is 30 years . The sex-ratio is 1,07 and intervall diagnosis-graft was 13 months . The myeloablative stem cell transplantation (MAT) based on Tushka protocol was employed in 103 pts including 56 in fi rst chronic phase (CP), 40 in accelerated phase (AP) and 7 in blast crisis (BC). The prevention of the graft versus host (GVHD) associated ciclosporine and méthotréxate according to Seattle protocol. RIC based on the use of Fludarabine and Busulfan was employed in 175 pts including 151 pts in fi rst CP and 24 in AP. The GVHD prophylaxis consisted of cyclosporine with mycophenolate mofetil. The grafts used are peripheral blood stem cells in 267 pts (96%), bone marrow in 9 pts (3,2%) and umbilical cord blood in 2 pts. Results: Aplasia is occurred in 181 pts (65%) with median duration: 10 days (2-48), overal median time to achieve neutrophils count > 500/mm 3 is at day 10 (10-55). Only 75 pts (27%) needed blood transfusion, 111 pts (40%) required platelets transfusion. No pt presented hepatic veno-occlusive disease. Acute GVHD occured in 121 pts (43,5%), it was between grade II and IV in 91 pts (32,7%. Chronic GVHD was observed in 175 pts (69%), extensive form in 116 pts (46%). The cytomegalovirus (CMV) infection was seen in 51 pts (18,3%). Relapse of disease occurred in 49 pts (19,5%) at a median time of 46 months , among them 20 pts were presented in molecular remission (immunosuppression discontinuation : 9, DLI with or not Imatinib: 7 and second myeloablative allograft: 4). TRM incidence is 29,4%. At November 2012, 167 pts (60%) are still alive with a median follow-up 85 months and 111 pts died (40%). Causes of death are dominated by GVHD (66 pts) and relapse (28 pts). The Overall Survival (OS) and Event Free Survival (EFS) are respectively 60,2% and 52%. Conclusion: Allogeneic HSCT still keeps its place in the CML treatment arsenal even with the availability of thyrosine kinase inhibitors. It remains toxic given the incidence of GVHD and TRM which remain high as observed in this series and others publications.

Tyrosine-kinase inhibitors can induce remission in patients with Philadelphia chromosome positive leukaemia at relapse after allogeneic stem cell transplantation: a single centre experience M. Schmitt, C. Hollenbach, F. Michel, B. Seyfarth, A. Schmitt, A. D. Ho, P. Dreger University Hospital Heidelberg (Heidelberg, DE) Background: The advent of tyrosine-kinase inhibitors (TKIs) dramatically changed the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This applies also to the use of TKIs in the context of allogenic stem cell transplantation (SCT). Material and Methods: In this survey data were collected from 45 patients (41 CML, 4 ALL; age 18-66 years) undergoing SCT at our institution. 13 of 45 patients received a standard myeloablative conditioning regimen including total body irradiation and cyclophosphamide S129 (TBI/CY), 32 patients a non-myeloablative conditioning regimen with fl udarabine and busulfan, treosulfan or with TBI. Results: 28 of 45 patients were treated with fi rst and second generation TKIs before SCT. 19 of 45 patients received TKIs of 1st generation, 9 of 45 patients TKIs of 2nd generation. Twenty-three patients were transplanted in fi rst chronic phase (CP), 17 patients in second CR. Five patients received an allogenic graft in blast crisis. As for their remission status 17 patients were with progressive disease (PD) before transplantation, ten patients were in minor cytogenetic remission (mCR), ten patients in hematological complete remission (hCR), and eight patients in cytogenetic complete remission (cCR). Three of 45 patients developed a mixed donor chimerism after allogenic stem cell transplantation on day +28, 42 showed a complete donor chimerism at that time. After allogeneic stem cell transplantation, 35 patients achieved a complete hematological remission and cytogenetic remission, 25 of them even a complete molecular remission. One patient reached a minor cytogenetic remission, 8 patients had progressive disease. 18 of 45 patients relapsed after transplantation. 14 of these 18 patients were again treated with TKIs, nine with TKIs alone. Five patients received additionally donor lymphocyte infusions (DLIs). Four patients at relapse received only DLIs, but no TKIs. After a follow up of two to nine years six patients were alive, all of them received TKIs, three additionally DLIs. Conclusion: This evaluation demonstrates that all patients with Philadelphia positive leukemia were treated at our institution with a TKI before allogenic stem cell transplantation after the advent of TKIs; 18 of 45 patients developed a relapse after allogenic stem cell transplantation despite myeloablative conditioning and the administration of a TKI after transplantation brought half of the patients into remission.

M. (2) , A. Nagler (1) (1)Chaim Sheba Medical Center (Ramat Gan, IL); (2)University of Turin (Turin, IT) Real time quantitative PCR (RQ-PCR) is the major method for follow up of CML pts. In pts undergoing allogeneic SCT (Allo-SCT) it has been shown that successive increase in quantitative BCR ABL transcript levels correlates with the clinical outcome and may serve as an early sign of disease relapse and an indication for a therapeutic intervention such as the addition of a TKI or DLI. Several methods were recently designed in order to increase the sensitivity of BCR ABL detection. Replicate RQ-PCR (rRQ-PCR) is based on the observation that the number of measurement repetitions infl uences the detection of rare transcripts, and was found to increase by 2 logs the sensitivity compared to conventional RQ-PCR. We evaluated the role of rRQ-PCR in the detection of MRD in a cohort of long term post Allo-SCT CML patients. Samples from 12 CML pts (M=7, F=5), median age 43 y, at a median time of 85 months after SCT (range 28-136) were tested. SCT was myeloablative (n=6) or with RIC (n=6), from a matched sibling (n=7) or a MUD (n=5), in fi rst chronic phase (CP1) (n=8) or at a later phase (n=4). rRQ-PCR was negative in 9/12 pts, while 3 pts had positive results in 1 (1.2%), 2 (2.4%) and 6 (7.3%) of 82 analyzed replicates, respectively. The sensitivity of rRQ-PCR was 10-5.5 or higher in all pts. Negative rRQ-PCR result was not related to the phase at SCT (CP1 vs. others), conditioning regimen (myeloablative vs. RIC), donor type (sibling vs. MUD) or the presence of GVHD. Median time from diagnosis to SCT was borderline longer in pts with positive rRQ-PCR results (61 vs. 25 months, p=0.08). Higher sensitivity RQ-PCR methods are able to further defi ne subgroups of post BMT CML pts and allow for a more accurate follow up of MRD.

Immune reconstitution and lymphocyte function in patients receiving nilotinib (Tasigna) maintenance therapy post allogeneic stem cell transplantation A. Nagler, Y. Volchek, N. Varda-Bloom, R. Somech, R. Yerushalmi, A. Shimoni Chaim Sheba Medical Center (Ramat Gan, IL) Relapse rate post alloSCT in advanced CML (>CP 1 ) and in Ph+ ALL is high. We assessed (study CAN107AIL03T) whether Nilotinib administration post alloSCT intensifi es remission and reduces relapses. 24 pts (M-13, F-11), age 36 years (range, 18-58) participated in the study, advanced CML -17 (BC-10, AP-7), Ph+ ALL -7. 22/24 pts underwent alloSCT (2 are pending) from an HLAmatched sibling (n=11), matched unrelated (n=8) or alternative donor (CB-2, Haplo-1). All, but one, had myeloablative conditioning (Bu/Cy or Flu/Bu-14, TBI/Cy-7). GVHD prophylaxis included CSA and methotrexate or MMF. 21/22 pts engrafted in median day+13 (range, 9-38) with 100% donor chimerism. TRT included mucositis in all pts, encephalitis-2, pericarditis-1, VOD-1 and infection-3. 3 pts died very early post transplant from sepsis and multi organ failure. Acute GVHD ≥ Gr II was observed in 10 pts (III-IV in 5). cGVHD was observed in 15 pts (extensive -9). 16/22 transplanted pts received Nilotinib (200mg x 2/d -10, 300mg x 2/d -6) starting at median day +38 (range, 30-158) post alloSCT. 6 pts did not receive Nilotinib post alloSCT due to early death -3, progressive disease -1, severe pancytopenia -1, refusal -1. Nilotinib administration was delayed or dose reduced/stopped in 9 and 7 pts, respectively due to toxicities. All, but 2 pts achieved MMR post alloSCT and 6 of them (CML) converted to CMR following Nilotinib therapy. Kinas mutation (G205E and F359V) were detected only in 1 pt with disease progression. With a median follow up of 16.5 mo (range, 2.5-38) 12 pts are alive while 12 died (Infection -5, GVHD -3, TTP-1, disease progression -3). In 2 pts disease progressed but responded to further therapy. All 6 pts that did not receive Nilotinib died (early death post allo-SCT -3, disease progression -1, GVHD Gr IV -2). Immunological evaluation post Nilotinib administration disclosed no signifi cant change in T, B and NK cell numbers and T cell mitogenic response. Thymic output (TREC) and receptor repertoire (Spectrotyping) analysis indicates continuous thymopoiesis in 8/13 evaluated pts. NK cytotoxic activity against K562 increased in 9/15 evaluated pts. In summary: Nilotinib maitenance therapy post alloSCT in pts with advanced CML and Ph+ALL did not interfere or jeopardized immune reconstitution and function including the number of immune cell subsets, T cell mitogenic response, TRC repertoire, thymic output and NK cytolytic activity post alloSCT.

Immunological reconstitution after allogeneic peripheral blood stem cell transplantation A. Michova, P. Ganeva, N. Stoyanov, M. Guenova, G. Arnaudov, G. Mihaylov, S. Toshkov Hospital for Hematological Diseases (Sofi a, BG) The aim of the study was to access the immune recovery of T-, B-and NK-cells for a period of 24 months after allogeneic stem cells transplantation (allo-SCT) performed in BMT unit (CIC 859). Materials and methods: Fourteen patients (pts) were enrolled in the study -6 female and 8 male, mean age 34 years (21-50), including 6 with acute myeloid; 7 with B-cell acute lymphoblastic, and 1 with plasmablastic leukemia. All pts received donor peripheral stem cells: 8 -from matched related and 6 from matched unrelated donors. According to the underlying disease 8 pts received CY/TB, and 6 -Bu/Cy conditioning myeloablative regimens. The percentage (%) and absolute count (AC) values of lymphocyte populations and subpopulations were determined in the PB at three time intervals: M1 at 3-6, M2 at 7-12 and M3 at 13-24 months after HSCT by fl ow cytometry (FACSCanto II, BD Diva v.6.1) using a lysis/no wash procedure, TruCount tubes (BD) and a 6-colour monoclonal antibodies combination CD3F/CD8PE/CD45PerCP/ CD4PE-Cy7/19APC/CD8APC-Cy7.T-cell subpopulations were assessed by CD4, CD8, CD28, CD7, CD45RA, CD57 and CD62L. Results: The mean lymphocyte AC determined by fl ow cytometry reached levels near the low range at M1 (1402 cells/ μ l), which remained stable at M2 (1393 cells/ μ l) and increased up to 2196 cell/ μ l at the 24th month. The recovery of CD3+T-cells showed an increase of % and AC as follows: at M1 -69% (992 cell/μl); M2 -63% (865 cell/μl); M3 -69% (1461cell/μl). Unlike T-cells, the dynamics of the NK (CD56+CD16+CD3-) cells showed a gradual decrease after the 6th month reaching 12% (224 cells/ μ l) at M3, remaining near the lower reference value. An increase in the percentage and AC levels of CD19+ lymphocytes was observed from 14 % (253 cell/μl) at M2 up to 19 % (465 cell/μl) at M3. The CD4:CD8 ratio was low for the whole period (0.69-0.61). The mean % of CD8+T-cells were stable above the upper reference level -45% (919 cell/μl) at M3. However, the % of some CD8+Tcell subsets (naïve, eff ectors and memory cells) were within the reference ranges, while late (CD28-CD57+) and intermediate (CD28-CD57-) eff ectors showed very high levels. Post-transplantation immune recovery is a long and multifactorial process. The results might further contribute to the more exact understanding of the particular stages of immunological reconstruction. Ackowledgements: Studies were supported by the National Science Fund.

Tracking CD8+ memory stem T-cells dynamics after allogeneic bone marrow transplantation: impact on GvHD occurrence N. Cieri, J. Peccatori, M. T. Lupo Stanghellini, F. Ciceri, C. Bonini San Raff aele Scientifi c Institute (Milan, IT) Graft-versus-host disease (GvHD) is caused by alloreactive donor T cells targeting host tissues. By sustaining a persistent alloresponse, long-living memory stem T cells (TSCM) with the ability to self-renew and the plasticity to diff erentiate into potent eff ectors, may represent crucial players in GvHD, when specifi c for alloantigens. We demonstrated that CD8+ TSCM, characterized by a CD45RA+CD62L+CD95+ phenotype, are able to mediate a potent xeno-GvHD when infused in immunodefi cient mice, with xenoreactivity preserved even upon serial transplants (Cieri, Blood 2012). Thus, we hypothesized that TSCM lymphocytes may exert a role in allogeneic hematopoietic stem cell transplants (HSCT). To verify this hypothesis and assess the impact of TSCM on immune reconstitution and GvHD incidence, circulating lymphocytes from 10 transplanted patients were analyzed 1-month post-HSCT. A selective accumulation of TSCM was documented, as the majority of circulating CD45RA+CD62L+CD8+ T lymphocytes was CD95+ and represented a higher fraction of total CD8+ T cells compared to healthy controls (P=0.0025). The percentage of TSCM correlated with aGvHD occurrence (P=0.0148) and severity, being significantly higher in patients with aGvHD grade III-IV than in those with aGvHD ≤ grade II (P=0.009). TSCM percentage 1-month after HSCT was predictive also for subsequent development of cGvHD (P=0.007). Patients with high frequencies of circulating TSCM required more intense immunosuppression than patients with low TSCM frequencies (P=0.012). Accordingly, there was a trend towards higher mortality in patients bearing higher TSCM frequencies. The extent of TSCM accumulation 1-month post-HSCT did not correlate with the dose of CD3+ cells infused, nor with the degree of donor/recipient mismatch. Finally, circulating T cells from 4 patients were evaluated prospectively. In 1 patient who did not develop GvHD, low TSCM frequencies remained stable over time, while in the other 3 patients, who experienced GvHD, a drastic reduction of TSCM percentages was observed after GvHD resolution (P=0.046). Our study quantify for the fi rst time TSCM cells after allogeneic HSCT and suggests that early TSCM accumulation is predictive for GvHD development. A prospective longitudinal study of TSCM dynamics post-HSCT in a larger cohort of patients is envisaged. If a causative role for TSCM in GvHD will be demonstrated, therapies to selectively target this T-cell subset may be designed to relieve GvHD burden.

Everolimus inhibits CMV-specifi c CD8 positive T-cells in a dose-dependent manner N. Jin (1), G. Malcherek (1), R. Zurleit (2) , A. Schmitt (1) , M. Freund (2) , A. D. Ho (1) , P. Dreger (1) , M. Schmitt (1) (1)University Hospital Heidelberg (Heidelberg, DE) ; (2)University Hospital Rostock (Rostock, DE) Objectives: Everolimus (RAD-001), a derivative of sirolimus, is a novel inhibitor of mammalian target of rapamycin (mTOR) that is recently used off -label for patients after hematopoietic stem cell transplantation (HSCT) and is useful in reducing cyclosporinerelated nephrotoxicity. Reactivation of cytomegalovirus (CMV) constitutes a frequent problem after both solid organ transplantation (SOT) and HSCT. Therefore we investigated whether everolimus has an impact on CMV-specifi c T cell responses. Methods: Peripheral blood mononuclear cells (PBMCs) from HLA-A2/CMV seropositive healthy volunteers were purifi ed by Ficoll and subsequently by MACS ® beads. CD8 positive cells were stimulated with HLA-A*0201-restricted epitope from CMVpp65 (NLVPMVATV) in a mixed lymphocyte-peptide culture (MLPC) in the presence of increasing concentration of everolimus. Flow cytometry and enzyme-linked immunospot (ELISPOT) assays were used to study the immunomodulatory eff ect of everolimus on CMV-specifi c CD8 positive T cells. Results: Proliferation of CD8 positive T cells after stimulation with CMV pp65 peptide and the frequency of CMV-specifi c T cells stained with pp65 tetramers were suppressed by low doses of everolimus in a dose-dependent manner. When we added everolimus at concentration corresponding to the therapeutical range of the drug (3-8 ng/ml), CD8 positive T cells were strongly suppressed (by 90%). Beyond proliferation, everolimus had a strong impact on the frequency of CD8 positive T cells expressing the activation marker CD137 and the secretion of cytokines. Secretion of interferon-γ and granzyme B was strongly suppressed similarly to what was shown for the proliferation. In addition we studied the infl uence of everolimus on T cells after stimulation with staphylococcal enterotoxin B (SEB) or phytohemagglutinin (PHA). Again, proliferation of T cells was inhibited in a dose-dependent manner. Conclusion: We demonstrate here that everolimus strongly hampers CMV-specifi c CD8 positive T cells. As reactivation of CMV plays a pivotal role for the outcome of patients after HSCT, attention must be paid to early detection and pre-emptive treatment of CMV reactivity in patients treated with everolimus.

CD4-positive lymphopenia at day +30 after transplant is a biological predictive factor for EBV reactivation F. Patriarca (1) Previous studies suggest that the risk of development of post transplant lymphoproliferative dosorders (PTLD) is overcome by blood monitoring of Epstain-Barr virus (EBV)-DNAemia after allogeneic hematopoietic stem cell transplantation (HSCT) and by the timely administration of Rituximab in cases with higher levels of EBV-DNAemia. The aim of this study is to evaluate the outcome of a strategy of EBV-DNAemia surveillance and pre-emptive Rituximab applied in 100 consecutive patients transplanted between January 2008 and December 2010, with the aim of identifying prognostic factors for EBV reactivation. Most of the patients received RIC regimens (67%) and were reinfused with PB (79%) coming from unrelated donors (68%) . All the 68% of patients who performed unrelated transplants were treated with ATG. EBV-DNA was evaluated by quantitative realtime PCR in whole blood specimens weekly in the fi rst 3 months after HSCT and every 2 weeks until immuno suppression. Preemptive therapy with rituximab was given to those patients who showed high viral loads defi ned as any value ≥ 10,000 cp/ml. Cumulative incidence of high load EBV-DNAemia was 14% at 12 months. Univariate analysis showed a signifi cant association between high EBV DNA loads and transplants from unrelated donors (p = 0.016), HLA-mismatching (p = 0.006), standard doses of ATG as GVHD prophylaxis (p = 0.002), and low CD4+ lymphocyte count at day +30 (p< 0.0001). In multivariate analysis, a CD4+ T-lymphocyte count higher than 50 mcgL at day +30 was the only factor signifi cantly associated with a reduced risk of EBV reactivation (OR 0.10; CI, 0.020-0.481; p = 0.004). Thirteen of 16 patients with high viral loads were preemptively treated with rituximab and achieved EBV DNA negativity. There were 3 patients who had already developed PTLD at the time of detection of high EBV DNA loads and obtained complete response after rituximab infusions and chemotherapy. Patients with high EBV DNA load had a signifi cantly higher TRM compared to patients with negative or low viral load (54% vs 16%, p = 0.009) and a trend to lower OS (55% vs 29%, p = 0.060). We conclude that CD4+ cell count at day +30 is a predictive factor for EBV reactivation and may help identify patients requiring closer monitoring. Although only 3% of patients progressed to PTLD and were all successfully managed, EBV reactivation was associated with higher TRM, mainly due to infections.

Early CMV-specifi c CD8+ T-cell responses monitored by pentamer staining correlate with protection against CMV reactivation after allogeneic stem cell transplantation A. Zabalza (1) , M. Ciaurriz (2) , L. Beloki (2) , N. Ramirez (2) CMV reactivation after allo-SCT is usually monitored by CMV-PCR. We present the results of a pilot study using Pentamers for monitoring CMV-specifi c CD8+ T-cells. 17 patients (pts) underwent allo-SCT from HLA-Id siblings (n=7) or HLA-matched unrelated (n=7) donors and were enrolled in this prospective study (3 pts died before day +100 and were not evaluable). The diagnosis of the 14 evaluable pts was acute leukemia (n=10), lymphoproliferative disorder (n=2) and myelodysplastic syndrome (n=2). Conditioning was myeloablative in 8 pts (7 CyTBI and 1 BuCy) and reduced intensity in the remaining 6 pts. Recipients of unrelated donor cells received Campath (10 mg/day, days -10 to -6). All pts and donors were positive for the HLA-A*0201 allele. Pentamers (Proimmune, UK) were directed against the epitope NLVPMVATV of the pp65495-503 protein of CMV in the context of HLA-A*0201. Samples were obtained from engraftment at 30-day intervals until day +180 and 2-monthly thereafter. Median follow-up was 10 months (2-25) after SCT. All pts engrafted at a median of 20 days (12-27). Acute GVHD occurred in 5 pts (median 54.2 days, range 18-92). Three patterns were observed. In 2 pts (14%) no CMV-specifi c CD8+ T-cells could be detected despite 5 episodes each of CMV-PCR reactivation requiring prolonged cumulative antiviral therapy (67 and 136 days each). In 6 pts (43%) CMV-PCR reactivation occurred at a median of 36 days and triggered a rapid increase of CMV-specifi c CD8+ T-cells (median 97.3 x 105/L, range 1. 3-279.7) . The CMV-PCR became immediately negative and antiviral therapy was stopped promptly after a median of 15 days (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Subsequent CMV-PCR reactivations (median 1.8, range 1-3) also lasted under 2 weeks in this group. Finally, 6 pts (43%) showed an early immune reconstitution with CMV-specifi c CD8+ T-cells detected (median 1.4 x 105/L, range 0. 3-2.85) in the absence of CMV-PCR reactivation at a median of 22 days (10-34) post-SCT. No CMV-PCR reactivation was observed in this group with a median follow-up of 7.5 months (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Monitoring CMV-specifi c T-cell immunity after allo-SCT in combination with CMV-PCR may be able to distinguish pts at higher risk of recurrent CMV reactivation and in need of prolonged antiviral therapy. Patients with increasing CMV-specifi c CD8+ T-cells detectable at the time of CMV-PCR reactivation may only need a short course of antiviral therapy, while those with early CMVspecifi c CD8+ T-cells may be protected from CMV reactivation.

The phenotypic and functional shift from donor-graftderived B-cells towards newly-produced B-cells two months after allogeneic stem cell transplantation is delayed in patients with acute graft-versus-host disease A. Mensen (1) After allogeneic hematopoietic stem cell transplantation (alloHSCT), donor graft-derived B cells only transiently provide immune protection in patients, and immune defects that contribute to an increased risk for severe infections occur. In this study, we determined for the first time the reconstitution kinetics of B cells after alloHSCT in patients suffering from acute leukemia. In a first cohort of patients, RT-PCR quantification of κ-deleting recombination excision circles (KREC), which are generated during B cell development, revealed a high positive correlation with transitional B cell recovery (generalized estimating equations analyses ß*=0.585 vs. ß*=0.383 for memory B cells), and indicated that the bone marrow B cell output started around day +60 post alloHSCT. Next, we used flow cytometry for phenotypical and functional (activation, survival and migratory markers) characterization of several B cell subsets after alloHSCT. Total B cell numbers were already decreased pre-transplant (mean cells per ml blood ±SEM: 11±3 alloHSCT, 43±8 healthy donor) and dropped even further within the first month after alloHSCT. Detectable B cells in the early phase post-transplant exhibited a highly activated phenotype (CD86+ and CD95+), and were putative of donor graft origin. The expression levels of the survival receptor BAFF-R and the chemokine receptors CCR7, CXCR5 and CXCR4 were significantly decreased. In accordance to our RT-PCR data, early onset of bone marrow B cell neogenesis was seen in about 50% of patients between day 60 and 90 after alloHSCT, characterized by a strong increase in cell number (75±31, day 90) and predominance of transitional B cells exhibiting normal expression of activation markers, but still reduced expression of BAFF-R and CCR7. Interestingly, B cell reconstitution was significantly delayed in patients with acute GVHD compared to patients without GVHD (88% vs 25%, p=0.04). In addition to the B cells, we also analyzed the kinetics of T cells and dendritic cells as potential interactive players. Pre-transplant numbers of plasmacytoid dendritic cells and CD4+ T cells were also significantly decreased. In summary, our data reveal a switch in the B cell subset distribution and pattern of functional characteristics, paralleling the shift of graft-derived B cells in favor to newly regenerating B cells two month after alloHSCT. Furthermore, incidence of acute GvHD signifi cantly delayed the onset of B cell reconstitution.

Introduction: Reconstitution of adaptive cellular immunity is pivotal to protect against viral infections post haematological stem cell transplantation (HSCT). Research on immune reconstitution has mainly been focused on the early period post HSCT. In contrast, little is known about the eff ects of early infections on the reconstituted cellular immune system in steady state conditions. Here, the impact of early cytomegalovirus (CMV) reactivation after HSCT on the lymphocyte compartment at one year post HSCT was studied. Methods: Children, who underwent HSCT for malignant and nonmalignant haematological disorders in our centre from 2002 to 2010 and were eligible for follow-up one year later (n=160), were included. Viral infections were routinely monitored by weekly serum viral DNA PCR in the fi rst 100 days. Peripheral blood mononuclear cells were drawn one year post HSCT and analyzed by multicolour fl ow cytometry. Results: CMV reactivated patients (n=46, PCR at least 1x > log 2.3) had signifi cantly higher lymphocyte counts than patients without CMV reactivation (n=114, PCR always < log 2.3). This eff ect was caused by an increase of CD8+T-cells (median 1152 vs. 390 cells/ uL, p<0.0001, Mann-Whitney test) and both CD8+ and CD8-γ-δ (gd) T-cells (all gd T-cells: median 86 vs. 41 cells/uL, p<0.0001), while numbers of CD4+T-cells, NK-cells and B-cells were comparable. No diff erences were found between donor-patient pre-transplant CMV serostatus combinations. However, a correlation of the maximum CMV load early post HSCT and CD8+ (p=0.040) and gd T-cell (p=0.021) counts one year post HSCT was observed. In a representative subcohort (n=53, 2008 -2010) , we more closely analyzed the diff erentiation stages of CD8+T-cells based on expression of CD45RA and CCR7. Patients with CMV reactivation (n=14) had, compared to patients without CMV reactivation (n=39), signifi cantly higher numbers of eff ector memory (EM, median 485 vs. 119 cells/uL, p<0.0001) and end-stage eff ector (EE, median 492 vs. 106 cells/uL, p<0.0001) CD8+T-cells, while naïve (N) and central memory (CM) cell numbers were similar in both groups (see fi gure). In contrast to CMV, this profi le of lymphocyte numbers and phenotype was not observed in patients after early EBV reactivation. Conclusion: We show that CMV reactivation early post HSCT is associated with expansion of the EM and EE CD8+T-lymphocyte compartments in steady-state one year post HSCT, without compromising the size of the naïve and CM pools available to respond to newly encountered pathogens.

Immune reconstitution after alternative haematopoietic stem cell transplantation: comparison of unrelated cord blood and mismatched unrelated donor haematopoietic stem cell transplantation S. Servais, E. Lengline, R. Porcher, M. Carmagnat, R. Peff ault de Latour, G. Maki, C. Granier, M. Robin, E. Clave, A. Xhaard, N. Dhedin, A. Toubert, H. Moins, G. Socie Saint-Louis Hospital (Paris, FR) There is no consensus about what is the best alternative source of stem cells when no suitable HLA-matched (un)related donor is identified for allogeneic hematopoietic stem cell transplantation (HCT): mismatched unrelated donor (mmUD) or umbilical cord blood (CB)? Data about immune reconstitution and risk factors for infection after alternative HCT are limited. Here, we compared immune reconstitution after CB-vs 9/10 HLA-mmUD-HCT. Methods: Sixty-six patients who underwent a fi rst HCT from either CB (n=30) or 9/10 HLA-mmUD (n= 36) at Saint-Louis Hospital (Paris) from 01/2005 to 12/2010 were evaluated. Immune reconstitution was prospectively assessed by fl ow cytometry on fresh blood samples collected at ±1month before and then at 3, 6, 12, 18, 24 and 30 months after HCT. The following phenotypes were studied: Natural killer (NK) cells (CD3-CD56+); B cells (CD19+) and their naïve (CD27-) and memory (CD27+) subsets; CD4+ and CD8+T cells and their naïve (CD45RA+CCR7+), central memory (CM:CD45RA-CCR7+), eff ector memory (EM:CD45RA-CCR7-) and late eff ector memory (LEM:CD45RA+CCR7-) subsets as well as regulatory T cells (Treg:CD4+CD25+CD127low). Results: Reconstitution of T cells was signifi cantly delayed in CB recipients compared with mmUD during the fi rst 12 months post-HCT (P<0.05), particularly for CD8+T cells subset (P<0.01). In contrast, NK cells recovered more quickly during the fi rst 6 months after CB-HCT (P<0.01). B cells counts were also higher in CB recipients till 24 months post-HCT (P=0.005). This resulted in signifi cant diff erences in the pattern of immune circulating cells after HCT in CB and mmUD recipients, particularly at 3 months post-transplant ( Fig.1) . Concerning CD4+ and CD8+ T cells, the distribution between naïve and memory subsets was diff erent in CB and mmUD cohorts as T cells from CB were characterized by smaller proportion of naïve cells and higher proportion of EM cells during early post-transplant period (P<0.01). There was no diff erence in term of Treg reconstitution. Concerning B cells, their reconstitution was characterized by a large predominance of naïve cells for both cohorts during the fi rst two years after HCT. Conclusion: In comparison with mmUD, HCT from CB was characterized by faster NK and B cells reconstitution but delayed T cells recovery, mainly for CD8+ and naïve compartments. If these different patterns of immune reconstitution may translate in different susceptibility for severe infections has to be determined. S133 P561 TREC after allogeneic stem cell transplantation as a predictive marker for relapse after AML and MDS/MPS M. Uzunel, D. Sairafi , J. Mattsson, M. Uhlin Therapeutic Immunology (Stockholm, SE) T-cell defi ciency after allogeneic stem cell transplantation (ASCT) is common and has major impact on clinical outcome. While T cells are the major eff ector population responsible for the graft versus leukemia (GVL) eff ect after ASCT their function is vital for inhibiting relapse. In this retrospective study, 210 patients with malignant disease were analyzed with regards to levels of T-cell receptor excision circles (TRECs) during the fi rst 24 months after transplantation. It has been shown that reconstitution of TREC levels after myeloablative conditioning concurs with return to normal composition of naïve T-cells and TCR repertoire. Patient blood samples were collected at regular intervals (2, 3, 6, 9, 12 , and 24 months) after ASCT. CD3+ cells were separated using direct antibody-coupled magnetic beads, followed by extraction of DNA according to a standard protocol. The δ Rec-?;J α signal joint TREC was measured using a Taq-Man real-time quantitative PCR protocol with primers and probes directed to the signal joint region. The patient population was divided in groups based on their malignant disease. CML (n=26), CLL (n=8), AML (n=50), ALL (n=93) and MDS/MPS (n=33). The level of TREC at the diff erent time points was then correlated to relapse-incidence and relapse-free survival (RFS).

No signifi cant correlation between TREC levels at any time point and relapse incidence or RFS could be seen in patients with CLL, CML or ALL. For patients with AML, TREC levels at 2 months post transplantation were signifi cantly correlated to both RFS at 5 years (TREC > median 78%, TREC < median 54%, p=0,01 ) and relapse incidence (TREC > median 13%, TREC < median 46%, p=0,038). For patients with MDS/MPS, TREC levels at 9 months post transplantation were signifi cantly associated with RFS at 5 years (TREC > median 100%, TREC < median 48%, p=0,01 ) and relapse incidence (TREC > median 0%, TREC < median 52%, p=0,01 ). This study shows the potential use of TREC measurement in peripheral blood to predict relapse in patients with AML and MDS/MPS after ASCT. Objectives: Anti-thymocyte globulin (ATG) is widely used in the conditioning regimen of children undergoing haematopoietic stem cell transplantation (HSCT) to prevent graft-versus-hostdisease and rejection of the graft. However, data on immune reconstitution following ATG are scarce. Methods: We retrospectively analyzed the engraftment kinetics and clinical parameters of 113 paediatric/adolescent patients (median age 11.9 years) undergoing HSCT following myeloablative conditioning with or without in vivo T-cell depletion. Patients with matched unrelated donor received either ATG-Fresenius (n=45, group 1) or Thymoglobuline Genzyme (n=30, group 2), while patients with matched sibling donor (n=38, group 3) underwent HSCT without in vivo T-cell depletion. Immune cell subsets (CD4, CD8, NK, CD19, naïve CD4) were determined on day +50, +100, +180 and +360 post HSCT. Results: Immune reconstitution in the three groups was comparable in most cell subsets (Table 1) . Important diff erences were lower average numbers of CD4+ cells following ATG-Fresenius compared to Thymoglobuline (p=0.049) and those not receiving ATG (p=0.002). By day +180, median CD4 cells were similar in all groups. Moreover, average naïve CD4+ cells were lower in group 1 and group 2 compared to group 3 (p<0.001). Concerning infectious complications, percentages of cytomegalovirus or adenovirus reactivation in the peripheral blood tended to be higher following ATG (group 1 and 2: 23/75, 31% vs. group 3: 3/38, 8%, p=0.29), while occurrence of graft versus host disease grade 3 and 4 was similar in the three groups (group 1 and 2: 10/75, 13% vs. group 3: 3/38, 8%, p=0.47). Epstein barr virus lymphoproliferative disease occurred only in patients following in vivo T-cell depletion (group 1: 3/45, 7%, group 2: 3/30, 7%). Conclusions: Following myeloablative conditioning, immune reconstitution of most cell subsets after day +50 is similar with or without in vivo T-cell depletion. Occurrence of naïve CD4 cells as a sign for thymic recovery is faster without ATG. Apart from transiently lower CD4 cells following ATG-Fresenius, immune reconstitution is not majorly infl uenced by the ATG preparation used.

Pre-clinical isolation and expansion of CMV-specifi c T-cells for adoptive immunotherapy based either on IFN-γ production or activation-dependent expression oF CD154 E. Albiero (1), K. Chieregato (1) , A. Alghisi (1) , C. Lievore (1) , M.A. Cassatella (2) , D. Madeo (1), F. Rodeghiero (1) , G. Astori (1) (1)San Bortolo Hospital (Vicenza, IT); (2) University of Verona (Verona, IT) Introduction: Cytomegalovirus (CMV) infection counts as some of the most signifi cant complications following allogeneic hematopoietic stem cell transplantation (HSCT). The capture of T-cells secreting cytokines or expressing T cell activation markers after specifi c viral antigens stimulation allows the isolation of CMV-specifi c T cells (CMV-T). Two strategies are currently clinically applied: isolation of CMV-T using streptamer technology, or isolation of cells secreting IFN-γ (IFN-g) in response to antigen stimulation (g-catch). Aim: We explored the T cell response of the anti-CMV CD4+ and CD8+ T cells obtained with either g-catch or by selection of CD154 diff erentially expressed upon stimulation with pp65, IE1 or both CMV peptides. Methods: Blood was obtained from CMV seropositive donors. PBMC were isolated after density gradient separation and cultured in RPMI medium with 1% antibiotic and 10% human AB serum (CTL medium). PBMC were stimulated with CMV-pp65 or/and -IE1 peptide pools, co-stimulated with CD28 and incubated at 37°C at 5% CO2. For CD154 experiments, cultures were stimulated in the presence of anti-CD40 antibody. For the isolation of CMV-T following stimulations, cells were either magnetically enriched by the g-catch or by CD154-microbeads (Miltenyi Biotec). After isolation, CMV-T were cultured in the presence of feeder cells in CTL medium supplemented with recombinant human interleukins for a maximum of 21 days. CMV-T were stained before and after selection for immunophenotyping (IF) and intracellular cytokine staining (ICC) and analysed by flow cytometer. Results: IF on the enriched fractions and ICC on expanded CMV-T allowed comparison of purity and enrichment between the two isolation methods and virus epitopes. The IFN-g secreting CD4+ T cells have been enriched up to 66% ( Figure 1 ) and with signifi cant CD8+ component too, with an highly variable expansion factor. Although isolation of CD154+ cells greatly favours enrichment of CD4+ T cells, a number of CD8+ T cells was simultaneously expanded depending on the type of peptide and of the simultaneous use of them. Conclusions: We have successfully generated IFN-g+ and CD154+ CMV-T cells upon stimulation with both CMV antigens. Improvement of the experimental protocols will be aimed at the functional CMV-T characterization and at the achievement of high frequencies of both CD4+ and CD8+ targeting IE1 and pp65 CMV epitopes with either CD154 selection or g-catch. Methods: We studied 61 adult patients with hematologic malignancies (24 AML, 13 ALL and 24 other malignancies), who received haploidentical grafts with PT-CY, following a myeloablative conditioning regimen. Genetic analysis included HLA-class I haplotypes of donor/recipient pairs for the expression of KIR-ligands and donor KIR genotype. Phenotypic and functional analyses were performed to study NK cell repertoire in the donor and in the recipient at diff erent time intervals post-HSCT. Results: We observed that 15/61 patients received BM from donors with A/A, while 46/61 from donors with B/X KIR haplotypes (21/61 cases with ≥2 B content score). Moreover, 20/ 61 patients were transplanted from NK alloreactive donors. A fast immune reconstitution was observed after BMT and post 1 month, lymphocytes were represented by 38% NK cells and 62% T (median values). At this time point NK cells appeared phenotypically immature: virtually all cells were CD56bright, CD94/NKG2A+ (i.e. inhibitory receptor specifi c for HLA-E), while low percentages of CD16, KIRs and CD57 positive cells were represented. However, these NK cells displayed a normal cytolytic activity revealed by degranulation assay upon K562 stimulation. A more mature phenotype, characterized by a majority of CD56dim cells and identifi cation of KIR+ NKG2A-NK cells, could be frequently observed only several (6-12) months after transplant. Relapse was seen in 5/20 patients receiving BMT from NK alloreactive donors, while 14/41 patients receiving BMT from no-NK alloreactive donors (p=0.3). Considering the B content score, 7/15 and 7/21 patients receiving BM from donors with 0 and ≥2, respectively, relapsed (p= 0.3). In AML patients, the impact of NK alloreactivity and B content score appeared to be more relevant (p=0.2) and p= 0.1, respectively). Conclusion: NK phenotype is immature following haplo-BMT. There is a trend for protection against relapse in patients receiving haplo-BMT from NK alloreactive and/or high B content donors, especially in AML. With larger number of patients we expect to see signifi cant diff erences. The speed of immune recovery following haploidentical allogeneic stem cell transplantation (haplo-SCT) is of central importance to overcome infectious complications and relapse. In order to evaluate the infl uence of graft manipulation on immune recovery we retrospectively examined the immune-reconstitution post haplo-SCT in 35 pediatric patients suff ering from high acute leukemia in a multi-centre (Frankfurt, Leiden, Ulm, Wuerzburg) longitudinal study. 17 patients received a CD34+ selected graft (group A) and 18 patients a T-and B-depleted graft (group B). Patients in both groups did not diff er in the mean age (p>0.2) and the underlying diseases (ALL, AML); (p>0.2). However, the conditioning regimes varied according to the underlying disease and the kind of graft manipulation. 14 and 3 patients received standard myeloablative conditioning regimen and reduced intensity conditioning regimen, respectively in group A vs. 5 and 13 patients in group B (p=0.002). In addition status of complete remission (CR) prior to haplo-SCT was lower in group A (11/17) compared to group B (17/18); (p=0.04). The incidence of graft-versus-host disease (GvHD) grad I-II was 7/17 and 9/ 19 patients in group A and group B, respectively. 2/17 and 4/18 patients of group A and B, respectively, even had a GvHD>grad III. The incidence rates of lethal infections were 1/17 and 3/18 patients in group A and group B, respectively.The main cause of death was relapse in both groups. The median follow-up time was 10 months (range 1.6 to 86 months) for all patients and 26 months (range 3.7 to 86 months) for survivors, respectively. In order to harmonize diff erences between groups, we performed a joint model of overall survival and the dynamics of leukocytes, lymphocytes, monocytes, T-cells and their subsets, NK-and B-cells. In our model, we considered two factors: Remission degree and the graft manipulation (group A and B). Age-matched monocytes regeneration was faster in patients without remission compared to those in remission (p<0.001). Furthermore, T-cells and T cell subsets recovered more quickly in group B (p<0.02). In contrast, NK cells and B cells expanded more rapidly in group A (p<0.004; p<0.02). Dynamics of all cell types had a signifi cant infl uence on overall survival. In conclusion, cell reconstitution dynamics was infl uential for overall survival, but showed a complex diversity with regard to the engineering graft procedure. Introduction: Cytomegalovirus (CMV) poses a threat to patients after HSCT. CMV reactivation might lead to CMV-disease associated with high morbidity and mortality. It is challenging to identify those patients at risk for developing CMV-disease or recurrent CMV-reactivation in need for prolonged treatment and more meticulous monitoring. Interleukin-7 (IL-7) and its receptor represent a key pathway preventing T cells from activation-inducedcell-death associated with the up-regulation of T lymphocyte survival factors; it also promotes T-cell expansion and long-term memory immune response. IL-7 induces phosphorylation of signal transducer and activator of transcription 5 (STAT-5), which enters the nucleus and binds to specifi c DNA sequences in the promoter regions of various genes, resulting in gene activation or repression. Method: We evaluated the function of the IL-7 signalling pathway by measuring the phosphorylation of STAT5 in CD4+ T cells, CD8+ T cells and TCR γ δ T cells in response to stimulation with IL-7 and IL-2 in blood from 40 HSCT-patients 1-6 months after HSCT. Patients were monitored weekly with a quantitative PCR from the time of engraftment for CMV viral load in whole blood until at least d. 100 after HSCT and thereafter approximately every two weeks in patients with GVHD or in those who had a previous CMV episode. Results: In general, a higher number of CD4+ T-cells, as compared to CD8+ T-cells, responded to IL-7 or IL-2 defi ned by STAT-5 phosphorylation. A more detailed analysis was performed comparing responses from patients who did not reactivate (CMV-), patients that did reactivate (CMV+), and patients with prolonged or recurrent reactivation (CMV++). Lower levels of constitutive STAT-5 phosphorylation was seen in CD3+ T cells obtained from the CMV+ group determined by one-way Anova (p-value= 0.0008). The % of cells with phosphorylated STAT-5 upon IL-7 stimulation was lower in CD8+ T cells in CMV+ patients (median 20. 6, 6.3, 7.5, 4.8, 5.6 and 5.3) and CMV++ patiens (median 10.6, 4.14, 5.37, 3.3, 2. 39 and 2.93) for time points 1-6 as compared to 21.2, 20.28, 16.8, 45 and 0.56) after HSCT (p-value = 0.03 determined by one way ANOVA). Conclusion: Reduced responsiveness to IL-7 is correlated to CMVreactivation. This ability is more pronounced in CD8+ T cells. Functional response analysis to IL-7 may provide a clinically relevant marker to identify patients at risk to develop CMV reactivation. Objectives: Hematopoietic stem cell (HSC) transplantation is a powerful tool to induce life-long immune tolerance to donor allo-antigens. The underlying mechanisms controlling hostversus-graft (HvG) responses are incompletely understood, but primarily involve peripheral regulation elicited during the phase of hematopoietic reconstitution. The purpose of this study was to investigate the effects of NKT cells on HvG responses and the relationship with other immunoregulatory networks, namely regulatory T cells and myeloid-derived suppressor cells (MDSCs).

Materials & Methods: We investigated in a mouse model HvG responses against male minor histocompatibility antigens HY after non-lethal myeloablative bone marrow transplantation. Recipient mice were CD1d-/-(with no NKT cells), wild type (controls) or wild type recipients after in vivo NKT stimulation with α GalCer. MDSC and Treg populations were assessed in parallel. Results: The absence of NKT cells during hematopoietic reconstitution greatly facilitated the engraftment of donor HY+ HSC. Accordingly, the stimulation of NKT cells antagonized HSC engraftment. During the hematopoietic expansion that follows cytotoxic regimen-induced myeloablation, the tempo and magnitude by which the various immune components reconstitute the host differed. The process involved also regulatory cells amongst which regulatory T (Treg) cells play a key role. The graft facilitating eff ect associated with the absence of NKT cells did not require Treg cells and was mediated by the selective expansion of CD11b+Gr-1int myeloid derived suppressor cells (MDSC) during hematopoietic reconstitution. The MDSC thus generated exhibited an immunosuppressive activity only if recipient mice were transplanted with antigenically diff erent donor HSC. Conclusions: In the absence of NKT, the increased formation of MDSC is solely suffi cient to inhibit HvG by producing Treg cell independent transplantation tolerance. S137 absent or defective neutrophil function (chronic granulomatous disease-CGD). Allogeneic hematopoietic stem cell transplantation (HSCT), which aims at producing stable donor engraftment, remains the only curative option for many PIDs. Objective: The aims of this study were to retrospectively analyze the variables aff ecting chimerism and to determine the impact of mixed chimerism (MC) on immune reconstitution, outcome and prognosis for patients with MC post-HSCT for PIDs, at Rambam Health Care Campus, Haifa, Israel, between 2000 and 2012. Patients and Methods: Included were 19 patients (10 boys, 9 girls) who had full or partial engraftment of donor hematopoietic SC, survived more than six months post-HSCT for PIDs, and had a mean age of 42 months (range, 1-180 months). Median followup was 114.3 months (range, 6-144 months). SC source: three related peripheral blood SC (PBSC), three haploidentical-PBSC, four unrelated cord blood (CB), nine related bone marrow (BM). All patients were subsequently divided into two groups according to immunodefi ciency type: group A (12) -PIDs with SCID (10 SCID, 2 Omenn syndrome); group B (9) -other PIDs "non-SCID" (3 CGD, 3 X-lymphoproliferative syndrome-XLP, 1 WAS). MC was defi ned as having host hematopoietic cells of 1-99% at any time post-HSCT. Donor chimerism was measured by STR and SGM plus kit. Variables tested for eff ects on MC included patient age, PID category, numbers of infused CD34+, source of SC, degree of HLA match and conditioning regimen. Immune reconstitution was retrospectively analyzed using clinical follow-up, diff erential white blood count, quantitative immunoglobulins, CD4 T cells, CD8 T cells, and CD19 B cells. Ten (41.7%) of 19 transplanted patients were diagnosed with MC. Only one (10%) patient (WAS) with MC developed prolonged hypoγglobulinemia post-HSCT. Conclusion: Stable MC post-HSCT in PIDs is common, provide stable immune reconstitution of both T-and B-cell function, suffi cient to cure the PIDs, similar to full chimerism, and might be a strategic observation for gene therapy. Graft rejection is higher among patients with MC less than 30% donor cells. Lower rates of GVHD and no related morbidity or mortality with stable MC was observed.

Anti T-cell globulin (ATG) induces antibody-dependent cellular cytotoxicity (ADCC) against haematologic malignancies S. Westphal, H. Brinkmann, S. Cordes, K. Grossmann, M. Kalupa, J. Mengwasser, K. Riesner, A. Wilke, R. Arnold, O. Penack Charité Berlin (Berlin, DE) Background: Recent clinical studies indicate that anti T cell globulin (ATG) can decrease the incidence of GVHD without increasing leukemia relapse rates, raising the question whether ATG induces T cell independent anti tumor eff ects. Antibody-dependent cellular cytotoxicity (ADCC), mediated by NK cells, is a relevant therapeutic mechanism of antibody mediated immunotherapy against cancer. Despite its broad clinical use, the eff ect of ATG on ADCC has not been studied in detail. Methods/Results: To investigate the eff ect of ATG on ADCC, we have established a fl ow-cytometry based method based on detection of CD107a as a marker for NK-cell degranulation. We fi rst confi rmed that the degranulation of NK cells correlated closely with ADCC, as assessed by standard cytotoxicity assays. We then investigated the eff ect of anti-Jurkat rabbit ATG (Fresenius Biotech, Gräfelfi ng, Germany) on ADCC against diff erent human hematologic malignancies: Acute myeloid leukemia (HL-60, K562), follicular lymphoma (Karpas 422), Burkitt›s Lymphoma (Raji), chronic lymphoid leukemia (EHEB), mantle cell lymphoma (JeKo-1) and T/ NK cell leukemia (YT). We found that ATG induced high amounts of ADCC not only towards T cell lymphoma/leukemia, but also against AML and diff erent B-cell lymphomas ( Fig.1 and Fig.2 ). The maximum ADCC was reached at a relatively low concentration of 20μg/ml ATG. Discussion: Our data suggest that ATG augments T cell independent anti tumor eff ects, providing a possible explanation for favorable clinical data on leukemia relapse rates after HSCT. The ability of ATG to induce ADCC against a broad variety of hematologic malignancies, as opposed to exclusively having eff ects on T cell derived malignancies, is most likely explained by eff ects of non T cell specifi c IgG. Interestingly, serum concentrations of non specifi c rabbit IgG at day +60 after HSCT in patients treated with 30mg/Kg ATG-F were well above 20μg/ml (Mastaglio, EBMT 2009), indicating that ADCC may be increased for a long period after ATG infusion. In our previous work, however, we found that high concentrations of ATG (found early after ATG infusion) resulted in depletion of NK cells and deterioration of NK cell function in vitro as well as in vivo (Transpl Immunol. 2007 Nov; 18:85, Bone Marrow Transplant. 2008 Feb; 41:377) . These data demonstrating a diff erential impact of ATG on NK cells and ADCC may be useful for development of HSCT strategies working with NK cell mediated anti tumor eff ects. Background: Reconstitution of the immune system following allogeneic stem-cell transplantation (allo-SCT) is a complex process that requires successful engraftment of the hematopoietic stem cell, as well as adequate thymic function. Although GVHD control, improvements in antibiotic spectra, and circumspection in the use of immunosuppressants have helped, too many patients still die of infections because of insuffi cient immunologic recovery. Sirolimus has been used alone and in combination with calcineurin inhibitors for prevention of allograft rejection after solid organ transplantation. In the fi eld of hematopoietic stem cell transplantation, the combination of sirolimus and tacrolimus has also resulted in a low incidence of acute GVHD and reduced transplant-related toxicity. Methods: We evaluated the immune recovery status of 24 patients who received the combination of sirolimus and tacrolimus as a GvHD prophylaxis compared to a historical control (n=21) using tacrolimus and methotrexate (MTX). They were conditioned with myeloablative regimens. Results: The incidence of acute GVHD in patients with sirolimus based regimen was lower. And the incidence of CMV or EBV reactivation in the same group was higher. The recovery of CD4+ T cells and natural killer (NK) cells seemed to be more delayed in recipients with sirolimus based regimen compared to those in patients with tacrolimus and MTX at 1 month after transplantation (8.8 ± 1.6 vs 14.9 ± 5.8 for CD4+ T cells, 35.7 ± 6.4 vs 53.4 ± 19.6 for NK cells). However, there was no signifi cant diff erence between in the recovery of CD4+ T cells and NK cells at 3 months after transplantation. In the aspect of humoral immunity, there was a trend to be lower in immunoglobulin-A and Ig-M levels during 1 month and 3 months after transplantation in patients with sirolimus based regimen. This diff erence was overcome around post-transplant 6 months. And regulatory T cells (CD4+CD25+Foxp3+) seemed to be higher in patients with sirolimus based regimen. Conclusion: The sirolimus based regimen is associated with wellcontrolled acute GvHD. Although the correlation between the increased risk of infection and delayed immune reconstitution was not confi rmed, the regimen might be cause of increasing the risk of opportunistic infection. Therefore we need an eff ort of early tapering of immunosuppressants and a careful monitoring for opportunistic infections in patients received sirolimus based regimen.

Neutrophil engraftment in paediatric haematopoietic stem cell transplantation following myeloablative conditioning: which factors do matter? H. Pichler (1) , V. Witt (1) , H. Boztug (1) , A. Lawitschka (1) , W. Holter (1), S. Matthes-Martin (1), G. Fritsch (2) (

Patients and methods: Neutrophil engraftment (NE) following myeloablative conditioning was retrospectively analysed in 112 children transplanted 2000-2012 in a single centre. Graft source was bone marrow in 94 and peripheral blood in 18 patients. 38 patients received grafts from matched sibling donors (MSD), whereas 74 were transplanted from matched unrelated donors (MUD). The median donor age was 27.4 years and in 47 patients the donor was <25 years. A total body irradiation (TBI)-based conditioning was used in 72 patients, whereas 39 received chemotherapy. Virus prophylaxis consisted of acyclovir in 63 and gancyclovir in 32 patients (Overview: Table 1 ). Engraftment was defi ned as the fi rst of three consecutive days with neutrophil counts >0.5x10 9 /L peripheral blood. The impact of the total number of infused CD34+ cells and of myeloid CD34+ cells (CD34+/ CD45dim/CD19neg/CD10neg) infused per kg recipient weight, donor age and origin (MSD vs. MUD), conditioning (TBI-based vs. chemotherapy based), and type of preemptive antiviral therapy on NE kinetics were evaluated. Results: Median time to NE for all 112 patients was 20 days (range: 10-40) after receiving a median of 4.1x10 6 /kg total CD34+ cells and 2.4x10 6 /kg myeloid CD34+ cells respectively. Patients given a low dose of total CD34+ cells (<3x10 6 /kg) engrafted equally to those given 3-6x10 6 /kg CD34+ cells or more. Likewise, the number of infused myeloid CD34+ cells did not correlate with NE. Stem cell source, donor age, conditioning, and antiviral agents did not seem to have an impact on NE. (Table 1) . Interestingly, patients transplanted from MSD engrafted earlier than those from MUD (median 17.5 days vs. 21 days; p=0.034). A subgroup analysis of MUD recipients moreover revealed a positive correlation between NE and total CD34+ cell numbers but not for myeloid CD34+ subsets. Conclusion: The median NE in our cohort was signifi cantly faster for MSD recipients, whereas neither the graft content of total CD34+ nor of the myeloid CD34+ cells had an impact on engraftment kinetics. The evaluation of donor age, stem cell source, conditioning or antiviral agents revealed no signifi cant infl uence on NE.

[P571] P572 Non-myeloablative haploidentical transplantation with G-CSF mobilized peripheral blood stem cells with high dose post-transplant cyclophosfamide: rapid lymphocyte recovery with prevalence of T regulatory cells, low incidence of infection and GvHD G. Andreola, F. Gigli, A. Gardellini, P. Mancuso, S. Liptrott, M. Negri, G. Martinelli, R. Pastano European Institute of Oncology (Milan, IT) Haploidentical bone marrow transplantation using high-dose, post-transplant cyclophosphamide (Cy) has been shown to be a feasible approach for patients lacking an HLA identical donor. In the attempt to reduce the associated risk of graft failure, relapse incidence and to boost immune recovery we decided to apply the same conditioning regimen using unmanipolated G-CSF mobilized peripheral blood stem cells (PBSC). From July 2010 to October 2012, 13 patients, aff ected by high-risk hematological malignancies received Cy, fl udarabine and TBI followed by infusion of haploidentical PBSC; post-transplant immunosuppression consisted of high-dose Cy on days +3 and +4, tacrolimus and micofenolate mofetile. At a median follow-up of 143 days (36-758), grade II acute Graft-versus-Host Disease (GvHD) developed in 1 patient, no chronic GvHD occurred in 8 evaluable patients and no graft failure was observed. Achievement of full donor chimerism was complete on CD3+ cells since day +28 in 8/13 evaluable patients, by day +84 in 9/11. CMV reactivation occurred in 10/12 patients at risk for reactivation at a median time of 34 days posttransplant and resolved with pre-emptive antiviral therapy in 9 patients; one heavily pretreated patient died of a fatal infection. Flow cytometry was used to monitor lymphocyte recovery on PB. Available data on 6 patients on day +56 show a median of CD3+ of 730 (160-1427) cells/μL, CD3+CD4+ of 213 (126-315), CD3+CD8+ of 487 (34-1112), which remained stable through day +84. Data on 3 patients on day +356 show recovery to values close or above normal: CD3+ 1304 CD3+ , 393, 1907 CD3+CD4+ 348, 244, 527; CD3+CD8+ 957, 148 , 1380 cells/μL. Notably, a very high proportion of recovering CD3+CD4+ cells expressed high levels of CD25, were CD27 low/negative and positive for FoxP3 (T regs): indeed on day +84 median percentage of T reg was 6.2% (5) (6) (7) (8) (9) (10) (11) (12) out of total number of CD4+ cells, higher than in healthy donors. High percentage of Tregs persisted through day +365 on the 3 evaluable patients. This is the fi rst report showing that haploidentical non-myeloablative PBSC transplantation with high-dose post-transplant Cy allows a rapid and sustained engraftment, a fast and complete lymphocyte recovery and it is not associated with major infections. We can postulate that the high recovery of T regs might be involved in the low incidence of GvHD. CMV reactivation remains a critical issue; further studies are needed to clarify recovery of CMV immunity and to establish better prophylaxis therapy. Transplantation of cord blood units as a stem cell source is increasingly used for the treatment of acute leukemias if HLA identical donors are lacking. Aside from graft versus host disease and relapse, infections considerably infl uence outcomes. Especially reactivation of herpes viruses such as CMV and EBV impact on mortality. We therefore monitored T-cell reconstitution of patients (n=6) after double cord blood transplantation (dUCBT) and compared our results to patients (n=65) receiving HLA matched G-CSF mobilized peripheral blood mononuclear stem cells (PBSC). All patients were analyzed by 7 color fl ow cytometry on days 30, 60, 90, 120 and 180 after transplantation. Using a standardized protocol we determined absolute cell counts of monocytes, CD4+ and CD8+ T-cells, B-and NK-cells. In addition, HLA A2 positive samples were analyzed with multimers to detect CD8+ T-cells specifi c CMV peptides (VLE, NLV) and EBV peptides (GLC, CLG, YVL). Reactivation of CMV and EBV was monitored weekly in the peripheral blood by quantitative PCR, chimerism was assessed by PCR of single nucleotide polymorphism. Comparison of both groups revealed principal diff erences in immune reconstitution of T-, B-and NK-cells, reactivation of CMV and EBV, and the achievement of full donor chimerism. All dUCBT patients reached full donor chimerism on day +30. CMV was reactivated in 27/65 PBSCT and in 4/6 dUCBT recipients. None of the dUCBT, but 19/65 PBSCT recipients reactivated EBV. CD8+ T-cells numerically reached normal levels on day +60 in PBSCT recipients (mean 536±792), whereas recipients of dUCBT generally displayed low counts during the follow up period of 180 days. Analyzing CMV and EBV specifi c CD8+ T-cells, dUCBT recipients displayed increasing numbers of CMV specifi c CD8+ T-cell counts on day +90, when CMV reactivation occurred before day +60. In contrast, in PBSC patients counts rose from day +60 to higher levels along with normalization of total CD8+ T-cell counts. B-cell counts normalized in dUCBT patients on day +90 (mean=468±531), but remained low in PBSCT recipients long time during the follow up, especially when Rituximab was used for treatment of EBV reactivation and/or steroids for graft versus host disease. Better survival occurred in PBSCT patients with early elevated CD4+ and CD8+ T-cell counts. High B-cell counts on day +30 also correlated with better survival (p=0,073) but increased the probability of EBV reactivation (p=0,002).

Evaluation of the thymic output after autologous HSCT according to the type of conditioning: irradiation versus chemotherapy S. Giebel, M. Glowala-Kosinska, J. Najda, A. Chwieduk, W. Fidyk, T. Kruzel, M. Sadus-Wojciechowska, T. Czerw, I. Mitrus, A. Smagur, L. Miszczyk, J. Holowiecki M. Sklodowska-Curie Memorial Institute, Gliwice Branch (Gliwice, PL) Stem cells present in the graft are predominant source of T cell recovery after HSCT. The process, however, requires proper function of the thymus, which may be negatively aff ected by many factors including toxicity of the conditioning regimen. Experimental data suggest that irradiation may be more harmful to the thymus compared to myeloablative chemotherapy. The goal of the current analysis was to verify this hypothesis in a clinical setting of autologous HSCT. The thymic function was evaluated by enumeration of circulating recent thymic emigrants (RTEs) determined by fl ow cytometry as CD4+CD31+CD45RA+CD62L+ cells. It was done before start of conditioning and on day +100 after autoHSCT. A total of 57 patients with hematologic malignancies (MM, n=32; NHL, n=22; other, n=3) were included in the study. Median age was 57 years. Patients were divided in 4 groups according to the type of conditioning: total body irradiation (TBI, 12 Gy) monotherapy (n=20), TBI + CHT (n=11), total marrow irradiation (TMI) monotherapy (n=11) and chemotherapy alone (BEAM or high-dose melphalan, n=15). The groups did not diff er in terms of age. CD34+ cell dose was signifi cantly higher for TBI+CHT compared with remaining groups. RTEs could be detected in peripheral blood of all subjects prior to HSCT (median 21, range 2-261 cells/uL) with no signifi cant differences between groups (Kruskall-Wallis test, p=0.95). On day +100 after autoHSCT the highest number of circulating RTEs was observed for TBI alone (9, 2-36 /uL) followed by TMI alone (7, 2-15 /uL) , CHT alone (5, 2-24 /uL) and TBI+CHT (3, 0-14 /uL) (Kruskall-Wallis test, p=0.03). In the post-hoc analysis (U Mann-Whitney test) the values for TBI alone were signifi cantly higher compared to TBI+CHT (p=0.01) and tended to be higher compared to CHT alone (p=0.11). Analysis of lymphocyte subsets on day +100 revealed no diff erences between groups for the number of circulating T CD4+ cells (p=0.41), T CD8+ cells (p=0.52) and B cells (p=0.24). The number of Treg cells tended to be lower for TBI+CHT compared to other groups (p=0.07) and the number of NK cells was lower for TBI alone than for other groups (p=0.003). We conclude that conditioning regimens have variable impact on thymic function after autoHSCT. As opposed to previously published data from animal models we demonstrated that TBI itself is not more harmful to the thymus than high-dose chemotherapy. In contrast, the addition of chemotherapy to irradiation increases signifi cantly the toxicity. Introduction: Dendritic cells (DC) play a key role in antileukemia and antitumor response through T cell-mediated tumor destruction. Objective: In order to evaluate the impact of DC immune reconstitution patterns following SCT on acute graft versus host disease (aGvHD), relapse and as a consequence the infl uence of those in survival we performed DC quantifi cation in both peripheral blood (PB) post SCT and the underlying graft. Methods: Myeloid DC (mDC) and plasmocytoid DC (pDC) were quantifi ed using 5 color fl owcytometry in single platform approach in the PB of 42 healthy donors (range 4-57yr), bone marrow (BM) and CD3/19 depleted peripheral blood stem cell (PBSC) grafts. In addition DC subpopulations were measured in PB at day +30, +60, +90, +120, +180 post alloSCT in 35 children and young adults (20 male/15 female, range 1-27yr) suff ering from acute leukemia (n=26) or solid tumor (n=9). Median follow-up period was 18.1 months (range 2-68). Results: Absolute numbers of mDCs in BM grafts (n=21) did not diff er from those in CD 3/19 depleted PBSCs (n=21). In contrast pDCs were signifi cant higher in the CD 3/19 depleted PBSCs. We observed a fast immune reconstitution of mDC and pDC in patients diagnosed with acute leukemia and receiving BM grafts compared to those patients suff ering form leukemia or solid tumor and receiving a PBSC graft. Most importantly, at the time points +60, +90, +120, +180 post alloSCT there was a signifi cant diff erence between survivors and non-survivors in the absolute number of both mDC and pDC. Low pDC and mDC count was associated with an increased death rate post SCT when using Kaplan-Maier estimator for the overall patients group and for the leukemia group. Conclusion: Our fi rst results showed both diff erences in DC subpopulations between BM grafts and CD3/19 depleted PBSC grafts and suggests that higher numbers of DCs post alloSCT may improve patient survival. However, this needs further investigations in larger and more homogenous patient cohort. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an unrelated donor, both voluntary adult (VUD) and cord blood (CB), is a well established strategy for patients with hematological disease lacking a sibling HLA identical matched donor. However, this procedure is associated with increased morbidity and mortality because of graft versus host disease (GVHD), slow recovery of immunity and a high risk of infections.We analyzed the immune reconstitution profi le of 31 consecutive pts receiving CB allo-HSCT (December 2006-June 2012)and 28 pts receiving VUD allo-HSCT (November 2009-May 2012) was analyzed by fl ow cytometry study performed at 3, 6, 9 and 12months after transplantation and then every 6 months. In the fi rst group of pts, the median age was 41 years(range 16-66), 24/31 pts received a myeloablative conditioning regimen; 22/31 received antithymocyte globulin as GVHD prophylaxis ; 26 were single unit transplant, 5 double unit cord blood transplants, median number of TNC infused was 2.28 x 107/kg, median number of CD34 infused was 3.09 x 105/kg. In the VUD group, the median age was 48.5 years(range 18-60), conditioning regimen was myeloablative in 19/28 pts; 27/28 received antithymocyte globulin as GVHD prophylaxis; the stem cell source was bone marrow (BM) in 7 pts, peripheral stem cells (PB) in 21 pts; median TNC infused was 2.17 x 108/kg and 8.79 x 108/kg respectively in BM and PB, median CD34 infused was 2.59 x 106/kg and 7.97 x 106/kg respectively in BM and PB. On 22 evaluable patient in the CB cohort and on 20 pts in the VUD cohort, the number of patients achieving a CD3 count > 0.5 x 109/l pts within 6 months from HSCT was 12 vs 17 in the CB and VUD group, also no diff erence at 6 months was observed in number of pts achieving CD4 count> 0.2 x 109/l (10 vs 8) and CD56 count > 0.1 x 109/l (20 vs 16) in the two groups. Signifi cant diff erence was observed in the CD8+ and in the CD19 + reconstitution: at 6 months from transplantation a larger number of patients in the VUD group achieved CD8>0.25 x 109/l (8 vs 18; CB vs VUD respectively; p=0.003) while a larger number of patients in the CB group achieved CD19>0.2 x 109/l (12 vs 3; CB vs VUD respectively; p=0.025). No signifi cant diff erence was observed in term of GVHD incidence (17 vs 10) , CMV (17 vs 15) and EBV (4 vs 7) reactivation between the two groups.These data are coherent with those reported in literature and the diff erences in CD8+ and CD19+ cell recovery, in our case, did not refl ect in diff erent incidence of GVHD or viral reactivation.

Rapid increase of CD8+ T-cell count in peripheral blood of paediatric patients after HLA-identical stem cell transplantation for african sickle cell anaemia A Isgrò (1) Background: Sickle Cell anemia (SCA) remain a disease with high risk of morbidity and early death, especially in African patients. Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCA. To analyze immunoematological reconstitution after transplant, we report our experience concerning 12 geno-identical HSCT for SCA-patients prepared with the same myeloablative conditioning regiment consisting of Busulfan and Cyclophosphamide. Patients and Methods: Twelve patients with a median age of 12 years (range, 2-16), aff ected by sickle cell anemia (SCA), received hematopoietic stem cell transplantations from HLAidentical, related donors following a myeloablative conditioning regimen. To analyse the mechanisms involved in immunological reconstitution post transplant, we analysed T cell subsets by fl ow cytometry at + 60 post transplant. Results: All patients had sustained engraftment and remained free of any SCA-related events after transplantation. Sixty days after the transplant, the patients had signifi cantly lower CD4+ T cells in comparison to the controls (15.6 ± 5.9 % vs. 47.5 ± 6% respectively), whereas CD8+ T cells were the fi rst lymphocytes to repopulate the peripheral blood with up to 45% of these cells being CD8+ T cells (in mean 48.5 ± 14.3 % vs. 20 ± 7%). All patients displayed reduced numbers of B cells versus normal value, and 10/12 patients had only 0% to 1% of control levels of CD19+ cells. CD3-CD56+ bright NK cells were 18.6 ± 12.2 %, whereas CD3-CD16+ (with cytotoxic functions) were 16.7 ± 11.8 %. Conclusion: Our primary fi nding include the following: 1) rapid increase of lymphocytes in peripheral blood after transplant; 2) rapid expansion of CD8+ T cell but not CD4 T cell counts. Probably reactivation of cytomegalovirus (CMV) infection, observed in 11/12 patients on the early stages of T-lymphocyte recovery after transplant, might induce a dramatic increase in CD8 but not in CD4 T-cell counts. Background: Pediatric obesity has become a world-wide epidemic. It is known to increase morbidity and mortality following allogeneic hematopoietic stem-cell transplantation (HSCT). There is limited information on its eff ect on engraftment among children receiving allogeneic HSCT. Body mass index (BMI) is a reliable indicator of body fatness. Previous studies have shown confl icting correlation between BMI and time to engraftment. In children, BMI-percentile is the recommended indicator of body fatness. In the present study we aimed to evaluate the correlation between time to engraftment and BMI and BMI-percentile in children undergoing HSCT. Methods: Height, body weight, age and time to engraftment of all children who underwent allogeneic HSCT at our institution between 2006 and 2010 were obtained from the health records. BMI-percentile was obtained using BMI for age, growth chart by gender from the Centers for Disease Control. Patients were divided into 3 groups based on the BMI percentile; group 1 <5%, group 2 ≥5% but ≤95% and group 3 at >95%. A Cox regression analysis of the 3 groups was done for BMI-percentile. A Linear regression analysis was done for correlations between BMI and time to engraftment. Results: 178 allogeneic HSCT patients were included. 11 children failed to engraft and were excluded from the analysis. No correlation between graft-failure and either BMI or BMI-percentile was observed. In a linear regression analysis time to engraftment was a function of the patients BMI (fi gure 1). There was a signifi cant correlation between higher BMI and shorter time to engraftment. Similarly, on a cox regression analysis group 3(>95% BMIpercentile) was associated with a shortened time to engraftment (fi gure 2). On survival analysis (time to engraftment, 100 day survival and overall survival) the BMI percentile group did not emerge as signifi cant. Conclusions: Though obesity is known to have a negative eff ect on HSCT, we found high BMI/ BMI-percentile to correlate with shorter time to engraftment. As BMI-percentile is a more accurate parameter for obesity in children, our results showed positive eff ect of BMI-percentile on time to engraftment.

Rabbit ATG results in improved lymphocyte count recovery compared to alemtuzumab after allogeneic transplant which predicts for better overall survival Z. Gul (1) (1) , Z. Alkadhimi (2) (1)University of Kentucky (Lexington, US); (2) Karmanos Cancer center (Detroit, US) Introduction: Alemtuzumab (AB) and antithymocyte globulin (ATG) are two of the common drugs used to reduce the risk of graft vs. host disease (GVHD) after allogeneic stem cell transplant (allo-HCT). Not much is known about the diff erences in immune reconstitution between these agents. Methods: We retrospectively evaluated lymphocyte (ALC) recovery at days 30, 60 and 90 post allo-HCT in patients (pts)who received Rabbit ATG and AB. Pts in ATG group received Tacrolimus (Tac), Sirolimus and ATG (4.5 mg/kg) for GVHD prophylaxis. Pts in AB group received AB (60 mg) with Tac and Methotrexate. ATG group was treated at Karmanos cancer center between June 2008-December 2010 while AB group was treated between January 2010 and May 2012 at Markey cancer center. The primary end point of the study was to evaluate the difference in ALC recovery between AB and ATG and to evaluate the impact of ALC on transplant outcomes. Cox proportional hazards models using stepwise selection were used for time to event analysis and repeated measured mixed models were used to evaluate predictors of ALC over the 3 observed time points. Results: There were 30 pts in AB group and 47 in ATG group. Median follow up was 239 and 444 days in AB and ATG groups respectively (p=0.07). Pt characteristics are described in Table 1 . Infused CD34 count was higher (P≤0.001) in ATG group (7.31 million /kg) compared to AB group (4 million/kg).Both groups were also different with respect donor recipient sex (P=0.004) and HLA mismatch (p<0.001). ALC was higher in ATG group compared to AB at day 30, 60 and 90 (p<0.001). After adjusting for study group, there was increased hazard of death for ALC day 90 < 400x 103/ml (p=0.048). Significant ALC predictors in a repeated measures model included interaction between time and study (p=0.038) when adjusted for Recipient CMV status and HLA mismatch. There was also increased risk of developing aGVHD (p=0.018), and CMV reactivation (0.045) in AB group using competing risk models to adjust for relapse or death events. The hazard of developing cGVHD was reduced in AB group (p=0.001). Conclusion: We determined that ALC is higher in pts who received ATG for T cell depletion compared to AB and this diff erence remains signifi cant over diff erent time points. There is also increased hazard of death in pts with ALC <400 103/ml at day 90 after allo-HCT. These are preliminary fi ndings which need to be confi rmed in a larger prospective study.

Characterising T-cell reconstitution in the fi rst 14 days after stem cell transplantation C. Inman, J. Croudace, B. Abbotts, Y. Chan, J. Nunnick, R. Powell, S. Nagra, R. Malladi, P. Moss University of Birmingham (Birmingham, GB) Stem cell transplant (SCT) is an accepted strategy for the treatment of high risk haematological disease and involves replacement of the recipient's immune system with that of an HLA matched individual. T-cell reconstitution post-SCT is critical in induction of both the graft versus leukaemia eff ect (GVL), and graft versus host disease (GVHD), and thus in determining the outcome of SCT. However, as thymic output is limited in adult leukaemia patients, thymic-independent pathways, primarily homeostatic proliferation, will be key to the shaping of the adaptive immune response.

Here we characterised the T-cell compartment of patients in the fi rst 14 days post-SCT. In all patients, >85% of T cells were proliferating at day 14 post-transplant, as measured by fl ow cytometric Ki67 staining ( Figure 1 ). This contrasted dramatically with a mean of 5% proliferating T-cells in healthy controls. As demonstrated in previous studies, by day 14 post transplant, the T-cells of all patients were of donor origin. In patients who subsequently went on to develop GvHD, there were higher numbers of both CD4+ and CD8+ T-cell numbers compared to patients who did not develop disease. Strikingly, V β usage analysis indicated a more oligoclonal repertoire in GvHD patients ( Figure 2 ). This work suggests that T-cell dynamics in the fi rst 14 days after transplant infl uence subsequent development of GvHD and, importantly, that T-cell expansion may be driven by diff erent mechanisms in patients that go on to develop GvHD.

Immune reconstitution after allogeneic haematopoietic cell transplantation: impact of the concentration of CD3+/CD4+ on day +30 in overall survival and transplant-related mortality J. Cerezo-Manchado, A. Martínez, C. Castilla-Llorente, I. Heras, F. de Arriba, P. Iniesta, M. Osma, F. Ortuño, V. Vicente Hospital Universitario Morales Meseguer (Murcia, ES) Immune reconstitution impairment after allogeneic hematopoietic cell transplantation (HCT) is one of the main pitfalls of this procedure and is matter of intense recent research. Among the main target of recent studies are lymphocyte populations because of their impact on overall survival (OS) and transplant-related mortality (TRM). However, this relationship is not fully elucidated. Aims: To determine the impact of the diff erent lymphocytes populations overtime in peripheral blood of patients undergoing HCT. Patients and Methods: Retrospective study of patients undergoing HCT at our institution from 2005 to 2010. Data were collected for peripheral blood concentration of immunoglobulins, leukocytes and total lymphocytes and concentrations per microliter (μl) of lymphocyte subsets CD3+, CD3+/CD4+, CD3+/CD8+, CD3-/CD56+ and CD19+, on days +30, +60, +100, +180, +360 and +720. Data on pre and postransplant clinical parameters were also collected. Statistical analysis was performed using SPSS. Results: 108 consecutive patients were included. We performed a univariate analysis for OS at 1 year, variables with p<0.1 were included: age, graft-versus-host disease (GVHD), CMV infection and concentrations of CD3+/CD4+, CD3+, CD3-CD56+, CD3+/ CD8+ on day +30, and the CD3+/CD4+ on day +100. A model was built in which chronic GVHD (cGVHD) and concentration of CD3+/ CD4+ on day +30 remained the only variables statistically signifi cant, p<0.05. To improve this model, ROC curves were created for each concentration of lymphocytes and the best cutoff points were chosen. The concentration of 90/μl of CD3+/CD4+ on day +30 was the most relevant cutoff point, with an area under the curve of 0.85 (95% CI, 0.96-0.74), sensitivity and specifi city of 0.82 and 0.85 respectively. All the cutoff points were used to create a new multivariate model in which only cGVHD (p<0.05) and the cutoff of 90/μl for CD3+/CD4+ on day +30 (p= 0.044), hazard ratio (HR) (5.7 95% CI, 1,04-31) were signifi cant for OS on day +360. Patients who did not reach the cutoff suff ered greater TRM (p=0.013) HR (7.5 95% CI, . The study at 2 years showed that this cutoff remained signifi cant for both OS and TRM (p= 0.032), HR (6.1 95% CI, 1.2-31) and (p=0.045) HR (5.7 95% CI, 1.04-32), respectively. Conclusions: Our results support the relationship between immune reconstitution, OS and TRM. The 90/μl cutoff for CD3+/ CD4+ on day +30 is able to predict those events in both the fi rst and second year post-transplant. Following haploidentical hematopoietic stem cell transplantation (HSCT),donor alloreactive natural killer(NK)cells favorably infl uence the outcome of transplanted patients by triggering graft versus leukemia (GvL)eff ects.The molecular mechanism underlying the GvL activity of NK cells is due to KIR/HLA class I disparity between donor/recipient pairs. KIR genotypes are important in controlling KIR repertoire. Furthermore, the activation of antibody-dependent cellular cytotoxicity (ADCC) mediated by polymorphic CD16 antigens may potentiate the GvL eff ect of NK cells. Following unmanipulated non T cell depleted HSCT, we evaluated(i)KIR genotype profi ling during immune reconstitution; (ii) reconstitution of KIR loci on the basis of donor KIR genotypes and (iii) polymorphisms of FCGR3A according to 158V/F and 48 L/ H/R in 16 donor/recipient pairs. DNA and RNA were isolated from peripheral blood using spin bind method and cDNA was obtained by reverse transcription using RNA as template and random primers. KIR genotyping and gene expression profi ling were performed using a KIR SSP typing kit which detects 17 KIR genes. Sequence based typing (SBT) assay was used to determine the FCGRIIIA-48 and -158 polymorphisms. Four pts developed severe acute Graft versus Host Disease (aGvHD),1pt relapsed and 8 pts deceased for GvHD, relapse or infections. Six of 16 pts had more than 2 KIRligand mismatches in GvH direction. Examining KIR profi les in recipient-donor pairs, we found that all framework genes (2DL4, 3DL2, 3DL3, 3DP1)were present in both donor and recipient cells, exhibiting at least one inhibitory KIR. During recipients hematopoietic recovery, we observed rapid appearance of donors KIR profi les. Only 1 pt with signs of GVHD and relapse did not reach full NK cell chimerism. During KIR reconstitution monitoring, we noted diff erent levels of 3DL1, 2DS1, 2DL2, 2DL3 KIR expression and 2DS4ins, 2DS2, 2DS3, 3DL3 KIR loss. Analysis of FCGRIIIA polymorphisms showed that 25% and 31% of patients and donors were homozygous for FCGRIIIA-158V allele, 75% and 69% were heterozygous carriers (V/F) and none of two groups was FCGRIIIA-158 F/F. For the FCGRIIIA-48 polymorphism, L/L, (68% and 75%), L/H, (6.2% and 6.2%), L/R, (19% and 12.5%); H/R (6% and 0%) were the detected genotypes. A clear linkage between the FCGRIIIA-48 and FCGRIIIA-158 polymorphisms (10/16 patients with the FCGRIIIA-158F/V were also FCGRIIIA-48L/L).

In conclusion, this method may be useful for monitoring chimerism and KIR reconstitution as well as alleles and nulls. The eff ectiveness and safety of pegylated-GCSF after autologous transplant has been demonstrated in several studies while few reports exist in the allogenic setting. We compared 17 patients (pts) treated with pegylated-GCSF, -6 mg in a single dose on day+4, to an historical control cohort of 45 pts who were treated with daily GCSF-Lenogastrim-from day+2 continued until neutrophil recovery after allogenic transplantation. Patients' characheristics are listed in Table 1 . Eight (27%)pts in GCSF and nine(83%) in the pegylated-GCSF treated group received a previous autologous transplantation, (p<0,001). The patients were well matched regarding the clinical and biological characteristics. The outcome of the transplant are shown in table II. Graft failure was observed in 15% and 12% of GCSF and pegylated-GCSF group,respectivel y(p=0.77). Neutrophil engraftment (ANC>1x10 9 /litre) was significantly faster (p<0,05)in the pegylated-GCSF group with a median of 12 days compared with 15 days in the LENOGASTRIM group,fi g 1.No diff erence was observed concerning platelet engraftment. The variables statistically signifi cant for a faster neutrophil engraftment were, both in univariate and multivariate analysis, the use of pegylated-GCSF (p<0,05) and the disease status at transplantation (p<0,03), whereas number of infused CD34+ cells (≥4x10 6 /Kg) was a signifi cant factor only in univariate analysis. The incidence of neutropenic fever was similar in the two cohorts of pts. The median number of febrile neutropenic days was 3 in the GCSF and 4 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) in the pegylated-GCSF group (p=0.422). No diff erence was observed regarding the duration of intravenous antibiotics (p=0.413) and about the response to fi rst line antibiotic therapy (p=0.55). Incidence of acute or chronic GvHD, mucosites and diarrhea was similar. The TRM at +100 days was 27% for GCSF and 29% for pegylated-GCSF treated pts (p=0.5). Also, no diff erences were seen regarding response rate at +90 after transplantation (p=0,71). At a median follow-up of 268 days (range 4-2674) no signifi cant diff erence was seen in estimated 2yEFS (40%; p=0.9). We conclude that pegylated-GCSF was associated with faster neutrophil engraftment after allogeneic SCT, without any diff erences observed regarding the outcome of the allogenic transpant procedure.

Intracellular ATP production in CD4+ T cells as an immune cell function assay after allogeneic haematopoietic stem cell transplantation M. Waterhouse, L. Konukiewitz, H. Bertz, J. Finke Freiburg University Medical Center (Freiburg, DE) Immune status assessment after allogeneic hematopoietic stem cell transplantation relies primarily on immunophenotypic analyses of T and B lymphocytes. However, this kind of approach does not analyze their functional capacity. Intracellular ATP levels in stimulated CD4 T-helper cells have been reported as an immune function marker in immunosuppressed patients undergoing solid organ transplantation. Nevertheless, few reports exist describing this functional marker in allogeneic hematopoietic SCT. Our aim was to compare the intracellular ATP content in stimulated CD4 cells with routine immunophenotypic analysis and their potential associations with the patient clinical status. A total of 45 samples from 39 patients were collected at fi xed time points after transplant (30, 100 and 365 days). Six patients were evaluated at day 30 and 100. Whole blood was stimulated for 18 hours with phytohemaglutinin. After stimulation CD4+ T cells were isolated, lysed and the intracellular ATP content was measured using a luciferin/luciferase mixture in a luminometer. A calibration curve was generated with ATP calibrators. A control group of 16 healthy volunteers was used as a reference. Mean ATP concentrations were 71, 190 and 230 ng/ml at 30, 100 and 365 days post transplant respectively. The mean ATP level in the control group was 300 ng/ml. No correlation was found between the number of white blood cells, CD3 and CD4 lymphocytes and the intracellular ATP content. In addition, there was no correlation between ATP levels and the regimen for GvHD prophylaxis or cyclosporine concentration. No signifi cant increase in ATP level was found in patients with acute GvHD. At day 30 all patients showed a low CD4 count and ATP content as well, while at day 100 the CD4 count was normal in 25% of the patients but all of them showed a low ATP level. At day 100 almost 90% of the patients with a normal white blood cell count and CD4 count but low intracellular ATP level showed clinical complications such as CMV reactivation, infections or relapse. Although, our patient group is small and clinically heterogeneous low ATP seems to indicate higher risk of post-transplant complications such as CMV reactivation, infections or relapse.

Higher lymphocyte counts at 3-to-6 months after haematopoietic stem cell transplantation predicts better outcome B. Tartakovsky, S. Frank, U. Rozovsky, E. Zigman-Hoff man, S. Trestman, L. Gepstein, F. Aviv, E. Naparstek Tel Aviv Sourasky Medical Center (Tel Aviv, IL) Objective: Monitor lymphocyte recovery by consecutive measurements of absolute lymphocyte counts 3 to 6 months (ALC 3-6) after autologous or allogeneic hematopoietic stem cell transplantation (HSCT), and correlate the level of reconstitution with transplant outcomes. Methods: Median ALC 3-6 post transplant was determined for each patient and the median of medians for autologous and allogeneic transplants were calculated. Patients were divided into two groups based on high or low (in respect to the median of medians) ALC 3-6. Patient, disease, conditioning and graftrelated variables were compared by appropriate statistics. Overall survival (OS) and disease free survival (DFS) were analyzed by Kaplan-Meier curves. Prognostic value of ALC 3-6 was assessed by Cox's regression model. Results: Median ALC 3-6 for autologous (105) and allogeneic (69) transplants was 1.3 x 10 9 and 1.08 x 10 9 cells/L, respectively. High ALC 3-6 was associated with better OS in autologous (median 61.9 months in the high group vs. 34.8 in the low group, p=0.04) and allogeneic (median 39.5 months in the high group vs. 13.2 in the low one, p=0.03) patients. Improved DFS (p=0.01) in the allogeneic high ALC 3-6 group was observed only for patients with acute leukemia. Multivariate analysis demonstrated high ALC 3-6 to be an independent prognostic factor for better OS and DFS in autologous transplants (p=0.001, CI 95% 0.314-0.749, p=0.03, CI 95% 0.968-0.434, respectively). Both autologous and allogeneic high and low groups did not diff er regarding engraftment, infectious complications and veno-occlusive disease of the liver. In autologous transplants, grade 4 mucositis was signifi cantly higher in the low ALC 3-6 group, while in the allogeneic transplants, low ALC 3-6 was associated with grade III/IV acute graft versus host disease. Conclusion: High ALC 3-6 after autologous and allogeneic HSCT correlates signifi cantly with a better survival. Moreover, high ALC 3-6 is an independent prognostic factor and predicts a better outcome for the autologous HSCT both in terms of OS and DFS.

Association of Foxp3 expression with haematological recovery after high dose chemotherapy with autologous stem cell transplantation T. Wrobel, J. Dzietczenia, E. Stefanko, I. Deren-Wagemann, M. Biedron, R. Poreba, K. Kuliczkowski Medical University (Wroclaw, PL) Foxp3 is a specifi c marker of natural T regulatory cells (Tregs).Some data demonstrate that various T-cells populations including Tregs participate in hematological recovery.Tregs can regulate hematopoiesis based on cytokine eff ector molecules they can produce. The hematological recovery after transplantation is important prognostic factor and is associated with survival of patients with hematological malignancies. The aim of study was to evaluate the expression of Foxp3 and its association with hematological recovery in patients with lymphoid malignancies after high dose chemotherapy with autologous stem cell transplantation (ASCT). 30 patients with lymphoid malignancies were included in the study. The median age of patients was 58 years (range:27-65 years).20 patients had multiple myeloma and 10 had non Hodgkin lymphoma. All patients underwent ASCT. Before ASCT complete remission was confi rmed in 10 patients and 20 patients achieved partial remission. We investigated the expression of Foxp3 of Tregs present in the peripheral blood before high dose chemotherapy followed by ASCT. The mononuclear cells from peripheral blood were separated by density-gradient centrifugation. The phenotype of T cells was evaluated with antibodies:FITC-conjugated antiCD3, antiCD8, antiCD14, antiCD19, aniCD25 and antiFoxp3; PE-conjugated antiCD4 and antiCD56.Three-colour immunofl uorescence stainging was performed. The expression of CD4+CD25+Foxp3+ T lymphocytes was analyzed on PAS fl ow cytometer. The results were statistically analyzed using STATISTICA 8.0.Statistical analysis was performed by means of Mann-Whitney's U-test and p<0,05 indicated a signifi cant diff erence. All patients engrafted after transplantation. The median time to ANC>0,5x109/L was 15 days (range: 10-22 days) and the median time of platelets engraftment (> 20 x 109/L) was 12 days (range: 9-16).The expression of Foxp3 on Tregs was signifi cantly higher in patients who achieved absolute neutrophils count before day 15 in comparison with patients who engrafted after day 15 (0,67±0,3 vs 0,48 ± 0,35; p<0,05).Patients who required less than 10 days to achieve platelets count >20 x 109/L had higher expression of Foxp3 on Tregs than patients with platelets engraftment longer than 10 days (0,80±0,34 vs 0,60±0,42; p<0,05).The results are shown in table 1. Our results show that the expression of Foxp3 on Tregs in patients treated with high dose chemotherapy followed by ASCT correlates positively with hematological recovery.This observation should be validated by larger study. Recent advances in stem cell manipulation techniques have allowed to optimize cellular composition of HLA-mismatched haploidentical stem cell grafts. Besides the indispensible hematopoietic stem cells, haploidentical grafts now contain a variety of cellular subsets of innate immunity, while αβ-T-and B-cells are specifi cally depleted in order to prevent graft-versus-host disease and lymphoproliferative disorders. The main innovation in the fi eld is the inclusion of γδ-T-cells in the graft, which aff ects reconstitution kinetics of early appearing T cells. We analyzed immune and haematopoietic reconstitution in 4 children transplanted with TCRab/CD19-depleted haploidentical stem cell grafts with a special emphasis on γδ-T-cell reconstitution. Grafts consisted of 8.5x10e6 CD34/kg, 8.8x10e4 CD3TCRab+/kg, 8.8x10e6 CD3T-CRgd+/kg, and 17.5x10e6 CD16+CD56+/kg BW. Haematopoietic reconstitution was rapid and complete in all patients (leuko-cytes>1000/μl after 11, thrombocytes>20.000/μl after 14 days). NK cells appeared rapidly (median of 248/μl on day 30), and decreased to 135/μl on day +100. T-cell counts reached >100/μl after a median of 34 days, 75% of these expressing the gd-TCR. The predominance of gd-T-cells decreased and by day +100 50% of T-cells were positive for the gd-TCR and 46% for the ab-TCR. Gd-TCR Immunoscope analysis revealed the molecular composition of the gd-population: the Vg9-chain was expressed by a median of 54%, Vg2 by 17.6% of gd-T-cells, the remaining Vgchains by less than 10%, respectively. Vd4-expressing subclones made up 53% of the whole gd-TCR-repertoire, followed by 33.4% Vd2+ subclones. The remaining Vd-chains were expressed by less than 7% of gd-T-cells. Distribution of gd-subclones was relatively stable over time, so that the contraction of the gd-T-cell population could not be attributed to the disappearance of specifi c Vg-or Vd families. These data provide new insight into the T-cell reconstitution kinetics after TCRab/CD19-depleted transplantation. The clonal distribution of Vg-and Vd-chains must be confi rmed in larger patient cohorts and correlated with clinical events suchs infection and relapse.

Signifi cantly delayed T-cell immune reconstitution under mycophenolate-containing triple immunosuppressive therapy after allogeneic stem cell transplantation T. Gromke (1) , A.H. Elmaagacli (2) , M. Ditschkowski (2) , M. Koldehoff (2) , M. Hlinka (2) , N.K. Steckel (2) , D.W. Beelen (2) (1)Universitiy Hospital Essen (Essen, DE); (2)Universitiy Hospital Essen (Essen, DE) Introduction: Mycophenolate mofetil (MMF), an inhibitor of inosine monophosphate dehydrogenase, is suspected to increase infections in transplanted patients (pts). Most data refer to organ transplantation but only few relate to allogeneic stem cell transplantation (SCT). Therefore we analysed the immune reconstitution after SCT under a triple immunosuppressive therapy with cyclosporine (CSA), prednisone and MMF. Patients and methods: Between 04/2002 and 05/2012 50 pts (male/female: 30/20, median age 50) underwent SCT -11 pts had a related, 39 pts an unrelated donor. All pts developed an insufficiently controlled Graft-versus-Host-Disease (GvHD) under medication with CSA and prednisone (GvHD analogous to NIH criteria: 1 pt mild, 42 pts moderate, 7 pts severe). Thus all pts started MMF at a mean time of 440 days (range 33-1599 days) after SCT. The total population of T-cells, T helper cells, memory T cells, B-cells and immunoglobulin G (Ig G) were monitored before and 3 and 6 month and at the longest follow-up date after start of MMF (mean: 901 days). Data were compared to them of 10 pts with a double immunosuppressive medication with CSA and prednisone. The course of GvHD, the dosage of CSA, prednisone and MMF, overall survival and relapse were documented. Results: After start of MMF T-cells neither decreased nor increased signifi cantly during the whole follow-up time. In comparison there was a signifi cant increase of T-cells by a factor of 2,8 under double immunosuppression during a comparable follow-up time. For T helper cells and memory T cells as so as for Ig G there were no signifi cant fi ndings in both groups. B-cells uninfl uenced by MMF increased non-signifi cantly a 1,7 fold more than B-cells under MMF. In the group with triple immunosuppression GvHD was improved in 9, worsened in 7 and unchanged in 34 pts. At a [P586] S149 nearly unchanged dosage of MMF, CSA/prednisone were reduced in 28/38 pts and increased in 9/8pts. 12 pts died, 2 because of relapse, 4 by GvHD, 1 by infection and 5 for other reasons. Conclusion: There is evidence for MMF leading to a signifi cantly delayed T-cell immune reconstitution after SCT. There also seems to be a not clearly signifi cant impairment of B-cell reconstitution. MMF does not seem to improve GvHD but might help to reduce CSA and prednisone faster. Further evaluation of more subpopulations of lymphocytes and character of infections under MMF medication in comparison to an adequate control group is needed.

The response to vaccines in children who underwent stem cell transplantation: preliminary results from a single centre S. Anak, E.E. Ozkan, A.A. Ozguven, G. Ozturk, A. Kilic, M. Onel, A. Agacfi dan Istanbul University, Istanbul Faculty of Medicine (Istanbul, TR) After stem cell transplantation (SCT), suppression of humoral and cell-mediated immunity continue for a long time. So reimmunization is necessary for patients (pts) who underwent SCT. The aim was to examine eff ectiveness of vaccination in SCT pts. Materials and Method: The study was performed between October 2009 and February 2011. Revaccination with inactive and toxoid vaccines commenced ≥12 months and revaccination with live attenuated vaccines commenced ≥ 24 months after SCT. Results: 53,8% of pts were seropositive against diphteria before vaccination. 46,2% of pts were weakly seropositive against diphteria, but all achieved protective antibody (ab) levels after one dose of vaccination. 46,2% and 38,5% of pts were seropositive against tetanus and pertussis before vaccination respectively. After single dose vaccination all seronegative pts against tetanus achieved protective ab levels but only %50 seronegative pts against pertussis achieved protective ab levels. %46,2 of the pts were seropositive against hepatitis B before vaccination, after single dose vaccination 50% seronegative pts achieved protective ab levels. After second dose of vaccination three seronegative pts achieved protective ab levels against hepatitis B. 53,8% of pts were seropositive against hepatitis A before vaccination. After single dose vaccination 83,3% of the pts achieved protective ab levels. The remaining one patient achieved protective ab levels after second dose of vaccination. %15,4 of pts were seropositive against measles before vaccination. After single dose vaccination %60 of pts achieved protective ab levels. Only %50 of pts achieved protective ab levels after second dose of vaccination. %61,5 of pts were seropositive against rubella before vaccination. After single dose vaccination %100 of pts achieved protective ab levels. %46,2 of pts were seropositive against mumps before vaccination. After single dose vaccination %50 of pts achieved protective ab levels. Two pts achieved protective ab levels after second dose of vaccination. %53,8 of pts were seropositive against chicken pox before vaccination. After single dose vaccination %66,7 of pts achieved protective ab levels. Conclusion: Preliminary results showed, pts had very good ab response against diphteria, tetanus, rubella and hepatitis A vaccines. But, protection after pertussis, hepatitis B, measles, varicella zoster and mumps vaccines were in moderate levels. Antibody levels must be followed-up closely.

T-cell LGL-proliferation and autologous stem cell transplantation: a report of two cases N. Stoyanov, T. Dikov, P. Ganeva, G. Arnaudov, G. Balatzenko, G. Mihaylov, M. Guenova NSBALHZ (Sofi a, BG) Large granular T lymphocytes (T-LGL) are known to be key eff ectors of cell-mediated cytotoxic immunity and normally are present in low counts.

Increased T-LGL numbers in peripheral blood are associated with either clonal (considered LGL-leukemia) or polyclonal T-LGL proliferations. Polyclonal LGL-expansions with inversion of the CD4/CD8 T-cell ratio are not uncommon after stem cell transplantation (SCT). However, signifi cant lymphocytosis has rarely been reported in the literature. We report 2 cases of polyclonal LGL-lymphocytosis after autologous SCT. Patient 1 -a 46-year-old male diagnosed with diffuse large Bcell lymphoma underwent ASCT three years after diagnosis. One month after transplantation he presented with marked lymphocytosis -81% in the WBC (19.3G/L) at the expense of large granular lymphocytes with cytotoxic phenotype CD3+CD2+CD 7+CD5+CD8+CD57+TCRα/β+. No cytopenias or splenomegaly were detected, hepatic and herpes viruses tested negative. Molecular studies disclosed a polyclonal proliferation. A month later, spontaneous reduction in lymphocytosis (71%, 8.7G/L) was registered. On month 6, with constant lymphocyte counts, bone marrow studies identified identical population accounting for 5% from all cells. A retrospective analysis of laboratory tests at diagnosis, revealed T-LGL-lymphocytosis bearing the same phenotype (45%, 2.5G/L). At latest follow-up (23 months after SCT) the patient has sustained complete response and borderline

LGLs (1.6G/L). Patient 2 -a 27 year-old male with Hodgkin's lymphoma was transplanted fi ve years after diagnosis. Three months later, full blood count revealed lymphocytosis 74% (5.2G/L) with a T-cell phenotype. Again, the population was proved polyclonal, no cytopenias or organ damage were found and viral etiology was appropriately excluded. Six months after transplantation, 55% (6.2G/L) T-LGL lymphocytosis persisted. Shortly after that the patient succumbed to his disease. Alarming polyclonal LGL-lymphocytoses after SCT are rare but the clinical team should be aware of this possibility. Mainstays in diagnosis include a high level of clinical suspicion and a combination of morphology, immunophenotyping beyond routine CD4/CD8 ratio and clonality assays. The clinical course is benign with lack of cytopenias or organ damage, virological studies, however, are obligatory.

LGL expansions may subside with time after immune reconstitution, a fact underpinned by case 1. This study is supported by the Bulgarian Science Fund. Introduction: Analysis of the distribution of lymphoid, myeloid and monocytic cell and immunoglobulin (Ig) level's in patients who developed Graft Versus Host Disease (GvHD) after allogeneic haematopoietic stem cell transplantation (AHSCT). Patient and methods: Thirty-nine patients who underwent AHCST in University of Erciyes, Haematopoietic Stem Cell Transplantation Unit were investigated.13 of patients were female (%33,3) and 26 patients were male (%66,6). Samples were obtained from peripheral blood (PB) examined by fl ow cytometric analysis.Ig assays were measured by nephelometric analyze. Sixteen patients had GvHD whereas 23 patient didn't have. Results: The diagnosis of patient were 20 acute myeloid leukemia (%51,2), 11 acute lymphoblastic leukemia (%28,2), 3 Hodgkin lyphoma (%7,6), 5 other diseases (myelodysplastic sydrome, non Hodgkin lyphoma, multiple myeloma, aplastic anemia) (%12,8). The median age of 50 patients was found 34,3 years (±10,9). Among the 16 patients with GVHD; 15 patients receiving immunosuppressive treatment, and 1 patient didn't. Neutrophil ratio in patients with GvHD was signifi cantly higher than in patients who didn't have GvHD (p=0,016). The ratio of natural killer cells (CD56+) and eosinophil was signifi cantly lower in patients with GvHD ( respectively: p=0,007, p=0,048). The ratio of CD4/CD8 in patients with GvHD become reversed; but there was no statistically signifi cant diff erence of number of CD4 and CD8 in between patients with GvHD and other group (p>0,05). The ratio of lymphocyte in patients with GvHD was signifi cantly lower than in patients who didn't have GvHD (p>0,05). There was no signifi cant diff erence in two group's monocyte ratio (p>0,05). IgE level's in patients with GvHD was signifi cantly lower than in patients who didn't have GvHD (p=0,02). There was no signifi cant diff erence in two group's IgA, IgG, IgM level's (p>0,05). Conclusion: Patients with GvHD and are using immunosuppressive treatment; higher neutrophil ratio and lower eosinophil and NK cells ratio than patients who don't have GvHD. The ratio of CD4/CD8 in patients with GvHD become reversed; but there is no signifi cant diff erence of number of CD4 and CD8. The ratio of lymphocyte in patients with GvHD is lower than in patients who doesn't have GvHD, but this isn't signifi cant diff erence.There isn't signifi cant diff erence between monocyte ratio. IgE level's in patients with GvHD was lower than in patients who didn't have GvHD.

Monitoring of long-term immune reconstitution in correlation with chronic graft-versus-host disease in paediatric recipients after allogeneic haematopoietic stem cell transplantation A. Lawitschka (1) We have performed a detailed analysis of the kinetics of immune reconstitution(IR) in pediatric patients(pts) after allogeneic hematopoietic stem cell transplantation(HSCT) and the impact of chronic graft-versus-host disease(cGVHD) in the long-term follow-up(FU). Peripheral blood samples of 155 pts surviving day +100 were analyzed. Overall blood leukocyte counts, major T cell (CD3+, CD4+, CD8+, and CD4/CD8 ratio) and B cell (CD19+, memory, immature) subsets, NK cell numbers (CD56+) as well as serum immunoglobulin (Ig) levels (IgG, IgA, IgM, IgE and IgG subclasses) were determined. Along those lines more than 700 analyses were evaluated at diff erent time points after HSCT, divided into early (<1 year, n=142), and late (>1-10 years, n=563) FU with a median of 97 months (range 5-232). cGVHD pts (n=40) included 12 pts with overlap (30%) and 28 pts (70%) with classic cGVHD and were subdivided according to their clinical features at the time of analysis into active, future and resolved cGVHD . Analyses in all pts showed lower leucocyte (6248 versus(vs) 7058, p<0.001) and lymphocyte (2095 vs 2448, p<0.001) counts between early(n=83) and late FU(n=72). T cells revealed diminished (p<0.001) CD3+ (1306 vs 1645) and CD4+ (442 vs 725) cells and a distorted CD4/CD8 ratio (0.83 vs 1.13, p<0.001). Relative numbers of B (CD19+) and immature B (CD19+CD21low) cells were elevated in early FU (22.7% vs 19.7%, p=0 .02 and 10.6% vs 8.1%, p=0.004). Overall memory B cells were diminished (13% vs 17.3% of B cells; p=0.006). Early FU pts showed reduced IgG and IgA levels compared to late (976 vs 1082, p=0.007 and 93 vs 139 mg/dl, p=0.0019). We asked whether cGVHD represents an additional confounding factor for IR during the two FU periods. Comparing early active to late active cGVHD, a diminution of CD4+ cells (350 vs 665 x10 6 /ml, p=0.001) and of the CD4/CD8 ratio (0.7 vs 1,0, p=0,05) was observed along with reduction of class-switched memory B cells (7.9 vs 16.7 x10 6 /ml, p=0.005). NK cells showed a clear-cut difference between the two time points in active cGVHD (242 vs 348 x10 6 /ml, p<0.03). The ratio of CD21-/CD27+ B cells was significantly increased in early active cGVHD (7.6 vs 2.7, p<0.03) . In future cGVHD only classswitched memory B cells and the ratio CD21-/CD27+ cells were different. Pediatric GVHD is associated with signifi cant disturbances in overall blood counts, T and B cell-subsets as well as Ig levels and the time point of analysis after HSCT may be of importance.

Azacitidine (AZA) versus best supportive care (BSC) before non-myeloablative allogeneic stem cell transplantation (RIC Allo-SCT) for myelodysplastic syndromes (MDS): a study by the SFGM-TC G. Damaj (1) , A. Duhamel (2) , M. Robin (3) , N. Milpied (4) , M. Michallet (5) , P. Chevallier (6) , Y. Beguin (7) , S Nguyen (8), B. Lioure (9), D. Blaise (10) , N. Mallaird (11), M. Rubio (12), N. Fegueux (13), J. Cornillon (14) , S. Francois (15) , M. Mohty (12), A. Hyun (16), C. Bulabois (17) , F. Garnier (18) Background: Although interim results suggest that AZA alone prior to allo-SCT may give similar results as standard inductiontype chemotherapy, the use of any cytoreduction before transplant is still debated, even in case of RIC. The aim of this study was to investigate the impact of AZA prior to allo-SCT compared with BSC in pts undergoing RIC for MDS. Methods: 128 consecutive pts who underwent RIC between Feb 1999 and Dec 2009 are reported. Inclusion criteria were: age > 18 and RIC from either sibling (n=78) or HLA-allele-matched unrelated donor (10/10) (n=50) for MDS following BSC (n=88; BSCgroup) or AZA alone (n=40; AZA-group). Pts who received prior cytoreductive therapy other than AZA alone were excluded. The stem cells source was blood (n=112) or marrow (n=16). Data quality was ensured using computerized discrepancy errors and vigorous on-site data verifi cation of every single fi le. HLA matching was double-checked. Since our study was not randomized, we used a propensity score to adjust P values for pts who received AZA and those who did not. Results: At diagnosis, FAB/WHO was: 35 RA/RARS/RCMD, 7 RAEB-1, 80 RAEB-2 and 6 RAEB-t/AML; Cytogenetics: fav (n=65), int (n=30), unfav (n=33). Pts in the AZA group were older (p=0.001) with higher IPSS at diagnosis (p<0.001) than those of the BSC-group and had more often an unrelated-donor (p<0.001). Of note, 33 (69%) of the pts treated with AZA-alone and 5 (7%) of those treated with BSC were considered responders at transplant (CR, PR, mCR or stable disease with hematological improvement) (p<0.001). The two groups were comparable for other patient characteristics and transplantation modalities. In the AZA group, the drug was started at a median of 192 days after diagnosis and discontinued at a median of 54 days before transplant with a median number of 4.5 cycles (range 2-26). In multivariate analyses adjusted with propensity score, having a poor cytogenetic risk was the only factor that adversely infl uenced relapse risk [HR=2.87; 95% CI 1.58-5.20] (p<0.0005). Bi-and multivariate analyses performed without then with propensity score tests showed neither AZA prior to allo-SCT nor response status at transplant to have an impact on OS, EFS, or relapse. Conclusion: Absence of cytoreduction before RIC allo-SCT did not seem to alter outcomes, regardless of the pre-transplant tumor burden and main disease characteristics. Prospective studies assessing more precisely which pts may benefi t from hypomethylating agents before RIC allo-SCT are required.

An impact of stem cell transplantation on long term survival of patients with MDS, an analysis of 25 years follow up from a single centre J. Cermák, A. Vítek, M. Lukášová, M. Marková-Tastná, P. Cetkovský Institute of Hematology and Blood Transfusion (Prague, CZ) An analysis of a long term follow up after allogeneic stem cell transplantation (SCT) was performed in 83 patients with primary myelodysplastic syndrome (MDS) who underwent SCT in the years 1987 -2009. A comparison of 37 transplanted patients with less advanced MDS with ≤ 5% of bone marrow (BM) blasts with subgroup of 128 patients treated with supportive care including growth factors only (SC) revealed no diff erence in median survival between both the groups (84,2 months for SCT v.s. 88,5 months for SC). Estimated 1 year and 3 years (E3yS) survival were similar, however, a signifi cant diff erence was observed in estimated 5 year survival (E5yS) (62.2% for SCT v.s. 40.6% for SC) as well for estimated 10 year survival (E10yS) (51,4% for SCT v.s. 25.8% for SC). The reason was a signifi cant number of leukemic transformation (28.9%) and comorbidities related death (19.5%) observed in SC group. None of the transplanted patients relapsed, late fatal infectious complications after SCT occurred in 10.9% of patients. In patients with > 10% of BM blasts, SCT performed in 27 patients was the only eff ective treatment with E3yS, E5yS, E10yS of 63.0, 55.6 and 51.2%, respectively. Median survival of transplanted patients was 71.4 months compared to only 12.5 months in 79 non-transplanted patients, where E3yS was 14.3% and 18.2% for low dose ARA-C and hypomethylating agents and 0% for chemotherapy or SC only. E5yS and E10yS of patients who were transplanted with ≥ 10% BM blasts at the time of conditioning was only 22.2% and 33.3% relapsed in contrast to those transplanted with < 10% BM blasts after chemotherapy where estimated 10 years survival was 66.7% with relapse rate of 22.0%. A high SCT related mortality was the main reason for relatively low number of long term surviving patients with MDS RAEB I.(6-10% of BM blasts), where median survival was 44.1 months and E5yS and E10yS were 31.2% and 26.7%, respectively. However, these results were still signifi cantly superior to those obtained with other treatment modalities with median survival of 11.8 months. Our results confi rm superiority of SCT as the only curative treatment in MDS patients with excess of BM blasts and support the usefulness of reduction of number of BM blasts prior to SCT as a factor aff ecting long-term survival. SCT also represents an eff ective treatment modality in younger patients with MDS without excess of blasts and concomitant risk factors eg. profound cytopenia or adverse karyotype.

Allogeneic haematopoietic stem cell transplantation in myelofi brosis: single-centre experience at the University Hospital in Bratislava E. Bojtarova, B. Ziakova, M. Zwiewka, L. Sopko, E. Demeckova, M. Mistrik University Hospital Bratislava (Bratislava, SK) Background: Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative treatment for myelofi brosis although its use is limited by substantial transplant-related mortality and morbidity. The aim of this study was to assess outcome in patients with myelofi brosis who underwent allogeneic HSCT. Patients and methods: We retrospectively assessed results of HSCT in 10 consecutive patients with primary myelofi brosis (n=9) or myelofi brosis evolving from essential thrombocythaemia (n=1). Patients received an allogeneic marrow (n=1) or peripheral blood stem cell (n=9) transplant from HLA-matched sibling (n=6) or unrelated (n=4) donors between January 1996 and December 2011. The median age at the time of HSCT was 43 years (range, 20-63). At the time of transplantation all patients were at intermediate (n=9) or high (n=1) risk according to the IPSS classifi cation. 5 of 10 patients received a myeloablative conditioning regimen: busulphan (BU)/cyclophosphamide (CY) in 4 patients (in 1 with antithymocyte globuline (ATG) before unrelated HSCT), total body irradiation/CY in 1 patient. 5 patients were prepared with a reduced-intensity conditioning regimen: included fl udarabine (FLU)/BU/CY (n=3) or FLU/BU (n=2), in 3 patients with ATG before unrelated HSCT. Splenectomy was performed in 3 patients prior to HSCT. Graft versus host disease (GvHD) prophylaxis was provided by combination of methotrexate + cyclosporin A (CsA), but in 1 patient prednisolone + mycophenolate mofetil due to renal toxicity of CsA. Results: All but 1 patient showed neutrophile engrafment (i.e. neutrophil count above 0.5 G/l) after a median of 18 days (range, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , in 8 of 10 patients platelet engrafment (platelet count above 50 G/l) was achieved in 14-135 days after HSCT (median 37 days). Chimerism analysis showed more than 99% donor cells in 8 patients, 1 patient with mixed chimera didn´t achieve complete donor chimerism after donor leukocyte infusion. Acute GvHD grades II to IV was observed in 4 patients, grades III to IV in 2, and extensive chronic GvHD in 3 of 8 evaluable patients. There were 2 patients who died from chronic GvHD and infection and 2 patients died from progressive disease. There are 6 patients surviving at 0.9 to 16.3 (median, 6.3) years for a 3-year Kaplan-Meier estimate of 68%. The median follow-up of surviving patients was 6,3±5,7 years. Conclusion: Allogeneic HSCT off ers long-term relapse-free survival for patients with myelofi brosis. Nijmegan Breakage syndrome (NBS) is characterized by an immunodefi ciency state, due to a defective DNA double-strand breaks repair mechanism. For this reason, patients with NBS are susceptible to develop infections and malignancies. Various type of lymphomas have been reported in patients with NBS. So far, to our knowledge, γδ T-Cell Lymphoma in association with NBS has not been reported. We describe a case of NBS with γ δ T-cell lymphoma that was apparent morphologically on hepatic biopsy. Peripheral lymphocytes were sent later for immunophenotyping and genetic studies to Haematology Research Laboratory which demonstrated a γδ T-cell clone and genetic clues. An HLA-compatible sibling bone marrow donor was available for transplantation. Hence, the patient underwent a non-myeloablative allogenic peripheral hematopoietic stem cell transplantation (HSCT) with a conditioning regime including antithymocyte globulin (5mg/kg/d for 3 days) and cyclophosphamide (50 mg/kg/d for 4 days). Prophylaxis against GvHD was given with cyclosporine and methotrexate. Following peripheral HSCT, neutrophil and platelet engraftment occurred on day +10. A chimerism study revealed 98% donor T-cell chimerism in the peripheral blood on day +60. The proportion of total lymphocytes, B cells, C4+ T cells, CD8+ cytotoxic T cells in the peripheral blood cells gradually increased with month. He had no cytopenia, active infection or any evidence of aGvHD on days +90 and +180. There was no evidence of abnormal lymphoma clone. During his current visit one year after transplantation, he was in hematological remission. Primary immunodefi ciency disease NBS may occur with unusual hematological features and peripheral HSCT from HLA compatible donor may overcome such a challenge by using non-myeloablative conditioning P597 Allogeneic stem cell transplantation for Diamond-Blackfan anaemia in Japan: a report from the Inborn Errors Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) H. Yabe, M. Inoue, K. Koh, K. Kawa, K. Kato, H. Sakam, Y 

Background: Allogeneic stem cell transplantation (SCT) is curative in patients (pts) with Diamond-Blackfan anemia (DBA) who are not responsive to steroids. Alternative donor (AD) transplant has been considered to be less encouraging because of the high incidence of graft rejection or GVHD. We retrospectively compared the outcome of Japanese DBA pts undergoing SCT from an HLAidentical sibling (IdSib) or from an AD. Patients and Methods: Forty pts with DBA (15 males and 25 females) have been treated by SCT between January 1987 and July 2010, and registered to the Transplant Registry Unifi ed Management Program (TRUMP). Median age at SCT was 5.5 years (range; 6 months to 38 years) and median observation period was 7.1 years (range 10 days to 24.7 years). Stem cell sources were IdSib bone marrow (BM) in 16 pts, related BM other than IdSib in 10 pts, HLA-matched/mismatched unrelated BM in 8 pts, and cord blood in 6 pts. Full-dose (4 days) busulfan-based regimen (regimen A) was used in 14 pts, half-dose (2 days) Bu with 3Gy TAI, Flu, CY, ATG (regimen B) in 6 pts, half-dose Bu with other combinations (regimen C) in 3 pts, non-Bu regimen (regimen D) in 17 pts. Ten pts in regimen D received 6 Gy or more dose of irradiation. Prophylaxis of GVHD was selected according to the donor. Overall survival (OS) and event-free survival (EFS) were analyzed using Kaplan-Meier estimates. Results: Sustained engraftment was obtained in 36 pts. Primary engraftment failure was observed in 2 pts (a case of IdSib BMT conditioned by CY/ALG and a case of maternal BMT conditioned by Flu/Bu) and late graft failure in 1 pts. One patient who received maternal peripheral blood died early to evaluate engraftment. Another patient transplanted unrelated BM died of TMA. The incidence of acute GVHD was as follows; grade 0, 18 pts; grade I, 12 pts; grade 2, 6 pts; grade III, 2 pts and grade IV, 0 pts. The OS and the EFS in entire cohort were 95% and 87%. The EFSs according to donor were 94% in IdSib, 80% in related BM other than IdSib, 88% in UBM and 83% in CB (83% in all AD transplant). The EFSs according to the conditioning were 100% in regimen A, 100% in regimen B, 67% in regimen C, 76% in regimen D, respectively. Conclusions: Recent improvement in outcomes of AD-SCT for DBA was recognized. Although regimen A is eff ective to obtain engraftment, dose reduction of Bu may be possible even in AD transplant when combined with low-dose TAI, Flu, CY, ATG. Objective: Griscelli syndrome (GS) is a rare autosomal recessive disorder characterized by pigment dilution, immunodefi ciency and occurrence of accelerated phase consisting of hemophagocytosis, pancytopenia and neurological manifestations. The prognosis is very poor unless early allogeneic hematopoietic stem cell transplantation (HSCT) is carried out, preferably before the development of the accelerated phase. Here, we report the results of the HSCT in children with GS. Methods: This study includes eight patients with GS (5 female and 3 males with ages ranging between 6 months-58 months, median 16 months) underwent HSCT between 1997-2011 at our center. One patient underwent additional two HSCT due to engraftmant failure. GS was diagnosed with history, typical phenotypic features, light microscopic examination of hair shafts and the develop ment of HLH. Mutational analysis was performed in one patient.

The pre-transplant features of the patients are shown on Table 1 . All patients received conditioning regimen including busulfan (12.8 mg/kg-16 mg/kg iv. or 16 mg/kg orally)+cyclophosphamide (200 mg/kg/day)±anti-thymocyte globulin (10 mg/kg/day for 3 or 4 days)/etoposid (900mg/m2). Cyclosporin A and metotrexate were used for graft versus host disease (GVHD) prophylaxis. Results: The results of transplantations was shown on table 2. Engraftment was achieved in 7 patients. The median time to neutrophil recovery was 13 days (range: 10-15 days) . None of the patients developed acute and chronic GVHD, veno-occlussive disease (VOD) was observed in 3 patients, mucositis in 5 patients, sepsis in 2 patients, pulmonary infection in 2 patients, atelectasis in 1 patients. Partial convulsion was observed in one patient on day +6. Interestingly one of the patients developed in situ melanoma two years after HSCT. Currently, the clinical condition of this patients is well. One patient died due to engraftment failure and infection, the other one died due to VOD. The remaining 6 patients are alive without disesae activation. The duration of follow-up was ranged between 17-182 months. Conclusion: Allogeneic HSCT is the unique curative procedure for GS, preferably before development of hemophagocytosis and CNS involvement. According to our knowledge, this report is the one of the largest series of children with GS underwent HSCT. Six of the 8 patients alive without disease activation for a long follow-up period. Introduction: Autosomal recessive infantile malignant osteopetrosis (IMO) is a heterogeneous group of genetic disorders that aff ect osteoclast development and/or function. The clinical course often leads to early death due to haematologic abnormalities/bone marrow failure. Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative treatment. In 35 patients transplanted in our unit from 1983 to 2007, severe early transplant-related complications and graft failure were frequently observed with an overall survival of only 46%. Objectives: In order to reduce transplant-related toxicity, we used a Busulfan/Fludarabine based conditioning regimen since October 2008. Methods: We analysed retrospectively the outcome of HSCT in 7 consecutive patients treated in accordance to the recent recommendations of osteopetrosis registry on behalf of ESID and EBMT. Results: The patients, 4 girls and three boys, presented IMO of early onset. Mean age at clinical diagnosis was 2.9 months, ranging from one diagnosis at birth due to positive family history to one at 6 months of age. Signs at onset were as followed: Hypo-Ca in 3, anaemia and/or thrombopenia in 4, visual impairment in 4 and abnormal fractures in 1 patient respectively. Genetic analysis revealed mutations in TCIRG1 in 5 patients and a homozygous mutation in RANK in two cousins. HSCT was performed as soon as possible after diagnosis. Patients' mean age at HSCT was 6.9 months (range 4.5 to 21, median age 5 months). Table 1 shows details on HSCT procedures. All but one patient received prophylactic Defi brotide. We used peripheral blood stem cells in all patients as stem cell source in order to obtain high numbers of CD34+ cells/kg recipient. Donors were haplo-identical parents in 4, phenoidentical parent in two and a 10/10 MUD in one patient. All but two patients engrafted with 100% donor chimerism. In one haplo-identical paternal HSCT primary graft failure occurred, but 100% donor engraftment was achieved following a second haploidentical maternal HSCT after 120mg/kg cyclophosphamide and 0,6 mg/kg Alemtuzumab. One patient developed multiorgan failure upon S. aureus sepsis on day 0 and died at day +55 without signs of engraftment. Transplant related toxicity was low. Conclusion: The recent recommendations of osteopetrosis registry on behalf of ESID and EBMT allow stable donor cell engraftment, also in a haplo identical setting, at a follow up of 6 months to 4 years and 2 months. Survival improved signifi cantly to 85,6% compared to our former results of 46%. Life-threatening infection caused by opportunistic pathogens is an early clinical hallmark of primary immunodefi ciencies including severe combined immunodefi ciency (SCID). Here, we describe the case of an six-month-old female infant who presented with severe Pneumocystis jirovecii pneumonia. The patient is the fi rst child of healthy consanguineous parents of Central European ancestry. Her previous development has been normal. Detailed immune cell phenotyping at diagnosis revealed a naïve phenotype in CD4+ and CD8+ T-lymphocytes and a predominance of transitional (CD38+ CD24+ CD10+) B-lymphocytes. Regulatory T-lymphocytes (defi ned as CD4+, CD25+, CD127-, CD45R0+ and CCR4+) were not detectable. Analysis of the α/β T-cell repertoire in peripheral blood of the infant patient showed normal expression of 26 T-cell receptor (TCR) BV-families determined by CDR3-size spectratyping and detection by length polymorphism. The novel entity of SCID was characterized by aγglobulinemia and profoundly defi cient T-cell function despite quantitatively normal T-and B-lymphocytes. Whole-exome sequencing revealed a single pathogenic homozygous nonsense mutation aff ecting caspase-recruitment domain 11 (CARD11) gene. CARD11 is a scaffold protein required for TCR-and B-cell receptor-(BCR) induced NF-κB activation as well as lymphocyte activation and proliferation, which is specifi cally expressed in hematopoietic cells. In reconstitution assays we demonstrated that the patient derived truncated CARD11 protein is defective in antigen receptor signaling and NF-κB activation. The infant was treated with peripheral blood stem cell transplantation (PBSCT) from a matched unrelated donor (MUD) at the age of 9 months. Due to preexisting brochiectasis a toxicity-reduced conditioning regimen for transplantation consisting of treosulfan, fl udarabine and alemtuzumab was used. Posttransplant graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine A and mycophenolate mofetil. The infant engrafted uneventfully. The patient was treated with several stem cell boosts and donor lymphocyte infusions because of increasing mixed chimerism with imminent autologous reconstitution and delayed immunological reconstitution. She is currently 14 months posttransplant and doing well. We show that an inactivating CARD11 mutation is linking defective NF-κB signaling with a novel cause of autosomal recessive SCID. Moreover reduced toxicity conditioning for PBSCT from a MUD is feasible in this novel entity of SCID. S154 transplant should achieve durable chimerism adequate to correct the underlying disorder, with minimal toxicity and with low rates of acute and chronic GVHD. For the last 9 years In Manchester we have included Alemtuzumab in our conditioning regimen -1mgs/kg over days -9 to -5 where an unrelated donor and 0.3mgs/kg over days -7 to -5 where the donor is an HLA matched family donor. All such transplants are using bone marrow (BM) or peripheral blood (PB) as the donor cell source. Materials and Methods: All children receiving a fi rst transplant with Alemtuzumab were reviewed. The diagnosis, donor, regimen (Reduced Intensity -RIC, Myeloablative -MAC), donor source (BM, PB), survival and engrafted survival (defi ned as time to inadequate chimerism or time to second transplant) were recorded. The incidence of acute and chronic GVHD, cause of death, immune reconstitution (T and B cell and CD4 and CD8 T cells) and virus isolation following standardised surveillance of blood, stool and urine were recorded. Results: 90 such were transplanted with an Alemtuzumab containing regimen. The diagnoses were non SCID immune defi ciency (n=33), Inborn Error (n=20), Constitutional (n=18) or Acquired (n=13) Bone Marrow Failure (n=18) or Haemoglobinopathy (n=6). 34 received an family donor and 56 a MUD donor. The cell source was BM in 52 and PB in 38. Overall survival was 91% in this cohort (SE 3%) and the engrafted survival was 81% (SE 4%). 8 patients had graft rejection and required repeat transplant -all had received RIC or non-pharmacokinetic guided busulfan in their fi rst transplant -and 7 of these children are long term survivors and one child died during the second transplant procedure. The need for second transplant is reduced in the later years of this follow up. 7 patients died after the fi rst transplant with adenovirus (n=1), complications of the original disease (n=2), Acute GVHD (n=3) and early multi-organ failure (n=1). Only 3 children in this cohort require continuing immune suppression or ECP for chronic GVHD. There were 95 viraemic episodes (32 CMV, 51 EBC and 12 adenovirus) Conclusion: We commend the use of Alemtuzumab in nonmalignant disorder. Although viral reactivation is common, mortality from all causes is low and the conditioning regimen achieves its twin aims of low chronic GVHD rates and high rates of durable engraftment. Fanconi anemia is a rare and heterogeneous inherited disorder. The natural history of FA is characterized by marrow failure and a risk for clonal evolution. Evolution to acute myeloid leukemia is the main cause of premature mortality. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is considered the treatment of choice in this situation but the evolution is usually poor post-HSCT (due to treatment-related mortality). From August 2006 to December 2011, 6 consecutive patients with FA who received a sequential treatment with chemotherapy and reduced-intensity conditioning for clonal evolution in four diff erent French institutions were reviewed. Five patients presented an AML and one a myelodysplastic syndrome. The sequential strategy consisted in a pre-transplant chemotherapy by fl udarabine 30 mg/m2/d 5 days and cytarabine 1gr/m2 x 2/d 5 days with granulocyte-colony stimulating factor injections (FLAG) followed early after by a reducedintensity conditioning [4 days cyclophosphamide 10 mg/kg , 4 days fl udarabine 30 mg/m2, 2 days anti-thymocyte globulin (3.75 mg/kg) and TBI (2 Gy) ]. The source of stem cells was cord blood for three patients and bone marrow for others. Graft versus host disease prophylaxis consisted in cyclosporine plus MMF. Median age of the patients at HSCT was 20.5 years . Pre-transplant chemotherapy and conditioning regimen were well tolerated. The median time between chemotherapy and the date of HSCT was 30 days. All patients engrafted. Median time to engraftment was 21 days (range 14 to 35) for neutrophils and 29 days for platelets. Donor chimerism was complete at day 100 for 5 patients. Septicemias were encountered in three patients (Staphylococcus, Enterobacter, and Candida) at 1, 3 and 4 months after HSCT, respectively. One patient developed a diarrhea to Campylobacter jejuni one month after HSCT and another patient underwent meatotomy. Acute GvHD (1 grade I and 1 grade II) occurred in 2 patients. Both responded to steroid therapy. Chronic GvHD occurred in two patients. After a median follow-up (FU) of 30 months , all patients are still alive in complete remission from the clonal evolution. With a median FU of 30 months, all patients are alive and free from their original AML or MDS. The number of patients is little but the usual evolution is very poor post-HSCT in this particular situation. We thus believe this study supports the use of a sequential strategy (FLAG and RIC HSCT) in FA patients with AML or MDS. Background: In X-linked adrenoleukodystrophy (X-ALD), a peroxisomal ß-oxidation disorder, approximately 30-35% of boys and a minimum of 10-20% of adult men will develop a progressive demyelination of the CNS, leading to neurocognitive decline and death within a few years. In adult men, this acute infl ammatory cerebral disease (ACER) may arise de novo or more frequently secondary to the adult neurodegenerative form of the disease, adrenomyeloneuropathy (AMN). Lacking established therapeutic options, we off ered in a pilot series ACER patients without relevant neurocognitive impairment HSCT on a compassionate use basis. Patients: Since 2006, a total of 9 men (age: 26-48 years) underwent BMT (n=7) or PBSCT (n=2) either from an HLA-identical sibling (n=1) or matched unrelated donor (≥9/10-HLA-identical). All patients showed infl ammatory CNS disease as demonstrated by contrast enhancement in MRI. They were uniformly evaluated in one institution before HSCT. 7 out of 9 patients had relevant AMN symptoms with 3 men not ambulatory without aid (Expanded Disability Status Score (EDSS) >5.5). The preparative regimen consisted of oral busulfan (4 x 4 mg/kg), cyclophosphamide (2 x 60 mg/kg), and ATG Fresenius ((4 x 10 mg/kg). Results: At a minimum follow-up of 4 months (median 34 months) 6 out of 7 patients are alive after BMT. All patients engrafted demonstrating a complete or predominant donor chimerism. Relevant acute GVHD grade >I occurred in only 1 patient. At least transient peripheral and central neurotoxicity was a problem in 7 and 4 patients, respectively. Peripheral neurotoxicity was associated with high fever and correlated with initial AMN defi cits. Moreover, there were severe infections (Grade ≥3) in 5 out of 6 men with extensive AMN. Two patients deceased directly from infections, another patient from subsequent ACER progression. CNS infl ammation was stopped in 6 out of 7 evaluable patients and a complete loss of intellectual functions could be prevented. Conclusion: HSCT is so far the only therapeutic option to prevent rapid death in ACER patients. The chosen approach seems to be relatively safe and feasible for patients lacking severe neurocognitive impairment and advanced AMN (EDSS <6). However, extensive motor defi cits or bladder dysfunction implicate a signifi cant risk for early infection and TRM. AMN is poorly infl uenced by HSCT, and will confer additional morbidity later on. Therefore, the transplant indication in ACER has to be evaluated carefully in experienced centers.

Allogeneic haematopoietic stem cell transplant in severe thalassemia patients in a single instituion with related and unrelated donors and myeloablative and reduced intensity regimens S. Hongeng, S. Hongeng, U. Anurathapan, N. Sirachainan, D. Songdej, A. Chuansumrit Ramathibodi Hospital (Bangkok, TH) Recently published reports indicate that the outcome of unrelated donor hematopoietic stem cell transplantation (HSCT) in patients with leukemia is comparable with that of transplantation from identical family donors. We would like to prove that the outcomes of related and unrelated transplantation are favorably comparable in children with severe thalassemia. We reviewed transplant outcome in 105 consecutive children with severe thalassemia who underwent allogeneic HSCT the related-donor stem cells (n = 60) or unrelated-donor stem cells (n = 35) between September 1992 and Dec 2012. Analysis of engraftment, frequency of procedure related complications, and thalassemia-free survival revealed no advantage from use of related-donor stem cells. The thalassemia-free survival estimate for recipients of related-donor stem cells was 92% compared with 80% in the unrelated-donor stem cells group (p = 0.09). The present study provides and evidence to support the view that it is therefore quite reasonable to consider unrelated HSCT as an acceptable therapeutic approach in severe thalassemia, at least for patients who are not fully compliant with conventional treatment and do not yet show irreversible severe complications of iron overload. Moreover, we also have proved that our new reduced intensity conditioning regimen approach can overcome the past poor result of HSCT in class 3 lucarelli thalassemia (age ≥ 10 years and hepatomegaly; liver > 5 cm below costal margin) patients (n = 21). Both of the thalassemia free survival and overall survival rates in this group are 92%. Finally, we have studied the cost utility analysis between HSCT and hypertransfusion with iron chelation therapy in thalassemia patients. We can prove that matched related donor transplantation in thalassemia patients appears to be a cost eff ective and aff ordable treatment for all thalassemia patients even class 3 lucarelli patients.

Haemopoietic stem cell transplant failure followed by switch to stable production of fetal haemoglobin: genetic background K Paciaroni (1), J. Borg (2) , P. Sjaak (2) , G. De Angelis (1) Introduction: High foetal haemoglobin (HbF) levels ameliorate morbidity and mortality in Sickle Cell Anaemia (SCA) and β-thalassaemia. The variability of HbF levels is genetically controlled by multiple genes and recent studies provide molecular mechanisms regulating the HbF production. Our group observed an unusual event: in three patients aff ected by β-globin gene disorders the reactivation of HbF synthesis has been documented after bone marrow transplant (BMT) failure and autologous reconstitution. In the present study the genetic background has been analyzed for such patients who exhibited reactivation of the HbF synthesis. Methods and results: Two β°-thalassaemia major cases were candidates for BMT: the fi rst thalassaemic patient, rejected at +40 days after BMT and the second one at +90 days after transplant. The autologous recovery was documented in both cases. Transfusion therapy was required to support anaemia until +118 and +162 days after transplant in the fi rst and in the second case respectively. Afterwards the Hb levels were steadily over 11.8 and 10.2 g/dl respectively without the use of transfusion support and the Hb electrophoresis revealed HbF 99.8% in both cases. As we write this at +81 and +69 months respectively of ongoing follow-up after graft failure, both patients maintain the sustained and full (99.8%) production of HbF and are transfusion-free. (See the fi gure). The third case is a SCA patient who failed to maintain the engraft of the haploidentical allogeneic transplant.Thirty-two months after the BMT failure, the HbF levels increased to 49.2 and the patient remains with stable Hb level over 11.4 gr/dl and without vaso-occlusive symptoms. (Figure) . The genetic analysis documented that all patients were carrier of the non-deletion form of hereditary persistence of HbF. Both thalassaemic patients exhibit the homozygosity for the -158 (C->T) point mutation in the G γ promoter sequence. The DNA of thalassaemic patients has been genotyped for the genetic variants at 3 principal loci involved in the interdividual HbF variation: HBS1L-MYB , BCL11A and KLF1. A high-HbF haplotype from MYB-HMIP2 locus locus has been documented in one of the two thalassemic patients (see the table). Conclusions: Reactivation of HbF synthesis can occur in the adult age and the high levels of HbF provide a therapeutic benefi t to the β-disorders. It is likely that the favourable genetic background in these patients concurred the full HbF production.

Establishment of integration-free iPS cell lines from Wiskott-Aldrich syndrome (WAS) patient fi broblasts capable of diff erentiation into the monocytic lineage through ex vivo culture system Y. Wang (1) , L. Lenaeus (2) , R. Mares (2) , T. Chang (3) , H. Huang (1) , J. Yee (3) (

Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodefi ciency disorder caused by mutations in the gene encoding Wiskott-Aldrich syndrome protein (WASp), which is an important regulator of the actin cytoskeleton required for many haematopoietic and immune cell functions. Patients of WAS exhibit thrombocytopenia, eczema, recurrent infections, high incidence of autoimmunity and malignancies due to immunodefi ciency. Severe WAS leads to an early death from infection or bleeding. The induced pluripotent stem cells (iPSCs) have shed lights on an innovative personalized cell therapy strategy for various primary defi ciency disorders. The restricted expression of WASp in hematopoietic cells makes it a promising candidate disease for stem cell gene-therapy approaches. Here we report the establishment of integration-free iPS cell lines from WAS patient fi broblasts, aiming for ex vivo disease modeling and future possible therapeutic approach. We reprogrammed the fi broblasts of a WAS patient with 3 episomal plasmids by nucleofection. The established iPSC clones exhibited similar morphology, cell surface markers and diff erentiation potential as normal human embryonic stem cells (ESCs), and contained no residue episomal DNA beyond passage 10. We then diff erentiated the WAS iPSCs into the hematopoietic lineage ex vivo through stromal cell co-culture system. In the presence of GM-CSF and M-CSF, we successfully expanded CD45+CD43+CD11c+ progenitors which could give rise to CFU-G, CFU-M and CFU-GM in colony forming cell assay. Further differentiation with proper cytokines showed normal maturation of those progenitors into CD80+CD209+HLA-DR+ dendritic cells and CD14+CD163+ macrophages, which were two vital cell populations of innate and adaptive immunity. Functional analysis of WAS iPSCs derived macrophages showed podosome formation defect which was consistent with the reported functional deficiency of patient's macrophages. However, the antigen uptake, processing, and phagocytosis of WAS iPSCs derived macrophages seemed unimpaired compared to normal human ESCs derived macrophages. Overall, we have generated integration-free WAS iPSC clones capable of diff erentiating into monocytic lineage and showing a disease-related phenotype. These iPSC clones may provide an ideal ex vivo system to study the role of WASp in the development of a functional immune system, and, upon gene correction, provide a safer, unlimited source for stem cell gene therapy for WAS patients. Up to 85% of patients with Chediak-Higashi Syndrome (CHS) develop acute haemophagocytic lymphohistiocytosis (HLH), termed the "accelerated phase (AP)". This is managed by immunochemotherapy consolidated by hematopoietic stem cell transplantation (HSCT). However, despite long term disease control, Tardieu et al (2005) reported frequent moderate to severe neurological defi cits and low cognitive abilities in long term survivors, developing by 24 years of age. The proposed cause is defective LYST protein function in neurons/glial cells.

We describe a female whose history suggests a potential role for chronic macrophage/ histiocyte activity in driving complications of CHS. First diagnosed with CHS and incidental Turner mosaicism at 20 months, she remained well until 4 years. She then became progressively fearful of movement over a 3 month period, at the end of which she developed fulminant CNS abnormalities (unable to speak, sit unaided or swallow, with nystagmus and strabismus). Multifocal white matter changes resembling acute disseminated encephalomyelitis (ADEM) were present on MRI. Cerebrospinal fl uid showed lymphohistiocytes and raised protein levels but she had no signs of systemic AP/HLH (normal blood count/ferritin, no hepatosplenomegaly). Plasma cytokine analysis was more consistent with macrophage activation than HLH [IL-1β 924 pg/ml (NR <5pg/ml), IL-6 9196 pg/ml (<10pg/ml)] (Flammiger et al, 2012) . She was treated according to the HLH-94 protocol and made rapid neurological recovery, within weeks gaining more developmental skills than at any stage pre-treatment. Matched unrelated male donor HSCT was performed subsequently and she achieved 100% chimerism, with almost complete resolution of MRI abnormalities. Three years post-HSCT she developed pigmented villonodular synovitis (PVNS) aff ecting one knee, accompanied by fever, night sweats, anaemia, CRP up to 288mg/L, high IL-1β (46.7 pg/ml) and IL-6 (161 pg/ml) -features not seen in typical PVNS. The PVNS was composed of mononuclear histiocytes of female origin. Immunotherapy failed but subtotal surgical debridement resolved all symptoms; she remains well 10 years later. This patient's serial problems suggest that impaired histiocyte/ macrophage control may produce chronic pathologies in CHS in the absence of AP/HLH disease. This in turn suggests that transplant should be performed as early as possible after diagnosis for those with well matched donors, or that drug therapies targeting macrophage/histiocyte activation may have a role. Objective: T-cell replete BMT from HLA-haploidentical family donors with post-transplant cyclophosphamide results in low GVHD rates, improved immune reconstitution and an overall outcome comparable to other alternative donor transplantations in adults with haematological malignancies. In non-malignant disorders such as sickle cell disease it results in high graft failure rates after non-myeloablative conditioning. In combination with more intensive preparative regimens this approach might help to overcome engraftment barriers in children with non-malignant diseases. Methods: Case report. Results: We report on a 5 year old girl with infantile onset infl ammatory bowel disease caused by a homozygous mutation in IL10RA who was lacking a matched related or unrelated donor. After conditioning with rabbit ATG Fresenius (30mg/kg), fl udarabin (160mg/m 2 ), thiotepa (10mg/kg) and melphalan (140mg/m 2 ) she received CD3/CD19-depleted PBSC from her mother. GVHD prophylaxis was mycophenolate mofetil (MMF). After a transient hyperinfl ammatory syndrome she primarily rejected this graft. Reconditioning with rabbit ATG Genzyme (4.5mg/kg), fl udarabin (120mg/m 2 ), thiotepa (5mg/kg), cyclophosphamide (60mg/kg) and TBI (2Gy) and second transplant with CD34 positive selected PBSC from the same donor on day +35 without GVHD prophylaxis resulted in primary graft failure again. At day +78 after the fi rst transplant she received a salvage graft from her HLA-haploidentical father using T-cell replete bone marrow followed by cylophosphamide (50mg/kg/d) on days +3 and +4. Conditioning comprised alemtuzumab (0.6mg/kg), fl udarabine (150mg/m 2 ), treosulfan (24g/m 2 ) and cyclophosphamide (29mg/kg). GVHD-prophylaxis was tacrolimus and MMF. This procedure led to complete bone marrow donor chimerism at d +42 after the third transplant with little toxicity and no GVHD. For poor graft function despite complete donor chimerism she later required a CD34 positive selected PBSC boost from her father on day +50. After 130 days of follow-up after the third transplant the patient is alive and well, has cleared a CMV infection and is free from signs of GVHD. Conclusion: Due to its high content of graft facilitating cells and probably selective depletion of alloreactive T-cells and tolerization induced by high dose post-transplant cyclophosphamide a T-cell replete haploidentical bone marrow might be able to overcome engraftment barriers and can be taken into consideration in case of primary graft rejection.

Successful stem cell transplantation in homozygous α-thalassemia 1: the fi rst case in Asia B.C. Pongtanakul, K. Sanpakit, V. Chongkolwatana Faculty of Medicine, Siriraj Hospital, Mahidol University (Bangkok, TH) Homozygouse α-thalassemia 1 is the most severe thalassemia disease. This group of patients presents with hydrops fetalis and always dies before or shortly after birth. We reported successful stem cell transplantation in homozygouse α-thalassemia 1. A Thai girl was born at 32 weeks of gestational age (birth weight 1,300 gm) with hydrops fetalis by cesarean section. Her mother was 33 years old came to our hospital because of toxemia of pregnancy and prenatal ultrasonography showed hydrops fetalis with massive ascites. Her hemoglobin at birth was 6.8 g/dl. She was intubated, abdominal, pleural paracentesis and total blood exchange transfusion immediately after birth. Her hemoglobin typing before total blood exchange transfusion was 100% of hemoglobin Bart's and DNA analysis showed homozygouse α-thalassemia 1 (South East Asian deletion). After she was stable from preterm complications, she was started on hypertransfusion every 3-4 weeks and kept pre-transfusion hemoglobin at 9-10 g/dl since the age of 3 months. She has 6/6 HLA matched with her older sister. She was underwent stem cell transplantation at the age of 1 year. The conditioning regimen consisted of busulfan 1.2 mg/kg/dose every 6 hours intravenously for 4 days and cyclophosphamide 50 mg/ kg/day for 4 days. GVHD prophylaxis was cyclosporine and short course metrotrexate. The stem cell source was bone marrow and total CD 34 counts was 9.41 x 10 6 cells/kg. Her transplantation complications were febrile neutropenia and mucositis. She had WBC engraftment at day+17 and DNA showed full donor chimerism at day+25. On day+112, DNA showed mixed chimerism with 41% of recipient's DNA but hemoglobin was still stable. Cyclosporine was stopped and she received donor lymphocyte transfusion (DLI) at the dose 1x10 7 cells/kg of CD3 from her sister every 2 weeks. After 4 times of DLI, she could achieve full donor chimerism. Now, she is 4 years old with post transplantation for 3 years and her DNA is still full donor chimerism. Her hemoglobin is 13 g/dl, normal hemoglobin typing. Her developmental milestones are up to her age. Conclusion: Homozygouse α-thalassemia 1 can be cured with stem cell transplantation. Preterm delivery with immediate total blood exchange transfusion, hypertransfusion and proceed to stem cell transplantation is possible treatment strategy to cure from this fatal disease. From our knowledge, this is the fi rst successful stem cell transplantation in homozygouse α-thalassemia 1 in Asia. Pulmonary haemorrhage (PH) is a well recognised complication of haematopoietic stem cell transplantation for Hurler's Syndrome (MPS 1H), previously suspected to be due to glycosaminoglycans (GAGS) accumulation in pulmonary tissues. However, introduction of pre-transplant enzyme replacement therapy (ERT) has not prevented PH despite improving upper airway obstruction. We report a male patient who underwent 5/6 matched cord blood transplantation (CBT) for MPS 1H at 18m after conditioning with fl udarabine, busulfan and ATG. He had required neonatal oxygen therapy and had suff ered recurrent chest infections during his fi rst year, including metapneumovirus and adenovirus infections both requiring ventilation. These left him with a permanently consolidated right upper lobe and need for long-term oxygen therapy. He was commenced on ERT at diagnosis of MPS-1H at 13 months and proceeded to transplant when off supplemental oxygen. On day 12 post-CBT he developed fever, stridor and respiratory distress requiring ventilation and then had an episode of cardiac arrest with pulseless electrical activity which responded rapidly to resuscitation. Platelets during this period were in the range 31-63 x 10(9)/L and no blood was seen in endotracheal aspirates. Echocardiogram showed a fractional shortening of 31%, and a dilated left atrium with moderate mitral regurgitation. He was treated for hypertension with nifedipine and received inotropic support which was gradually weaned to stoppage. He subsequently engrafted satisfactorily without GVHD, normalised his respiratory rate and oxygen saturations, was feeding well, and was due for discharge by day 49 post-transplant. He then developed respiratory distress without underlying infection, and rapidly deteriorated to unresuscitatable cardiorespiratory arrest with fresh blood issuing from his nose and mouth. His platelet count at that time was 17 x 10(9)/L. Findings at post-mortem included diff use pulmonary haemorrhage, presence of iron laden macrophages (suggestive of previous PH), GAGS infi ltration of the mitral valve and marked pulmonary venous hypertensive (PVH) changes. Previous reports have suggested that platelet counts of 40+ are not protective against PH in these patients. The risk of PH may also be exacerbated by allogeneic responses, particularly following CBT. This patient's problems suggest that PH may have cardiogenic origin, with mitral regurgitation producing secondary PVH, making a case for more proactive cardiac drug therapy even without overt cardiac failure.

Stem cell transplants in chronic granulomatous disease: single centre report V. Grassi, F. Bolda, R. Baff elli, A. Beghin, C. D'Ippolito, A. Soresina, A. Lanfranchi, F. Porta Children's Hospital (Brescia, IT) Bone marrow transplantation (BMT) is the only curative treatment for chronic granulomatous disease CGD). We grafted 5 children aff ected by CGD, 4 from MUD and 1 from a matched family donor. Pt 1 at the age of 3 yrs received full conditioning and MUD BMT. At day + 15 engraftment was present, but the child became lethargic. A CT scan demonstrated a cerebral mass compatible with an aspergillus infection. Despite antifungal therapy the child died on day +25 post-BMT. Pt 2 , aged 6 yrs and 3 aged 18 months, two brothers, were diagnosed CGD. Pt 2 received matched familial BMT after conditioning with Bu Mel ATG . He engrafted on day +15, after discharge, being a full donor chimera, he reactivated a viral infection that led on day +60 to GVHD and PPT and subsequently died of cerebral bleed. Pt 3 received familial phenoidentical BMT. He engrafted on day +12. Donor chimerism declined from 100% to 39% within two mos. Therefore BMT was boosted with CD34+ cells reaching 60%. Pt 4 received PBSC form a MUD and engrafted nicely on day +15 and is a full chimera. Pt 5 aged 12 yrs with chronic intestinal disease received a MUD PBSC after a RIC BU conditioning . He engrafted nicely at day + 15. Six<month later he died of heart failure due to a pregress cardiac insuffi ciency. In our experience BMT in CGD remains the only curative therapy in severly aff ected pts (i.e. MICI), RIC BU conditioning plus PBSC at present is the golden standard that decreases toxicity risks and shortens aplasia. S159 Lymphocyte biology P612 Infl uence of in vitro IL-2 or IL-15 alone or in combination with Hsp 70 derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors: a thorough study towards GvL eff ects of NK cells against leukaemia I. Hromadnikova (1) , P. Pirkova (1) , L. Sedlackova (1) , A. Fiserova (2) (1) Charles University (Prague, CZ); (2) Institute of Microbiology, Academy of Sciences (Prague, CZ) NK cells represent a potential tool for adoptive immunotherapy against solid tumors and leukaemia. Membrane-bound Hsp70 acts as a tumor-specifi c marker enhancing NK cell activity (1, 2) . We have demonstrated that human leukaemia cell lines were positive for cell surface Hsp70 expression (5, 6) . Incubation of peripheral blood lymphocytes with Hsp70 derived 14-mer peptide (TKD) plus a low dose IL-2 initiates the cytolytic and migratory capacity of NK cells toward Hsp70 membrane positive tumor cells (3, 4) . This study is a part of comprehensive study focused on the inducement of GvL eff ects through NK cells against leukaemia. Using FACS, the eff ect of in vitro stimulation with IL-2 or IL-15 alone or in combination with TKD on cell surface expression of NK activatory receptors (CD16, NKG2D, NKG2C, NKp46, NKp44, NKp30, KIR2DL4, DNAM-1 and LAMP1) and NK inhibitory receptors (NKG2A, KIR2DL2/L3, LIR1/ILT-2 and NKR-P1A) in healthy individuals was studied. Results were expressed as the percentage of receptor expressing cells and the amount of receptor expressed by CD3-CD56+ cellular population. CD94, NKG2D, NKp44, NKp30, KIR2DL4, DNAM-1, LAMP1, NKG2A and NKR-P1A were upregulated after the stimulation with IL-2 or IL-15 alone or in combination with TKD. KIR2DL2/L3 was upregulated only by IL-15 and IL-15/TKD. Concurrently, an increase in a number of NK cells positive for CD94, NKp44, NKp30, KIR2DL4 and LAMP1 was observed. IL-15 and IL-15/TKD caused also cell number rise positive for KIR2DL2/L3 and NKR-P1A. Cell number positive for NKG2C and NKG2A was increased only by IL-2 and IL-2/TKD. The diverse eff ect of IL-2 or IL-15 w or w/o TKD on cell surface expression was observed in CD16, NKp46 and LIR1/ILT-2. Although NK cytotoxicity fi nally depends on the type and the expression of ligands on the target cells interacting with NK activatory and inhibitory receptors, the study showed clearly how NK cells were infl uenced under in vitro conditions in the presence of other immunocompetent cells by low-dose interleukins themselves or in combination with TKD peptide. CD8 T-cell responses against several WT1-derived peptides have been characterized and are supposed to contribute to disease control after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Also the identifi cation of human leukocyte antigen (HLA) class II-restricted CD4 T-cell epitopes from WT1 is a challenging task of T cell-based cancer immunotherapy to improve the eff ectiveness of WT1 peptide vaccination. Here we demonstrate HLA-DR-restricted CD4 T-cell responses in leukemia patients after allo-HSCT to a highly immunogenic 9-mer WT1 peptide that was primarily reported as an HLA-A*02 restricted epitope. CD4 T-cell depletion completely abolished IFNγ induction in response to WT1 126-134, and antibody-mediated blockade mapped peptide presentation to HLA-DR (IFN-γ ELISPOT Assay, fi g.1). Beyond cytokine production, a fraction of WT1 126-134 specifi c CD4 T-cells was CD107a positive after WT1 126-134 peptide stimulation, indicative of their cytotoxic potential. By fl ow cytometry analysis it was demonstrated that WT1 126-134 specifi c CD4 T-cells were mainly functional cytotoxic CD4 T-cells, and subpopulations of them were eff ector memory cells. Longitudinal analysis showed that WT1 126-134 specifi c CD4 T-cells persisted for months or even longer after allo-HSCT and expressed a monoclonal or oligoclonal T-cell receptor V-β repertoire. Such expanded WT1 126-134 reactive CD4 T-cells were absent in the donor of the stem cell graft, suggesting that antigen-specifi c T-cells had expanded in the recipient in response to tumor cells.

In conclusion, we demonstrate for the fi rst time that a 9-mer WT1-derived peptide can induce HLA DR-restricted cytotoxic CD4 T-cell responses. The simultaneous stimulation of CD4 and CD8 T-cells is presumably essential for a strong and persistent immune response. In tumor specifi c T-cell responses against low affi nity antigens like WT-1, the capability of one single peptide antigen to bind to HLA-class I and class II may increase the opportunity for an effi cient tumor specifi c T-cell response which may contribute to disease control after allogeneic HSCT. The common structural basis of HLA class I and class II molecules binding to primary and secondary peptide anchor motifs by covering the central 9-10 amino acids, might be a fi rst explanation for the investigated phenomenon.

Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T-lymphocytes M.M. Rosado, M.E. Bernardo, M. Scarsella, A. Conforti, E. Giorda, S. Biagini, S. Cascioli, F. Rossi, M. Vivarelli, I. Guzzo, L. Dello Strologo, F. Emma, F. Locatelli, R. Carsetti Ospedale Pediatrico Bambino Gesu (Rome, IT) Objectives: Bone marrow (BM)-derived mesenchymal stromal cells (MSCs) represent a promising tool for immunoregulatory and regenerative cell-therapy; however, their specifi c role in modulating B cell function is controversial and still incompletely understood. Here, we studied the role of BM-derived MSCs in modulating Blymphocytes stimulated with a polyclonal activator (CpG) in healthy donors (HDs) and in two pathologic conditions in which B cells induce/maintain infl ammation and tissue damage, i.e. Systemic Lupus Erythematosus (SLE) and patients receiving kidney transplantation. Methods: We established an in vitro culture system to analyse the eff ects of MSCs on B-cell proliferation, plasma cells diff erentiation and antibody secretion after stimulation with CpG for 7 days. We compared B cell function in the presence and absence of MSCs in diff erent experimental conditions: total peripheral blood mononuclear cells (PBMCs), sorted B cells, PBMCs without T cells, sorted B cells mixed to sorted T cells. B-cell proliferation and plasma cell diff erentiation were measured by FACS analysis, whereas antibody secretion was quantifi ed by ELISA in culture supernatants. Results: We found that, both in HDs and in patients, in vitro B-cell proliferation, plasma-cell diff erentiation and antibody production are inhibited in the presence of MSCs co-cultured with PBMCs+CpG, but not when sorted B cells are cultured with MSCs+CpG. Inhibition is restored in CpG+MSC co-cultures when sorted T cells are added to sorted B cells, suggesting that this eff ect is mediated by T cells, with both CD4+ and CD8+ subsets playing a role. Removal of Treg cells from culture did not alter MSC-dependent inhibition of B-cell proliferation and antibody production. IL-6 and IFN-γ are likely involved in T-cell dependent inhibition of B-cell function by MSCs since the level of these cytokines was increased in the supernatant. Conclusion: In our culture system BM-derived MSCs inhibit B cell function with a T-cell dependent mechanism. This fi nding has to be taken into account in the design of innovative MSC-based strategies in SLE and kidney transplanted patients, in whom T-cell function is often impaired by the immunesuppressive therapy. Stimulation with CpG of total PBMCs in presence of MSCs could predict the success of MSC therapy to treat patients with autoimmune diseases or at risk of solid organ rejection. (1) , W. Qasim (1), K. Gilmour (1), R. Chiesa (2) , M. Hubank (1) , P. Amrolia (2) , P. Veys (2) (1)Institute of Child Health (London, GB); (2)Great Ormond Street Hospital (London, GB) Objective: In contrast to bone marrow (BM) or peripheral blood (PB), early T cell reconstitution after cord blood (CB) transplant is CD4 biased and associated with a relatively lower incidence of GVHD. In view of emerging evidence that foetal and adult T cells arise from ontogenically diff erent populations of haemopoietic stem cells, we have investigated whether these diff erences refl ect diff erential gene expression in CB and PB T cells. Methods: We compared the gene expression profi le on fl ow cytometrically sorted naïve CD4+CD45RA+CCR7+ T cells derived from normal donor CB and PB using Aff ymetrix Human Gene 1.0 ST arrays. Diff erentially expressed probe sets were identifi ed using Bioconductor package "limma". The threshold for identifying signifi cant genes was set at a false discovery rate of 5% and foldchange of ≥ 2. Pathway analysis was performed using Ingenuity and Gene Set enrichment analysis software. Results: In 2 separate gene expression profiling experiments comparing CB and PB naïve CD4 T cells (n=5 total), Principal Component Analysis showed CB and PB T cells segregated separately with 243/232 differentially expressed genes. 69 genes were differentially expressed in both experiments, of which 90% were up-regulated and 10% down-regulated in the CB CD4 T cells. Of these overlapping genes, 11 (i.e. TNF, JUN, EGR1, SOX4, BCL11A, TNFAIP3, TOX, CD69, IKZF2, GZMA, PAK1) were T lineage specific and 4 (i.e. GZMA, AUTS2, IGF2BP3, RGS1) have previously been identified as characteristic of foetal CD4+ T cells. Of these 69 genes, 8 (i.e. TNF, JUN, NFKBIA, EGR1, SGK1, KLF6, PAK1, HIST1H2BM) were involved in cell cycle progression. Pathway analysis showed that TNFR1 /TNFR2 signalling were the most upregulated pathways in CB CD4 T cells and within these pathways genes causing proliferation rather than apoptosis were up-regulated. Conclusion: Our data demonstrate that CB CD4 T cells are genetically distinct from their counterparts in PB and this may explain their preferential expansion and tolerogenic propensity. In particular, the TNFR pathways may play a critical role in this. Further studies are underway to determine if gene expression in T cells after CB transplantation recapitulates ontogeny, switching from a foetal profi le early after transplant when T cells are derived from those transferred with the graft to an adult profi le when stem cell derived T cells emerge at later time-points.

Vγ9Vδ2 T-cells recognize and kill chemotherapy-resistant acute myeloid leukaemia cells via movement of lytic granules controlled by CD226 participated ERK1/2 phosphorylation K. Wu, Y. He, H. Fu, Y. Hu, L. Sheng, H. Huang School of Medicine, Zhejiang University (Hang Zhou, CN) Background: Julie Gertner-Dardenne et al. recently reported Vγ9Vδ2 (gd) T cells recognized and killed acute myeloid leukemia (AML) cells. The questions therefore arise as to what is the eff ect of gd T cell on chemotherapy-resistant AML cells, whether the resistance aff ect gd T cell cytotoxicity. We focused on this intresting point and accessed the possible eff ect and mechanisms. Methods: gd T cells were expanded in the presence of 2uM zoledronate and IL-2.6 AML cell lines HL-60,NB4,K562 and their chemotherapeutics-resistant cell lines HL-60/ADR,K562/AO2, NB4/R1 as well as primary cells from 15 refractory/resistant AML patients were used as target cells. Cytotoxicity was measured by fl ow cytometry using CFSE and 7-AAD.The extracellular signal-regulatory kinase1/2 (ERK1/2) activation was analysed by western blot using the method of mixing gd T cells with an equal number of paraformaldehyde-fi xed target cells.CD107a expression was detected after 4h coincubition of gd T cells and target cells. The surface molecules were detected by fl ow cytometry.Specifi c ERK1/2 inhibitor PD098059 or blocking mAbs were incubated with gd T cells 1 hour before further experiments. Results: gd T cell effi ciently kill chemotherapy-resistant AML primary cells at diff erent eff ect:target(E:T) ratios (Figure1A). The resistance did not decrease T cell cytotoxicity compared with matermal cell lines (Figure1B). gd T cell binding to tumor cells for 5 min was suffi cient to maximally activate ERK1/2, demonstrated by its tyrosine phosphorylation. ERK1/2 activation was achieved in gd T cells after contact with gd T -sensitive K562 and K562/ AO2 cells,but not gd T -resistant HL-60 (Figure1C). PD098059, block degranulation of gd T cells, which occur upon target ligation (Figure1D). PD098059 also inhibited the cytotoxicity of gd T cells. To further clarify the mechanism,we assessed the expression of ligands of CD226, which has been found to play an important role in gd T cell killing AML cells, on diff erent AML subsets above, and found no signifi cant decrease of expression in resistant AML cells(Figure1E). Blocking CD226 inhibited ERK1/2 activation of gd T cells after contact with gd T -sensitive K562 and K562/AO2 cell (Figure1F), and inhibited gd T cell -mediated lysis (Figure1G). Conclusion: These results showed gd T cells effi ciently kill chemotherapy-resistant AML cells, and documented a a pivotal role of CD226 induced ERK1/2 in gd T eff ector function, possibly by its control of movement of lytic granules.

Introduction: We have recently shown that prophylactic donor lymphocyte infusions (pDLI) in patients with high risk leukemia augments the graft-versus-leukemia eff ect (GvL), however, they were associated with a relatively high incidence of GvHD (Liga et al, BBMT, in press). Strategies to preserve a benefi cial GvL eff ect without GvHD are needed. IL2 plays dual role in immune responses, contributing to both the generation of eff ector T cells and the maintenance of regulatory T cells (Tregs). Recently, low dose IL2 therapy has been advanced as a potential immune modulator able to "tweak" the immune response to aid transplant tolerance and to suppress GvHD (N Engl J Med. 2011; 2055-66) Objectives: We aimed to investigate the impact of priming lymphocytes with low dose IL2 on their proliferative responses to allo-stimulation in vitro.

Methods: CD3+ T cells purifi ed from healthy individuals by MACS negative selection were primed (p-T cells) or not (np-T cells), with or without (ctl) low (LD,100U/ml) and high (HD,1000U/ml) doses of hrIL2 for 7 days. Composition of T-cell cultures was analyzed by fl ow cytometry (CD4 /CD25 /PD1 /FOXP3 /Helios expression). In vitro alloproliferative capacity of the p-T cells was analyzed with CFSE cell proliferation assay by using them as responder cells in mixed lymphocyte cultures (MLC), with irradiated allo-PB mononuclear cells as stimulators. Results: Proliferation (CFSE stain), activation (CD25+) and exhaustion (PD-1+) was signifi cantly increased in HD p-T cells, as compared to LD p-T cells, np-T or ctl cells. LD-IL2 priming increased the number of CD4+/CD25+/FOXP3+/Helios+ natural Tregs (mean±SEM, 3.3±0.7) as compared to np-T (1.013±0.2), ctl (1.8±0.4) and HD p-T (1.4±0.4) cells. LD p-T cells showed significantly decreased response rate to allo-stimulus in MLC as compared to np-T and ctl cells. Conclusions: Our results indicate that in vitro priming of T cells with low dose of IL-2 reduces their alloproliferative capacity, probably owing to the maintenance of regulatory T cells. Furthermore, LD p-T cells displayed phenotypic characteristics predictive of high capacity to persist, expand and function after adoptive cell transfer in vivo. In vitro priming of T-cells with LD-IL-2 might prove

S162 an easy, cheap and GMP compatible strategy to minimize GvHD without compromising GvL of pDLI. (1), U. Hegenbart (2) , S. Schönland (2) , N. Kröger (1) (

Lenalidomide (len) is an immunmodulatory drug used for multiple myeloma and other haematological diseases. We and other have pioneered the use of len after allogeneic stem cell (allo SCT) transplantation. The drug is known to up regulate pro infl ammatory cytokines like TNF α and IFN α which might contribute to the incidence of GvHD in the context of allo SCT. In our dose fi nding study we found 18% of infections. We therefore analysed the immunological data for our patients with a focus on the T cell development in patients with a clinical signifi cant infection and those without. Interestingly both groups showed a decrease in their total number of CD3+ T-cells. This eff ect was more prominent in the group with infections. Further the number of CD4+ T helper cells decreased also in both groups but those patients with infections dropped to a level below 200/μl. In contrast CD8+ T-cells were not aff ected by len treatment. To understand this clinical data we treated T-cells in vivo with len and observed a diff erential response of the CD4 and CD8 compartment towards the drug. While CD4 cells showed a growth arrest, CD8 cells were nearly unaff ected. This observation can be explained by a diff erential expression of p15, a cell cycle inhibitor of the ikn4 locus, in CD4 and CD8 cells after len treatment. We suggest that this diff erential response is accountable for the incidence of GvHD triggered by CD8+ cells and a higher risk for infection due to inbibited CD4+ cells. Therefore we conclude that len treatment beside its eff ects on cytokine expression infl uences the cell cycle regulation in T cells which should be further investigated to understand its way of action on immune cells.

Graft versus host disease is one of the major complications in haematopoietic stem cell transplantation (HSCT). In order to modulate this disease, regulatory T cells (Treg) have been proposed as a cellular therapy. Treg cells have been described as suppressor of cells that are responsible for GvHD, such as T cells, but on the other hand they also suppress Natural killer (NK) cells, key players of the Graft versus Leukaemia (GvL). It has been showed that Treg cell may suppress NK cells in certain conditions, but no information is available on the eff ects of NK cell diff erentiation. Due to the critical role of NK cells in HSCT, we addressed this question. Because of the rising use of umbilical cord blood (CB) as a source of stem cells for HSCT, this study examined CB NK cell diff erentiation through an in vitro 5-week culture. CD34+ stem cells were cultured in the presence or not of resting or TCR-stimulated allogeneic CB Treg cells. To determine Treg cells eff ect on diff erent stages of diff erentiation, Treg cells were added at a ratio of 1 to 4 (Treg to NK cells) at 2, 9, 16, 23 and 30 days of culture. When TCR-stimulated, Treg cells were pre-incubated for 48 hours with plate bound CD3, soluble CD28 and Interleukin-2 and then added to the culture. Interestingly, a 90% reduction in NK cell count was detected when TCR-stimulated Treg cells were added at day 9. In contrast, the remaining had a normal phenotype and was fully functional. Surprisingly, high levels of secretion of IL-10 were observed in this particular condition. No eff ect was observed when resting Treg cells were added to the culture at any time on NK cell count, viability, phenotype and function. These results may strongly suggest an effect on CB NK cell differentiation in vitro by IL-10 CB Treg cells. This study may provide more information to determine if NK cell differentiation and NK cell mediated GvL is impaired by a possible CB Treg cell therapy.

L. Gómez-García, J. Sánchez-García, J. Serrano, R. Rojas, A. Rodríguez-Villa, F. Martínez, P. Gómez Hoapital universitario Reina Sofía (Cordoba, ES) Objectives: Allogeneic hematopoietic stem cell (HSC) transplantation is a potentially curative modality for hematologic diseases. Donor T cells contained in the graft exert in receptors benefi cial anti-tumor and anti-infection eff ects, but also the detrimental graft versus host disease (GVHD) by recognizing HLA disparities recipient's tissues (skin, liver, gastrointestinal). Analysis and isolation of subpopulations naive-memory T cells involved in GVHD and anti-infective protection is the key to the future development of graft engineering. In this study we sought to determine the correlation of circulating naïve/memory total and CMV-specifi c CD8lymphocytes with clinical variables mainly the incidence of GVHD and CMV-disease. Materials and Methods: We analyzed peripheral blood samples from 19 HLA-I*0201patients (paediatrics n = 7) and adult (n = 12) who underwent HSCT from November 2005 to December 2011. We studied maturation profi le (naive -memory) with CD27, CD45RO, CD62L MnAbs of total CD8 lymphocytes and specifi c anti-CMV characterized with anti-HLA tetramers pp65. Results: The proportion of naive-memory CD8 lymphocytes post-HSCT is greatly skewed according to donors' age, with a statistically signifi cant predominance of population naive CD27 + (p = 0.010) if the donor was younger than 40 years and CD45RO-(p = 0.026) if the donor was older than 40 yrs. Patients who underwent conventional conditioning regimen harboured also statistically signifi cant higher frequency of naïve CD27 + populations than those receiving reduced-intensity conditioning regimen (p=0.034). Although patients who develop acute GVHD contained a larger number of naive CD8+ lymphocytes, these diff erences did not reach statistical signifi cance. We also showed a signifi cantly higher number of population specifi c CD8 anti-CMV (p= 0.033) in patients who developed CMV infection and underwent valganciclovir treatment. Conclusions: Circulating CD8 populations post alo-TPH are signifi cantly infl uenced by donor age and type of conditioning and CD8 + anti-CMV TPH are more frequently detected especially post-post-infection.

Impaired function and proliferation of NK cells from patient granulocyte colony-stimulating factor mobilized leukapheresis Y. Xiong, Y. Wang, J. Stoltz, D. Bensoussan, V. Decot CHU de Nancy (Vandoeuvre les Nancy, FR)

Objective: Granulocyte colony-stimulating factor (G-CSF)mobilized peripheral blood stem cell (PBSC) collections are increasingly emerging as the graft of choice in many centers for autologous transplantation, and with increasing frequency in allogeneic transplantation. In an allogeneic setting, natural killer (NK) cells have a critical role in graft versus host disease and graft versus leukemia eff ects. However, the impact of G-CSF on NK cells response remains unclear. In this study, we compared NK cell phenotype and functions isolated from PBSC collections from both healthy donors and patients mobilized with G-CSF. Materials and Methods: After informed consent, NK cells were isolated from 150 mL fresh blood sample from healthy donors, 3 mL of fresh PBSC transplant from allogeneic healthy donors and 3 mL of fresh autologous PBSC transplant from patients, enriched using a CD3/CD19 depletion method and expanded for 14 days in the presence of 50 ng/mL interleukin (IL)-15. Expression of NKG2D, KIR2DL1, KIR2DL2, KIR2DL5, and CD137 was monitored by fl ow cytometry during expansion and cytokine secretion was followed using Cytometric bead array. NK cell cytotoxicity was evaluated at the end of the culture. Results: Highly T-and B-cell depleted NK cells were obtained. The percentage of CD16+/CD56+ NK cells was signifi cantly diminished in G-CSF mobilized PBSC from patients after expansion and proliferated less than NK cells from normal peripheral blood or G-CSF mobilized PBSC from normal donors. The fi ve receptors studied were up regulated after 14 days of culture, and the expression of NKG2D, KIR2DL1 and CD137 was signifi cantly diff erent between the three origins of NK cells. NK cells sorted from G-CSF mobilized PBSC from patients also exhibited a diminished ability to kill tumor targets. Conclusion: The findings presented here show that G-CSF administration to patients decreases NK cell population, proliferation and function. Overcoming this impairement in lymphoid capacity may be important to facilitate post-transplant immunotherapy.

G. Sconocchia (1), S. Caratelli (2), A. Coppola (2), G. Spagnoli (3), G. Lanzilli (1), M. Lucibello (1), S. Ferrone (4), R. Arriga (2) (1

Natural killer (NK) cell/cancer cell conjugation leads to reciprocal cellular damage. Nature and specifi city of this phenomenon in post-activated NK cells are unclear. Using standard immunological methods, we assessed the eff ects of human and mouse cancer cells on post-activated human and mouse NK cells. Human, allogeneic, malignant cells triggered human NK cell alteration (NKCA) including FcγRIII (CD16) down-regulation, NK cell loss and apoptosis. In contrast,allogeneic PBMC, depleted of NK cells, failed to induce significant NKCA. Mouse allogeneic leukemia cells induced mouse NK cell loss and apoptosis while syngeneic, allogenic mouse splenocytes, depleted of NK cells, and xenogenic cancer cells did not, suggesting that NKCA preferentially involved allogeneic, malignant cells. After 10 days PBMC culture, in the absence of cancer cells, post-activated and unstimulated NK cells showed some CD16 antigen down-regulation while became resistant to cancer cell dependent NKCA and maintaining cytotoxic function. Actinomycin D restored NKCA in long term NK cells (LTNKC) suggesting that the resistance to NKCA utilized RNA transcription. TAPI-0, a functional analogue of the tissue inhibitors of metalloproteinases (TIMP) 3, reversed cancer cell dependent NKCA underlying a role for a restricted group of metalloproteinases (MMPs) in the generation of this phenomenon. LTNKC resistance to NKCA was associated with increased levels of TIMP3 gene expression and sustained contents of soluble TIMP3 in the supernatants of LTNKC cultures. This study provides evidence that TIMP3 plays a role in the protection of LTNKC from cancer cell dependent NKCA.

A novel multiple imputation method for uncovering HLA disease associations using unrelated donor registry databases L. Gragert (1), S. DiPrima (1) , M. Albrecht (1) , M. Zhang (2) , X. Zhong (2) , P. Hari (2) Aim: Finding HLA associations for disease in retrospective studies is challenging primarily due to poor statistical power due to unavailability of large well-defi ned case and control datasets. Fortunately, the National Marrow Donor Program (USA) registry has accumulated large numbers of disease cases from patient searches for allogeneic stem cell transplants along with HLAtyped controls from donor recruitment. We aimed to use this data to uncover HLA associations for transplantable diseases. Methods: We developed sets of HLA-typed case/control datasets from the NMDP registry for several US populations. Because most HLA typing has allelic ambiguity, we utilized a multiple imputation framework which assigns allele-level HLA-A~C~B~DRB1~DQB1 haplotype pairs based on a probability distribution calculated from ambiguous subject HLA typing and reference population HLA haplotype frequencies. Replicate studies each with potentially-varying HLA haplotype assignments were performed to ensure that the HLA typing ambiguity was incorporated in the statistical model. We ran multivariate logistic regression using a generalized linear model controlling for the covariates of age, geographic location, and gender to calculate odds ratios, P-values, and 95% confi dence intervals for HLA allele and haplotype variants. Results: In a study of 2,887 European-American Multiple Myeloma (MM) patients compared to 500,000 controls, we found signifi cant HLA associations. B*07:02 was predisposing for MM with an odds ratio (OR)of 1.27 and a P-value of 0.0001. Meanwhile B*44:02 was protective (OR=0.858. P-value=0.0491). Other associations were observed for A*66, B*27, C*16:01. In some cases grouping alleles into allele families resulted in more statistically-signifi cant associations, while in other cases confounding between alleles within a family made grouping undesirable. Combinations of multiple risk variants within haplotype and genotypes had an additive or dose-dependent eff ect. Conclusion: The combination of large registries and the application of this multiple imputation statistical framework provides a unique opportunity to study HLA associations for transplantable disease at a higher resolution than ever. We are expanding this framework to examine amino acid polymorphisms and sequence feature variant types (SFVTs) within HLA molecules. International collaboration with additional registries and experts in disease is needed to fully exploit the potential of this method and secure grant funding.

Natural chimera identifi ed during routine histocompatibility testing for haematopoietic stem cell transplantation: a case study Z. Grubic, J. Kelecic, K. Stingl, R. Zunec Clinical Hospital Centre Zagreb (Zagreb, HR) Chimerism, a state described as a presence of two genetically distinct cell lines in an organism, routinely occurs in patients who were subjected to medical procedures such as transplantation or transfusion. However, this state can also appear naturally, as a consequence of feto-maternal transfer of cells through placenta during pregnancy. In this report, we describe a case of natural chimerism identifi ed during a routine histocompatibility testing. S164 A six months old boy was diagnosed with a Severe Combined Immunodefi ciency Syndrome (SCID). In preparation for Hematopoietic Stell Cell Transplantation (HSCT), the patient and his parents underwent HLA testing. Genomic DNA was extracted from peripheral blood cells and HLA-A, -B, -DRB1 typing was performed by Luminex technology. Typing results of the patient's HLA-B locus were not interpretable. All samples were re-typed for HLA-B by PCR-SSP. Patient's sample could not be interpreted using commercial software due to several weak positive reactions. The typing was repeated on a sample of patient's bone marrow and the results were again non-interpretable. The analysis was extended to HLA-C locus, however, the patient's alleles were again not possible to determine due to several weak reactions, either for blood or bone marrow. Five out of 16 microsatellites (HUMTH01, HUMSE33, D1S1656, D18S535, D15S659) were informative and demonstrated three alleles in patient's sample (two maternal and one paternal) out of which paternal allele appeared with a distinctly lower intensity. The retrospective manual interpretation of results obtained for HLA-B and -C loci revealed that weak positive reactions were indeed due to the paternal HLA-B and -C alleles and that the patient had both maternal and one paternal allele. Finally, the DNA from patient's buccal cells was isolated and HLA-B and -C loci were re-typed by PCR-SSP. The analysis revealed that the patient inherited one paternal and one maternal allele. This fi nding was confi rmed by analysis of informative microsatellites, which demonstrated only one maternal and one paternal allele in patient's buccal cells. The initial failure to recognize the chimeric state of the patient was due to the mother's homozygosity at the HLA-A and -DRB1 loci. In summary, combination of several diff erent typing methods including the manual interpretation of results was necessary to obtain the HLA typing results of the patient and subsequent successful search for an unrelated donor.

Immunogenetics is often erroneously considered a static science. This is not the case, since every year tens of new alleles are discovered and a plenty of new insights stems in antibody-mediated and cell-mediated immune response to allografts. Most physicians involved in transplantation sciences are not fully aware of these developments because these novelties are too often targeted at a highly specialized audience. At the same time even immunogenetists have troubles at staying updated in their fi elds of interest because of the proliferation of published journals and the clear multidisciplinarity of transplantation immunology. Modern web tools (such as RSS feed aggregators) facilitate continuing immunogenetics education sparing precious time to busy scientists. Anyway there is currently a lack of Web 2.0 platforms for sharing immunogenetics knowledge. The not-for-profi t "Immunogenetics and Transplantation blog" (http://immunogenetics.blogspot.com) was developed with Web 2.0 in mind to allow interaction with visitors. The blog, launched on November 1, 2011, was arranged on the well-known Blogger platform, allowing consultation onthe-go thanks to its simplifi ed mobile interface. In the fi rst year of life the blog posted > 70 paper abstracts and received > 25,000 visits, which is a good results for a highly specialistic fi eld. Among blog features, visitors can enjoy : 1) ability to search and comment each post; 2) polls on current topics of interests; 3) easy e-mailing, sharing and cross-linking to social networks for each single post; 4) shareable Google calendar with deadlines and dates for most important world congresses on immunogenetics and transplantation ; 5) useful links; 6) interactive chatbot; 7) single-click, inline translation to 10 diff erent languages; 8) ability to join free text or video chats; and 9) a mobile app for Windows Phone and

S165 Android devices. The interface has been designed to attract even the laziest or unexperienced user, and post subscription can be easily achieved for offl ine reading.

HLA (human leukocyte antigen) genotypically identical siblings are preferred as donors in hematopoietic stem cell transplantation (HSCT) because the inheritance of identical HLA haplotypes by descent includes identity for all gene variations within the two parenteral haplotypes. Matching for HLA in unrelated HSCT does not mean that non-HLA genes in HLA region also matched. Present of frequent haplotypes in patient positively aff ects the probability and speed of identifying unrelated donor. Patients carrying at least one of the 10 most frequent Caucasoid HLA haplotypes have the highest chances of the quick identifi cation of matched donor. Those patients have a decreased probability of acute graftversus-host disease without increased risk of relapse compared to patients without frequent haplotypes. Frequencies of HLA allele and their associations vary from one geographic region to another.

Objective: To estimate the distribution of HLA-A*/B*/C*/DRB1*/ DQB1*haplotype frequencies in Russian patients in need of HSCT. Methods: 201 patients (Caucasoids) with diff erent hematological disorders awaiting allogeneic HSCT (related or unrelated), whose HLA-haplotypes were identifi ed by family segregation analysis with certainty, were included in the study. HLA-A*/B*/C*/DRB1*/ DQB1* genotyping was done using PCR-SSP Kits (Invitrogen, WI, USA). Results: 21 out of defi ned HLA haplotypes occurred in our patients three and more times. Our patients carried all of the 10 most frequent Caucasoid haplotypes, but their distribution had some peculiarities. The most frequent haplotype was A*03-B*07-C*07-DRB1*15-DQB1*06, which was identifi ed in 17 patients (8.5%). 13 patients (6.5%) carried A*01-B*08-C*07-DRB1*03-DQB1*02. A*02-B*13-C*06-DRB1*07-DQB1*02 was the third according to frequency (5%), it was revealed 10 times in 9 patients. 3 haplotypes of the 10 most frequent Caucasoid haplotypes occurred less than three times: twice A*02-B*40-C*03-DRB1*13-DQB1*06 (1%) and A*30-B*13-C*06-DRB1*07-DQB1*02 (1%), and once A*29-B*44-C*16-DRB1*07-DQB1*02 (0.05%). Only 23.9% of the patients had at least one of the 10 most frequent haplotypes, 2% of the patients had two such haplotypes. Conclusion: The investigated patients had peculiarities in distribution of HLA haplotype frequencies. Possible solution of the problem to fi nd HLA compatible donor at least for the part of our patients is to increase donor pool size in diff erent regions of Russian Federation.

Evaluation of sequence-based HLA typing: a single centre's experience A. Siorenta, V. Vrani, S. Tryfonidou, S. Tryfonidou, E. Stamathioudaki, A. Iniotaki General Hospital of Athens ''G.Gennimatas'' (Athens, GR) Aim:To evalute Sequence Based Typing(SBT) as a method for HLA four digit high resolution typing and allele identifi cation in patients for hematopoietic stem cells transplantation and their potential unrelated donors. Methods: 559 HLA-A,-B,-C and DRB1 loci were tested and analyzed by SBT using commercial SBT kits,an automatic AB 3500XL Analyser and the kits software. Exons 2,3 and 4 were analyzed for class I and exon 2 for class II loci. For allelic ambiguities defi nition we used Heterozyguous Ambiguity Resolution Sequencing Primers (HARPs). All loci were typed in parallel with HR SSO/SSP. Results: Unambiguous four digit allelic results were observed for 223/559(39,9%) loci by SBT. Using HARPs we were able to improve the resolution for 160(28,6%) more loci, achiving a total of 383(68,5%) unambiguous results. For the rest 176(31,5%) loci further testing needed to rule out the ambiguities from 18,3% HLA-A, 36,1% HLA-B,70,3 % HLA-C and 21,7% HLA-DRB1 loci. Analysing the results from SSO/SSP typing we resolved ambiguities in 136/176 loci while 40 remained unresolved and assigned using NMDP guidelines and population frequence tables. Conclusions:Implementation of SBT increases alleles resolution but we still need SSO/SSP to rule out ambiguities. In order to increase allele resolution using SBT it is necessary to extend the analysis to other exons and proceed to new HARPs. Objectives: We and others have reported abnormalities in the regulatory T lymphocytes (Treg) of hematopoietic stem cell transplant (HSCT) recipients with chronic graft-versus-host-disease (GvHD). Because of the clinical similarities between chronic GvHD and scleroderma (SSc), we analyzed the Treg lymphocytes of pediatric SSc patients (jSSc) and identifi ed decreases in both resting and activated Treg lymphocytes. In addition, we identifi ed an increased frequency of CD45RA expressing eff ector memory (EMRA) CD4 T lymphocytes that uniformly express CCR7 and CD28, which are not uniformly expressed by the increased EMRA T lymphocytes present in elderly individuals. We, therefore, cross-sectionally analyzed allogeneic pediatric HSCT recipients more than 1 year following HSCT for the presence of CCR7 expressing EMRA CD4 T lymphocytes as possible eff ector T lymphocytes in chronic GvHD. Methods: HSCT recipients were classifi ed as 1: no history of acute or chronic GvHD; 2: history of only acute GvHD; 3: active chronic GvHD; and 4: history of resolved chronic GvHD. Peripheral blood leukocytes of the normal individuals and the HSCT recipients were analyzed by FACS analysis for the frequency of EMRA CD4 T lymphocytes and their expression of CCR7 in addition to quantifying the frequency of resting and activated Treg lymphocytes using the Miyara classifi cation and 6 color FACS analysis. Results: Elevated frequencies of EMRA CD4 T lymphocytes were present in all HSCT groups except HSCT recipients with only a history of acute GvHD (Group 2). Increased expression of CCR7 by the EMRA T lymphocytes was present in all HSCT recipients except those with a history of only acute GvHD. HSCT recipients without a history of GvHD or resolved chronic GvHD (Groups 1 and 4) had relatively normal numbers of resting Treg (rTreg) lymphocytes while HSCT recipients with active chronic GvHD or a history of only acute GvHD had reduced frequencies of rTreg lymphocytes. Conclusion: CCR7 expressing EMRA CD4 T lymphocytes may be an eff ector T lymphocyte population in the pathogenesis of human chronic GvHD in the content of abnormalities of rTreg lymphocytes. The presence of adequate numbers of rTreg lymphocytes can result in an absence of chronic GvHD or its clinical resolution in spite of the presence of increased numbers of CCR7 expressing EMRA T lymphocytes. Thus, active chronic GvHD may be due to the action of CCR7 expressing EMRA CD4 T lymphocytes in the context of immune dysregulation.

Overexpression of miR-181a in donor T-cells: a potential target to ameliorate GVHD C. Lee, I. Dallmann, A. Ganser, M. Scherr, M. Eder, C. Koenecke Hannover Medical School (Hannover, DE) (*MS, ME and CK contributed equally to this work) Objective: Over-expression of miR-181a in T cells enhances T cell receptor sensitivity. We hypothesized that alteration of miR-181a expression in donor T cells changes donor-T cell responses after allogeneic hematopoietic stem cell transplantation (HSCT). Therefore, miR-181a might be a therapeutic target to prevent GVHD or to induce graft-versus-leukemia/lymphoma eff ects. Methods: Lentiviral gene transfer was used to enhance miR-181a expression in murine T-lymphocytes. Lentiviral transduction and miRNA expression were quantitated by FACS analysis of transgenic eGFP expression and miRNA-specifi c RT-PCR, respectively. Functionality of miR-181a-high T cells was tested in vitro and in vivo in a C57BL/6 into BDF1 mouse model. Traffi cking of donor T cells was assessed at diff erent time points after HSCT. Results: Transduction effi cacy of lentiviral gene transfer into primary T cells was between 50% and 70% for both, control and miR-181a lentiviral constructs with consistently higher transduction rates for the controls. Up to 200-fold miR-181a-over-expression in T cells was detected when compared to non-or mock-transduced controls. Unspecifi c in vitro stimulation with anti-CD3 and anti-CD28 beads led to signifi cantly less proliferation of

S167 miR-181a-high-T cells as compared to control-T cells, as measured by 3H-thymidine incorporation. Competitive in vivo homing assays showed that allogeneic miR-181a-high-T cells home less effi cient to GVHD target organs than control-T cells. Moreover, the absolute number of miR-181a-transduced-T cells recovered from injected mice was signifi cantly reduced compared to control-T cells after allogeneic transplantation. Summary: We developed a robust protocol for lentiviral gene transfer into primary T cells for immunotherapy. Our data suggest that miR-181a over-expression in allogeneic T cells leads to reduced proliferation after unspecifi c stimulation in vitro and allogeneic stimulation in vivo and could therefore serve as a potential therapeutic target to reduce GvHD.

The combination of RAD001 and mycophenolat mofetil for pre-and post-transplant immunosuppression following non-myeloablative haematopoietic stem cell transplantation in canine littermates C. Mueller, S. Lange, J. Werner, R. Wacke, D. Killian, A. Knueppel, G. Knuebel, H. Vogel, C. Roolf, C. Junghanss University of Rostock (Rostock, DE) Background: A common immunosuppression (IS) following allogenic hematopoietic stem cell transplantation (HSCT) is the combination of Cyclosporin A (CsA) and Mycophenolat Mofetil (MMF). The mTOR-inhibitor Everolimus (RAD001) is used in solid organ transplantation and has been tested for prevention of graft-versus-host disease. Here we investigated a combination of RAD001/MMF as pre-and post-transplant IS following nonmyeloablative HSCT. Methods: On day (d) 0 all dogs (n=8) received HSCT from its MHCidentical siblings. The non-myeloablative conditioning consisted of 200 cGy total body irradiation on d -1. RAD001 was given with 1,5 mg BID from d -1 to +49 and tapered until d +56. MMF (20 mg/ kg bw BID) was administered from d 0 to +28 and tapered until d +42. Pharmacokinetic data were measured on d +5 and +21.

The chimerism values of the peripheral blood mononuclear cells (PBMC) and granulocytes (G) were tested weekly (weeks 1-11) and afterwards in larger intervals. Blood cell counts as well as renal and liver enzymes were controlled at frequent intervals. Activity, diarrhoea, ingestion and weight loss were assessed up to d +56.

Data were compared to a historical CsA/MMF group (CON). Results: All dogs engrafted. The maximal donor chimerism was median 84% (33-96%) for G on median d +18 and 58% (3-85%) for PBMCs on median d +25. Median platelet nadir of the RAD001 group was 0 * 10 9 /L versus nadir CON: 35 * 10 9 /L (p=0,001). The duration of thrombocytopenia was increased up to median 36 (29-36) days compared to CON median 4 (0-13) days (p=0.001). Median leukocyte nadir was 1 * 10 6 /L versus CON (2.4 * 10 6 /L, p<0.05). Subsequently 5 of 8 (63%) animals rejected their grafts. One dog remained with a stable chimerism after d +273. Two dogs died (d +19 and +25) of infection. Pharmacokinetics of RAD001 and MMF showed a median trough level of 17.3 (9.4-35.7) ng/mL and 0.3 (0.1-1.3) μl/mL. The median area under the curve (0-12h) was 27. 1 (14.8-49.4 ) ng/mL*h for RAD001 and 2.5 (0.7-3.4) μg/mL*h for MMF. All dogs developed clinically mucosal viral infections at the clinical course. The toxicities for RAD001/MMF compared to the CON were signifi cantly increased for all qualities (overall p<0.05). Conclusion: RAD001 and MMF is feasible as pre-and posttransplant IS in a HSCT model but associated with signifi cant toxicities including a prolonged platelet recovery time as well as increased infections. Therefore optimal RAD001 dosing in HSCT settings need further investigations.

Serum albumin level predicts survival of acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation with myeloablative conditioning F. Ayuk, T. Zabelina, L. Bussmann, R. Veit, C. Wolschke, H. Lellek, U. Bacher, A.R. Zander, N. Kröger University Medical Center Hamburg (Hamburg, DE) Introduction: Acute graft-versus-host disease (aGVHD) is a major cause of mortality after allogeneic stem cell transplantation (allo-SCT). Till date there are no validated biomarkers predicting the outcome of patients (pts) who develop aGVHD. A decrease in serum albumin ≥ 5g/dL from pre-transplant baseline to development of aGVHD has been reported to predict outcome of aGVHD after non-myeloablative conditioning. Methods: We retrospectively analysed 495 consecutive adult patients who underwent allo-SCT at our center between 2005 and 2009. All pts received myeloablative conditioning which was full intensity in 123 (39.9%) and reduced intensity in 185 (60.1%) pts. AGVHD was recorded as from day 5 till 100 after transplant. GVHD was graded according to Przepiorka et al. and treated with 2mg/kg methylprednisolone. The impact of the initial grade of aGVHD, serum albumin and other relevant pre-transplant donor and patient characteristic on overall survival (OS) was estimated by Kaplan-Meier method. Cox regression models were used to estimate hazard ratios. Results: In all, 308 pts (62%) developed aGVHD grades I-IV which was initial grade I in 118 (38,3%), II in 127 (41,2%) III in 48 (15,6%) [P631] S168 an IV in 15 (4,9%) pts. 1 year OS was 82%, 65% and 60% % for grades I, II and III respectively und 60% for II-IV combined. Only 1/15 pts with aGVHD IV was alive after 3 months. Pre-transplant albumin level did not signifi cantly impact 1/5 yr. survival (65/48% vs. 71/54%, p = 0.3). for patients with albumin ≤ 34 (low) and > 34 (high) respectively. Neither did decrease ≥ 5g/dL from pre-transplant baseline to development of aGVHD (56/49%% vs. 70/52%, p = 0.42). However serum albumin level at time of diagnosis of aGVHD predicted outcome: 1/5 yr OS was 60/40% for pts with low vs. 75/63% for pts with high albumin, p = 0.001. In patients with gastrointestinal (GI) aGVHD II-IV (n = 50) 1 yr OS was 32% for low vs. 68% for high albumin, p = 0.01. On the other hand, survival of patients with only skin aGVHD II-IV (n = 68) was 72% for both low and high albumin. Results of cox regression multivariate analysis are summarized in table 1. Conclusion: Our results indicate that serum albumin is a relevant prognostic biomarker in adult patients who develop GI-aGVHD after myeloablative conditioning.

Tissue-specifi c homing of NK cell subpopulations impacts GVHD prevention

Clinical studies exploiting the impact of natural killer (NK) cells in allogeneic hematopoietic stem cell transplantation (HSCT) have provided promising results. It is known that NK cells are a heterogeneous population and can be divided into functionally distinct NK cell subpopulations. Murine NK cells can be separated along their expression of CD27 and CD11b and CD117 (c-kit). However, the functional relevance of distinct NK cell subsets in graft-versushost-disease (GVHD) has not been investigated in detail so far. Here we report on diff erent genomic, phenotypic, functional and migratory properties of four distinct NK cell subsets. Our data clearly demonstrate that CD27+ NK cells revealed the highest IFN-g production upon coculture with tumor cells and/or IL-2, whereas the CD11b+ NK cells express multiple genes of cytotoxic pathways and develop the highest cytotoxic capacity towards tumor cells. Furthermore, the CD11b+ NK cell subset signifi cantly reduced T cell proliferation induced by allogeneic dendritic cells in mixed lymphocytes reactions. Next, we analyzed the migratory capacity and tissue-specifi c homing of the diff erent NK cell subsets by in vivo bioluminescence imaging (BLI) of adoptively transferred FACS-sorted Luc+CD45.1+ NK subpopulations in autologous and allogeneic bone marrow transplantation. Of interest, FACS analysis and in vivo imaging revealed that CD11b+ NK cells preferentially migrated to peripheral GVHD target organs.

Finally, this study addressed for the fi rst time the role of distinct NK cell subpopulations in the development of GVHD in a fully MHC mismatched HSCT mouse model. Importantly, we identifi ed the CD11b+ NK cell population as the NK cell subset that signifi cantly diminished GVHD. BLI of Luc+CD11b+ NK cells revealed that this subset migrates to the colonic tissue to prevent development of GVHD colitis as shown by colonoscopy. In summary, our comparative study outlines that only CD11b+ NK cells, migrating to the peripheral GVHD target organs and providing the most effi cient cytolytic capacity directed against allogeneic dendritic cells, protect against GVHD. These new insights are highly relevant for the selection of optimal NK cell subsets in the fi eld of cellular immunotherapy.

Cytokine gene polymorphisms and severe acute graftversus-host disease (grade ≥II) after allogeneic haematopoietic stem cell transplantation from HLA identical siblings

Graft-versus-host disease (GvHD) is one of the most important complications after allogeneic hematopoietic stem cell transplantation (HSCT) and infl uences morbidity and mortality. Polymorphisms at genes coding for several proinfl ammatory cytokines and for their related receptors or receptor inhibitors are involved in this complication. To assess the role of cytokine gene polymorphisms on acute GvHD (aGVHD), we analysed 189 pairs of donor and recipients transplanted from HLA identical sibling for malignant hematological diseases between 2000 and 2007. The median recipients age at transplantation was 43.4 years . Two third of the patients received bone marrow before myelo-ablative conditioning regimen, the median delay between diagnosis and transplantation was 9 months (1-76). Five diff erent polymorphisms from 3 cytokine genes were analyzed: IL-10 -592C/A, -819C/T and -1082G/A, IL-1β -511A/G and TGFβ1 -509C/T. All the pairs were studied for each gene polymorphism using the Taqman technology as previously described (Malkki 2007) . Univariate analysis found a signifi cant negative impact of donor genotypes carrying IL1β A allele (p=0,02) or IL10-592 A allele (p=0,03) on aGvHD. We did not fi nd any eff ect associated with IL10-819 and -1082 polymorphisms, but as previously described (Lin 2003) , the presence of IL10 A-T-A haplotype in the donor, signifi cantly increased the risk of aGVHD (p=0.043). We performed a multivariate analysis on aGVHD incidence taking into account TGFβ1-509, IL-10-592 and IL1β polymorphisms, together with other known risk factors. A higher incidence of aGVHD was found in pairs where donor has an IL1β A allele (HR 4,16 -p=0,0031) and increased when the

S169 donor is A/A (HR>15 -p=0,0091). For IL10-592, the impact of the A allele was found diff erent when carried by the donor (higher risk of aGVHD, HR=3,52 p=0,00083) or the recipient (lower risk of aGVHD, HR=0,48 p=0,024), but this eff ect seems only signifi cant in pairs where donor did not carry any A allele (rec AC x don CC -HR 0.2 -p=0.05). Donor with TGFβ1-509 T allele was found to have a signifi cant lower risk of aGVHD (HR 0,42 -p=0,02). (table 1) . The role of the cytokine cascade in the physiopathology of GVHD is well established. Our study documents the possible role of IL-1β, TGFβ1 and IL10 gene polymorphisms in this setting. A proven association of cytokine gene polymorphisms with acute GVHD would enable the clinician to modify the therapeutic strategy and enhance the outcomes. Background: Genetic aberration of TNFRSF14 occurs in half of patients (pts) with follicular lymphoma (FL). TNFRSF14 is a ligand for BTLA, a receptor which inhibits T cell responses. Activated B cells effi ciently present antigens, and BTLA signaling is important in control of donor T cell alloresponses that mediate acute graftversus-host-disease (aGvHD) after allogeneic haematopoietic stem cell transplantation (AHSCT). We therefore hypothesized that TNFRSF14 aberrations in FL may reduce BTLA-mediated inhibition of alloreactive donor T cells after AHSCT resulting in increased frequency or severity of aGvHD. Objective: To investigate the impact of TNFRSF14 aberrations on outcome of FL pts undergoing AHSCT. Methods: 21 FL pts undergoing T-cell replete reduced-intensity conditioned AHSCT were included in the study. Tumour DNA from pre-ASCT lymph node biopsies was screened for TNFRSF14 mutations and deletions by Sanger sequencing and multiplex ligation-probe amplifi cation respectively. Cumulative incidence (CI) of aGvHD and treatment-related mortality (TRM) were calculated with FL progression as a competing risk. Results: TNFRSF14 aberrations were identifi ed in 10/21 pts (48%). 5 pts had mutations (of which 4 had deletions of the second allele) and 5 pts had deletions without mutations. Disease and donor characteristics were similar in pts with and without aberrations. There was no signifi cant diff erence in the CI of aGvHD in pts with or without TNFRSF14 aberrations. However all 4 pts that died from aGVHD had TNFRSF14 aberrations (3 pts had mutations, 2 with additional deletions of the other allele). There was a signifi cantly higher CI of death from aGvHD and a trend to lower overall survival in pts with TNFRSF14 aberrations compared to those without TNFRSF14 aberrations (38% vs. 0% (p=0.03, Fig. 1 ) and 40% vs. 74% (p=0.06, Fig. 2 ) respectively). Conclusions: This study is the fi rst to describe the potential impact of TNFRSF14 aberrations in FL on outcome after AHSCT. Even in this small cohort of pts, the presence of TNFRSF14 aberrations, particularly biallelic loss, was associated with increased death from aGvHD. These fi ndings require confi rmation in a larger cohort and in vitro studies to determine the functional impact of TNFRSF14 aberrations on allogeneic T cell responses. However, our results suggest FL patients with TNFRSF14 aberrations may benefi t from more aggressive immunosuppression to reduce the incidence of fatal aGvHD after AHSCT. (1) 

Introduction: Despite many improvements in the fi eld of HSCT, acute graft versus host disease (aGVHD) remains a life-threatening complication and reduces the effi cacy of HSCT substantially. Especially the outcome of patients with severe steroid-resistant aGVHD remains very poor. Therefore, new therapeutic strategies for the treatment of aGVHD are needed. Objective: The feasibility of the generation of Mesenchymal Stromal Cells (MSC) expanded with human plasma and platelet lysate (hPPL) was tested as well as the feasibility and safety of S170 the application of hPPL-MSC in patients with steroid-refractory aGVHD. As mechanisms in humans are poorly understood, phenotypical and functional changes in immunological cell types and cytokine levels were investigated before, during and after infusion of MSC. Methods: 50 patients with steroid-refractory aGVHD grade II to IV were included in an open-label, non-randomized prospective phase I/II study and received up to four MSC infusions. Clinical parameters as well as a comprehensive phenotypical and functional analysis was performed. Results: Between January 2009 and July 2012, 50 patients were included, 2 patients dropped out due to fast relapse of their primary malignancy. 48 patients were thus available for analysis of whom 7 children. Median overall grade was III, organs involved were skin (52%), gastrointestinal tract (88%) and liver (35%). No severe side effects were observed. Complete overall response was observed in 24 patients (50%) after a median of 53 days (range 3-116 days). The overall survival was significantly better in responders when compared to non-responders (p <0.001). Immunological monitoring suggests that anti-viral and anti-leukemia reactive T-cells are well preserved in all patients who responded to MSC treatment. In addition, we identified biomarkers which associate even 2 weeks after MSC infusion with a complete resolution of GVHD, which occurred usually after months and studied the microenvironment of the gut in selected patients. Conclusion: Generation and infusion of hPPL-MSCs in steroidresistant aGVHD grade II-IV is feasible, safe and appears to be eff ective. Infusion of MSC did not impair anti-virus and antileukemia reactive T-cells. Identifi ed biomarkers predict very early a usually late clinical resolution of GVHD, cellular biomarkers are found to be located within the gut and are thus most likely both, relevant for the biology of the disease and useful to early guide clinical decisions.

Acute graft-versus-host disease (aGvHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), thus early investigator-independent diagnosis is important for early intervention. Using capillary electrophoresis coupled on-line to mass spectrometry (CE-MS) to monitor urine of patients after allogeneic HSCT a proteomic pattern consisting of 17 differentially excreted peptides was generated. Ten peptides have been identifi ed to date as various collagen fragments (indicating disturbances in metabolism of collagen or early organ damage), fragments of fi bronectin and albumin. In addition, fragments of β-2-microglobulin (β2M) and CD99, an activation marker of T-cells, are excreted in patients with aGvHD depending on severity. These peptides correspond to proteins which are present in human plasma and can be detected by antibodies allowing direct comparison with proteins described by others as plasma biomarker at the time of diagnosis of acute GvHD. 69 patients transplanted at Hannover Medical School were included in this fi rst analysis. The majority were transplanted for acute leukaemia (n=48) from matched, unrelated donors (n=39), HLA-identical siblings (n=18) or mismatched donors (n=12). Reduced intensity conditioning was used for 20 patients and 63 received T-cell depleting antibodies prior to HSCT. Samples were collected prospectively from patients at onset of aGvHD (n=20), patients at similar time-points early after HSCT without aGvHD (n=14), patients at diagnosis of chronic GvHD (cGvHD; n=13) and patients without GvHD (>day +100; n=33) and analyzed with CE-MS, ELISA and Bio-Plex. The previously published biomarker sIL-2Rα, IL-8, sTNFR1, ST2/IL-1R4, HGF, REG3α and Elafi n (Levine et al., 2012) as well as CD99 and β2M (CE-MS-analysis) were analyzed in all plasma samples. Elafi n and HGF were not useful to distinguish patients with aGvHD or cGvHD from those without. None of the known plasma biomarker were able to distinguish acute from chronic GvHD, as they are rather marker for infl ammatory processes. But our results confi rm that β2M and CD99 are fi rst of all detectable in urine and plasma of patients with aGvHD and secondly diff erentially excreted according to severity of disease. In addition, both marker are capable of distinguishing patients with aGvHD from those with cGvHD with high sensitivity and specifi city. Reproducibility of the preliminary results and the predictive power of those biomarker will be tested in a blinded, prospective validation set.

Dendritic cells (DC) are centrally involved in the development of acute graft-versus-host disease (GVHD) following allogeneic hemopoietic cell transplantation (alloHCT) and previous work has shown that DC expression of the activation marker CMRF-44 correlated with subsequent acute GVHD. The traffi cking of immature DC from blood to GVHD target organs is likely to be regulated by chemokine receptors expressed on activated DC and published data suggests that CCR5 is important in alloHCT. We found diff erences in chemokine receptor expression on DC subsets in normal individuals and showed that, although the major CD16+ myeloid blood DC subpopulation did not express CCR5, it was induced on CD16+ DC after culture in allogeneic MLR supernatant, an eff ect mediated largely by interferon-γ. In 42 patients monitored to day 100 post alloHCT, CCR5 was expressed on a signifi cant proportion of CD16+ DC (p = 0.0001, compared to normal cells). The maximum percentage of CCR5+ CD16+ DC in patients at any time post-transplant correlated with acute GVHD: mean 27.5% (0-50%) in GVHD grades II-IV, mean 11.6% (0-44; p=0.0006) in grades 0-I. The maximum percentage CCR5 positive prior to developing grades II-IV GVHD (mean 22.7%, 0-50%) was higher than in grades 0-I GVHD (mean 11.4%, 0-38%) (p=0.0285). CCR5 levels >20.5% on CD16+ myeloid DC predicted grades II-IV GVHD with a sensitivity of 66.7% and specifi city of 86.7%. These observations may refl ect DC activation and altered DC homing during the alloimmune response to alloHCT, and could allow early therapeutic intervention prior to the clinical diagnosis of GVHD. Acute graft-versus-host disease (aGvHD) of the skin following hematopoietic stem cell transplantation (HSCT) is diffi cult to clinically diff erentiate from other underlying causes. Elafi n has been reported to be specifi c for skin-aGvHD, but no longitudinal follow-up is available as to whether elafi n can predict response to steroids. We aimed to determine in a retrospective longitudinal study the role of elafi n in monitoring skin aGVHD. All children transplanted in our unit between 2004-2012 who developed severe (≥ grade 2) aGvHD with skin involvement (n=33) were evaluated. Skin biopsies (n=31) from 25 aGvHD patients were available and compared to 23 biopsies from patients without aGvHD (n=13) or non-HSCT recipients. Biopsies were stained for elafi n, a biomarker reported to be specifi c for skin-aGvHD. The intensity of Elafi n expression on skin biopsies was scored and the mean score was signifi cantly higher in skin-aGVHD biopsies than in controls (4.3 versus 1.8; p<0.0001). In addition, Elafi n scores in biopsies after HSCT distinguished aGvHD from other causes (sensitivity 88.5%, specifi city 92.3%) Biopsies especially in children are not always feasible and ELISA for biomarkers are commercially available giving results within 4 hours. Elafi n and three other previously reported biomarkers, sIL2Ra, HGF and TNFR1, were longitudinally measured in sera from pre-HSCT until at least day 50 after aGvHD. Sera of 27 patients were available. At the start of aGvHD, Elafi n, sIL-2Ra and sTNFR1 concentrations in serum were signifi cantly elevated, compared with samples before onset of skin-aGvHD (p=0.007, <0.0001 and 0.0002). In addition, these concentrations were signifi cantly higher than serum levels in patients without aGvHD (n=12). Only elafi n concentrations correlated at the day of biopsy with the pathology report showing increased levels in aff ected patients (p=0.0021). HGF concentrations were signifi cantly lower in patients refractory to steroids prior to and at onset of aGvHD. Based on these data, sIl-2Ra and sTNFR1 are not specifi c for skin GvHD and may be related to other organs involved in aGvHD. In contrast, serum elafi n is a suitable alternative for diagnostic biopsies for skin-aGvHD. However response to steroids cannot be predicted on the basis of Elafi n concentrations. Early intervention with second line salvage therapy should be considered in patients with low HGF concentrations. Assessing response to treatment of gastrointestinal acute graftversus-host disease (aGvHD) may be hampered by persistent diarrhea resulting from damage to the gut in the absence of ongoing aGvHD. Histological examination of gut biopsies confi rm the diagnosis but are invasive. Biomarkers may be an alternative diagnostic tool. We aimed to study biopsies and biomarkers to evaluate the response to treatment with mesenchymal stromal cells (MSC) in children. In this study, 22 patients received MSC for severe steroid refractory aGvHD of the gut (confi rmed by a biopsy in 20 patients). In 82% (n=18) diarrhea persisted after the fi rst MSC and a second (and in 3 cases a third) MSC infusion was considered. A second gut biopsy was taken from 12 patients before subsequent MSC infusion and in 8 of these biopsies no signs of active aGvHD were seen. Three patients with a positive biopsy responded to subsequent MSC infusion. Eleven patients showed a complete (CR), 6 a partial response (PR) and 5 no response at 28 days after starting MSC therapy (1-3 infusions) . In addition, previously reported biomarkers were assessed. Patient samples were longitudinally measured starting before SCT until 50 days after the last MSC infusion. At the start of aGvHD, serum concentrations of sIL-2Rα, sTNFR1, REG3α and soluble cytokeratin 18 fragment (sCK18F) were signifi cantly elevated compared with samples before onset. Response to MSC at day 28 was predicted by sIL-2Rα concentrations on day 7 post MSC. Patients with CR/PR (n=17) had lower sIL-2Rα concentrations compared to non-responders (n=5) (p=0.015). sCK18F at start of aGvHD and at initiation of MSC therapy discriminate between CR and PR/NR (p=0.01). Serum levels of sCK18F were signifi cantly raised at the day of a positive gut biopsy ( Figure 1 ). Individual results of these tests showed a wide variation in values. Conclusion: This is the fi rst report to assess the usefulness of biopsy versus biomarkers in children with aGvHD treated with MSC. Biopsy evaluation after MSC infusion eff ectively distinguishes children requiring additional MSC infusions. We confi rm that biomarkers are elevated at the onset of GvHD and although predictive of those children who responded to MSC therapy, failed to distinguish between persistent aGvHD and post infl ammatory malabsorption ( Figure 2 ). Sequential biopsies remain essential and should be included in clinical trials of experimental cellular therapy. Further study of biomarkers is warranted.

Inolimomab for children with steroid-refractory acute graftversus-host disease: a national multicentre phase II retrospective analysis M. Ouachee-Chardin (1), B. Neven (2) , L. Deville (2) , I. Hirsch (2) (4), G. Plat (5) , V. Gandemer (6) , P. Lehert (7), A. Fischer (2) (

One hundred twenty-three children were evaluated retrospectively for the treatment of steroid-refractory acute graftversus-host disease (aGVHD) with Inolimomab, a murine anti-IL2R. Hematopoietic stem cell transplantations(HSCT) were performed between 1995 and 2012. Diseases were non malignant inherited diseases (63%) and hematological malignancies (37%). Median age was 4,3 years. Donors were Matched-related (27%), Matchedunrelated (32%), Mismatched-unrelated (13%), Haplo-identical (21%) and Cord Blood (7%). The graft source was BM (80%),PBSC (12%) and CB (8%). 37% patients had a myeloablative conditioning. The median time to aGVHD was 13 days after HSCT. The baseline grade of aGVHD was I in 19%, II 46%, III 25% and IV 10%. The median delay between aGVHD and Inolimomab was 16 days. The median dose was 0.4mg/kg and the median treatment duration of 27 days. We observe 55% complete responses and 14% partial responses for a total response rate of 69% and with no side eff ects. Among the responders, 26% relapse. Incidence of infection during treatment was 19%. A logistic model on complete response provide evidence of the high predictive negative eff ect of the GVHD baseline grade [Odds Ratio(OR): 5.24]. No particular target organ was a signifi cant predictive factor for treatment response or survival. However, multi-organ involvement predicted worse survival with 34%, 45% and 52% of death for patients with one, two, and three or more organs involved, respectively (p=0.234). The observed overall survival probability was 59%, with a median survival time of 463 days. Survival was also signifi cantly improved for responders (Relative Risk: 0.413; p=0.002). As shown by multivariate Cox model, the survival was signifi cantly lower for patients with non malignant inherited diseases [Hazard Ratio (HR) =2.88, p<.001] compared with hematological malignancies, and female patients were associated with higher mortality (HR=1.72, p=.049). For both response and survival, the success rates were signifi cantly increasing with year of transplantation. Chronic GVHD (cGVHD) occurred in 56% patients, extensive in 42%. cGVHD incidence was 78%, 72%, 42% for Non Responders, Partial Responders and Complete Responders (Anova, p=.017). Patients with hematological malignancies were observed with signifi cantly less cGHVD (OR=.29, p=.012). Fifty-one patients died, 17(33%) before day 100 and 34(67%) after day 100, mostly of infections (55%) and GVHD (51%). In conclusion, Inolimomab is well tolerated and eff ective for steroid-refractory aGVHD in pediatrics.

Because of its potent immunomodulatory eff ect together with presumably high safety profi le, apoptotic cells infusion (ApoCell) was tested in addition to cyclosporine and methotrexate, as prophylaxis of graft-versus-host disease (GVHD) in HLA-matched myeloablative allogeneic bone marrow transplantation (alloBMT) from a related donor. We conducted a phase I//IIa clinical trial where we treated 13 patients (median age, 37 years; range, 20-59 years) with advanced hematologic malignancies (7 patients with ALL, 5 patients with AML (4 patients with MDS that transformed to AML and one patient with AML de novo), and 1 patient with CML that received conventional myeloablation with 35, or 70, or 140, or 210x106 cell/kg of donor ApoCell, on day -1 of transplantation. Ten serious adverse eff ects were reported with all being not related (seven) or unlikely to be related (3) to ApoCell infusion. Out of hundreds adverse eff ects, only three were reported as possibly related to ApoCell infusion (with no defi nite or probable adverse eff ects). The non-relapse mortality at day 100 and 180 after transplantation was the same, 7.7%. The overall survival at 100 and 180 days after transplantation was 92% and 85%, respectively. The incidences of acute grades II through IV GVHD for all 13 patients and for the two higher doses were 23% and 0% (six patients), respectively. Biomarker ratio levels including tumor necrosis factor receptor I (TNFR1), hepatocyte growth factor (HGF), interleukin 2 receptor α (IL-2Ra), and interleukin 7 (IL-7), supported the clinical data. These results suggest that single-infusion high-dose donor early apoptotic cells in HLA-matched myeloablative alloBMT is a safe and potentially eff ective single-agent prophylaxis of acute GVHD occurring after myeloablative alloBMT. Introduction: In allogeneic hematopoietic stem cell transplantation (HSCT), the anti-CD52 antibody Alemtuzumab is frequently used for T-cell depletion (TCD) to prevent graft versus host disease (GVHD). We demonstrated long term persistence of functionally impaired glycosylphosphatidylinositol (GPI)-anchor negative eff ector T-cells in patients receiving high dose (100mg) Alemtuzumab in combination with a dose reduced conditioning regimen (Fludarabin/Melphalan). Despite TCD, half of our patients developed acute GVHD. Since regulatory T cells (Treg) play a major role in GVHD, we asked whether GPI-anchor negative Treg are present in our patients. Methods: We analyzed peripheral blood samples of 12 patients with acute GVHD (aGVHD), 7 with chronic GVHD (cGVHD), and 10 patients without GVHD after Alemtuzumab-mediated TCD. Treg were identifi ed as CD3+CD4+CD25+ cells either FoxP3+ or CD127-and investigated according to their CD52-expression. FLAER staining confi rmed that the lack of CD52 was due to missing GPI-anchors. We analyzed the activation-markers GARP, HLA-DR and CD45RA and studied Treg populations in the time course of patients who recovered from aGVHD and those with ongoing late aGVHD. In individual patients, we isolated GPI-anchor positive and negative Treg by FACS-Sort, expanded them and performed Treg suppression assays. Results: GPI-anchor negative Treg were observed in all patients. The percentage of GPI-anchor negative Treg was signifi cantly elevated in patients with aGVHD: median 80.35% (range 56,2-96,8%) in comparison to 17,4% (range 0-57,8%) in patients with cGVHD or without GVHD. Activated Treg were exclusively detected among GPI-anchor positive Treg. Patients resolving from aGVHD restored GPI-anchor positive and activated Treg. The percentage of GPIanchor negative Treg populations remained high in patients with ongoing aGVHD and we found no activated Treg even under long term immunosuppression. First experiments with sorted Treg suggest that GPI-anchor negative Treg were unable to suppress T-cell proliferation. Summary: We demonstrated for the fi rst time the reconstitution of GPI-anchor negative Treg in patients following Alemtuzumabmediated TCD. These Treg were functionally altered and less likely to exhibit an activated phenotype. Ongoing aGVHD was associated with high percentages of GPI-anchor negative Treg suggesting that their functional alteration might play a role in aGVHD pathophysiology.

Extracorporeal photochemotherapy (ECP) as fi rst-line therapy for acute graft-versus-host disease (aGVHD) after unmanipulated haploidentical bone marrow transplantation following non-myeloablative conditioning/reduced intensity regimen (NMA/RIC) L. Morabito (1) , L. Castagna (1) 

Background: Steroids are used as front-line therapy of aGVHD, with an increased risk of infectious complications. To reduce the incidence of infections in the setting of haploidentical T-replete (TR-H) bone marrow transplantation patients developing aGVHD, we decide to perfom ECP as fi rst line therapy to treat aGVHD. Patients and methods: Since 2009, 43 received TR-H with NMA/ RIC regimens. Patient characteristics are listed in table 1. Conditioning regimens consisted of Cy, fl udarabine, and low dose TBI in 40 patients, and thiotepa, fl udarabine, Cy and low dose TBI for 6 patients. GVHD prophylaxis consisted of Cy 50 mg/kg day +3 and +4, tacrolimus and MMF, from d+5. ECP was performed using the off -line technique and started as soon as possible after aGVHD diagnosis. The ECP schedule consisted of 4 rounds of two procedures per week, 3 rounds of two procedures every other week, and fi nally 2 procedures every month until clinical improvement. Decision to discontinue ECP was made on a case-by-case basis, taking into account clinical response (including IST changes), logistical reasons, and the decision of the treating physician. Results: Grade 1-4 aGVHD was diagnosed in 13 patients (30%) and grade 2-4 aGVHD in 10 (23%). The median time to aGVHD was 52 days (d) (range 38-81). All patients had grade 2 skin aGVHD and only 1 grade 4 liver aGVHD. Three patients received steroids because of logistical problems. 7 out of 10 patients was treated by ECP alone. In 3 patients steroids therapy was administered waiting for ECP and stopped in a week. ECP was started after a median time of 3 d (range 1-30) from aGVHD diagnosis. The median number of ECP was 15 (range 9-44) and the median duration was 99 d (range 40-368). All but one patient achieved complete response, and 1 partial remission. One patient achieved partial remission. The median time to response was 14 d (range . Tolerance to ECP was good and no patients developed severe toxicities. Infectious complications after ECP were rare and no lifethreatening. Chronic GVHD was diagnosed in 2 patients (18%). 4 patients died: 1 from heart failure secondary to hemocromatosis, 2 from disease progression and 1 from aGVHD toxicity after donor lymphocyte infusions for treat relapsed disease. Conclusions: This study suggests that fi rst line ECP is eff ective and well tolerated in patients developing aGVHD after TR-H. However, these results are preliminary and have to be confi rmed in a more consistent cohort of patients.

GSTT1 mismatch constitutes a risk factor for acute and chronic hepatic GVHD and infl uences patient survival M.J. Martinez-Bravo, C. Calderón, N. Rodríguez, I. Espigado, A. Núñez-Roldán, J.A. Pérez-Simón, I 

Introduction: Glutathione S-transferase T1 (GSTT1) and GSTM1 are drug-metabolizing enzymes and are highly expressed in liver and kidney. GSTT1 is absent in 20% of the Caucasian population, while GSTM1 in 50%. In liver and renal transplantation, we have reported that GSTT1-negative patients who received a GSTT1positive graft have a higher risk to develop chronic rejection. In addition, UDP glucuronosyltransferase 2 family, polypeptide B17 (UGT2B17) catalyzes the transfer of glucuronic acid. This protein is highly expressed in liver and prostatic tissues and is absent in 12% of the Caucasian population; UGT2B17-mismatch is a risk factor for graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Objective: The aim of this study was to analyze the infl uence of these mHAs in the development of acute or chronic hepatic (h) GVHD. One hundred forty-four patients with hematologic malignancies undergoing HSCT, between 2003 and 2011 in Hospital Virgen del Rocío (Seville, Spain), were included in the study. Methods: We performed the mHAs genotyping by Polymerase Chain Reaction (PCR) of recipient DNA and their corresponding donors. Three combination groups are detailed in Table 1 . We consider mismatch the null-donor and positive-recipient combination and matched the other three possible combinations. Conclusions: In conclusion, we identify GSTT1 disparity as a risk factor to develop acute and chronic hepatic GVHD and to infl uence survival after HSCT.

Introduction: Hematopoietic stem cell transplantation (HSCT) remains the only cure for most haematological neoplasms, however the mortality rate is high (40 to 60%) and recovery is mainly limited by complications such as graft-versus-host disease (GVHD). High resolution HLA matching has improved survival in HSCT over recent years, however acute GVHD (aGVHD) still remains a serious complication. Specifi c novel diagnostic markers that would predict for the occurrence and severity of aGVHD could reduce the incidence and mortality of this disease. There is substantial evidence to indicate that the inappropriate production of cytokines and chemokines contribute to the pathogenesis of aGVHD. The aim of study was to investigate the expression of selected candidate genes in order to identify novel early diagnostic markers for GVHD which may in the future reduce the rate of mortality of this disease. Methods: In order to investigate gene expression in aGVHD we used RNA from a human skin explant assay which has been shown to predict GVHD in patient cohorts and in addition RNA from clinical aGVHD skin samples taken at the onset of aGVHD and normal skin samples. For our initial screening process we used three custom taqman low density arrays and then further validated these results. Results: Our study identifi ed four genes whose expression was signifi cantly up regulated in aGVHD skin, they were, CXC chemokine type 9 (CXCL9), transporter associated with antigen processing 1 (TAP1), leucocyte immunoglobulin like receptor type 5 (LILRA5) and ubiquitin D (UBD) (p=0.0007, 0.0174, 0.0402 and 0.0441 respectively). In addition we identifi ed three genes, complement C1Q and tumour necrosis factor-related protein 7 (C1QTNF7), interleukin 1 receptor type 2 (IL1R2) and leucocyte specifi c transcript 1 (LST1), whose expression was signifi cantly down regulated in aGVHD skin (p=0.0002, 0.0028 and 0.0138 respectively). Six of these genes CXCL9, TAP1, LILRA5, UBD, IL1R2 and LST1 are induced by IFN γ whereas C1QTNF7 is an adipokine, members of the adipokine family have been associated with the innate immune response. Conclusion: These seven genes or their protein products could potentially be used as diagnostic markers for GVHD or in predicting its severity and are currently being evaluated in independent cohorts.

Introduction: Clinical advantage of human fetal membranes cells (hFMCs) has been documented in more than 100 years ago in burns. In recent years hFMCs raised signifi cant attention as source of stromal cells and may also be of potential benefi t in regenerative medicine. We have previously shown that hFMCs suppress human lymphocyte proliferation in vitro in mixed lymphocyte culture (MLC) and may reverse graft-versus-host disease (GVHD) in vivo. Further studies have shown that suppressive function of hFMCs is dependent on cell-to-cell contact. In the present report we evaluate the suppressive function of hFMCs in xenogeneic setting to explore the underlying immunosuppressive mechanisms. Methods: Isolated hFMCs from passage 3 or 4 were used in series of ex vivo MLC and in vivo (mouse model GVHD) animal experiments. C57BL/6 and BALB/c mice, as two allogeneic strains, were used for MLC experiments as well as donor and recipient in an experimental GVHD setting. Results: Our fi ndings show that despite species diff erences, hFMCs suppress proliferation and activation of mouse lymphocytes. The immunosuppressive eff ect is not strain limited and lymphocytes from both strains were suppressed. Balb/c lymphocyte proliferation, against allogeneic (B6 lymphocyte), mitogen (Con A) and xenogeneic (human PBL) stimulation, were decreased by 75% to 80% following addition of 25% of hFMC to the culture. Similar fi nding were observed when C57BL/6 splenocyte were used as responder cells. The immunosuppressive function of hFMCs was not due to T reg cell induction or through trans-well culture setting, meaning that cell to cell contact was needed. Subsequently we applied hFMCs at diff erent time points following allogeneic bone marrow transplantation in a well-established mouse model of GVHD. The preliminary results are promising and infusion of hFMCs 3 days after allogeneic BMT increased survival of the animals. However, the hFMCs cell dose and injection time need to be optimized. Conclusion: FMCs may be a valuable source of stromal cells for GVHD. The isolated FMCs are strong immunesuppressive cells not only in allogeneic setting but also in xenogeneic systems. Further improvements regarding isolation, culture and application are needed. Introduction: Although multiple biomarkers of acute intestinal GVHD (GI-GVHD) have been identifi ed, the translation of these from the bench to the bedside remains complex. The aim of this study was to evaluate fecal calprotectin (FC) as a single biomarker for the diagnosis and follow up of GI-GVHD in adult patients with haematological malignancies who underwent allogeneic stem cell transplantation (SCT) at our center. Patients and Methods: From January 2012, 22 consecutive SCT patients had been monitored for FC (normal range: 0-50 mg/kg) with at least 2 samples/patient (range 2-13). Fecal samples were collected at 2 week intervals until day 90 from SCT or at the onset of symptoms of GI-GVHD, even after day 90. Table 1 summarizes patients' characteristics. The diagnosis of GI-GVHD was based on standard clinical criteria, together with other microbiological and histopathological tests.

Results: Seven of 22 tested patients (32%) were diagnosed with GI-GVHD. In this group FC median value was 467mg/kg (range 29-5000) at the onset of symptoms; only one of these 7 patients presented FC levels in the normal ranges at the diagnosis and during follow-up (<50mg/kg). In one of the 22 patients included in the study the clinical diagnosis of GI-GVHD was not supported by the endoscopic and histological fi ndings and in this patient, the FC median value was 60mg/kg (range 6,25-120). FC median value in all other 14/22 patients (64%) without GI-GVHD was 44mg/kg (range 6-163). For a cut-off point value of 200mg/kg, sensitivity for the test was 86%, specifi city 100%, positive predictive value 100% and negative predictive value 94%. We couldn't observe a correlation between FC levels at the onset of GVHD and severity of clinical symptoms. In fact FC median value was 728mg/kg (range: 258-5000) in patients in stage 1 GVHD compared with 467mg/kg (range: 29-3121) in patients in stage 2-4. We observed that patients achieving stable FC values under 200mg/ kg at the follow-up (in 4 of the 6 patients with abnormal FC fi ndings at the onset of GVHD -true positive) had a more favourable outcome and prognosis. Conclusion: Our data confirm that FC is specific, inexpensive, non-invasive test and easy to perform. This biomarker can improve the diagnosis of acute GI-GVHD with an optimal cutoff level of 200mg/kg. This test seems to be promising also for the evaluation of the activity of GI-GVHD during follow-up and it could be used as a potential decisional tool for anti GVHD therapy modulation.

Objective: Mesenchymal stem cells (MSCs) are multipotential cells which are capable of diff erentiating into a variety of cell types. Due to their immunomodulatory properties, MSCs have been used as cell-based therapy to reduce grafts-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). As reactivation of cytomegalovirus (CMV) constitutes a frequent problem after HSCT, we studied whether MSCs may also have an infl uence on CMV-specifi c T cell responses. Methods: For mixed lymphocyte reaction (MLR), CD8 negative peripheral blood mononuclear cells (PBMCs) from donor A were co-incubated with CD8 positive cells from donor B (APC:T cell ratio=8:1) for 6 days. MACS®-purifi ed CD8 positive T cells from buff y coats of HLA-A2/CMV seropositive healthy volunteers were stimulated with a HLA-A*0201-restricted CMVpp65 (NLVPMVATV) peptide in a mixed lymphocyte-peptide culture (MLPC). Bonemarrow derived MSCs from human platelet lysate (PL) or fetal calf serum (FCS) based medium were co-cultured with the MLR and MLPC. Flow cytometry and enzyme-linked immunospot (ELISPOT) assays were used to study the immunomodulatory eff ect of MSCs on CMV-specifi c CD8 positive T cells. Results: Both PL-and FCS-cultured MSCs inhibited the proliferation of CD8 positive T cells after stimulation with CMV pp65 peptide, and reduced the number of CMV-specifi c T cells stained with pp65-specifi c MHC-tetramer by more than 60%. Similarly, MSCs suppressed the frequency of activated CD8 positive T cells expressing CD137 and the secretion of cytokines like IFN-γ and granzyme B. In addition we confi rmed the modulatory eff ect of MSCs in MLR, as we observed inhibition of T cell proliferation. Conclusion: MSCs have strong immunosuppressive eff ects on alloreactive T cells and infusion of MSCs could be a promising immunotherapy for GVHD. However, MSCs can also inhibit CMV specifi c CD8 positive T cells. Therefore attention must be paid to early detection and pre-emptive treatment of CMV reactivation when patients are undergoing therapy with MSC. Acute GvHD (aGvHD) of the GI-tract is a severe complication after allogeneic stem cell transplantation (SCT). Since an early treatment of aGvHD is essential a rapid diff erentiation between aGvHD and infections is necessary. For the fi rst time this study describes systematically magnetic resonance imaging (MRI) fi ndings in intestinal aGvHD. Methods: Prior to conditioning 46 consecutive patients planned for allogeneic SCT underwent as baseline investigation abdominal MRI on a whole-body 3T MR-scanner. The sequence protocol included axial and coronal T2 weighted sequences, an axial diffusion weighted sequence and a dynamic T1 weighted, contrast enhanced sequence. All patients with severe GI-tract symptoms or with signs of skin aGvHD received a second MRI immediately after onset of symptoms. In addition, all patients with severe GI tract symptoms received endoscopic examination of the upper GI-tract and colon. MRI fi ndings of patients with histologically proven intestinal aGvHD (GvHD group) were compared with the results from patients with isolated aGvHD of the skin or non-GvHD related GI-tract symptoms (control group). Results: 8 patients (GvHD group) suff ered from histologically proven intestinal aGvHD. In the control group 3 patients had isolated skin aGvHD, 1 patient had CMV colitis and 4 patients experienced diarrhea without specifi c diagnosis. In all GvHD group patients a unique MRI pattern was detected: Gut involvement presented as long-segment (>20cm) bowel wall thickening with submucosal edema. Mucosal wall was signifi cantly thickened in patients with intestinal aGvHD in comparison with control group patients as well as with baseline data (mean large bowel wall thickness: baseline 0.35mm, GvHD group 0.9mm, control group 0.36mm; mean small bowel wall thickness: baseline 0.38mm, GvHD group 0.79mm, control group 0.34mm). A mucosal diff usion restriction was seen in all GvHD group patients. The perfusion of the bowel spared the submucosa while demonstrating strong mucosal perfusion: In the T1 sequence 2 minutes after gadolinium injection a 2-fold enhancement was detectable in the bowel wall of the control group. In contrast, the mean enhancement was 2.8-fold in small bowel wall segments aff ected by aGvHD. Conclusions: In intestinal aGvHD a specifi c MR-appearance with long-segment aff ection of the bowel concomitant with marked bowel wall edema, restricted mucosal diff usion, mucosal hyperemia and ascites was detected. This unique MRI pattern might allow an early non-invasive diagnosis of intestinal aGvHD. The placenta protects the developing fetus from the mother's immune system. Fetal membranes have been used for almost a century to treat severe burn injuries, indicating that these tissues can promote wound healing. We have previously found that fetal membrane cells (FMCs) isolated from term placenta prevent alloreactivity in vitro. FMCs share many features with bone marrow-derived mesenchymal stromal cells (MSCs), which we previously introduced to treat severe acute graft-versus-host disease (GVHD). Here, we tested FMCs for treatment of steroid-refractory acute GVHD. After two passages in culture, approximately 10 9 FMCs were obtained from one single placenta, although not all cells from passage 0 and passage 1 were used for expansion. The FMCs were positive for CD29, CD44, CD73, CD90, CD105, CD49d, ICAM-1, PD-L1 and PD-L2, but were negative for hematopoietic, endothelial, and epithelial markers. Microsatellite polymorphism analysis showed that FMCs were of maternal origin. All FMCs used showed normal karyotype. Nine patients who had undergone hematopoietic stem cell transplantation and who had developed steroid-refractory grade III-IV acute GVHD were given 0.9-2.8 x 106 FMCs/kg at 15 infusions. Median age was 57 years. There was no toxicity from infusion of FMCs. Two of eight evaluable patients had a complete response and four had a partial response, giving an overall response rate of 75%. Two patients showed no response at all. Three patients are alive from 6 to 21 months after HSCT. One patient is well and two have chronic GVHD.

To conclude, we have developed a protocol for generation of large quantities of stromal cells with immunosuppressive capacities that are accessible without any invasive procedures. FMCs may be successfully used for immune modulation and tissue repair. It is now widely assumed that MSCs secrete a number of immunemodulatory factors, which impair infl ammation and thus help to suppress GvHD. Exosomes are secreted cell organelles, which exert immune-modulatory properties. These small membrane vesicles are released by a huge variety of diff erent cell species, including MSC. Methods: Here, we purifi ed exosomes from bone-marrow derived MSC of four diff erent unrelated stem cell donors and compared their immune modulatory properties in vitro. Next, we administered immunosuppressive MSC-derived exosomes in escalating doses into a 22-years female patient suff ering from a severe therapy-refractory cutaneous and intestinal GvHD grade IV. We monitored the clinical eff ects on an in-hospital basis and correlated this with the levels of infl ammatory cytokines measured in the patient's plasma. Results: We show that even though all propagated MSC lines released exosomes, exosome-enriched fractions diff ered in their potential to modulate immune responses in vitro. Administration of the exosome-enriched fraction with the strongest immune suppressive in vitro eff ect into the GvHD patient was well tolerated and appeared to be safe. During the course of the exosome therapy a clear reduction of the pro-infl ammatory cytokines IL-6, IL-8 and IL-17 was observed in the patient's plasma. In line with the reduced anti-infl ammatory cytokine reaction, the clinical GvHD symptoms improved signifi cantly. The cutaneous and mucosal GvHD showed a remarkable response within two weeks which was stable even after 16 weeks following the MSC-exosome therapy ( Figure 1 ). The diarrhea volume, too, was objectively reduced after exosome therapy (before: average (avg.) 3,1 l/die, after: 1,3 S177 l/die, Figure 2 ). Due the clinical response achieved the dosage of the immunosuppressive agents -particularly of steroids -could be reduced signifi cantly (before: avg. 125 mg/d; after: 30 mg/d).

Conclusion: To our knowledge this is the fi rst attempt to deliver MSC-derived exosomes in therapy-refractory GvHD. The application was well tolerated and led to a signifi cant and sustainable decrease of GvHD symptoms. Further research is warranted, but it appears to be a promising new treatment option in the otherwise dismal situation of refractory GvHD.

The The use of third party Treg from cord blood has been reported in HSCT. This present study investigated the effi cacy of third party Treg from peripheral blood in preventing GvH tissue damage. Methods: Mixed lymphocyte reaction and an in vitro human GvHD skin explant model were used to assess the ability of third party Treg to modulate alloreactivity of CD8+ T cells and prevent cutaneous GvH tissue damage in comparison to the eff ect of Treg from donor origin i.e autologous to CD8+ T cells. Treg of third party or donor origin were identically processed using published isolation and expansion protocols. Results: Activation, proliferation and expression of skin homing markers on allo-stimulated CD8+ T cells were signifi cantly reduced in the presence of third party Treg. Activation of CD8+ T cells was measured by CD69 and CD25 expression and this was suppressed to the same extent by both allogeneic and autologous Treg. Expression of skin homing marker CLA was also reduced in the presence of autologous and allogeneic Treg with no significant diff erence between the two. CD8+ T cell proliferation was measured by 3H thymidine incorporation, both autologous and allogeneic Treg signifi cantly reduced allo-stimulated CD8 T cell proliferation. There was a trend to suggest autologous Treg prevented proliferation to a greater extent than allogeneic Treg however this was not statistically signifi cant. Secreted levels of IFNγ, measured by CBA fl ex in MLR supernatants, were signifi cantly reduced by both autologous and allogeneic Treg. Skin sections of recipient origin incubated with recipient PBMC primed donor PBMC in the absence of any Treg showed grade III tissue damage whereas in the presence of either donor or third party Treg the damage was limited to grade I, the same as medium control. Conclusions: Our data suggests that third party Treg are able to suppress cutaneous GvH reactions to the same extent as donor Treg by preventing eff ector T cell proliferation and migration into the skin. It may be feasible to use third party Treg for GvHD immunotherapy when it is diffi cult to collect Treg and HSC from the same donor.

The relationship between gut microbiota and immune system recovery in children who underwent allogeneic haematopoietic stem cell transplantation (HSCT)

Objectives: The injury of gastrointestinal tract from conditioning regimen plays a crucial role in aGVHD onset, because it leads to systemic translocation of infl ammatory stimuli that enhances activation of host antigen presenting cells. Gut microbiota (GM) exerts a key role in the development and function of the gut associated lymphoid tissue and of the innate and adaptive immune system (IS).The GM has the capacity to shape the immune response outside the intestine and to modulate a considerable range of T cell functions as Th17, Th1, Th2 and regulatory T cells. Aim of this study is to evaluate phylogenetic and functional dynamics of GM in children undergone allogeneic HSCT and its correlation with immunological recovery after HSCT and predisposition to aGVHD. Methods: Stool samples were collected before HSCT and, from the day of engraftment, every 2 weeks till 100 days after HSCT, aiming to analyze changes occurring on GM during the recovery of IS. They were screened using the HTF-MicroBi.Array, a validated LDR-based diversity microarray, that is a fast and sensitive tool, capable to a specifi c detection and approximate relative quantifi cation of 16S rRNAs covering the majority of the intestinal bacterial inhabitants and able to reliably characterize the gut microbiota architecture. Results: 5 pediatric patients (4 M) underwent allogeneic HSCT. 3 received a match related donor, 1 match unrelated and 1 mismatch unrelated. All received bone marrow; the conditioning regimen was busulphan-based in 4 and TBI-based in 1.

HSCT deeply rearranges the gut microbiota profi le, which progressively recover an healthy-like asset within 100 days from HSCT. In the 4 patients with aGVHD, the appearance of GvHD seems to temporarily compromise this recovery. Non-GvHD patient maintained a peculiar after-HSCT gut microbiota structure with high Lactobacillus abundance, coherently with Jenq et al. 2012.

Conclusions: The results of this preliminary longitudinal study suggest a link between GvHD and the trajectory of the re-building process of the symbiotic relationship between host and intestinal bacteria. More patients will be enrolled and sequencing techniques will be applied to faecal samples in order to better investigate the relationship between grade and localization of GvHD, IS recovery and intestinal microbiota dynamics. Jenq RR, al.Regulation of intestinal infl ammation by microbiota following allogenic bone marrow transplantation. JExpMed 2012:209,903-911.

Atypical cutaneous GVHD after cord blood transplantation in adult recipients R. Saccardi (1) Background: Cord Blood (CB) has been increasingly used in the last 10 years as an alternative source of haematopoietic stem cells for transplant. The incidence and severity of GVHD in HLApartially mismatched transplants has been reported to be lower than for adult donors. We report here the occurrence of skin GVHD showing atypical features at both clinical and histological level in adult recipients of unrelated CB transplants (CBT). Methods: Forty patients underwent CBT in our Institution from 12/2006 to 10/2012. Median age at HSCT was 43 yrs (range 16-66), M/F distribution was 21/19; HLA antigens matching was 4/6 (32) and 5/6 (8). A single Unit was used in 31 pts, a double in 9, with a median of of 3 TNCx10E7/Kg infused (range 1.7-6). Myeloablative/ non-myeloablative conditioning regimen ratio was 28/12. GVHD was classifi ed according to NIH guidelines. Skin biopsies were collected in case of any rush of undetermined signifi cance, fi xed in formalin, processed and stained with haematoxylin/eosin. Results: Twenty-one patients developed a GVHD at a median of 73 days after CBT (9-333). GVHD forms at onset of fi rst occurrence were acute (12), acute late onset (4), overlap (3) and chronic (2) . A second occurrence of GVHD was shown in 6 patients and a third in one, respectively, with a total of 33 GVHD episodes. In 10 episodes (30.3%) an atypical rush with erythematous-squamous patches suggestive of an eczema-like or atopic dermatitis was shown. Such an abnormal feature occurred in acute late onset (6) , chronic (2), acute (1) and overlapping (1) GVHD forms, respectively. Four out these 21 patients (2 typical and 2 atypical) died for GVHD-related reasons. In all these cases, histopathology revealed epidermal hyperplasia, spongiosis and a dermal mixed infl ammatory infi ltrate with lymphocytes and eosinophils, in some cases associated with folliculitis. There was no evidence of the typical apoptotic or fi brotic tissue damage commonly associated to GVHD, therefore confi rming the clinical evidence. Conclusions: Improving diagnosis and treatment of GHVD in CB recipients is crucial for the outcome of this increasingly used procedure. We report unusual eczema-like eruptions in CB recipients.

Although the signifi cance of such observation is still unclear, we suggest that they represent atypical, eczema-like GVHD rashes.

Prospective clinical and immunological studies are needed for a better understanding of these unusual features, which may lead to GVHD underdiagnosis.

A prospective phase II trial: the combination of tacrolimus and rabbit anti-thymocyte globulin (Thymoglobulin® Thymo) to prevent acute graft-versus-host disease in patients receiving HLA-matched related haematopoietic stem cell transplantation (1) (

Background: Acute graft versus host disease (aGVHD) continues to be a cause for signifi cant morbidity and mortality in patients undergoing HLA matched related (MR) hematopoietic stem cell transplantation (HSCT). Common pharmacologic methods for the prevention of aGVHD usually include a calcinuein inhibitor and either methotrexate or mycophenolic acid. These combinations although eff ective may lead to mucositis, delayed engraftment as well as GI toxicity. Recently we have shown that Thymoglobulin (Thymo) may be added to immunsuppresive regimens with acceptable toxicity and low incidence of both acute and chronic GVHD.

Methods: This is a Phase II trial investigating the effi cacy of tacrolimus (Tac) and Thymo for the prevention of GVHD. Thymo was given as 4.5 mg/kg divided doses on days -1,-2, and -3 in combination with Tac. The primary end point was cumulative incidence of grade II-IV aGVHD. Secondary end points were: median day of engraftment, chronic GVHD, non-relapse mortality (NRM), relapse, overall and progression free survival (OS & PFS) using Kaplan-Meier. Results: Between January 2011 and June of 2012, 21 patients (pts) were enrolled. The Median follow-up time is 13.3 months (95% CI 6.8 -19.0 months). All pts received peripheral blood stem cells from HLA 8/8 matched sibling donor, and daily G-CSF starting day +6 till engraftment .Patient characteristics are described in Table 1 . Cumulative incidence of grade II-IV aGVHD at 12 months posttransplant was 33% (CI 14 -54%). Incidence of Grade III-IV aGVHD was 9.5% (1.5% -26.6%), (3 grade I, 5 grade II, and 2 grade IV). Median day of aGVHD was 26 (range17-82). Median day of engraftment was 11 (range 7-11). Incidence of cGVHD was 38% (CI 15 -61%), ( 2 Grade I, 1 grade II, and 6 grade III). Incidence of NRM at 21 months was 15% (CI 3 -33%). The incidence of relapse at 21 months was 26% (CI 7 -52%). Median PFS and OS have not been reached. PFS and OS was 62% and 74% at 1 year respectively. Five deaths occurred due to: relapse (2), aGVHD(1), cGVHD (1), and cardiac arrest (1) . Four patients experienced disease relapse, with only one Pt relapsed before day 100 (31-397). There were 5 cases of CMV by PCR (24%), 3 EBV by PCR (14%), 3 HSV (14%), 4 BK cystitis (19%), 11 bacterial infections (52%), and 4 cases of oral candidiasis (19%).

Conclusion: These early results suggest that the combination of Thymo, and Tac in pts undergoing MR HSCT is well tolerated and associated with encouraging rate and severity of acute GVHD. Introduction: In reduced intensity cord blood transplantation (CBT) post transplant immune disorders, including early immune reactions (PIR) and acute GVHD, are potential complications following CBT in adult patients. Such reactions might increase the risk of organ dysfunction, leading to high rates of transplantationrelated mortality, particularly in patients who do not respond to primary therapy, which usually consists of steroids. Infl iximab, a chimeric monoclonal antibody against tumor necrosis factor α, has shown activity against steroid refractory acute GVHD. Patients and Methods: We retrospectively reviewed 275 patients who underwent single-unit reduced intensity cord blood transplantation consecutively from November 2007 to June 2011 at Toranomon Hospital. Patients who were in poor performance status (ECOG PS >3), had active bacterial or fungal infections at the time of conditioning were excluded. The most frequently used conditioning regimens were fl udarabine, alkylating agent (melphalan or busulfan) with total body irradination (TBI), tacrolimus plus mycophenolate mofetil for GVHD prophylaxis. Patients in whom acute GVHD developed received methylpredonisolone 1-2 mg/kg per day. If no partial or complete resolution of symptoms occurred, they were considered steroid-refractory and proceeded to infl iximab treatment. The dose of infl iximab was 5 mg/kg/day once weekly for at least 1 course. Results: 54 patients among this group developed steroid refractory acute GVHD. Of these, 21 who received infl iximab were analyzed. GVHD prophylaxis was with only tacrolimus(n=15) and mycophenolate mofetil+tacrolimus(n=6). All of them developed grade III to IV GVHD. Median follow-up time of survivors was 548 days (range, 222-1152). The overall response rate was 62% (n=13), and 9 patients (43%) experienced complete response (CR). 5 patients (24%) did not respond and 3 (14%) had progressive GVHD. Overall survival (OS) was estimated as 31% at 2years post-treatment. Four patients who responded subsequently died, one of exacerbation of GVHD, three of infections. All the 8 unresponsive patients died of GVHD. Five patients (21%) had non-Candida invasive fungal infections. Sixteen patients(79%) had bacterial infections. Conclusion: Infl iximab was well tolerated and active for the treatment of steroid-resistant acute GVHD even following re-duced intensity cord blood transplantation. However, it is associated with a high rate of infections.

Elevated plasma level of thrombomodulin early after allogeneic haematopoietic stem cell transplantation is associated with severe acute GVHD and increased risk of non-relapse mortality. (1), H. Hashimoto (2) , N. Shimizu (3) Objective: Citrulline is an amino acid produced by enterocytes of the small intestine and serum citrulline concentration has been proposed as a marker of enterocytes mass and function. Our study was focused on evaluation of the feasibility of citrulline levels in patients after allogeneic stem cell transplantation in relation to intestinal form of graft-versus-host disease (GvHD Citrulline levels are very low shortly after allogeneic stem cell transplantation with the myeloablative conditioning due to the toxic intestinal damage. Signifi cantly low levels of citrulline were observed also in patients suff ering with intestinal form of GvHD later on. Other observations in larger groups of patients are necessary before any specifi c recommendation for citrulline levels monitoring in intestinal GvHD can be made.

Background: The carcinoembryonic antigen (CEA) family is involved in intercellular binding interactions that aff ect various normal and pathogenic processes associated with cellular growth and diff erentiation. In human, the CEA family are subdivided into the CEA-related cell-adhesion molecules (CEACAMs) and the pregnancy-specifi c glycoproteins (PSGs). Never before the infl uence of CEACAMs on patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) was evaluated.

Methods: Here we analyzed in a retrospective study 33 patients (pts) for CEACAMs expression that underwent allogeneic HSCT for various diseases and analyzed their outcome. CEACAMs expressions were performed by fl ow cytometry and ELISA in whole blood, serum and urine samples. Results: We report the analysis of 19 pts with acute leukemia (58%), 5 pts with chronic leukemia (15%), 4 pts with MDS (12%) and 5 pts with advanced NHL (15%). The median age at transplant was 50.5 (range, 18-69) years. In this cohort 12 pts received grafts from HLA-identical siblings (36%), 16 pts from matched (49%) and 5 pts from mismatched (15%) unrelated donors. Transplantat consisted of unmanipulated peripheral blood stem cells (n=26, 79%) or bone marrow (n=7, 21%). Of all pts, 7 (21%) had relapsed after transplant. Among these pts, 31 (94%) developed acute GVHD (21 pts had an acute GvHD of grade ≥ 2). There was no signifi cant correlation between CEACAMs expression after transplant between the variant leukemic disorders in the whole blood and the urine samples. Analysis of each CEACAMs for relapse showed no statistically diff erences. For CEACAM-6, we found a moderate up-regulation in pts with acute GvHD ≥ 2 versus acute GvHD <2 (p<0.1). In pts with severe acute GVHD (grade >3) comparing all other pts, we found signifi cant induction of CEACAM-1 (118.5 ng/ml vs. 198.3 ng/ml, p<0.05) in urine samples and CEACAM-1 (109.2 vs. 157.5 ng/ml, p<0.04) in serum samples. However, no statistic diff erences were found in the CEACAM-1 in regards to chronic GVHD. Conclusions: These results suggest that pts with high levels of CEACAM-1 confi rms a relevant association of the development of acute GVHD and CEACAM profi ling could be an early indicator of severe acute GvHD. Steroid refractory graft versus host disease (GVHD), is one of the major causes of morbidity and mortality after allogeneic peripheral stem cell transplantation(ASCT). The role of mesanchymal stem cell transplantation (MSCT) has been demonstrated in the treatment of steroid refractory acute GVHD. The effi cacy of MSCT in chronic GVHD has been reported in a limited number studies including only few number of patients.We aimed to revise our MSCT results and evaluate its feasibilty and effi cacy. We retrospectively evaluated eight patients who had steroid refractory acute and chronic GVHD after ASCT in Ankara Oncology

Hospital transplantation unit between 2009-2012. The demographic features and transplantation details of the study cohort were summarized in Table 1 . Mesanchymal stem cell transplantation was performed after failure of 3 or 4 lines of GVHD treatment with consent from regulatory authorities of our country. Organ involvement and grades of GVHD were summarized in Table 2 .

Mesanchymal stem cells were expanded from either HLA identical donors or third party. All but one patient had only one mesanchymal stem cell infusion.

Median infused mesancyhmal stem cell number was 1,38 (1, (1) (2) (3) (4) (5) x10e6/kg. Median follow up was 8.5 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) months. In patients who had mesancyhmal stem cell transplantation for steroid refractory acute GVHD, overall response rate was 100%( 4/5,80% CR+1/5,20% PR). In chronic GVHD group,two out of three(67%) patients had partial remission. All of our patients are alive and maintain their response status.

Most of the studies with MSCT has been performed in patients with steroid refractory acute GVHD. Although our patient numbers were low, our results were comparable with the response rates in the previous studies. MSCT seems to be a feasible option for steroid refractory chronic GVHD. Introduction: Graft Versus Host Disease (GvHD) is a major cause of morbidity and mortality after allogeneic haematopoietic stem cell transplantation (AHSCT). Patient and methods: A total of 100 patients who underwent AHCST in University of Erciyes, Faculty of Medicine, Haematopoietic Stem Cell Transplantation Unit were investigated, retrospectively. All transplantation procedures were performed from fullmatch donor and Seattle regimen was used for GvHD prevention. The frequency of acute GVHD (aGVHD) and factors related with development of aGvHD including recipient age, donor age, recipient gender, donor gender, recipient-donor gender match, blood group compatibility, amount of CD34+ given and conditioning regimen were investigated. Results: The diagnosis of the patients were as follows: acute leukemia in 67 patients (%69,1), aplastic anemia in 7(%7,2), non-Hodgkin lymphoma in 6(%6,2), other diseases in 17(%17,5) (Hodgkin lyphoma, myelofi brosis, myelodysplastic syndrome, chronic myelogenous leukemia, chronic lymphocytic leukemia, paroxysmal nocturnal hemoglobinuria). 36 of patients were female (%36) and 64 patients were male (%64). 57 (%58,8) of patients were given non containing total body irradiation (TBI) conditioning regimen, 40(%41,2) of patients were given total body irradiation (TBI). The median age of 100 patients was found 33,3 years (±11,04). The frequency of aGvHD was %23,7 (23 patient We have recently shown in a single centre prospective study that that in vivo low-dose alemtuzumab (≤ 20 mg total dose) during conditioning combined with only CsA post-transplant may efficiently prevent severe acute and chronic GVHD after sibling and matched unrelated PBSCT for acute leukemia (BMT 2011; 46: 1363 -1368 . In contrast, a multicenter de-escalation prospective British study (Blood 2010; 116: 3080-3088) in patients with various diagnoses suggested that the minimum dose of alemtuzumab in sibling HCT for effi cient GvHD prophylaxis should be 30mg. Probably this conclusion does not apply to patients with acute leukemia, as all patients in the British study who experienced II-IV acute GvHD in the 20mg alemtuzumab dose had a CD52-expressing tumor at the time of transplantation. Here, we update our experience of low dose alemtuzumab as GvHD prophylaxis in 60 consecutive patients (pts). Thirty-two pts were transplanted for AML, 20 for ALL, 2 with biphenotypic leukemia, 1 with untreated MDS RAEB-2, 1 with blast crisis CML (T315I+ mutation), 2 with AA, 1 with PNH and 1 with NHL. 73% of the pts had high risk diseases. Twenty-six patients were transplanted from sibling donors (43%), 33 patients from VUD (55%) and 1 patient from a matched related donor (2%). All pts but 2 received peripheral blood stem cells. The fi rst 10 pts received a total dose of 20 mg alemtuzumab pre-transplant, the next 6 pts a total dose of 15 mg and thereafter 39 pts received a total dose of 10 mg. Overall, 18 (32%) out of 57 evaluable pts developed acute GvHD I-IV. Severe acute GvHD (grade III-IV) was observed in 5 pts (9%) after a median of 32 days (range, 13-95). All pts, but two responded to corticosteroid therapy (88%). There was no signifi cant diff erence in the aGvHD incidence between sibling and VUD pts. Chronic GvHD was observed in 14 (26%) pts at median on day 159 (120-318). cGVHD was limited in 12/14 pts cGvHD, extensive in 2/14pts, mild in 3/14, moderate in 9/14 and severe in 2/14 pts. Only 2 pts are still receiving immunosuppresion for cGvHD. After a median follow up of 529 days (range 4-1826), 38 out of 60 pts are alive (63%), and 22 (37%) died (TRM n=12, Relapse n=10). The estimated 1-and 2-year OS probability for all pts is 79% ±5.3% and 62% ± 6.9%, respectively. In conclusion, in vivo low dose Campath (≤ 20 mg total dose) confers an effi cient GvHD prophylaxis in patients with acute leukemia.

A. Spyridonidis, P. Muranski, S. Kerkar, K. Tanimoto, N. Hensel,

Though adoptive therapy with viral specifi c T-cells has proven safe and eff ective for both prevention and treatment of post-transplant viral reactivation, improved strategies are still needed to increase the general applicability of this approach. We tested a simplifi ed rapid strategy of the generation of a single product of CD4+ and CD8+ cytotoxic T-lymphocytes (CTL) lines recognizing cytomegalovirus (CMV), Epstein-Barr-(EBV), Adeno-(Ad) and BK-virus. Dendritic cells derived from elutriated monocytes were pulsed with overlapping 15mer pepmixes spanning CMV-pp65 and IE-1; EBV-LMP2, BZLF1 and EBNA1; Adv-Penton, Hexon; BKV-LT, ST and VP1 alone or in combination (Mix) and subsequently were co-cultured with autologous lymphocytes obtained from the initial elutriation in presence of IL-7, IL-15, and low dose IL-2. For detection of antigen specifi c CTLs, cells were stimulated with test pepmix or control superantigen in the presence of Brefeldin A, anti-CD28 and CD49d, washed, stained for T-cell subset markers and then permeabilized and intracellular-stained for IFNγ, TNFα, IL-2, CD107a. Quadrivirus-specifi c IFN-γ-producing CD4+ and CD8+ CTLs were successfully induced in all 12 donors (CD4+ 5.8±6.8%, CD8+ 7.3±7.9%). Induction of reactivity in cultures containing individual pepmixes was comparable with results from the cultures containing combination of all studied peptide libraries, supporting the feasibility of developing of a quadrivirus-specifi c product in a single mixed culture. Two rounds of expansion resulted in signifi cant increase in frequency of CD8+ antigen-specifi c cells, while there was no change in reactivity of CD4+ cells. The predominant specifi city was against CMV in CMV-seropositive donors (n=6; CD3+:8.7±8%, CD4+:3.6±5.9%, CD8+:5.1±3.6%). Signifi cant CMV-reactivity of CTLs was also induced in CMV-seronegative donors (n=6; CD3+:1.6±1%, CD4+:1.2±0.7%, CD8+:0.4±0.3%). The expanded T cells retained predominantly naïve or central memory phenotype and only a small subset demonstrated undesirable markers of terminal diff erentiation or senescence. Furthermore, the anti-viral cells were polyfunctional, as evidenced by simultaneous production with IFNg of TNF-α and (to a lesser degree) IL-2. In conclusion, we demonstrate a simple, rapid (9 days) GMPcompatible methodology to generate a single preparation of polyclonal CTLs specifi c for four viruses that are frequent causes of post-transplant mortality or morbidity. A 28 year old patient presented with chronic myeloid leukaemia (CML) in chronic phase at our unit. The patient was 9 weeks pregnant and this posed several treatment problems, the most challenging being that the use of chemotherapeutic agents could cause signifi cant damage to the unborn fetus. At presentation full blood count results showed WBC 213x10 9 /L, Hemoglobin 9.6 g/dL and platelets 907x10 9 /L. A clinical decision was made to manage the patient with leucopheresis twice a week and daily aspirin during the fi rst trimester of her pregnancy. The leucodepletion procedures were performed using the Spectra Optia™ Apheresis System with the recently released WBC Depletion protocol.

Results: Over the course of treatment, the patient's WBC shows a stepwise decline; the WBC in the patient fell from 211.7x x10 9 /L at the start of the fi rst procedure to 41.4 x10 9 /L at the end of the treatment course. Results are illustrated below.

Average WBC collection effi ciency of 15% (3% -24%) and average percentage leucodepletion of 28% (17% -35%) were not particularly high, which would refl ect a more conservative approach to the management of this patient during her fi rst trimester. Over the course of treatment, the platelet count reduced from 927x10 9 / L to 449x10 9 /L and the average platelet depletion was 30.2%. Non-desired cellular loss was acceptable and relatively constant in each procedure with an average red blood cell loss to the product of 2.8%. The fl uid balance was maintained automatically at or near to the 100% mark and there were no complications in all the procedures. Conclusion: We conclude that treating the patient with leucodepletions using the Spectra Optia™ Apheresis System during the fi rst trimester of pregnancy was the correct choice of treatment. At 12 weeks of gestation, the patient was commenced on Interferon (3 million units subcutaneously three times a week). A healthy baby was delivered at term and was breastfed for 8 weeks.

The patient continues to be in chronic phase and was started on Nilotinib 8 weeks post delivery. Objective: Mobilization of hematopoietic stem cell (HSCs) can be achieved either by the combination of chemotherapy plus growth factors or by the growth factors alone. However there is no consensus concerning the dose of growth factor alone that should be administered, with ranges varying from 5 μg to 16 μg / kg body weight. In this context, we report our experience in mobilization of HSCs, using growth factor alone at the dose of 15 μg /kg in MM, Hodgkin's lymphoma (HL) and non-Hodgkin lymphoma (NHL). Patients and methods: A total of 122 ASCT were performed in our center, from May 2009 to July 31st 2012. This concerned 88 patients with MM, 30 with HL and 4 others with NHL. Mobilization started with G-CSF alone (fi lgrastim) at the dose of 15μg/kg/daily subcutaneously for 5 days. Apheresis was performed at day-2 and day-1 using a device type Spectra Optia CMN, and the CD34+ count was assessed by fl ow cytometry. Failure of mobilization was defi ned as a level of CD34+ lower than 2.106/kg, after two leukapheresis. In our study, patients were divided into three groups: optimal (>5.0 × 106 CD34+cells/kg), suboptimal (2.0-5.0 × 106 CD34+cells/kg) and poor (<2.0 × 106 CD34+ cells/kg) mobilization groups. Results: The average number of apheresis was 1 and that of CD34+ was 3.48x106/kg in MM and 3.60x106/kg in HL and NHL. Failure of mobilization represented 6 cases (5%) of the 122 ASCT done.The most adverse events were, bone pain and headache were reported for 49% and 25% patients, respectively, fever in 25% and asthenia in 18%.Conclusion:Our study show an overall success rate of 96% over a total of 163 leukapheresis done. The use of growth factor alone at a dose of 15μg/kg/day allows a high level of CD34 + cells with suboptimal stem cell collection (75%) and a very low failure rate (5%) without severely adverse events and very acceptable results of engrafment.

Objectives: Determination of the number of viable CD34+ cells is important for clinical decision-making in stem cell transplantation. Flow Cytometry (FCM) is standardly used for enumeration of hematopoietic stem cell levels in bone marrow, cord blood, peripheral blood, and apheresis products. As the dead cells and debris can disturb the correct interpretation of the FCM results, the apoptotic cells should also be excluded from the viable cell determination. A cell membrane permeability marker, 7-Aminoactinomycine D (7-AAD), is currently used as a standard DNA intercalating dye to determine the amount of dead and early apoptotic stem cells by FCM. However, these cells are more diffi cult to identify due to the low intensity of 7-AAD in them. Furthermore, 7-AAD can nonspecifi cally bind to cells and increase as such the number of non-viable cells. DRAQ7 (Biostatus, Shepshed, UK) is a novel more intense staining viability probe fl uorescing in the farred that does not enter intact cells but when the membrane integrity is compromised, it enters and binds readily to nuclear DNA to report cell death, reducing the potential for false-positives. Methods: DRAQ7 and 7-AAD were both tested in the ISHAGE protocol with and without Syto16 (an inert probe which does not interfere with cell viability) to provide detailed characterization and tracking of cell death. Fresh and cryopreserved Hematopoietic Progenitor Cells (HPC) from Apheresis (HPC-A) were analysed on a Beckman Coulter Navios fl ow cytometer using CD34 and CD45 monoclonal antibodies. The number and the pattern of viable, apoptotic and dead stem cells staining defi ned by both dyes were compared. Results: Our results show a better staining of apoptotic stem cells by DRAQ7. Furthermore, we found signifi cant more (2.2 fold higher, P<0.05, n=6) dead Syto16low/-/7-AAD+ stem cells with a median frequency of 28% (range 2-37%) than dead Syto16low/-/DRAQ7+ stem cells with a median frequency of 13% (range 1-15%). Conclusion: The preliminary data demonstrate that 7-AAD causes more apoptosis compared with DRAQ7 in the same stem cell samples. These results suggest that DRAQ7 is a more suitable viability dye to determine the correct amount of existing dead and apoptotic stem cells and therefore should be incorporated in FCM research and clinical protocols, especially in the CD34+ stem cell enumeration assay.

The cord blood unit (CBU) is an important source of stem cells to reconstitute the hematopoietic system after transplantation in patients with onco-hematologic diseases. The limited number of progenitor stem cells present in CBU compared to other sources of stem cells requires a strict control of all procedures necessary for its therapeutic use from collection to transplantation. During the process of cryopreservation cells structures are subjected to thermal shock, which could alter the functional capacity of the cells. Before CBU's release to Transplant Centers for transplantation, it is mandatory to perform quality controls (QC) on CBU's satellite samples. Calabria Cord Blood Bank (CCBB) performed a validation study to assess and confi rm the reliability of CQ results of satellite samples compared with CQ results of related CBU. We used n. 10 CBU not eligible to be banked and released for transplantation. CBU and related satellite samples have been stored in liquid nitrogen, then were thawed and washed. The following CQ were performed and determined: number and viability of total nucleated cells, mononucleated cells, CD34+ cells, colony-forming cell growth. The viability after thawing and washing was assessed by fl ow cytometry with 7-AAD and also viability of total nucleated cells was assessed by trypan blue.

The results are presented as mean ± SD; additionally the linear correlation coeffi cient (R2) and P(value) were determined. Paired T test was used to asses diff erences between CBU and satellite samples.

There was no signifi cant diff erence between CBU and satellite sample's results for all parameters assessed. In conclusion, our validation study showed that satellite samples predict the total cell content and functionality of the CBU. These results confi rm that CQ performed on satellite samples before the CBU's release for transplantation are a reliable method to verify the CBU cell content.

Used bone marrow fi lters can be a source of suffi cient number of expanded human mesenchymal stromal cells C. Barkats, I. Resnick Hadassah University Medical Center (Jerusalem, IL) Background: Bone marrow (BM) derived human mesenchymal stem cells (hMSC) have a growing number of indications for clinical use. BM donation is problematic for a non-conventional treatment, and as such the possibility to use a side product of BM harvesting -used bone marrow fi lters was re-evaluated. According to current knowledge, there is a single publication which characterized BM fi lters as a poor source of hMSC for clinical use [Sundin et al., 2008] . Materials and methods:Six fi lters for MSC expansion were used. Filters from BM harvesting sets were collected from operating room in sterile normal saline. Cells from fi lters were counted, re-suspended in specifi c medium for MSC (DMEM Low Glucose with 15% Fetal Bovine Serum (FBS), 1% Penicillin-Streptomycin-Nystatin and 1% Glutamine), then seeded in 75 cm2 fl ask (8*10 6 cells per fl ask in total volume of 20ml). The medium was changed twice weekly until confl uency. Cultures were washed with phosphate buff ered saline and then trypsinized, washed again and resuspended for a fi rst passage in 182 cm2 fl asks (1.5*10 6 cells per fl ask in a total volume of 35 ml). Results: From each fi lter 80*10 6 to 150*10 6 MSC were received in total after one passage. During simultaneous MSC expansion from the same BM samples (n=2), fi lters showed similar or superior kinetics growing velocity ( Figure) . Immunophenotype from both fi lters and bone marrow derived hMSC was similar (CD90+CD73+HLA-ABC+CD105+ and CD45-CD3-HLA-DR-). There were no cases of microbial contamination. Filter derived products were used for the treatment of 5 patients with acute graft versus host disease. Conclusion: hMSC can be successfully extracted and expanded from BM fi lters trapped material which are normally discarded. (3):238-42.

Separation of lymphocyte populations from peripheral blood progenitor cell products using a novel microchip based acoustophoretic platform A. Jamal (1) Objective: Processing of peripheral blood progenitor cells (PBPC) for clinical transplantation or research applications aims to effectively select or deplete specific cell populations. Usually, fluorescence-or magnetically-based sorting techniques are used for PBPC processing. Here, we investigated the performance of a novel microchip-based ´acoustophoresis´ technique, utilizing ultrasound for the separation of lymphocyte subsets from PBPC. By applying an acoustic standing wave field on to a continuously flowing cell suspension in a micro channel, cells can be separated depending on their physical properties, such as size and density. Methods: PBPC samples were obtained from patients (n= 16) and healthy donors (n=6). Following density gradient centrifugation, cells were labelled with either anti-CD4 or anti-CD8 microbeads (Dynal) and sorted on an acoustophoresis-microchip. In parallel, control magnetic sorting was performed. PBPC samples, target and waste fractions were analysed for separation effi ciency, recovery, T-cell function and progenitor cell content. Results: The mean separation efficiency of CD4+ lymphocytes to the target fraction was 87 ± 7% with acoustophoresis compared to 95 ± 8% for control magnetic sorting (n=19). Viability of sorted cells was 95 ± 4% (acoustic) and 97 ± 3% (magnetic). Following further technical improvement of the chip, purities obtained with acoustic sorting of CD8+ lymphocytes were 96 ± 3% compared to 93 ± 4% for magnetic sorting (n=3). The median recovery of acoustically selected lymphocytes was the 57%. Leukocyte subpopulation analysis performed after CD4 selection showed a relative increase of CD8, CD19, CD34, CD56, CD14 cells in the nontarget fractions. These changes were due to the removal of CD4 cells and found to be within the expected range. Functional testing of sorted CD4+ cells showed unimpaired mitogen-induced proliferation capacity as well as cytokine production. Results from hematopoietic progenitor cell assays indicated a preserved colony-forming ability post-sorting of non-target cells.

Conclusion: The acoustophoresis technique can be utilized to effi ciently sort bead-labelled lymphocyte populations from PBPC samples with high purity and recovery without impairing lymphocyte function. Acoustophoresis is, thus, an interesting technology for PBPC processing, which has furthermore the potential to off er a single platform technique for multi-parameter cell separation. Haematopoietic Stem Cells Transplantation (HSCT). The graft is usually thawed bedside and shortly reinfused without any manipulation. Infusion-related toxicity is usually mild, although severe reactions have been reported. Washing the product after thawing would allow an easier management of the infusion and of the logistics, due to the prolonged stabilization of the graft. We report here the validation of a fully automated washing method through an international, prospective, multicenter trial. Methods: Forty-three patients undergoing autologous HSCT according to local protocol were enrolled in 4 European Centers (Florence, Murcia, Marseille and Basel), following a pre-clinical study aimed to validate the procedure. PBSC were thawed and washed before infusion with the SmartWash™ program on Sepax2® (Biosafe, Switzerland). Standard lab parameters were collected before and after washing. Clinical outcome was prospectively assessed by infusion-related adverse events scoring and engraftment parameter. Results: All the washing procedures were completed without any laboratory problems in the participating centers. The additional active manpower, as compared to the unmanipulated infusion, was around 12 mins/bag. After washing, the mean (SD) recovery of viable CD34+ cells was 73.9% (21,8) with reference to the frozen product. In no cases any loss of viable CD34+ cells was reported during the washing procedure. Inter-laboratory variability showed no statistical difference in CD34+ recovery even though cellular composition of the apheresis was heterogeneous.The infusion-related toxicity was negligible (1 grade 1 out of 43 patients, according to CTC-NCI scoring system) and all patients achieved a sustained engraftment: median day of recovery of neutrophils >500x10 9 /L and platelets >20x10 12 /L was: 9 (12-18) and 12 (7-30), respectively. No significant differences in engraftment kinetic were shown across the participating centers.

Conclusions: The SmartWash protocol on Sepax® 2 is an effi cient and safe automated method to wash thawed PBSC grafts in a closed, clinical-grade system. The washed product is stable and clinically feasible for several hours after thawing. Benefi ts for clinical staff s include a lower frequency of infusion-associated adverse events as well as a reduced burden as compared to management of thawed products at the bedside.

Introduction: In 2008, biosimilar G-CSF XM02 (Ratiograstim®, Tevagrastim®, Biograstim®) has been fully approved for all indications of the reference fi lgrastim (Neupogen®) on the basis of extrapolation. This extrapolation raised questions in the EBMT on the effi cacy and safety of biosimilar G-CSF for stem cell mobilization. In a recent review by Shaw EB et al. (Haematologica 2011; 96:942-7) , the World Marrow Donor Association (WMDA) recommends biosimilars not be used for mobilization unless the donor is followed on a study. Only after collection of comprehensive data G-CSF biosimilars could be considered routinely. Here, we performed a meta-analysis on the subject. Methods: The databases PUBMED and Google Scholar were consulted for full papers, the EBMT 2012 Abstract Book for abstracts regarding the mobilization of stem cells with biosimilars. Results: Our own group (Onkologie 2011; 34(S6):280 (P926); full BMT paper in press) used biosimilar G-CSF XM02 vs. reference G-CSF (Neupogen®) to mobilize stem cells in 22 healthy donors.

Harvest of CD34+ cells, composition of graft, number of leukapheresis procedures as well as engraftment was similar to a control group mobilized with Neupogen®. Frequency and grade of usual side eff ects like bone pain was comparable to the control group. All patients engrafted in time (median d+16). Hitherto, there are 19 reports on mobilization of autologous stem cells in S185 patients with multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). In 213 patients with MM, 205 patients with NHL and 32 patients with HD, autologous stem cells were mobilized using biosimilar G-CSF XM02. Again, harvest of CD34+ cells, composition of graft, number of leukapheresis procedures as well as engraftment was similar to in a control. Frequency and grade of usual side eff ects was as in the control group. All patients engrafted. Detailed information will be displayed in the conference. Conclusion: Mobilization of stem cells in the allogeneic as well as the autologous setting has been performed in 11 healthy donors as well as in 450 patients with myeloma and lymphoma. Harvest of stem cells as engraftment was successful and within the range of expectation from the experience with the reference G-CSF. No unex-pected side eff ects were observed, neither at the time of the mobilization nor during follow-up. So far no observation has been made which opposes the use of biosimilar in the mobilization of autologous and allogeneic grafts.

Multiple myeloma patients mobilizing poorly with G-CSF achieve a signifi cantly higher haematopoietic stem cell harvest with additional administration of plerixafor Introduction: About 10% of multiple myeloma (MM) patients are considered to be "poor mobilizers" with a CD34+ cell count ≤ 20/ μl in the peripheral blood after chemotherapy and stimulation with granulocyte colony-stimulating factor (G-CSF). Addition of the CXCR-4 inhibitor plerixafor (Mozobil®) might increase the efficiency of CD34+ stem cell harvest with even fewer leukapheresis procedures needed. Here we retrospectively analyzed data from multiple myeloma (MM) patients at our institution to evaluate the eff ect of plerixafor in this setting. Methods: Twenty-two MM patients were mobilized with or without chemomobilization and G-CSF. Patients received plerixafor after fi rst or second mobilization due to low CD34+ cell count in peripheral blood (PB) or poor yield of collection. A median amount of 6.60 (3.33-11.54) μg/kg BW G-CSF and 0.25 (0.16-0.41) mg/kg BW plerixafor was applied. One to four leukapheresis procedures were performed. Results: Patients were categorized into two groups according to their CD34+ stem cell count in PB : group A ≤ 20/μl and group B >20/μl. Group A harvested 3.84 (0.29-9.43)×10E6/kg BW CD34+ cells, group B 8.18 (5.5-14.34 -4) . A minimum cell yield ≥ 2x10E6 CD34+cells/kg BW was harvested in 11/12 patients in group A and 10/10 patients in group B. Conclusion: Mobilization of hematopoietic stem cells with additional plerixafor was well tolerated. The median hematopoietic stem cell harvest in group A (≤ 20 CD34+ cells/μl PB) was signifi cantly higher after additional mobilization with plerixafor. Our results provide safety and effi cacy data for the use of plerixafor in patients who are considered to be poor mobilizers. As several previous studies demonstrated that in poor mobilizers a suffi cient stem cell number cannot be harvested, the use of plerixafor should be upfront considered in this subgroup of patients. Even in patients with a CD34+ cell count > 20/μl in PB (group B), addition of plerixafor signifi cantly increased the consecutive stem cell harvest. Fewer leukapheresis procedures were needed with plerixafor to reach the requested amount of stem cells. HLA-haploidentical stem cell transplantation (HSCT) may be complicated by high rates of graft failure and severe GVHD due to strong bidirectional alloreactivity. High-dose Cy, when administered in a narrow window after HSCT has been shown to attenuate GVHD and facilitate engraftment by eliminating alloreactive T cells while sparing quiescent hematopoietic stem cells, far more resistant to cytotoxic chemotherapy. Aim of the study: to evaluate safety and effi cacy of post-transplant Cy after T cell-replete marrow HLA-haploidentical HSCT for advanced hematological malignancies. Methods: between April 2010 and August 2012, 25 patients with hematologic malignancies (n=21 AML/MDS; n=2 LMC; n=2 lymphomas) have been enrolled, the majority (60%) of whom were in advanced phase of disease (n=13 relapse/refractory; n=2 accelerated phase/blast crisis) at the time of transplant. Seven patients had received a previous allogeneic HSCT. Thirteen patients received a tandem approach consisting of de-bulking high dose chemotherapy followed by the conditioning regimen and HLA-haploidentical marrow infusion. Patients received either a reduced-intensity conditioning including fl udarabine-Cy and single dose 200 cGy TBI (9 patients), or a myeloablative regimen consisting of thiotepa-fl udarabine and i.v. busulphan (15 patients) or thiotepa-fl udarabine-melphalan (1 patient), followed by T-cell replete bone marrow. Postgrafting immunosuppression consisted of Cy 50 mg/Kg/day on days +3 and +4, mycophenolate mofetil and tacrolimus. All patients received G-CSF after transplantation Results: neutrophil engraftment occurred in 23 of 24 evaluable patients at a median of 18 days (range 14-24 days). The incidences of grades II-IV and grades III-IV acute GVHD were 26% and 4% respectively. Bacteremia occurred in 8 patients, 13 patients developed viral infections (n=12 CMV reactivation, n=1 EBV reactivation). After a median follow-up of 264 days (range 124-936 days), 14 patients (56%) are alive, 9 of whom are in complete remission.

Overall survival and event-free survival at 1 year were 43% and 40% respectively. The 1-year cumulative incidence of transplantrelated mortality was 31% . Conclusion: our recent experience confi rms the feasibility of HLAhaploidentical HSCT with high-dose post-transplant Cy in heavily pretreated patients with acceptable early morbidity and mortality. Longer follow-up on a larger series of patients is need to evaluate long-term clinical outcomes.

Autologous haematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma: fi rst part of a consensus on behalf of the European Group for Blood and Marrow Transplantation investigators M. Mohty (1), K. Hübel (2) , N. Kröger (3), M. Aljurf (4) , J. Apperley (5) , G. Basak (6) , A. Bazarbachi (7), K. Douglas (8), I. Gabriel (5), L. Garderet (1) , C. Geraldes (9), O. Jaksic (10) Background: Autologous haematopoietic stem cell transplantation with peripheral blood stem cells (PBSCs) is nowadays a standard therapy in multiple myeloma (MM) and lymphoma patients. However, current mobilisation strategies vary between centres and a signifi cant no. of patients is unable to mobilise suffi cient PBSC yields. Methods: Based on currently available literature and clinical practice, a group of 28 experts from the European Group for Blood and Marrow Transplantation (EBMT) attempted to achieve a consensus on the best approaches to mobilise PBSCs in MM and lymphoma patients and on potential optimisation options for poor mobilisers.

Results: For MM patients, steady state mobilisation (cytokines only) or chemotherapy-based regimens according to national guidelines are recommended. For lymphoma patients, diseasespecifi c chemotherapy approaches are suggested to avoid the burden of additional chemotherapy cycles. For selected lymphoma patients who are in complete remission and/or are ineligible for chemo-mobilisation, steady state mobilisation may also be an option. To optimise steady state or chemo-mobilisation protocols and increase graft yields, the addition of new mobilisation agents such as plerixafor are suggested. Over the past years several factors have been described in the literature to be predictive of poor PBSC collection, including older age, more advanced disease stage, higher no. of prior treatment lines, prior treatment with fl udarabine or melphalan, and prior irradiation. However, the most robust predictor for poor PBSC collection is presumably the CD34+ cell count in PB before apheresis. For patients with <10 CD34+ cells/microlitre in PB prior to apheresis, preemptive plerixafor use is suggested to reach a target apheresis count of 2.0 Mio CD34+ cells/kg. For patients with 10-20 CD34+ cells/microlitre in PB prior to apheresis, a dynamic approach is recommended taking into account patients' disease characteristics and treatment history. Readily available and robust techniques to determine CD34+ cell counts are needed. Conclusions: PBSC mobilisation can presumably be optimised by choosing an appropriate strategy adapted to each patient, based on disease and treatment features. A low CD34+ cell count in PB prior to apheresis is a candidate predictor for poor PBSC collection. Thus, CD34+ cell count determination might estimate the patient's risk for poor PBSC collection and allows a proactive intervention to rescue mobilisation failure.

Successful autologous stem cell transplantation is reliant on the ability to harvest suffi cient stem cell dose either via the use of G-CSF ± standard chemotherapy mobilisation. Although the exact mechanism of G-CSF's mobilising eff ect is debated, down-regulation of the chemokine CXCL12 may be involved. For most patients a satisfactory cell dose can be harvested: however, about 15% of patients mobilise PBSC poorly which has signifi cant implications for their long term management. Recent published data examining a small group of autograft patients suggested that elevated serum glucose concentrations impair stem cell mobilisation via a defect in activation of the sympathetic nervous system which causes a blockade of G-CSF induced down-regulation of CXCL12(1). This was indicated by a low CD34 count at time of harvest and delayed engraftment post transplant. We extended this investigation by examining autograft patients referred for peripheral blood stem cell (PBSC) harvest in the West of Scotland between 2009 and 2012. Clinical data were available on 256 patients. 5% (n=13) patients were confi rmed as diabetic.

No signifi cant diff erence was seen between diabetic and nondiabetic patients with regards to median peak CD34/ul count after mobilisation (59 vs 63.7, p=0.83) or median total CD34 dose obtained (6.81 vs 6.34, p=0.48). However, the small number of diabetic patients may indicate a diffi culty in identifying a diff erence in this data set. Other potential confounding factors include the age and sex of patients which were at variance between the two groups [median age 61yrs vs 56yrs, p=0.0045 and male sex n=12 (93.3%) and n=130 (52.2%)] in the diabetic and non-diabetic cohort respectively. However, as increasing age generally has a small negative eff ect on PBSC mobilisation, the higher mean age of the diabetic cohort would be expected to enhance, rather than to mask, any impact of diabetes on mobilisation. There is confl icting data on whether gender aff ects mobilisation, but if so then the eff ect is very modest. These data do not indicate that the existence of diabetes per se signifi cantly infl uences PBSC harvesting and would suggest that other factors play a more important role in accounting for the success of stem cell mobilisation. SCU remain stored and unused at last F-U (Fig.1) . Among 274 patients who never reinfused cryopreserved SCU, disposal was performed in 62(22%); causes of disposal were death in 54 and allogeneic transplantation in 8; 4 SCU were eliminated, due to technical reasons. Kinetics of the 1st reinfusion shows that 99% of the SCU has been used within 24 months; only one patient received the 1st ASCT 6 years after the collection. There was a signifi cant diff erence in the SCU kinetics of reinfusion, according to the underlying disease: for AL patients the chance of being reinfused 12 months after SCU collection was almost null, while it was not negligible for MM or NHL patients (Fig.2) . A multivariate logistic regression was performed considering the outcome variable of non-reinfusion. The analysis, center-adjusted, confi rmed that probability of non-use was signifi cantly increased in patients with AL, collections with less than 2x10e6 CD34/kg and in lower age groups. These data could serve as a valid basis to support rational recommendations for cost-eff ective storage and disposal of SCU.

Eff ective TcR α/β+ cell depletion using the CliniMACS® system to produce peripheral blood progenitor cell products for haploidentical transplantation J.H. Dykes (1) Background: Rigorous depletion of TcRα/β+ cells whilst preserving valuable TcRα/β+ cells in the stem cell graft is an attractive alternative to CD3+ T-cell depletion for prevention of GvHD in HLA-mismatched transplantation. In the current study, we investigated the performance of the novel CliniMACS TcRα/β product line for depletion of peripheral blood progenitor cell (PBPC) products intended for haploidentical transplantation. Study design and methods: PBPC were harvested from 8 HLAhaploidentical donors. The cells were sequentially labelled with TcRα/β-Biotin reagent and CliniMACS anti-Biotin reagent and processed with the CliniMACS device using the D3.1 program (n=8) with the DTS (Depletion Tubing Set). TcRα/β -cell depleted grafts were produced with a target cell dose of ≥ 5 × 106 CD34+ and ≤ 1 × 105 TcRα/β + cells per kilogram of recipient body weight. In fl ow cytometric analysis viable TcRα/β+ cells were defi ned by their cell scatter properties of lymphocytes, positivity for CD45 (bright), CD3 and TcRα/β and negativity for propidium iodine staining, as well as lack of CD13-, CD19-, CD14-and TcRα/β-expression. Bright fl uorescent dyes were selected for TcRα/β (PE) and CD3 (APC) staining. The fl ow cytometric dot plot of a "spiked" sample (10:1 mixture of depleted target fraction: non-target TcRα/β+ cells) was used to adequately set the gate for TcRα/β+ cell detection. A minimum of 106 events were acquired for analysis. Results: The median log10 TcRα/β-cell depletion rate was 4.6 (range 3.0-5.0), corresponding to a median of 0.0017 % (range 0.00041-0.036%) TcRα/β+ cells in the target fractions. The median recovery of CD34+ cells was 94% (range 85-99%) and the median recovery of TcRα/β+ cells was 79% (range 72-95% Introduction: Immunomagnetic depletion of TCR α/β (TCRab) positive cells from the hematopoietic stem cell (HSC) graft is a new method of graft processing, which removes potential eff ectors of graft-versus-host disease, sparing presumably important populations, such as NK cells and γ/δ T-cells. This method was adopted as a basic graft processing platform for haploidentical (haplo) and matched unrelated donors (MUD) in our center since May 2012. We report herein the technical results of the procedure. Methods: Overall 34 procedures were performed between May and November 2012. Grafts were GCSF-mobilized PBSCs derived from MUD (n=23) and haplo (n=11) donors. Initial characteristics of the graft were similar with median total nucleated cell (TNC) count = 57x109, CD34 = 416x106, TCRab = 13,9x109, CD19 = 3,5x109. The only diff erence was in the time period from apheresis to processing start, which was a median of 48 and 22 hours for MUD and haplo, respectively. The procedure of TCRab and CD19 depletion was performed with appropriate reagents and Clini-MACS Plus instrument, Miltenyi Biotec, according to manufacturer's instructions. Magnetic reagent volumes were adjusted to TNC and labeled cell count. Product analysis was performed on FACS CANTO II cytometer, BD according to Miltenyi Biotec protocol. Results: Median recovery of CD34 cells was 93% and 90% for MUD and haplo. Median log depletion of TCRab cells was 3,9(2,9-4,7) and 3,9(3,3-5) (fi g 1.). Median log depletion of CD19 cells was 2,9(1,8-3,9 ) and 3,1 (2, 7) , respectively. The only factor that signifi cantly correlated with depletion eff ectiveness was the ratio of magnetic reagent TNC capacity to the real TNC count (fi g. 2). Conclusions: TCR α/β and CD19 depletion with CliniMACS technology is a robust and eff ective method of graft processing for HSC transplantation. The method secures target graft quality independent of the graft source, transportation and processing delay up to 48 hours. An excess of the immunomagnetic reagent correlates with greater depletion of the labeled cells.

Development of a cryopreservation process for donor lymphocytes using a closed bag system R. Peter, D. Gasch, I. Nachtigall, E. Schafnitzel, K. Götze, H. Menzel, C. Peschel, A. Krackhardt Technical University Munich (Munich, DE) Infusion of donor lymphocytes off ers a salvage option for selected patients after allogeneic stem cell transplantation. We have previously developed a simple method for cryopreservation of peripheral blood stem cells within a functionally closed system that fulfi ls GMP guidelines and allows for processing without a cleanroom facility. The actual objective comprises the modifi cation of our system for processing, portioning and cryopreservation of donor lymphocytes. At our clinic, patients usually receive subsequently 1x10 6 , 5x10 6 , 10x10 6 and 50x10 6 donor lymphocytes per kg bodyweight (BW). The fi rst donation is removed directly from the apheresis product. For subsequent donations, the cell number is fi rst adjusted within a transfer bag to 50x10 6 /kg BW in a volume of 95ml and transferred to a cryobag of the fi rst Cell Cryo Freeze Prep Set (CCFPS). After disconnection, the transfer bag is connected to a plasma collection bag containing 150ml of donor plasma. 40 ml of the undiluted cell suspension are transferred to the plasma collection bag resulting in a dilution of 1:5 after fi nal preparation. Therefore, the plasma collection bag was connected to a second CCFPS followed by addition of DMSO (5ml per bag) and distribution to two cryobags. Similarly, DMSO was added to the cryobag of the fi rst CCFPS and all cryobags were crypreserved followed by long-term storage below -140°C. Numbers of CD3/CD45 cells were analyzed after each preparation step by fl ow cytometry. A total of 6 processes have been completed. The mean content of the donations were 2.4 CD3/CD45 cells/kg BW for the fi rst donation, and 13.5, 13.7 and 52.5 for the following donations. The standard deviation was 0.57, 4.85, 3.83 and 5.82, respectively. The cell number applied to the patient will be adjusted according to the exact number of lymphocytes measured after preparation and the medical need. Vitality of nucleated cells after cryopreservation was >90% (trypan blue staining). Sterility was analyzed for both CCFPS preparations revealing no contamination in all processes performed. These data demonstrate that cryopreservation of donor lymphocytes in a closed bag system is feasible and off ers superior advantages: The process is simple, safe and cost-saving and the dosage of CD3+/CD45+ cells to be infused to the patient can be individually adjusted by the clinician according to the eff ectively measured number of cells within the cryobag after preparation and the specifi c condition of the patient. .2 ): patient's death (47%), microbial contamination (22%), structural damage to the bags (16%); insuffi cient amount of CD34+ content (5%) and mistakes/damages in the labels (1,5%). Among the 36 interviewed centers only 9 reported the use of a specifi c consensus for disposal of the bags and 17 had a specifi c policy for the discharge. The results of this preliminary survey suggested that in Italy the amount of the unemployed SCU is relevant, particularly as regards the SCU stored > 10 years. This situation raises serious concerns about: 1-the increasing limitations of the room space available for SCU cryopreservation in the next future; 2-the increasing costs of long term cryopreservation of SCU, with low chance to be reinfused for ASCT; 3-ethicality of destroying autologous SCU stored, based on the loss of ASCT indication (if it has never been performed) or to keep the chance of a successive ASCT (for those patients keeping exceeding SCU, after the 1st ASCT). Hematopoietic stem cell (HSC) mobilisation in peripheral blood (PB) is prerequisite for successful collection in apheresis procedure S190 and subsequent autologous HSC transplantation. The number of CD34+ cells in PB prior to apheresis is one of the most important predictors of successful HSC collection. In case of low CD34+ numbers apheresis can be prolonged with more blood volumes (BV) processed to improve yield due to additional recruitment of CD34+ cells from bone marrow (BM). Also, administration of CXCR-4 antagonist plerixafor in poor mobilisers leads to increase in PB CD34+ numbers due to shift from BM to PB. In order to evaluate role of CD34+ recruitment in patients mobilised with plerixafor in comparison to non-plerixafor mobilisations in standard volume (SV) and large volume (LV) In conclusion, the eff ect of CD34+ recruitment was less pronounced in plerixafor group. This may be due to prior redistribution of CD34+ cells from BM to PB. However it is still signifi cantly higher in LV apheresis group suggesting that LV apheresis can additionally improve yield in poor mobilizer subgroup of patients after addition of plerixafor. Feto-maternal microchimerism suggests immunological tolerance between mother and fetus. Thus, we performed primary hematopoietic stem-cell transplantation (HSCT) from mismatched mother to thalassemic patient without an HLA-identical donor. 42 patients with thalassemia major were conditioned with 60 mg/kg hydroxyurea and 3 mg/kg azathioprine from day -59 to -11, 30 mg/ m2 fl udarabine from day -17 to -11, 14 mg/kg busulfan starting on day -10 were administered orally 3 times daily over 4 days in the fi rst 17 patients, and corresponding dose of busulfan give intravenous in the following 25 patients, and 200 mg/kg cyclophosphamide,10 mg/kg Thiotepa, and 10 mg/kg ATG (Fresenius) daily from day -5 to -2. 34 patients received CD34+ mobilized peripheral and bone marrow progenitor cells; 8 patients received marrow graft selected PBSC CD34+ and BM CD3/CD19 depleted. T-cell dose was adjusted to 2x105/kg by fresh marrow cell add back at the time of transplant. Both groups received cyclosporine for graft versus host disease prophylaxis for two months post transplant. 3 patients died , 12 patients reject their grafts, and 27 showed full chimerism with functioning grafts at a median follow-up of 56 months. The overall survival, thalassemia free survival and mortality is 90%; 59% and 11%. To analyze immunohematologic reconstitution, particularly NK cells, we evaluated 13 thalassemia patients after 20 and 60 days and 1 year post transplantation with T cell-depleted HLA-haploidentical stem cells. NKs were the fi rst lymphocytes to repopulate the peripheral blood. A signifi cant increase in CD4+ and CD8+ markers paralleled an increase in CD3-CD16+ NKs, especially with full engraftment. In order to increase the T-cell depletion of PBSC while maintaining the anti-infectious and the engraftment facilitating eff ects of the depleted grafts, we have introduced the depletion of αβ T Lymphocytes using the CliniMacs System. In addition to the Cd3 depletion, αβ-depleted grafts contain large number of γδ T lymphocytes studies were then conducted to determine if γδ T cells were capable of preventing graft rejection in the context of haploidentical transplant. Using this new strategies in 3 haploidentical transplant in thalassemia patients we observed more rapid immunological reconstitution after 60 days post transplant, with an increase of T cells (CD4+ and CD8+), B cells (CD19+) and NK cells (especially CD3-CD16+, with cytotoxic potential) in the peripheral blood of these patients.

Every-other-day administration of G-CSF following autologous peripheral stem cell transplantation does not change time to neutrophil engraftment: a prospective randomized study H.A. Ozkan (1), U.G. Ozer (1), C. Bal (2), Z. Gulbas (1) (

It is well established that recombinant human granulocyte colony stimulating factor (G-CSF) accelerates neutrophil recovery following autologous peripheral stem cell transplantation (APSCT). However, the optimal timing for initiation of G-CSF therapy following APSCT is still not clear. A number of studies have been conducted to determine this timing. Most of these studies investigated whether delayed use (day +3 to day +8) of G-CSF therapy was as safe and effi cient as with early use (day 0 to day +1) of G-CSF therapy after transplantation. We conducted a prospective randomized study comparing the eff ect of daily administration to every other day administration of G-CSF (300 μgr of fi lgrastim) on neutrophil engraftment following APSCT for non-myeloid hematologic malignancies in adult patients. Duration of G-CSF administration, incidence of blood stream infections, duration of febrile neutropenia, duration of non-prophylactic antibiotic therapy, transfusion requirements, duration of hospitalization and G-CSF costs were also studied. Forty seven patients with diagnosis of lymphoma and multiple myeloma undergoing high-dose therapy and APSCT were randomized to receive post-transplant daily or every other day G-CSF therapy both beginning on day +1. Both groups were comparable with regard to age, sex, diagnosis and antecedent therapy as well as the number of stem cell infused. There was no signifi cant diff erence in time to neutrophil engraftment between the two groups (p=0,31). The duration of G-CSF administration was signifi cantly less in the intermittent group (p<0,001). There were no detectable diff erences seen in the number of febrile days, duration of non-prophylactic antibiotics, the incidence of blood stream infections, transfusion requirements and the duration of hospitalization. There was a trend towards a faster platelet recovery in the intermittent G-CSF treated patients, although the diff erence was not statistically signifi cant compared to daily G-CSF treated group (p=0.059).The number of doses of G-CSF used per transplant is signifi cantly reduced with intermittent employment, resulting in a signifi cant reduction in drug costs.

The clinical outcomes were shown in Table I . In conclusion, these data seem to suggest that every other day use of G-CSF therapy is as safe and eff ective as with daily use of G-CSF therapy following APSCT for non-myeloid hematologic malignancies in adult patients.

A comparison of post-thaw cord blood unit (CBU) quality as a function of time with and without the use of 10% dextran and 25% albumin as reconstitution media R. Nath (1) Background: Best measure of the quality of a CBU is its timely engraftment post stem cell transplant (SCT). Total nucleated cell count (TNC), CD34 count and determination of viability using tryphan blue and 7 AAD are surrogates for CBU quality. This study examines the eff ect of time on these quality control variables of CBU frozen in 10% DMSO post thaw with and without reconstitution with 10% dextran and 25% albumin. The results are important to determine the optimal time limit of CBU infusion post thaw for patients undergoing CBSCT. Methods: 15 CBUs frozen in 10% DMSO were thawed at 37°C water bath. 5 CBUs were reconstituted by adding media consisting of 10% dextran and 25% albumin to equal one half of the total syringed volume + 5ml. The other 10 CBU were thawed without the addition of reconstitution media. Trypan Blue viability and 7-AAD viability (by fl ow cytometry), and CD34 viability (by fl ow cytometry) were assessed for each of the CBU immediately post thaw, 30 minutes 1, 1.5, 2 ,4 and 6 hours post thaw. Results: The drop in the total viability of the cells as measured by Trypan Blue (TB) as well as the viability of the CD34+ cells was faster if the reconstitution media was not used. In the presence of the reconstitution media, the viability of the CD34+ cells stayed stable till 1.5 hours (see graph A) whereas there was a sharp decline after 30mins without reconstitution medium (see graph B). Conclusion: As the viability of the CD34+ cells is important, and we need to look at the plateau of the CD34+ viability curve to select a point before which the cells should be infused and the reconstitution media gives a longer and more workable time (1.5 hours) compared to cells that are not in reconstitution media (30 mins). The eff ects of alemtuzumab on peripheral blood nucleated cells (PBPC) grafts need better defi nition. As haematopoietic cells express CD52 antigen, the optima cell number, antibody concentrations or eff ect of complement in the graft are not known. Methods: PBPC from normal 5 allogeneic stem cell donors harvested by apheresis and incubated with incremental concentrations of alemtuzumab (10-2 to 10-5 mg/mL for 30 min at 20ºC or at fi xed dose of 10-3 mg alemtuzumab was added to 0.1, 0.5 and 1x107 cells/mL in the presence of fresh or heat inactivated AB serum as source of complement were studied. Supernatants were

[P684] S192 removed and stored at -70 ºC and concentrations tested with ELISA assay. Pelleted cells were enumerated before and after exposure to alemtuzumab and analysed using 4 colour fl owcytometry in a Facs Calibur instrument. The mean-fl uorescent intensity and cell numbers were recorded. Selected CD34+ lineage negative cells we incubated at 10-5 to 10-2 mg/mL alemtuzumab for 30 min at room temperature and cultured in methylcellulose in CF-GM assay with IL-3 and G-CSF 10 mg t 37ºC. The colony numbers were compared to control cultures. Results: Incremental concentrations of alemtuzumab led to signifi cant (2 log) reduction in the CD3, CD4, CD8 populations which plateaued at 10-3 mg/mL without further drop at 10-2 mg/mL. However CD20+, myeloid (CD33, CD13) and monocytic (CD14) cells were reduced by 1 log at the highest concentration. Fresh AB serum led to a signifi cantly higher reduction in the CD4 and CD8 cells. Highest CD4 (4 log) and CD8 (3 log) death was obtained at 1 x107 cells/mL. Analysis of supernatants for soluble alemtuzumab showed a signifi cant reduction in the antibody concentration when the cell number was increase from 0.1 to 1 x10 7 /mL implying utilisation of the antibody by target cells. At the highest cell concentration the antibody was below the level of detection of the assay. Incremental concentrations of alemtuzumab did not aff ect the number of CFU-GM implying lack of cytotoxicity on early progenitor cells.

Conclusions: Alemtuzumab depletes all cells expressing the CD52 antigen and has the highest activity on CD3 and particularly on CD4 cells. Addition of complement and incubation at higher cell number resulted in signifi cantly higher cell depletion. Thus cell numbers and plasma depletion must be done with caution to prevent loss of complement activity when manipulating grafts that were incubated ex vivo with alemtuzumab.

Increasing demand for stem cell collection for therapeutic use, including tandem transplants and donor lymphocyte infusions, has caused pressure on the storage space available for haematopoietic progenitor cell (HPC) products. Additionally HPC collections using the Optia apheresis machine produce larger volume harvests than those using the Spectra. As Spectra machines are being superseded by Optias, this may pose storage challenges for other centres. In a retrospective study of 50 consecutive Optia and Spectra harvests, collection volumes were 228.3mls ±11.57 and 199.8mls ±4.7 respectively. To minimise the volumes stored and also to reduce patient exposure to the cryoprotectant dimethylsulphoxide (DMSO), the ratio of cell concentration to cryoprotectant mix has been optimised in our centre. HPC products are cryopreserved using a fi nal concentration of 6% DMSO, where the freeze mix comprises 12% of the total product volume and is made from equal quantities of DMSO and saline. In comparison, most centres use a 10% fi nal DMSO concentration achieved by the addition of a 50:50 mix of 20% cryoprotectant to the HPC product. This would have resulted in a 38% increase in cryopreserved volume in the cohort studied, compared with our method which has the additional benefi t of fewer bags stored and reduced DMSO exposure for the patient. Pre and post thaw fl ow cytometric viability studies conducted inhouse have validated our approach at consistently > 93% viable CD34 cell recovery. Furthermore, there is no adverse impact on patient engraftment. Red cell contamination of the HPC product is apheresis dependent. Our aim is to collect low haematocrit (HCT) products (4%) resulting in fewer lysed red cells in the cryopreserved product.

With high HCT donations steps are taken to minimise exposure to lysed red cells and the resultant free haemoglobin. Harvests are cryopreserved in portions to ensure products containing no more than 0.25mls/kg of red cells are given to patients in any one infusion episode. Infusion sessions may be either several hours or a day apart to allow for hydration and avoid overloading with lysed RBCs. A signifi cant reduction has been noted in infusion related complications including increased blood pressure, severe headaches, renal pain and occasionally seizures or collapse necessitating admission to intensive care. This has been apparent particularly in small children.

Mobilization using biosimilar granulocyte colony stimulating factor (Zarzio) for autologous CD34+ cells preparation and application into the heart of patients with dilative cardiomyopathy M. Sever (1), B. Vrtovec (1), M. Cukjati (2), L. Lezaic (1), G. Poglajen (1), A. Socan (1), D. Zontar (1), H. Podgornik (1), P. Mali (2), S. Stanisic (3), P. Cernelc (1) Aim of the study: In this retrospective study we have looked into the transplant outcomes(overall survival,disease free survival,GvHD and immune reconstitution) of T-cell depletion with Alemtuzumab in the stem cell bag of HLA fully matched unrelated donor allografts. Patients and methods: 14 patients received a myeloablative conditioning with TBI/cyclophosphamide (n=10) or busulphan/ cyclophosphamide (n=4). 12 patients had AML in CR and 2 CML (1 chronic phase 1 accelerated phase). All the patients received PBSC grafts and ciclosporin as GvHD prophylaxis along with 15mg of Alemtuzumab in the bag.The median age of the patients were 32.9 (median 17-49). The median follow up was 39 months (range 5-142mo). Results: The 3 year overall survival was 52%. All patients engrafted with a median neutrophil engraftment of 12 days (11-16) and a median Platelet engraftment (PLT>20 unsupported) of 16 days (range 13-21). 42% of patients developed Grade I-II GvHD but none severe grade III-IV. The non relapse mortality was 18% in the first year (all infection related) and the overall relapse rate was 29% (4/14). Immune reconstitution of a CD4 count >200 was observed at a median time of 5 months (range 1-17 months). Conclusion: The strategy of T-cell depletion with Alemtuzumab ex vivo is a simple and eff ective way in reducing transplant related mortality and Graft versus host disease while it maintains a potent graft versus malignancy eff ect and provides a rapid immune reconstitution. Prospective studies with higher number of patients are needed to confi rm these results and defi ne the appropriate dosing of alemtuzumab in the stem cell bag. Conclusions: In our experience the use of BTZ at induction regimen before ASCT at MM's patients shows that it doesn't aff ect the achieve of HSC, and is better than treatments used before the BTZ era. Patients treated with BTZ didn't need more aphaeresis process to achieve the same amount of CD34+ HSC, and wasn't more likely to fail mobilization, than patients treated with other regimens. We have also seen that BTZ not infl uence the risk of being poor mobilizers as alkylating chemotherapy has previously demonstrated. The use of BTZ in induction regimen keeps us to make an ASCT in the most of the patients with MM.

Apheresis bag lymphocyte count is predictive of absolute lymphocyte count at day +15 post-autologous stem cell transplant for myeloma PLR Nicolson (1), D Hollyman (2), R. Lovell (1) Conclusion: A-ALC is predictive of ALC-15, which in turn is predictive of outcome following autologous stem cell transplant. We feel the explanation behind these fi ndings lies in the fact that a higher lymphocyte dose in the stem cell bag encourages better lymphocyte engraftment and these cells then have a superior autoimmune anti-tumour eff ect.

Searching for an alternative to Cobe Spectra for stem cell collections: comparison of Amicus and Optia cell separation devices C. Kreissig (1), I. Rehfeld (1), J. Bux (2) (

Introduction: End of 2011, stem cell collection facilities were informed by the Terumo BCT Company about the end of life campaign for the Cobe Spectra device. These plans caused a lot of trouble, because the Spectra device is accepted as the gold standard for stem cell collections all over the world. As many others we had to decide, which device we will use in the future for allogeneic and autologous stem cell, lymphocyte and granulocyte collections. Material and Methods: As in many other European countries it is regulated by German authorities how to validate a new technical device and procedure before starting its use in routine production of a stem cell transplant. Because we need a license for our stem cell products, we geared our comparison investigation to German guidelines, which are published by Paul-Ehrlich-Institut. So we performed twelve collection procedures for allogeneic and autologous stem cell products respectively. We compared following results: stem cell count in product, collection effi ciency, contaminating cells, platelet loss in donors or patients, practicability and limitations of the procedure. Results: Amicus and Optia devices both collect autologous and allogeneic stem cell products. Nevertheless there are some diff erences, which we show in table. Conclusion: We found Pro's and Con's for both devices. Amicus collects a smaller volume and fewer platelets. So it is much more suitable for autologous stem cell collections, if products will be cryopreserved and patients are suff ering from thrombopenia. Amicus cannot collect granulocytes and stem cell products contain higher amounts of CD3-positive cells, which can play an important role in mismatched allogeneic transplantations. Optia collects varying and unpredictable volumes. That can cause problems, if cryopreservation is planned. Platelet loss in patients or donors is much higher than in Amicus collection procedures. Optia has a granulocyte collection protocol. Stem cell products contain fewer CD3-positive cells, which can be an advantage in mismatched transplantations. The decision, which device replaces Spectra best, should focus on the product type.

Long-term outcome of a randomized trial, comparing intraosseous versus intravenous bone marrow transplantation H. Hägglund (1), M. Remberger (2), O. Ringden (2) (1)Dept of Hematology (Stockholm, SE); (2)Dept of Immunology, CAST (Stockholm, SE) In 1998, we reported a randomized study comparing intraosseous (io) versus intravenous (iv) transplantation of allogeneic hematopoietic stem cells. The conclusion of the study was that io infusion of bone marrow cells could be done safely. However, our secondary aim, to speed up the time to engraftment of neutrophils or platelets, was not achieved. Aiming to reduce the graft failure problem after cord blood transplantation, Frassoni et al studied io infusion of cord blood cells.

[P693] S195 Their study indicated a high rate of successful engraftment and a low incidence of acute GVHD. In our 1998 study, 38 patients were transplanted with bone marrow from sibling donors (i.o. (n=8) i.o.+ iv (n=10) and iv (n=20)). The majority of the patients were diagnosed with acute or chronic leukemia (33/38). With a median follow-up of 15.6 (14. 2-16.1) years, 15 patients are alive. We did not experience any graft failure after i.o. infusion and no diff erences in chronic GVHD, TRM, relapse or PFS when comparing the io and iv groups. We conclude that long-term outcome of io infusion of bone marrow stem cells is safe and that the results are similar to those from the current clinical practice of iv infusion. The long-term consequences and experiences of io as compared with iv infusion of bone marrow would most likely be the same after peripheral blood or cord blood intraosseous stem cell transplantation. Further randomized studies are warranted to answer the question whether it is time to switch from iv to io HSCT regardless of stem cell sources. Background: Plerixafor is a new CXCR4 antagonist that induces the mobilization of CD34(+) hematopoietic stem cells from bone marrow to circulation. Limited experimental data suggest that plerixafor+ Granulocyte-Colony Stimulator Factor (G-CSF) mobilized apheresis products (HPC-A) are functionally diff erent from G-mobilized HPC-A. Aim of the study: To evaluate the eff ects of plerixafor injection on graft composition in terms of lymphocytes subsets, monocytes and on gene expression profi le of molecules involved in immune network, cellular adhesion, engraftment. Methods: Fourteen patients aff ected by multiple myeloma were included in the study. All patients received G-CSF alone or after high dose cyclophosphamide to mobilize stem cells. Six patients received plerixafor pre-emptively owing to poor mobilization or poor collection yields. The rest of the patients constituted the control group. Graft composition was evaluated by fl ow cytometric analyses in terms of CD34+, CD3+, CD4+, CD8+, CD19+, CD56+, CD14+ cells. Gene expression profi les were evaluated on peripheral blood samples after G-CSF administration and, when plerixafor was injected, daily after every dose.

Results: The amount of T suppressor cells (CD3+/CD8+), NK cells (CD3-/ CD16/56+), B cells (CD19+) in the graft was all signifi cantly higher in the plerixafor group. On the contrary, T helper cells (CD3+/CD4+) was more representative in the other group. Monocytes were higher in plerixafor group and the amount increased with subsequent dose of the drug. Gene expression profi le documented CD83 and TNF levels signifi cantly higher in the peripheral blood after plerixafor administration. Conclusion: Plerixafor determines modifi cation of apheresis product respect G-CSF in terms of cellular types. Futher studies are needed in larger group patients to confi rm these data and to analyze their impact on immune reconstitution, longterm engraftment, patient outcomes after autologous stem cell transplantation.

Chemo-GCSF mobilization is associated with lower lymphocyte count in the apheresis bag than mobilization with GCSF alone in patients with myeloma PLR Nicolson (1) Introduction: In cardiovascular regenerative medicine, various approaches have been used for the stem cell therapy in patients with dilated cardiomyopathy (DCM). Intramyocardial stem cell transplantation is expected to improve ventricular remodelling and survival. In our study, autologous CD34+ haematopoietic progenitors intended for the myocardial regeneration were collected after mobilization with G-CSF, then the CD34+ fraction was enriched and collection effi ciency was evaluated. Methods: Samples from 40 adult patients were used to prepare CD34+ haematopoietic progenitor stem cell enriched and concentrated products intended for autologous transplantation. The fi nal volume of therapeutic transplant was 8 mL. The median age of patients was 54 years. Immunomagnetic separation by targeting CD34 antigen using CliniMACS (Miltenyi Biotech) was used to enrich CD34+ cells. For the quality analysis, samples were taken from each apheresis product pre-and post-immunomagnetic selection. After staining cells with anti-CD45, anti-CD34 and 7-AAD, fl uorescent beads were added for evaluation of viable CD34+ count by fl ow cytometry and the CD34+ cell separation effi ciency was calculated.

Results: The average of CD34+ cells recovery after immunomagnetic separation was 63%±22, cell purities (%CD34+/%CD45+) increased from 0.7%±0.3 to 62%±35 after enrichment. A fi nal average dose was 109 x 10E6 cells/product. The average viability of CD34+ cells in our cell products prepared for implantation was as high as 97%. S196 Conclusion: Our protocol for the enrichment of autologous CD34+ cell products for intramyocardial application in patients with dilated cardiomyopathy by means of CD34+ immunomagnetic isolation is suitable for further clinical application based on high enrichment of the target CD34+ cell population. Further studies for the analysis of stem cell subpopulation in these autologous grafts are on the way.

Relationship between transfusion requirements and CD34-positive cells infused in autologous stem cell transplant patients. Single centre experience F. Almagro Torres (1), P. González Sierra (1), M.M. Trujillo Pérez (2), M.J. Martínez Quesada (1), P. Luque Ortega (2), J.A. López López (1), A. Alcala Muñoz (1), A. Carrero González (2) (1)University Hospital of Jaen (Jaen, ES); (2) The probable cause may be the low variability between the number of infused cells. Most of patients have received between two and three million per kg. Logically, the patient who received higher number of transfusions of red blood cells will present higher requeriments of platelets pools.

In future studies it will be necessary to analyze another variables like quality of infused product (viability, leukocyte count poly-morphonuclears…) or study a cohort of patients with more diff erence in the number of cell infused (>4 x 106 cells/kg vs <4 x 106 cells/kg) to determine if there is any relation with the variables studied.

Aldehyde hydrogenase activity in mobilized peripheral stem cell products and its relationship with engraftment S. Civriz Bozdag (1), P. Topcuoglu (2) , M. Ozkan (2), O.I. Ilhan (2) , O. Arslan (2) , T. Demirer (2) , G. Gurman (2) , A. Uysal (2) , M. Beksac (2) (1)Ankara Oncology Hospital (Ankara, TR); (2)Ankara University (Ankara, TR)

Stem cell transplantation, is the only curative treatment option for the malign and benign hematological diseases. Mobilized peripheral blood after granulocyte colony stimulating factor, is the mostly preff ered stem cell source. Determination and collection of CD34(+) hematopoietic stem cells(HSC) by fl ow cytometry is the routine method used in transplantation units. Aldehyde dehydrogenase, a functional marker, which is widely exspressed in the early hematopoietic progenitors can also be used for identifi cation of HSC. We aimed to asess the expression of ALDH, CD90 and CD38 markers in addition to CD34 in the mobilized peripheral blood samples and apheresis products to identify HSC. We also planned to determine the correlation between neutrophil, platelet engraftment and CD34(+)ALDHbr cell numbers infused. We included 19 autologus stem cell transplantation patients with diff erent diagnosis and 6 healthy donors for allogeneic stem cell transplantation. CD34ALDHbr cell percentage in the apheresis products of autologus and allogeneic transplantation patients were 0.78% and 0.49% respectively. CD34(+) and ALDHbr cell numbers were correlated in the peripheral blood and apheresis products (r=0.651, p<0.001, r=0.710, p<0.001). There was no difference in the peripheral blood and apheresis products, between the autologus transplantation group and healthy donors, according to ALDH, CD34 expression. Neutrophil and platelet engraftment was not correlated with CD34(+)ALDHbr cell numbers. In conclusion, as we could not show a relationship betweeen ALD-Hbr cell number and engraftment, it seems useless to determine ALDHbr cells in apheresis products.

Characteristics of patients with autograft containing less than 2x10 The main condition for successful autologous stem cell transplantation (AutoSCT) is the number of CD34+ cells in the autograft. The aim of the study was to fi nd out the clinical features of patients which autotransplant contained less than 2x10 6 CD34+ cells/kg. There were 14 patients with autograft failure. The median age of these patients was 47.5 years (19-62). Their diagnoses were myeloma (6 patients), nonHodgkin lymphoma (3 patients), acute myeloid leukemia (3 patients), and acute lymphoblastic leukemia (2 patients). Before stem cell collection the patients were treated with 1 to 4 regimens of chemotherapy. 3 regimens were used for stem cells priming: G-CSF only (5 patients), cyclophosphomide (Cph) 1-3 g/m 2 only (8 patients), and combination of high dose chemotherapy plus G-CSF (1 patient). The median of mono nuclear cells in the autograft was 1.9x10 8 kg (1.0-5.8 ) and the median of CD34+ cells was 0.51x10 6 kg (0.03-0.72). There were 36 patients with more than 2 10 6 CD34+ cells kg in the control group. There was no signifi cant diff erence in the age, number of previous lines of chemotherapy, total dose of antracyclines and number of aphaeresis which were done with Cobe Spectra between study and control groups. At the same time there was association between graft failure and dose of Cph less than 2.5 g m 2 . As there was no any possibility to repeat stem cell collection 8/14 patients were transplanted after conditioning with BEAM and Melphalan 200 mg m m 2 . The engraftment was reached in all patients with restoration of granulocyte count ≥ 0.5 10 9 l on the 12-30 days and platelets ≥50 10 9 l on the 12-100 days. Nevertheless there was much more number of infectious episodes (>54%) and number of platelets transfusions (>75%) in the study group compared with the control group.

The conclusion is that it is necessary to use the combination of G-CSF plus plerixafor in the cases with the dose of Cph for priming is less than 2.5 g m 2 . Objectives: rapid identification of eligible cord blood units (CBU) for banking is an important issue in hemopoietic stem cell (HSC) procurement. Distinct targets of CD34+ cells in CBU may identify grafts for small and adolescent/adult unrelated patients or potentially available for directed donor allogeneic/autologous storage.

Methods: Considering thresholds of CD34+ cell content of 3 and 2x10e6 (1x10e5/kg in recipients >30kg or >20kg, respectively) and a threshold content of 1x10e6 CD34+ cells which may be stored as mimimum dose in directed donor allogeneic/autologous setting, we analyzed a consecutive series of 1309 CBU. CBU were collected for autologous banking without any volume-based pre-selection criteria. Predictors of distinct content of CD34+ cells have been assessed by ROC curve analysis. Results: Median TNC and CD34+ cells of the entire series were 6.97x10e8 (range 0.36-34.9) and 1.47x10e6 (0-20.56) . Volumes ranged from 21 to 163 ml, with a median of 73.8. For the lowest CD34 target of 1x10e6, the best predictor at ROC analysis was TNC with a threshold of 6.63x10e8; volume resulted less predictive with a value of 68.1 ml (AUC of 0.900 and 0.856 respectively; Fig.1 ). For targets of 2 and 3 CD34x10e6, ROC curve analysis confi rmed a stronger predictive power of TNC, above the collected volume, with a threshold of 7.55x10e8 (3.77x10e7/kg for a patient of 20kg; AUC 0.870 vs 0.826 for collected volume) and 8.98x10e8 (3.00 x10e7/kg for a patient of 30kg; AUC 0.880 vs 0.811 for collected volume), respectively (Fig.1) . A restricted analysis on CBU >80 ml showed similar results, indicating TNC as the best predictor but with appreciable reduction of AUC (0.81, 0.76 and 0.80 for >1, >2 and >3). ROC analysis by combining all predictors (TNC, volume, TNC2, volume2, age of mothers, types of delivery, birth weight) gave worse results than TNC alone .

Conclusions: This analysis carried out on a large, unrestricted (by volume criteria) CBU series shows that TNC alone is the best predictor of distinct targets of hematopoietic potential with the chance to predict banking of CBU potentially useful for distinct patients' categories or for directed allogeneic/autologous storage. Three classes of CBU might be identified with a high sensitivity and specificity (Fig.1) . Collection of all these CBU categories in a sole banking strategy would translate into the possibility to exploit the cord blood source with a success rate of 66%.

Plerixafor ( Purpose: We studied the factors associated to mobilizationwith granulocyte colony-stimulating factor (G-CSF) used alone, for peripheral blood stem cell (PBSC) collection for noncryopreserved autologous stem cell transplantation (ASCT) in multiple myeloma. Methods: Ninety eight patients with multiple myelomawereretrospectively analyzed between May 2009 and November 2012. All had auto graft at age less than 65 years old and none of them had previously received chemotherapy for mobilization. PBSC leukapheresisusing an Optia Spectra machine and CMN1 software with a default settingwas started after four day of mobilization with originators G-CSF (Neupogen®or Granocyte®) or biosimilarfi lgrastim (Zarzio®) at a dose of 15 mcg/kg subcutaneously once daily. The products were stored before reinfusionin a conventional blood bank refrigerator at 4°c. Patients were defi ned as three groups; optimal mobilizers with CD34+ rate >5x106/kg, sub optimal mobilizers with CD34+ rate between 2 and 5x106CD34+/kg and non-mobilizers with CD34+ rate<2x106. (1), A. Rone (2), C. Giles (2), A. Chaidos (2), EJ Kanfer (2), D.H. Macdonald (2), D. Milojkovic (2), D. Marin (1), J. Pavlu (2), J.F. Apperley (1), A. Rahemtulla (2) (

Progression or relapse occurs in the vast majority of patients with multiple myeloma (MM) who undergo up-front autologous haematopoietic cell transplantation (AHCT1), which remains a cornerstone of treatment. Limited data are available regarding the value of salvage therapy with a second AHCT (AHCT2) in patients who relapse/progress after AHCT1, and the factors that determine outcome of AHCT2. We analysed all MM patients who underwent salvage AHCT2 at Hammersmith Hospital (HH), later Imperial College Healthcare NHS Trust (ICHNT), over a 18-year period (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . The patient population is derived from a multi-ethnic community of approximately two million in an equal-access healthcare system and includes a large proportion of patients that received novel agents for treatment of relapse/progression after AHCT1. Between January 1994 and December 2011, a total of 404 MM patients underwent AHCT1. Of those, 83 patients received AHCT2 for relapse/progression following AHCT1. Median time to progression after AHCT1 for patients who received AHCT2 was 21.5 months (range, . Median interval between AHCT1 and AHCT2 was 35.4 months (95%CI: 9-93). Median age at AHCT2 was 60.9 years (range, 32-73).Most patients who underwent AHCT2 (77%) had received treatment with novel agents between AHCT1 and AHCT2, and 28% of patients were from ethnic minority groups. Non-relapse mortality at 100 days after AHCT2 was 7% (n=6). Median overall survival (OS) from AHCT2 was 31.5 months (95%CI: 22 -41 with bortezomib, and conditioning with full-dose melphalan (200mg/m2) were associated with better PFS. In multivariate analysis, only disease status and time to progression/relapse remained associated with better PFS. In summary, salvage AHCT2 is an effective treatment option in patients with chemosensitive relapse/progression and prolonged remission after a prior autograft.

Allogeneic haematopoietic stem cell transplantation in fi rst-line high-risk multiple myeloma patients: evolving strategies with the immunomodulating drugs M. Michallet (1), M. Sobh (1), J. El Cheikh (2), S. Morisset (1), A. Sirvent (3), O. Reman (4), J. Cornillon (5), R. Tabrizi (6) , N. Milpied (6), J. Harousseau (7), H. Labussière (1), F. Nicolini (1) , M. Mohty (7), D. Blaise (2), P. Moreau (7), M. Attal (8), H. Avet-Loiseau (7) (1)Centre Hospitalier Lyon-Sud (Pierre Benite, FR); (2) We evaluated the efficacy and toxicity of tandem auto-HSCT strategy followed by RIC and allo-HSCT with the post-allo-HSCT use of bortezomib and DLI in high risk (β 2 microglobulin level >3mg/L, del13, t(4;14) or del17p) multiple myeloma patients (Group1). We compared our results to those observed after traditional tandem auto-RIC-allo-HSCT without bortezomib (Group2 Background: The rational design of therapeutic vaccines requires the use of sequences that can induce robust, diverse and long lasting antigen-specifi c T and B-cell responses in the majority of the patient population. We recently demonstrated that signal peptide (SP) domains have exceptionally high number of MHC class I and II epitopes per sequence length. This improved MHC binding relies on their hydrophobic nature but also bare antigen specifi city. Namely, diff erent SPs exhibit high antigenic variability with no particular sequence identity while maintaining the consensus motif needed for their original function as chaperones.

Following this rationale we developed ImMucin, a 21mer peptide, encoding the entire SP domain of MUC1, a tumor-associated antigen expressed by most solid and hematological tumors including multiple myeloma (MM). Results: A phase I/II open label study was initiated to assess the safety (as a primary end-point) and effi cacy (as a secondary end point) of ImMucin, in 15 MUC1-positive asymptomatic MM patients following autologous stem cell transplantation with residual disease or progression. Patients received 12 bi-weekly vaccination of 100mcg ImMucin plus 250mcg hGM-CSF. Interim analysis conducted on 7 patients who completed the study suggests a high safety profi le for the vaccine with only temporary (up to 24 hours) mostly local mild adverse events which resolved spontaneously. Immunomonitoring analysis by ICS-IFN-γ, tetramer and anti-SP antibodies demonstrated a unique combination of robust ImMucin-specifi c IFN-γ production by CD8+ (18-80 fold increase) and CD4+ (4-80 folds increase) T-cells with pan HLA properties in all 7 patients, as well as a 1.4-10 folds increase in anti-ImMucin serum concentration in 5/7 patients. Specifi c immunity could already be detected after 2-4 vaccinations In-addition, a decrease in soluble MUC1 levels was observed in all 4 patients who had abnormal (>300pg/ml) levels at screening. Levels dropped from 3500-10000pg/ml at screening to 50-290pg/ml in 3/7 patients and from 9000 to 3000pg/ml in an additional one. We also observed a stabilization or reduction in FLC, M-protein disease markers and in bone marrow MM cells in 4/7 patients following the treatment. Conclusions: These results confi rm a high safety profi le with robust immunodominant properties and are suggestive of clinical effi cacy for the ImMucin vaccine.

High rates of prolonged molecular remissions after tandem autologous non-myeloablative allografting in newly diagnosed myeloma . Conclusions: evidence suggests improved response rates using triplet regimens with slightly increased toxicity; but, survival does not appear to be improved by triplet therapy. More contemporary regimens including lenalidomide or carfi lzomib were not included given the lack of randomized data. Additional well-designed RCTs are needed to determine the survival benefi t of triplet over doublet combinations.

Prognostic relevance of 18-FDG PET/CT in multiple myeloma patients treated with allogeneic transplantation (2), R. Fanin (1) (

F-18-FDG positron emission tomography integrated with computed tomography (PET/CT) has been reported to be useful for screening of myelomatous lesions in multiple myeloma (MM) at diagnosis and for monitoring response to therapy and prognosis after autologous stem cell transplantation (auto-SCT). Aim of the present study was to prospectively evaluate the prognostic signifi cance of PET/CT in MM patients who received allogeneic stem cell transplantation (allo-SCT). All patients were studied with PET/ CT before and within 6 months after allo-SCT. The number and the size of focal lesions (FL) were recorded and PET/CT was considered positive if it showed at least 1 FL. The outcome of PET/CT positive and negative patients was compared in term of cumulative incidence of relapse (CIR ) and OS after allo-SCT. A total of 29 patients with a median age of 54 years (44-65) were analyzed. At diagnosis 14% had renal failure and 10 % had plasma cells in peripheral blood and/or in cerebrospinal fl uid. Del (13q), t(4;14) or del(17p), detected by FISH, were present in 50%. All patients received upfront auto-SCT , followed by allo-SCT within 3 months in 11 cases, while in the other 18 cases allo-SCT was performed after failure of previous auto-SCT. Median time between diagnosis and allo-SCT was 19 months (9-129). Conditioning was with Fludarabine plus 2 Gy TBI (73%) or melphalan 140 mg/mq (27%) Sixty-nine per cent of patients were transplanted from HLA matched unrelated donors. Chemosensitive disease was present in 73% of patients before allo-SCT. Two-year PFS and OS of the entire population were 42% and 31%, respectively. Before allo-SCT , 38% of the patients had a negative PET/CT, 24% presented ≤3 FL and 38% had > 3 FL. The entity of PET/CT involvement before allo-SCT infl uenced clinical outcomes. In particular, patients with positive PET/CT had a signifi cantly higher CIR and shorter OS in comparison with patients with negative PET/CT (2-year CIR 82% vs 32%, P=0.03, 2-year OS 23% vs 52% , P= 0.04). After 6 months from ASCT, PET/CT was negative in 45% of the patients and remained positive in 55% of them. Complete FDG suppression at PET/CT after allo-SCT conferred lower CIR and prolonged OS than persistence of FL (2-year CIR 32% vs 84%, P=0.008, 2-year OS 53% vs 21% , P= 0.003).

In conclusion, complete FDG suppression before and 6 months after allo-SCT was strictly related with achievement of durable disease control and longer OS.

The role of allogeneic stem cell transplantation in the treatment of multiple myeloma L. Volin, H. Uotinen, R. Niittyvuopio, E. Juvonen, A. Nihtinen, J. Heiskanen, V. Lindstrom, T. Ruutu Helsinki University Central Hospital (Helsinki, FI) The treatment of multiple myeloma (MM) has been rapidly evolving with novel drugs, but this disease is still regarded as incurable. The place of allogeneic stem cell transplantation (SCT) in the treatment of MM is unclear. It off ers the possibility to harness the curative potential of the graft-versus-myeloma eff ect, but high SCT-related mortality (TRM) has limited its use. We report our experience of 120 patients treated with allogeneic SCT since the year 2000. The median age of the patients was 50 (range 28-65) years and 52% were males. Forty-nine patients received a myeloablative (MAC) and 71 patients a reduced intensity conditioning (RIC the external beam radiation to be "focused" upon the site of the neoplasm, reducing the radiation dose administered to nonaff ected tissues. This conformal radiation technique increases the therapeutic window of external beam radiation. We hypothesize that IMRT will allow the selective administration of higher doses of external beam radiation to bone marrow than Total Body Irradiation (TBI) without increasing the toxicity to normal tissues beyond that induced by TBI. Herein, we report our preliminary experience. Methods: We are carrying out a Phase 1 study using a modifi ed 3+3 cohort dose escalation study where IMRT conditioning was delivered using Tomotherapy® prior to stem cell re-infusion in a second ASCT in patients with relapsed and/or refractory myeloma ( Figure 1 ). Our modifi ed dose escalation schema allows us to limit doses to specifi c organs when dose limiting toxicity is reached for a specifi c organ, while escalating the doses in other organs where dose limiting toxicity is not reached. Baseline characteristics, prior therapies and duration of prior responses were documented. Dose limiting toxicities and radiation toxicities were assessed by the Regimen Toxicity scale and LENT-SOMA respectively. Results: Seven patients (5 males and 2 females) with a mean age of 54 years received a second ASCT using IMRT conditioning, where all patients had previously received a Melphalan 200mg/m 2 ASCT. Median follow-up from 2nd ASCT is 16 months. Patient demographics, disease characteristics, therapy received as well as pragmatic clinical outcomes are summarized in Table 1 . No dose limiting toxicities were noted with IMRT ASCT at 18Gy. Conclusion: Tomotherapy® delivery of IMRT based ASCT is safe and has the potential to improve the quality and duration of responses in patients with relapsed myeloma. Background: There are considerable concerns regarding the appropriate use of health care resources to reduce costs and waiting lists associated with autologous (Auto) hematopoietic progenitor cell transplantation (HPCT). One of the strategies to reach this goal is outpatient-based. We report the results of an outpatient, home-treatment program for patients (pts) receiving high-dose chemotherapy (HDC) and stem cells support. Patients and Methods: Between July 2010 and December 2012, supportive care in the aplastic phase after HDC was transferred from the hospital to the home setting using three diff erent approaches. Eligible pts had received treatment with a single course of High-Dose Melphalan (HDM) (200 mg/mq) followed by Auto-HPCT for Multiple Myeloma. In the fi rst inpatient cohort (IN), the supportive care designed for at home use was administered in hospital until neutrophil recovery to 0.5 x 10(9)/l. In the second outpatient cohort (OUT), pts were discharged the day after HPCT, but supportive care was delivered daily in the outpatient clinic. The third home care cohort (HC) consisted of pts who were discharged the day after HPCT and then received all subsequent supportive care at home, without any check-up in hospital, with the assistance of specialized home care transplant professionals. In the OUT and HC, pts were required to have an available caregiver at home to help monitoring patient's condition, drug administration and fl uid intake. In case of refusal of outpatient treatment or lack of available caregivers, pts were included in the inpatient cohort. Results: 82 pts were treated (IN=47, OUT=24 HC=11). IN were hospitalized (as days of hospitalization after HPCT) in the aplastic phase for a median of 16 days. OUT attended the outpatient clinic in the aplastic phase for a median of 9 days. In the OUT cohort, a patient could not be discharged after stem cells infusion, due to general malaise, and readmissions to hospital were 2/24 due to chemotherapy-related toxicity and severe arrhythmia, respectively. In the HC cohort, pts were seen at home twice a day for a median of 10 days and readmission to hospital was necessary in 1 case due to fever. No infectious deaths or unexpected emergencies occurred in the OUT or HC cohort. Neither was there any suggestion of an increased number of fevers, infections, or other complications.

Conclusions: At home management in the aplastic phase after HDM and Auto-HPCT is feasible without major concerns of increased toxicity or infections. Background: MM is a disease of older pts with a median age of 69 at diagnosis, but a signifi cant number (6%) of pts are younger than 50 at diagnosis. Although, there are a few reports that address the outcome in younger pts, there is limited information on their disease characteristics, response to therapy, and overall outcome. Methods: We compared the characteristics and outcome of 341 younger pts (<50 years) with 1129 older pts (≥50 years) who received high-dose chemotherapy and auto-HCT at our institution between July 1988 and December 2011. All pts received auto-HCT in fi rst remission or for primary refractory disease. The primary objective was to compare the response rates, progression-free (PFS) and overall survival (OS) between the younger and older groups. Results: Pt characteristics are summarized in the attached table.

No signifi cant diff erence in baseline characteristics was noted between groups, including ISS score, β-2-microglobulin (B2M), cytogenetics, lactate dehydrogenase (LDH), serum creatinine, bone marrow plasma cell infi ltration, and serum calcium levels.

The younger cohort had a higher LDH (p=0.0006) and lower B2M (p=0.037) at the time of auto-HCT, and was less likely to have received novel agents (thalidomide, lenalidomide or bortezomib) as induction (p=0.0001). Median follow up for all pts and for surviving pts was 39.5 and 42.2 months, respectively. There was no signifi cant diff erence in time to neutrophil engraftment or complete response (CR) rate between the 2 groups; although there was a higher rate of partial response (PR; p=0.003) and very good partial response (VGPR; p=0.005) among the older group. Median PFS for <50 years vs. ≥50 years was 28.2 and 30.9 months, respectively (p=0.72). Median OS was 91.8 and 78.0 months, respectively (p=0.07). Pts <50 years who received novel agents for induction had similar PFS but a longer OS (p=0.04; Figure) than older pts who received novel agents. On univariate analysis, use of novel agents for induction, B2M <3.5 at diagnosis or at the time of auto-HCT, and auto-HCT after the year 2000 were associated with signifi cantly longer PFS and OS. Conclusions: Both younger and older pts with MM had similar CR rates and PFS after auto-HCT. There was a trend towards longer OS in younger pts, which became signifi cant when restricted to pts receiving novel agents for induction. (1) (2) (3) (4) . The median number of CD34+cells/ kg x 106 collected was 11 (5.72 -36.57) . No case of febrile neutropenia requiring hospitalization and IV antibiotics was observed. One patient (2.1%) required red blood cell transfusion and 7 (14.9%) required platelet transfusions. Conclusion: Etoposide +G-CSF is a highly eff ective and safe mobilization regimen in MM patients.

The Extramedullary plasmocytoma (EP) is a plasma cell tumor which involves soft tissues, without any signs of systemic spread. EP have an incidence of 7%-17% in patients (pts) at the time of diagnosis and 6%-20% during the course of the disease. It can be found at any body sites. Response to conventional treatments is poor. Objective: in our study we wanted to test the hypothesis that standard US could detect EM and that contrast-enhanced ultrasound sonography (CEUS) could detect microvascular changes (MC) and possibly suggest response to treatment. Methods: we prospectively examined patients (pts) who were admitted on our BMT ward to undergo either ASCT or allo-BMT. All pts received abdominal and soft tissues (ST) US and all lesions detected were biopsied. All lesions were assessed with CEUS which utilizes a second generation sulfur-exafl uoride-based contrast media. CEUS allows for real-time imaging of the microcirculation. Results: out of 115 pts (enrolled in the last 3 years) we found 11 pts having EP (9.6% incidence). Sites involved were : retroperitoneum (N=3 pts), liver (N=2 pts), pancreas (N=3 pts), ST (N=3 pts), pleural (N= 1 pts), lung (N= 1), spleen (N=1). Disease status at EP diagnosis: VGPR (8) or SD (2) Introduction: Autologous hematopoietic stem-cell transplantation (AHSCT) has established itself as the preferred therapy for younger patients diagnosed with multiple myeloma. Throughout its history, one of the main challenges of AHSCT has been the difficulty in mobilising the necessary stem cells. In 2002 a scoring system was introduced in order to reduce the apheresis procedures needed (Table 1 ). Under this system, the patient is evaluated premobilisation in an attempt to detect patients with a risk of poor mobilisation (poor mobilisers). The patient is thus 'scored' and this score is then used to outline the treatment. Target: Evaluate the infl uence of the mobilisation system score on the stem-cell apheresis process, based on the study of the processed volemia ratio and the number of performed aphereses. Study Design and Methods: A total of 77 patients with multiple myeloma treated with ASHCT, aged between 47 and 66 were evaluated. 23 underwent ASHCT before the scoring system was established ( Group 1, 1996 Group 1, to 2002 , while 54 were treated with the scoring system already in place ( Group 2, 2003 Group 2, -2011 . The analyzed parameters were the volemia ratio (blood volume processed in the apheresis (liters) / patient volemia) and the number of apheresis procedures. G-CSF (Granulocyte Colony Stimulating Factor) was used for mobilisation, dosed at 10 μg/kg for 4 to 5 days. If the pre-treatment score was over 2.5 points the patient was categorised as a poor mobiliser and the C-GSF dose was doubled.

Results: The reduction in both the volemia ratio (Table 2 ) and number of extractions (Table 3) in post-score treatments was statistically signifi cant. New pre-transplant regimes such as vincristine, doxorubucin and dexamethasone (VAD), other thalidomide-bortezomib combinations or the disuse of melphalan may have had eff ects on the measured improvements. In our study, only 5 Group 2 patients had received melphalan as induction treatment. In this 5 patients, both observed parameters are inferior to the mean values obtained in Group 1. Conclusion: The study shows that the score-based prediction system facilitates obtaining the hematopoietic stem cells needed in AHSCT. The number of apheresis procedures as well as the volemia ratios fell signifi cantly using the prediction score.

D. Schneidawind (1), K. Oehrlein (2), K. Weisel (2), C. Faul (2), L. Kanz (2), W. A. Bethge (2)(1

Published experience with allogeneic hematopoietic cell transplantation (allo-HCT) as salvage treatment of relapsed (REL) or progressive (PRO) multiple myeloma (MM) after autologous HCT (auto-HCT) in the era of proteasome inhibitors (PI) and immunomodulatory drugs (ID) is limited. From 2001-2012 27 consecutive patients (pts, median age 52 years (yrs), range 38-67, f=7, m=20) with REL (n=7) or PRO (n=20) after single (n=11) or tandem (n=16) auto-HCT were treated with salvage allo-HCT at the University Hospital Tuebingen. Busulfan/cyclophosphamide (CY)/total marrow irradiation (n=8), fl udarabine(FLU)/CY/2Gy total body irradiation (n=8), FLU/melphalan (n=5), FLU/thiotepa/melphalan (n=2) or FLU/treosulfan (n=4) were used for conditioning. Immunosuppression consisted of antithymocyte globuline, calcineurin inhibitor combined with mycophenolate mofetil or methotrexate. Allo-HCT was performed after a median of 29 months after auto-HCT. G-CSF mobilized peripheral blood stem cells from matched related (n=8), haploidentical (n=2), matched unrelated (n=14) or mismatched unrelated (n=3) donors were used. No grafts were rejected. 9 pts received donor lymphocyte infusions after a median of 353 days in the absence of graft-versus-host disease (GVHD) due to mixed chimerism (n=1), REL (n=4) or PRO (n=4). Median follow-up was 1426 days (range 184-3512) resulting in an estimated 4-year overall survival (OS) and event-free survival (EFS) of 37% and 15%, respectively. Cumulative incidence of non-relapse mortality (NRM) and REL/PRO at 4 yrs was 22% and 63%. Auto-HCT (n=11, 2001 -2005 for induction prior to allo-HCT showed a decreased OS compared to induction regimens containing thalidomide (n=2), lenalidomide (n=7) or bortezomib (n=6) S209 and the role of DLI and pretransplant characteristics in patients who had a suboptimal response to an autologous stem cell transplant (less than a year of Progression free survival) and underwent a T-cell depleted allograft for multiple myeloma. Patients and methods: 19 patients received a reduced conditioning non-myeloablative transplant with Fludarabine/Melphalan and in vivo Alemtuzumab. All the patients received PBSC grafts and ciclosporin as GvHD prophylaxis along with 30mg of Alemtuzumab IV over one day for sibling donors and 50mg IV over 2 days for unrelated donors. 9 patients had a sibling donor and 10 had a graft from an unrelated donor. The median age of the patients was 48.7(median 38-59). The median follow up was 41 months(range 3-110mo). 9 patients had an IPSS score of 1, 5 had an IPSS score of 2 and 5 had an IPSS score of 3 at diagnosis. 7 of the patients were in CR2 at the time of transplant 9 were in PR2 and 2 in VGPR2. The average lines of treatment was 3 pretransplant (range 2-5). Results: The 3 year overall survival was 47%. The non relapse mortality was 11% in the fi rst year. All patients engrafted with a median neutrophil engraftment of 16.5 days (10-35) and a median Platelet engraftment (PLT>20 unsupported) of 20days (range 13-27). 50% of patients developed Grade I-II GvHD but only 15% severe grade III-IV. 9 patients received DLI 4 for mixed chimerism and 5 for disease relapse. IPSS score and disease status pretransplant were not signifi cant in predicting overall survival and disease free survival but the number of treatments pretransplant was predictive of non relapse mortality (p:0.04). The overall relapse rate was 52% (10/19) . Interesting enough acute GVHD was not signifi cant for infl uencing disease free survival but patients who received DLI had an improved Overall survival (P:0.05). Conclusion: Although the number of patients in our study is low Reduced intensity conditioning allografts for myeloma is an efficient and low toxicity treatment for those who had a suboptimal response post autologous stem cell transplant. The role of preemptive DLI need to be explored as well as post transplant maintenance treatment(or a combination of both) to maximise the response and minimise relapse rates. However it is still remains debatable whether a reduced intensity allograft is a curable option for these patients as late relapses can occur. Results: Of 14 patients treated with TT/Mel regimen (male 6; female 8; median age 63), 9 were receiving fi rst ASCT and 5 were receiving second ASCT. At the time of transplant 2 patients were in CR, 3 in VGPR, 5 in PR, while the other 4 showed stable or progressive disease; median number of prior treatment lines was 3 (range 2-8). All patient received peripheral blood stem cells (Median number of nucleated cells reinfused 3,5x108/kg) and engrafted, with a median number of days to neutrophil count ≥1000/mm3 of 9,5 (range 9-11), and a median number of days to platelets count ≥20.000/mm3 of 12, 5 (range 11-17) . No patients died for transplant related mortality; median number of days of hospitalization was 11 (range 9-15). Most common adverse events included standard toxicities: 4 patients (28%) experienced oral mucositis (2 grade II/III), 6 patients (42%) gastrointestinal mucositis (3 grade II/III) and only 1 patient experienced a mild liver toxicity, which was self-limiting. Fever of unknown origin, responding to empirical antibiotic therapy, was observed in 5 patients (35%). The overall response rate was 42% (5CR/1VGPR), 1 patient maintained PR (7%), while the other 7 showed active disease after ASCT (5 of them performed ASCT as salvage therapy for high risk disease). At a median follow-up of 12 months, 5 patients died for disease progression, while 9 were alive; median overall survival was of 9,6 months and disease free survival was of 6,4 months. Conclusion: TT/Mel regimen was feasible and well tolerated in terms of toxicity; response rate and survival were as expected for MM, but effi cacy in terms of disease control should be investigated in larger studies.

Use of pegylated G-SCF compared to G-SCF to mobilize patients with newly diagnosed myeloma undergoing ASCT: why is a single injection unable to overcome years of practice with G-CSF? V. Robin (1), L. Garderet (2) , A. Triff et (3), M. Lambermont (4), A. Deweweire (5), C. Doyen (6) , S. Ikhlef (2) , I. Van Riet (7), D. Mayne (1) Autologous Stem cell transplantation (ASCT) remains the golden standard treatment in naïve Multiple Myeloma (MM) patients eligible for this procedure. To date,G-CSF is the most common cytokine administered for peripheral blood stem cell (PBSC) mobilization however a proportion of patients fails to mobilize adequately. Pegylated G-CSF (Peg-GCSF) was considered for mobilization while reducing the duration of treatment and off ering better control of the leukapheresis process.From May 2006 to November 2011, 68 pts with newly diagnosed MM were included into a phase II randomized trial. Responders to 3 to 4 cycles of induction therapy were randomized to receive mobilization treatment by fi lgrastim 10 μg/kg daily administered until last day of leukapheresis (arm A, n= 23) vs a single injection of pegG-CSF 12 mg (arm B, n= 23 ) vs pegG-CSF 18 mg (arm C, n= 22 ). Induction chemotherapy with lenalidomide was not tolerated in this study due to raising concern about its ability to adversely aff ect mobilization. One patient was excluded from the analysis since induction therapy contained lenalidomide. Given the narrow mobilization peak observed from previous studies using PegGCSF, CD34+ count was required 48 hours post growth factor (GF) administration until a minimum of 10 CD34+/μL was reached determining the fi rst day of leukapheresis. In 19 patients (28%), the 48 hours post GF was missed due to organizational issues.

The CD 34 peak was reached 72 hours after GF administration in arm A; 96 hours in arms B and C.The optimal yield was considered as a min of 4 x 106 CD34/Kg and the minimal yield a min of 2 x 106 CD34/Kg. Patients unable to reach the minimal yield were considered as mobilization failure. This concern 4 patients (Arm A = 1; Arm B = 1 and Arm C = 2). Leukapheresis data are showed in table 1. No patient did present a primary graft failure and 1 did receive a transplant back up.11 patients were mobilized again by G-SCF while they had a suffi cient count of peripheral CD34 cells. These protocol violators were excluded from the transplant analysis since reinfused cells were issued from the second mobilization or from a combination of both. In summary, mobilization by PegGCSF was successful and showed no delay in hematological recovery as showed in table 2. The use of PegGCSF 18 mg showed no additional benefi t compared to 12 mg. Altogether, these results suggest that despite very good results obtained with PegGCSF, use of GCSF has grown into an habit.

BSBMT/UKMF myeloma X relapse (intensive) trial: barriers to recruitment and randomization C. Morris (1), C. Williams (2), S. Bell (3), M. Fletcher (3), A. Szubert (3), K. Yong (4), J. Cavet (5), J. Cavenagh (6), J. Snowden (7), J. Ashcroft (8), J. Brown (3), G. Cook (9) (1)Queens Univeristy (Belfast, GB); (2) The proportion of patients recruited into clinical intervention studies remains disappointingly low and initiatives to improve participation are very much needed. In trials where there is a randomization between to very diff erent interventions e.g. transplant/non transplant option these elements are magnifi ed. Despite the successful early closure of the BSBMT/UKMF Myeloma X relapse trial with 297 patients registered (174 randomized), recruitment to this study has been diffi cult. Eligible patients with MM relapsing after a prior ASCT were approached for enrollment into this study aimed to examine the clinical utility of a second autologous stem cell transplant. The central trials unit recorded the reason for non-entry from a multiple-choice list, with clinicians being invited to give further details on the reason for non-entry. These details have been analyzed to provide an insight in to trial recruitment diffi culties,

S211 to ascertain what may be protocol-specifi c or indigenous to the patient demographics. In total, 392 patients screened for trial participation did not enter the study. 73 patients failed to meet criteria with regard to eligibility of whom the largest group were 13 patients who had early relapsed disease that did not meet the trial entry criteria together with 9 patients who were relapsing but symptom free and a further 4 patients whose relapse was not confi rmed on bone marrow aspirate taken for this study. 35 patients were inappropriately referred to participating centres having had no previous transplant and a further 34 patients had relapsed within the time stipulated for remission post fi rst transplant. 25 patients were referred inappropriately at the time of diagnosis while 15 were in second or subsequent remission. 85 patients declined to take part in the study, of these 13 patients did not want to undertake the travel to the centre performing the study and wished to have treatment closer to home. 32 patients did not want to have a second transplant; in contrast 15 patients declined as they wished to ensure they did receive a transplant as part of their relapse therapy, 3 patients opted to enroll in alternative studies. 15 patients screened for the trial were not recommended to take part by their doctors and a further 12 were considered too unwell to participate. These data highlight problems in undertaking clinical studies, and serves to underline the importance of careful patient selection, especially in relation to perceived patient choice.

Successful combined haemopoietic stem cell and kidney transplantation from HLA-identical sibling donor in patient with multiple myelomas L. Lengyel (1), P. Remenyi (1), A. Barta (1), A. Batai (1), Z. Csukly (1),

(2)National Institute of Oncology (Budapest, HU) ; (3)University of Semmelweis (Budapest, HU) Introduction: Very few cases of double transplantation from the same donor (haemopoietic stem cell and kidney) are reported in multiple myeloma patients. Methods: In our patient aged 43 multiple myeloma (κ light-chain, t,11,14) was diagnosed on the background of chronic renal insuffi ciency in Nov.2008. Very good partial remission was achived with bortezomib-thalidomide-dexamethasone (VTD) therapy and hemodialysis. The patient underwent autologous periferal blood stem cell (PBSC) transplantation after single melphalane (140 mg/m>2) conditioning regimen. Complete remission (CR) was achived, but the anuria remained, so we decided to do double transplantation, as he had a HLA-identical brother. G-CSF mobilized allogeneic PBSC was collected from the sibling donor, and the allo-graft was cryopreserved. After this stem cell collection the kidney transplantation was carried out from the same donor, on 21 Apr.2011 succesfully. Rapamune and tacrolimus were applied as immunosuppressive (ISU) treatments. Seven months following the successful kidney transplantation the allogeneic PBSC transplantation was done at the incipient relapse of the underlying disease on 24 Oct.2011. Conditioning regimen for the allogeneic transplant included total body irradiation (with the protection of the new kidney in the low pelvic region) + melphalane 140 mg/ m>2. Rapamune and tacrolimus were continued for graft versus host disease (GVHD) prevention. Several complications developed, as severe oro-pharyngeal mucositis, neutropenic fever, sepsis with acute renal insuffi ciency. Acute GVHD (gut) gr.II. was verifi ed with colon biopsy on 28 post-transplant day and treated with 2 mg/kg methylprednisolone successfully. Result: This "double" transplantation was successful: our patient is well, living in CR of multiple myeloma, his renal functions are normal and he has got a complete donor chimerism, no GVHD activity 20 months following kidney and 14 months following the allogeneic PBSC transplantation. He receives only tacrolimus as ISU treatment in decreasing dose since Sep.2012.

Summary: The combined HLA-matched PBSC and kidney transplantation for multiple myeloma with renal failure for patient with a sibling donor gives an opportunity to control the underlying disease with graft-versus myeloma eff ect. There is no kidney graft rejection because of the full donor chimerism, and the patient can be free of ISU drugs , in contrast to patients undergoing a cadaver kidney transplant.

Thiotepa/melphalan as conditioning regimen for multiple myeloma patients not achieving complete remission after the reinfusion of autologous HSC. Preliminary data from a multicentre study M. Musso (1), A Crescimanno (1), M Martino (2), G Messina (2), G.

Thiotepa is widely used in the conditioning regimens for autologous and allogeneic transplants, due to its acceptable toxicity profi le also in association with other chemotherapic agents, and of proven eff ectiveness. The objective of our experience is the assessment of feasibility and effi cacy of Thiotepa / melphalan association as conditioning in patients already undergoing reinfusion of autologous peripheral blood stem cells, which have not achieved complete response; other eligibility criteria include age between 18 and 70 years, ECOG ≤ 2, adequate cardiac function (FEV> 45%), hepatic (bilirubin ≤ 2mg/dl and / or AST / ALT <3 times normal) and renal function (creatinine <1.6 mg / dl, and / or creatinine clearance 65mlmin), serology for hepatitis B and C negative or absence of viral replication, signing the informed consent.

The treatment schedule consists of Thiotepa 225mg/mq on day -5 and Melphalan 140 mg / sqm on day -2, followed by infusion of peripheral blood stem cells on day 0. Our experience includes 15 multiple myeloma patients , median age 58 (range 24-70), M / F 8/7. We infused a median of 5,1x106/Kg CD34 + cells (range 3,25-7,06); haematological recovery were observed on day 12 (range [10] [11] [12] [13] [14] [15] [16] [17] and 12 (range 0-22) for ANC / mmc and PLT> 20000/mmc, respectively. The transfusion requirements stood at 1 (range 0-5) and 1 (range 0-3) for RBC and PLT units, respectively. Extraematological toxicity consisted mainly in CINV and mucositis up to grade 3 CTC ( only in one patient there was liver toxicity grade 2), febrile episodes occurred in 9 patients (5 microbiologically documented infections), the lenght of hospitalization was of 20 days (range 20-30).

The above data have shown comparable to those seen in patients undergoing conditioning with melphalan. Our preliminary experience demonstrates the safety and feasibility of the proposed scheme in terms of toxicity, a larger series of patients and a longer follow-up time will be able to provide data on the eff ectiveness (EFS and OS). Background: allogeneic haematopoietic stem-cell transplantation (allo-HSCT) is a potentially curative therapeutic approach for patients with hematologic malignances, including multiple myeloma (MM). However, the role of allo-HSCT in MM is controversial due to the high attributable procedure-related mortality previously reported. Objective: to analyze the outcome of patients with MM undergoing allo-HSCT vs. others hematological diseases in a single center. Patients and method: we retrospectively studied 102 patients (pts) with a median age of 48 years (range 2-64), who underwent allo-HSCT in our institution between January 2007 and November 2012. The patients› baseline diseases were: MM 30 pts (29%), AML/ MDS 33 pts (32%), ALL 19 pts (18%), and NHL/HL 20 pts (21%). 43% of pts had undergone a previous transplant. 51% pts received allo-HSCT from siblings, and 49% from unrelated donors. The source of HSC was peripheral blood in 55%, bone marrow in 39% and umbilical cord blood in 6% cases. All pts with MM received conditioning with fl udarabine (150 mg/m 2 ), melphalan (140 mg/m 2 ) and thymoglobulin (1.5-3 mg/kg). The rest of the cases received conditioning with standard (61 pts; 85%) or reduced intensity (11 pts; 15%) regimens. Median follow-up of the series was 24 months (range: 1-72). Results: median hospital stay was 35 days (range: 24-79), with no diff erences among diseases. Peritransplant mortality was 5% (0% for pts with MM, and 7% for the rest). Overall survival (OS) at day +100 was 88 % (93.4% for pts with MM, and 87.5% for the rest). The rate of progression/relapse was 30% for pts with MM, and 29.2% for the rest. The OS rate at 2 years was 77 % for MM pts, and 58.3% for the rest. Progression-free survival at 2 years was 58% for MM pts, and 67% for the rest. There were no signifi cant betweengroup diff erences in OS and PFS. Conclusions: in our experience, allo-HSCT for pts with MM is a potentially curative and feasible therapeutic approach, with a procedure-associated morbimortality similar to that of other hematological malignances. Introduction: Autologous stem cell transplantation (ASCT) is standard approach for initial or treatment of relapses for multiple myeloma (MM) pts younger then 65 years. ASCT is connected with better overall survival (OS) and progression free survival (PFS)in comparison with conventional therapy. Aim: We retrospectively analyzed pts with MM treated with ASCT in our center from 1998. till 2010. Methods: Ninety nine procedures of ASCT in 85 de novo MM pts were performed after one or two lines of initial treatment. Male/ female ratio in our group was 49/ 36, average age was 52 years (37-64). Majority of pts, 56 (66%) were in III clinical stage. Pts have received 3-6 cycles of induction (VAD, CTD or TAD). Prior to ASCT, 31 pts (36%) were in CR+VGPR, 38 pts (45%) in PR, 9 pts (10,58%) were in less then PR and 5 pts (5,88%) had PD. Median time from diagnosis till ASCT was 13,9 months . Single ASCT was done in 85 pts (86%), tandem in 4 (4,7%) and secondary in 10 (11,76%) pts. Mobilization was combination of Cyclophosphamide (Cy) and Etoposide with G-CSF in 77 pts (91%) or Cy alone with G-CSF in 8 pts (9%). Seventy one pts (86%) were conditioned with Melphalan (Mel) (200mg/m 2 ), while 14 pts (16%) were conditioned with Buslulphan (16 mg/kgBW), Cy (120 mg/kgBW) and Mel (140 mg/m 2 ). MNC were collected mostly with one "high volume" apheresis and median number was 9,85x10 8 /kgBW (range 3,8-28x10 8 ). OS and duration of response were showed with Kaplan Meier method. Results: Engraftment was observed on +12. day after ASCT (range 8-36), respectively. In 2 pts there were no reconstitution and in 3 pts it was delayed. Overall response rate (ORR) is achieved in 73 (91%) pts. After ASCT, 46 pts (54%) have achieved CR+VGPR, while 27 pts (32%) were in PR. Nineteen (24%) pts have died and 61 pts (76%) are still alive. Median PFS for 32 pts (40%) after ASCT was 13 months. In 10 of those pts, we have done secondary ASCT. Median OS in 80 pts (2 have died during the procedure and 3 were lost from following) is 40 months with maximal follow up for 57 months. Conclusion: Achievements of CR+VGPR before and post ASCT are important predictive factor for OS and PFS. Better OS and PFS were achieved in those pts in whom ASCT was performed early. Transplant related mortality (TRM) is observed in heavily pretreated pts who were transplanted more then 12 months after diagnosis. TRM in our group is 5%. New agents and better supportive therapy together with ASCT with well defi ned maintenance will improve treatment results even more. Introduction: MM is the main indication for high dose chemotherapy with ASCT The recent development of novel agents like bortezomib, thalidomide, has improved response rates.There is concern about their possible deleterious eff ects on PBSC (peripheral blood stem cell) collection and engraftment following ASCT. We analyzed retrospectively our experience with conventional chemotherapy (VBCMP/VBAD) induction and a novel regimen (VTD) in newly diagnosed MM patients and compare their infl uence on stem cell yield and engraftment effi ciency. Patients and Methods: We reviewed 31 newly diagnosed, symptomatic MM patients treated with ASCT as part of frontline therapy from November 2003 to November 2012. They received: group A: VBCMP/VBAD alternating regimen,6 cycles (4 before PBSC collection) 22 patients (pts) and group B: VTD 6 cycles (9 pts). Pts characteristics were homogeneous in both groups (see table 1 ). All patients were mobilized with GCSF 10mcg/kg/d for 5 days after induction treatment for PBSC collection. Stem cells (SC) were frozen to -80ª C by non-controlled rate freezing with DMSO 5%. All patients underwent ASCT with Melphalan 200 as conditioning regimen and received GCSF 5mcg/kg/d from day +5. Results: The response rate prior to ASCT for group A was 13.6% CR(complete response), 86.4% PR (partial response); in group B it was 66.7% CR, 11.1% VGPR (very good partial response) and 22.2% PR. Median number of CD34 in PB (peripheral blood) prior to apheresis was 30 (10-66)/mcl in group A and 53 (10-70)/mcl in group B. In both groups the median number of apheresis performed was 2. The median number of CD34 was 2.9x106/Kg in group A and 3.05x106/kg in group B; median number of MNC (mononuclear cells was 8.42x108/kg and 5.73x108/kg in group A and B respectively. No patient developed adverse events during the mobilization and apheresis procedure. One patient in group A (4.7%) failed (< 2x10e6 CD34/Kg) the fi rst mobilization attempt and received Cyclophosphamide+G-CSF with successful collection. All patients received ASCT as planned and achieved engraftment. Median time to neutrophil and platelet recovery was 11 days(d) 9-15) and 11d(11-30) respectively in group A and 11d(10-13) and 10(9-13)in group B. Median number of packed red blood cells (PRBC) and platelets transfusions were 2(0-10) and 2 in group A and 2(0-2)and 2(0-3) in group B. Conclusion: In our experience VTD is an eff ective induction regimen for MM with an appropriate stem cell yield and time to engraftment after ASCT, not inferior to our previous chemotherapy regimen. No eff ective treatment exists for neuroinfl ammatory and neurodegenerative disorders. Future treatment of multiple sclerosis (MS) aims at restoring myelination and neurological functions as well as re-induction of self-tolerance. Mesenchymal stromal stem cells (MSC) are known to be anti-infl ammatory and multi-potent.

Using MSCs from green fl uorescent donors for treatment of autoimmune encephalitis in mice, we documented that MSCs can cross the blood-brain barrier, regulate autoimmunity and control paralysis. Based on these observations we pioneered a phase I/II open clinical trial using autologous bone marrow derived MSCs in 13 patients with severe MS failing all conventional modalities and14 patients with very advanced amyotrophic lateral sclerosis (ALS). We confi rmed that treatment with MSCs is feasible, safe and potentially eff ective. Based on our published preliminary study, a total of >250 patients were similarly treated at our center, mostly patients with MS, ALS, autism, stroke, each treated with 106 MSC/ Kg intrathecally and additional 0.5-1x106 MSC/Kg intravenously. Treatment was uneventful with self-limited headache due to lumbar puncture being the most frequent complaint (70%). A total of 60% of patients with MS reported improved outcome, some with very signifi cant objective improvement of EDSS score. No major side eff ect were developed or reported during a follow up period of nearly 6 years. In ALS treatment seemed to delay disease progression although further prospective studies are needed to confi rm effi cacy of treatment. Treatment seemed to be eff ective in autism with objective signs of improvement confi rmed by pediatric neurologist in one of 5 children and by the parents in other 4. More recently, we discovered a new technology for diff erentiation of bone marrow, adipose tissue and cord/placenta derived MSCs into neural stem cells, oligodendrocytes, astrocytes, dopaminergic neurons and also to motor neurons. We conclude that treatment with multi-potent undiff erentiated MSCs is safe and potentially eff ective for immune regulation of MS possibly also for facilitation of remyelinization. Treatment with MSCs should be investigated prospectively in MS and additional neurodegenerative disorders. In the future diff erentiated MSCs may provide better opportunities for more eff ective regeneration of neurological defi cits caused by destructive neurological diseases. Pre-clinical investigations are underway to confi rm effi cacy of diff erentiated MSCs. Objective: Endothelial-colony forming cells (ECFCs) can be readily expanded from human umbilical cord blood and can facilitate repair of endothelial injury. E-selectin and SDF-1α are produced following endothelial injury and can regulate endothelial progenitor homing. Mechanisms of vascular repair specifi c to the mode of injury have not been well described in homogenous cell populations such as ECFCs and are needed for development of more eff ective vascular repair strategies. Methods and Results: Lipopolysaccharide (LPS)-induced endotoxic injury to mature human umbilical vein endothelial cells (HUVEC) was compared with hypoxic and radiation injury. E-selectin expression in HUVEC cells is markedly increased (208-fold) following LPS-induced injury and facilitates increased ECFC adhesion and migration function in vitro. SDF-1α expression remains unchanged in LPS-treated HUVEC cells but increases more than 2 fold in fi broblasts undergoing similar endotoxic injury. SDF-1α induces expression of E-selectin ligands on ECFCs and facilitates greater E-selectin-mediated adhesion and migration of ECFCs in a CXCR4-dependent manner. Induction of E-selectin expression in HUVECs following hypoxic or radiation injury is negligible, however, while SDF-1α is increased markedly following hypoxia, highlighting injury-specifi c interactions between mediators of vascular repair.

Conclusion: E-selectin mediates adhesion and migration of ECFCs following endotoxic endothelial injury. SDF-1 α augments E-selectin mediated ECFC adhesion and migration in a CXCR4-dependent manner, highlighting the importance of injury-specifi c mediators in the coordination of vascular repair.

Cord blood embryonic-like stem cells are a heterogeneous population that lack self-renew capacity C. Alvarez-Gonzalez (1) It is now clear that human umbilical cord blood (hUCB) can be a source of not only Haematopoietic Stem Cells but also a range of diff erent stem cells populations, including a very rare embryoniclike stem cell (ELSC) population. This fraction has been described as lacking CD45 expression but expressing markers typical for pluripotent stem cells. The aim of this work was to characterise, isolate and expand this stem cell fraction for future regenerative medicine purposes. Methods: Cord blood mononuclear cells (CBMC) were prepared by lysing red blood cells (BD PharmLyse), or by density gradient centrifugation (Ficoll-Paque PREMIUM). The CBMCs were enriched for ELSC cells by negative selection by biotin-conjugated antibodies (Ab) to CD235a, CD11b, CD123, CD45, and CD61 and passage through an LD column following incubation with anti-microbead conjugated Ab. The resulting population was characterized for surface and intracellular markers by fl ow cytometry, fl uorescence microscopy and RT-PCR and plated into diff erent stem cell culture conditions. Results: We isolated a small population with high density and nuclei/cytoplasm ratio and expressing the stem cell markers CD34 and CXCR4, but in opposition to some reports, not CD133. Despite the expression of pluripotent markers such as Sox2, Oct3/4, and Nanog at the mRNA level, these cells did not shown any expansion in vitro using a variety of culture conditions frequently used to grow embryonic and/or adult stem cells. Further analysis by Flow Cytometry of the lineage-(mature leukocyte markers) CD45population, showed the presence of a new Lineage-CD45-Nestin ± population that has not described previously in hUCB.

Conclusions: The Lineage-CD45-stem cell fraction is a heterogeneous population representing a very low percentage of the stem cells present in the hUCB. The presence of this heterogeneity could explain the diff erences among reports. Groups could be sorting diff erent subpopulations by the use of distinct methods. The presence of Nestin could correspond to a previously described mesenchymal progenitor called small-sized nestin-positive bone marrow stem cell (S-BMSC); nevertheless more work is needed to clarify this correlation. Finally, the fact they did not show any capacity for self-renewal might indicate a quiescent population and could cast doubt on their defi nition as ELSC. However, only by identifying a homogenous population is this likely to be resolved.

Toxic eff ects of detergents on mesenchymal stromal cells for repopulation of decellularized heart valves S. Sergeevichev (1), V. Sergeevicheva (2) The prognosis for patients with rhabdomyosarcoma or osteosarcoma presenting with primary metastatic or recurrent disease is poor. New therapeutic approaches beside conventional chemotherapy are needed for this group of patients. NK cells are well known to provide MHC-independent recognition of transformed or otherwise stressed cells, leading to cytolysis and local production of proinfl ammatory cytokines, which makes them a promising tool for tumor immunotherapy.

We analyzed the activity of NK cells from fi ve patients with diff erent sarcomas (osteosarcoma, rhabdomyosarcoma, clear cell sarcoma : 6.4-9.5 ) and led to median time to ANC>500/μL and PLT>20.000/μL of 9 (IQR: 8-9) and 9 days (8-10), respectively. 3 poor mobilizers (one in 3rd line) were successfully rescued with off -label plerixafor. Conclusions: To our knowledge this is the largest series reporting results on mobilizations for GCT. Results prompt a preemptive harvest for high risk pts and/or a potential new indication of plerixafor in a subset of pts for whom multiple HDCT courses are still a potentially curable option (3rd-4th line setting). Reinfusion of a large number of CD34+ cells leads to a rapid engraftment and is recommended. (5) ES, were enrolled and submitted to an ASCT after a reduced intensity conditioning regimen consisting of Thiotepa + Melphalan. The donor was an identical sibling in 5 cases or an unrelated donor (UD) in 4. At time of transplant 6 pts were in partial remission (PR), 2 in complete remission (CR) and 1 in progressive disease (PD). Graft versus host disease (GVHD) prophylaxis consisting of Cyclosporin A + Anti-lymphocytic serum and short term methotrexate in UD setting. Stem cells sources were bone marrow in 6 cases and peripheral blood in 3.

Results: The reconstitution of bone marrow function was obtained in all the 9 pts. Acute GVHD of grade II-IV occurred in 4 pts and a complete marrow donor chimerism was observed after 40 and 60 days in sibling and UD setting respectively. After a median followup of 25 (6-37) months, 3 pts died for progressive disease after relapse, 1 pts is alive after relapse and 5 are alive and well. The 2 years probability of overall survival (SE) and event free survival S217 (SE) were 0.55 (0.19) and 0.40 (0.17) respectively. The 100 days treatment related mortality probability was 0.00. Conclusions: Our experience shows the feasibility and the effi cacy of a reduced intensity conditioning regimen followed by ASCT from related or unrelated HLA identical donor to improve the prognosis of ES in relapsed or resistant paediatric patients.

Results of high-dose chemotherapy with autologous haematopoietic stem cell transplantation in the treatment of paediatric brain tumours G Gevorgian (1), E. Morozova (1), I. Kazantsev (1), T. Iukhta (2), S. Safonova (2), Y. Punanov (2), O. Goloschapov (1) (N=5), germinoma (N=4), pineoblastoma (N=2) and atypical teratoid rhabdoid tumor (N=3) received HDCT with auto-HSCT after induction chemotherapy, radiotherapy and surgical treatment. At the moment of HDCT 13 patients were in complete remission (CR), 14 patients were in partial remission (PR) and 3 patients had stable disease (SD). The conditioning regimen for single auto-HDCT consisted of cisplatin, etoposide, and ifosfamide, or carboplatin, etoposide and thiotepa, or thiotepa and temozolomide. In tandem HDCT, the fi rst conditioning regimen was carboplatin and etoposide with intraventricular/intrathecal metotrexat, the second was thiotepa and cyclophosphamide with intraventricular/intrathecal metotrexat. Bone marrow (N=20), peripheral blood stem cells (N=5) or both (N=5) were used for stem cell sources. The mean transplanted CD34+ cell dose was 5.27 x 10 6 /kg (range, 1.0-8.9 x 10 6 /kg). Results: The median follow-up is 12 months (range, 1-82). The median time to engraftment was 16 (range 12-30) and 17 (range 13-86) days after the fi rst and second auto-HSCT, respectively. All patients with SD at the moment of auto-HSCT died of disease progression. Eight of 27 patients with CR or PR relapsed 1-11 months after HDCT, the other 19 patients are currently in CR. The following therapy toxicity was observed: liver toxicity grade 2-3 (N=21), skin toxicity grade 3-4 (N=6), severe mucositis grade 3-4 (N=15), nausea/vomiting grade 3-4 (N=10), infectious complications grade 3-4 (N=18). Two patients died of toxicity. Overall survival (OS) in all groups was 44% and disease free survival (DFS) was 35%. OS was signifi cantly better among high-risk patients in 1st CR compared to patients in 2nd or following CR: 69% and 30%, respectively (p=0,05). The same correlation was observed in DFS: 46% and 26%, accordingly (p=0,04). Conclusions: HDCT with auto-HSCT in pediatric patients with high-risk CNS tumors may be a feasible option for patients in CR or PR after induction chemotherapy. It is ineff ective as a salvage therapy in refractory patients. Objectives: Over the last few years, several targeted agents (TA) have proven, within large randomized trials, to improve survival in advanced renal cell carcinoma (aRCC), thus establishing new standards for both fi rst and subsequent lines of treatment. Despite the improvements achieved with TA, immunotherapy still remains the only treatment which is able to induce long-lasting complete responses in aRCC. More recently, the activity of more sophisticated immunotherapeutic agents reinforced the idea that the manipulation of the immune system could play a key role in this setting. The aim of this study was to evaluate the feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous cytotoxic T lymphocytes (CTLs) in patients with advanced RCC. Materials Aand Methods: CTLs were generated by stimulating CD8-enriched lymphocytes with dendritic cells pulsed with apoptotic autologous tumor cells in the presence of IL-12 and IL-7. Anti-tumor CTLs thus obtained were rapidly expanded in an antigen-independent way and then reinfused after lymphodepleting chemotherapy with cyclophosphamide and fl udarabine, followed by subcutaneous administration of low dose IL-2. Disease status was assessed after every second infusions. Eight patients, median age 51, have been enrolled so far, after signing informed consent, 6 with clear cell RCC, 1 with papillary RCC and 1 with mixed papillary and collecting ducts RCC. The median number of metastatic sites was 4 (2-7) and the median time between diagnosis of RCC and biopsy was 55 months Antibody-mediated in-vivo T-cell depletion is common prior to unrelated (URD) or mismatched allogeneic stem cell transplantation (alloSCT) and optional in HLA-identical sibling (FAM) alloSCT. While anti-thymocyte globulin (ATG) is the current standard, alemtuzumab is an alternative. The optimal dose of alemtuzumab has not been defi ned. This retrospective analysis compares low-dose alemtuzumab with ATG in URD alloSCT and with no antibody in FAM alloSCT. Twenty-eight patients treated with alemtuzumab (10mg, HLAmismatch: 20mg) were matched to 28 patients who have either received ATG (URD) or no antibody (noAB) according disease, disease stage, age, transplant type, and risk state. Both groups were compared for engraftment, outcome, disease-free (DFS) and overall survival (OS), GvHD, freedom from GvHD (ff GvHD) and transplant-related mortality (TRM).

No signifi cant diff erences were found between the groups for leukocyte engraftment, GvHD, ff GvHD, TRM, DFS and OS. There was a trend for reduction of cGvHD by alemtuzumab (p=0.05). A transplant-type stratifi ed subanalysis consolidated equivalency of alemtuzumab and ATG in URD-SCT and indicates possible superiority of low-dose alemtuzumab compared to noAB in FAM-SCT. Low-dose alemtuzumab as part of conditioning regimen prior to alloSCT is safe and comparable to standard ATG. Prospective trials, particularly comparing alemtuzumab vs. noAB in FAM alloSCT should be conducted. (1), J. Peccatori (2) , N Shem-Tov (1), A. Lo Russo (2), R Yerushalmi (1), M. Bernardi (2) , A Nagler (1), F. Ciceri (2) (

Allogeneic SCT is curative approach in AML and MDS. Reducedintensity conditioning (RIC) is feasible in patients (pts) not eligible for myeloablative conditioning (MAC), however relapse rates are increased, especially in pts not in remission. Fludarabine-treosulfan (FT) is an eff ective regimen with limited toxicity. A small dose-fi nding study recommended treosulfan 14 gr/m2 x3 for further studies based on a trend for lower relapses and similar low toxicity compared to lower doses. To better defi ne the outcome after FT and the role of diff erent doses, we analyzed a cohort of 216 pts with AML (n=137) or MDS (n=79) given treosulfan 12 gr/m2x3 in one institution (FT12, n=123) or 14 gr/m2x3 in a second (FT14, n=93 Allogeneic SCT is potentially curative therapy for patients (pts) with lymphoid malignancies. The combination of fl udarabine and treosulfan (FT) has been introduced over the last few years as a relatively dose-intensive, reduced toxicity regimen. It was predominantly explored in myeloid malignancies but there is only limited data in lymphoid malignancies. We studied 54 pts with diff use large B-cell lymphoma (DLBCL, n=17), Hodgkin lymphoma (HL, n=11), T-cell lymphomas (n= 12), follicular/ mantle cell lymphoma (n=9) and CLL with Richter's transformation (n=5). The median age was 53 years (range, 23-70), 31 had chemo-sensitive disease at SCT (CR-23, PR-8) and 23 were chemo-refractory (SD-7, PD-16). 33 pts had a prior autologous SCT. The donor was an HLA-matched sibling (n= 28) or unrelated (n=26). The median follow up is 13 months (range, 1-38). 12 pts had non-relapse mortality (NRM), 3 died of infections, 5 of GVHD (3 acute, 2 chronic), 4 of organ toxicities. The cumulative incidence of NRM was 27% (95%CI 16-46% were predictive of shortened PFS. In conclusion, FT is a promising preparative regimen for allogeneic SCT in pts with lymphoid malignancies. Similar to the experience in myeloid malignancies, NRM rates are reasonable, considering the relatively heavily pretreated and high-risk pt group (43% chemo-refractory, 61% with prior autologous SCT). This is also a dose intense regimen as refl ected by the relatively low relapse rate. Outcome was favorable in pts with chemosensitive disease, but a subset of pts with chemorefractory disease at SCT could also be salvaged. This regimen merits further study in larger comparative studies.

Metabolic enzyme gene variants predispose children receiving a busulfan/cyclophosphamide-based myeloablative conditioning to veno-occlusive disease P.V. Huezo-Diaz (1), C.R.S. Uppungunduri (1) The genes that code for these enzymes contain potential functional variants that may slow down elimination of Bu (GSTA1*B and CTHser403Ile), or increase the activation of Cy (via CYP2C9*1). Individually GSTA1*B and CTHser403Ile have been found to be associated with the occurrence of VOD, whereas the presence of CYP2C9*1 has shown a trend with VOD occurrence. Our objective: To investigate the occurrence of VOD in relation to these genotypes in a gene-gene interaction model. Sample and Methods: Sixty-seven children (50% males, median age 6.5yrs) receiving iv Bu/Cy based myeloablative conditioning regimen were included in this study. Ursodeoxycholic acid was provided as a prophylaxis for VOD. A TaqMan based assay was used for genotyping the chosen SNPs: GSTA1 rs3957356, CTH rs1021737 and CYP2C9 rs1799853. The occurrence of VOD at day 50 was analyzed in relation to the risk genotypes using a Multifactor dimensionality reduction (MDR) analysis. We used the presence of GSTA1*B and CTHser403Ile in a recessive model, and the presence of CYP2C9*1 in a dominant model. Results: Incidence of VOD (Seattle criteria) was 12.1%. The MDR analysis results are shown in table 1, where the last model was chosen as the best by the MDR program. Conclusion: The MDR analysis chose the three gene variant combination, as the best model to predict VOD in children taking a Bu/ CY conditioning regimen before undergoing HSCT, thus there is a gene-gene interaction occurring between these genes. However, caution must be taken because we did not have any individuals with all three risk genotypes, thus the program inferred the risk by observing the data from the other patients which had the two risk genotype combinations. Nonetheless, these results show that either of the models shown in table 1 could be used to predict the occurrence of VOD, some with more sensitivity than others. The consequences of these predictions could give clinicians the option for providing additional prophylaxis or alternative treatments to these patients. Pesaro risk class 3 patients treated with standard protocols continue to have an increased rejection rate which could be as high as 17% to 38%. In 1997 we adopted a new treatment protocol (Pc26) for class 3 patients which lead to reduced rejection and improved DFS (Blood 2004; 104:1201) . However, our subsequent experience with Pc26 showed an elevated rejection rate in class 3 patients which prompted us to modify Pc26 to overcome this complication. A total of 48 class 3 patients with median age of 11 years (range, 5-16) were treated: 26 patients with original Pc26 and 22 with modifi ed Pc26 (Pc26m). Patients had severe iron overload with median serum ferritin of 2626 ng/mL (range, 777-10222) and liver iron concentration of 20,8 mg/g (range, 5-40.7). Median liver fi brosis score was 2 (range, [1] [2] [3] [4] [5] . Median number of RBC transfusions was 140 units (range, 25-307). Treatment regimen involved an intensifi ed preparation with 3 mg/kg of azathioprine and 30 mg/kg hydroxyurea daily from day -45 from the transplant, fl udarabine 30 mg/m 2 from day -16 through day -12, followed by conditioning with iv busilvex, thiotepa 10 mg/kg and CY 160 mg/kg. GVHD prophylaxis was with CSA/methylprednisolone/MTX. Graft rejection occurred in 4 patients treated with Pc26 and none in patients given Pc26m with a cumulative incidence (CI) of 16% (95% CI 5%-32%) and 0% respectively (p=0.06).The probability of OS for patients treated with Pc26 and Pc26m was 85% (95% CI, 67%-94%) and 85% (95% CI 64%-94%), respectively. Respective probabilities of DFS were 73% (95% CI, 52%-88%) and 85% (95% CI 64%-94%) (p=0.52). The CI of grade II-IV acute GVHD was 46% (95% CI 26%-64%) and 28% (95% CI 11%-49%) (p=0.25) in Pc26 and Pc26m arms, respectively. Median follow-up for surviving patients was 77 months (range, 70-10) in Pc26 and 48 months (range, 1-67) in Pc26m arms. There were 4 deaths in Pc26 and 3 in Pc26m groups. Treatment protocol was well tolerated without any signifi cant toxicity. None of the patients had grade 4 toxicity. Most frequent grade 3 toxicity was AST and ALT elevations. Three patients in Pc26 and 2 in Pc26m groups had grade 2 hemorrhagic cystitis. One patient in each group had moderate liver VOD resolved with supportive care.

In conclusion, this novel treatment protocol eff ectively prevented graft rejection and increased DFS in class 3 patients who usually have preexisting organ damage because of iron overload and/or hepatitis while avoiding excessive nonhematologic toxicity.

Equivalent outcome between reduced-intensity versus conventional myeloablative conditioning haematopoietic stem cell transplantation for patients older than 35 years with acute myeloid leukaemia M. Sebert (1) Although reduced intensity conditioning regimen (RIC) has been used for over a decade in older patients (pts), the benefi t of this approach in younger pts with AML compared with the standard regimen (MAC) is still discussed. We compared the outcomes for pts with AML over 35 years (yrs) using RIC or MAC HSCT. From 01/2000 to 12/2010, 132 consecutive pts older than 35 yrs with AML received HSCT in our center, either from siblings (n=87) or HLA 10/10 matched unrelated donors (n=45). MAC (n=72) and RIC (n=60) regimens were defi ned as previously described (Bacigalupo, 2009 Conclusions: These results suggest that OS is infl uenced by stem cell source rather than the use of ATG in AHSCT with MSD and 10/10 MUD. ATG has no impact on OS for patient who received CSP and its use should be discussed. Autologous HSCT is a standard treatment of multiple myeloma. High-dose melphalan alone or in combination with TBI is most frequently used for conditioning. In our center we initially applied TBI (12 Gy) alone followed by melphalan monotherapy in two subsequent transplant procedures. In the current prospective trial, TBI is substituted by total marrow irradiation (TMI, total 12 Gy, 4 Gy fractions on days -3, -2, -1) applied with the use of helical tomotherapy, in order to reduce toxicity. In addition, patients are examined with FDG-PET and in case of evidence of active sites of the disease they receive additional 'boosts' (total 24 Gy, 4 Gy

S223 fractions on days -9 to -4). Second HSCT with melphalan (total 200 mg/m2 on days -3, -2) is performed after 100 days. Out of 50 subjects planned as a total study population, 20 patients were included between March and August 2012 and could be evaluated for early safety and effi cacy of TMI, which was the goal of this scheduled interim analysis. Median age was 57 (44-65) years and disease status as follows: CR (n=1), VGPR (n=6), PR (n=10), SD (n=3). Three patients received TMI + additional 'boosts' . All patients experienced absolute agranulocytosis (ANC<0.1x10e9/ L) and all recovered neutrophils >0.5 x10e9/L after 11 (10-13) days and PLT >50 x10e9/L after 12 (11-16) days. Neutrophil engraftment was signifi cantly faster for TMI compared with the historical control of 50 patients treated with TBI alone (p=0.01). Four (20%) patients treated with TMI experienced grade 2-4 adverse events, including grade 2 infection + neutropenic fever (n=1), grade 2 nausea (n=3), grade 2 (n=1) and 3 (n=1) diarrhea. The incidence of grade 2-4 toxicities was signifi cantly lower compared to TBI group (50%, p=0.03). Disease status was evaluated on day +100 after autoHSCT with TMI. All three patients with SD prior to HSCT achieved PR, two PR patients achieved VGPR, one VGPR patient converted to CR. In the remaining 15 cases the response status did not change, except for one patient who progressed. All subjects proceeded to the second autoHSCT with conditioning based on melphalan and all engrafted.

Conclusions: Results of this interim analysis indicate excellent tolerance with preserved myeloablative potential of TMI at the dose of 12 Gy. The toxicity profi le appears favorable in comparison with TBI at the same total dose. The trial will be continued to evaluate effi cacy and long-term safety of the double autoHSCT incorporating TMI ± PET-guided 'boosts' , as a personalized treatment approach.

Impact of ATG-containing myeloablative conditioning on patient outcome after single-unit allogeneic cord blood transplantation L. Pascal (1) Purpose: Previous studies suggested that ATG-containing myeloablative conditioning for allo-SCT from an unrelated donor resulted in decreased incidence of extensive chronic GVHD without compromising survival. However, the use of ATG incorporated within the conditioning regimen prior to allogeneic cord blood transplantation (allo-CBT) is still controversial. Patients and Methods: We report on 91 consecutive patients who underwent single-unit unrelated allo-CBT in 3 French transplantation centers (Lille, Nantes and Bordeaux) for acute leukemia (n=66, 73%), myelodysplstic syndrome (n=17, 19%) and lymphoproliferative disorders (n=8; 9%). Median age at transplant was 12 years old (range, 0.7-56). CB units were fullmatched (6/6, n=18; 20%), one-antigen mismatched (n=30, 33%) or 2-antigen mismatched (n=38; 42%). The median cell dose was 4.6 107/kg (range, 0. 5-22.2) . All patients received myeloablative conditioning including 51 with TBI. In this series, 46 received ATG ('ATG' group), whereas 45 did not ('no-ATG' group). Only patients receiving the ATG brand Thymoglobuline® (Genzyme Corporation, Cambridge, USA) were included because this was the only ATG brand approved in France for use in allo-SCT. In the ATG group, the drug was given at the dose of 5 mg/kg (n=27) and 7.5 mg/kg (n=15). Two patients received less than 5 mg/kg for intolerance. ATG was discontinued at a median of 5 days before transplant with a median number of 2 days of perfusion (range [1] [2] [3] [4] [5] .

Results: The two groups were comparable for patient characteristics and transplantation modalities. OS, EFS, relapse, NRM, acute grade 3-4 GVHD and chronic GVHD were 47%, 30%, 48%, 23%, 19% and 21%, respectively. In multivariate analysis, the use of ATG was the strongest parameter associated with a decreased OS and EFS rates with [HR = 1.99, 95% CI: Conclusion: Unlike what has been reported in allo-CST from unrelated donor, the addition of ATG to preparation regimen seems to have a detrimental impact on survivals in patients undergoing single-unit myeloablative allo-CBT. However, prospective studies assessing more precisely which patients may benefi t from ATG in this setting are required.

Post transplantation outcome of patients with acute myeloid leukemia in fi rst complete remission after non-myeloablative F5 Bu2 r-ATG2 conditioning regimen: a bicentric retrospective experience C. Oudin (1), P. Chevallier (2) Reduced intensity conditioning (RIC) regimens has allowed performing allogeneic hematopoietic cell transplantation (HSCT) in previously disregarded old or unfi t patients. RIC has reduced non-relapse mortality (NRM), but post transplant morbidity and mortality as well as disease control remain a challenge. We studied the post-HSCT outcome of older or comorbid patients with 1st complete remission acute myeloid leukemia who received a RIC with fl udarabin (Flu), busulfan(Bu) and rabbit anti-thymoglobulin (rATG Fanconi's Anemia (FA) manifests clinically with progressive development of aplastic anemia (AA), myelodysplastic syndrome (MDS) or acute myeloid leukemia. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for these hematological manifestations. Over the last few years there is convincing evidence supporting the use of fl udarabine based conditioning regimens in HSCT for Fanconi's Anemia patients. However, graft failure and rejection remains an important concern, especially in the setting of alternative donors and hyper transfusion. Many eff orts have been directed towards improving engraftment rate without increasing toxicity. We present our experience in HSCT for FA using fl udarabine-cyclophosphamide (Flu-Cy) based conditioning regimen with or without the addition of busulfex (Flu-Cy-Bu). Patients and Methods: Sixteen patients with FA who underwent Flu-Cy based conditioning HSCT in our center from 1987 till 2012 were included. Ten patients were included in the Flu-Cy group, and six in the Flu-Cy-Bu group.

Patients' characteristics are detailed in table 1.

Results: The median time to neutrophil and platelets engraftment was 19 days (range 10-37) and 19 days (range 9-56) in the Flu-Cy group and 22 days (range 9-32) and 24 (range 10-28) in the Flu-Cy-Bu group, respectively. Two patients In the Flu-Cy group (20%) and 1 patient (16.6%) in the Flu-Cy-Bu did not engraft. Acute GVHD (grade ≥2) occurred in 1/8 and 3/5 patients in the Flu-Cy group and Flu-Cy-Bu group, respectively. At the time of this report, 1/8 and 2/5 patients in these groups suff er from chronic GVHD, respectively. Veno-occlusive disease was reported in 3 patients In the Flu-Cy group and in 1 patient in the Flu-Cy-Bu group. With a median of 50 months follow up in the Flu-Cy group and 29 months in the Flu-Cy-Bu group all 10 patients and 4/6 patients, are alive and with normal blood counts (fi g. 1; p=0.055). Death causes were multi organ failure (n=1) and encephalitis (n=1) in the Flu-Cy-Bu group.

Conclusions: Fludarabine based regimen in HSCT for Fanconi's Anemia patients is a tolerable regimen with high OS and good toxicity profi le. Although the number of patients treated in the Flu-Cy-Bu group is too small to draw defi nitive conclusions, the addition of Busulfex to the Flu-Cy conditioning regimen in HSCT for FA does not seem to improve engraftment, and is associated with increased treatment related mortality and possibly GVHD. Conditioning regimens used in autologous hematopoietic cell transplantation (AHCT) for Hodgkin's (HL) and Non Hodgkin's lymphoma (NHL) are considered equal. During the last 2 years a new conditioning regimen was constructed in our unit consisting of intravenous Busulphan (Busilvex) (9.6mg/kg), Etoposide (800mg/m 2 ) and Melphalan (140mg/m 2 ) (BuEM). We retrospectively analysed the outcome of patients (pts) who underwent AHCT following standard BEAM and BuEM regimen in our unit. The pts were stratifi ed by age, pre-transplant disease phase and previous lines of treatment. In total, 50 pts conditioned with BuEM (group A) and 93 with BEAM (group B) were included. Group B pts were selected among 184 conditioned with BEAM during the last decade. Stratifi cation by disease risk was followed by a 1:2 selection. Fifty percent of the pts were younger than 34 years old in both study groups (range 11-68). The pts of group B more likely suff ered from HL (63) than NHL (30); whereas disease diagnosis for group A was HL in 28 and NHL in 22 pts. Disease was chemoresistant to salvage treatment in 46% of group A versus (vs) 23% of group B pts. There were no other signifi cant diff erences concerning the patients' characteristics such as age above median, pretransplantation lines of treatment (1-2: 40%, 3-4: 46%, ≥5: 14%), disease status (complete remission: 27%, primary refractory:52%, relapse: 21%, advanced stage disease: 52%). Complete remission post-AHCT was obtained in 50% of group A and 56% of group B pts. Progression free survival (PFS) at 2 years and overall survival (OS) were similar among the study groups (66% vs 63% and 80% vs 78% respectively). Given the fact that there were more pts with chemoresistant disease in group A, a second matched pair analysis was conducted upon stratifi cation by disease chemosensitivity to salvage treatment instead of age as a risk factor. Effi cacy was again similar for both regimens. In multivariate analysis favorable factors in terms of PFS were HL, chemosensitivity to salvage treatment and stage <IIB whereas in terms of OS non-bulky disease, HL and stage <IIB. Treatment related mortality (TRM) was 3.2% (3/93 pts) in group B and none in group A. There are currently no randomized studies clarifying the optimal conditioning. In this study the two regimens, BEAM and BuEM, were found to be equivalent. Additionally, the effi cacy of the newly designed BEM regimen in chemoresistant and advanced stage disease is encouraging. We conclude that this retrospective study suggests that ATG can prevent graft-versus-host disease without obvious risk of relapse resulting in similar progression-free and overall survival in HLAidentical peripheral blood stem cell transplantation which has to be confi rmed in a randomized trial. Introduction: Glutathione transferases (GSTs) are important in the metabolism of busulfan (BU), and GST gene variants may explain some of the interindividual variability in pharmacokinetics. The present study evaluates the association between GST genotypes, BU pharmacokinetics and correlation with short-term outcome and toxicity after allogeneic hematopoietic stem cell transplantation (HSCT). The study included 114 consecutive adult patients who received oral BU conditioning pre-HSCT. The two fi rst BU doses were given as fi xed doses (1 mg/kg BW), then adjusted to a target average steady state concentration (Css) of 900 ng/mL. Short term toxicity was evaluated by weight gain, increase in bilirubin and omission of methotrexate on day 6 and/or 11 as a surrogate markers for toxicity. Results: Following the fi rst dose, BU Css ranged 600-1780 ng/mL (median 1000) and 70 % of the patients presented estimated BU Css above target (median 19% higher). On the two fi rst days of therapy, BU exposure was signifi cantly diff erent between GSTA1 genotype groups (P<0.01). Patients with GSTA1*B/*B and *A/*B genotypes demonstrated median 16 % (P<0.01) and 12 % higher Css (P<0.05) and 13 % and 9 % lower clearance/bioavailability (CL/F) (P<0.05) on day 1 compared to GSTA1*A/*A patients. The total mortality rate at 30 days, 3 and 6 months post-HSCT was 8 % (9 pts), 20 % (23 pts) and 29 % (33 pts), as shown in Table 1 . The 3 month mortality was associated with higher initial busulfan levels (median 1090 vs. 980 ng/mL, P<0.05). Higher busulfan levels after the fi rst dose (>75 percentile) were associated with increased levels of toxicity markers ( The benefi cial eff ects of anti-thymocyte globulin (ATG) were reported to depend on the intensity of the conditioning regimen.

Here, we performed a single-center retrospective analysis focusing on the use of ATG and the intensity of conditioning regimen. From March 2005 until June 2011, 294 patients who underwent allogeneic hematopoietic stem cell transplant (HSCT) were eligible for this analysis. In patients with ATG (ATG-group), most patients received an unrelated HSCT (92%) and in patients without ATG (non-ATG-group), most patients received a related HSCT (86%). The cumulative incidences of grade II-IV acute graft-versushost disease (GVHD) and chronic GVHD were signifi cantly lower in ATG-group compared to non-ATG-group (P=0.039 and P=0.022, respectively). There was no signifi cant diff erence in terms of nonrelapse mortality, relapse, overall survival and progression-free survival. Grouped according to the intensity of the conditioning regimen (conventional myeloablative conditioning [MAC] vs reduced-toxicity conditioning [RTC] vs reduced-intensity conditioning [RIC]), the cumulative incidences of chronic GVHD were signifi cantly lower in ATG-group in addition to a MAC or a RTC, but not in addition to a RIC, which might be due to less tissue damage in RIC and thereby less auto-antigen presentation and cytokine induction as trigger of GVHD. In summary, the benefi cial eff ect of ATG as GVHD prophylaxis was preferentially seen in patients receiving a MAC or RTC. This fi nding needs further validation in prospective trials. We report the results of a retrospective analysis on 112 patients who underwent HLA-matched sibling donor RIC HSCT receiving either ATG or alemtuzumab. All patients received a uniform protocol of fl udarabine and bulsulfan. For T-cell depletion and GVHD prophylaxis 59 patients received alemtuzumab (20mg iv x 5 days) followed by cyclosporin A post-transplant. 53 patients received ATG (Thymoglobulin, Genzyme; total 6mg/kg iv over 3 days) followed by cyclosporine A post-transplant.

[P766]

Diagnoses included MDS (IPSS Int-1 or greater, n=50), AML (n=55) or MPD (n=7). Median recipient age was 54yrs for ATG and 55yrs (39-72) for alemtuzumab. All patients received PBSC with median CD34 cell dose of 5.9 x10 6 /kg (0. 7-17.5 Introduction: Obesity has considerably increased worldwide in recent years. As chemotherapy agents may not be equally distributed in adipose tissue, this raises concerns about the appropriate chemotherapy dosing in obese patients, and capping chemotherapy doses is not infrequent in this population. The American Society of Clinical Oncology (ASCO) guidelines do not recommend capping doses of standard chemotherapy, as reduction from standard doses might compromise progression-free survival (PFS) and overall survival (OS) in the curative setting. However, whether this policy should be applied to patients receiving high-dose therapy (HDT) with autologous stem cell rescue (ASCR) with the potential for signifi cantly increased toxicity is unclear.

Objective: The aim of this study was to describe the dosing of HDT conditioning regimens in patients with a body surface area (BSA) >2m2 and to analyse the potential impact on outcome of capping chemotherapy doses in these patients. Results. Most of pts had lymphoma, 1 multiple myeloma, and 1 Ewing sarcoma. 6/8 patients underwent to an autologous transplant. Disease status at TR-H was: 1 complete remission, 2 progressive disease, and 5 partial remission. All but two pts had a Sorror score >2, Karnofsky score was less than 70% in 5/8 pts. Immediate tolerance was good and no pts developed nausea or vomiting nor parotid hyperplasia. No pts had oral mucositis. The median time to ANC >500/μL, and platelet recovery >20,000/μL was 23 and 26 days, respectively, and this was not diff erent from data obtained with conventional low grade TBI. Full donor chimerism was evident at day 30 in all evaluable patients (7/8). Only 1 pt developed acute GVHD ≥2. No chronic GVHD was observed. 4/8 died because of PML, invasive lung aspergillosis, liver failure, and heart failure.

Conclusion: This small retrospective analysis suggests that TMI/ TLI could substitute conventional low dose TBI, with a suffi cient degree of immunesuppression of recipient, allowing engraftment and full donor chimerism. The mortality due to toxicity was felt to be due to poor patient characteristics.

Incidence and severity of oral mucositis after allogeneic stem cell transplantation with busulfan-containing conditioning is dependant on application route and dose C. Scheid (1) Busulfan and Fludarbine (BuFlu) are currently the most widely used reduced intensity regimen (RIC) in treating malignancies with allogeneic stem cell transplantation (Allo-HSCT). The total dose of Bu is usually 12.8 mg/kg intravenously (i.v.) in myeloablative regimen, or 6.4 mg/kg i.v. in RIC, in which antithymocyte globulin (ATG) always added to enhance engraftment. We fi rst reported this new myeloablative Bu (9.6 mg/kg) Flu regimen in aged and/ or intolerable patients with severe concurrent medical condition, and to evaluate its safety and effi cacy. The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytarabine 2 g/m2 on d -9; Bu 3.2 mg/kg/day iv. ×3days ( on d -8 to -6); Flu 30 mg/m 2 i.v.×5 days (on d-6 to-2) and semustine 250 mg/m2 on d -3. All 23 patients, median age 49 (6~66) years, with myeloid malignances at standard (n=6) or high risk (n=17), underwent HSCT with human leukocyte antigen (HLA) matched sibling donors. The source of stem cells was G-CSF mobilized bone marrow (G-BM) plus G-CSF mobilized peripheral blood (G-PB) in 20, G-PB alone in 2, and non-mobilized BM in 1. Graft versus host disease (GVHD) prophylaxis included cyclosporin A, mycophenolate mofetil and short term methotrexate. The median time of neutrophil recovery (>0.5×10 9 /L) and platelet recovery (>20×10 9 /L) were 16 and 14days. therapy most widely used as conditioning regimen is the BEAM protocol, which foresees the administration of Nitrumon 300 mg/sm day -6, Cytosine Arabinoside (Ara-C) 200 or 400 mg/sm and Etoposide 200 mg/sm once a day from day -5 to day -2 and Melphalan 140 mg/sm day -1. Ara-C, when used in the scheme of therapy for the treatment of lymphomas, is administered in high doses (1-2 gr/sm) because its known to be more eff ective.

With the intention to increase the effi ciency of the BEAM protocol, we modifi ed the treatment schedule accordingly: Nitrumon 300 mg/sm day -5, Ara-C 2 gr/sm and Etoposide 200 mg/sm once a day for 3 days from -4 to -2 and Melphalan 140 mg/sm day -1. The aim of the study was to evaluate the toxicity of the treatment and the resumption of the myelopoiesis in the fi rst phase, and subsequently its effi cacy. From April 2007 to March 2012 we treated 44 patients. Patients characteristics, toxicity and haematological recovery are shown on the table below. All patients received HSCs from peripheral blood with an average of 6.3 x 10 6 cells/Kg (range 3.6-14.1) and granulocyte growth factor (Filgrastim) was administered from day +6. The treatment did not cause intense nausea or vomiting, nor pulmonary, hepatic and renal toxicity. The mucositis and transfusion requirement were not high. Two patients died, one case with relapsed-resistant disease, heavily pre-treated and at high risk of infection, of sepsis at day +7, and one case with refractory disease, for its progression at day +46. The hematological resumption resulted as that of the traditional BEAM protocol. Hospital discharge was possible after 11-17 (median 13) days after the transplant. The modifi ed BEAM protocol with high dose Ara-C resulted a well tolerated treatment with no higher toxicity respect to traditional BEAM. The outcome of this conditioning regimen will be evaluated after a year since the last case treated. Allogeneic stem cell transplantation (SCT) after myeloablative conditioning (MAC) can cure high-risk haematological malignancies but in older patients and those with signifi cant comorbidities it has high non-relapse mortality (NRM). In 1989, to enable patients unfi t for MAC with an otherwise dismal prognosis to benefi t from the graft-versus-tumour eff ect, we developed a reduced intensity conditioning (RIC) protocol: LACE. It consists of oral lomustine 200 mg/m 2 (day -7), iv etoposide 1000 mg/m 2 (day -7), iv cytarabine 2000 mg/m 2 (days -6 and -5) and iv cyclophosphamide 1800 mg/m 2 (days -4, -3 and -2 Graft-versus-host disease (GvHD) remains the major barrier to successful allogeneic stem cell transplantation. Standard prophylaxis regimens for GvHD comprise combinations of the calcineurin inhibitors cyclosporin or tacrolimus with methotrexate or mycophenolate mofetil. These combination strategies are not able to prevent GvHD in a signifi cant proportion of patients. Aside from their toxic properties, continuous immunosuppression delays immune reconstitution and diminishes the desired graft-versus-tumor eff ect. Post-transplant cyclophosphamide has been used as GvHD prophylaxis in the haploidentical setting and in the context of bone marrow transplantation after myeloablative conditioning.

In this monocenter phase II trial, we attempted to test the effi cacy, safety and impact on immune reconstitution of post-transplant cyclophosphamide as sole GvHD-prophylaxis in peripheral blood stem cell transplantation following reduced-intensity conditioning (RIC) in patients with myeloma or lymphoma. Eleven patients were treated (median age 49, range 26-61 years). All patients received a RIC regimen with Fludarabin and Busulfan and T cell-replete peripheral blood stem cells followed by 50 mg/kg/d of cyclophosphamide on day 3 and 4 after transplantation (5 MRD, 4 MUD, 2 mMUD). Median engraftment occurred on day 18, 20,5 and 17 in leukocytes, neutrophils and platelets. All patients evaluable had full donor chimerism on day 28. The incidence of acute grade II-IV and grade III-IV GVHD for all patients was 45% and 27%, respectively. Non-relapse mortality at day 100 and day 365 was 18% and 45%, respectively. Overall and event-free survival at one year after transplantation was 55% and 36%, respectively, with a median follow-up of 543 days. Interim analysis after seven patients demonstrated fast T-and B-cell recovery including increased regulatory T-cell frequencies in comparison with a historical patient cohort receiving calcineurin inhibitors as GvHD prophylaxis. Updated results on immune recovery and clinical results for all eleven patients will be presented. Post-transplant cyclophosphamide can be used as single-agent GvHD prophylaxis in patients transplanted with peripheral blood stem cells and allows a fast immune recovery with respect to B-and T-cell reconstitution. Grade III-IV acute GvHD rates and NRM were comparably high for RIC transplants with the limitation of a relatively small patient number. Three out of eleven patients did not require any systemic immunosuppression until day+100 and further on.

Outcome of reduced toxicity allogeneic stem cell transplantation with Campath-1H for myelofi brosis: a single centre experience A. Publicover (1) [P778]

Results: There was one patient died before engraftment. The myeloid engraftment and platelet engraftment were obtained at a median of 12 days (range: [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Background: the descriptions of the diff erent conditioning regimens (CxRs) for allogeneic HSCT are confusing and sometimes do not refl ect their characteristics ("conventional'' vs. "mini/micro", or "high-intensity" vs. "reduced-intensity" or "myeloablative" vs. "nonmyeloablative/submyeloablative" transplants). Objective: we aimed to describe and compare the intensity of the CxRs most frequently used in our center. Methods and patients: we report the outcome of 100 consecutive patients who underwent allo-HSCT with fi ve diff erent CxRs, between 2007 and 2012 in our center. Among those patients, 51% had lymphoproliferative disorders (lymphoma, multiple myeloma), 44% acute leukemias (myeloblastic or lymphoblastic) and 6% other diseases. 29% received classical intensive schemes (BuCy2, Cy-120/TBI-12, Cy-200) (group A), 50% Flu-Mel (fl udarabine: 150 mg/m 2 ; melphalan: 140 mg/m 2 ) (group B), and 21% Flu-Bu (iv) (fl udarabine: 150 mg/m 2 ; busulphan: 9-12.8 mg/m 2 ) (group C) (table). Low dose ATG (Thymoglobulin at 1.5-3.5 mg/kg) was used in the three groups. Results: microbiologically documented infections, and early acute GVHD were more frequent in group A. Neutropenia and thrombocytopenia were more frequent and profound in group A (c/w both B and C groups), and in group B (c/w group C). Patients in group A (c/w those in both B and C), and in group B (c/w those in group C) needed more platelet transfusions. Duration of admission was longer in group A (c/w both B and C groups). Peritransplant mortality was very low in the three groups (0% in group C The median number of CD34+ cells infused was 4.3 x 106/kg/bw. Engraftment was attained in 32/33 patients, after a median of 10 days (9-11) for neutrophils >0.5x109/L and of 12 days (8-17) for platelets >20x109/L . Grade 3/4 oral mucositis was reported in 18/33 cases (54%), requiring opioids for a median of 7 days (2-10) in 15. Grade 3 nausea/vomiting and diarrhea were observed in 4/33 (12%) and 24/33 (73%) patients, respectively; total parenteral nutrition was given to 24 patients for a median of 6 days (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Twenty-two patients had fever; in 8/22 a bacteremia was documented (5 GRAM+, 1 gram-, 2 mixed). In addition, 1 candidemia and 1 cytomegalovirus reactivation were observed. The non-relapse mortality was 6% (2/33) due to neutropenic enterocolitis and cholecystitis complicated by septic shock. Currently, 30 patients are alive and progression-free after a median follow-up of 7 months (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . One patient treated with active disease progressed within two months from transplant. Our results support the feasibility of the FEAM regimen in terms of engraftment in lymphoma patients undergoing an ASCT. No pulmonary toxicity was observed, while gastrointestinal adverse events were reported in more than 70% of cases. A larger sample size and a case-control comparison with patients receiving the BEAM regimen are necessary to demonstrate that the use of FTM may be a valid therapeutic option. Background: Intensifi cation of conditioning has been attempted by adding anti-leukemic agent to the standard myeloablative regimen of allogeneic hematopoietic stem cell transplantation (HSCT) to reduce disease relapse. We have already reported a favorable outcome of allogeneic HSCT with intensifi ed conditioning consisting of TBI-cyclophosphamide (CY) plus high-dose cytarabine (HDCA) for ALL patients (Am J Hematol, 2012). In addition, we have also reported a successful outcome of TBI plus HDCA (without CY) for myeloid malignancies, in which HDCA was combined with G-CSF in order to increase the susceptibility of leukemic cells to cytarabine (Biol Blood Marrow Transplant, 2008) . This time, we retrospectively evaluated the outcome of allogeneic HSCT using a more intensifi ed conditioning consisting of TBI-CY and HDCA combined with G-CSF for high-risk myeloid malignancies. Patients and methods: Patients with myeloid malignancies (AML, CML, and MDS) who underwent allogeneic HSCT using a conditioning consisting of TBI (12 Gy), CY (120 mg/kg), and HDCA (any doses) concomitantly infused with G-CSF (5mcg/kg) at Keio University Hospital (Tokyo, Japan) were selected from the institutional database. Transplant outcome was analyzed retrospectively by using database and medical records. (14), HL (7), acute leukemia (2) and CLL (2) . All patients were heavily pre-treated (16 had received an autologous transplant). Only 1 patient was in 1st complete remission (he had pneumonia and severe renal failure with dialysis during the induction therapy); 13 were in 2nd or subsequent CR, 2 in PR, and 9 in resistant or progressive disease. Mean HCT-CI was 1 (range 0-3 Background: The use of high-dose chemotherapy followed by autologous stem cell transplantation is an important treatment option for selected patients with hematological malignancies. Hovewer, the high chemotherapy doses of conditioning regimen may determine neutropenic complications, including bacterial and fungal infections, that in rare cases can be fatal. The post-transplant administration of fi lgrastim reduced the time to neutrophil recovery and has therefore become standard practice in many institutions. Alternatively, the long-acting fi lgrastim formulation, pegfi lgrastim, can be administered as a single 6 mg dose and has a signifi cantly increased half-life, partly due to a decreased renal clearance. Patients and methods: In this study, data of 112 consecutive adult patients who received an auto-SCT between January 2009 and May 2012 and fi lgrastim (56 pts) or pegfi lgrastim (56 pts) after transplantation were retrospectively examined. Diagnoses were non Hodgkin lymphoma (40 pts), Hodgkin lymphoma (28 pts) and Multiple Myeloma (44 pts). Standard conditioning regimens (HD-Melphaln or BEAM) were used. The mean CD34+ stem cell doses infused were 4.5 and 5.1 x106/kg (p=ns) for the pegfi lgrastim and fi lgrastim group; the groups were matched for age, sex and underlying disease. Patients of the fi lgrastim group received daily subcutaneous injections of 5 mg/Kg/day starting at the day +3 after transplantation until ANC>1 x109/L; patients of the pegfi lgrastim group received a fi xed dose of 6 mg subcutaneously on day +3 post-transplantation. Results: The median time to an ANC of 0.5 x109/L was 9 and 10 days (p=0.04), respectively, in the pegfi lgrastim and fi lgrastim groups. There was no signifi cant diff erence in the platelet engraftment between the pegfi lgrastim and fi lgrastim groups (11 vs 12 days, respectively, p=ns). The median number of days with febrile neutropenia in the pegfi lgrastim group was 2 (range 1-5) versus 3(range 1-6) in the fi lgrastim group(p=0.09). There was no diff erence in the incidence of documented infections ( 23% in the pegfi lgrastim vs 25% in fi lgrastim, p=0.8). Median hospital stay ( from day 0) was 15 day for pegfi lgrastim and 16 days for the fi lgrastim group (p=0.2); there was no signifi cant diff erences in survival at day +100 or at 1 year . Conclusions: We conclude that a single injection of pegfi lgrastim administered on post-transplant day+3 shows comparable safety and effi cacy profi les to +3 daily injections of fi lgrastim.

The addition of one-day rest between last ATG infusion and stem cell infusion did not aff ect GvHD occurrence after allogeneic transplantation with fl udarabine-busulfan-ATG conditioning I. Introduction: antithymocyte globulin (ATG) is part of conditioning regimens for allogeneic stem cell transplantation (AlloSCT) with the aim of reducing graft-versus-host disease (GvHD), due to in vivo T-cell depletion. ATG administration may be accompanied by fever, chills, headache or other side eff ects that aff ect patient's management and can cause a delay in stem cell infusion. In order to improve ATG tolerance, since November 2010 we modifi ed our fl udarabine-busulfan-ATG (FBA) conditioning for RIC transplants with the addition of 1-day rest between the last ATG administration and stem cell infusion. There were no modifi cation of drugs or GvHD prophylaxis: fi ve days of fl udarabine, two days of i.v. busulfan, and two days of ATG Thymoglobuline (5 mg/kg total dose) were administered during conditioning (FBA); in presence of a mismatched unrelated donor (MMUD), MMF was added to ciclosporinee. Aim: to analyse whether the addition of 1-day rest impacted on outcome of adult patients receiving AlloSCT after FBA conditioning with respect to previous no-rest modality, in particular acute grade 2-4 or grade 3-4 GvHD. Methods: the 1-day rest cohort (ATG-rest) was compared with a previous consecutive cohort of patients (no rest) transplanted at our center. Analysis of acute GvHD among the two groups was performed as well as of chronic GvHD, OS, PFS, NRM, relapse/ progression. Estimates were calculated at 2 years post-AlloSCT. Results : a total of 51 and 57 patients were included in ATG-rest and no-rest cohorts respectively. Ten patients received transplantation the day after the scheduled date therefore they were not included in the analysis. Follow-up was longer in the no-rest group : median 27 months (21-37) vs. 15 (11-20) , p<0.0001. No signifi cant diff erences of patients' age, diagnosis and disease status were observed whereas matched unrelated donors (MUDs) were higher in the ATG-rest group (Table 1) . No diff erence in OS, PFS, NRM, acute GvHD (grade 2-4 or 3-4) (fi gure 1) or chronic GvHD were observed (Table 1) . Unexpectedly, relapse/progression rate was lower in the ATG-rest group: HR = 0.42 (0.16-0.97, p=0.04), although disease status was not signifi cantly diff erent between the two cohorts.

Conclusion: the addition of 1-day rest between last ATG administration and stem cell infusion did not impact on GvHD occurrence after AlloSCT after FBA conditioning; on the other hand, the finding of a reduced rate of relapse/progression in the ATG-rest group deserves to be investigated and requires longer follow-up.

CAMPATH is an anti-CD52 monoclonal antibody used as an immuno suppressive drug in the pre-transplant conditioning regimen. It depletes T cells eff ectively by targeting CD52 antigens, which are expressed abundantly on the majority of lymphocytes except plasma cells, granulocytes, erythrocytes, platelets, and haematopoietic stem cells (HSC). The eff ects of CAMPATH on peripheral blood (PB) T cells are well documented, however, little is known about its eff ects on other immune cell types and, to date, nothing has been studied on cord blood (CB) cells. CD52 expression on resting and activated PB and CB cells was studied. In general, CD52 expression was signifi cantly lower in activated cells compared to resting cells across all cell types for CB samples. In contrast, activated PB cells expressed signifi cantly higher level of CD52 in comparison to resting cells. Despite diff erent level of CD52 expression between CB and PB, they followed a similar trend with T cells (including naïve and memory T cells), B cells, and NKT (natural killer T) cells having comparable level of CD52 while natural killer (NK) cells expressed the least CD52. A viability study was designed to study the potency of CAMPATH in inducing PB and CB immune cell death. Although diff erent concentrations were used, CAMPATH induced apoptosis and necrosis in a comparable manner, having the same eff ects on CB/PB T

A maximum response towards CAMPATH treatment was observed at 24-hour. In resting CB/PB samples, the cells were completely necrotic by 24-hour whereas, in activated CB/PB cells, there was 40-60% of apoptosis but no necrosis was observed at 24-hour. It was confi rmed that HSC do not possess CD52 antigen. However, CD52 starts being expressed as HSC diff erentiate into myeloid and lymphoid progenitors/cells. Colony-formation-unit assays were performed to study whether CAMPATH aff ects colony formation even though HSC do not express CD52 antigens. Study showed that CAMPATH signifi cantly decreased the formation of red and white colonies compared to the untreated samples.

A better understanding of the impact of CAMPATH on immune cells would be useful to contribute to the future clinical application of the drug in order to achieve optimal effi cacy.

[P788]

The outcome of allogeneic haematopoetic stem cell transplantation (allo-HSCT) in adult patients older than 50 years P. Introduction: Following haploidentical, G-CSF primed, unmanipulated BMT, donor/recipient chimerism, hematopoietic reconstitution and risk of relapse have not been described until now. Therefore, we sequentially studied molecular chimerism and its relationship with patient outcome in 56 recipients undergoing an haploidentical transplant for malignant disease. Materials and Methods: Fifty-six patients (median age 39 yrs, range 16-70) underwent an unmanipulated haplo-BMT for the following high-risk malignant diseases: AML (n=32), ALL (n=10), CML (n=2), NHL (n=3), LH (n=5), plasmacell leukemia (n=3) and dendritic-cell leukemia (n=1). According with the disease status, 32 patients in CR1 or CR2 were considered in an early stage at transplant and, 24 in advanced stage. Thirty-six out of 56 patients were prepared with a myeloablative conditioning regimen (MAC), while 20 patients received a reduced intensity conditioning (RIC). All patients were given an identical GvHD prophylaxis. Donors were primed with G-CSF at dose of 4 mcg/Kg/d subcutaneously for 7 days. BM was infused unmanipulated at day 0. Chimerism analysis was sequentially performed by "STR fi ngerprint" at day +15, +30, +60, +100, +180 and +360 after transplant. Results: Sequential molecular monitoring results are summarized in table below: * Subsequent Relapse Disease relapse occurred in 8 patients conditioned with MAC (n=5) or RIC (n=3), 7 out of these 8 patients were in advanced phase at time of transplant. Along the early or late follow-up, MC preceeded relapse in all patients. Moreover, 9 patients transplanted in advanced phase are currently surviving disease free and show a persistent CC at >2 years after transplant. Conclusion: haploidentical, unmanipulated, G-CSF primed BMT following either MAC or RIC regimen provides an high rate of engraftment with hematopietic reconstitution of donor origen. MC seems to be predictive for disease relapse and the molecular chimerism monitoring could be helpful in driving post-tansplant therapy in order to prevent overt disease recurrence.

Chimerism testing based on short tandem repeats (STR, microsatellites) is currently the most widely used technique to monitor engraftment after allogeneic stem cell transplantation. Accurate prediction of relapse as early as possible is important for timely decision of pre-emptive immunotherapy. The STR-PCR, recently standardized by the EuroChimerism Consortium, may permit detection of mixed chimerism at a sensitivity ranging between 0.8 and 1.6%. However, this detection limit may still be too high in AML with rapid kinetics. Assessment of chimerism within bone marrow CD34-positive precursor cell fraction may provide earlier and more specifi c information. Because of low number of CD34positive precursor cells in blood, a sensitive method would be needed to monitor such microchimerism in peripheral blood.

Recently a new chimerism analysis system (Abbott AlleleSEQR), based on quantitative PCR, was introduced. By this method a sensitivity of at least 0,01% can be reached for accurate quantifi cation of low level microchimerism. We hypothesized that in AML patients with an ultra-high risk of relapse, viz AML with primary induction failure or blastic MDS with poor cytogenetics, targeting donor chimerism of 100% as measured by a sensitive method could result in a lower relapse risk. To determine whether any additional information could be obtained by more sensitive testing, we performed parallel STR-PCR and Abbott AlleleSEQR chimerism assays in 109 DNA-samples. The serial samples were collected from 11 AML/MDS -patients, starting from 3-4 weeks after transplantation. (range 90,50%-99,99%). The results suggest that alleleSEQR-PCR is more sensitive than STR-PCR in detection of recipient derived cells. The high sensitivity of the microchimerism assay allows the detection of very low amounts of recipient derived cells also from peripheral blood and thus a separate isolation of CD34-positive precursor cells from bone marrow may become unnecessary for exlusion of eventual relapse development. However, more clinical follow-up data are needed before defi nitive conclusions can be drawn.

Introduction: The real-time quantitative PCR (RQ-PCR) has gained interest for haematopoietic chimerism evaluation after allogeneic stem cell transplantation due to the high sensitivity and accuracy. The aim of our study is to analyze the usefulness of this method for prediction of chronic graft versus host disease (cGvHD) in patients after allotransplantation with reduced intensity conditioning (RIC). Materials and methods: We evaluated early hematopoietic chimerism in 15 patients after RIC allografted for haematological malignancies from fully HLA-matched not-related (12) or sibling (3) donors. Blood samples were collected from donors and recipients prior to transplantation (Tx) and from the recipients on days +5, +10, +15, +30, +60 and +100 after Tx. Peripheral blood mononuclear cells (PBMC) were isolated on density gradient (Lymphofl ot, Biotest) and cascade separated into CD56 Pan T Cell Isolation Kit II CD4 CD8 using monoclonal antibodies (MACS, Miltenyi Biotec). DNA from cells was extracted automatically (Nuclisens easyMag, Biomerieux) and investigated by RQ-PCR TaqMan technology, on ABI PRISM 7700 (Applied Biosystems). Chimerism was based on the analysis of two specifi c markers -one for donor and one for recipient, chosen out of 33 insertion/deletion or null alleles. The sensitivity of each RQ-PCR performed with artifi cial chimeric DNA samples was 0.05%. Results: Clinical symptoms of cGvHD was observed in 3/15 patients. The level of donor chimerism on the day 5th and 10th after transplantation in recipients who developed cGvHD was signifi cantly higher than in patients with no cGvHD. This diff erence was observed in all cell lineages (Figure) .The donor chimerism >97% on the 10th day after transplantation in CD4+ was the best predictor of the cGVHD: it was observed in 3/3 patients with cGvHD and in none of 12 patients with no cGVHD (p< 0.007).

[P791]

Conclusions: 1/ RQ-PCR permits to reliably follow early chimerism after allogeneic transplantation 2/ Preliminary results suggest potential value of this method to predict cGvHD after transplantation in patients with RIC. Introduction: Although the origin of circulating cell-free nucleic acids in plasma is unknown, cell disruption is the most likely explanation. In this context, our goal was to quantitatively monitor chimerism in cell-free plasma DNA and to evaluate its usefulness for the improved diagnosis of complications after allo-SCT. Patients and methods: The study comprised 270 plasma samples from 29 allo-SCT patients, with a median follow up of 45,8 months (14,6-74,7). Plasma was separated from blood cells by centrifugation at 1600g for 10 min at 4ºC and cell-free plasma DNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen). Quantitative chimerism analysis was performed by microsatellite PCR (STR; AmpFlSTR SGM plus, Applied Biosystems) in whole blood (WB), T-cells (CD3+) purifi ed using immunomagnetic means (Miltenyi Biotec) and cell-free plasma DNA. Results: During the fi rst year of allo-SCT, the number of patients with mixed chimerism (MC) in cell-free plasma DNA was higher than that in WB and T-cells (Table 1 ). MC in cell-free plasma DNA was observed for a longer time after transplant than "cellular" MC, with a median of 105 vs. 40 and 27 days for cell-free plasma DNA, T-cells and WB, respectively. Chimerism analysis revealed two groups of patients. One group with MC in both cell-free plasma DNA and "cellular DNA", in which the percentage of recipient plasma DNA ranged between 10-30%, probably mostly derived from hematopoietic cells. The other group presented MC in cellfree plasma DNA but complete "cellular" chimerism (100% donor) in which cells the percentage of recipient plasma DNA was lower than in the former group (1-10%), and most probably derived from non-hematopoietic cells. A greater number of patients with graft versus host disease (GVHD), mainly acute but also chronic, presented MC in cell-free plasma DNA and complete chimerism in WB and T-cells ( Table 2 ). The presence of recipient cell-free plasma DNA could be derived by cell disruption in GVHD target organs. Discussion: Quantitative follow-up of chimerism in cell-free plasma DNA, does not reproduce the results of "cellular" chimerism, as reported previously, and therefore, could not replace it for post-SCT follow-up. On the other hand, chimerism analysis in cell-free plasma DNA could be combined with the conventional follow-up of "cellular" chimerism for an improved diagnosis of lifethreatening complications such as acute and chronic GVHD.

Hematopoietic chimerism analysis is important in the follow-up of patients undergoing allogeneic stem cell transplantation (HSCT) because it can predict disease recurrence, graft-versus-host disease and graft failure. However, mixed chimerism (MC) states in which normal recipient hematopoietic cells are found has been described. To detect the patients who are at risk of leukemia relapse is vital to detect residual leukemia in the form of minimal residual disease (MRD). The objective of this study is to simultaneously detect residual leukemic cells in the form of MRD and host hematopoiesis in the form of MC in a rapid one step assay. A multiplex PCR for the detection of short tandem repeats (STR), NPM1 and FLT3-ITD mutation was performed in 278 samples from 20 selected patients. All the included patients had both mutations

S245 at diagnosis and 1 to 3 informative STR (D1S80, SE33, D7S1517 and D4S2366). NPM1, FLT3-ITD and chimerism status were individually analyzed in parallel using a standard singleplex PCR. After transplantation 18 patients showed an increasing rate of MC. In 13 patients with MC both mutations were found at the same time of MC, while one patient with MC only a NPM1 mutation was detected at relapse. Six patients with increasing MC did not show NPM1 or FLT3-ITD mutation at any time and these patients did not showed any sign of relapse. Two patients in remission showed complete donor chimerism and were negative for FLT3-ITD and NPM1. Correlation coeffi cient of chimerism percentage between singleplex and multiplex PCR was 0.98, while the correlation coeffi cient for FLT3-ITD mutated/unmutated ratio was 0.89 for both PCR systems. Our one step assay provides clinical applicability in patients with MC for rapid simultaneous detection of chimerism status, NPM1 and FLT3-ITD mutation in AML patients undergoing HSCT. Allogeneic stem cell transplantation (alloSCT) is a curative treatment option for patients with acute myeloid leukaemia (AML). Relapse after alloSCT is still a major cause for the treatment failure. Molecular genetic (FLT3, NPM1 mutations) and cytogenetic riskcategories have an important impact on the prognosis of patients undergoing alloSCT. However, it has been shown that there is a closely relationship between the level of minimal residual disease (MRD) and relapse in leukemia patients. We analyzed 165 AML patients transplanted at our institution. We examined the contribution of cytogenetic aberrations and molecular genetic markers detected prior alloSCT to survival, relapse, and mortality after transplantation. Furthermore, we analysed MRD status after consolidation therapy and in post-transplant period. We classifi ed genetic/cytogenetic status before alloSCT into 2 groups: low risk: good and intermediate-risk karyotype, FLT3-wt, NPM1-mutated cases and high risk: adverse-risk cytogenetic, FLT3-ITD mutated cases. A low risk karyotype was present in 75 patients, whereas 90 patients had a poor cytogenetic risk. 66 patients were treated with standard myeloablative conditioning regiments prior to alloSCT, 83 patients received reduced intensity conditioning and 16 non-myeloablative conditioning. 51 patients had a matchedrelated donor and 114 patients had a matched-unrelated donor.

Overall survival (OS) in the group of patients with low cytogenetic risk was 839 days as compared with 613 days in high risk group. The low risk cohort also showed a lower relapse (33% vs. 51%, p<0,03) and mortality rate (20% vs. 71%, p<0,003). We analysed MRD status in all AML patients after consolidation therapy. MRD negative patients are characterised by favourable prognosis as compared with MRD positive patients, OS 87% vs. 53%, p<0,001. We conclude that risk-stratifi cation combining molecular genetics and cytogenetics aberrations at the time of diagnosis with post-consolidation MRD status improve identifi cation of high-risk category of patients.

A comparative analysis of post-hSCT chimerism by qRT-PCR, VNTR and STR

Introduction: Monitoring chimerism is an important part of the hSCT giving valuable information about successful engraftment, rejection and/or disease relapse. Several methods have been described to determine the level of chimerism. In this research we report results from chimerism analysis by a SyberGreen qRT-PCR based method comparing it to VNTR and STR. Material and methods: 88 patients/donors pairs who underwent HLA related or unrelated allogeneic myeloablative and nonmyeloablative hSCT from two diff erent institutions in São Paulo, SP/Brazil were selected. The National Information System for Ethics and Research with Human Beings -SISNEP had approved the study. Clinical data was collected from each patient's fi le by accessing it manually or electronically. Two VNTR loci APO-B and D1S80, two multiplex amplifi cation systems, AmpFlSTR® SGM Plus® and AmpFlSTR® Identifi ler® Plus (Applied Biosystems) and eight SNPs were selected. In order to identify informative alleles, all recipient pre-hSCT samples and donors were screened for every marker as previously described. A marker was considered informative when it had a diff erent allele for recipient and donor, either in homozygous or heterozygous state. Chimerism was then determined in samples collected from recipients at diff erent times after the hSCT. VNTR analysis provided a qualitative determination of the type of chimerism. For STR and SNP analysis, Mixed Chimerism (MC) was defi ned as the detection of up to 95% of donor cells, whereas Complete Chimerism (CC) was defi ned as the detection of less than 5% of autologous cells. Results and conclusions: In general, CC and MC were detected by all three techniques, however, STR and SNP/qRT-PCR showed to be more powerful in discriminating donor/recipient cells. STR and SNP have the highest level of informativity, 84.09% and 81.82% respectively; combined, STR and SNP showed 98% sensitivity, STR/VNTR showed 92%, while the 3 techniques together, showed 90%. In summary, VNTR may be a reliable and cheap, but limited source for chimerism analysis. STRs, still the Gold Standard however requires specialized and expensive equipment. SNPs with a SybrGreen qRT-PCR based technique has become a reliable, sensitive, fast and less expensive alternative. Obviously there are limitations common to all three, including DNA quality and quantity, number of markers and individual level of informativity. However, with good DNA quality and quantity and a very polymorphic platform of high informative markers success can be attained.

Objectives: The Wilms' tumor gene 1 (WT1) is highly expressed in a large proportion of human acute leukaemias and other haematological malignancies. Many studies have been performed to determine the role of WT1 in haematopoiesis and leukemogenesis. Despite the large number of studies, the results still remain controversial. WT1 expression was repeatedly proved to be a strong prognostic factor as well as a marker for minimal residual disease (MRD). However, other studies did not confi rm these results. Apart from the initial level of WT1, there is a growing number of papers showing the relevance of WT1 expression level before stem cell transplantation (SCT) and also during the follow up of transplanted patients. Methods: To investigate WT1 expression pattern of these patients, we analyzed bone marrow samples (BM) of 20 children with de novo AML, who underwent SCT. WT1 mRNA level was determined at the time points of diagnosis, pre/post SCT and also at relapse. In majority of the patients (N=15), the follow up samples from various time points during the treatment were available as well. RQ-PCR assay for absolute quantifi cation of total WT1 was designed according to Europe Against Cancer Program recommendations. To defi ne the normal level of WT1 expression, the samples of normal (N=23) and regenerating (N=30) MRD-negative BM were used as controls. Results and Conclusion: We found that the initial WT1 level is similar to the level detected at relapse (median 3.4 and 3.2 logs respectively). During the follow up, the WT1 expression in remission samples remains below the physiological background of healthy donors. We analysed possible correlation between the pre-and post-SCT levels of WT1 expression and the survival of patients. There was no statistical diff erence in WT1 pre-and post-SCT levels in a group of patients who subsequently relapsed compared to those who remained in complete remission. Analysis of WT1 expression in follow up samples confi rmed that WT1 level is upregulated at relapse. However, in 4 out of 5 patients who relapsed after SCT, the samples preceding the haematological relapse showed WT1 expression similar to the normal BM. Therefore due to rather infrequent BM aspirations during the follow up of the patients, WT1 monitoring in childhood AML undergoing SCT is unlikely to bring any benefi t for the treatment of these patients. Supported by the project (Ministry of Health, Czech Rep) for conceptual development of research organisation 00064203 (University Hospital Motol, Czech Rep) and UNCE204012.

Human Cytomegalovirus(HCMV) is a major pathogen in Bone marrow transplant recipients (BMT) and it was shown that more than one CMV strain may be involved in CMV infection, reactivation and or disease. The aim of the present investigation was to assess the composition, distribution and quantity of diff erent CMV-strain were characterized at diff erent polymorphic viral genes. Quantifi cation was done for individual CMV gN and gH genotypes by genotype specifi c real time quantitative PCR assays, which allowed an exact quantifi cation of the distinct gN and gH genotypes by genotype-specifi c real time quantitative PCR assays, which allowed an exact quantifi cation of the distinct gN and gH genotypes in mixtures down to a relation of 5% to 95%. In 25% BMTs only one CMV strain was identifi ed within two years post transplantation, independent from the donor recipient serostatus. In 75 % other BMTs a mixture of 4 to 8 CMV-strains was detected. The quantitative analysis showed that in these patients' individually diff erent patterns of CMV-genotype mixtures as well as independent viral load dynamics of each replication genotype occurred. Composition of CMV-genotypes did not diff er substantially among the two compartments blood and urine. The present data indicate that the emergence of CMV-strain in the post transplant period exhibits a specifi c pattern for each patient. On one hand patients even with a CMV-strain input from donor and recipient may have only one CMV-genotype emerging over two years of post transplantation. On the other hand also a variety of CMV genotypes mixtures may emerge after Bone Marrow Transplantation and, as made visible now, co infecting CMV genotypes show individually diff erent viral load. Dynamics over time.

Analysis of chimerism after allogeneic hematopoietic stem cell transplantation (HSCT) in the post-transplant period has become the most important tool to monitor engraftment of donor stem cells or detect the recurrence of leukemic cells. In cases, in which no specifi c tumour marker is available, a multiplex PCR-based approach using sets of short tandem repeats (STRs) currently serves as standard method for chimerism analysis. Although STRs show high power of discrimination between donor and recipient this method provides limited sensitivity that does not reach below 1%. Real time PCR (qPCR) is known to be a more sensitive approach for the quantifi cation of minimal residue disease (MRD) and the early detection of imminent relapse. However some drawbacks exist to use this approach within clinical routine especially in high percentage donor chimerism analysis. The aim of this study was to compare the performance of an established highly informative STR-multiplex application with a new developed approach using allele-specifi c qPCR assays detecting insertion/deletion polymorphisms (INDELs). The INDEL-assay thereby consists of a multiplex-approach targeting 44 INDELs and respective allele-specifi c qPCR assays. Genomic DNA was genotyped by using a 12 STR-PCR assay and the newly developed 44-INDEL assay, respectively. STR-PCR and INDEL-qPCR analysis were performed using serial dilutions of mixed DNAs simulating chimerism. STR-PCR results were compared with allele-specifi c qPCR results towards informativity, sensitivity and linearity of both methods. To simplify the application of this combined strategy in chimerism analysis a software tool for data evaluation was established. The presented work demonstrates the benefi ts and suitability of insertion/deletion loci but also points out that an optimal application range has to be applied. The combined approach of fi rst line multiplex STR analysis to monitoring engraftment in conjunction with subsequent allele-specifi c qPCR analysis for highly quantitative chimerism analysis provides the best strategy of reliable monitoring of post-transplant progress of allogeneic HSCT. Objective: The aim of our study was to develop methods for determining minimal residual disease (MRD) for patients with acute S248 leukemia, using deletions in gene IKZF1 (transcription factor IKAROS) as a marker. Methods: The presence of deletions δ 2-7 and δ 4-7 IKZF1 was examined in 95 patients with acute leukemia (AML -26, ALL -64, biphenotypic acute leukemia (BAL) -5) at diff erent stages of disease. Locus-specifi c primers and TaqMan probes for real-time PCR were designed to quantify deletions δ 2-7 and δ 4-7 mutIKZF1. Results: The frequency of deletions IKZF1 in the general population of patients with acute leukemia was 11% (n=10), and in patients with ALL, 12% (n=8) . But, at the same time, deletions were detected for 31% (5 of 16) of patients with Ph-positive ALL. Two patients with BAL had a deletion in the IKZF1 gene. Within the group of patients with AML and healthy volunteers the abovementioned mutations were not detected. IKZF1 mutations were found in the group of patients with detected chromosomal aberrations as well as in patients with normal karyotype tumor cells. The IKZF1 gene deletion was not detected in patients at molecular remission. At the same time the number of cells with deletion proportionally increased data on other markers: cytogenetic and molecular (defi nition of the chimeric transcripts) at relapse. We found out a correlation between mutIKZF1 amplifi cation and a number of blasts (R=0.62, p=0.017), chimeric transcripts level (R=0.91, p=0.000001) and donor chimerism (R= -0.63, p=0.02). The sensitivity of mutIKZF1 detection is less then chimeric transcripts level measurement (88%), but the specifi city was observed the same (100%). Conclusions: Deletions in the gene IKZF1 can be used as a marker for evaluation of minimal residual disease in patients with ALL without other informative molecular markers.

Introduction: Long-term stable mixed chimerism (MC) is a rare phenomenon after hematopoietic stem cell transplantation (HSCT) characterized by 5-95% residual recipient hematopoietic cells. The mechanisms directing hematopoietic recovery to MC in some patients and to full donor chimerism (DC) in others are poorly understood. In this study we compared DC patients with long-lasting stable MC patients for a median of 9.5 years (range 5 -16.5) post-HSCT in patients with non-malignant diseases. Methods: Chimerism analysis was performed for all patients at regular intervals post-HSCT on peripheral blood samples. The cell lineages analysed were T-lymphocytes (CD3), B-lymphocytes (CD19) and myeloid cells (CD33).

Results: Several factors signifi cantly associated with the likelihood of stable MC development in patients were identifi ed, e.g. younger donor age, sibling donor and conditioning regimen. Furthermore, development of acute-graft-vs.-host disease (aGvHD) and blood stream infection (BSI) was signifi cantly more prevalent in the DC patient group. Lastly, fl uctuations in the recipient: donor chimerism ratio decreased over time after HSCT in MC patients. Discussion: A young donor presumably has more naïve immune cells, which might lead to a state of clinical tolerance between donor and recipient cells in the patient, as substantiated by the fact that aGvHD was primarily observed in the DC group. Also, sibling donor cells are a closer HLA and minor histocompatibility antigen match than unrelated donor cells and as thus will be less prone to induce immune-mediated killing of recipient cells. In this study, younger donor age and sibling donor were correlated, as the sibling donors were signifi cantly younger. Additionally, milder conditioning regimens may also stimulate MC development. Furthermore, MC was not linked to a worse prognosis, as both aGvHD and BSI development were more prevalent in the DC group. BSI might be increased in DC patients due to newly developing immune cells that still require priming, while MC patients maintain their recipient memory cells for immediate targeted responses.

Allogeneic SCT is curative therapy for patients (pts) with AML and MDS. Relapsed disease is the most common reason for treatment failure and outcome after relapse is often poor. Over the last 6 years our policy was to off er second SCT from a diff erent donor to pts who had an available second donor and were in relatively good medical status, most often after re-induction attempt. 129 AML/ MDS pts relapsed after SCT during this period and 26 (20%) were able to proceed to second SCT from diff erent donor. The median age was 51 years (19-78). 20 pts were initially given SCT from matched sibling, 12 were re-transplanted from a second sibling and 8 from matched unrelated donor (MUD). 6 pts were initially transplanted from MUD and re-transplanted from a different MUD. The initial conditioning regimen was myeloablative (MAC, n=10), reduced-toxicity (RTC, n=12) or reduced-intensity (n=4). The second regimen was most often fl udarabine and treosulfan (FT, n=15) for those not given treosulfan before, including all prior MAC recipients. Other regimens were fl udarabine and busulfan (n=7) or FLAMSA (n=4). The median time from fi rst SCT to relapse was 12 months (2 months -9 years), 7 within 6 months. 10 pts were in remission at second SCT with prior therapy, 9 were chemo-refractory, 7 were re-transplanted with no re-induction attempt. Median follow-up is 14 months . 24 pts engrafted in a median of 13 days (9-26). 2 pts died early from infections and 2 from GVHD with 2-year cumulative incidence of NRM of 16%(95%CI, 6-38). 13 pts relapsed after second SCT, 2-year cumulative incidence 52%(95%CI, 34-77), 10 of them died. The estimated 2-year OS and disease-free survival is 37% (95%CI, 14-60) and 33%(95%CI, 13-53), respectively. Pts re-transplanted in chemo-sensitive or untreated relapse had a better outcome than those with chemo-refractory relapse, 2 year OS 49% and 17%, respectively (p=0.05). Pts given FT for second SCT also fared better than the other regimens, 2-year OS 65% and 18%, respectively (p=0.01). 3 of 7 pts with relapse less than 6 months after SCT are long-term survivors after second SCT. In conclusion, second SCT from a diff erent donor is feasible in a subset of pts with AML/ MDS relapsing after SCT. Toxicity with the new RTC regimens, such as FT is acceptable. This is a promising option for pts able to be successfully re-induced or re-transplanted early with a pre-identifi ed second donor. These observations merit further confi rmation in larger studies. 

We have retrospectively analysed 122 consecutive patients undergoning allogeneic stem cell transplantation (allo-SCT) who received a total of 191 DLI in the period from 1995 to 2012. Indications for allo-SCT were AML (44), MDS (18), lymphoproliferative disease (19), ALL (9), CML (28), IMF (4). Reason for DLI was hematological relapse (77), molecular relapse (32), mixed chimerism (10) . The cohort consisted of 77 men, median age was 43 years (20 -68). PBPC/BM were used in 75/47 pts, 85 pts were transplanted after myeloablative conditioning (MC), 74 pts were transplanted from an unrelated donor (27 of them were mismatched). Patients received a median of 1 (1-7) DLI, cumulative median of cell dose was 2.0 x 107 CD3+ cells/kg (0.1 -172). The median time from allo-SCT to fi rst DLI was 13 months . Median followup after fi rst DLI was 14,5 months (1-204). A total of 22 (18%) pts developed aGVHD and 23 (19%) pts developed cGVHD after fi rst DLI. Overall mortality due to GVHD was 6%.

In univariate analysis (UVA) we identifi ed: allo-SCT-DLI interval ≤12 months, diagnosis (dg) type, DLI + chemotherapy, hematological relapse, and previous aGVHD as predictive factors of GVHD. At the last follow-up, 62 pts (51%) are alive, 60 pts died; 43 pts died of relapse, 14 pts died of TRM. Median survival after fi rst DLI of all pts was 33,5 months, and 14,5 months for non-CML+IMF pts resp. The estimated 3-years OS, PFS and TRM for all pts and pts excluding CML+ IMF resp was 50% and 30%, 38% and 23% and 15% and 26% resp. A more detailed analysis was performed in pts excluding CML and IMF (n=90). In UVA we identifi ed less advanced disease at allo-SCT, allo-SCT -relapse interval >12 months and cGVHD after DLI as factors positively infl uencing OS and PFS after fi rst DLI and MC and aGVHD as negative factors for TRM. In MVA, these results were confi rmed only for the allo-SCT -relapse interval and cGVHD in terms of OS and cGVHD for PFS. Conclusion: We report very encouraging long-term survival in non-CML pts of 30% in such unfavorable prognostic group of pts relapsed after allo-SCT with acceptable toxicity. Signifi cantly better survival was observed in patients with cGVHD after DLI. Comparable results using DLI from unrelated and even mismatched donors are also encouraging and suggest the possibility of a wider use of the potential of adoptive immunotherapy in highrisk patients. (1) We found that two SNPs in donor side: NKG2D (rs1049174 G/C) and CTLA-4 CT60 A/G (rs3087243), and one SNP in patient side: Fas -670 C/T (rs1800682), signifi cantly infl uenced the risk of relapse post-HSCT. (2) In 94 patients with acute myelogenous leukemia (AML), more than half (58.3%) of patients receiving grafts from donors with the CTLA-4 CT60 variant genotype (AA) experienced relapse, but the incidence decreased to 22.4% in those receiving grafts from donors with the CTLA-4 CT60 wild-type allele (P=0.011). AML patients with the Fas -670 homogeneous variant allele (TT genotype) had a higher incidence of relapse compared with those with the wild-type allele (CC or CT genotype) (TT: 43.9% vs. CC/CT: 16.7%, P= 0.02). However, the eff ects of CTLA-4 CT60 and Fas -670 polymorphic futures were highly signifi cant in AML but did not show any trend in ALL patients.

(3) Intriguingly, donor with NKG2D G allele-positive haplotype, a haplotype expected to induce greater NK cell activity, was an independent protection factor against relapse both in patients with AML (RR=4.767, P<0.0001) and ALL (RR=3.233, P=0.016). Conclusions: Our fi ndings are the fi rst report of genetic variations in GVL reaction pathways and relapse risk. Transplant patients would benefi t from accurate risk assessment taking into account donor and patient genetic data, as well as other risk factors. Background: The prognosis of patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (alloSCT) is poor. We postulated that after initial control of the leukemic cells by chemotherapy, rapid induction of a profound alloimmune response is essential for long-term control of the disease. We therefore explored a treatment strategy consisting of robust cytoreduction, followed by increasing doses of donor lymphocyte infusion (DLI) in the neutropenic phase after chemotherapy, boosted by interferon-α (IFN) administration, until graft versus host disease (GvHD) developed, with subsequent gradual control of GvHD. Study Design: 44 subsequent patients with relapsed AML after alloSCT were evaluated. Patients with poor performance status (n=3) or presence of severe GvHD (n=4) at the time of relapse received palliative treatment only. 5 patients with smoldering relapses received DLI without prior cytoreductive treatment. 32 patients received remission induction chemotherapy, followed by DLI at 3 weeks after the start of treatment. Reasons for not receiving DLI were chemotherapy-related death (n=1) and chemotherapyrefractory disease (n=9). Additional IFN was to be administered in case no acute GvHD occurred within 3 weeks after DLI. Results: Median follow-up of surviving patients was 63 months (range 24-128 months). Estimated 2-year overall survival (OS) of the entire cohort was 23% (95%CI 10-35%) and 36% (95% CI 16-57%) after re-induction treatment and DLI. In all patients receiving DLI, the impact of acute GvHD on survival was calculated with a Cox regression model, including onset of acute GvHD as a time-dependent variable (table 1). Development of grade 1-3 acute GvHD (but not grade 4 acute GvHD) was associated with superior OS as compared to absence of acute GvHD (hazard ratio 0.22, p=0.03). Conclusions: In conclusion, effi cient cytoreduction followed by DLI during the neutropenic phase and subsequent interferon treatment if needed to induce a profound immune response represents a potentially curative option for relapsed AML after alloSCT. The induction of a graft versus leukemia eff ect as indicated by the presence of grade 1-3 acute GvHD is correlated with long-term survival.

[P808] P809 The ability of malignant cells to evade immune destruction is a key hallmark of cancer. Allogeneic haematopoetic stem cell transplantation (HSCT) is one of the most powerful immune based strategies to tackle leukaemia, however the re-emergence of even extremely low levels of leukaemic cells after HSCT is predictive of progressive disease. Immunotherapy in the form of donor lymphocyte infusions (DLI) is capable of restoring long-term remission in many relapsed patients, but the key question of whether this is achieved this by a single attack capable of eradicating the small number of residual leukaemic cells or whether the eff ect of these lymphocytes persists and generate a sustained attack on the residual clonal cell remains unanswered.

In an attempt to answer this fundamental biologically question of tumour eradication versus tumour control, we questioned whether low levels of leukaemic cells in patients treated with DLI for relapse following HSCT was predictive of progressive disease. We examined the patterns of transcript variation in 116 patients with chronic myeloid leukaemia (CML) who had received DLI for relapse following sibling (n=51) or unrelated donor (n=65) HSCT. Patients achieving complete molecular remission (defi ned by two consecutive negative BCR-ABL1 PCRs) were allocated to one of three groups based on transcript patterns which have previously been shown to predict the probability of relapse following HSCT; persistently negative (no more than 1 positive result), intermittently positive (multiple positive result, but never more than 2 consecutive positive results) and persistently positive (more than 2 consecutive positive results). The primary endpoint was relapse defi ned by existing criteria. Following DLI, 84 (72%) patients achieved CMR. Of these 84 patients 69 (82%) subsequently developed intermittently (n=34) or persistently (n=35) detectable transcripts at low levels. Despite these high numbers of patients developing low-level detectable BCR-ABL1 transcripts indicative of residual low-level disease, the probability of molecular relapse was exceptionally low (6.7% at 10 years) and not signifi cantly diff erent between the groups (0%, 4.2% and 10% for persistently negative, intermittently positive and persistently positive respectively (p=0.37). Form this data we conclude that immune manipulation with DLI produces long-term remission by exerting sustained suppression of malignant cells without eradicating the disease. However results should be taken with caution due to the low number of patients in the low risk and very high risk groups and to the retrospective nature of the study. The disease risk index is an easy and feasible prognostic score for HSCT and may help identify patients that would benefi t from TDEP.

Cytomegalovirus (CMV) replication remains a major cause of complications after allogeneic hematopoietic stem cell transplantation S252 (HSCT). However, recent studies found an association between CMV reactivation and a reduced risk for relapse of acute myeloid leukemia. We therefore set to study the impact of CMV replication on the outcome of subjects undergoing allogeneic HSCT for Hodgkin Disease (HD) or Non-Hodgkin Lymphoma (NHL). We retrospectively analyzed 92 patients receiving allogeneic HSCT from a HLA identical sibling and treated with the same conditioning regimen including thiotepa, fl udarabine and cyclophosphamide. CMV replication, detected by pp65 antigenemia positivity, occurred at a median of 40 days (range 9-530) in 45 patients (49%) and was independent from disease histology, donor/recipient sex combination, pre-transplant disease status, previous lines of chemotherapy, acute GVHD (Table I) . Forty-four patients experienced relapse at a median of 186 days (range 34-1022): 13 had S253 pre-relapse CMV reactivation and 31 did not, compared with 29 and 13 in patients who did not relapse, respectively (p=0.0005).

In univariate analysis (Kaplan-Meier) patients with pp65 antigenemia positivity had a signifi cant improvement in progression free survival (PFS) and relapse free survival (RFS) relative to patients without CMV reactivation (p=0.047 and p=0.03, respectively), especially in the subset of patients with HD (p=0.03) and with disease in complete remission pre-transplant (p=0.04). In univariate analysis, overall survival (OS) and treatment related mortality (TRM) were not infl uenced by pp65 antigenemia. In multivariate analysis including disease type, pre-transplant disease status, type of conditioning and pp65 antigenemia, the last one was confi rmed as a strong independent predictor for RFS (HR: 0.3; p=0.01) together with pre-transplant disease status and disease type (HD, CLL and aggressive NHL compared to follicular lymphomas) (Table  II) . In multivariate analysis, pre-transplant disease status was an independent factor for PFS, OS and TRM. CMV reactivation was an independent variable negatively aff ecting TRM (HR: 4.3; p=0.04) ( Table II ). In conclusion CMV reactivation after allogeneic HSCT for lymphoma represents a multi-faceted event infl uencing patients outcome, both by reducing relapse risk, especially for HD, and increasing the chance of TRM.

Introduction: Relapse is a major cause of failure of allogeneic transplantation, and has been associated with very poor patient outcomes. A second allograft is an accepted therapy, and use of reduced-intensity conditioning (RIC) has lessened transplantrelated mortality (TRM). However, factors infl uencing outcome have yet to be clearly defi ned. Methods: The BSBMT analyzed 132 patients receiving a second allograft as treatment for relapse. Patients were identifi ed from the BSBMT Data Registry and transplant centres provided follow up data. Results: The median time between transplants was 23 months (range 1m-16y). The median age of patients was 25 (range 1-64); 66% were adults (≥18). The diagnosis was acute leukaemia in 55%. Conditioning for the second allograft was RIC in 69% (compared to 31% at prior transplant). In-vivo T-cell depletion was used in in 36%. The donor was a sibling (46%), unrelated donor (52%) or other relative (2%); in 63% the same donor was used. The stem cell source was peripheral blood (PB) (74%), bone marrow (18%), BM+PB (6%), cord (1%) and cord+PB (1%) (compared to 46%, 50%, 1%, 3% and 0% respectively at prior allograft). 47% were transplanted in complete remission and stable engraftment occurred in 95%. Overall survival (OS) and progression free survival (PFS) were 38% and 29% respectively at 5 years. TRM was 22%. On multivariate analysis, factors associated with worse OS included <1 year between allografts (HR=2.39, p=-0.0005), use of nonsibling donor (HR=1.73, p=0.017) and adult patients (HR=1.68, p=0.036). Factors associated with worse PFS again included <1 year between allografts (HR=1.78, p=0.017) and adult patients (HR=1.78, p=0.021). Absent or grade I acute graft-vs-host disease (GvHD) was associated with worse progression free survival (HR=1.59, p=0.047) but had no impact on OS. There was no eff ect of chronic GvHD or stem cell source on patient outcome, and no other factors tested were signifi cant. Conclusion: A second allograft is an eff ective treatment for patients with relapsed malignant disease, and nearly half of those transplanted more than 1 year following their initial allograft can expect to be alive in 5 years. Whilst outcomes are better in children and those with sibling donors, nearly a third of adult patients and those with unrelated donors can achieve long-term survival. Contrary to earlier studies, we did not fi nd an association between chronic GvHD and OS, although higher grades of acute GvHD improved PFS.

Clinical impact of pre-and post-transplant residual disease status detected by multidimensional fl ow cytometry in 120 adult patients with acute leukaemia C.C. Li (1) , J.L. Tang (1)

Purpose: Allogeneic hematopoietic stem cell transplantation (SCT) gives a chance to rescue patients with acute myeloid and lymphoblastic leukemia (AML/ALL). Little has been investigated on prognostic impact by residual disease (RD) status detected by fl ow cytometry. Materials & Methods: 120 consecutive adult patients, 86 AML and 32 ALL and 2 acute biphenotype leukemia, receiving allogeneic SCT between Jan. 2010 and Dec. 2012 were included in this study. Multidimensional fl ow cytometry were analyzed on bone marrow aspirates before conditioning therapy (pre-SCT) and at hemogram recovery after transplant (post-SCT). RD was defi ned as any level of blasts population with deviation from normal antigen expression patterns. Results: Before SCT, 68 patients were RD-negative (RD-) and 52 RD-positive (RD+), while at post-SCT evaluation, only 13 patients remained RD+. After a median follow-up time of 20 months (range, 0 -34 months), patients of pre-SCT RD-had a signifi cantly better overall survival (OS) than those of pre-SCT RD+ (median, not reached vs 6 months, P < 0.001). Similarly, OS was superior in post-SCT RD-group than post-SCT RD+ group (median, 26 months vs 3 months, P < 0.001) (Fig 1) . Cumulative incidence of clinical relapse at one-year was 36.2% in patients with negative RD both before and after SCT, and was 89.7% in patients with persistent RD status (P < 0.001). Multivariate analysis showed that presence of RD pre-SCT remains an independent poor risk factor for OS (hazard ratio, 5.0; 95% CI, 2.3-10.7; P < 0.001) ( Table 1) . Conclusion: These data suggests that detection of RD may identify poor risk SCT patients and this fi nding needs to be confi rmed with more patients enrollment and longer follow-up. Preemptive intervention before clinical relapse may be benefi cial to improve transplant outcome.

L. Castagna Relapsed Hodgkin lymphoma (HL) remains a therapeutic challenge especially if salvage treatments including high-dose chemotherapy fail. In such situations, allogeneic stem cell transplantation (alloSCT) is a potential curative option in which the graft-versuslymphoma (GvL) eff ect can lead to immune mediated sustained tumor control. However, in the early phase after alloSCT, the risk of relapse is increased due to attenuated immune cell activity. In this situation, conventional systemic cytotoxic therapies are usually associated with a high mortality. We hypothesized that treatment with brentuximab vedotin, a new anti-CD30 antibody drug conjugate, would be a promising approach for relapsed HL after alloSCT as it selectively targets lymphoma cells and might enhance a GvL response by immunogenic cell death. Moreover, the combination with donor lymphocyte infusions (DLI) could further increase the GvL eff ect. Four patients with relapsed HL after alloSCT were consecutively treated with brentuximab vedotin and DLI in an alternating regimen. All patients were included into a named-patient-program (Millenium) and gave their written consent. Blood collections and assessments were approved by the institutional review board. Evaluation of treatment response was performed clinically and with computed tomography scans following established criteria. Moreover, metabolic changes were analyzed by FDG-PET/CT scans. To assess the induction of a GvL eff ect, we developed an in-vitro method using co-cultures of patient PBMCs (pre and post treatment) and well characterized CD30+ HL cell lines and controls as surrogate targets.

[P814]

[P814]

Clinical evaluation showed that all 4 patients had marked clinical and metabolic responses with a median duration of disease control of 582 days (range 259-1308) after treatment initiation which is still ongoing in two patients. Sensory polyneuropathy and mild thrombopenia were the most common side eff ects. Assessment of immunologic changes showed no signifi cant tumor specifi c T cell reactivity prior to treatment. In contrast, a signifi cant increase of HL specifi c T cell activation could be observed in-vitro in all patients after treatment (Fig 1) . Reactive HL specifi c T cells mainly co-expressed CD161 and CD4 suggesting a TH17 like phenotype. Taken together, we present evidence that CD30-targeted therapy with brentuximab vedotin and DLI induces sustained clinical responses and tumor specifi c immunity in HL patients in an allogeneic setting which warrants further investigation in a larger population. Relapse is the major cause of death after allogeneic haematopoietic cell transplantation (HCT) for haematological malignancies and can be treated with donor lymphocyte infusions (DLI). Initial low dose DLI followed by escalating DLI doses have been used to minimize the risk of GVHD in patients with relapsed chronic myeloid leukemia (CML). The impact of initial CD3+ cell dose on outcome after DLI in patients treated for other haematological malignancies is limited. We retrospectively analyzed data of 70 patients with relapsed haematological malignancies after HCT treated with DLI over the last 20 years. The primary objective of this analysis was to determine the eff ect of the initial DLI CD3+ cell dose on overall survival (OS). The median age of the cohort was 41 years (range, 18 -63), 59% were male. DLI were given for treatment of CML (n=18) acute myeloid leukemia (n=27), myelodysplastic syndrome (n=3), acute lymphoblastic leukemia (n=7), multiple myeloma (n=7), lymphoma (n=7) and paroxysmal nocturnal haemoglobinuria (n=1). Patients received transplants from related (n=50) or unrelated (n=20) donors. Thirty patients (43%) received non-myeloablative conditioning regimens. The median time intervals from HCT to relapse and HCT to DLI were 12 (range, 1-100) and 14 months (range, 1-169), retrospectively. Thirty-one patients (44%) received DLI with or without imatinib, whereas in 39 (56%) cytoreductive chemotherapy before DLI was administered. Initial DLI CD3+ cell dose/kg was ≤1x10 7 (n=25; Group A), >1.0 to ≤10x10 7 (n=25; Group B), and >10x10 7 (n=17; Group C), in 3 patients the cell dose was not available. Twenty patients received escalating doses of CD3+ cells. Twenty-three (49%) patients are still alive with a median Overall Survival (OS) of 15 months (range, 0.6-210) after DLI. OS rates at 2 years were 57%, 45%, and 31% for Groups A, B, and C, respectively.

Initial DLI CD3+ cells/kg >10x10 7 was statistically signifi cantly associated with an increased risk of overall mortality after DLI (p=0.038, Figure 1 ) compared to lower doses. Our results show that an initial DLI CD3+ cell dose/kg >10x10 7 is associated with increased risks of mortality after DLI, without reducing the risk of relapse. These fi ndings are clinically relevant, and support a recommendation to infuse ≤10x10 7 CD3 cell/kg for treatment of recurrent hematological malignancies after HCT. Additionally, molecular monitoring of patients is warranted to allow the use of DLI at an early relapse stage.

Azacitidine for relapse treatment in myeloid malignancies following allogeneic haematopoietic stem cell transplantation T. Tessoulin (1) Relapse after allograft (allo-HSCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remains the main cause of treatment failure and is associated with poor prognosis and short survival. Pharmacological immune-modulation, chemotherapy with or without DLI or second allo-HSCT are classically used as slavage therapy, but usually yield disappointing results with a relatively high toxicity, highlighting the need for novel salvage therapies in this situation.

Between Sept. 2006 and Sept. 2012, thirty-one pts (median age, 57 y (range, 14-69) with de novo AML, n=13; secondary AML, n=6; MDS, n=12; were treated in our institution with Azacitidine (AZA) for relapse occurring at a median of 3.7 months (range, 1.7-37.6) after allo-HSCT. AZA was given SC at 75mg/m2/d for 7 days per cycle. Grade III-IV toxicities were observed in 32% of cases. AZA had to be discontinued due to toxicity in 8 pts. 35% of the pts had to be readmitted to hospital due to complications of AZA. These fi ndings suggest that AZA might be a potentially eff ective strategy for relapse of high risk myeloid malignancies post allo-HSCT, without unexpected toxicities or de novo GVHD. Prospective studies, but also pre-emptive strategies using AZA are needed in such high risk diseases. Nineteen and 27 pts received myeloablative and reduced intensity conditioning respectively. The indications for DLI were relapse of lymphoma in 7 pts, ALL -25 pts and disease progression -14 pts. Chimerism at the time of DLI was lower than 50% of donor in 20 pts. The median number of DLI was 2 per patient (range 1-6). Total cell dose ranged from 1x10 5 to 3,3x10 8 (median 5x10 6 ) CD3+/kg. Ten pts received DLI alone, and 36 pts received DLI in combination with chemotherapy, tyrosine kinase inhibitors, IFN-α, IL-2, GM-CSF. Results: CR was achieved in 14 pts (30%): 10 pts (34%) with ALL, 1 pts (14%) with HD, and 3 pts (30%) with NHL. Duration of response ranged from 1 to 36 months. Relapse occurred in 8 pts (ALL -5, NHL -3) with CR after 3-12 (median 9,5) months. Acute graft versus host disease (GVHD) grade III-IV occurred in 4 pts, and in 2 pts it was fatal. Extensive chronic GVHD occurred in 4 pts. For all pts fi ve-yr OS was 21%. At the time of follow-up 12 pts are alive, including 7 in CR. Conclusions: Using DLI may help to achieve CR in pts with lymphoid malignances who relapse or have disease progression after allo-HSCT, however CR is not durable. Thus new treatment approaches in patients with lymphoid malignances still need to be investigated. 

Background: We know that the most common cause of treatment failure in stem cell transplantation is relapse of disease. For relapsed acute leukemia and other hematologic malignancies after allogeneic stem cell transplantation, the prognosis is poor and life expectancy is limited for these patients. However, second allogeneic stem cell transplantation still has the promising graftvs-leukemia eff ect and is the only curative therapy for selected patients.

Method: This is a retrospective study in the past 7 years. For relapsed hematolgic malignancy patients after fi rst stem cell transplantation and the ECOG performance status is 0 or 1, we treated with reduced intensity (RIC) or myeloablative conditioning (MAC) regimens directly or after salvage chemotherapy to induce second remission. [P821]

The 5-year overall survival rate is 37% for all 24 patients and 55% for the 10 AML patients. Conclusion: Second allogeneic stem cell transplant is feasable and durable survival is still promising for selected relapsed patients after fi rst transplantation but the treatment modality is very individualized either with RIC or MAC allotransplant according to patients disease entity and disease status. Patients with AML who relapse after HSCT have a poor prognosis and treatment options are currently limited, with unsatisfactory results. The 5-AZA has been a major advance in the treatment of high-risk myelodysplastic syndromes and AML with 20%-30% blasts. We evaluate our experience with 5-AZA for the treatment of patients with AML who relapse after HSCT. Methods: We conducted a multicenter retrospective analysis and identifi ed 24 patients treated with 5-AZA, from Sep/08-Feb/12. Median age was 56 years,71% were men.The median WBC: 7.7 x109/L and BO blasts: 45%. 65% showed <30%blasts of the relapse and 29% MDS. Unfavorable cytogenetics in 37% and intermediate 54%.46% had relapsed after auto-HSCT and 54% Allo-HSCT (7 RIC and 5 NRD). Low incidence of GVHD. The dose of AZA was 75 mg/m2/dayx7 days, having received at least one cycle. Treatment response was assessed according to the criteria of the International Working Group 2006. Quantifi cation of regulatory T cells (Treg) during treatment by fl ow cytometry at 0,2,4 and 6 months.

Results: The median relapse from HSCT was 8 months, with the same subtype of LAM (65%) and dysplasia (26%). Patients received a median of 5 cycles . Three received chemotherapy prior to the start of AZA (2 +5 and FLAG (n2) .The best response was 54%: 13% CR, during 7, 8 and 26 months respectively, 8% CRi, 4% PR and 30% stable disease. 46% had treatment failure due disease progression. One patient underwent a second Allo-HSCT and two received DLI. The main adverse eff ects were hematopoietic toxicity grade 3-4: 91%, infections (51%) and 38% need hospitalization due to febrile neutropenia. There were no treatment-related deaths. We observed an increase of Treg cells, progressively. At follow-up (median 15 months), the median survival was7 months and OS 1-year and 2-year was 50% and 23± 1% respectively. Median OS in the AUTO-HSCT was 15 months versus 6 months in ALLO-HSCT (p =0.02). The univariate analysis; initial favorable response to treatment (p=0.002), freedom time to relapse after HSCT (p =0.012) and <30% blasts (p =0.002) were signifi cant predictors of survival. Nevertheless, there was no correlation between, overall survival, use of high doses of azacitidine, prior chemotherapy and cytogenetic risk. 71% die due to progression. Conclusions: our experience with 5-AZA for the treatment of patients with AML who relapse after HSCT, not candidates for intensive chemotherapy, achieved initial response and OS of 50%. The AZA may represent an eff ective alternative, easy management and well tolerated.

Ph(+) Acute Lymphoblastic Leukemia (Ph+ALL). We retrospectively studied the effi cacy of TKIs in 7 patients [men/women: 4/3, median age=45y (22-60)] with Ph(+) Leukemias (ALL:5/CML:2), who relapsed after Allo-HSCT (median time=6m, 2-20). All had received TKIs (1st generation: 5, 1st+2nd generation: 2) and the 5 Ph(+) ALL subjects, TKIs plus chemotherapy. At transplantation, 3 patients were in complete molecular remission (CMR) and 4 in hematologic and cytogenetic remission but with detectable molecular load. Grade I acute graft versus host disease (aGVHD) `developed in 4/7 patients and at the time of relapse, 5 patients had limited chronic GVHD for which they were receiving immunosuppression as prophylaxis. Disease recurrence appeared as hematologic, molecular (confi rmed in 2 consecutive samples) or extramedullary (CNS) relapse in 3/2/2 cases, respectively. The immunosuppression was discontinued and they were treated with TKIs either as a single agent (4/7) or in combination with chemotherapy (CNS infi ltration: 2, hematologic relapse: 1). All patients in hematologic or molecular relapse responded to TKIs, with a median response time 25 m (9-74). Patients with molecular relapse maintain CMR long term (74 m and 36 m), while hematologically relapsed patients relapsed again. The patients with CNS disease died 10 m and 3 m after relapse due to refractory disease and suicide, respectively. The remaining 5 patients are alive, 2 in CMR and 3 under TKIs in combination with chemotherapy, and without GVHD, despite discontinuation of immunosuppression. In conclusion, TKIs may represent a safe and eff ective option for the treatment of relapsed Ph(+) Leukemia after Allo-HSCT, particularly when they are administered at early stages of relapse. The latter, underlines the importance of close molecular monitoring for early detection of minimal residual disease. TKIs may provide durable responses without negatively impact the quality of life due to the outpatient administration. However, issues that need further investigation on the role of TKIs in the post-transplant relapse are, the duration of treatment, possible combinations with other therapeutic approaches (chemotherapy, DLIs), any potential impact on GVHD and the probability of the induction of extramedullary disease. Objectives: Parenchyma and stroma represent in every organ of the body the functional and structural units, respectively. Mesenchymal stromal cells (MSC) -traditionally associated with a structural support activity -have recently been attributed with more complex functions. In particular, MSC regulate self-renewal and diff erentiation of haematopoietic stem cells (HSC) and, in conjunction with bone marrow (BM) macrophages, modulate their mobilization. The aim of this study was to investigate the ability of MSC to drive HSC diff erentiation in an in vitro co-culture model. Materials and methods: Unfractionated BM cells or sorted progenitor cells were co-cultured with MSC derived from BM of wild-type (WT), inducible nitric oxide synthase knock-out (NOS2-/-) and TNF receptor 1 and 2 knock-out (TNFR1/R2-/-) mice for four days. Expression of CD11b and Gr-1, and of monocyte and macrophage markers was evaluated by FACS analysis of cell suspensions collected. Real time PCR (RT-PCR) profi le of M1 and M2 markers was carried out on CD11b+ cells isolated from the co-cultures, using BM cultured alone as control.

Results: MSC induced the expansion and diff erentiation of different subsets of mature myeloid cells from haematopoietic BM cells. Based on the diff erential expression of CD11b and Gr-1, three cell subsets recapitulating myeloid diff erentiation could be identifi ed. We observed that MSC induced diff erentiation targeted common myeloid progenitors (CMP) or granulocyte/macrophage progenitors (GMP), but not the primitive HSC. CD11b+ sorted cells obtained at the end of the co-culture exhibited a functional profi le characterised by high levels of both anti-and pro-infl ammatory markers, such as Arginase-1 (Arg-1) and NOS2. Macrophage diff erentiation was dependent on the presence of NOS2, because MSC obtained from the BM of NOS2 defi cient mice could induce the diff erentiation of other myeloid cells but not macrophages. TNF-α but not IFN-γ was able to drive NOS2 upregulation in MSC. This was confi rmed by the lack of diff erentiation when MSC were defi cient for TNF receptor 1 and 2 (TNFR1/R2-/-). Conclusions: MSC have the ability to drive myeloid diff erentiation via a NOS2-and TNFR-dependent pathway. Background: Inherited as well as acquired mitochondrial DNA (mtDNA) mutations are considered relevant in both, aging and cancer. Little is known about mutations within the respiratory chain region and its infl uence on intracellular reactive oxygen species (ROS) production of hematopoietic cells during aging. Here, we used conplastic mouse strains to investigate whether mtDNA within the complexes III and IV of the RC infl uence hematopoiesis during aging. Methods: Bone marrow cells (BMCs) and peripheral blood cells of two conplastic mouse strains (C57BL/6N-mt129S1/Svlmj (mt129S1) and C57BL/6N-mtNOD/LtJ (mtNOD)) with specifi c mtDNA mutations in complex III and IV of the RC were analyzed at defi ned ages (3, 6, 12, 18, 24 months) . The background strain (C57BL/6Ntac (B6)) served as control. White blood count (WBC), hemoglobin (HGB), hematocrit (HTC) and platelets (PLT) were studied. Furthermore, Lin-, Sca-1+, c-Kit+ population (LSK cells), CD3, CD45R, Ter119 and CD11b were immunophenotyped by fl ow cytometry. Additionally, BM histologies were analyzed at all defi ned ages. Studies were accompanied by analyses of intracellular ROS, mitochondrial superoxide (MitoSOX) as well as aging related protein analyses (western blot). Results: WBC of mutated mtDNA strains decreased during aging compared to 3 months values of the same strain. In contrast, the WBC of B6 mice remained unchanged. Similarly, HTC and HGB of the mutated strains decreased over time. PLTs counts did not change signifi cantly over time. BM of all mice strains showed hypercellularity at 12 months. The LSK cell population increased from 3 to 12 months in all strains, but LSK cell frequency of mt129S1 (2.3%) and mtNOD (2.9%) was lower than in B6 (3.8%) mice at 12 months. Of interest, CD3 cell frequency increased in mt129S1 and mtNOD over time, whereas its frequency in B6 remained unchanged. In contrast, CD45R cells decreased in both mutated strains as well as the B6 control. Preliminary results of ROS production and protein phosphorylation indicate a heterogeneous pattern with diff erences varying between strains and time points. Conclusion: MtDNA mutations in complex III and IV infl uence murine hematopoiesis during aging. In particular, erythropoiesis, B-cell lymphopoiesis as well as WBC are narrowed compared to the control group. Further investigations are warranted.

Objectives: Mesenchymal stromal cells (MSC) modulate the function of several immune cells. Such an activity is infl uenced by the infl ammatory milieu and the fi nal outcome is the result of a fi ne adjustment of cellular players at the infl ammatory site. Our aim is to investigate the interactions of MSC and lymphoid cells during the infl ammatory response in vivo using established mouse models of acute and chronic peritonitis. Materials and methods: thioglycollate(TG)-induced peritonitis (acute model; mice received one dose of TG i.p.) and chlorhexidine gluconate(CG)-induced peritoneal fi brosis (chronic model; mice received 3 doses of CG/week for 3 weeks). Following the induction of acute or chronic peritoneal infl ammation, bone marrow-or adipose tissue-derived MSC were injected into the peritoneal cavity and the infl ux of infl ammatory cells into the peritoneum, their phenotype and cytokine profi le analysed by fl ow cytometry and mRNA expression. Results: In TG-induced infl ammation, MSC led to a remarkable reduction of the infl ammatory response, as measured by total number of cells mobilized into the peritoneal cavity. MSC inhibited both the initial neutrophil infi ltration and the later monocytes/ macrophage accumulation. As a result of MSC administration, the diff erentiation of monocytes into infl ammatory macrophages was also prevented. These changes also led to a decrease of the overall levels of infl ammatory cytokines, such as TNF-α and IL-6. In the chronic infl ammatory model, MSC administration also reduced the infl ux of infl ammatory cells to the peritoneum, but only when the MSC were administered close to the onset of infl ammation. Phenotypic analysis of the peritoneal cavity's cells and histological analysis of the peritoneal membrane showed only a minor immunomodulatory eff ect of MSC in this setting. Conclusions: Overall, our results suggest that the infl ammatory environment has a signifi cant impact in the fi nal outcome eff ect of the in vivo administration of MSC. We envisage that the information obtained from these two infl ammation models are fundamental to understand the immunoregulatory properties of MSC in more complex models of multiple tissue infl ammation and injury, like graft-versus-host disease.

Objectives: Mesenchymal stromal cells (MSC) have the capacity to regulate the proliferation of immune cells being such an activity subjected to environmental cues. One of the key mechanisms regulating MSC-mediated immunomodulation is essential amino acid (EAA) metabolism. In this study we have assessed the profi le of a number of EAA consuming enzymes in MSC exposed to a variety of cytokines or infl ammatory environment. Materials & Methods: MSC generated from the murine BM of wild types and genetically KO for diff erent molecules were investigated for their immunosuppressive activity by functional assays and transcript profi le. Results: We observed that when MSC were exposed to CD3/CD28activated splenocytes, the most notable increase was observed at the level of nitric oxide synthase 2 (NOS2) which was up-regulated between 3000 and 6000 folds. As previously reported by other studies, NOS2 is the major eff ector mechanism of immunosuppression because the ability of MSC obtained from NOS2 defi cient mice (NOS2-/-) to inhibit T cell proliferation was completely abolished. Therefore, we decided to investigate a number of cytokines for their ability to increase the levels of NOS2. NOS2 transcripts were prominently up-regulated in the presence of TNF-α stimulation. Whilst IFN-γ did not produce any eff ect, it synergized with TNF-α by inducing up to 15,000-fold increase in NOS2 expression.

To determine the role of TNF-α in MSC-mediated immunosuppression, MSC isolated from mice defi cient for TNF-α receptor 1 and 2 (TNFR1/R2-/-) were tested for their ability to inhibit Con A-stimulated splenocytes. The immunosuppressive activity of TNFR1/R2-/-MSC was reduced by 50%, but not completely inhibited as observed using NOS2-/-MSC. In contrast, the level of NOS2 expression in TNFR1/R2-/-MSC after exposure to activated splenocytes signifi cantly increased 1000-folds. Conclusions: Our results indicate that TNF-α plays an important role in stimulating MSC immunosuppressive activity mediated by NOS2, but also demonstrate that the existence of TNF-α independent pathways involved in MSC-mediated immunosuppression. The identifi cation of these pathways is mandatory to maximize MSC therapeutic potentials and stratify patients responsive to MSC. Genetic screenings are in progress in our laboratory to answer this question.

Objectives: Mesenchymal Stromal Cells (MSCs) exhibit potent immune-modulatory activities that have been successfully harnessed in cellular therapies. A number of molecules eff ecting this function have been described but their expression appears to be dependent on the microenvironment to which MSC are exposed. We have observed that molecules such as tumour necrosis factor-α (TNF-α) have a dramatic impact on MSC gene expression profi le. Nuclear Factor Κ-Light-Chain-Enhancer of Activated B Cells (NF-κ B), a transcription factor activated by TNF-α, is a key pathway in the regulation of immune responses. Our aim was to study whether NF-κ B pathway is required for MSC to exert immunosuppressive activities. Methods: MSC were either transfected with shRNA targets IKK β (IκB kinase complex β) or pre-treated by IKK β inhibitors. Real-time PCR was used to quantify the expression level of genes which are regulated by NF-κ B. We assessed the immunosuppressive activity by measuring the eff ect of silenced and control MSC on the in vitro proliferation of stimulated splenocytes. The immunosuppressive activity was tested in vivo using a thyoglicollate-induced peritonitis: MSC pre-treated with IKK β inhibitors were injected i.p. following thyoglicollate. Peritoneal fl uids were collected and analyzed by FACS.

Results: The immunosuppressive ability of MSC was abolished by knocking-down or inhibiting IKK β in vitro. Interestingly, the in vitro immunosuppressive activity was not aff ected by IKK β inhibition if MSC were added in a transwell system. Real-time PCR showed that NOS2 expression in MSC was signifi cantly reduced in the presence of IKK β inhibitors. In vivo, the injection of MSC treated with IKK β inhibitors exhibited a reduced anti-infl ammatory activity in thyoglicollate-induced peritonitis. Conclusion: Our data shows that MSC immunosuppressive activity is abolished both in vitro and in vivo when NF-κ B pathway is switched off or inhibited. We conclude that MSC 'licensing' is largely dependent on the infl ammatory microenvironment to which they are exposed.

Objective: In this study, the role of Promyelocytic leukemia gene (PML) on regulating the proliferation and diff erentiation of human mesenchymal stem cells (hMSCs) was explored. New downstream genes that might responsible for PML's regulation were found and possible mechanisms were analyzed. Methods: After approval by institutional review board, hMSCs were isolated from the bone marrow of volunteers by Ficoll-paque and confi rmed by fl ow cytometry. The lentiviral vector which encodes full length human PML cDNA was transfected to hMSCs. Mock-transfected and normal cells were used as controls. RT-PCR and western blot were used to detect mRNA and protein expression. Proliferation level was measured by MTT. Flow cyto metry was used to analyze the apoptosis and cell cycle. Osteogenic diff erentiation of hMSCs was induced by osteo-inductive medium for 7 to 14 days. The location of PML protein was detected by immunofl uorescence. cDNA microarray was used to scan gene expression profi le and look for meaningful changes. Results: The expressions of PML-mRNA and protein in hMSCs increased time-dependently with cell proliferation and osteogenic diff erentiation, while PML-NBs in hMSCs also increased in number and size. When PML was over-expressed, the proliferation of hMSCs was inhibited by 69.86% on day 4(P<0.05). The percentage of early apoptotic cells in PML-transfected group was 10.3±4.23%, higher than mock-transfected (2.53±0.77%) (P<0.05) and normal cells (2.18±1.88%) (P<0.05), which was consistent with a decreased production of two cell apoptosis-associated proteins: pro-caspase-3 and PARP, and an increased production of cleaved caspase-3. The calcium deposits in osteo-induced hMSCs had an obvious increase detected by von kossa staining on day 7 in PML-transfected cells, while the mRNA expressions of osteogenic diff erentiation-related genes (SPP1, IBSP, BMP2, and Osterix) were up-regulated and the activity of ALP also increased, which indicates PML can promote hMSCs' osteo-diff erentiation. With microarray scanning, we found FGFR-2 was signifi cantly downregulated in PML-transfected cells, which is a fi broblast growth factor receptor substrate. The interaction between PML and FGFR-2 need further study. Conclusion: Our data indicates that PML regulates hMSCs as an inhibitor of cell proliferation but a promoter of osteogenic diff erentiation. Further studies will lead us know better of hMSCs' function and give more possibility on its clinical application.

Objectives: Ischemic cardiovascular diseases are a leading cause of mortality in the industrialized world. Cell-based therapies have S262 been tested to promote revascularization, mainly through the release and actions of paracrine factors that may inhibit apoptosis and support migration and proliferation of resident endothelial cells (ECs). Given the superiority of cord blood (CB)-derived stem cells versus peripheral blood derived cells, we tested the hypothesis that conditioned medium (CM) from apoptotic CB-derived mononuclear cells (CB-MNCs) could induce proliferation and migration of ECs, leading to angiogenesis in vitro. Methods: Human Umbilical Vein Endothelial Cells (HUVEC, Lonza) were cultured in Endothelial Basal Medium (EBM2) supplemented with SingleQuotes. MNCs were isolated from CB by density gradient centrifugation, γ-irradiated (70Gy) to induce apoptosis and incubated in EBM2 for 72h to obtain CM. MNCs viability after γ-irradiation was evaluated by fl ow cytometry ( S263 IFN-γ (Fig.1) . To correlate in vitro potency with in vivo activity, high potency MSC (AUC=242) were used to prevent GvHD in mice. GvHD, as measured by weight loss, was found to be signifi cantly inferior in MSC-treated group (Fig. 2) . Conclusions: Our potency assay appears reliable and able to discriminate MSC with diff erent immunosuppressive magnitude in vitro. This capacity is batch-specifi c rather than donor-related. We also show that diff erent cells can have diff erent sensitivity to licensing with IFN-γ. Our data indicate the assay predicts MSC efficacy in vivo.

Changes in the hematopoiesis occuring during aging, diseases and their therapy might be refl ected in composition of the stromal microenvironment. The aim of the study was to investigate the dynamics of colony forming unit fi broblasts (CFU-F) in the bone marrow (BM) and proliferative potential of BM-derived multipotent mesenchymal stromal cells (MSC) in patients after allogeneic hematopoietic stem cell transplantation (alloHSCT). AlloHSCT was performed to 20 patients (8 male, 12 female) with various diagnosis. Conditioning was myeloablative in 12 patients and reduced intensity in 5. After informed consent BM was aspirated before conditioning and 30, 60, 90, 120, 180 and 360 days after alloHSCT. MSC and CFU-F were cultured in standard conditions. Cumulative MSC production was counted after 5 passages. CFU-F concentration in patients before transplantation decreased 1,5 fold comparing to donors . In 30 days after alloHSCT concentration of CFU-F in BM of patients decreased more than 4 fold. Further it gradually increased and 1 year after alloHSCT mount to 75% (22.4±14.8) of value before transplantation. No diff erences were revealed between patients received myeloablative and reduced intensity conditioning regimen. In patients older than 35 years regeneration of CFU-F concentration was slower, than in younger patients. Before alloHSCT CFU-F concentration in patients with ALL was comparable with donors level. It decreased signifi cantly 30 days after alloHSCT and didn't restored fully, while in patients with AML and CML it was 3 times lower before transplantation and reached initial level 1 year after alloHSCT. Before alloHSCT cumulative MSC production was decreased 5 fold and median time to passage in patients was 1,5 times longer, than in donors. In 30 days after alloHSCT median time to passage increased 3 times, than decreased slowly during 1 year. Cumulative MSC production decreased 5 times. Proliferation of MSC was more eff ective in patients younger than 35 years. MSC's growing time was altered in patients for all period of observation. Cumulative MSC production is mostly damaged in patients with CML.

This data suggest signifi cant damage of stromal precursor cells during alloHSCT. CFU-F concentration and MSC growth parameters didn't reach initial level even in 1 year after alloHSCT. Invalid regeneration of stromal microenvironment after alloHSCT may be one of the major causes of hematopoietic interruption in these patients. Lymph nodes are disseminated structures located in privileged regions of the body where they drain the aff erent lymph. They play a key role in the maintenance of self tolerance in steady state conditions, and they restrain infl ammation to specifi c sites during the ongoing of the immune response. They comprise cells from hematopoietic origin recognized as eff ectors of acquired immunity, and a stromal compartment, composed of various mesenchymal cell types including mesenchymal stem cells (MSC), follicular dendritic cells (FDC), and fi broblastic reticular cell (FRC) cells. Whereas MSC and FDC have been identifi ed as key regulators of T and B lymphocytes, the function of FRC has been thought for a long time to be restricted to structural tasks. However recent investigations have demonstrated that FRC also participate to T and B lymphocyte control.

In this study, we found that human MSC amplifi ed in vitro in the presence of platelet supernatant exhibit a phenotype resembling that of FRC (CD31-, CD54low, CD44+, CD146+, α SMA+) suggesting that they spontaneously diff erentiated toward this lineage. When incubated with poly IC in vitro they showed similar phenotypic alterations than murine FRC exposed to poly IC in vivo, namely an increase in MHC-I, CD54 and B7-H1 expression. Moreover MSC incubated with poly IC or γ-interferon actively depleted the culture medium in L-tryptophan indicating that the indolamine 2,3 deoxygenase was activated, and such media could not support T cell proliferation. Altogether these observations suggest that the systemic antiinfl ammatory eff ect exerted by MSC when infused intravenously (as documented by their ability to control steroid resistant graft versus host disease) may refl ect the physiological regulation that MSCs, or their progeny diff erentiated in FRC exert in the lymph nodes when exposed to local infl ammation. Introduction: Knowledge of cryopreservation biology and potential toxic eff ect of DMSO on stem cells during cryopreservation (cryo) is essential to prevent loss of stem cells, and to maintain equivalent recovery and viability of nucleated cells, in case of adverse event.

To investigate the potential toxic eff ect on stem cells due to prolonged exposition to DMSO, we increase the time of DMSO cell exposition before cryo, or after thawing or a combination of both. Method: We selected 4 cord blood units non suitable for clinical use. Each unit was divided in 25 vials of 1 mL and tested for TNC, CD34+ cells, viability (7-AAD) and CFU-GM. 5 vials was analized without cryo and 20 vials were cryopreserved using 10% DMSO in nitrogen vapour freezer. We simulated adverse event occurring during cryo, due to delay of start of controlled rate freezing: 5 sample were cryopreserved immediatelly after adding DMSO solution (T0), 5 after 15 min of delay (T15), 5 after 30 min (T30), 5 after 45 min (T45) and 5 after 60 min (T60). In order to investigate if toxic eff ect was due to exposition pre-cryo or after thawing, samples cryopreserved at T0 were tested immediatelly after thawing(T0-T0), after 15 min (T0-T15), after 30 min (T0-T30), after 45 min (T0-T45) and after 60 min (T0-T60). The same protocol was applied at samples cryopreserved at T15, T30, T45 and T60. In order to analyze the biological and functional eff ect on HPC due to DMSO exposition each vial was tested for TNC, CD34+ cells, viability (7-AAD) and CFU-GM. Results: No signifi cative diff erencies was documented on TNC, CD34+ cells, viability and CFU-GM after DMSO exposition precryo on T15, T30 and T45, compared to T0 tests (ideal condition). A loss of CFU-GM is observed at T60. Tests performed after thawing show the same results: only after 60 min of delay CFU-GM are signifi cantly decreased. When both conditions are presents, the CFU-GM progressivelly decreased at T30-T45 and at T60-T45 condition.

Conclusions: This study shows an unespected resistance at the toxical eff ect of DMSO even after prolonged exposition pre-cryo or after thawing. When occurred a delay >30 min during pre-cryo phase combined to a delay >45 min after thawing, or delay >60 min pre and >45 min after, toxic eff ect is detectable and critical, simulating an adverse event during cryopreservation or during stem cell infusion (when HPC are thawed). We consider that 30 min exposition pre-cryo + 30 min exposition after thawing dosn't aff ect biological and functional activity of stem cells.

Background: Human umbilical cord blood (CB) is a reach source of several stem cell (SC) populations including not only hematopoietic SCs (HSCs) but also non-hematopoietic mesenchymal SCs (MSCs), unrestricted somatic SCs (USSC) and progenitor neural SCs (HUCB-NSC). Recently, unique population of very small embryonic-like SCs (VSELs) has been also identifi ed in CB samples. These cells exhibit: 1) very small size (<6 μm), 2) CD45-/ Lin-/CD133+ phenotype; 3) large nuclei containing primitive euchromatin and 4) expression of markers of pluripotent SCs (e.g. Oct-4, Nanog). Aim: Oct-4+ VSELs may be predominantly found among CD45-/ Lin-/CD133+ CB cells, but also in some extend in fractions expressing CD34 or CXCR4 markers. However, co-expression of CD34 and CXCR4, as well as other surface antigens has never been examined on CD45-/Lin-/CD133+ VSELs. Moreover, new more eff ective isolation strategies based on antigen expression are essential for their future applications. Results: We used multiparameter fl ow cytometry (LSR II; BD Bioscience) and imaging cytometry (ImageStream system; Amnis Corp.) to quantitatively examine co-expression of CD34 and CXCR4 on CB-derived VSELs. We found VSELs as heterogeneous fraction of non-hematopoietic SCs in terms of co-existence of these crucial three SC markers. We examined that more than half (54 %) of CD45-/Lin-/CD133+ VSELs may co-express CD34 antigen, however only small fraction (0,025 %) possess CXCR4 antigen, indicating diff erent properties of these fractions. Similar heterogeneity was also found in population of CD45+/ Lin-/CD133+ HSCs. The majority of these cells ( Objectives: Busulfan is an alkylating agent commonly used in children as part of conditioning regimen in allogeneic (allo-SCT) and autologous (auto-SCT) stem cell transplantation. Oral formulation was replaced for intravenously way. We have analyzed secondary eff ects in the use of intravenous busulfan ( Results: The transplant-related mortalities (TRM) at 100 days were 6.8% and 5.5% in allo and auto-SCT, respectively. 25 patients developed acute GVHD (58.1%) after allo-SCT and none after auto-SCT. Three patients had EVOH (1 in auto-SCT group and 2 in allo-SCT group). There were no signifi cant diff erences in TRM, EVOH, and neurological, gastrointestinal, metabolic or skin toxicity when comparing IV-Bu in single or divided doses. Neurological toxicity tends to be higher in those who received four days of IV-Bu compared to 3 days (p=0.061 Fisher test). In auto-SCT there was no diff erences in TRM, EVOH or toxicity among patients receiving IV-Bu in one or multiple daily doses. In the global series (allo+auto SCT) children who received 4 days of IV-Bu had more neurological toxicity compared which those who received 3 days of IV-Bu (p=0.026 Fisher test). Conclusion: In our study we found no signifi cant diff erences in terms of complications, EVOH and TRM when comparing IV-Bu in a single daily dose or divided in 4 daily doses in allo-SCT. Neurological toxicity is signifi cantly higher in children who received IV-Bu 4 days compared to 3 days.

Introduction: Treosulfan is a bi-functional alkylating agent which causes less veno-occlusive disease (VOD) than Busulfan and does not require anticonvulsant prophylaxis and drug monitoring. We have previously published our results of 70 children who received Treosulfan in combination with either Cyclophosphamide or Fludarabine prior to Haematopoietic Cell Transplantation (HCT) for Primary Immunodefi ciency (PID) or Severe Immune Dysregulation. We showed that toxicity was lower and T cell chimerism was better in those that received Fludarabine. Methods: One hundred and twenty-six children received Background: In the UK and Eire children with leukaemia are treated on national trials/guidelines which make recommendations for HSCT in high risk disease based on perceived benefi t over chemotherapy alone. Despite HSCT a number of children relapse, when the role of second HSCT becomes controversial. We report the fi ndings on 50 patients (18 AML, 32 ALL including 5 Infant ALL, and 10 Philidelphia Chromosome positive ALL) who underwent a second HSCT for relapsed acute leukaemia between 1996 and 2012. 34 were male and the median age at fi rst HSCT was 9 years (range 6 months to 18 years), at 2nd HSCT the median age was 11 years (range 15 months to 22years). The median time between 1st and 2nd SCT was 23 months (range 2-93 months). Method: we analysed retrospective data obtained from an electronic questionnaire which was distributed to every Paediatric allogeneic HSCT unit in the UK and Ireland. Patient demographic information was correlated with the diagnosis of acute leukaemia, length of fi rst remission, type of conditioning used prior to HSCT 1 and HSCT 2, length of remission post HSCT1 and the presence and grade of Graft Versus Host Disease (GVHD) following each transplant. The Overall Survival (OS) outcomes were recorded according to status at last review. Results: Of the 50 patients there are 20 survivors (40 %) of second HSCT in the population examined (10 male). 62.5% of females survived whilst 29% of males are still alive.12 (37.5 %) of ALL patients survive whilst 9 (50%) of AML patients are alive.

The median interval between transplants in survivors was 24 months (range 6-83 months), and 16.5 months (range 2-93months) for deceased patients. The presence of Chronic GVHD confers a survival advantage over no GVHD, although the numbers are small and do not reach signifi cance. The presence of any GVHD confers an early survival advantage (median survival =37 months) over no GVHD (median survival = 12 months). Conclusion: This review demonstrates an OS of 40% in a high risk heavily pre-treated group of patients. Female survival at 62.5% is superior to that of males. GVHD plays a role in achieving durable remission, however our data suggests that GVHD related mortality leads to loss of this advantage. HLA mismatches allow to monitor the chimerism status of several cell populations by fl ow cytometry with specifi c monoclonal antibodies against HLA alleles even in very low cell numbers.

We report a cohort of 90 pediatric patients who received T cell depleted haploidentical grafts. Diagnoses: leukemias n=43, solid tumors n=28, non malignant diseases n=19. Graft manipulation was carried out by magnetic microbeads and the clinimacs™ device. Conditioning regimens were TBI, Bu or Mel based and comprised ATG or OKT3. Immunosuppression with mycophenolate mofetil (MMF) was given in most patients. Flow cytometry chimerism of T cells in peripheral blood was started at day 0 and was repeated weekly. In all patients, residual autologous T cells

S268 were detectable after conditioning. 14/90 patients (15%) rejected the graft between day 19 and 86 (median day 33). The portion of autologous T cells within the fi rst week (day 0-7) was predictive: Non-rejectors had a median percentage of 46±5% recipient T cells detectable (n=42 analyses) whereas rejectors showed a signifi cant higher percentage (85±7%, n=13 analyses, p<0.001). In more than 90% of the rejectors the portion of detectable autologous T cells exceeded 60%. Thus, the risk of rejection for patients with >60% detectable recipient T cells was 41% (12/29 rejected), whereas patients with <60% recipient T cells had a risk of 4% (only 1/27 rejected; p=0.001). In non-rejectors, recipient T cells where detectable at a very low level (median 0.7/μl) up to day 60 without proliferating, whereas strongly increasing and signifi cantly higher numbers were observed in rejectors (from 3/μl at day 0-3 up to 617/μl at day 15-18; p< 0.05 for all data pairs). Donor lymphocyte infusions (DLI) and cessation of MMF were performed in 12 patients with increasing residual recipient T cells to prevent rejection (1-4 infusions, median number: 1; starting dose: 25.000 CD3+cells/kg). Recipient T cells were reduced/eradicated in 7/12 patients (60%) after DLIs and no rejection occurred. In 5 patients DLIs had no impact on increasing recipient T cells, resulting in graft rejection in 4 out of these 5 patients.

Conclusions: The percentage of residual recipient T cells in the fi rst week posttransplant was predictive, since patients with >60% detectable recipient T cells had a signifi cantly higher risk to for graft rejection. Rejection was associated with increasing recipient T cells. Intervention with DLIs may prevent rejection. (20) and sAML (7). Eighty MUD-Tx (40%), 48 MSD-Tx (24%), 43 auto-Tx (21.5%) and 29 haplo-Tx (14.5%) were carried out. Peripheral blood (PB) was the graft source in 136 Tx (68%), bone marrow (BM) in 58 (29%), BM+PB in 5 (2.5%) and cord blood in 1. Busulfancontaining regimen was applied in 154 Tx (77%), Treosulfan in 27 (13.5%) and other incl. RIC in 19 (9.5%). Majority of subsequent Tx were performed using Treosulfan (50% Subsequent allogeneic transplants performed with reduced toxicity regimen in children with AML, MDS/JMML do not signifi cantly worsen the patients' condition and quality of life. Subsequent procedures can off er a curative option for some patients or at least inhibit the progression and prolonged survival. Background: Mesenchymal stromal cells (MSC) have been reported to successfully treat steroid refractory acute gastrointestinal graft-versus-host disease (GI aGvHD). GI function in children responding to MSC and who have survived severe GI aGVHD has not been described.

Methods: From Dec 2004 to Aug 2012, children treated in our unit with MSC for steroid refractory GI aGvHD (>stage 2), were included and later GI complications evaluated. Results: 22 patients 10 male 12 female aged 10 mths-18yrs were included. GI aGVHD was histologically confi rmed in 91% (n=20). Eleven children responded completely (CR: no evident GVHD clinical/biopsy proven) and 6 partially (PR: at least one grade) at 30 days after the 1st MSC infusion, (1-3 infusions total), with 5 no response/progression. Sixteen patients survived >100 days post 1st MSC infusion and were evaluated. Three patients developed GI fi brosis and obstruction of the small bowel. One girl, aged 15 months with extensive disease, required long-term total parenteral nutrition (TPN) and died 3 yrs later from cGHVD. In a boy aged 15 yrs, fi brosis was localized to the terminal ileum and caecum. He underwent surgical resection, but later developed diarrhea due to cGVHD of the pancreas. Another boy, aged 3¾ yrs required local surgical resection of a preterminal ileum stricture complicating cGVHD of the gut. Two girls aged <1 year, developed ascites, one with evident esophageal varices and portal hypertension. Both required intermittent mechanical drainage and long term diuretics. Eight children in total all aged < 4 years developed protein losing enteropathy, without histological aGVHD, which persisted more than 4 months. TPN/enteral feeding was necessary and protracted. Growth was severely impaired likley due to chronic immunosuppression and post infl ammatory malabsorption. One girl aged 18 years developed alloimmune hepatitis, and another 9 year old girl developed alloimmune cytopenia. Both required extensive additional immunosuppression and eventually recovered. Of the surviving children 10 developed cGVHD. Only two children had no evident GI sequalae. Conclusion: Despite high response rates to MSC, most children experienced subsequent complex protracted gastro-intestinal or hepatic diseases, which was worse in young children. We highlight the need for extended follow-up in children enrolled in novel treatment studies as response rates alone do not refl ect the burden of complications ensuing after resolution of severe aGVHD.

Treosulfan-based conditioning for hematopoietic stem cell (HSC) transplantation in inborn errors of metabolism has been recently S269 introduced into clinical practice. The optimal regimen for diff erent types of non-malignant diseases remains undetermined. 

Myeloablative allogeneic stem cell transplantation (AlloSCT) remains the only curative therapy for patients (pts) with Sickle Cell Disease (SCD). Reduced toxicity conditioning (RTC) regimens such as Busulfan(BU)/Fludarabine (FLU)/Alemtuzumab (AT) have been successfully utilized in children with malignant and non-malignant diseases. Between 8/27/04 and 11/1/12, 18 pts (15M:3F) underwent a related RTC AlloSCT for SCD (HbSS=14, HbS/βThal=4, HbSC=4). Conditioning: Bu (4mg/kg x 4d < 4 yrs and 12.8mg/ kg x 4d > 4 yrs), Flu(30mg/m 2 x 6d), and AT (2mg/m 2 x 1d, 6mg/ m 2 x 2d, and 20mg/m 2 x 2d). One pt had Melphalan (70mg/m 2 ) instead of BU due to Busulfan allergy. Donor sources: 15-6/6 HLA matched related bone marrow (BM), 3-6/6 related cord blood (CB). Median age was 8.9 yrs (2.3-20.2) . BM median cell doses of 6.5 x 10 8 TNC/kg (2.3-11.3) and 5.4 x 10 6 CD34/kg (1.5-15.4) vs. CB of 3.6 x 10 7 TNC/kg (3.4-7.9 ) and 2.9 x 10 5 CD34/kg(2.1-3.6), respectively. GVHD prophylaxis: Tacrolimus/mycophenolate mofetil (MMF) (n=17),Prednisone/MMF(n=1). Time to mean neutrophil and platelet recovery was 19.4±8.5 and 31.1±20.9 days, respectively.

One pt met the defi nition of primary graft failure, but with addition of tacrolimus developed stable mixed donor chimerism. Mean percentage whole blood and CD71+ donor chimerism on days 100,180,365 and 730 was 90±17, 90±11, 88±9, and 93±3, and 90±12, 88.6±9, 87±9 and 97±2, respectively. Probability of grades II-IV acute GVHD was 16.7% and chronic extensive GVHD was 6.7%. Four pts developed CMV reactivation with one currently receiving treatment. No pt had evidence by echocardiogram of pulmonary hypertension at 1yr(n=17) and 2yrs(n=13) post SCT.

Of the 11 pts with no spleen function pre-SCT, return of function was demonstrated in 4/11 pts at 1yr and 4/8 evaluable pts at 2 yrs post SCT. 14 and 12 pts had a repeat MRI at 1 and 2yrs with stable/ improved fi ndings with the exception of one who had an embolic CVA on MRI 7 months that completely resolved. Of the 10 pts evaluable for comparison pre and 2yrs post SCT, the mean predicted Forced Vital Capacity changed from 88±23% to 94±12% and the mean predicted Forced Expiratory Volume changed from 90±27% to 93±14%. Probability of Event Free Survival and Overall Survival is 100%. In conclusion, RTC followed by HLA matched sibling AlloSCT eff ectively promoted long term stable donor engraftment in children and adolescents with SCD while at the same time preserving or improving long term organ stability.

A Isgrò (1), M Marziali (1), M Ribersani (1), P Sodani (1), J Gaziev (1), A Roveda (1), K Paciaroni (1), C Gallucci (1), G De Angelis (1), L Cardarelli (1), C Alfi eri (1), D. Fraboni (2), G Lucarelli (1) (

Background: Allogeneic haematopoietic stem cell transplantation (HSCT) is the only curative treatment for SCA. We report our experience concerning 20 geno-identical HSCT for African SCA-patients prepared with the same myeloablative conditioning regiment consisting of Fludarabine, Busulfan and Cyclophosphamide. Patients and Methods: Twenty patients with a median age of 12 years (range, 2-17), aff ected by sickle cell anemia (SCA), received hematopoietic stem cell transplantations from HLA-identical, related donors following a myeloablative conditioning regimen. Before HSCT, the patiens showed vaso-occlusive crisis, acute chest syndrome, or hemorrhagic stroke. The cell source was bone marrow. GVHD prophylaxis consisted of the association of cyclosporine(CSA)-short MTX.

To analyse the eff ect of transplant on "normalization" of intramedullary apoptosis, we studied Fas (CD95+) and caspases-3 expression on erythroblast subpopulation. Using both CD71 and FSC parameters, we obtained 3 principal erythroid populations, which we labelled A, B, C erythroblasts (Ery. A, Ery. B, Ery. C). Ery A (CD71high FSChigh) were basophilic, Ery. B (CD71high FSClow) were late basophilic and polychromatic, whereas Ery. C (CD71low FSClow) were orthochromatic erytroblasts and reticulocytes. Results: All patients had sustained engraftment. One patient died for acute distress respiratory syndrome after HSCT. The probability of survival, SCA-free survival, and transplant related mortality were 94%, 94%, and 6%, respectively. All surviving patients remained free of any SCA-related events after transplantation.

We observed an expansion of Ery A, Ery B and Ery C population at baseline, probably as an essential process needed to maintain a costant red cell production in SCA patients. After BM transplant decreased levels were observed especially on Ery A and Ery B populations in parallel to a reduction of Fas expression and an initial increase of caspases 3 on more mature Ery C population, as reported during later steps of "normal" erythroid cell maturation. Conclusion: These results confi rm that is possible to off er more than 90% chances of cure to SCA children. There is an excellent survival rate and a return to normal life. We also observed a "normalization" of erythroid populations, in parallel with decreased intramedullary apoptosis rate, suggesting normal erythroid maturation in ex-SCA patients after HSCT. 

Objectives: We report our single-center experience regarding safety and feasibility of repetitive administration of escalating doses of IL-15-activated cytokine-induced killer (CIK) cells in high risk patients with hematological or solid malignancies after allogeneic stem cell transplantation (SCT). Methods: Seven patients (aged 2-69 years, median age: 15 years) one with 4th impending relapse of acute myeloid leukemia (AML), one with 2nd overt relapse of AML, one with 4th molecular relapse of chronic myeloid leukemia, all after haploidentical SCT, as well as one patient with 3rd overt relapse of AML, and one patient with secondary AML and impending relapse, both after matched unrelated SCT, who failed donor lymphocyte infusion or natural killer cell therapy, received CIK cells after written informed consent, and case-by-case evaluation by the regional board (Regierungspräsidium Darmstadt, Germany) on a compassionate use basis. Prior to some of the infusions, patients in part received chemotherapy for reduction of leukemia load. Likewise, another two patients, one patient with alveolar rhabdomyosarcoma and one with Ewing sarcoma, both after haploidentical SCT received CIK cell infusions. CIK cells were generated from freshly isolated or cryopreserved peripheral mononuclear cells (PBMC) of the original stem cell donors.

Results: In total, 31 infusions (1-9 infusions per patient) were administered, with escalating cell numbers ranging between 0. S272 <0.75 and/or the age of donor <4 years might predict the risk for second donation. T. Feuchtinger, L. Joachim, J. Feucht, S. Kayser, P. Lang, R. Handgretinger University Children's Hospital Tübingen (Tübingen, DE) Refractory viral infections with persistent viral pathogens cytomegalovirus, Epstein-Barr virus and adenovirus (CMV, EBV, ADV) cause serious morbidity and mortality after allogeneic stem cell transplantation (SCT) due to a defi cient T-cell immunity. Adoptive T-cell transfer represents a promising approach in chemo-refractory viral infections using short term ex vivo protocols with small T-cell doses for induction of protective immunity. Since protection against multiple pathogens is required for most patients, T-cell transfer against multiple specifi cities may decrease multiple virus related morbidities. Our aim was the development of a standardized good manufacturing practice (GMP)-grade ex vivo protocol to generate multivirus-specifi c T cells in a short term single step approach for adoptive T-cell transfer. Virus-specifi c T cells were generated by stimulating donor peripheral blood mononuclear cells (PBMC) with virus-derived immunodominant T-cell epitopes (pp65, Hexon, EBNA-1), followed by enrichment of virus specifi c CD4+ and CD8+ T cells using interferon-γ capture technique. Feasibility was shown for the isolation of T cells for all three viral antigens in one single step and took 12 hours. All specifi cities (CMV, EBV, ADV) could be confi rmed in the T-cell product. Four children were treated with adoptive T-cell transfer. No infusional toxicities or graft versus host disease were seen. Induction of a pathogenspecifi c T-cell response could be shown in vivo, that was associated with the kinetics/improvement of the viral infection. In conclusion, induction of antiviral T-cell responses was feasible with a tri-virus-specifi c adoptive T-cell transfer ex vivo. Simultaneous T-cell stimulation with a mix of several antigens did not lead to extensive antigenic competition. Treating patients with multivirus-specifi c T cells resulted in reduction of viral burden. We also observed an increased frequency of virus-specifi c T cells in case of a subsequent virus reactivation post adoptive transfer of multivirus-specifi c T cells. This renders the approach also attractive for prophylactic use of multivirus-specifi c T cells. Multi-centre clinical studies have to evaluate effi cacy of this approach in the future.

Objectives: Viral reactivation or de novo Infection with human pathogenic Adenovirus (AdV), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) are frequent complications after allogeneic stem cell transplantation. Drug treatment against these infections is often not suffi cient. Adoptive cytotoxic T-lymphocytes (CTL) therapy is a possibility and has been used successfully. In addition relapse of the underlying disease is the other major cause of treatment failure. Screening for minimal residual disease (MRD) allows identifi cation of impending relapse and preemptive immunotherapy such as the application of donor lymphocyte infusions (DLI) or the transfer of cytokine induced killer (CIK) cells may in principle prevent relapse in a group of high risk patients. Methods and Results: CIK cells are generated from peripheral blood mononuclear cells (PBMC) of HLA-A*0201 CMV-seropositive healthy donors according to the standard protocol. Besides the standard stimulation with INF-γ on day 0 followed 24h later by OKT-3 and IL-2, IL-15 is added every 3-4 days and viral antigen in the form of peptides or protein is presented in the medium from day 0 on to increase the frequency of existing virus-specifi c CTL. Anti-CMV-specifi c CTL are identifi ed by fl ow cytometry after staining with PE-conjugated HLA-A*0201/pp65 495-504 pentamer and FITC-conjugated anti-CD8 antibody at certain days. The incubation with viral antigen leads to an up to 7.5 fold increase (n=6) of CMV-specifi c CD8+ cells. In subsequent in vitro experiments the increased cytotoxicity of antigen-stimulated CIK cells against viral antigen-loaded T2 cell line is shown. In the verifi ed and maintaining killing against leukemia cell lines the main killing mechanism is mediated via the NKG2D and MIC A/B pathway. To distinguish between the unspecifi c NKG2D-killing and the specifi c T-cell receptor mediated killing, the NKG2D pathway needs to be blocked to show the cytotoxicity of the viral-specifi c CIK cells in comparison to the non-antigen-stimulated fraction. Conclusion: The generation of dual-specifi c CIK cells may be an improved immunotherapy after stem cell transplantation inducing cytotoxicity against leukemia cells and might help to clear virus reactivation. 

Objectives: Cord blood transplantation (CBT) has emerged as a therapeutic option for a number of nonmalignant disorders aff ecting the bone marrow and other organs. However, the limited number of patients in these disease categories that have undergone unrelated CBT (UCBT) up to now, and the short follow-up periods, suggest that additional study is needed to determine the benefi ts of these alternative therapies Here, we report an analysis of the outcome of UCBT in children and adolescents with nonmalignant disorders in Korea.

Methods: This is a multi-center, retrospective study based on data reported to the Korean Cord Blood Registry relating to patients with nonmalignant diseases between 1994 and 2008. All CB units in the registry were obtained from Korea cord blood banks. Results: Sixty-fi ve patients were eligible for this study. The patients were separated into three groups: 24 patients with acquired severe aplastic anemia, 16 with inherited bone marrow failure syndrome (iBMFS) and 25 with primary immune defi ciency/inherited metabolic disorder (PID/IMD). The cumulative incidences (CIs) of neutrophil and platelet recovery were 73.3% on day 42 and 71.9% on day 180 post-UCBT, respectively. By day 100, the CI of acute grade II to IV graft-versus-host disease was 32.3%. At a median follow up of 71 months, 5-year overall survival (OS) and event free survival was 50.7% and 40.6%, respectively. Deaths were mainly due to infection, pulmonary complications and hemorrhage. In a multivariate analysis, presence of more than 3.91 x 10 5 /kg of infused CD34+ cells was the only factor consistently identifi ed as signifi cantly associated with rate of neutrophil engraftment (P = 0.04) and OS (P = 0.03). Survival rate (37.5%) and CI of neutrophil engraftment (37.5%) were lowest in patients with inherited BMFs. In iBMFS, use of a conditioning regimen including total body irradiation (TBI) was associated with worse survival (66.7% in TBI-vs. 0% in TBI+, P < 0.01) due to increased treatment-related mortality. In PID/IMD, patients receiving myeloablative conditioning including fl udarabine showed signifi cantly higher engraftment (100%) and survival rate (87.5%) than patients receiving other conditioning regimen. Conclusions: When cell dose and other factors are optimal, UCBT seems to be a feasible therapy for nonmalignant disease in children and adolescents who lack an appropriate related HLA matched donor. The strategies to reduce transplant-related toxicities would improve the outcome of UCBT in nonmalignant diseases.

Treatment of lymphoma in patients with adenosine deaminase defi ciency prior to transplantation A. Shah, N. Kapoor, H. Abdel-Azim, K. Mahadeo, P. Gaynon, R. Killen, R. Parkman Childrens Hospital Los Angeles (Los Angeles, US) PEG-ADA provides replacement therapy to patients wtih ADA Defi cient SCID. However, PEG-ADA does not fully restore cellular abnormalities. There have been 7 previous reports of ADA -SCID patients developing lymphoma. Of these, only 6 remain alive with most patients not having responsive disease prior to transplant. We report 2 patients who received PEG-ADA for 13 years and developed EBV + B cell lymphoma while on PEG ADA. These patients responded to therapy only in the absence of PEG-ADA. Patient 1 began PEGA -ADA therapy at 6 months of age and despite normal levels of ADA, developed metastatic B cell lymphoma (brain, bone , hepatic, splenic and mediastinal). She did not respond to multiple course of therapy, including high dose cytoxan, high dose methotrexate and steroids. After PEG -ADA was discontinued she had a greater than 50% response with etoposide and cytarabine. She underwent an HLA matched 9/10 mathed unrelated transplant using fl udarabine and melphalen and achieved a complete remission of her lymphoma. Patient 2 began PEG ADA therapy at 4 months of age and developed a metastatic B cell lymphoma at 14 years of age. He was taken off of PEG ADA at the time of his chemotherapy and achieved a complete remission after receiving R-CHOP. He is now undergoing a matched unrelated transplant. We speculate that while on PEG-ADA, the immunologic surveillance by T cells is defective and does not allow for adequate elimination of the EBV infected cells. However, the presence of PEG-ADA does not allow for the complete destruction of these same EBV infected malignant cells. Therefore, EBV driven malignancies in ADA-defi cient patients need to be treated aggressively, without the presence of PEG-ADA, in order to achieve an adequate tumor response. In conclusion: there is a strong correlation between BKV viremia/viruria and impaired cellular and humoral immune recovery after allo-HSCT. Probability of HC development in children after allo-HSCT depends on patients age, BKV viremia (>10 3 copies/ml)/viruria (>10 7 copies/ml) and on the profi le of CD8+ cell recovery.

Biotech GmbH (Tübingen, DE) T and B cell depletion of haploidentical peripheral stem cells with CD3/CD19 coated magnetic microbeads prevents GvHD and allows to coinfuse large numbers of donor NK cells and other accessory cells. The anti CD3 specifi c OKT3 antibody was routinely used as rejection prophylaxis without aff ecting CD3 negative cells. Due to its restricted availability, it had to be substituted by polyclonal ATG preparations with a longer half life period and comprising a broader variety of antigens. We present data with reduced ATG doses given at the beginning of the conditioning regimen in order not to impair cotransfused NK cells and immune recovery. A total of 20 pediatric patients received 3x10 mg/kg ATG-F (Fresenius) starting at day -12, followed by fl udarabine (160 mg/m 2 , d -8 to -5), thiotepa (10 mg/m2 d -4) and melphalan (140 mg/m 2 d -3 to -2). Median time to ANC>500 was 9 days. Graft rejection occurred in 2/20 patients (10%). Acute GvHD grade II-IV was observed in 1/18 (6%) patients without rejection. Extensive chronic GvHD occurred in 1/18 patients. Immune recovery was monitored and compared with a historical group receiving OKT3 and the same chemotherapy (n=34 . ATG serum levels were measured in 9 patients by fl ow cytometry (amount of ATG binding to the Jurkat cell line, defi ned as T cell specifi c rabbit IgG). Median peak levels of 23.7 μg/ml specifi c rabbit IgG were reached between day -8 and -6 and dropped to 1.9 μg/ml at day 0. In vitro incubation of NK cells from healthy donors with a comparable dosage of ATG-F (1 μg/ml) resulted in 26 % apoptosis and 0.2 % necrosis (70% vital cells) after 24 hours. Conclusions: ATG-F was started at an early time point, resulting in low serum levels of specifi c ATG at day 0 and in a fast NK cell recovery. In vitro results suggested, that the majority of NK cells will not be damaged herewith. Immune recovery of T and NK cells was comparable to that of a historical control group who received OKT3. This approach will be also of interest for other transplantation strategies in which various components of the grafts and additionally given T cells have to be preserved.

Fc-optimized CD19 antibody: results of a pilot study P. Lang (1) 

We investigated an Fc-optimized chimeric antiCD19 antibody on a compassionate use basis in pediatric patients at very high risk of relapse prior to and after allogeneic, HLA matched (n=2) or mismatched (n=9) fi rst or subsequent stem cell transplantation (SCT). Our aims were: 1) to further reduce leukemic load in otherwise refractory patients (therapeutic use) or 2) to prevent relapse after SCT in patients without detectable leukemic load but at extremely high risk (prophylactic use). 18 patients with B-lineage ALL (CR1-3 without MRD, n=8; CR1-3 with detectable MRD, n=8; active disease, n=2; previous SCT 15/18) received a mean number of 11 (range infusions of an anti-CD19 mAb (4G7SDIE) over 6 hours weekly or every second week posttransplant. In 8 patients, additional infusions were given prior to last SCT. Dosages ranged from 5 to 50 mg/m2. The infusions were well tolerated without any acute side eff ects. Depletion of CD19+ B cells occurred in all patients, which required i.v.-substitution of immunoglobulines. 1 severe infection (zygomycosis) was observed up to now. Minimal residual disease (MRD) or overt relapse (>50% blasts) was detectable in bone marrow aspirates prior to therapeutic mAb administration in 8/18 and 2/18 patients, respectively. Prophylactic CD19mAb infusions were given posttransplant without measurable MRD levels in 8/18 patients and in another 2 patients (who did not respond to pretransplant CD19mAb but reached MRD negativity after SCT) due to an extremely high relapse risk. In 4 out of 6 patients with detectable MRD, leukemic load was reduced for at least 1 log or eradicated by the mAb. 2 other patients responded to antiCD19 treatment as well but received additional therapy. 2 out of those patients relapsed, 6 other patients are in remission after 1st antibody application with a median follow up of 185 days (range 17-464 days). Both patients with overt relapse did not respond. 2/10 patients with prophylactic mAb infusions relapsed after 161 and 177 days, 8 other patients remain in molecular remission since 75-108 days. Taken together, a response could be documented in 4/6 patients; a total of 13/18 patients are in remission (median follow up 143 days).

In conclusion, promising antileukemic eff ects have been observed in this pilot study. A further clinical trial is in preparation. Conclusion: This large series shows that RIC allo-SCT is feasible with acceptable toxicity in pediatric patients, especially in cases of lymphoid malignancy. Prospective studies are needed to confi rm the role of RIC allo-SCT in the pediatric setting, with a special focus on long-term side eff ects, which are a matter of concern in children. (2), neuroblastoma (2), juvenile myelomonocytic leukaemia (2), infant acute lymphoblastic leukaemia (2), HLH (1), T-cell lymphoblastic lymphoma (1) and infant acute myeloid leukaemia (1) . Conditioning regimens varied. 7 patients were aged 3-11 months. 6 had pre-existing intra-thoracic pathology (HLH 1, 4 proven or probable malignancy, 1 diaphragmatic eventration). Three patients had prior or co-existing chest infection (1 Pneumocystis, 1 Parainfl uenza 3, Cytomegalovirus 3). None satisfi ed full criteria for VOD. Common/recurring presenting signs included tachypnoea (10), persistent tachycardia (4), thick mucus secretions (3), fl uid retention (4), hepatosplenomegaly (3), oxygen requirement (7) and radiological bilateral chest infi ltrates/pneumonitis (4) . Earliest signs of PAH were at a median of D11 (D-3 to +150) post-HSCT, but echo confi rmation was only evident by a median of D32 (D9-D150). Pulmonary hypertensive changes were seen in 2/2 biopsied patients. Therapy comprised either prostacyclin and/or sildenafi l (9 pts, maximum doses 30ng/kg/min and 1mg/kg QDS respectively) or oxygen therapy alone (1) . In one, with late presentation coexistent with CMV reactivation, PAH resolved during CMV therapy. 8 (73%) patients had complete resolution of PAH. Three (27%) had PAH as cause of death. Conclusions: Aetiology remains unclear in many cases and may comprise a mixture of pre-transplant, infective and allogeneic factors. However this data shows that PAH, although well recognised in non-malignant HSCT, can also occur in patients transplanted for a range of malignancies. Echo changes may not be present at onset of symptoms but a high index of diagnostic suspicion and early treatment may contribute to recovery. Various T-cell depletion strategies have been used over time to minimize GVHD and maximize sustained engraftment and early immune reconstitution in alternative donor transplants with variable success rates.

ing results in haploidentical HSCT. We report a child with Wiskott Aldrich syndrome (WAS) treated successfully using this method. Methods: A one year old boy with WAS (c.7781G>A mutation in intron 8) and disseminated CMV infection requiring ventilation for CMV pneumonitis at aged 4 months was admitted for haploidentical paternal HSCT in the absence of a suitably matched family or unrelated donor. He was pre-treated with ganciclovir and on admission CMV PCR was negative. After admission he was started on prophylactic foscarnet. He was conditioned using rabbit ATG (15mg/kg total day-12 till day-9), busulfan, fl udarabine and thiotepa. Cyclosporine and mycophenolate mofetil were used for GVHD prophylaxis. Stem cells were mobilised using GCSF and peripheral blood stem cells were harvested. T-cell manipulation was performed using Miltenyi clini-MACS system. Total nucleated cell dose was 10.9x 10 8 /kg, CD34 + cells dose was 21.9 x 10 6 /kg, TCRα β cells were 1.3 x 104/kg (4.5 log reduction), CD19 cell dose was 3.1 x 10 4 /kg (3.7 log reduction) and TCRγδ cell count was 3.2 x 10 7 /kg. Results: Polymorphonuclear cell and platelet engraftment was seen on D+15 and D+17 respectively. Chimerism on day +16 showed 100% donor cells. Lymphocyte subsets were closely followed post transplant. There was no evidence of acute GVHD. His post transplant course was complicated by CMV reactivation which was treated with therapeutic doses of foscarnet. His CMV became undetectable at day +36 post transplant. Figure 1 compares CMV viral load and T cell recovery. He was discharged in a stable condition at day + 50 post-transplant on oral valganciclovir.

Conclusion: This appears to be a promising technique in haploidentical or MMUD HSCT with early and sustained engraftment, early immune recovery and less risk of GVHD. This is the fi rst reported case of haploidentical HSCT using this technique for primary immunodefi ciency in United Kingdom. patients (94% Allo) underwent BAL; 1yr probability of requiring BAL was 43% Allo, 8.5% Auto and yielded a 40% diagnostic infectious etiology (Fig. 1) . LB was performed in 10% of HSCT recipients with a diagnostic yield of 94% ( Fig. 1 )(P<0.0001). There were no grade III/IV toxicities probably or defi nitely attributed to either procedure. In a multivariate analysis the need for requiring BAL following MAC Allo was signifi cantly associated together (HR=85, P=0.0002). The probability of OS was 20.2%, 17.5% and 67.4% in pediatric HSCT recipients who required BAL, LB or neither, respectively (Fig. 2) . In the multivariate analysis, the need for BAL was associated with a signifi cant risk of mortality (HR=2.96; P<0.0001). Conclusion: In summary, in this large cohort of pediatric HSCT recipients, approximately 34% and 8% with APC required BAL vs. LB, respectively. Both BAL and LB were safe and well tolerated and yielded a diagnostic success of 40% and 94%, respectively. Future prospective studies are needed to determine which pediatric HSCT recipients should undergo BAL vs. LB and to improve longterm mortality from APC. S278 malignancies, bone marrow failure syndromes, and some inherited disorders. Over the past decades, major landmarks and advances have been achieved in the fi eld of allo-SCT with respect to conditioning regimens, choice of stem cells source, as well as supportive care. With this background, we conducted a study to assess the outcome of pediatric transplanted in a single institution over a 3 decades period. All patients who received allo-SCT in our pediatric hematology department between 1983 and 2010 were included in this analysis. This period was a priori divided into two parts namely 1983-1999 and 2000-2010 , the latest period corresponding to the initiation and development of cord blood allo-SCT and introduction of the so-called reduced-intensity conditioning (RIC) regimens in some subgroups. In all, 250 patients were allografted and 272 allo-HSCT were performed The main characteristics of the patients and the most relevant aspects of allo-SCT are shown on Table 1 . The use of a myeloablative conditioning (MAC) regimen was predominant between 1983 and 1999 while RIC regimen represented 16% of the procedures after 2000 (p=9. .Bone marrow was the major stem cell source between 1983-1999 compared to 2000-2010 (96% vs 65%, p=2.10-10). After 2000, cord blood was introduced as stem cell source for 25% of cases and peripheral blood stem cell for 9%. Overall survival (OS) was signifi cantly higher in the second period (64% versus 52%, p=0.03) (Fig.1) . Also, non-relapse mortality (NRM) at 5 years was signifi cantly lower after 2000 (29% versus 9%, p=0.0002). The cumulative incidence of relapse was 25% between 1983-1999 and 34% between 2000-2010 (p=0.11) . Concerning the cumulative incidence of mortality due to relapse or progression was not statistically diff erent between the 2 periods (20% vs 26%, p=0.26). Finally, between the 1983-1999 period and the 2000-2010 period, the cumulative incidence of death related to GVHD was signifi cantly reduced (13% versus 3%, p=0.001).

In conclusion, this large analysis performed over a 3 decades period confi rms that major advances in terms of outcome were achieved over the time in the pediatric allo-SCT population. The safety of the procedure and the overall outcomes have signifi cantly improved, despite the increasing use of alternative stem cell sources such as cord blood cells and HLA-matched unrelated donors.

Extracorporeal photochemotherapy for acute graft-versushost disease: an 11 year single paediatric centre experience S. Giardino, F. Bagnasco, E. Lanino, G. Morreale, G. Dini, M. Risso, M. Montera, P. Terranova, D. Di Martino, P. Toselli, A. Arleo, P. Messana, L. Tenerini, M. Faraci G. Gaslini Children's Research Institute (Genoa, IT) Introduction: Extracorporeal photochemotherapy (ECP) represents a recognized treatment of acute and chronic Graft versus Host Disease(aGvHD/cGvHD). Actually no clinical prognostic factors of response to ECP and no schedule based on organ GvHD involvement are reported. Patients: In the last decade, 160 allogeneic stem cell transplants (allo-SCT) performed at G. Gaslini Institute in children with malignant (70.6%) or non-malignant (29.4%) disease were complicated by either acute (51.2%), chronic (6.3%) or both forms (42.5%) of GvHD. ECP was performed in 36 cases with aGvHD (grade I-II=13; grade III-IV=23) and 10 with cGvHD (limited=2; extensive=8). Organs involved were skin (n=26), gut (n=18), and liver (n=10). Treatment schedule included an induction phase (2 times weekly, at least 16) and a maintenance phase (2 times every 2 weeks, at least 8) according to clinical response and organ involvement. ECP was performed with discontinuous methodology, using separated cell separation (COBE SPECTRATM) and UVA irradiation. Results: After a median follow-up of 3.5 years(0.1-12.1), 75% of children with aGvHD responded, either completely (61.1%) or partially (13.9%). Response by organ was 85%, 77% and 50% for cutaneous, intestinal, and hepatic involvement, and was obtained after a median of 7, 6.5 and 6 ECP-procedures, respectively. Overall response in cGvHD was 70% (complete 20%, partial 50%) after a median of 18 ECP-procedures. Conclusions: Our results confi rmed ECP feasibility and effi cacy in cutaneous and visceral acute and c-GvHD; the response to ECP, when obtained, occurred within the fi rst 7 procedures in a-GvHD and later in c-GvHD forms(18 procedures); steroid tapering represented the only variable predicting response and survival.

A boost of donor-derived CD34±selected peripheral blood cells without further conditioning in paediatric patients with poor graft function after allogeneic haematopoietic stem cell transplantation S. Giardino, M. Schmidt, M. Faraci, E. Lanino, G. Dini, M. Podestà, P. Terranova, D. Di Martino, F. Sabatini, G. Morreale G. Gaslini Children's Research Institute (Genoa, IT) Introduction: Poor graft function (PGF) is defi ned as a mono-, bior tri-lineage cytopenia appearing at least 2 weeks after allogeneic hematopoietic stem cell transplantation (allo-HSCT). PGF is defi ned primary if recipients fail to achieve sustained graft function, secondary if occurs after complete hematologic recovery. The aim of this study is to report a single centre retrospective experience in 7 children who received boost of donor-derived CD34±selected cells (CD34±boost) for a primary or secondary PGF. Patients: Between 2002 and 2011, 7 patients (pts) with a median age of 11.7 years (range 3.8-18) with malignant (n=2) or non malignant disease (n=5) received CD34±boost, without further conditioning, for primary (n=6) or secondary PGF (n=1). PGF was diagnosed after a median of 199 days (range 62-465) by allo-HSCT from a matchedrelated (2 pts) or alternative (5 pts) donor, which was prepared with a myeloablative (n=2) or non-myeloablative (n=5) regimen. Chimerism was mixed in 1 pt, while all others were full donor. Acute Graft versus Host Disease (GvHD) occurred in 6 pts (grade I=4, grade IV=2) and chronic-GvHD in 4 pts (extensive=3, limited=1). After a single apheresis of G-CSF-mobilized peripheral blood from the original donor, a median of 4.52x10e6/Kg CD34+ positively selected (CliniMACs; Miltenyi) cells were infused (range 1. 2-18.4) . At time of boost, median neutrophils (PMN) count was 0.61x10e9/ L(0.1-3.5), 6 pts were platelets (PLTs) and 5 red cell transfusions dependent. Infectious events before CD34±boost included 6 viral reactivations(5 CMV and 1 herpes zoster), 3 severe bacterial events and 1 pulmonary aspergillosis. Results: Tri-lineage recovery was observed in all pts. PMN count exceeded 2×10e9/L after a median of 30 days(range 8-60), PLTs and red cells transfusion independency was achieved 28 (range 6-250) and 40 days (10-120) after CD34±boost respectively. The single pt with mixed chimerism converted into complete donor 3 months after CD34+ boost. The median follow-up was 2.5 yrs (1.1-10) . NRM was absent and 1 pt died of leukemia relapse. No signifi cant infectious episode nor acute GvHD reactivation were observed; the 3 pts with extensive chronic GvHD experienced a signifi cant improvement after CD34+ boost. Conclusion: Our experience confi rms that CD34±boost represent an eff ective and safe approach of PGF also in pediatric pts, obtaining a better control of infections and acute and chronic GVHD, but largest studies are need to evaluate the role of CD34±boost in GvHD control.

Acute kidney injury after allogeneic HSCT in children: incidence and prognostic factors A. Kuiper, L.C. De Bock, A.Y. Konijnenberg, J.J. Boelens, M.B. Bierings, M.R. Lilien UMC Utrecht, children's hospital (Utrecht, NL) Objectives: In a pediatric allogenic hematopoietic stem cell transplantation (HSCT) cohort we aimed to identify predictors for acute kidney injury (AKI).

Methods: All children (0-18 years) who received an allogenic HSCT in the Wilhelmina Children's Hospital Utrecht between January 2004 and July 2011 were included. HSCT data were prospectively collected, while data concerning renal function and possible prognostic factors were retrospectively extracted from patient fi les. AKI was defi ned as at least a doubling of baseline serum creatinine within 3 months after transplantation (≥ Acute Kidney Injury Network stage 2 Conclusion: In a cohort of pediatric allogenic HSCT patients, a high incidence of at least one episode of AKI was found. The incidence of AKI appeared to be lower in children who were transplanted for non-malignant diseases. Furthermore, hyperbilirubinemia showed to be an independent predictor for AKI. Finally, AKI is related to higher non-relapse mortality.

Treatment of refractory acute myeloid leukaemia with alloreactive natural killer cell conditioning followed by 2Gy TBI and stem cell transplant P.L. Tan (1) We present an instructive case of a 14-year-old boy with therapyrelated AML secondary to osteosarcoma treatment who relapsed 21 months after a matched unrelated donor stem cell transplant. At the time of relapse, the patient had a poor Karnofsky score (60%) related to graft-versus-host disease complications and was fi rst treated with intermediate intensity salvage chemotherapy

S280 which failed to induce remission. With 31% leukemic blasts present in the bone marrow, he received adoptive NK cell therapy as described by Miller et al. (Blood 2005 . Probability of 1-yr progression-free survival (PFS) and OS were 50% (CI95: 30-70%), and 47% (CI95: 26-64%) respectively. Conclusions: These preliminary results suggest that this conditioning regiment including CLO dose 52 mg/m 2 coupled with Ara-C (65mg/m 2 ) and TBI (1200 cGy) followed by AlloSCT is safe and well tolerated in CAYA with poor-risk ALL or AML. Our results are promising with respect to a low risk of day 100 TRM and leukemic relapse rate in this very poor risk patient population. This approach should be considered in better risk CAYA patients with ALL/AML who require AlloSCT. 

Aim: To investigate the regimen-related toxicity (RRT), nonrelapse mortality (NRM), graft failure rate, and relapse occurrence in children with hematologic malignancy conditioned with treosulfan-based preparative regimens for 2nd or 3rd hematopoietic stem cell transplantation (HSCT) from matched sibling ( median 30). After 131 months, the probability of relapse-free survival for all patients was 0.654, while probability of event-free survival was 0.429. Conclusion: Long-term results of treosulfan-based preparative regimens for 2nd or 3rd HSCT in children with hematological malignancies demonstrate its low early RRT, excellent myeloablative eff ect, and at least acceptable NRM and anti-leukemic eff ect in this high-risk subset of pediatric patients. Results: Myeloid engraftment was achieved in all children. Acute and chronic GvHD rate after MSD-HSCT was 15.6% and 15.6%, while after MUD-HSCT 7.7% and 7.7%, respectively. 100-day transplant-related mortality after MSD-HSCT was 6.3% (2/32), and 0% (0/13) after MUD-HSCT (p=0.754). Relapse rate was 21.9% (7/32) in patients transplanted from MSD, and 7.7% (1/13) in transplanted from MUD (p=0,467). After 70 months the probability of relapse-free survival for patients transplanted from MSD was 0.74, and 0.93 in those transplanted from MUD (p=0.193) , while probability of event-free survival was 0.69 and 0.93, respectively (p=0.106).

Conclusions: MUD-HSCT in children with HR-AML in CR1 seems to demonstrate results, which are not inferior to results of MSD-HSCT, and thus could be considered as standard procedure in this subgroup of children with AML. O. Amon, H. Billing, P. Lang, T. Feuchtinger, H. Teltschik, R. Handgretinger University Hospital of Tübingen (Tübingen, DE) Since 2009 an online system for ECP is available for children with body weights of less than 40 kg: CELLEX, manufactured by Therakos Inc.,needs a minimal extracorporeal blood volume of 180 ml and works with a minimal blood fl ow of 5 ml/min. Between October 2009 and November 2012 n = 22 patients 1.5-18 years of age and with acute or chronic GVHD after stem cell transplantation S282 have been treated with CELLEX in Tuebingen. n = 18 patients suffered from skin and gut GVHD (whereof 6 patients had liver GVHD additionally). n = 4 patients suff ered from lung GVHD. Body weight was 10-67 kg (with a mean of 23.9 kg). All patients were refractory to standard immunosuppression including corticosteroids. 17/22 patients (77%)achieved complete or partial remission of their GVHD with ECP. In all these successful treatments a reduction of the corticosteroid dose by at least 50% wass possible. Currently we treat patients with GVH with 2 treatment sessions weekly in the fi rst month, followed by 2 treatments every other week in month 2-4 and 2 treatments every 4 weeks in months 5+6. We have no diffi culty using Hickman catheters or other central venous catheters already in place as venous access. In case of mucous bleeding with GVHD of the gut we use regional citrate anticoagulation instead of heparin. Bacterial (e.g. MRSA) or viral (e.g. Hepatitis C)infections are no contraindication to ECP treatment,since this an immunomodulating rather than an immunosuppressive procedure. Remarkable is the high success rate of ECP in children and adolescents with GVHD, the short treatment time of about 2 -2.5 hours and minimal or no adverse eff ects. Corticosteroid treatment can be discontinued in many patients and thus the risk of severe infections diminished.

Peripheral blood stem cell harvest in pediatrics is required for two main applications: Peripheral blood stem cell (PBSC) collection for autotransplantation and extracorporeal photochemotherapy (ECP The low extracorporeal volume of Spectra Optia (170 ml) seems to be advantageous in pediatrics, but this device has not been validated for low collection fl ows. Our experience showed that Optia can be used in children weighing less than 15 kg for ECP and PBSC collection. For both techniques, our fi rst patient's data must be confi rmed in order to know if procedure elongation is off set by collection effi ciency increase and loss of platelets decrease.

T. Bauters, V. Bordon, S. Van Lancker, P. Schelstraete, H. Robays, G. Laureys, Y. Benoit, C. Dhooge Ghent University Hospital (Ghent, BE) Background: Protective immunity to vaccine preventable infectious diseases might be lost over time following hematopoietic stem cell transplantation (HSCT). Systematic reimmunization is important to re-establish appropriate immunity and to prevent infectious diseases related morbidity and mortality. Limited data are available on the appropriate follow-up of vaccination schedules in pediatric HSCT patients. This study aims to ascertain whether the guidelines for vaccination recommended in our hospital are followed and to which extent of conformity they are used. (1), JJ Seo (2), HJ Im (2) (4), J. Yoon (5) , H. Park (5) , B. Park (5) , JW Lee (6), H. Kim (6) , H. Kang (6), KD Park (6), HY Shin (6) (

Objective: High-dose chemotherapy and autologous stem cell transplantation has improved the outcome of pediatric patients with high-risk solid tumors. However, approximately 10 to 30% of patients fail to collect the minimum number of hematopoietic stem cells for transplantation. Plerixafor was recently approved as a new mobilization agent in combination with G-CSF in adult patients. However, there are limited data for effi cacy and safety in plerixafor usage in children. Several studies for small population have reported that plerixafor in combination with G-CSF might be also safe and eff ective in pediatric patients. Therefore, we S283 retrospectively reviewed our experience regarding the effi cacy and adverse eff ects of plerixafor in pediatric patients in Korea. Methods: A retrospective analysis was performed in 26 pediatric patients from 6 centers in Korea who received plerixafor as part of the mobilization regimen between August 2009 and August 2012. Plerixafor was administered in second apheresis round in all patients who had failed to achieve suffi cient CD34+ cells in the fi rst apheresis round. Results: The median age was 10.3 years (21.-25.5) . All patients received plerixafor and G-CSF before hematopoietic stem cell collection. Nineteen patients also received chemotherapy as part of their mobilization regimen. While the median number of CD34+ cells collected in the fi rst apheresis was 1.23 x 10 6 /kg (0.18-8.26), the median number of CD34+ cells collected in the second apheresis was 5.10 x 10 6 /kg (0.24-70.55) (P = 0.006). A median 3.5-fold more CD34+ cells were collected after the plerixafor administration and 5.4 fold more CD34+ cells were harvested in patients who mobilized CD34+cells less than 2.0 x 10 6 /kg in the fi rst apheresis. Although 6 patients achieved CD34+ cells more than 2 x 10^/kg in the fi rst apheresis, 16 patients achieved CD34+ cells more than 2 x 10^/kg after plerixafor administration. Transplantation was performed in 22 patients. Median day of neutrophil engraftment and platelet engraftment were 9 days and 29 days, respectively. Four patients showed visual hallucination after plerixafor usage. Conclusion: The combination of plerixafor and G-CSF was also effi cacious in peripheral blood hematopoietic stem cell collection in children. However, there may be a potential neurotoxicity in younger children. Further study should be performed before wider application of plerixafor in pediatric patients.

Capillary leak syndrome in the paediatric population: incidence, risk factors and prognostic value J. Daniels, G. Lucchini, J. Sörensen, A. Jarisch, E. Rettinger, A. Willasch, T. Klingebiel, P. Bader Goethe-University (Frankfurt/Main, DE) Objective: Capillary leak syndrome (CLS) is complication occurring after stem cell transplantation (SCT), which consists in a loss of intravascular fl uids into interstitial spaces after endothelial damage. CLS incidence is around 20% among adults, and so far unknown in the pediatric population. Risk factors for CLS are the use of G-CSF as well as the burden of pre-transplant chemotherapy. We aimed at assessing CLS incidence, risk factors and impact on survival in a pediatric cohort of patients. Methods: With a retrospective study we revised the clinical charts of all the patients <18 years of age undergoing SCT between Jan 02 and May 12 at our Institution. CLS was defi ned by at least 2 of the following criteria: weight gain >3% in 24 hours, generalized oedemas (ascites, pleural eff usion, pericarditis), positive intake balance under diuretic administration, sudden hypotension (10% reduction of MAP 

A. Krauss, Y. Sverdlov, A. Gruspan, I. Yaniv, J. Stein Schneider Children's Medical Center of Israel (Petah Tikva, IL) Extracorporeal photopheresis (ECP) has become an oft-used therapy for the treatment of acute and chronic graft versus host disease (aGVHD and cGVHD, respectively) after hematopoietic stem cell transplantation (HSCT). ECP is not inherently immunosuppressive and has few side eff ects, making it a tempting therapeutic option for the treatment of steroid refractory GVHD; issues of vascular access present practical obstacles to its use in children and young adults. We describe our experience using ECP in children after HSCT at our center. We performed 20 courses of ECP in 17 children (age 1.6 -18 yrs) between January 2010 and December 2012. ECP restarted after a hiatus of at least 4 weeks is counted as a new course. Primary diagnoses of our patients (pts) were malignant disease in 13 pts and non-malignant disease in four. Nine courses of ECP were performed for aGVHD, 6 for cGVHD, and 5 for pts with overlap syndrome (OvS). Most pts had ECP initiated as second-line therapy; in 2 cases ECP was initiated as fi rstline therapy due to underlying infectious complications where steroid-avoidance was imperative. Pts underwent a median of 9 treatments (range 2-90). Vascular access for ECP included Permacath ® in 9 courses, Hickman® catheter in 2 courses, temporary arterial line in 2 courses, temporary peripheral (venous) lines in 1 course, and a combination of the above in 6 courses. ECP was discontinued in 1 pt due to issues of vascular access. We have observed 10 (50%) complete responses (CR), 3 (15%) partial responses (PR), and 6 (30%) mixed responses (MR). 14 pts (70%) could be weaned from their initial steroid dose. Among pts with aGVHD, CR occurred after 6/9 (67%) courses and steroid dose could be tapered in 5 cases. In pts with cGVHD, CR was seen in only one pt, with PR and MR in 3 and 2 pts, respectively. Steroids could be tapered in 5 (83%) pts. Among 5 pts with OvS, 3 achieved CR, 1 had an MR and one pt was resistant. Steroids were tapered in 4 pts. There were 10 deaths in the cohort, 3 from GVHD . In addition, 1 pt with CR in all 3 initially involved organs developed progressive bronchiolitis obliterans and died of respiratory failure, and 1 pt with severe steroid myopathy died of culture-negative sepsis. Three pts died of sepsis, one of fulminant hepatic failure (aspergillus niger and Penicillium species) and 1 of disease relapse. Our results support the use of ECP as a feasible, eff ective treatment for GVHD in children after HSCT. was bone marrow (67.6%). Conditioning regimen and prophylaxis against GVHD were administered according to our practice at that time and type of transplant. Results: One patient presented primary and eight secondary graft failure. One out of nine patients presenting graft failure survived. Fifteen patients (40%) developed acute GVHD grades II-IV and 8 of 25 assessable patients (32%) chronic GVHD; extensive cGVHD 2 of 25. Early complications were: hypertension (100%), mucositis grades II-III (51%), infections (43%), liver toxicity grade > 2 (35%), renal dysfunction (27%) and hyperglycaemia (24%). The main late eff ects, with a median follow-up of 14 years (range: 2 mo-23 y), were endocrine (gonadal dysfunction (90%), hypothyroidism (20%), GH defi ciency (20%) and diabetes mellitus (10%) and skeletal disorders (hip necrosis). Five patients developed malignancies: AML (2), tongue carcinoma (1), pharyngeal carcinoma (1) and basocellular carcinoma (1) Background: In low-and middle income countries there is a dire shortage of bone marrow transplantation (BMT) centers. In these areas, non-malignant disorders such as thalassemia, sickle cell disease and aplastic anemia are the most common indication to BMT. In particular, thalasssemia major is the most common life-threatening non-infectious disorder of childhood in South Asia where a substantial proportion of aff ected children do not survive beyond adolescence. The Cure2Children Foundation an International Non-Governmental Organization based in Florence, Italy, has supported, both fi nancially and professionally, the start up of two centers, one in Pakistan and one in India, for the cure of transfusion-dependent thalassemia by bone marrow transplantation (BMT) according to shared recommendations and within an intensive cooperation program based on on-line and on-site focused training. This is the fi rst outcome analysis focusing on initial results in start up centers in lower income settings. Methods: A total of twelve consecutive patients were included in this analysis, the initial six from the Children's Hospital of the Pakistan Institute of Medical Sciences, Islamabad-Pakistan, and the initial six from the South East Asia Institute for Thalassemia, Jaipur-India. Both these centers had never performed BMT before and these patients where purposely chosen as the focus of this report because they represent the steepest phase of the learning curve and thus supposedly the ones at highest risk of unfavorable events related to the start up phase. Patients were 6 years or younger at transplant day, and received allogenic BMT from a compatible related donor. Findings: At a median follow-up of 5.9 months, the absolute neutrophil recovery was reached at a median period of 15.5 days, and platelet recovery at 18 days. Median period of hospital stay was 49 days, and actuarial thalassemia-free and overall survival, were both 91.7%. The mean total cost of a BMT including follow-up was 12,858 USD. Interpretation: In low resource settings matched-related low-risk BMT for thalassemia can be performed with outcomes comparable to richer countries and with a fraction of the costs. Within structured and intensive cooperation, good outcomes can be obtained from the very beginning. This observation may have important implications to increase access to cure thalassemia major worldwide and to face the dire shortage of BMT services in low-to middle income countries.

Graft-versus-host disease after allogeneic haematopoietic stem cell transplantation in children and adolescents with thalassemia S. Pakakasama, S. Klamchuen, S. Hongeng, S. Sirireung, U. Anurathapan, D. Songdej, S. Sasinil, N. Sirachainan, A. Chuansumrit Mahidol University (Bangkok, TH) Graft versus host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT). Most of GVHD data was concluded from studies of HSCT in patients with hematologic malignancies. Thalassemia is the most common genetic hematologic disease and indication for HSCT in our country. Therefore, the aim of this study was to evaluate the prevalence, severity, and risk factors for acute and chronic GVHD in children and adolescents with severe thalassemia after HSCT. We performed a retrospective study of thalassemia patients receiving HSCT between October 1992 and August 2012 at our institute. Acute GVHD was graded according to Seattle criteria. Chronic GVHD was analyzed using recent NIH criteria. There were 92 HSCT performed in 89 patients (48 males) with a median age of 7 years 6 months (range 4 months to 17 years 3 months). The types of thalassemia included HbE /β thalassemia (n=69), homozygous β thalassemia (n=22), and HbH disease (n=1). Myeloablative (MA) (n=74) and reduced intensity (RI) (n=18) regimens were used. Donors were HLA-matched siblings (n=62), unrelated donors (n=28), and haploidentical mothers (n=2). Bone marrow was the most common source of stem cells (62%). The median CD 34 cell dose was 7.49 x 106 cells/kg (range 0.61-22.08 x 106 cells/ kg). Most of recipients received CsA and MTX after MA regimen.

FK506 and MMF were mostly given in recipients after RI regimen. ATG was used in HSCT with alternative donors or RI HSCT. Acute GVHD grade II-IV was diagnosed in 34 (37%) patients (28 classic, 4 late, and 2 persistent) with the median day of 23 days after HSCT (range 5 -90 days). Using unrelated donor was the signifi cant risk for acute GVHD (OR 3.5; 95%CI, ). The chronic GVHD was identifi ed in 28 (30.4%) patients (27 classic and 1 overlap). The severity of chronic GVHD was stratifi ed into mild (n=17), moderate (n=6), and severe (n=5). The most common sites of chronic GVHD were skin and buccal mucosa. GVHD related mortality was found in 4 patients (3 acute and 1 chronic). Seventy-fi ve patients (84.3%) have been alive without disease at the time of this analysis. Unrelated HSCT was signifi cantly associated with adverse outcome (OR 3.2; 95%CI, 1.1-9.3).

In conclusion, acute and chronic GVHD were diagnosed in 37 and 30.4% of children and adolescents after HSCT for thalassemia. Unrelated HSCT increased risk of acute GVHD and unfavorable outcome.

Outcomes of patients undergoing allogeneic stem cell transplantation in childhood for myelodysplastic syndrome and juvenile myelomonocytic leukaemia: a single centre experience P. Keslova, P. Sedlacek, R. Formankova, P. Riha, L. Krol, M. Sukova, M. Snajderova, T. Svobodova, J. Stary University Hospital Motol (Prague, CZ) Myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) represent a small but important group of haematological malignancies in childhood. Stem cell transplantation (SCT) is a curative option for most of these patients. With markedly improved prognosis quality of life becomes increasing concern because of manifestation of late complications and long-term eff ects that are secondary to treatment exposures related to HSCT. We analyzed outcome and late eff ects in a group of patients ( 

Central nervous system involvement after haematopoietic stem cell transplantation in children I. Velichko (1) , N. Stancheva (2) , T. Bykova (2) , O. Paina (2) , E. Semenova (2) , L. Schugareva (3) 

A.

Yesilipek (1), V. Uygun (2) , N. Eker (1) (2, (2) (3) (4) (5) 2) . Median log depletion of CD19 cells was 3,5 (2, 3) . Patients received CD34/kg -11,3 x106 (2, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , CD3/kg -17,8 x 104 , CD19/kg -3,5 x104 (0,9 -35) . One patient died of sepsis before engraftment. Primary engraftment was seen in 16 (80%) pts. Secondary engraftment was seen in 18 (93%). Grade 0-2 GVHD was seen in 17 pts, grade 3 in 3 pts. Median follow-up is 4,8 years. Five pts died of transplantrelated causes. Twelve patients died of disease. Overall survival at 5y is 19%(CI=6-33), event-free survival at 5y is 9,3%(CI 1,6-26) (Fig 1 and 2 

of ERT, these patients should be considered for alternative therapeutic strategies such as immune tolerance induction or allogeneic HSCT.

M. J. Gutierrez, E. Fernandez, E. Pereira, C. Espadinha, A. Barbosa, N. Miranda, I. Ferreira, G. Teixeira, M. Abecasis IPO Lisbon (Lisbon, PT) The use of peripheral blood progenitor cells (PBPC) to allow rapid bone marrow recovery after high dose chemo/radiotherapy is now well established in the treatment of some pediatric malignancies. However due to the small size and low weight of most patients (pts) technical problems such as extracorporeal volume balance, venous access, anticoagulation and side-eff ect management need special attention.

We have reviewed our experience in pediatric pts at our institution. From January 2007 to June 2012, 60 pts aged ≤ 16 years were referred to our centre for PBPC collection and autologous transplantation. In 14 pts PBPC were collected for 2 or more transplants, of whom 10 had enough PBPC in a single mobilization, while 4 needed further procedures, including one who was given plerixafor. Median age was 6 years (5 months-16 years), mean weight 40kg (7 to 92kg) with 16 pts <15kg. Diagnosis were neuroblastoma (22), lymphoma (11), Ewing's (9), PNET (5) and others (13). Pts were mobilized with G-CSF alone (40%) for a median of 6 days (4-12) or G-CSF plus chemotherapy (57%) for a median of 11days (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , with 2 pts being given G-CSF followed by G-CSF plus chemotherapy. Collections were performed using a Cobe Spectra separator version 4.7 until 2009 and 6.1 AutoPBSC thereafter. In 92% of procedures a central line was used. A median of 1.4 collections per patient were performed (1) (2) (3) , with a median 3.2 (1.7-5) blood volumes processed per leukapheresis. A median number of 5.3x10 6 CD34+ cells/kg were harvested per pt. Five pts, aged 3-15years, were given Plerixafor due to mobilization failure (median peripheral blood CD34+ cells 5x10 6 /microL before and 20.5x10 6 /microL after plerixafor). No signifi cant adverse events were observed during or immediately after collection. Forty-nine pts (82%) were transplanted and the median time to reach N>0.5x10 9 /L was 11 days. Eleven pts (18%) were not transplanted, 7 due to disease progression, 2 because of an inadequate CD34+ cell collection and 2 were no longer considered as transplant candidates due to complete response of the underlying disease. Twelve of 14 pts underwent 2 or more transplants (2 pts died before transplant). Median time to reach N>0.5x10 9 /L was identical for pts receiving single or tandem transplants. Our experience shows that PBPC collection in pediatric pts, even in those with very small weight, can be eff ectively achieved by a dedicated clinical and technical team.

Pulmonary hypertension following paediatric allogeneic stem cell transplantation: improved outcome after treatment with sildenafi l R. Vlug, R. Bertels, A. Lankester, R. Bredius, D. Bresters, F Smiers LUMC (Leiden, NL) Objective: To identify risk factors for pulmonary hypertension (PHT) following hematopoietic stem cell transplantation (HSCT) in children.

Methods: Case report of 3 patients seen in our clinic and review of 18 more patients described in the literature. Results: Three children (age 4-5 months), two boys with juvenile myelomonocytic leukemia (JMML) and one girl with severe combined immune defi ciency (SCID), developed PHT after HSCT with matched unrelated donors (MUD). Conditioning was busulfan based in all. All children engrafted uneventfully. No GVHD was apparent. VOD developed in one of the JMML patients which was successfully treated with diuretics and defi brotide. Patients presented at day 59, 66 and 73 post transplant with afebrile, tachypnea and coughing. PHT was diagnosed within 1-10 days by echocardiography. Treatment included combinations of sildenafi l (3), milrinone (2), bosentan (1) and prostacyclin (1) . PHT resolved in all cases. Long-term follow-up revealed mild restrictive pulmonary abnormalities in one.

In the literature, 18 additional children (0.1-16 yrs; 9 male) have been reported with PHT following HSCT. Primary disease was leukemia (4), SCID (4), malignant infantile osteopetrosis (OP, 8), Fanconi anemia (1) and hemofagocytic lymfohistiocytosis (HLH, 1). Conditioning was busulfan-based in 16/21 cases. Donors were matched (5) or mismatched (7) family and MUD (5) . Four patients developed VOD; 2 patients developed graft-versus-host disease and 7 were diagnosed with transplant associated thrombotic microangiopathy (TMA). All patients presented with dys/tachypnea and hypoxia between eight days and eight months after HSCT. Patients were diagnosed with PHT 1-60 days after presentation. Eleven patients were diagnosed by echocardiography, 5 by cardiac catheterization, 1 by lung biopsy and 1 at autopsy. Treatment was diverse with combinations of inhaled nitric oxide (10), tacrolimus (1), prostacyclin (8) sildenafi l (4), defi brotide (4), nicardipine (1), and diltiazem (1) Introduction: In the last two decades the use of unrelated cord blood (UCB) as an alternative source of haematopoietic stem cells has become a well-established procedure in the treatment of both malignant and non-malignant diseases (NMD). We report the G. Gaslini Children's Institute experience on UCB transplantation in NMD. Patients and methods: From 1/1997 to 9/2012, we performed 23 UCB transplants in children with NMD (8 inborn errors of metabolism; 7 histiocyte disorders; 3 primary immunodefi ciencies; 3 osteopetrosis; 2 CAMT). HLA matching was 4/6 in 4 pts, 5/6 in 13 pts and 6/6 in 6 pts. The median age at transplant was 21 months (range 3-71) and the median weight was 12 Kg (range 4,2-27). Only 3 pts received a non-myeloablative preparative regimen. All pts received Graft-versus-Host-Disease (GvHD) prophylaxis including ATG, CyA and steroids. A median of 9,6 x 10 7 /Kg (range 6,2-28,7) TNC/recipient BW were infused. Results: The Transplant Related Mortality (TRM) was 13% (3/23 pts); 1 pt died of infection on day +14 without engraftment and 2 pts experienced late TRM (+170: surgical complication; +205: GvHD). Among the 22/23 pts evaluable for engraftment, 5 (22,7%) experienced graft rejection (primary in 2 cases and early secondary in 3); 3 of them were rescued with a second transplant and 1 is alive without evident disease after autologous reconstitution. Median time to recovery was 19 days (range 11-43) for neutrophils and 41 days (range 21-160) for platelets. 15 pts reached complete donor chimerism; 2 pts still present stable mixed chimerism 17 and 46 months after UCBT. Acute GvHD occurred in 11/17 (65%) pts who engrafted:

gr. 1-2 in 8 (47%), gr. 3 in 2 (11,7%) and gr. 4 in 1 pt (5,8%). 6/15 (40%) pts at risk developed chronic GvHD (limited:3; extensive:3). 7/16 evaluable pts with a 6-month-minimum-follow-up presented at least one autoimmune complication: 4 developed haemolytic anemia, 3 idiopatic thrombocytopenic purpura, 2 thyroiditis. Currently, at a median follow up of 42 months (range 3-133), 19/23 pts are alive (OS 82,6%) and in good clinical conditions. All of them had a total or partial remission of their underlying disease. No patient with a 1-year-minimum-follow-up shows active GvHD. Conclusions: Our analysis, although carried out on a limited number of UCB transplants in NMD, confi rms literature data about engraftment, TRM, GvHD and OS. Our data also highlight the higher rate of immunological complications reported in younger patients.

The impact of pre-transplant disease load on outcome in children with acute lymphoblastic leukaemia in the current era M. Bierings (1), J Boelens (1), W. Kollen (2) , B Versluys (1) Methods: ALL upfront therapy was according to the DCOG ALL 10 protocol. In this protocol therapy intensity was stratifi ed, mainly by early response to therapy as measured by MRD. High risk patients were in general eligible for allogeneic transplant in CR1. ALL R3 was the protocol for relapsing patients. Conditioning regimen consisted of total body irradiation (TBI) in combination with etoposide, except for children < 3 years who were conditioned with a chemotherapeutic regimen. In the most recent period the conditioning regimen has been adapted for all children to busulphan/fl udarabin/clofarabin. Graft-versus-Host (GvH) prophylaxis was dependent on donor origin and stem cell source. Outcome data were provided by both SCT centres. Results: Since 2010 37 children with ALL have been transplanted in the Netherlands. 3 patients were excluded (1 Fanconi with ALL, 1 Down with ALL in CR3, 1 second SCT for relapse after 1st SCT). 13 patients were MRD positive at SCT, 11 negative and of 10 patients MRD at transplant was not available.

In the MRD positive group 4/13 patients relapsed, 2 patients died due to TRM. In the MRD negative group only 1/11 patients relapsed. In the group with unknown MRD at transplant 2/10 relapsed. Most patients in the MRD positive group who relapsed had high disease loads at transplant. Of the patients who relapsed 4/7 had acute GvH > gr 2. Conclusion: These results confi rm diminished impact of MRD pre-transplant for children with ALL in the current era. However, especially in the small group of patients with high disease load pre-SCT the relapse risk is persistingly high. This warrants additional interventions in this group pre-transplant.

Catheter-directed intra-arterial organ-specifi c anti graftversus-host disease (GVHD) steroid therapy for children with steroid resistance or dependence P. Stepensky, A. Blum, I. Resnick, A. Klimov, S. Grisariu, B. Avni, R. Or, M. Shapira Hadassah Medical Center (Jerusalem, IL) Purpose: We previously showed that intra-arterial targeted steroid (IAS) therapy is useful even in adults suff ering from steroid refractory graft vs. host disease (GVHD). Here we aim to describe the safety and effi cacy of (IAS) injection using for the treatment of steroid resistant or dependent GVHD in children.

Methods: Consecutive pediatric patients with steroid resistant or dependent GVHD grade 3-4 treated with 2 IAS protocols (12 with protocol I, 8 with protocol II; table 1) were enrolled. All patients received combined standard GVHD treatment including at least cyclosporine and 2 mg/kg of methylprednisolone prior to IAS. Steroid resistance was defi ned as one of the following: GVHD progression after 3 days standard treatment, lack of response to at least 7 days standard treatment or incomplete response to 14 days. Steroid dependence was defi ned as a GVHD response, which relapsed with decrease in the steroid dose. Results: Twenty children (13 males and 7 females, median age 12.4 years, range 3-17 years) with steroid resistant or dependent GVHD underwent 30 IAS (GI -19, liver -2, combined liver and GI -9) within a median time of 39 days from GVHD diagnosis. Fifteen children were transplanted due to malignant diseases whereas 5/20 suff ered from non-malignant disorders. No signifi cant side eff ects as renal impairment or injection site complications were noted. Partial response was evident in 70% of the patients and 10/20 (50%) achieved complete remission. The one year survival in our cohort was 36% (fi gure 1). Death occurred due GVHD complications in 11/13 while one child died from H1N1 infl uenza and one from progression of disease. Conclusion: Data from this largest pediatric cohort of IAS reported to date suggests that IAS may be a safe and eff ective means of inducing response in patients with steroid resistant or dependent GVHD. We recommend to routinely combining IAS for such patients. Further research is warranted to assess the optimal dosing and administration protocol.

[P895]

Haematopoietic stem cell transplantation in children: one centre's experience E. Rochette, F. Demèocq, B. Peirera, E. Doré, F. Isfan, C. Paillard, J. Kanold CHU Clermont-Ferrand (Clermont-Ferrand, FR) This study reviews the experience of 200 (177 pts 1-52.3] in lymphomas indications and 35. 7% [13.6-58.9 ] for solid tumors (p=0.0014). The OS in . Although as with most other clinical results in fi elds with rapidly evolving technologies and long term study period, interpretation must be made with caution these data documented trends and changes in allo-HSCT in children in our center are comparable to other paediatric reports appearing in the literature. They refl ect a change in the indications and a marked advancement in UD allogeneic HSCT transplantation. Allo-HSCT in patients with nonmalignant diseases and solid tumors tended to increased. During the past years, the number of HSCT with RIC and haploidentical HSCT has increased in connection with the conduct of multicenter clinical studies by our center.

Background: Umbilical cord blood is a rich source of haematopoietic stem cells (HSC) and its use as an alternative to bone marrow and peripheral blood stem cells in HSC transplantation has expanded rapidly over the last 5-10 years. Reduction of the volume and red cell content of umbilical cord blood prior to cryopreservation is required to reduce the required storage pace, the amount of free haemoglobin in the graft and the amount of cryoprotectant used. Current methods designed for red cell depletion and volume reduction prior to freezing and storage may not comply with GMP, are expensive, time consuming, and produce an unacceptable loss in cell viability and yield. Aim: Evaluate the performance of the Pall Select System in regards to volume reduction, cell recovery, growth potential and viability of recovered stem cells for non regular use within a busy transplant programme for directed harvests. Method: 8 samples were obtained for the study, cord blood was harvested from the placenta post partum. Following fi ltration pre and post aliquots were tested comparing volume reduction, White cell count, CD34+ cells, Cell viability and colony forming units. Results: Total collection volume showed a median reduction from 80ml (pre) to 23.5ml (post), shown to be signifi cant (P=0.0005).

Red cell volume showed a median reduction from 30.34ml (pre) to 2.040ml (post), shown to be signifi cant (P=0.0005). CD34% viability showed a median reduction from 97% (pre) to 92.5% (post), shown to be not signifi cant (P=0.0560). Total White cell count showed a median reduction from 0.595x109/L (pre) to 0.323x109/ L (post), shown to be signifi cant (P=0.0416).Total CD34 cell count showed a median reduction from 0.1318x107 (pre) to 0.1056x107 (post), shown to be not signifi cant (P=0.1858). Conclusion: The Pall Select system demonstrated that it is possible to reduce product volume and red cell content without a clinically signifi cant loss of nucleated cells, in line with manufacturer's specifi cation. In order to comply with the new national and international standards the system could be considered for introduction into clinical practice for directed cord blood harvests. S291 diabetic coma, cealiac disease, associated with haematopoietic progenitor cell transplantation (allo-HSCT) and idiopathic. In the literature we found only two case reports: a case of OMS associated with childhood ALL and a report of OMS associated with allo-HSCT AML CR2 in a adult. Here, we present a case of OMS associated with unrelated donor cord blood transplantation (UCBT). Case report: A 4-year-old girl with refractory anemia with excess blasts underwent matched UCBT. The patient was conditioned with thiotepa, intravenous busulfan, fl udarabine and thymoglobulin, with cyclosporine A and prednisone for graft-versus-host prophylaxis. She was admitted at day 45 post-HSCT by unstable walking and sudden onset opsoclonus. There was marked further neurological deterioration with dysarthria and hypotonia. On clinical examination she was alert and irritable. She had ataxia, bilateral opsoclonus, overall hypotonia, osteotendinous hyperrefl exia and positive Babinski sign. CT and MRI brain revealed no focal lesions or bleeding or mass eff ect. The cyclosporin level was acceptable. Viral PCR (HSV-CMV-EBV-HHV-6) in CSF and blood were negatives. CSF culture was negative. Chest X-ray, abdominal ultrasound and urine catecholamines were normal. Peripheral blood smear without schistocytes. After neurology opinion a clinical diagnosis of SOM was made. Immunoglobulin therapy is initiated with methylprednisolone achieving a progressive improvement of the neurological symptoms and rehabilitation treatment until complete resolution. At day 163 post-HSCT she presented immune cytopenias (anemia and thrombocytopenia) refractory to corticosteroids, immunoglobulins and rituximab. Unfortunately she died of her hemolysis. Administration of allogeneic mesenchymal cells was pending.

Conclusions: In our case the resolution of the OMS is satisfactory, without neurological sequelae. OMS should be included in the diff erential diagnosis of neurological complications after HSCT.

A. Alfred (1), S. Suri (2) , G. Gupte (3), P. C. Taylor (2) (

Graft versus host disease (GVHD) following small bowel transplantation (SBT) occurs in about 6-16% % cases having a signifi cant impact on transplant related mortality and morbidity particularly in context of a non cancerous setting. In this report we describe the response of steroid and antibody therapy resistant GvHD post SBT to Extracorporeal Photopheresis (ECP). A fi ve year old girl underwent ABO matched isolated SBT for microvillus inclusion disease in January 2012. As GvHD prophylaxis she received 6 doses of Basiliximab (20mg) and was maintained post transplant on Tacrolimus and Prednisolone. One week post SBT she developed a transient patchy macular, erythematous rash over the abdomen, buttocks and the limbs which settled spontaneously. 8 weeks post SBT she presented with widespread macular rash with hyperpigmented lesions. A biopsy confi rmed diagnosis of skin Grade III-IV skin GvHD was made. Gut biopsy showed mixed chimerism but no evidence of GvHD. She received Methylprednisolone 1mk/kg and doses of Infl iximab and Basiliximab. Due to lack of response she went on to receive 3 doses of mesenchymal stem cells. Following an initial transient response the rash worsened in 2 weeks following the last dose. She was noted to have rising EBV titres though axillary node biopsy showed reactive changes only. At the time of referral to the ECP unit in August 2012 she was on Prednisolone 0.5mg/kg and oral Tacrolimus. Cutaneous GvHD aff ected 70% of body surface area (BSA) with heavily pigmented, lichenoid punctate lesions with intense indurated and exfoliated erythema of palms and soles and severe pruritus. No other organs appeared to be involved. She commenced on weekly paired ECP treatment delivered via a femoral catheter with blood priming. No alterations to immune suppression were made in the fi rst 6 weeks. By week 6 there was a reduction in erythema to 30 % BSA with particular improvement in the hands and soles. She was commenced on a slow steroid taper at this point and the treatment was given every 10 days. 3 months post ECP she is receiving Prednisolone 0.25 mg/kg with level adjusted Tacrolimus. There is continuing response to ECP with erythema now confi ned to face and palms. The pruritus has regressed with no intercurrent infections and stable EBV titres. The steroid taper has not been associated with fl are up GVHD .This case report highlights that fact that ECP is a valuable therapeutic intervention in cases of steroid and antibody refractory GvHD. 1 year old, the oldest 16 years (median 7.5 years). Weight categories for donors (range 10-99kg) <20 kg (n=8; 15%), 20-40kg (n=27; 51%) and >40kg (n=18; 34%), type of graft collected: BM (n=45; 85%), PBSC (n=4; 8%), BM+PBSC (n=3; 6%), BM+CB (n=1; 2%). Indication for HSCT was malignant disease in 66% or nonmalignant disease. In two patients the same sibling donor was used for re-transplantation. In most cases BM was used for HSCT. There were no serious adverse events due to GA. Most donors reported soreness at the site of collection of BM but responded well to analgetics. Donors stimulated with G-CSF reported pain and hematoma at the site of injection. In one donor CVC insertion was complicated by hemothorax with necessity of short-term drainage. Despite this event collection of the graft was possible and the donor is well. Hospital stay was in average 2-3 days for BM collection and 6-7 days for separation of PBSC. Donors are regularly monitored for blood tests and general condition at our clinic one year after harvest. There is a hypothesis about higher risk of malignancy in donor stimulated with G-CSF whose sibling suff ered from malignancy. In one case a donor was diagnosed with acute myeloid leukemia 10 years after the donation of BM for a brother transplanted for acute lymphoblastic leukemia. Supported by conceptual development VO 00064203. 

Hematopoietic Stem Cell Transplantation (allo-SCT). Serum galactomannan antigen (GM) detection is a useful tool for the diagnosis of invasive aspergillosis in high-risk patients, although in children the promising results seen in adults have not been clearly confi rmed. In this sense, we have analyzed in this prospective study our experience in pediatric patients undergoing allo-SCT and who received antifungal prophylaxis with a mold active drug as voriconazole. Patients and Methods: A total of 59 children <18 years were enrolled in this study from Jun-2006 to Mar-2012. Median age was 9 years (range: [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . All patients received voriconazole from day -1 at a dose of 5 mg/kg/12 hours (n=13) or 7 mg/kg/12 hours (n=46) until a highest dose of 200 mg/12 hours. We consider neutropenic period from day 0 to one week after neutrophils recovery (>500/mm3). Proven or probable IFD was diagnosed according to EORTC/MSG criteria. The GM was measured twice weekly and was considered positive if the index value was >0.5 in two consecutive test or >0.8 in a single test. Results: Only two (3.4%) children developed IFD (probable aspergillosis) during neutropenia while on prophylaxis with voriconazol. In this series 51 (86.4%) patients completed successfully the prophylaxis during this period without adverse eff ects, no empirical or preemptive antifungal therapy neither IFD. A total of 4 (6.7%) receptors required empirical (n=2) or preemptive (n=2) antifungal therapy with amphotericin B once stopped voriconazole, one of them developed IFD. In 3 (5.1%) children was detected adverse eff ects due to voriconazole prophylaxis and needed a defi nitive withdrawal; these adverse eff ects were solved when voriconazole was discontinued. In this series a total of 299 GM test was performed. A total of 13 (22%) children presented positive GM test and only one of them developed IFD. Sensibility and specifi city per patient GM test were 50% and 78.9%, respectively. Positive and negative predictive values were 7.6% and 97.8%, respectively. Conclusions: With a successfully prophylaxis rate of 86.4%, voriconazole is eff ective as antifungal prophylaxis in children undergoing allo-SCT during neutropenic period. GM test shows low sensitivity and specifi city in our series, with a high rate of false positives. GM results in children should be cautiously analyzed in order to avoid precipitated decisions. (1), or unrelated cord (1) , and in CON: related bone marrow (257), related peripheral stem cells (5), or unrelated cord (86).

Results: In the whole cohort, the incidence of aGvHD grade II-IV and III-IV was 14.8%, and 7%, and chronic GvHD 8.1%; the incidence was not diff erent between NC, MAC and RIC groups. Recipients of cord blood HCT had a higher incidence of grade II-IV aGvHD (22.5%) compared to others (12.8%; P=0.029). OS for all patients was 72%; no diff erence in OS was noted between NC, MAC or RIC groups, nor was there a diff erence in OS in patients with malignant disorders and non-malignant. OS was higher in recipients of fully matched related donor HCT (75%) when compared to recipients of partially matched related donor HCT (60%) and unrelated cord HCT (67%; P=0.028). Acute aGvHD grade II-IV and chronic GvHD were associated with lower survival. Conclusions: The data indicate that HCT can lead to long-term survival among VYC. Use of no conditioning or reduced intensity conditioning did not decrease incidence of GvHD and did not improve survival. Recipients of fully matched related donor HCT and those with no evidence of aGvHD or chronic GvHD have better long-term survival. (n=9), an unrelated donor (UD) (n=7) or an HLA-matched relative donor (n=2). Three of the patients underwent second transplantation from the same donor because of the engraftment failure. The patients' preperative regimen were nonmyeloablative with fl udarabine, low dose cyclophosphamide (20 mg/kg) and antithymocyte globulin (ATG) except one patient who was taken thoraco-abdominal irradiation. Results: The median follow up was 10,5 months (1-75 months). The 5 year estimate of overall survival (OS) for the whole cohort was 76%. It was 58%, 100% and 100% when the donor was an HLAidentical sibling, an UD and a relative. Transplant related mortality was 9% (in the fi rst years of our transplant center). Conclusion: FA patients undergoing HSCT can be successfully cured with fl udarabine based preparative regimen even in the absence of an HLA-identical sibling donor. (54) from MUD. ABO and Rh typing was performed by standard blood banking methods. The clinical endpoints in this retrospective study were incidence of acute and chronic graft versus host disease (GVHD), venooclusive disease (VOD) and treatment-related mortality (TRM) according to blood group incompatibility. Univariate analysis was performed using chi2 test, all P values are 2-sided and P less 0,05 is considered to indicate statistical signifi cance. Results: From the whole cohort of 138 allogeneic transplants, blood group incompatibility was observed in 57% (78) and was signifi cantly higher among MUD (67% i.e.36/54) than in MRD (50% i.e.42/84) (p= 0,04). Both in compatible and incompatible transplants more frequently as source were used PBSC (58% and 68% respectively). Major AB0 incompatibility was seen in 23 (30%), minor in 30 (38%), bidirectional in 14 (18%) and Rh in 11 (14%) patients. Combined Rh and AB0 incompatibility was seen in 20 patient/donor pairs, including 7 cases with major, 9 with minor and 4 with bidirectional AB0 incompatibility. There was no related acute haemolysis during graft infusion in the whole cohort. During engraftment time, one patient developed haemolytic crisis 9 days after HSCT. One boy suff ered from pure red cell aplasia with resolution upon corticoid treatment. Incidence of acute GVHD II-IV was signifi cantly higher in mismatched 50% vs 35% matched patients (p= 0,01). There was no diff erence in the incidence of chronic GVHD (30% vs 41%, p= 0,10). We observed that the type of AB0 incompatibility does not infl uence the incidence of acute nor chronic GVHD (p=0,33). VOD occurred in 7% (4/60) matched and 12% (9/78) mismatched pairs with no statistical diff erence (p=0,33). In the whole cohort TRM was 14,5% and there were no diff erence between groups (15% and 14%, p= 0,91). Conclusion: In allogeneic HSCT in paediatric patients blood group incompatibility between patient and donor was associated with higher incidence of acute GVHD, but there were no diff erence in chronic GVHD, VOD or TRM. (1), J. Song (2) , J.E. Park (1) (

Background: The prognosis of very high risk group acute lymphoblastic leukemia (VHR ALL) in childhood is generally poor in spite of intensive chemotherapy. Recently, allogeneic hematopoietic stem cell transplantation (Allo-HSCT) was used to treat the patients with VHR ALL. We studied the clinical course and outcomes of children with VHR ALL intended treat with Allo-HSCT after chemotherapy. Methods: 16 children who were diagnosed as VHR ALL and were intended to treat Allo-HSCT at the department of Pediatrics in Ajou University Hospital between June 2001 and June 2010. We analyzed their cumulative survival rate and clinical characteristics among them. Results: Among 148 ALL patients, 16 (10.8%) were classifi ed as VHR ALL. Eight of them had Philadelphia chromosome, four were infant ALL with mixed lineage leukemia (MLL) gene rearrangement, seven had hyperleukocytosis. Fourteen received Allo-HSCT and the other two could not received Allo-HSCT. Bone marrow or central nervous system (CNS) relapse was the main cause of mortality in the patients who received Allo-HSCT. Event free survival (EFS) and overall survival (OS) in all patients were 64.7% and 57.7%, respectively. EFS in the patients Philadelphia chromosome, infant ALL with MLL gene rearrangement and hyperleukocytosis were 58.3%, 100% and 37.5% respectively. Conclusion: EFS in patients with hyperleukocytosis at the time of diagnosis is as low. Therefore novel or additional aggressive treatment modalities may be required in hyperleukocytosis patients. However infant ALL with MLL gene rearrangement was used bulsulfan/cyclophosphamide as a conditioning regimens may have promising survival outcomes. Introduction: Germ-cell tumors (GCTs) represent 3% of all pediatric neoplasms. The origin can be gonadal or extragonadal and extracranial or intracranial. The role of high dose chemotherapy (HDC) with autologous stem cell transplantation (AHSCT) in high risk or relapsed patients (pts.) with GCTs is controversial but long term remissions could be observed. Patients and methods: We present 9 patients (males:2, females:7) who received HDC and AHSCT in Hungary between July 1, 2009 and June 30, 2012. The median age at transplantation was 2,84 years (range 0, 5-15,9 years) . Seven out of 9 pts had extragonadal extracranial tumor, 1/9 had intracranial and 1/9 had ovarian tumor. All children were transplanted with peripheral stem cell grafts. Patient's stem cells were mobilized with granulocyte colony-stimulating factor at a dose of 10 microgram/kg subcutaneously twice daily. The following conditioning regimens were used: Cyclo/VP16/Carbo/Thio/Mel (4 patients), VP16/Carbo/Thio (2 patients), and Cyclo/VP16/Carbo, or Bu/Thio/VP16 or Bu/Mel (1 patients each). Results: The mean infused CD34 cell dose was: 5.84x 10*6/kg (range 2,5-12,84). Engraftment was achieved at the median time of day +10 (range 9-11). The median follow up time from transplant was 1,58 years (range 0,44-4,11). All relapses occurred within one year after AHSCT, and both patients had died. Even there are not enough data for a statistical analysis, the survival of 7 out of 9 pts is a very promising result in a high risk group of cases. All deaths occurred due to a therapy resistant relapse, and there was no treatment related mortality (TRM).

Conclusions: Survival of patients with HR or relapsed GCTs improved with HDC plus AHSCT according to our results. A favourable outcome could be achieved without TRM. To characterize the future role of HDC with AHPCS as a salvage therapy for children with GCT an international cooperation and a database are warranted.

Haematopoietic progenitor cell collection in very low weight paediatric patients S.M Lopes, F. Bordalo, A. Bernardo, M. França, S. Ferreira, F. Amado, M. Rosales, S. Roncon IPO Porto (Porto, PT) The collection of haematopoietic progenitor cells (HPC) by aphaeresis is a well established procedure with documented advantages, in both adult and paediatric patients candidate to autologous transplant. The adverse reactions associated with the procedure are few, and of low to moderate severity, allowing for the collection of younger and lighter patients. We aimed to retrospectively analyse the HPC collections performed in our patients with very low weight. From 2004 to 2011, we collected HPC for autologous transplant in 7 children with a weight ≤10kg and a diagnosis of neuroblastoma. In all cases a two way central venous catheter was inserted, in order to begin collection on the 5th day of mobilization with G-CSF (11μg/kg/day), on the Cobe-Spectra® cell separator. The kit was primed with one compatible packed red cells unit, with adjusted haematocrit. Two children were transfused with packed red cells after the collection due to a haemoglobin count <7.5 g/dL. There was no need for platelet transfusion as all present a post collection count of >100.000x106/L. The anticoagulant used was ACD-A. In order to prevent citrate toxicity, serum calcium levels were measured (at baseline, every 30 min and after the procedure), and was correct by continuous perfusion, according to clinical or laboratory results. Our group of patients consisted in 1 boy and 6 girls, with a median age of 10 months (7 -55) and weight of 9 kg (6.7 -10) . An average of 3 blood volumes (2 -4) were processed at a rate of 14 ml/min (11 -25). On the fi rst day of collection, the median CD34 cell count was 29/ μl (1-94), with a total CD34 cell dose collected of 8.6x106/ kg (3.8-39.79 ) in 5 children. In 2 of the children a 2nd mobilization was necessary, performing 1 additional aphaeresis in one case (5.5x106/kg) and 2 in the other (29.8x106/kg). The collection of HPC by aphaeresis in small children is an efficient and well tolerated technique, performed in most cases as an outpatient procedure. This success is the result of a multidisciplinary team with specifi c training in aphaeresis, supported by an haemotherapy specialist, an oncology paediatrician and a clinical pathologist.

Introduction: AB0 mismatch is not a barrier to allogeneic hematopoietic stem cell transplantation (HSCT). However, the impact of an AB0 compliance or mismatch (minor, major, bidirectional) on the outcome of the transplantation remains controversial. Aim: We analyzed whether AB0 mismatch aff ects: the red blood cell (RBC) transfusion requirements, risk of early and late transplant related complications (TRC), mortality (TRM), relapse and overall survival (OS). Material and Methods: The data of 73 patients (pts) transplanted from siblings (30) and unrelated donors (43), because of neoplastic (47) and nonproliferative (26) disease was analyzed. There were 21 girls and 52 boys, with a median age of 9 (0-21) years. 58 pts were assigned to myeloablative, 14 non-myeloablative regimens and 1 was transplanted without conditioning. The main source of graft was bone marrow (60) and in 13 pts mobilized peripheral blood. Minor, major or bidirectional AB0 mismatched HSCT was performed in 19, 22 and 4 pts, respectively. Remaining 28 HSCT were AB0 matched. In major AB0 mismatch RBC and plasma were depleted, but in minor plasma was removed. Results: The median follow-up was 25 (0.4-93) months. The pts were balanced within presented above group with respect to gender, age, disease, clinical status, donors, conditioning regimens, GvHD prophylaxis, graft source, G-CSF using, counts of CD34, NC, CD3 cells. All pts except 1 engrafted. The results of myeloid and platelets engraftment were similar in all group (P>0.05). Most of pts were supported with RBC transfusion. Median duration of this support was: 46, 49, 55 and 110 days and median volume was: 38, 41, 39 and 75 ml/kg, respectively in above mentioned groups and these results were not diff er (P>0.05). No severe hemolytic reactions were noted. The frequency of venoocclusive disease was higher (P=0.009) in minor AB0 mismatch. Chronic GVHD was observed more often in major AB0 mismatch (P=0.033) but its extensive form occurred more often in bidirectional mismatch (P=0.045). The probability of TRM within the 1st 100 days, 1st year and at the end of follow up was higher in minor AB0 mismatch (P=0.002, P=0.004 and P=0.001, respectively). OS within 1st 100 days was signifi cantly lower in minor AB0 mismatch (P=0.009) and lower but not signifi cantly within 1st year (P=0.099), and at the end of follow-up (P=0.064). Conclusion: In the pediatric setting minor AB0-mismatched HSCT might have an unfavorable impact on transplant outcomes.

Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by the defi cient generation of reactive oxygen metabolites in phagocytic cells. As a decisive prophylaxis and antibiotic therapy of bacterial and fungal infections usually allows control of infections for many years, the indication for Hematopoietic Stem Cell Transplantation (HSCT) has been confi ned to patients for whom HLA-identical donors can be identifi ed. We report on a patient with a positive family history for X-linked CGD who was diagnosed at birth. Even though antibiotic (Cotrimoxazole) and antifungal (Itraconazole) prophylaxis was commenced in early infancy, the patient suff ered from recurrent lymphadenitis, chronic infl ammatory bowel disease and multiple bacterial pneumonias. At the age of 10 years he developed pulmonary aspergillosis with fungal osteomyelitis of his 4th rib, which could neither be controlled by repetitive surgery nor systemic antibiotic and antifungal therapy for a period of more than 4 months. As no HLA-identical donor could be identifi ed, he received a T-cell depleted haploidentical transplant (donor: father; CD34+:1x10e7/kg; CD3+: 0,8x10e4/kg) after conditioning with Busulfan (17,6mg/kg), Fludarabine (150mg/m2), Thiotepa (10mg/kg) and Campath (1mg/kg). Even though T-cell recovery is still incomplete (CD3+: 600/μl) the patient is free of any severe infections after more than three years of follow up. Summary: In selected patients with CGD and invasive infections, not manageable with conservative or surgical measures, HLA-haploidentical HSCT is a feasible therapeutic option in the absence of an HLA-identical donor. By gene therapy-as another alternative treatment option-permanent cure could not be achieved until present. Since patients with CGD have an isolated defect of phagocytic cells they are most probably less threatened by viral disease after T cell depleted HSCT with prolonged T-cell recovery as patients with malignancies or lymphoid immunodeficiencies.

Alemtuzumab as fi rst-line treatment in haemophagocytic lymphohistiocytosis leads to improved survival prior to HSCT: a single centre experience D. Moshous (1)

Introduction: Haemophagocytic lymphohistiocytosis (HLH) are rare life-threatening conditions aff ecting granule-mediated cytotoxicity. Known genetic causes include mutations in PRF1, UNC13D, STX11, and STXBP. HLH is rapidly fatal in the absence of specifi c treatment. Remission from overwhelming HLH is required prior to allogeneic haematopoietic stem cell transplantation (HSCT), the only curative approach. A major breakthrough was achieved through the HLH-94 protocol, a combined chemo-and immunotherapy that greatly improved the survival of children with HLH, but only 71% of the patients survived until HSCT. Objectives: As HLH is a primary T (NK) cell immunodefi ciency with massive CD8 T lymphocyte infi ltration and macrophage activation, we hypothesized that immunotherapy may be less toxic by targeting directly the T cells that are primarily involved in triggering HLH while sparing myeloid cells. So far, Anti T cell polyclonal Antibodies, (Antithymocyte globulins, ATG) associated to steroids and cyclosporine have been used successfully in HLH, as previously reported by our group. The humanized anti-CD52 monoclonal antibody Alemtuzumab (Campath-1H) effi ciently depletes T cells in vivo, as well as B cells and other lymphoid subsets. As Alemtuzumab does not activate T cells, it may be better tolerated than ATG, notably in infants, and may improve survival until HSCT. Methods: We analysed retrospectively our experience of 16 consecutive patients who received Alemtuzumab combined with steroids as fi rst line therapy for HLH. Results: The patients presented severe HLH of early onset (0-527 days of life, median 33). Eight patients had CNS disease at onset. Mutations in the known FHLH genes were found in all but two patients (PRF1 in 10, UNC13D in 2, STX11 in 1 and STXBP2 in 1). Patients received a total dose of 2.5 to 6.5 mg/kg of Alemtuzumab. Complete remission prior to HSCT was obtained in 12 (time to achieve remission: 15-35 days, median 30), partial remission in 3 patients, who then received ATG. Only 1 out of 16 patients did not respond to Alemtuzumab, nor to VP16 as second line treatment. Survival until HSCT was 100%, overall survival after HSCT 62,5%. Conclusion: We observed acceptable toxicity and excellent response rates in 16 consecutive patients treated with Alemtuzumab as fi rst line therapy for HLH. Our preliminary data suggest that immunotherapy with Alemtuzumab may represent a valuable alternative to ATG in the treatment of HLH. A prospective multi-centre study is indispensable and will be started in France.

Long-term outcome of haematopoietic stem cell transplantation in Hurler disease: a single centre experience I. Zaidman (1) Introduction: Hurler disease is rare autosomal recessive lysosomal disorder caused by defi ciency of α-L-iduronidase. Clinical features include progressive courses with severe multiorgan system involvement and short life expectancy. The only option to long-term outcome is haematopoietic stem cell transplantation (HSCT). Aim and objectives: To review the outcome of 6 patients with severe mucopolysacharidosis (MPS) type IH, Hurler syndrome, who underwent HSCT between the years 2000-2012 in one medical center in Haifa, Israel. Median age was 15.5 months (9 -25 mo). Three patients received Matched sibling donor (MSD), two patients Mismatched family donor (MMFD), one underwent two SCT MMFD, and one patient got unrelated cord blood. All children received myeloablative conditioning regimen. One patient received intravenous enzyme replacement therapy before and 6 months after HSCT. Results: Four patients are alive with median follow up -7.8 yr ( 3 m -12 yr). Two patients have full donor chimerism and two have stable mixed chimerism. Only 1 child had symptoms of aGVHD grade II, no patient had cGVHD. Two patients died from pulmonary hemorrhage during engraftment period. Long-term followup revealed mild developmental delay in 3/4 patients but no regression. 2/4 had nonprogressive mitral and aortic thickening. All four have hearing problems necessitating hearing aids and progressive corneal opacities to various extents. All patients have orthopedic problems: three -severe kyphoscoliosis, two kids have hip dysplasia, two patients underwent bilateral surgical repair of severe genum valgum. Conclusions: HSCT can prolong survival and preserve cognition in very young children with the most severe form of MPS I. Some clinical manifestations appear to be irreversible and continue to progress despite HSCT. Better tissue matching techniques, improved graft-vs-host prophylaxis and more targeted conditioning regimens have improved morbidity and mortality associated with HSCT. Objective: According to the protocol GPOH-SAA-94 children diagnosed with severe aplastic anemia (SAA) and a matched sibling donor (MSD) received hematopoietic stem cell transplantation (HSCT) as fi rst line therapy whereas immunosuppressive therapy with antithymocyte globulin and cyclosporine was given to patients without a donor. Here we report the outcome 88 children with SAA (46 male/42 female) included in the study GPOH SAA 94 given an allograft from a MSD between 12/1993 and 06/2011. Patients and Transplant Procedure: Median age at diagnosis of very severe (53), severe (29) and non-severe (6) AA was 10.4 (1.9-16.5) years. SAA was associated with exposure to drugs/toxins (2), hepatitis (8), other infections (4) or idiopathic (74). All patients were transplanted following preparation with cyclophosphamide (200 mg/kg) and antithymocyte globulin (ATG) after a median time of 46 (7-251) days. Source of stem cells was bone marrow (85) or peripheral blood (3) . Graft versus host disease (GvHD) prophylaxis was cyclosporine and methotrexate in the majority of patients. Results: Neutrophil engraftment was observed in all patients after a median time of 19 (6-45) days. Eight patients experienced secondary graft failure (GF). Two of these died during the subsequent HSCT, 3 were rescued with a second allograft and 3 are alive following other therapies (none (1), immunosuppressive therapy (1), cytokines (1)). Complete donor chimerism (> 90%) was detected in all but 6 patients without GF (miss. data on 16 pts). Acute GvHD grade II-IV and grade III-IV occurred in 8 (9%) and 2 (2%) patients, respectively. Twelve out of 86 patients at risk (14%) developed chronic GvHD that was extensive in one patient. After a median follow up of 5.9 (0.73 -17.7) years 84 patients are alive; resulting in a probability of overall survival of 0.95 (0.91-0.99). Two patients died following fi rst HSCT due to acute toxicity (cardiac arrest) and fulminant aspergillosis, two patients died during second and third HSCT for GF. pOS was signifi cantly better for patients transplanted more recently (0,91 ≤ 2000 vs 1,0 > 2000, p=0.049). There was no diff erence in pOS, incidence of GF or occurrence of acute or chronic GvHD according to disease severity, interval from diagnosis to HSCT, type of ATG used during conditioning, number of transplanted cells and CMV status of donor and/or recipient. Conclusion: MSD HSCT following conditioning with cyclophosphamide and ATG is a safe and eff ective therapy for children with SAA.

A. Shaw (1) . CD3 chimerism was often low in the early months after transplant but tended to climb thereafter (see fi gure). Acute GvHD developed in 3/33 (9%) and chronic GVHD in 1/33 (3%); all those with GVHD were in the highest third of fi rst evaluable CD3 chimerism values (>84% at a mean of 30d)(p=0.037). Only 5 patients had CD3 chimerism of <10% at 3 months posttransplant. Of these, one received CD34-selected stem top-up at 5m and a second a 2.5x 10E4 DLI at 2.5 months, both due to persisting thrombocytopenia/neutropenia (cytopenias subsequently resolved). A third developed recurrent SAA secondary to parvovirus infection at 19m post-HSCT and underwent successful retransplantation from the same donor. The fourth had persistent HSV infection and has only 19% WB chimerism at 14m post-HSCT. Conclusions: Despite excellent long term survival and low rates of GVHD, CD3 chimerism was predictive of outcome after IVTCD HSCT in paediatric SAA. High CD3 chimerism at one month correlated signifi cantly with GVHD, and CD3 chimerism of <10% with engraftment problems. The reason for progressive "competitive advantage" for donor CD3 cells during the fi rst year is not clear.

Equivalent outcome between reduced-intensity versus conventional myeloablative conditioning haematopoietic stem cell transplantation for childhood MDS: a report from the MDS working group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) D. Hasegawa (1) Background: Allogeneic hematopoietic stem cell transplantation (SCT) using reduced intensity conditioning (RIC) may provide opportunities to obtain a signifi cant clinical eff ect without the adverse eff ects, however, the benefi t of this approach in younger patients with MDS compared with the risk of toxicity of standard regimen (MAC) is still discussed. We retrospectively compared the outcomes for patients with childhood MDS using RIC or MAC, especially about those with refractory anemia (RA) and refractory anemia with excess of blasts (RAEB/ RAEBt). Patients and methods: We reported the outcome of 459 childhood MDS patients age at the fi rst transplantation 20 years or younger who underwent allo-SCT and analyzed according to the type of conditioning regimen (MAC vs RIC) before allo-SCT registered in the JSHCT database between 1991 and 2009. The preparative regimen was classifi ed as RIC if it included non-myeloablative chemotherapy (total dose of busulfan ≤ 8 mg/kg or <280mg/m2) with or without total body irradiation (TBI) ≤ 8 Gy. Also, MAC included myeloablative chemotherapy (total dose of busulfan ≥ 9 mg/kg or >280mg/m2) with or without TBI > 8 Gy.

Results: Their median age at transplantation was 9 years (range: 0-20 years) and the median follow-up period was 1,047 days (3 -7,075) . Four hundred fi fty-nine children consisted of bone marrow (N=353), peripheral blood stem cell (N=42), and cord blood transplant (N= 64). According to the year, the transplantation results were signifi cantly superior for the later period (2006 -2009) Conclusions: This survey showed that conditioning intensity did not aff ect survival rate for childhood MDS patients. Considering that the preparative regimen using MAC lead to inevitable retarded growth and infertility, transplantation using RIC for children with MDS might be warranted. A prospective study focused on the comparison of RIC and MAC for children with MDS will be needed to confi rm these issues.

Haploidentical MNC: multiple intrathecal administration is safe and eff ective in some paediatric high-grade gliomas N. Subbotina, I. Dolgopolov, M. Budarin, V. Boyarshinov, R. Pimenov, G. Mentkevich Institute of pediatric oncology (Moscow, RU)

The results of chemo-and radiotherapy of unresectable highgrade gliomas are still very poor both in adults and children.

Nowadays immunotherapy is becoming a new therapeutic option for these patients. Diff erent types of immunotherapy are being investigated in various phase I/II trials. Since 2006 we had 8 patients (2-19yrs) with relapsed or refractory high-grade gliomas: (AA-3, GB-3, DIBSG-2) for whom all standard therapeutic modalities had failed. All pts received regular intrathecal injections of allogeneic MNC from related haploidentical donors along with s/c auto-dendritic cells vaccinations. The median numbers of MNC injected per procedure were: CD34+ 5,2x106; CD3+ 6,5x108; CD56+ 1,1x108. In responders we performed in total 31, 33 and 60 cell injections correspondingly. All pts tolerated intrathecal therapy well. We also didn't see any sort of systemic eff ect of multiple allogeneic MNC administration.

The results of treatment were as follow: PR-3pts, PD-5pts. To the abstract submission date 3pts (38%) are alive with no tumor progression for 71, 59 and 58 months respectively; 5pts (62%) died of further DP in short time period. In summary, this treatment modality is feasible and therapeutic eff ect can be achieved in some cases. More pts are needed for further investigations. There were neither local adverse events nor systemic eff ects of intrathecally injected allogeneic MNC. Objectives: Using HLA matched siblings in hematopoietic stem cell transplantation (HSCT) has been always the fi rst choice for hematologists since the prognosis is better comparing to non-sibling transplantation. However, when there is no HLA-matched sibling, seeking through bone marrow and cord blood registries are preferred inevitably. Some studies showed that using other-related donors including parents, aunts, uncles and even grandparents could be appropriate for HSCT. In the present study we sought for the results from other-related HSCT in non-malignant disorders.

Methods: This is a retrospective study from pediatric transplantation unit of our center in which the patients (age<15 years) who underwent HSCT of any non malignant disorders and their relatives (other than siblings) were as donors included in the study. The principal data including graft-versus-host-disease (GVHD) occurrence, GVHD grade, overall survival (OS) and disease free survival (DFS) were used as primary outcomes in this study. Results: Seventy-fi ve patients including 51 boys and 24 girls with median age 5 years old (3 months-14 years) were found through the data registry bank. Of all diseases, 61 % (n=45) of patients had Major-Thalassemia or Fanconi anemia (table 1) . Of GVHD analysis, 56 % (n=42) and 32% (n=24) have experienced acute GVHD and chronic GVHD respectively. Of survival analysis, 24-month OS and DFS were 71.4% (SE: 5.3%) and 69% (SE: 5.4%). Conclusion: Other-related donors seem to be an invaluable source for HSCT especially in societies where consanguinity is common.

Donor selection in T cell-depleted paediatric haploidentical haematopoietic stem cell transplantation B. Herrero, M. Gonzalez-Vicent, I. Martínez, L. Fernández, M.A. Díaz, A. Pérez-Martínez Hospital Niño Jesus (Madrid, ES) Objectives: Various donors are generally available for haploidentical hematopoietic stem cell transplantation (haplo-SCT). In this work we evaluate clinical and immunological factors that should be considered when selecting donors for T cell depleted haplo-SCT. Methods: From 2005 through 2012, we retrospectively analyzed 48 haplo-SCT outcomes in 45 children performed in our center. In 22 patients the diagnosis was acute lymphoblastic leukaemia, in 13 patients was acute myeloblastic leukaemia, and in 4 patients was myelodisplastic syndrome and in 6 cases the diagnosis was solid tumours. Patients were in fi rst complete remission (17), second complete remission (17), third complete remission (7) and progressive disease (4) . Conditioning consisted in a fl udarabinebased reduced intensity regimen without serotherapy. In 26 cases donor selection was performed based in donor-recipient HLA-I studies and in 22 cases donor selection also included donor KIR receptor, KIR haplotype and in vitro Natural Killer cell cytotoxicity studies. Results: The mother was chosen as donor in 34 haplo-SCT (71%), the father in 11 (23%) and a brother or sister in 3 cases (6%). The median times to neutrophil and platelet recovery were 13 days (10-21) and 11 days (8-21). Graft failure probability was 30±6%. Primary graft failure occurred in 6 (12%) and secondary graft failure in 8 (17%) haplo-SCT. From failure engraftment patients 10 (71%) are alive without evidence of disease. Acute graft-versushost disease (aGVHD) more than grade II probability was 15 ± 5%. Relapse rate was 30±8%. Transplant-related mortality rate was 25 ± 6%. With a median of follow up of 2 years, survival probability was 52±7% and dependent on disease status (fi rst remission vs. more advanced disease; HR = 45.5; P = .02), aGVHD (less than II vs. more than II; HR: 0.12; P=0.001) and donor KIR ligand group (C1C1 vs. no C1C1; HR=0.14, P=0.034). Although no statistical diff erences were found between how we chose the donor, we observed a tendency to improve overall survival (64±1 vs. 41±1, P=0.1) and relapse free survival (81±09 vs. 56±1, P=0.1) when we chose the donor including donor KIR receptor, haplotype and NK cell cytotoxicity studies.

Conclusion: Haplo-SCT are a good option for patients who need a transplantation for be cured. Haplo-SCT from homozygous C1 donors had the best patient survival. We also should consider NK cell alloreactivity lab studies to choose the best donor available and improve haplo-SCT outcome. CMV reactivation post allogeneic haematopoietic stem cell transplantation (HSCT) is associated with signifi cant morbidity and mortality. Preemptive therapy (PT) based on viral load as assessed by CMV PCR (cytomegalovirus polymerase chain reaction) appears to improve outcomes but the impact of viral load at fi rst reactivation on subsequent outcome is unknown. Objectives: We evaluated the medical records of 43 patients with a history of CMV reactivation following HSCT at our unit between 2007 to 2011. Inclusion criteria were simply recipient and or donor CMV seropositivity prior to HSCT. In all patients, CMV PCR was measured twice a week until day 100, and antiviral therapy was initiated following the protocol described in Table 1 . PT included treatment doses for 2 weeks or until PCR negativity, followed by another 2 weeks of maintenance doses, followed by prophylaxis with valaciclovir. Subgroups are described in Table 2 .

Results: A majority, 26 of 43 patients destined to reactivate CMV did so by day 35. The time to reactivation was delayed in recipients of sibling grafts (median day 35) when compared to those receiving unrelated or family mismatched cells (median day 29). Data on PT was available from 31 patients of who 21 received PT as per protocol. Nineteen of 21 patients responded achieving CMV PCR negativity after a median of 10 days of initiation of PT (range 3-42). There was no relationship between the response to

S299 PT and the source of stem cells, recipient or donor seropositivity, or the conditioning protocol. Seventeen of 31 patients experienced recurrence of CMV reactivation. Patients with recurrent reactivation had a greater (2 fold) median peak viral load at fi rst reactivation (1831) when compared with those who reactivated only once (925). The median time to recurrence was 35 days since the fi rst negative PCR result. There was no diff erence in time to PCR negativity between the fi rst and the subsequent episodes of reactivation.

Conclusions: In this small group of patients we were unable to detect any signifi cant diff erence in the dynamics of CMV viral load in the diff erent subgroups. The risk of recurrence of reactivation remains high despite a good response to preemptive therapy A high viral load at fi rst reactivation was more common in patients with recurrence of reactivation. It is possible that patients with high viral loads at fi rst reactivation are candidates for longer duration of therapy in order to avoid recurrence. [P920] S300 a major complication associated with higher morbidity and mortality. CMV DNA monitoring and pre-emptive therapy decreases CMV disease and is associated with improvements in TRM. More recently CMV reactivation has been associated with a GVL eff ect. This analysis describes impact of CMV reactivation with regard to outcomes and GvL in 198 consecutive patients with MDS and AML who received a uniform protocol consisting of fl udarabine, busulfan and alemtuzumab(100mg). CMV reactivation was detected by qPCR on peripheral blood. OS, DFS, TRM and CIR was performed according to Donor/Recipient(D/ R)CMV IgG sero-status and reactivation post-HSCT. Time to reactivation defi ned as early or late(>day+45) was reviewed to determine eff ect on outcomes. D/R serostatus showed better outcomes for Neg/Neg group 5yrOS of 53%(p=0.035), 5yrCIR of 33% (p=0.04) and trend to better 5yr DFS of 48%(p=0.08) with no diff erence in TRM. Comparing neg/ neg group with the Non-Neg/Neg, diff erences were found in DFS and CIR (p=0.05 and 0.079, Figure 1 and 2). No diff erences were seen for matched vs mismatched serostatus. Groups were not different with regard to IPSS score, cytogenetic risk, donor, remission status pre-HSCT or GVHD.

Of the 198 patients analysed, 47% had at least 1 CMV reactivation after transplant (59% in high risk). Median time of reactivation was 38 days. Interestingly 17% of the Neg/Neg group had detectable DNA viraemia the majority of which were late infections(60%). For CMV reactivation global analysis of OS, DFS, TRM and relapse did not show diff erences comparing the reactivated vs non-reactivated group. However for patients with late CMV reactivation compared with those with early reactivation and the non-reactivated group outcomes showed improved OS(p=0.060), DFS(p=0.047), and CIR(p=0.046), (Fig 3 and 4 )without diff erences in TRM(p=0.706).

To our knowledge this represents the largest analysis of CMV reactivation using an Alemtuzumab based protocol. Importantly D/R CMV. IgG serostatus or the presence of CMV reactivation aff ected TRM. We confi rm the results of other groups demonstrating less relapse and potential GvL eff ect for CMV reactivation however the timing of reactivation was important. The eff ect of decreased CIR in the Neg/Neg group appears contradictory however is explained by the occurrence of primary CMV viraemia in this group. Prospective analyses should be performed to support these fi ndings.

Safety and immunogenicity of high dose infl uenza vaccine compared to standard dose in allogeneic haematopoietic stem cell transplant recipients N. Halasa, B. Savani, M. Grigsby, R. Simons, C. Summers, J. Bourgeois, L. Wang, M. Jagasia Vanderbilt University (Nashville, US) Background: Recipients of allogeneic stem cell transplants (allo-SCT) do not respond to trivalent inactivated infl uenza vaccine (TIV) as well as healthy controls; therefore, alternatives are needed. Since high dose (HD) TIV is now available, it may elicit better immune responses than standard dose (SD) infl uenza vaccine. Objective: To determine the safety and immunogenicity of HD-TIV compared to SD-TIV in allogeneic hematopoietic SCT recipients.

Methods: This was a randomized, double-blind, phase I safety and immunogenicity trial comparing HD to SD TIV in adult allo-SCT recipients at least 6 months post-transplant and not on immunosuppressive therapy for treatment of active GVHD. Subjects were randomized in a 2:1 fashion to receive 2010-11 or 2011-2012 TIV as either 0.5 mL of HD (60 ug per antigen) or SD (15ug per antigen). Hemagglutination inhibition (HAI ) titers to infl uenza virus antigens as well as complete blood count, quantitative CD4, CD8, and CD19 and serum IgG were measured prior to the fi rst TIV dose and 28-35 days later. Results: Forty-four subjects were enrolled (19 in year 1 and 25 in year 2) at a median of 7.9 m after allo-SCT (range, 5.7-105.6 m). The median age was 50.1 y (19.6-72.8), 61.4% were male, 100% white. The most common reasons for transplant included AML, ALL, and MDS. 29 subjects were given HD and 15 SD. No diff erences in demographic or lab data between the two groups were noted, except the HD dose group had higher median IgG level (676 vs. 469, p=0.025). Selected safety data are shown in Table 1 , with more reports of any local symptoms in the HD group compared to SD. No SAEs were attributed to vaccination. Immunogenicity results are shown in Table 2 , with the HD group having a higher percentage of individuals with titer >1:40 and higher geometric mean titers (GMT) after TIV for H3N2 antigen. Conclusions: No diff erences were noted for systemic reactions between the HD and SD groups; however, the HD dose had higher frequency of any local reactions. The HD group had higher percentage of individuals with post-vaccination >1:40 titer and GMT for H3N2 antigen. These data support a phase II immunogenicity trial.

[P921]

Varicella zoster virus disease after allogeneic haematopoietic stem cell transplantation. Incidence, risk factors and complications G. Fjaertoft, J. Winiarski, P. Ljungman, M. Uhlin, M. Remberger, J. Mattsson Karolinska Institutet (Stockholm, SE) Objective: To study the incidence, possible risk factors and complications of Varizella-zoster virus (VZV) disease after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Patients: A total of 860 patients were studied retrospectively for the occurrence of VZV disease after allo-HSCT. The median age was 38 years (<1-71). The majority of patients had a malignant disease (n=737, 86%). The donor was as follows: HLA-identical related: 311, MUD: 437, mismatched: 112. Myeloablative conditioning was given to 431 patients and 429 received reduced intensity conditioning. The stem cell source was: Bone marrow (233), peripheral blood stem cells (572) and cord blood (55). A total of 85 (10%) of the patients had been given mesenchymal stromal cells (MSC) as treatment for graft-versus-host disease (GvHD) or hemorrhagic cystitis (HS). Results: 194 (23%) of the 860 patients studied had a history of VZV disease. The median time from allo-HSCT to the appearance of VZV disease was 177 days (range 0-2510 days). According to multivariate analysis risk factors for VZV disease was: Day of engraftment >d16 (RH 1.51, p<0.01), TBI ≥6Gy (RH 1.55, p=0.004) and MSC (RH 1.49, p<0.01).

For 24 (2,8%) of the patients the VZV disease was generalized. 25 patients suff ered from "post-herpetic neuralgia" defi ned as pain continuing more than 1 month after the VZV-disease. 11 patients (1,3%) experienced other more severe complications to their VZV disease: Visceral zoster (2), encephalitis (1), meningitis (1), facial palsy (1), endophtalmitis (2), keratitis (1)and blepharitis (1) . Two patients were hospitalized because of secondary bacterial infections necessitating i.v. antibiotics. The overall 5 year survival did not diff er between patients with and without VZV disease (68% in both groups). Conclusion: VZV disease represents a rather frequent, most often painful and sometimes severe complication after allo-HSCT. In our opinion a safe and eff ective regime for the prevention of VZV disease after allo-HSCT is well motivated at least for patients with risk factors. Background: Blood stream infection (BSI) after allogeneic hematopoietic stem cell transplantation (HSCT) is a well-known complication during the pre-engraftment phase. Knowledge of trends in etiology and antibiotic susceptibility of BSI are important as the time to eff ective antibiotic treatment is closely associated with survival in bacteremic patients with septic shock. Methods: BSI during pre-engraftment phase was studied retrospectively in 521 patients undergoing HSCT at our center in 2001-2008. Incidence, risk factors, outcome and microbiology fi ndings were investigated and compared with BSI in a cohort transplanted 1975-1996. Results: The incidence of at least one episode of BSI was 21% and the total attributable mortality 3.3%. The rate of gram positive and gram negative BSI was 80% and 13%, respectively. Gram negative BSI was more frequent both in 2001-2004 and in 2005-2008 compared to 1986-1996 (p=0.023 for 2001-2004, p=0.001 for 2005-2008) , with fl uoroquinolone resistant E. coli as the predominant fi nding. BSI with viridans streptococci and E. coli occurred signifi -cantly earlier after HSCT than BSI with Enterococci spp, median time 4, 8 and 11 days, respectively (p<0.01 both for viridians streptococci verus Enterococci spp. and E. coli versus Enterococci spp.). Risk factors for BSI in multivariate analysis were transplantation from unrelated donor and cord blood as stem cell source, while peripheral blood as stem cell source was protective. Conclusions: BSI remains a cause of morbidity and mortality in HSCT recipients. The risk for gram-negative BSI increased over time in parallel with an increased rate of quinolone resistance. However, the incidence and attributable mortality of gram negative BSI remained low why continued prophylaxis with ciprofl oxacin is appropriate.

Adenovirus surveillance and pre-emptive treatment lead to low virus-related mortality despite frequent viraemia in a paediatric stem cell transplantation unit M, Mynarek, T, Ganzenmueller, A. Mueller-Heine, C. Mielke, A. Gonnermann, R. Beier, M.G. Sauer, B. Eiz-Vesper, U. Kohstall, K.W. Sykora, A. Heim, B. Maecker-Kolhoff Hannover Medical School (Hannover, DE) Human adenovirus (HAdV) infection is associated with signifi cant morbidity and mortality after pediatric hematopoietic stem cell transplantation (HSCT). The optimal surveillance and treatment strategies are under discussion. Recently, screening of fecal samples has been promoted in addition to blood screening for earlier identifi cation of infected individuals. We performed a retrospective analysis of HAdV PCR results and clinical outcomes in 238 consecutive pediatric HSCT recipients transplanted at Hannover Medical School between Jan 2003 and Feb 2012. All patients underwent prospective weekly quantitative HAdV PCR testing from blood; 111 patients had additional prospective weekly stool PCR screening. The incidence of HAdV-DNAemia was high (50%), and HAdV blood loads >1,000 copies/ml were detected in 15.5% of all patients. 26 patients (11%) displayed HAdV-related symptoms. The mortality rate directly attributed to HAdV seemed low (2 patients; 0.8%), accounting for 5.1% of all deaths (n=39). Blood HAdV load >10,000 copies/ml was a signifi cant and independent risk factor for poor survival. Detection of HAdV-DNAemia before day +50 after HSCT was a major risk factor for the development of HAdV blood loads >10,000 copies/ml. Detection of HAdV in stool correlated with blood loads, but preceded blood loads >10,000 copies/ml only by a median of fi ve days. Therefore, it marginally contributed to early recognition of patients at risk of high blood load HAdV-reactivation. However, routine monitoring of HAdV in stool samples may have contributed to early recognition of symptomatic HAdV-mediated enteritis, which is likely to be underdiagnosed early after HSCT due to frequent non-specifi c diarrhea. Moreover, transmission precautions were initiated after detection of HAdV in stool, which may have helped to control nosocomial spread. Preemptive treatment with cidofovir led to stable or reduced viral loads in 70% of patients. Our data suggest that routine PCR-monitoring for HAdV and preemptive treatment of high-risk patients result in a low HAdVrelated mortality. We recommend preemptive treatment with cidofovir in pediatric HSCT-recipients after detection of HAdV blood loads >10,000 copies/ml or persistent HAdV blood loads >1,000 copies/ml, even in the absence of symptoms. Moreover, we suggest treatment of every symptomatic infection, both localized and systemic. Invasive fungal infection (IFI) has emerged as a leading cause of morbidity and mortality among HCT recipients. In this study we report an overview on the incidence of IFI by analyzing 10year data collected prospectively on 350 consecutive patients who received an allogeneic HCT in our center between 2001 and 2011. Patient, donor and transplant characteristics are described in Table 1 . We included only IFI defi ned as probable or proven in accordance with published guidelines. We identifi ed 39 cases of IFI (prevalence 11,1%), of which 30 were due to invasive aspergillosis (IA) (22 probable and 8 proven (Aspergillus fl avus 5, Aspergillus fumigatus 3)), 1 to Fusarium solanis infection, and 8 to Candidemia (C. albicans 3, C. krusei 4, C. parapsilosis 1). The median day of onset for IA and Candidemia was day 55 (12-3023) and day 35 (11-187) respectively, whereas the Fusariosis infection occurred on day 140 post-transplant. IA involved lung in 29 cases and brain in 1; Fusariosis involved skin and blood; Candemia occurred in blood (n=6) or in blood, liver and spleen (n=2). Imaging fi ndings in pulmonary IA on CT scan included: macrododules > 1 cm in 13 patients, consolidation in 7, clusters of small nodules in 7, cavitary lesion in 2, and non specifi c ground-glass opacifi cation in 2. The 5-yr and 10-yr cumulative incidence (CI) of IFI was 11.3% (IA 8.9%, Candidemia 2.4%) and 12.5% (IA 10.1%, Candidemia 2.4%) respectively. In univariate analysis there was no signifi cant correlation between recipient factors (age, gender, ferritin, underlying disease, previous transplant, disease risk) or transplant factors (type and intensity of conditioning regimen, stem cell source), and occurrence of IFI, whereas the use of antithymocyte globulin (ATG) and the development of both acute and chronic graft-versus-host disease (GvHD) were signifi cantly associated with an higher CI of IFI. In multivariate analysis we found 4 risk factors signifi cantly associated with an higher CI of IFI: recipient age > 50 years (Hazard Risk (HR) 1.65 (p=0.05); acute GvHD (HR 1.59, p=0.01); chronic GvHD (HR 1.62, p=0.001; CMV infection (HR 1.37, p=0.003). Five of the 39 patients with IFI died for this complication, in all cases from IA. The 10-yr overall survival for the 311 patients with no evidence of IFI was 42% as compared to 17% of the 39 patients with IFI (p=0.006). These results emphasize that IFI represent a signifi cant complication in HCT recipients. Background: computed tomography (CT) guided bronchoscopy with bronchoalveolar lavage (BAL) is widely used for the diagnosis S303 of pulmonary infections, but its diagnostic value and safety in children after allo-HSCT is not suffi ciently studied. The purpose of this study was to evaluate effi ciency and safety of BAL in diagnosis pulmonary infections in this cohort. Materials and methods: 189 BAL samples from 127 pediatric allo-HSCT recipients were analyzed in 2009-2012. Median age was 8,5 y.o. We performed high-resolution CT guided bronchoscopy with endoscopic video system EVIS EXERA II Olympus with an external diameter of the distal end tubes of the 3.6 mm and 4.9 mm in a specialized endoscopy room or ICU (12%) . Diff erent methods of anesthesia were performed, depending on the age and the degree of respiratory failure of patients with mandatory monitoring of vital functions of the body and oxygen levels. The samples obtained were sent immediately to the laboratory for classic and molecular detection methods. Results: Signifi cant pathogens were detected in n=149(78%) of BAL (bacteria -n=57(39%), fungi -n=56(37%), viruses -n=36(24%), mixed infections -n=34(22%). In 52% of samples from 36 patients with invasive pulmonary aspergillosis fulfi ll EORTC/MCG 2008 criteria the results of galactomannan (GM) tests in BAL fl uid were positive despite negative results of GM tests in serum and microscopy and culture of BAL. P.jiroveci infection was revealed in three patients (2%), mycobacterial infection -in two (1,3%) . No major complications occurred during bronchoscopy. Transitory hypoxemia was observed in 28% of patients, nasal bleeding -5%, and bradyarrhythmia -2%. Conclusion: CT guided bronchoscopy with BAL remains a very important procedure for the diagnosis of pulmonary infections. Complex investigation of BAL fl uid can reliably detect signifi cant pathogens. The use of the indirect diagnostic tests (GM, PCR) signifi cantly increases the diagnostic value of BAL. Bronchoscopy performed with modern video endoscopy equipment and adequate anesthetic can safely be used in children after allo-HSCT.

Objectives: The Invasive fungal disease (IFDs) remains a major concern in patients received hematopoietic stem cell transplantation (HSCT). We conducted this study to better understand the epidemiology, diagnosis and treatment practice of IFDs in HSCT recipients.

Methods: This is a multicenter, prospective observational study for IFD in HSCT patients in China. All patients receiving HSCT from Jan 2011 to Oct 2011 in 32 sites were enrolled and observed to 6 months after transplantation. Uniform case report form was used to collect patient characteristics, IFD diagnosis, antifungal agents used during hospitalization and survival status. The diagnosis of IFD was based on the 2008 EORTC/MSG criteria. Results: A total of 1401 HSCT patients were enrolled. The median age of patients was 30 years (1~66yrs); 62% were male. 75% of them received Allogeneic-HSCT and 25% for Autologous-HSCT. 65.7% of patients' stem cell source was peripheral blood, 3.5% were from marrow and 28.2% were from both of them. 9.6% of patients had previous IFD. 384 IFD episodes were identifi ed among 1401 patients, 100 episodes were proven/probable IFD. The 6 months cumulative incidence, based on the fi rst IFD (proven/probable), was 6.7% overall, and was 2.8% in auto-HSCT, 8.0% in allo-HSCT (12.5% in haplo-HSCT, 11.1% in unrelated matched HSCT, 3.1% in sibling matched HSCT). Lung is the most commonly observed infection site (76.5%, 166/317). 83.9% of recipients received antifungal prophylaxis; Fluconazole (61.4%) was the most used agent. The incidence of proven/probable/possible IFDs in patients with/without prophylaxis was 20.3% and 48.2% respectively. Among 516 patients who received antifungal therapy, empirical therapy (82.0%) was the most common strategy for initial antifungal treatment. Itraconazole (38.6%) and voriconazole (31.6%) were the most common fi rst-line agents.

62.0% (320/516) of patients' protocol had been adjusted at least once, 27.8% (89/320) of them due to the lack of eff ectiveness. The overall 6 month mortality was 13.4%, while 23.6% for the patients with proven/probable/possible IFDs. Conclusion: This study provided the epidemiology data of IFDs in Chinese HSCT recipients. Allo-HSCT recipients had higher risk to develop IFDs, especially Haplo-HSCT recipients. The mortality of HSCT recipients with IFDs was high. Empirical therapy accounted for three fourth of initial treatment strategy in clinical practice. Antifungal prophylaxis was highly relevant to reduce the risk of IFDs, and should be recommended for HSCT recipients.

Identifi cation of an HLA-A*24:02-restricted adenovirus serotype 11 epitope recognized by cytotoxic T-cells N. Imahashi (1) Subgroup B adenovirus (AdV) serotype 11 (Ad11) is the prominent pathogen for hemorrhagic cystitis, and occasionally causes disseminated infection with fatal outcome in immunocompromised patients. Due to the limited effi cacy of antiviral drugs, adoptive T cell therapy for AdV has been explored. Although previous studies have identifi ed several T-cell epitopes of subgroup C AdV, those of Ad11 have not been identifi ed. Here, we describe a novel Ad11 hexon epitope restricted by HLA-A*2402, the most common HLA class I molecule in Japanese population, that could be used for adoptive T cell therapy. Ten synthetic Ad11 hexon protein-derived nonamer peptides which bound to HLA-A*24:02 were selected by a computer algorithm and MHC stabilization assay. Weekly stimulation of peripheral blood mononuclear cells from HLA-A*24:02+ healthy donors for three weeks with each of these ten peptides induced INF-γ producing CD8+ T-cells specifi c for three peptides, referred to as peptides X, Y, and Z. Of these three peptide-specifi c CD8+ Tcells, only peptide X-specifi c CD8+ T-cells produced signifi cant quantities of IFN-γ against Ad11 infected K562 cells which were transduced with HLA-A*24:02 (K562/A*24:02 cells). Furthermore, peptide X-specifi c CD8+ T-cells eff ectively lysed peptide X loaded K562/A*24:02 cells, but not peptide unloaded K562/A*24:02 cells or peptide X loaded K562 cells, in 51Cr release assays. These results indicate that peptide X is naturally processed in Ad11 infected cells, presented in the context of HLA-A*24:02, and recognized by CD8+ CTLs.

In conclusion, we have identifi ed a novel HLA-A*24:02-restricted Ad11 hexon epitope X that could be used for adoptive T cell therapy for Ad11 infection and to monitor CTL responses to Ad11 among HLA-A*24:02+ patients using MHC tetramers. Background: Pre-emptive therapy of cytomegalovirus (CMV) , has signifi cantly reduced, if not eliminated, the risk of progressing to CMV disease. The question we addressed in this study, is whether CMV viral load , is a predictive factor for outcome. Aim of the study: Test whether maximum CMV load is predictive of survival; if so whether this has changed with transplant eras, or is associated with specifi c donor types. Patients: We therefore studied 940 patients allografted 1990-2010. The donor was a matched sibling (SIBS) (n=468) , a family mismatched donor (n=152), an unrelated donor (UD) (n=247) or an unrelated cord blood (UCB) (n=73). All patients had developed a positive antigenemia, at a median interval of 45 days from transplant. The median number of pp65 antigen positive cells (Ag+) at diagnosis of CMV was 2/10 4 PBMC, and the maximum number of AG+ cells was 7. The median age was 40 years. The conditioning regimen was myeloablative (MA) in 615 and reduced intensity (RIC) in 325. Results: The overall actuarial 10 year survival of the 940 patients with CMV Ag-emia was 43%. It was 45% vs 41% for patients presenting with < /> 2 Ag+ cells (p=0.01) and 50% and 35% for patients with a maximum number of AG+ cells < /> 7 x10 4 (p<0.0001). The diff erence in OS was seen also when selecting patients grafted more recently (2000 -2012) . The diff erence in OS is due to a higher transplant related mortality (TRM) in patients with a high viral load (35% vs 22%, p<0.0001), whereas the cumulative incidence of relapse related death (RRD) is identical 23% vs 21% (p=0.4). The eff ect was evident only in patients grafted from SIBS (50% vs 24%m p<0.0001), and not in patients grafted from alternative donors (42% vs 41% p=0.6) (Fig.1) . It was also more pronounced in older patients (> 40 years of age) as compared to younger patients.

In multivariate Cox analysis on OS, age <40 (RR 0.4), low CMV load (RR 0,7) and early disease phase (p=0.7) were very strong favourable predictors. Conclusions: We confi rm that the maximum number of CMV Ag+ is a strong predictor of outcome, in patients grafted from SIBS and not in patients grafted from alternative donors. It is unclear whether this is due to a diff erent prophylaxis strategy in the latter, in whom we have always used foscarnet, whereas high dose acyclovir is used for SIBS. 

Infl uenza is an important infection in patients after allogeneic HSCT. Peripheral blood lymphocytes were collected prior to and a month after seasonal infl uenza vaccination during two seasons (2010-11 and 2011-12) . 30 patients from two centers were included in the study. The median time after transplant to vaccination was 239 days (97 to 818 d). A whole blood assay was used to quantify IFN-γ production responses directed against several diff erent infl uenza antigens. IFN-γ levels of >10 pg/ml above the mean level of the medium control was chosen as indicating a specifi c T-cell response before vaccination. An increase of 10 pg/ml was chosen to indicate a vaccination response. Most of the recipients showed strong IFN-γ production in response to PHA (positive control) both prior to and after vaccination. Before vaccination, IFN-γ production to the diff erent infl uenza strains was very diverse and could be observed between 2 and 14 patients. 11

patients had no detectable IFN-γ production to any strain, while 7 patients responded to fi ve or more antigens. There was no correlation between the likelihood of having a specifi c response against at least one strain and the time from HSCT. After vaccination, between 4 and 9 patients exhibited increases in IFN-γ production, depending on the viral strain tested. No diff erence was seen in the INF-γ response rates and time after HSCT. There was no diff erence between the response rates to the major infl uenza strains (H1N1, H3N2, or B). PBMCs from 12 HLA-A*02 individuals were additionally analyzed by FACS for infl uenza specifi c CD8 T-cells using two infl uenza specifi c dextramers A*02 GILGFVFTL Matrix 1 protein, A*02 RLATGLRNV hemagglutinin [HA] . A median increase from 0.13 to 0.325% of A*02 RLATGLRNV HA specifi c CD8 T cells was observed (p= 0.04) one month after vaccination. 5/12 individuals responded with at least doubling of the % HA specifi c CD8 T-cells, 5/12 individuals had measurable activity but no increase, and 2/12 individuals had no HA specifi c reactive CD8 T-cells, 10/12 individuals who had HA specifi c CD8 T cells also had an increase in IFN-γ production tº at least one of the infl uenza A strains, no increase in A*02 GILGFVFTL matrix1 specifi c CD8 T cells or CMVpp65 specifi c CD8 cells (median % 0.26 to 0.22) was observed. We conclude that IFN-γ production and an increase in infl uenza specifi c CD8 T cells can be elicited by vaccination with tri-valent infl uenza vaccine.

The clinical relevance needs to be determined. Background: Adenovirus (Adv) infections are a major cause of morbidity in hematopoietic stem cells transplantation (HSCT). The aim of the study was to determine risk factors for Adv infection and disease in pediatric HSCT patients to defi ne the patients who should benefi t of a screening for Adv. Methods: Between September 2010 and December 2011, 65 pediatric HSCT patients were prospectively followed for 12 months and were weekly tested for adenovirus in blood and stool. Shedding was defi ned as a positive detection in stool only, systemic infection as positive detection in blood, and disease as infection with Adv associated symptoms. Univariable and multivariable Cox models were used to defi ne predictive factors for shedding in stool, systemic infection and disease with estimated hazard ratio (HR) of event as a measure of association. Results: Cumulative incidence of shedding in stools, infection and disease at 3 months post-HSCT were 39%, 21% and 17% respectively. There was a strong predominance of the subgenus C (55.6%) whereas other species were far less observed: A (11.1%) B (7.4%) D (3.7%) and F (7.4%). Risk factors were age under 6 years,

cord blood transplantation, mismatch unrelated donor and corticosteroids in preventing GvHD for shedding in stool (HR=2.6, HR= 4.0, HR=9.1, HR= 3.6, respectively); the same factors were selected for predicting disseminated infection (HR=8.3, HR =4.2; HR=11.1, HR=4.3 respectively) as well as grade 3-4 GvHD (HR=3.0). Risk factors for Adv disease were cord blood transplantation (HR=3.8) and grade [3] [4] . Based on multivariable models, mismatch unrelated donor (HR=3.4) and age below 6 (HR= 2.9) remained associated with shedding in stool, while grade 3-4 GvHD and cord blood transplant remained associated with infection or disease (HR=2.9, HR= 4.1; HR=3.5, HR= 3.7 respectively). Association of AdV detection with presence of other viruses and association between AdV load in stool with viremia will be given. Conclusions: Age<6 years, mismatch unrelated donor, cord blood transplant appear the most appealing risk factors for Adv infection and should be considered to initiate a molecular screening for Adv. Adv infected patients with cord blood transplant and/or grade 3-4 GvHD must be considered for early anti-Adv intervention.

A prospective study of the predictive value of blood BK viral load for haemorrhagic cystitis in paediatric patients who underwent allogeneic haematopoietic stem cell transplantation S. Cesaro (1), G. Tridello (1), M. Pillon (2), E. Calore (2), M. Tumino (2) , N. Carucci (2), S. Varotto (2), L. Barzon (3), C. Messina (2) (

Objectives: To assess the predictive value of quantitative determination of blood BK virus (BKV) load for the occurrence of hemorrhagic cystitis (HC) in the fi rst 100 days after hematopoietic stem cell transplantation (HSCT). Methods: From April 2005 to December 2011, patients (pts), aged<18 years and undergoing a fi rst allogeneic-HSCT were assessed weekly by blood quantitative PCR for BKV, until day + 100. To investigate if the cut-off for HC of BKV-load varied according to the time from HSCT, we considered the maximum value up to two weeks prior to the following time-points: day + 30, day + 45, day + 60 and day +100. A receiver-operator characteristic (ROC) curve was plotted to detect the value with higher sensitivity and specifi city > 80%. Follow-up data are as at June 2012. Results: 107 pts, 66 males (62%) and 41 females (38%), with a median age at HSCT of 7.7 years (range 0.7-17.3), were enrolled. The underlying disease was leukaemia or lymphoma in 82 (77%), solid tumours in 1 (1%) and non malignant disease in 24 (22%). The donor origin was: sibling, 32 (30%); matched unrelated donor, 32 (30%); and mismatched unrelated donor, 43 (40%). The stem cell source was bone marrow, 73 (68%), peripheral blood, 13 (12%), and cord blood, 21 (20%). The conditioning regimen was based on total body irradiation in 43/107 patients (40%). At a median time of 25 days from HSCT (range 7-98), 20 pts developed grade II-IV hemorrhagic cystitis (HC): the 100-day cumulative incidence being 19.2% (95% CI 13-29). The 90% of pts had symptoms: dysuria and strangury (83%), pollakiuria (72%), and abdominal pain (67%). The median duration of macrohematuria was 13 days (range 2-71). The BK virus was positive on blood in the 75% (15) of pts, with a median value of 14,151 genomic copies/ml (range 7,661-3,159,500).

Since that the majority of the HC episode occurred by day + 30, a ROC curve was plotted only for this period. A BKV load of 1023 genomic copies/ml had a sensitivity of 100%, a specifi city of 86%, a NPV of 100% and a PPV of 39%. After a median follow-up of 3 years, the overall survival was 69% (CI 58-77). Among the 32 deaths, 13 were due to progression disease and 19 to transplant related causes. Three patients died with bleeding but none of them had suff ered from HC. Conclusion: A BKV load of 1023 genomic copies/ml had the highest sensitivity and a good specifi city to predict HC occurrence by day + 30. The low PPV is consistent with the multifactorial pathogenesis of HC. The most common dsDNA virus infections (whether single or multiple) were CMV (54%), AdV (31%), BKV (23%) and EBV (7%). By transplant type (HCT vs SOT), the most common infections (single or multiple) were CMV (56% vs 68%), AdV (36% vs 20%) and BKV (28% vs 10%). Approx. 30% (95/320) of pts had evidence of multiple (2) (3) (4) (5) dsDNA virus infections; the most common coincident infections in the same pt were CMV+BKV at 34/95 (36%), AdV+BKV at 28/95 (29%) and AdV+CMV 22/95 (23%). Younger age (p=0.0004), black race (p=0.047) and HCT (p=0.039) were significantly associated with multiple dsDNA virus infections. Conclusions: A signifi cant proportion of expanded-access and EIND pts qualifying for CMX001 therapy had evidence of multiple dsDNA infections. Pts enrolled post-HCT, particularly children, appear to have an increased likelihood of multiple dsDNA virus infections. The potential for broad-spectrum clinical benefi t with CMX001 is being evaluated in these pts and will be further explored in future clinical studies.

Factors associated with overall mortality in patients with mucormycosis after allogeneic haematopoietic stem cell transplantation and chemotherapy M. Popova (1) Clinical and treatment variables were analyzed for their eff ects on overall survival and mortality. Signifi cant variables in univariate analysis were introduced into a Cox model. Results: There were 10 proven (53%) and 9 probable (47%) cases of M in 19 pts with predominantly acute leukemia 74% (14). Median date of M onset after alloHSCT was D+117 (14-449), CT -D+24 . In 3 pts M was diagnosed post-mortem. In 11 pts (58%) bronchoscopy were performed, and in all cases it was informative for the diagnosis. In 13 (68%) cases diagnosis was confi rmed by culture. Etiologic agents of M after alloHSCT were Rhizopus spp. 86% (6), Rhizomucor spp. 14% (1), after CT -Lichtheimia spp. 50% (3), Mucor spp. 33% (2), Rhizomucor spp. 17% (1). In 7 pts (37%) M was diagnosed after or simultaneously with invasive aspergillosis (IA) and in 1 case with candidemia (C.guilliermondii). The 12weeks OS after diagnosis of M in alloHSCT was 25%, in CT -78%, 6 months OS was 25% and 67%, and 1 year OS was 17% and 56%, respectively. We established positive and negative prognostic factors of 12-weeks, 6-months and 1-year OS after diagnosis of M.

Positive prognostic factors are outlined in table 2. Negative prognostic factors in alloHSCT recipients were IFD before alloHSCT (mortality 37,5% vs 0%, p=0,004) and hemoptysis (mortality 33,3% vs 0%, p=0,04). Conclusion: M are frequently (42%) associated with other IFD. In alloHSCT with M the 12-weeks and 6-months OS was 25%. Combination antifungal therapy improved the 12-weeks and 6-months OS. In CT pts OS at 12-weeks was 78%, 6-months and 1-year was 67% and 56%, respectively. Use of amphotericin B in fi rst line therapy and surgery improved OS in CT group with M. Negative prognostic factors in alloHSCT recipients were IFD before the HSCT and hemoptysis. There were 6 proven (50%) and 6 probable (50%) cases of M in 12 pts with predominantly acute leukemia 58% (7). Median date of M onset after alloHSCT was D+117 (14-449). One case of M was diagnosed post-mortem. Main clinical forms of M were pulmonary 75%, rhinocerebral 8,3%, subcutaneous/osteomyelitis 8,3%, and bowel 8,3%. In 9 pts (75%) bronchoscopy was performed, in 100% cases it was informative for the diagnosis. In 7 cases (58%) diagnosis was confi rmed by culture. Etiologic agents of M were Rhizopus spp. 86% (6), and Rhizomucor spp. 14% (1). In 7 cases (58%) M was diagnosed after or simultaneously with invasive aspergillosis (IA). Twelve-weeks OS after diagnosis of M was 25%, 6-months OS in -25%, and 1-year OS -17%. We established positive prognostic factors of 12-weeks, 6-months and 1-year OS after diagnosis of M (table 2) . Negative prognostic factors were IFD before alloHSCT (mortality rate 37,5% vs 0%, p=0,004) and hemoptysis as a symptom of M (mortality rate 33,3% vs 0%, p=0,04). Conclusion: Incidence of M was 3%. A lead etiological agent of M in alloHSCT recipients was Rhizopus spp. -86%. Main clinical form of M was pulmonary -75%. In 58% cases M were diagnosed simultaneously with IA. In alloHSCT recipients with M the 12-weeks and 6-months OS was 25%. Positive prognostic factors were age < 18 y.o., haplo type of alloHSCT, and combination antifungal therapy. Negative prognostic factors were IFD before the HSCT and hemoptysis. Multimer monitoring to detect cytotoxic T cells (CTL) directed against latent viruses (e.g. Cytomegalovirus (CMV) and Epstein-Barr virus (EBV)) in patients after allogeneic haematopoietic stem cell transplantation (HSCT) has been reported earlier. We reason that successful immune reconstitution of CMV-and EBV-CTL depends on a functional immune response in the donor. Thus, the number of CTL transferred with the graft was investigated. We established multimer monitoring in grafts prior to transplantation and investigated infl uences of (1) sample storage conditions, (2) the apharesis procedure including G-CSF-stimulation and (3) correlation of multimer staining with CMV and EBV serostatus and CTL functionality. We analysed the number of CMV-and EBV-CTL using 6 HLA class I multimers (A*01:01, A*02:01, A*24:02, B*07:02, B*08:01, B*35:01). Functional activity was tested by IFN-γ ELISpot. Antiviral CTLs were analysed in whole blood (WB) prior to and after G-CSF mobilisation (WBM) before apheresis, in samples from the apheresis tubing fi lter (R) and in the graft (G). To detect eff ects of sample storage time and temperature, we repeatedly measured WB samples from patients after HSCT. Staining results in samples after 24 h, 48 h and 72 h, stored either at room temperature or 4°C, were compared to results obtained from fresh samples. Storage at 4°C for up to 48 h yielded reproducible results. Analysis of 163 samples from stem cell donors showed that the unspecifi c background was signifi cantly higher in R and G samples compared to freshly collected samples. After subtraction of background, percentages of cells stained with specifi c multimer lay within the same range for all sample types. Using a threshold of ≥0.1% multimer positive events in the CD3CD8 subpopulation to identify antigen-experienced individuals, multimer staining results correlated with CMV serostatus in 127/157 and with EBV-serostatus in 61/110 samples analysed. Multimer staining and ELISpot results correlated for 41/62 samples and 16/51 samples after restimulation with CMV or EBV antigens, respectively. Immunodominance of pp65 versus IE-1 (A*02-epitopes) and of BZLF1 versus EBNA3A (B*08-epitopes) was analysed, pp65 epitope yielded higher numbers of CTL in 23/31 patients, BZLF1 in 8/13 patients. Our results show that multimer monitoring can be readily used to quantify antiviral CTL in stem cell donors and grafts. The frequency of CTL is not aff ected by the mobilization and apharesis procedure. Tables I and II summarize the response data. A comparison of reported practices with the expert recommendations is provided in both tables. Similar clinical practice patterns are reported among the majority of PBMT centers with regard to (1) the use of intravenous immune globulin (2) indications to initiate therapy for cytomegalovirus (CMV), adenovirus and BK virus;

(3) criteria used to test for/ change therapy when CMV resistance is suspected; (4) use of inhaled ribavarin for respiratory syncitial virus (RSV); (5) prophylactic antibiotic coverage; (6) use of voriconazole in the setting of aspergillosis; (7) hospital visitation and home environment precautions. Clinical practice patterns regarding surveillance for late onset CMV was the least consistent and varied from the recommendations of the joint guidelines. 57% of PBMT centers do not monitor voriconazole levels (the lack of recommendation in the joint guidelines and associated clinical practice is incongruent with emerging data). Conclusion: Similar clinical practice patterns regarding infectious diseases, are reported among the majority of PBMT centers which are accredited by FACT in the United States. However, there is reported variation among PBMT centers regarding surveillance for late onset CMV. There also appears to be an evidence-gap regarding the need for monitoring of voriconazole levels among PBMT patients. Introduction: Catheter-related infections (CRI) account for a considerable amount of treatment related morbidity and mortality during allogeneic hematopoietic stem cell transplantation (HSCT). Central venous catheters (CVC) impregnated with antibiotics are considered to reduce CRI, but little is known about the impact in the setting of allogeneic HSCT. Even though this setting is characterized by an accumulation of risk factors for CRI, with long duration of catheterization, high frequency of manipulations (blood samplings, injections, etc.), frequent administration of parenteral nutrition and blood products and neutropenia. Materials and Methods: This retrospective cohort study evaluated 117 allogeneic HSCT recipients of whom the fi rst 58 were provided with CVC impregnated with silver zeolite (S-CVC) and the following 59 with CVC impregnated with minocycline/rifampin (AB-CVC). The analysis included all patients receiving the fi rst allo-geneic HSCT in our unit between 05/11 and 07/12 using a nontunneled triple lumen CVC implanted to the jugular vein. Results: The baseline characteristics concerning patient, donor and disease were comparable between the two groups except for the ECOG performance status found to be signifi cantly poorer in the AB-CVC group.

In the AB-CVC group we found a signifi cant reduction of catheter-related local infection (10.2 vs. 41 .4%, p<0.01), patients with bacteremia (6.8 vs. 34.5%, p<0.01) and catheter colonization (5.2 vs. 29.8%, p<0.01). Additionally the frequency of fever in neutropenia was signifi cantly reduced in the AB-CVC group, as we found a reduced percentage of days with fever in neutropenia per patient [11.5 vs. 18.3%, p=0.034; fever due to in vivo T-cell depletion (mainly ATG) was not considered and only days with inserted CVC were analyzed]. The frequency of days with fever during the whole period with inserted CVC was not signifi cantly diff erent between the groups (9.0 vs. 9.5%, p=0.385), but the onset of fever occurred later after CVC insertion in the AB-CVC group: after 15.2 vs. 12.8 days (p=0.055).

Conclusion: The application of minocycline/rifampin impregnated central venous catheters in allogeneic HSCT leads to a signifi cant reduction of infectious complications.

[P937]

Prospective study on usefulness of bedside ultrasound sonography to diff erentiate and diagnose enterocolitis from chemotherapy-related-diarrhoea in neutropenic patients undergoing autologous stem cell transplantation E. Benedetti (1)

Neutropenic enterocolitis (NEC) is a life threatening complication of haematological patients (pts) treated with chemotherapy (CHT) with mortality rate up 50%. Early diagnosis is crucial to start conservative medical management (CMM) which appears the optimal strategy for most cases. NEC should be always suspected in Neutropenic pts with abdominal pain (AP), fever (F) In the pts with CRIM F+D+AP were never present simultaneously and US never revealed BWT. US allowed an early recognition of pts with CRIM progressing to NEC, showing abrupt BWT >4 mm, always accompanied by a sudden increase of AP. All pts with NEC were promptly treated conservatively but 1/32 who underwent a small bowel surgical resection and 87% survived. Median time to clinical response from diagnosis of NEC to improvement of symptoms was 24h, even with persistent neutropenia. In conclusion: US allowed to diff erentiate CRIM from NEC. US monitor of intestinal BWT allowed to fi nd progression from CRIM to NEC. The improvement of symptoms during persistent neutropenia indicates that an early US-guided diagnosis of NEC is mandatory to initiate a prompt treatment to reduce mortality. US follow up in ASCT patients is a cheap, not-radiation-based, bedside technique useful to diff erentiate CRIM form a life threatening complication such as NEC. The source of stem cells was bone marrow. Conditioning regimens were NMA (n= 45, fl udarabine, Cy and low dose TBI) and myeloablative (n= 3, thiotepa, fl udarabine and busulfan). All patients received Cy at days +3 +4, tacrolimus and mycofenolate mofetil. Prophylaxis against molds, bacteria, and CMV was used. Three periods after HCT were defi ned: very early (0-30 days), early (31-100 days) and late (>100 days). Results. Overall, viral infections were diagnosed in 72% of patients, fungal infections occurrence in 6%, and bacterial infections in 39% (fi g 1).

In the very early period, 44 patients had fever. All had a thoracic CT scan at time of fi rst febrile peak and 18% had pneumonia and 5 documented (2 CMV, 1 RSV, 1 H1N1, 1 Staph Aureus). 39% bacterial infections, and 39% viral infections, 4% fungal infections. In the early period, 53 infections were observed. Viral infections were documented 59% of patients (27 viremia, 7 BK virus cystitis, 1 CMV gastritis and 1 JC encephalitis), bacterial infections in 14% (3 gram positive bacteraemias and 1 clostridium colitis and 2 E coli cystitis), and fungal infections in 6%. Pneumonia was diagnosed in 15% of patients (5 non documented, 1 proven and 2 probable lung aspergillosis, 1 infl uenza pneumonia).

In the late period, 32 infections were diagnosed. Viral infections were documented in 27% of patients (10 viremia, 2 pneumonias), bacterial infections in 16% (5 bacteraemias and 2 pneumonias) and fungal infection in 2% (hepato-splenic candidosis). 11% had pneumonia (3 no documented, 2 gram positive, 1 mycoplasma 1 RSV) (fi g 2).

Pneumonia incidence was 39% due to virus 33%, bacteria 22%, aspergillus 11%, and no documented 34%. 5 patients died from infections in the early period and all but one (JC virus encephalitis) related to pneumonia. Conclusion: Infectious complications were frequent after TR-H, mainly in the early period. Pneumonia were a cumbersome problem leading to 5 deaths. Invasive fungal infections incidence were low due to low incidence of GVHD.

Generation of self-diff erentiating CMV-antigen-expressing DC for in vitro expansion of CMV-CTL for adoptive transfer P. Varanasi, S. Borchers, A. Daenthanasanmak, A. Schneider, G. Salguero, B. Eiz-Vesper, R. Stripecke, M. Messerle, U. Koehl, A. Ganser, E.M. Weissinger Hannover Medical School (Hannover, DE) Adoptive transfer of CMV-specifi c cytotoxic T cells (CMV-CTL) may be a potent therapeutic tool to control CMV infection in immunocomprised patients. However, wide application is hampered by (1) the lack of CMV-CTL in seronegative donors, (2) low frequencies of CMV-CTL in CMV-seropositive donors may lead to insuffi cient numbers of CMV-CTL for direct adoptive transfer and (3) extensive in vitro expansion of CMV-CTL may lead to T cell exhaustion. We aim to optimize in vitro stimulation and expansion of CMV-CTL by generating self-diff erentiating DC (smartDC) expressing CMV-antigens using lentiviral vectors (LV) instead of conventional DC (moDC) diff erentiated and loaded with antigen ex vivo. Two tricistronic self-inactivating lentiviral vectors were constructed expressing the human GM-CSF and IL-4 genes as well as the CMV antigens pp65 or IE-1. Expression of transgenes was verifi ed by lentiviral transduction of 293T cells followed by ELISA and western blot assays. For generation of smartDCs, CD14+ cells were pre-stimulated with IL-4 and GM-CSF and transduced overnight. SmartDCs were phenotyped by FACS for CD14, CD209, CD83 and HLA-DR expression, ex vivo diff erentiated moDC from the same donor served as controls.

ELISA results showed expression of hGM-CSF (mean 0.23 μg/ml) and hIL-4 (mean 0.43 μg/ml) in 293T cells after transduction with both vectors. Expression of CMV proteins pp65 or IE-1 was confi rmed by western blot. Monocytes transduced with the LV readily developed DC-phenotype after 7 days in culture without addition of cytokines as determined by microscopy and FACS analysis, which showed expression of DC markers comparable to that of moDCs. These preliminary results indicate that the smartDCs express the transgenes without changing phenotypic properties. Stimulation of T cells from naïve and CMV-seropositive donors is currently investigated and compared to pp65 or IE-1 peptide pool loaded moDC. Expanded T cells will be analysed extensively not only for recognition of CMV-epitopes, but will be subtyped (memory and eff ector; CD45RA, CCR7, CD27, CD28) and analysed for expression of exhaustion markers (PD-1, TIM-3, CD57) and functional activity (intracellular staining for IFN-γ, TNF, CD107a, IL-2) in order to generate CMV-CTL that will be eff ective, non-exhausted and display high proliferative and cytotoxic potential. Bckground: An ineff ective immune response may contribute to HBV persistence. The hypothesis was that persistent HBV positive individuals would prone to other virus infection in allogeneic transplant setting. Based on HBV serological marks, the enrolled patients were classifi ed into 2 groups. A group was HBsAg positive,B group was anti-HBs positive. Design and Methods: A retrospective cohort study of patients between February 2010 and August 2011 was followed up at June 2012.We investigated the effect of HBV serological marks on early CMV DNAemia following haplo-identical allo-HSCT. Both of donors and recipients with CMV-IgG negative were excluded. All the patients were conditioned with a GIAC protocol.The occurrence of aGVHD,cGVHD and early CMV DNAemia were calculated by Kaplan-Meier curves, respectively. Cox regression analysis was performed to identify the risk factors for early CMV DNAemia.

Results: The total number of patients was 135 cases including 44 (A group) and 91 (B group). Median age was 30 years (range: 14-56). Both of 2 cohorts showed similar hematological recovery. Signifi cant higher occurrence of early CMV DNAemia(<100 days) were observed among A group compared to B group (77.3% and 28.2%, respectively; P=0.000). Culmulative incidences of acute GVHD in 2 groups were similar for grades I-IV (50.0% and 55.8%, respectively; P=0.261) and grades II-IV (27.3% and 30.3%, respectively; P=0.649). 2 cohorts showed similar cumulative incidences of chronic GVHD and 1-year overall survival (67.9% and 79.6%, respectively; P=0.529). We analyzed possible factors correlated with the occurrence of early CMV DNAemia, including recipient age (≤30 years, >30 years), recipient sex, HBV serological marks (A and B group), diagnosis, risk stratifi cation, MNC dose, CD34+ cell dose, CD3+ cell dose, early neutrophil engraftment, early platelet engraftment, absolute lymphocyte count on day 30(ALC30) and the occurrence of acute GVHD before CMV DNAemia. Multi variate analysis identifi ed HBsAg positive mark (P=0.006; OR=3.614; 95% CI=1.441-9.067) and the occurrence of acute GVHD before CMV DNAemia (P=0.000; OR=9.216; 95% CI=3.518-24.144) as high risk factors for early CMV DNAemia following haplo-identical allo-HSCT. Conclusions: Our data showed HBV persistent recipients was at high risk for active CMV infection following haplo-identical Allo-HSCT. The host immusurvilence seems altered by HBV persistence and leads to an increased risk for CMV infection after haplo-identical Allo-HSCT.

Introduction: Antifungal prophylaxis with azoles is considered standard in allogeneic hematopoietic stem cell transplant(HSCT). Sirolimus is increasingly used for prevention of graft-versus-host disease (GVHD). Voriconazole and sirolimus coadministration has signifi cant drug interactions. Data on sirolimus and voriconazole coadministration are sparse. We conducted a retrospective analysis of 68 patients with hematologic malignancies who underwent an allo-HSCT using sirolimus, tacrolimus, and low-dose methotrexate for GVHD prophylaxis and received concomitant voriconazole prophylaxis. Methods: Between April 2008 and June 2011, 68 patients(M/F: 44/24), median age 51 years (range: 24-69) were transplanted for non-Hodgkin's lymphoma (60%), chronic lymphocytic leukemia/ small lymphocytic lymphoma (22%), Hodgkin lymphoma (12%) and acute lymphoblastic leukemia/ myelodysplasia (5%). Conditioning regimen was NMA/RIC in 67 patients and MA in 1 patient. Donors were HLA-matched related 38%, matched unrelated 48% or 9/10 HLA-mismatched unrelated 13%. Micafungin was given from admission until azole initiation. All patients received voriconazole with a 90% Sirolimus and 67% Tacrolimus reduction at Voriconazole initiation. Results: Voriconazole was coadministered for a median of 114 days .

The median daily dose of sirolimus before voriconazole initiation was 4.6mg (1-12) and 0.6mg (0.2-2)at steady state of coadministration. The median daily dose reduction of Sirolimus at start and steady state of coadministration was 90% (80-92) and 84% (0-95), respectively. The median serum sirolimus trough level before and at steady state of voriconazole coadministration was 6.4ng/mL (2-17.9 ) and 6.5ng/mL (3-11.2) , respectively. 29% of the patients prematurely discontinued voriconazole because of adverse events: 18 % elevated LFTs in (12% LFTs >3 times upper normal limit), 3% prolonged QT, 3% visual disturbances and 5% others. 7 patients developed acute renal failure (serum creatinine >2 mg/dL), 4 of them required modifi cation of the immunosuppressant treatment. 1 patient developed thrombotic microangiopathy. No sinusoidal obstructive sydrome was reported. 7 % of patients were considered at high risk for Invasive Fungal infection (IFI) pre-HSCT. Two patients (3%) presented with possible IFI at day 100. Conclusions: Sirolimus and Voriconazole coadministration with an empiric 90% sirolimus dose reduction and monitoring of sirolimus through levels is safe, well tolerated and eff ective. with CMV reactivation did not present positive detection of CMV after a 21-day median duration preemptive treatment with ganciclovir. Cumulative incidence of day 100 grade II-IV acute GvHD, 1-year chronic GvHD and day 100 transplantation related mortality (TRM) were 37%, 36% and 9%, respectively. CMV reactivation and serostatus were not associated with increased GvHD and TRM or short survival. Only the presence of acute GvHD as a time dependent variable was signifi cantly associated with increased TRM (p=0.005). Two-year overall and progression free survival were 56% and 34%, respectively. Conclusion: Donor and recipient CMV serostatus and acute GvHD are independent factors for increased CMV reactivation in highrisk MM patients undergoing RIC Allo-SCT. However, we did not fi nd any infl uence of CMV reactivation on post transplantation outcome. CMV monitoring and pre-emptive treatment strategy could in part explain these results. Novel prophylactic measures such as immunotherapy and drug prophylaxis need to be considered in this specifi c group of patients, warranting further prospective studies. Invasive fungal infections (IFI) such as candidiasis and mold infections cause signifi cant morbidity and mortality among immunocompromised patients in recent years. Micafungin, a new echinocandin, inhibits fungal cell wall β-glucan synthesis, with potent activity against most species of Candida and Aspergillus. The aim of this observational study was to investigate the effi cacy and safety of Micafungin in prophylaxis of invasive fungal infections (IFI) in high risk adult patients with various haematological diseases receiving haplo-identical allogeneic stem cell transplantation (Allo-SCT). 26 patients were identifi ed. Only 2 patients had a history of possible aspergillosis before transplant treated by voriconazole. The patients received a median of 4 lines (2-7) of chemotherapies before Allo-SCT. Thirteen patients (50%) received at least one prior auto-SCT; and 8 patients (31%) received a previous Allo-SCT. 24 patients (92%) received a reduced intensity conditioning regimen (RIC), with Fludarabine, Cyclophosphamide and Total body irradiation (TBI) 2 Gy based (80%), or Fludarabine, Busulfan, and Cyclophosphamide based (8%) or other (4%). while two patients (8%) received a myeloablative conditioning regimen with thiotepa. The treatment was initiated at the beginning of the transplant conditioning regimen until the hospital discharge. Patients received a median of 29 infusions (range, 15-85) of Micafungin (50 mg/day i.v. as a 1h infusion). Results: None of our patients discontinued the treatment for drug-related adverse events. Micafungin was not associated with any hepatotoxicity. Only one patient (4%) discontinued the treatment because an early disease progression. At last follow-up, there are 21 patients (81%) who are alive, with a median follow-up of 10 months (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . three patients (12%) dead because disease progression and two patients because graft failure. In all patients no candidas and/or Aspergillus species was documented after 3 and 6 months from transplant. None of our patients presented a positive galactomannan antigenemia >0.5.Four patients presented an acute GvHD grade II and 2 patients presented a chronic GvHD. Conclusion: Micafungin has a good safety and tolerability profi le, with an effi cacy in preventing IFI in this high risk population. Our data provide support for an effi cacy study in a prophylaxis setting, but prospective and comparative clinical trials using Micafungin are urgently needed to defi ne the role of this drug in prophylaxis after haplo-identical Allo-SCT. Background: Hemorrhagic cystitis (HC) is a common cause of morbidity after allogeneic stem cell transplantation (allo-SCT), often associated with BK virus infection. Cidofovir (CDV) is an acyclic nucleoside analogue with a broad range of antiviral activity, including BK virus and thus it has been proposed as treatment for HC after allo-SCT. Methods: We retrospectively evaluated 59 consecutive pts (median age 45 years) who received CDV for HC after allo-SCT from 2008 to 2012. All pts were aff ected by hematologic malignancies, 39 had active disease at allo-SCT. Donors were HLA identical sibling (8), family mismatched (39), unrelated volunteer (11), cord blood (1). All pts received a myeloablative conditioning regimen. BK viral load was determined on urine by TaqMan PCR. CDV

S317 was administered at the dose of 5mg/kg/week intravenously (i.v.) in 41 pts and intravescically in 21 pts (4 double treatments). The median dose number of CDV doses was 2 (range 1 to 8).

Results: HC occurred in median 14 days after allo-SCT (range -4 to 330). Median duration of symptoms was 34 days (range 6 to 166). At treatment onset 13 pts had grade 0-I HC, 13 grade II, 24 grade III and 9 grade IV. In 55 cases (93%) high BK viral load was detected in urine (BK virus median load 10 7 cp/ml) before treatment.

After treatment the reduction of BK viruria was documented in 29 out of 33 evaluable cases (87%). Improvement of HC grade was observed in 41 pts (70%) and a complete clinical response within 7 days from last CDV dose was observed in 30 cases (51%). Worsening of HC leading to urological intervention occured in 5 treated pts. Four pts died with an ongoing uncontrolled HC: 2 of acute Graft-versus Host Disease, 1 of pneumonia and 1 of relapse. During i.v. CDV treatment 22 pts (54%) had a viral reactivation (Cytomegalovirus n=14, Epstein-Barr Virus n=8, Herpes Simplex-1 n=3, Herpes Simplex-6 n=4) and 2 pts developed acute renal failure requiring drug discontinuation. Conclusions: CDV treatment after allo-SCT is associated with a reduction of BK viruria load and HC clinical responses in more than half of cases. Viral reactivations under CDV treatment should be better investigated in the allo-setting, since the long-half life of the drug and its potential nephrotoxicity limits the possibility of concomitant antiviral therapy with other agents. Our data warrant prospective randomized trials to investigate the role of CDV in allo-SCT.

We have previously shown that human cytomegalovirus (HCMV) reactivation infl uences NK cell reconstitution in adults receiving intrabone umbilical cord blood transplantation (UCBT). With this rationale, we designed a study to compare NK cell reconstitution in pediatric patients undergoing haploidentical (after depletion of both α/β+ T cells and CD19+ B cells) hematopoietic stem cell transplantation (haplo-HSCT) for hematological malignancies who did or did not experience HCMV reactivation. These patients were also compared to a group of patients who were given either intrabone or iv UCBT. Twelve children given i.v. UCBT, 26 children given haplo-HSCT and 14 adults receiving intrabone UCBT were included in this study and analyzed up to 1 year after HSCT. Peripheral blood samples were collected at 1, 3, 6 and 12 months after transplantation. In agreement with the fi ndings observed in adults given intrabone UCBT, also in haplo-HSCT patients, NK cells achieved a fully diff erentiated stage of maturation more rapidly when a HCMV reactivation occurred. Indeed, a relevant fraction of NK cells expressed a mature phenotype characterized by the KIR+NKG2A-signature 3 months after transplantation in patients undergoing HCMV infection/reactivation (see fi g. 1). However, since in haplo-HSCT patients the graft contains donor-derived NK cells, we cannot exclude that a fraction of mature NK cells found in the recipients represents long-lived NK cells derived from the donor. At diff erence with UCBT patients, in haplo-HSCT recipients we did not observe a signifi cant expansion of the CD56-CD16+ NK cell subset, which represents an aberrant and usually hyporesponsive subset. Remarkably, in all cohorts of patients, we detected the emergence of highly diff erentiated NK cells characterized by the NKG2C+CD57+ phenotype, when HCMV infection occurred. This NK cell subset, that has already been described in both HSCT and solid organ-transplant recipients after HCMV reactivation, could harbour "memory" or "long-lived" NK cells.

Our results indicate that HCMV infection/reactivation, by providing stimulatory signals to NK cells undergoing maturation, drives NK-cell development in patients who do not receive antigen-experienced, donor T cells, such as those given haplo-HSCT or UCBT. Moreover, this favourable infl uence on NK cell development could promote the emergence of "memory" or "long-lived" NK cells able to protect patients from infections and maybe from leukemia recurrence. (1) (1) (

Objective: The spectrum of infections that develop among patients who receive unmanipulated, G-CSF-primed bone marrow transplantation from a haploidentical family donor has not been described. Therefore, we evaluated incidence and type of infections occurring in this setting during the fi rst 100 days after transplantation. Methods: Data regarding infectious episodes and outcome during the fi rst 100 days after transplantation were retrospectively analyzed for 53 consecutive patients (30 in complete remission and 23 in refractory or recurrent active disease) undergoing haploidentical BMT. Results: The probability of overall survival for patients at 100 days post-haploBMT was 83%(s.d.+5). The 100-day cumulative incidence of grade II-IV acute GVHD was 30, 2% (s.d.+4). We observed 63 viral infections in 43 patients, 60 bacterial infections in 53 patients and 10 fungal infections in 8 patients. Furthermore, 40 out of 53 patients (75%) reactivated Cytomegalovirus infection, and 20 patients (38%) showed BK viruria. Encephalitis occurred in 2 patients due to JCV and BKV, respectively. A vesicular rash due to adenovirus was documented in 1 patient. Twenty-six (49%) patients had septicemia with or without septic shock, 30 (56%) patients had catheter-related infections, 17 (32%) patients had pneumonia (2 due to infection with a K. pneumoniaecarbapenemase producer and 1 with Chlamydia pneumoniae) and 1 patient had meningitis. One proven, 4 probable, and 3 possible fungal infections were documented in 8 (15%) patients. Overall, 9 of 53 (17%) patients died within 100 days after transplant. For 8 of these 9 patients (4/30 in the complete remission group, 4/23 in the active disease group) an infectious disease (1 hepatic abscess, 3 cases of septicaemia, 2 cases of encephalitis, 1 case of pneumonia, and 1 case of haemorrhagic cystitis) was the main cause of death. The infection-free survival at 100 days was 85%. Conclusion: Fifteen per cent of the patients studied died from infections during the fi rst 100 days post-transplant. No diff erences in the percentage of subjects died for infection were observed between standard and high risk group of patients.

Predictors for invasive fungal infection in paediatric allogeneic haematopoietic stem cell transplantation recipients J. A. Hol, T.F.W. Wolfs, M.B. Bierings, C.A. Lindemans, A.B.J. Versluys, A. De Wildt, C.E. Gerhardt, J.J. Boelens UMC Utrecht (Utrecht, NL) Background: Invasive fungal infection (IFI) remains an important cause of transplant-related mortality amongst hematopoietic stem cell transplantation (HSCT) recipients. To improve outcome after HSCT, we need to identify patients who are most at risk. This study was aimed to fi nd predictors of IFI after pediatric allogeneic HSCT. Patients and methods: All children who received allogeneic HSCT in the Wilhelmina Children's Hospital Utrecht between January 2004 and July 2012 were included. HSCT data were prospectively collected. Probable and proven IFI were classifi ed according to EORTC/MSG criteria. We retrospectively classifi ed all patients into high or low risk groups for developing IFI using pre-and post-HSCT criteria, based on available literature. We analyzed predictors for the occurrence of IFI, our main endpoint, using Cox regression models. We used logistic regression models to analyze the association between other HSCT related complications and IFI. Other outcomes were overall survival (OS) and treatment related mortality (TRM). Results: 209 patients were included: 105 malignant and 104 nonmalignant. Donors were 98 cordblood, 54 family/sibling donor and 57 unrelated marrow. Median age was 6.6 years (range 0. 2-22.7) . The cumulative incidence of proven and probable IFI was 12% (n=25). Within patients classifi ed into the high risk group to develop IFI (n=88), 15 patients (17.0%) developed IFI. 52 patients became high risk during post-HSCT course, of which 9 patients (17.3%) developed IFI. In patients classifi ed as low risk (n=69), only 4 (5.8%) developed IFI (OR 0.325; p 0.047). In multivariate analysis, predictor for the occurrence of IFI was an a priori TRM risk >20% (based on EBMT-risk score). Logistic regressive results showed an association between the administration of high dose steroids and the occurrence of IFI (OR 4.458; p 0.010). Patients who developed IFI showed an increased risk of treatment related mortality (TRM) (OR 6.299; p 0.00), and subsequently the overall survival (OS) was lower (p=0.006). Conclusion: We demonstrated that risk group stratifi cation for developing IFI using criteria based on available literature, correlated well with the actual occurrence of IFI in children after HSCT. Pre-HSCT predictor was an a priori TRM risk >20%. Post-HSCT the use of high dose steroids was strongly associated with development of IFI. Risk group stratifi cation should guide intensity of monitoring for IFI and use of anti-fungal prophylaxis.

Clinical effi cacy and management of primary antifungal prophylaxis with posaconazole in high-risk haematology patients I. Sánchez-Ortega (1), I. Cuesta (2) 

We have previously reported the use of posaconazole antifungal prophylaxis in a small series of 33 early phase alloHCT [BMT2011; 46(5):733-9]. Now, we present our experience on the effi cacy and clinical management of primary antifungal prophylaxis with posaconazole in 262 consecutive high-risk episodes (161 AMLchemotherapy, 79 alloHCT and 22 grade II-IV GVHD) from 123 hematology patients prospectively included in a single-center study (2007) (2008) (2009) (2010) (2011) ; CEIC Bellvitge; EPA 008/08). Our management algorithm included a comprehensive diagnostic approach for patients with persistent fever (CT scans, microbiological samples and cultures from urine, blood, BAL and other infected sites), as well as preemptive serum galactomannan (GM) tests twice weekly from the start of the risk episodes. Breakthrough IFD as per EORTC criteria occurred in 10 episodes (3.8%, Table 1 ): 5 invasive candidiasis (1.9%; 3 glabrata, 2 tropicalis) and 5 invasive aspergillosis (IA=1.9%; 1 proven, 4 probable), 8 after AML-chemotherapy and 2 in alloHCT/GVHD, leading to 4 IFD-related deaths (1.5%). Of note, 2 cases of IA occurred during an outbreak and co-infection with H1N1. Posaconazole was substituted for IV antifungal therapy in 34 additional episodes (13.0%) based on an individualized clinical judgment for persistent fever, intolerance or side-eff ects. The vast majority of episodes (218, 83.2%) completed posaconazole prophylaxis as planned. A total of 2972 serum GM tests were performed in this study (median 11 per episode, , and were all negative in the majority of episodes (188, 71.7%). Positive GM results contributed to the diagnosis of all 5 episodes of IA reported. Also, positive GM tests were documented in 30 additional episodes (11.4%) where patients remained on posaconazole prophylaxis, alive, and never developed other criteria of IFD. Such false positive (FP) GM tests (1-6 per episode; optical index 0.59-6.11) were more common when performed preemptively in asymptomatic cases (26, 86.7%) than as part of a diagnostic workup in persistently febrile symptomatic patients (4, 13.3%; p<0.001). Our results confi rm the effi cacy of posaconazole prophylaxis in high-risk hematology patients in real-life clinical practice. They also suggest that,

S319 in this context of very eff ective anti-mold prophylaxis with a low incidence of IA, serum GM should be preferably used as part of diagnostic algorithms for symptomatic cases, rather than as a preemptive surveillance in asymptomatic patients.

Chronic myeloid leukemia (CML) is a clonal disorder associated with chromosomal translocation t (9; 22). The fusion gene encodes for the chimeric oncoprotein BCR-ABL, associated with deregulated constitutive tyrosine kinase (TK) activity, leading to leukemogenesis. The second generation TK inhibitor (TKI) Nilotinib (Novartis, East Hanover, NJ) is an aminopyrimidine derivative of imatinib with an increased binding affi nity to the chimeric p210 BCR-ABL, recently approved for upfront use in CML. Allogeneic stem cell transplantation (SCT) is currently reserved for patients (pts) in CP after the failure of second line TKI or for patients in advanced phase disease. SCT remains the treatment of choice in patients with Ph+ALL. TKIs can be used successfully pre -SCT as a bridge to SCT in advanced disease and post-SCT in order to prevent disease recurrence. HCMV is one of the leading causes of morbidity and mortality post SCT in particular in pts transplanted for advance CML and pts with graft vs. host disease (GVHD) While, preemptive antiviral therapy has reduced the occurrence of HCMV disease post SCT, the use of all currently available antiviral drugs is often limited by toxicity, low oral bioavailability, and drug resistance. The mechanisms facilitating HCMV entry into the host cells are not clearly understood. Blocking the platelet -derived growth factor receptor-α (PDGFRα) has been shown to inhibit HCMV internalization and gene expression. Recently, Imatinib has been shown to inhibit PDGFRα phosphorylation. As Nilotinib is a more potent PDGFR inhibitor, we assessed the in vitro antiviral activity of Nilotinib against HCMV. Nilotinib exhibited a signifi cant dosedependent inhibition of the virus upon pre-incubation with the drug. Moreover, Nilotinib demonstrated a ~4.5-fold higher antiviral activity against HCMV when compared to imatinib, with IC50 values of 0.39 μM and 1.75 μM, respectively. No viral inhibition was found upon addition of the drugs after viral adsorption -compatible with inhibition of an early step of infection, invoving viral binding/entry into the cell. These fi ndings identify a promising new target for antiviral therapy, representing an alternative paradigm for treatment with compounds combining anti-cancer and antiviral activity. The potent anti-HCMV activity demonstrated for Nilotimib may be of clinical relevance in patients with advanced CML undergoing SCT. (1) Monocyte-derived Dendritic Cells (moDCs) have been traditionally used as vaccines capable of eliciting specifi c T cell responses against tumors and infections. Another innate immune eff ector cell, Natural Killer (NK) cells, endowed with antitumor and antiinfection capacities, have been adoptively transferred to treat against malignancy and pathogens. In our study, we investigate the potential of Aspergillus fumigatus derived β(1,3)glucan (BG) pulsed moDCs as NK cell manipulators, which might give new perspectives in optimization of DC based vaccines. DCs were generated from positive selection of CD14+ cells from peripheral blood mononuclear cells (PBMCs) and cultured for 5-6 days in serum-free GMP grade medium supplemented with GM-CSF and IL-4. On day 2, immature DCs (iDCs) were maturated (mDCs) with BG or Tumor Necrosis Factor-α (TNF-α). DC profi le was characterized by quantifying the expression of CD1a, CD14, CD40, CD80, CD83, CD86, HLA-I, HLA-DR, CCR7, Dectin-1, IL12p35 and IL15. Autologous NK cells, obtained by negative selection of PBMCs were cocultured with DCs for 24h at a ratio of 1:1. After coculture, NK cells were studied for the expression of defi ned markers, among them were CD69, HLA DR, CD25, CD83, CCR7, cytokines (interferon γ, IFN-γ), transcription factors (T-bet). NK cell cytotoxicity was evaluated against the leukemic cell line K562 via the degranulation marker CD107a. Results: DC-NK cell interaction further increased the expression of costimulatory molecules and HLA antigens as well as the release of IL12p35 onmDCs. In parallel, mDCs stimulated NK cells stronger than iDCs and they potentiated the cytotoxic capacity of NK cells towards K562. In addition, mDCs induced the

S320 expression of HLA DR, CD25 and CD83 on NK cells. Interestingly, this eff ect was signifi cantly higher when NK cells were stimulated by BG mDCs than with TNF-a mDCs. Using neutralizing antibodies against Dectin-1, which is the receptor of BG on DCs, we observed a decrease of the stimulatory capacity of BG mDCs. Our study proposes the NK cells as a new target for DC vaccination. By comparing the classical DC maturation adjuvants, BG showed to escalate the stimulatory eff ect of DCs towards NK cells. Furthermore, BG mDCs induce the expression of a specifi c NK cell profi le which could promote the interaction of NK cells with T cells. These data might be relevant for the design of DC vaccines and future immunotherapeutic strategies against cancer and infections.

Therapeutic nucleic acid ligands: a potential source of interference with concomitant antiviral therapy T. Yang (1) An increasing number of nucleic acid based drugs achieved FDA approval and entered clinical trails (e.g. "antisense" or "immunostimulatory CpG" oligodeoxynucleotides (ODNs), aptamers, ribozymes, RNA interference or defi brotide). But so far, no or not much information is available whether these compounds might i) compete with chemically and structurally related drugs, e.g. nucleoside analogues (NA) widely used in cancer or antiviral therapy, or ii) interfere with the intracellular nucleic acid metabolism.

In the present report we provide evidence that defi brotide (DF), a polydisperse mixture of single-stranded oligodeoxyribonucleotides (15 to 30 kD), e.g. used for treatment of hepatic veno-occlusive disease and other endothelial disorders, antagonizes antivirals (e.g. acyclovir or ganciclovir) in vitro and in vivo. In standard drug resistance assays, using either an acyclovir sensitive herpes simplex virus (HSV) strain (V0631508) or the ganciclovir sensitive murine γherpesvirus 68 (MHV68), 4 μM of DF restored viral replication in the presence of 25-50 μM acyclovir and ganciclovir, respectively. This was confi rmed by quantitative PCR of viral DNA. In case of acyclovir, deoxythymidine turned out to be the main competitor for intracellular phosphorylation mediated by virus thymidine kinase. To further extent our fi ndings, MHV-68 infected mice were treated with ganciclovir (25mg/kg/day) in presence or absence of DF (10mg/kg/day). After 4 days of treatment, mice were sacrifi ced and the genomic load of MHV 68 was determined. Here, a signifi cant increase (p > 0,05) of viral replication in the presence of DF was observed. Taken together, these data strongly suggest that treatment with nucleic-acid-based drugs might interfere with concomitant antiviral therapy. 

Background: Epstein Barr Virus (EBV) disease is a well-known complication in the transplant setting. Routine monitoring of EBV DNA-emia (referred to as viremia) by quantitative polymerase chain reaction (PCR) and pre-emptive Rituximab therapy are recommended in high-risk patients. We conducted a study to analyse the results of EBV monitoring in a consecutive cohort of these high risk patients. Methods: We prospectively monitored all patients considered at high risk for EBV reactivation and Post-trasplant Lymphoproliferative Disease (PTLD) during the fi rst 6 months after SCT (alternative-donors, T-cell depletion (TCD) and/or severe refrac-tory acute graft versus host disease (aGVHD) by quantitative PCR between 2006 and 2012. Rituximab was given as pre-emptive therapy (375mg/m2 intravenously) for EBV viremia (>1000 copies/ml in whole blood). Results: After a median follow-up of 609 days, 27 of the 131 patients included (21%) developed EBV viremia, for a 1-year incidence of 28.5% (95% CI:18.7-38.3) at a median of day +72 and 12 (9%) developed PTLD for a 1-year incidence of 13% (95% CI:5.8-20.2) at a median of day +90. Factors associated with EBV reactivation and EBV-PTLD in univariate analysis were the same: absence of Rituximab administration before haematopoietic stem cell transplantation (HCT) (p=0.1 and p=0.01), prior HCT (p=0.02 and p=0.03) and TCD (Campath or ATG) in the 6 months before HCT (p=0.03 and p<0.01), respectively. In multivariate analysis, the factors associated with higher risk of EBV reactivation and PTLD were: prior HCT [HR 4.9 (95% CI:1.2-19.9; p=0.03) and HR 2.5 (95% CI:1.2-5.5; p=0.02)] and TCD during the 6 months pre-HCT [HR 3.4 (95%CI: 0.9-13) p=0.07) and (HR 6.4 (95%CI:2.3-18) p=0.01], respectively. The 2-year overall survival (OS) was 41% (95% CI: 32-50) and EBV reactivation was not associated with impaired survival (p=0.4). EBV-PTLD was considered the primary cause of death in 4 patients. Comments: The incidence of EBV reactivation and PTLD in our high risk population was 28.5% and 13% respectively. The risk factors associated with their appearance were previous HCT and use of T-cell depletion during the 6 months pre-HCT. The development of EBV reactivation does not seem to be associated with lower OS in the pre-emptive Rituximab-strategy setting. (4), M. Zitkova (5) , Z. Racil (5) , M. Labudikova (6) , J. Vitkova (6) , L. Raida (6) , I. Skoda-Gorican (7), M. Sever (7), J. Pretnar (7), D. Hrabankova-Navratilova (8) Introduction: HEPA fi ltration is designed to minimize airborne microbial contamination and is generally recommended for HSCT. Because probably not every transplant center is able to provide it and because more data about the incidence of pneumonia and mortality are warranted, we decided to conduct the following survey. Methods: Prospective observation. Specifi c monitoring cards distributed within Central and East European transplant centers in cooperation with the East Forum EBMT-Nurses Group. Results: In 1/2012-6/2012, total 689 consecutive patients were included into the observation. In the autologous HSCT group (n= 400) the pneumonia developed in 14/400 (3,5%) till day +100 post-transplant (median day +9 (-3 ±50)), and was the cause of death in 2/14 (14%) of aff ected patients. There were 239/400 (59%) HSCT performed in single-bed rooms (190/239 HEPA fi ltered) and 161 (41%) in two-beds room (28/161 HEPA fi ltered). There was no diff erence in general mortality till day +100: 4,5% in HEPA vs. 4,9% in non-HEPA fi ltered rooms (p=1,0). In the allogeneic HSCT group (n=289) the pneumonia developed in 24/289 (8,3%) till day +100 post-transplant (median day +11(-2 ±75)), and was the cause of death in 11/24 (45%) of aff ected patients. There were 281/289 (97%) of the Allogeneic HSCT performed in singlebed rooms (254/281 HEPA fi ltered) and 8 (3%) in two-beds room (without HEPA fi ltration). The only important and almost statistically signifi cant risk factor for pneumonia development (p=0,05) was corticosteroids treatment for GVHD. There was no diff erence in general mortality till day +100: 14% in HEPA vs. 17% in non-HEPA fi ltered rooms (p=0,6). Conclusion: incidence of pneumonia till day +100 in the autologous HSCT setting is generally very low and autologous HSCT may safely be performed in two-beds rooms and in rooms without HEPA fi ltration. Twice more pneumonia infections were observed in the allogeneic HSCT, especially in patients on corticosteroids, with high mortality rate and predominant fungal etiology. No signifi cant impact of HEPA fi ltered rooms on mortality rate was observed in both autologous and allogeneic HSCT. The limitation of our observation include various antimicrobial prophylaxis used, no data on air-fl ow direction and air-pressure positivity in the rooms, and low presence of non-HEPA rooms in allogeneic HSCT setting in general. Introduction: Invasive fungal infections cause signifi cant morbidity and mortality in HSCT recipients. Although fl uconazole has been widely used for antifungal prophylaxis in these patients, it is not eff ective against invasive aspergillosis. Micafungin provides antifungal activity against Candida and Aspergillus species, and previous studies have demonstrated its effi cacy when used as a prophylactic agent for fungal infection in neutropenic patients.

Here, we evaluated and compared the incidence rate of proven or probable invasive fungal infections (IFIs) with antifungal prophylaxis using micafungin or fl uconazole. Methods: This is a prospective, single center, phase II, ongoing study involving adult patients who receive allogeneic or autologous HSCT. Patients were randomly assigned to micafungin (50mg/day i.v) or fl uconazole arms (400mg/day p.o.) in the ratio of 2:1. The treatment was initiated within 24 hour of stem cell infusion, and lasted for up to 21 days of post-transplantation. Results: Between March 2010 and August 2012, a total of 74 patients were enrolled (micafungin, n=54; fl uconazole, n=20). The main underlying disease for allogeneic transplantation (n=64) were acute myeloid leukemia (39%), acute lymphoid leukemia (27%) and myelodysplastic syndrome (11%); and multiple myeloma was the most common reason (60.0%) for autologous transplantation (n=10). Baseline characteristics were compared, and there was no signifi cant diff erence in gender, transplantation type (allo vs auto), donor (sibling vs unrelated) and conditioning intensity (myeloablative vs reduced intensity) between two treatment arms. During study period, proven or probable IFIs were identifi ed in 7 of 54 for micafungin arm (13%), and 3 of 20 for fl uconazole arm (15%) (p=1.0). Overall mortality at 100 days after transplant was 14.9% (11/74), and patients who experienced proven or probable IFIs showed signifi cantly higher mortality (6/10, 60%) than patients who did not (5/64, 7.8%) (p<0.001). Among treatment arms, 100-day mortality following HSCT was higher in fl uconazole arm (4/20, 20%) compared to micafungin arm (7/54, 13%), although there was no statistical signifi cance (p=0.474). Conclusion: In this preliminary result, the incidence of proven or probable invasive fungal infections (IFIs) in HSCT recipients with micafungin prophylaxis was comparable to that of fl uconazole prophylaxis.

Objectives: Invasive aspergillosis (IA) is a frequently lifethreatening complication of allogeneic haematopoietic stem cell transplantation. Recent epidemiologic studies suggest an incidence of 5-10%. It is now recognised that in addition to cases occurring during the neutropenic post-transplant phase there is a late peak of cases who have chronic graft-versus-host disease (GVHD) and are receiving steroid or other immunosuppressive therapy. There has been an increasing focus on what host immune factors may account for individuals' susceptibility to IA. We investigated circulating monocytes from this cohort of patients compared with circulating monocytes from healthy controls in a pilot study to determine their ability to phagocytose A. fumigatus (Af ) conidia. Methods: After providing informed consent 7 adult patients with grade II-III chronic GVHD, requiring steroid or other immunosuppression, and 7 healthy volunteers respectively donated 30ml blood each from which monocytes were harvested using the method described by Serbina NV et al, J Immunology 2009, vol 183,pp 2678-87. Briefl y, monocytes were purifi ed and selected using MACS reagents and CD14 magnetic beads and next stained with anti-CD14 label. Af were diff erentially labelled with Alexa-Fluor 647 succinimidyl ester dye. Conidia and monocytes were co-incubated for 3 hours in a ratio of 2:1 following which the numbers of conidia ingested was determined using FACS analysis and confocal microscopy. Viability of the ingested conidia was determined by standard plating on agar medium and counting the number of colony forming units (CFU). Supernatants from each interaction were collected at times 0h and 3h, frozen, and later analysed for pro-infl ammatory cytokines using a 7-plex assay (Meso Scale Discovery).

Results: There was no diff erence between donors and patients in the number of conidia ingested by monocytes. However an analysis of the ability of monocytes to kill Af conidia showed there was a reduced killing (expressed as median% conidia killed for each cohort) by patients' monocytes compared with donors' monocytes. The cytokine experiment revealed that patients' pro-infl ammatory responses were impaired; in particular interferon γ and IL-12 responses were reduced at 3h compared to controls. Conclusion: The study of circulating monocytes' responses to Af deserves further investigation as a potential biomarker of susceptibility to IA in patients with chronic GVHD. Background: We previously reported (EBMT 2003 ) that in our pediatric transplant unit (1993 to 2002), the incidence of proven invasive aspergillus (IA) was low, occurred early in the transplant period and survival was compromised in those receiving serotherapy. Since then, Dutch pediatric oncology recommendations for screening, drug therapeutic monitoring (DTM) and recognition of azole resistance has resulted in changes in management strategy. Methods: We reviewed data from January 2003 to July 2012 and compared the results to our previous study, to determine whether recent strategies have altered outcome for children with IA undergoing hematopoietic stem cell transplantation (HSCT). Results: The comparative data sets for children undergoing HSCT in our unit with proven IA are summarized in Table 1 .

Although infection rate remains low in our unit we have noted a dramatic change in the timing of occurrence of documented IA compared to our earlier observations (median of 66 days v 13 days resp.). Children with late onset IA (>50days post ) were more likely to have undergone unrelated donor HSCT and have associated graft dysfunction (i.e. failure or delayed engraftment). In contrast to earlier observations, survival is no longer limited to those children undergoing identical related bone marrow transplantation. Two patients received preemptive granulocyte transfusions (GT) to facilitate a successful transplant, a treatment not readily available in the previous era. Three patients developed proven azole resistant IA and as testing was not available in the previous study no comparisons can be made. DTM revealed the majority of children required dose adjustment to achieve therapeutic prophylactic doses of either itraconaozole of voriconazole. Again no comparison can be made with earlier observations. Conclusion: Proven IA remains an uncommon event in our unit and mortality is low (2%). Changes in clinical practice have seemingly aff ected the timing of presentation. Patients with leukemia and aplastic conditions receiving azole prophylaxis prior to referral, with dose optimization by DTM, may have reduced early HSCT infection. Our study shows that graft dysfunction is a risk factor together with GVHD for the occurrence of IA. We recommend close microbiological monitoring and prophylaxis with rigorous DTM control in this specifi c post transplant group. Azole resistance and its impact on survival remain unclear and is presently being closely monitored on a national basis.

International multicentre data gathering for the establishment of a database and a radiologic software that can be used for the diff erential diagnosis of brain lesions of a suspected infectious origin F. Zennaro (1), D. Zanon (1), D. Grosso (2) , T. Minuzzo (3) , N.

At present the diagnosis of infections at brain level is the most complex of all, both because of the location, hard to reach with the interventionist diagnostic techniques and of the diffi culty of interpreting radiologic images.

Considering that brain infections in oncohaematologic patients undergoing chemotherapy or a transplant of haemopoietic stem cells (HSC), and therefore seriously immunosuppressed, are those with the worst prognosis, it is very important to make the interpretation of the diagnostic imaging techniques currently in use easier and more homogeneous, thus making it possible to apply targeted treatments in the shortest time possible. The Brain Supporters Project aims at creating an international data base capable of gathering an extensive collection of radiologic images of brain lesions together with the relevant clinical, laboratory and microbiological data. Starting from this data base the possibility is envisaged to develop an "intelligent" software that through the use of multi-dimensional analysis techniques, variational methods and classifi cation procedures taking advantage also of neural networks and Bayesian forecasting models, can detect, highlight and diff erentiate the minimal and yet peculiar diff erences in the "radiologic footprint" connected with the local alterations of brain tissue produced by each individual pathogen, thus becoming an objective diagnostic aid not infl uenced by the individual interpretation given by the operator. An internet site will be created, www.brainsupporters.eu, freely accessible to oncohaematologic centres world-wide. The radiologic images with confi rmed diagnosis collected in the data base will then be subject to a blind evaluation (without knowing the microbiologic diagnosis) by a team of specialists belonging to at least two of the Centres taking part in the project, so as to obtain an independent confi rmation of the diagnosis. The images will then be classifi ed by aetiologic agent and subsequently by age group and by clinical characteristics of the patients. It will thus be possible to evaluate if and how the "radiologic footprint" of lesions due to the same pathogen is modifi ed depending on the diff erent characteristics of the host. All the images collected, suitably classifi ed by pathogen and subdivided in accordance with the diff erent host characteristics, will become part of a gallery, accessible on line, having advanced research and image comparison functions. S323 infection. Patients's features were outlined in Table1. The initial dose of VGC was 900 mg bid until obtaining undetectable level of CMV copy, and the dose of 900 mg in a day continued additionally one or two weak. We routinely have screened 1 or 2 times a week for CMV. Preemptive treatment was initiated for CMV infection when detected two consecutive positive tests of quantitative polymerase chain reaction for CMV (QIAsymphony SP, QIAGEN, Valencia, CA). Results: CMV infection was detected in median of 42 days (42-400 days). Median duration of infection was 26 days. Most of patients (n=49) were successfully treated by oral VGC. We switched oral VGC to parenteral GCV treatment in two patients for increasing copies of CMV during the treatment. Relapse of CMV infection after VGC therapy detected in 4 patients (%8). But we used VGC therapy again in 3 patients. We observed no CMV disease in early or late period. Severe hematological toxicity was observed in two patients (% 4) that required drug discontinuation. Additionally oral VGC following cessation VGC treatment due to markedly decreasing copies was used in 15 patients. Relapse was observed in only one patient after cessation of VGC therapy in this group. No patients developed severe hematological toxicity. Conclusion: Preemptive oral VGC for CMV infection after allo-HSCT should use safely and eff ectively. Nevertheless, prospective randomized trials should be done to yield defi nitive results. Results: There were no statistically signifi cant diff erence between the two treatment arms (n=119; 68 fl uconazole, 51 posaconazole) for any demographic variables, duration of neutropenia, steroid therapy, and duration of antifungal prophylaxis. Patients who received posaconazole had a lower incidence of proven or probable breakthrough IFD within the fi rst 100 days of allo-HCT as compared to those on fl uconazole (2% vs 15%; p=0.018). While the two drugs were generally well tolerated, mucositis (posaconazole 11.8% vs fl uconazole 0%; p=0.005) and liver toxicity (posaconazole 3.9% vs fl uconazole 0% p=0.18) leading to temporary discontinuation was only seen in posaconazole recipients. Death attributable to fungal infections was seen in 1 (2%) posaconazole recipient and 1 (2 %) fl uconazole recipient (p>0.05). Kaplan Meier analysis of survival at 100 days of transplant was similar between the treatment arms (posaconazole 92% vs fl uconazole 88%; p=0.48). Conclusion: Our experience suggests that posaconazole probably confers better protection against IFD during the early phase of allo-HCT. The issue of mucositis leading to temporary discontinuation of antifungal prophylaxis in posaconazole recipients remains a major concern and may be resolved with intravenous preparation.

[P960]

Computed tomography pulmonary angiography (CTPA) for the diagnosis of invasive mould disease in recipients of allogeneic haematopoietic stem cell transplantation E. Lewis, M. Stanzani, G. Battista, C. Sassi, P. Viale, F. Bandini, F. Bonefazi, M. Arpinati, M. Cavo, N. Vianelli University of Bologna (Bologna, IT) Background: Serum galactomannan (GM) antigen is routinely used to aid the diagnosis of invasive aspergillosis, but the sensitivity of the test is reduced in recipients of allogeneic HSCT (allo-HSCT) and with antifungal prophylaxis. Methods: We examined the sensitivity and specifi city of a pulmonary vascular occlusion sign visualized by CTPA in allo-HSCT patients with a diagnosis of possible, probable or proven invasive mold disease (IMD) according to EORTC/MSG defi nitions. Patients who received allo-HSCT (n=20) for AML/MDS (n=8), ALL (n=7), lymphoma (n=1), or chronic myelodysplastic syndromes (n=4) underwent CTPA if they had a lesion on initial CT scans suggestive of IMD. IMD diagnosis was subsequently confi rmed on the basis of culture, histopathology and/or antigen results. Results: CTPA was positive in 16/20 of patients, 13 of whom eventually met EORTC/MSG defi nitions for proven or probable IMD (12 Aspergillus, 1 Mucormycosis + Aspergillus). The remaining 3/20 of CTPA positive patients had possible IMD. Among the 4 CTPA negative patients, 3 had bacterial pneumonia, and 1 patient had probable IMD based on GM antigen and CT. In CTPA positive patients, GM antigen was positive in serum of 12/16, and in the bronchial alveolar lavage (BAL) fl uid of 4/4 patients. Considering only proven or probable IMD, a positive CTPA fi nding had a sensitivity (92%), specifi city (50%), positive predictive value (81%) and negative predictive value (75%) for IMD. Conclusions: CTPA may be an alternative to serum or BAL GM antigen testing for establishing the diagnosis of probable or proven IMD in allo-HSCT patients. Allogeneic stem cell transplantation (SCT) expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. The control of persistent pathogens such as cytomegalovirus (CMV), adenovirus (ADV) and Epstein-Barr-virus (EBV), will ultimately depend on the restoration of adequate T-cell immunity.

Risk of viral complications is even higher under GvHD treatment or prophylaxis. The virus-specifi c T-cell responses in peripheral blood have been shown to be a good marker of immunological protection, but have not been used for clinical decision making and the guidance of drug plasma levels. Therefore, we performed a prospective clinical trial in and tested 95 samples from adult and pediatric patients after SCT receiving pharmacologic immunosuppression with steroids, Cyclosporin A, Tacrolimus or Mycophenolate. T-cell responses were compared to patients without immunosuppression. T-cell responses were analyzed ex vivo against pp65 (CMV), hexon (ADV) and EBNA, LMP (EBV) using intracellular cytokine staining and CFSE. The T-cell responses in vitro under low, high and supraphysiologic plasma concentrations of the respective drugs were investigated. Under the direct infl uence of steroids, activated, virus-specifi c T-cells underwent apoptosis. Cyclosporin had the strongest inhibition on virus-specifi c T-cell immunity, whereas low therapeutic levels allowed T-cell responses to develop. Relevant diff erences in the frequencies of virus-specifi c T cells could be detected in correlation to the level of immunosuppression. The use of multiple immunosuppressive drugs leads to a reduction in the number of patients with detectable antiviral T-cell responses whereas the strength of T-cell responses (if present) was neither infl uenced by the type nor by the number of immunosuppressive drugs. Therefore detection of virus-specifi c T-cell responses but not the amount of IFN-γ production could be used to guide the level of immunosuppression in case of viral complications after SCT. In conclusion we could show that detection of virus-specifi c T-cells could be used to guide the level of immunosuppression in case of viral complications after allogeneic SCT, since emergence of in vivo T-cell responses was closely associated with a clearance or reduction of the viral load. (1) (1)United St. Istvan and St. Laszlo Hospital (Budapest, HU) ; (2) Semmelweis University (Budapest, HU) Introduction: Despite improved anti-infective strategies bacterial infections still remain a major cause of morbidity and mortality in immunocompromised children. In the ever changing world of bacterial resistance selection of an optimal antibiotic treatment has become challenging. 

Increased risk of CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation: experience of a single centre G. Console, G. Messina, M. Martino, R. Fedele, T. Moscato, E. Spiniello, A. Pontari, M. Cuzzola, G. Irrera Centro Trapianti Midollo Osseo (Reggio Calabria, IT) Introduction: Mycophenolate Mofetil (MMF) is increasingly used for prophylaxis and therapy of GVHD in allogeneic stem cell transplantation. In some reports of use of MMF in solid organ and bone marrow transplantation a high incidence of CMV disease has been described. Aim of the study: we evaluated the frequency and course of active CMV infection in patients who received MMF compared to who received Methotrexate ( Glass, V. Bastubbe, S. Dingeldein, M. Nickelsen, M. Zeis, N. Schmitz Asklepios Klinik St. Georg (Hamburg, DE) Patients with severe acute or chronic GVHD undergoing intense immunosuppressive therapy have a high risk of severe opportunistic infections frequently determining outcome. Invasive fungal infections (IFI), especially invasive aspergillosis, are frequent and often fatal in such patients. In recent years substantial progress has been made in prophylaxis and treatment of IFI. Posaconazole given prophylactically in patients with severe GVHD has been shown to decrease the incidence of IFI and death attributed to fungal disease in a prospective randomized study. We retrospectovely analyzed whether posaconazol prophylaxis was eff ective in reducing fungal infections in a large allogeneic program. From January 2008 to July 2011 we treated 80 episodes of either acute GVHD grade II-IV or chronic GVHD in 53 patients who received prednisolone at doses of more than 0.5 mg/kg BW. The median age was 52.5 years (19.8 -73.7 years), the median duration of corticosteroid application was 44.5 days (3 -308 days), the median duration of inpatient treatment was 19.2 days (4 -98 days) Our institutional standard operating procedures recommend the use of prophylactic posaconazole (200 mg tid) which was given in 52 of 80 cases. In 28 cases we decided against posaconazole because a less intensive immuno-supression was anticipated at start of prednisolon treatment. In fact this group showed showed a shorter duration of treatment(median 36 vs 46 days) and a lower number of patients with of prolonged usage ( > 44 days) of prednisolone (39 vs 56%) as compared to the other patients . In 16 of 52 cases (30.8%) with posaconazole prophylaxis an interventional treatment with either caspofungin ( 7 cases) or voriconazole (9 cases) was started. FUO / sepsis were the main reasons to start treatment in 8 cases, pneumonia was the leading condition in other 8 cases. Two patients received second-line treatment ( 1 case caspofungin after voriconazole, 1 case voriconazole after caspofungin). In 5 out of 52 cases (9.6%) the EORTC criteria of a possible IFI were fulfi lled. There were no cases of a probable or proven IFI. There was no death attributable to IFI. In patients with severe GVHD and intensive immunosuppression, prophylaxis of IFI by posaconazole results in a very low specifi c morbidity and mortality. 

Atovaquone as initial prophylaxis of toxoplasmosis after allogeneic haematopoietic stem cell transplantation E. Klyuchnikov, A. Mendorf, C. Langebrake, F. Ayuk, T. Zabelina, G. Amtsfeld, H. Rohde, C. Wolschke, A. Zander, U. Bacher, N. Kröger University Cancer Center Hamburg-Eppendorf (Hamburg, DE) Toxoplasmosis is a rare and critical early complication after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in seropositive patients (pts). Both trimethoprim/sulfamethoxazole (T/S) and atovaquone (A) have anti-toxoplasmosis activity and may be used for post-transplant prophylaxis as both also have an anti-Pneumocystis jirovecii eff ect. We analyzed the safety and effi ciency of both drugs concerning the development of post-transplant toxoplasmosis as well as toxicity profi les. We retrospectively analyzed 140 consecutive adult pts ( as alternative for T/S due to: elevation of serum creatinin (n=12), bilirubin (n=7) and/or skin rash (n=3). No active toxoplasmosis was reported under continued prophylaxis during one year post-transplant with either T/S or A. However, not unexpected, two cases of symptomatic toxoplasmosis with focal (n=1) and general (n=1) neurologic symptoms were observed at days +119 and +64 post-transplant after conversion to inhalative pentacarinate (which does not have an anti-toxoplasmosis activity) as 2nd alternative due to intolerance to A. A was better tolerated than T/S: a nephrotoxic eff ect measured as serum creatinin elevation ≥1.2 md/dl during fi rst 100 days occurred in 0% of pts in the A group and in 42% of pts (median: day +30) in the T/S group (p=0.006). A hepatotoxic eff ect measured as serum bilirubin elevation ≥1.2 mg/dl in the fi rst 100 days post-transplant occurred in 0% of pts in the A group and in 15% (median: day +17) in the T/S group (p=0.02). Time to leukocyte and platelets engraftment did not diff er between both groups. Nausea and vomiting occurred under both drugs in equal range. Atovaquone is an eff ective drug and was well tolerated by patients, so that can be applied for the prophylaxis in T. gondii IgG positive patients who cannot tolerate trimethoprim/sulfamethoxazole in the allo-HSCT setting. A large prospective randomized trial to support these data is required. Objectives: Mould-active antifungal prophylaxis is increasingly used in patients who are at a very high risk for invasive fungal infections. Micafungin, a novel echinocandin, has been approved by the EMA for the prophylaxis and treatment of invasive candida infections in stem cell transplant recipients and patients with leukemia and prolonged neutropenia. Methods: Between June 2011 and June 2012 sixty-five patients with an anticipated duration of neutropenia of more than 7 days received 100 courses of primary antifungal prophylaxis with micafungin 50 mg i.v. once daily. The median number of days with micafungin prophylaxis was 14 (range, 2-48) starting on the first day of chemotherapy or when ANC counts dropped < 0.5 G/L. Underlying diseases were acute leukemia (75%), lymphoma (14%), myeloma (7%), myelodysplastic syndrome (3%) and severe aplastic anemia (1%). Treatment types were induction/consolidation and/or salvage chemotherapy courses (54%), stem cell transplantation (40%), and other types of chemotherapy (6%). Results: The incidence of proven and probable breakthrough invasive fungal infection according to the revised EORTC/MSG criteria were 6% (6/100) and 3% (3/100), respectively. There were two blood-stream infections caused by yeasts (C. krusei, Trichosporon asahii) and four IFIs caused by non-aspergillus moulds diagnosed by biopsy of either lung or skin lesions. Susceptibility patterns were only available only for the two yeasts showing micafunginresistance only for the Trichosporon asahii isolate. The three cases of probable IFI were diagnosed by CT scan only. During 41 courses of prophylaxis with micafungin patients showed fungal colonization documented by weekly surveillance cultures from various body sites. Species diagnostic of 97 fungal isolates revealed C. spp. in 41 (42%), C. glabrata in 20 (21%), C. albicans in 17 (18%), C. krusei in 7 (7%), S. cerevisiae in 4 (4%), C. dubliniensis in 2 (2%), and C. famata, C. guilliermondii, C. haemullonii, C. parapsilosis, C. robusta, and Rhodotorula glutinis each in 1 (1% each). None of the isolates showed micafungin-resistance. Conclusions: These real-life data on micafungin as primary antifungal prophylaxis in adult patients with hematological malignancies at a very high risk for IFI demonstrate an acceptable low incidence of proven breakthrough IFI of only 6%. Emergence of micafungin-resistant Candida strains during prophylaxis was not observed.

Mould-active antifungal prophylaxis in high-risk allo-HSCT recipients C. Alarcón, C. Martínez-Múgica, R. Fernandez, A. Gonzalez, P. Palomo, A. Gonzalez, F. Jonte, C. Rayón, C. Vallejo Hospital Universitario Central De Asturias (Oviedo, ES) Background: Invasive fungal infection (IFI) is a frequent complication associated with high morbidity and mortality rates among allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. The use of mould-active prophylaxis (MAP) in high risk patients, particularly in those with active graft versus host disease (GVHD) and those with long-lasting neutropenia, has proved to reduce the incidence of IFI. Our standard practice includes the mentioned approach (use of MAP in high-risk patients S328 cells transplanted. In group-1 the median age was 51ys (19-74) with 68% under the age of sixty; in group-2 the median age was 62 ys (18-71) with 67% over sixty ys (p=0.005). The patients who receveid PEG required fewer days of hospitalization compared to the patients in the group-2 (median days 22 vs 24 respectively), without statistical diff erence (p=0.06). Median time to engraftment, as the time to reach an absolute neutrophil count (ANC) greater than 0.5x10 9 /L was 10 days, the same for both groups, with a better trend in the group-1 (graphic n.1). There were no statistically signifi cant diff erences regarding the gastrointestinal toxicity. Mucositis grade III-IV was observed in 23 patients of the group-1 and 11 of the group-2 (p = 0.26). Diarrhea of grade III-IV was observed in 8 and 7 patients respectively in the two groups (p=0.09). Not signifi cant diff erences were observed in the incidence of febrile neutropenia and in the median duration of febrile neutropenia. In our experience, we found a statistically signifi cant diff erence (p = 0.04) about infections documented on blood cultures and other microbiological analysis: 34% in PEG group and 59% in G-CSF group (graphic n.2). In summary both PEG and G-CSF groups, have similar outcomes in terms of ANC engraftment, toxicity and to prevent febrile neutropenia after ASCT. Our experience showed a lower rate of microbiologically documented infections in the PEG group. These preliminary data, although limited, suggest that PEG is safe and effi cacious alternative to daily dose of G-CSF after ASCT. J Romejko-Jarosinska, B. Ostrowska, K. Domanska-Czyz, M. Swierkowska-Czeneszew, L. Poplawska, E. Wojciechowska-Lampka, H. Polowniak-Pracka, E. Ochman, M. Ochman, E. Waker, J. Walewski MSC Memorial Cancer Center (Warsaw, PL) Treatment with rituximab in a close sequence to auto-HCT may result in a delayed immunologic recovery, late neutropenia, and the incidence of problematic infections (S Servais et al. Brit J Haematol 2010; 150: 379-381) . On the other hand, many but not all patients with recurrent lymphoma are treated with rituximab-containing salvage regimens ahead of time with the aim of achieving a cytoreduction before transplant. The purpose of this study was to evaluate the rate of neutropenia-related post-transplant complications in patients who received prior rituximab-containing treatment within one year of auto-HCT or more than one year (R+ group), compared to patients who never received the antibody (R-group 

The effi cacy of posaconazole prophylaxis for the prevention of invasive aspergillosis in acute leukaemia patients who underwent Allo-HSCT H. Ozkan (1) , UG. Ozer (1) , C. Bal (2) , Z. Gulbas (1) (

Background: Invasive fungal infections (IFI), especially invasive aspergillosis (IA) are an important cause of morbidity and mortality after allogeneic hematopoietic stem-cell transplantation (Allo-HSCT). Therefore, the prevention of IFI up-front has become the major goal in patient care in these high-risk patient populations. Posaconazole seems to be a valid alternative to old triazoles as it off ers both an extended-spectrum activity and an acceptable toxicity profi le. In this retrospective, single-center study we evaluated the effi cacy of posaconazole for the prevention of IA in patients with acute leukemia who underwent Allo-HSCT between May 2010 and October 2012. Methods: A total of 62 patients, 40 with acute myeloid leukemia (AML), and 22 with acute lymphoblastic leukemia (ALL) were analyzed. Primary prophylaxis with posaconazole was commenced on day 0 with a dose 400 mg/bid. Failure of prophylaxis was characterized as progressive clinical or radiologic parameters compared with baseline, and as switch to another systemic antifungal agent. The observation period lasted from start of prophylaxis until to the day +100. Results: Posaconazole prophylaxis failed in 20 patients (32.2%).

While possible IA was observed in 5 patients (8%), no proven/ probable IA was documented. The potential risk factors for failure of prophylaxis were evaluated by multivariate analyses as well as univariate analysis (Table I) . The multivariate analysis showed that the following factors were associated with failure of prophylaxis: remission status of disease up-front Allo-HSCT and type of conditioning regimen. Patients with active disease up-front Allo-HSCT or usage of cyclophosphamide + busulfex as a conditioning regimen were more likely to have failure of posaconazole prophylaxis. In addition, overall mortality (fi rst 100 days) was much higher in the patients having prophylaxis failure (20% vs 0%, p=0.018). Conclusions: Posaconazole was eff ective oral antifungal prophylaxis in acute leukemia patients who underwent Allo-HSCT. However, having an active disease up-front of the HSCT and usage of cyclophosphamide + busulfex as a conditioning regimen were associated with failure of posaconazole prophylaxis. The physicians must identify IA cases as soon as possible in order to guarantee early and adequate treatment to these high-risk patient subpopulations.

Cerebral toxoplasmosis following allogeneic haematopoietic stem-cell transplantation H. Ozkan, E. Hakko, K. Karaman, U. Ozer, Z. Gulbas Anadolu Medical Center Hospital (Kocaeli, TR) Background: In this retrospective, single center study we reviewed our cases of toxoplasmosis in adult patients with hematological disorders who underwent allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) between June 2010 and November 2012. Methods: Toxoplasma infection and disease was defi ned in accordance with European Group for Blood and Marrow Transplantation-Infectious Diseases Working Party guidelines. Trimethoprim-sulfamethoxazole (TMP-SMZ) 800/160 mg once a day was used daily from start of conditioning regimen to day -1, and then three times a week from day +50 to +180 in the absence of myelosuppression as prophylaxis against Pneumocystis carinii pneumonia. All patients received cyclophosphamide (Cy) 50 mg/kg i.v. on days +3 and +4. At day +5, all patients began cyclosporine A (CsA) with a target plasma level of 100-200 ng/ml, and it was tapered off by day +180 in the absence of GvHD. In addition to CsA, all haploidentical and unrelated HSCT recipients received mycophenolate mofetil (MMF) until day +35 at a dose 1 gr/day. MMF and/or corticosteroid were initiated in the presence of GvHD despite use of CsA.

Results: A total of 170 Allo-HSCT recipients of whom 98 from HLA-matched sibling donors, 70 from haploidentical donors, and 8 from HLA-matched unrelated donors were defined. Neuroradiologic imaging studies were performed in 17 patients with unexplained fever and/or neurological complications. Among 17 patients, 7 had metabolic encephalopathy, 2 had Guillan-Barre like syndrome, 3 had CNS relapse of underlying malignancy, and 5 (2.94%) had cerebral toxoplasmosis (1 possible, 4 probable).

The results of polymerase chain reaction (PCR) of cerebrospinal fluid specimens were positive in all 5 cases except one with a negative PCR result but with a good response to toxoplasmosis therapy. All cases with cerebral toxoplasmosis promptly initiated TMP-SMZ (TMP 10 mg/kg/day) i.v. and clindamycin (600 mg i.v. qid). 2 cases died directly because of toxoplasma infection complications. 1 case achieved excellent improvement in toxoplasmosis however he died because of disease relapse. Alive 2 cases who have been under toxoplasmosis specific treatment showed steady improvement of the cerebral toxoplasmosis. Conditioning and immunosuppressive regimens of the 5 cases are presented in Table 1 .

Conclusion: Physicians dealing with Allo-HSCT should be aware of the occurrence of cerebral toxoplasmosis, especially in highly endemic areas, and prompt diagnosis and treatment are needed to improve outcome.

[P973]

Gram-negative bacteraemia in paediatric patients undergoing allogeneic haemopoietic stem cells transplantation M. Averyanova, V. Vavilov, S. Bondarenko, E. Semenova, A. Volkova, A. Galkina, L. Zubarovskaya, B. Afanasyev R.Gorbacheva Memorial Institute for Pediatric Hematology and Transplantation (Saint-Petersburg, RU) Background: Gram-negative infection is an important cause of morbidity and mortality after allogenic hemopoetic stem cells transplantation (alloHSCT). Aim: To characterize frequency, etiology of gram-negative bacteremia (GNB), factors which determinate mortality from sepsis in patients receiving alloHSCT. Patients and methods: We performed a retrospective case-control study to examine frequency, risk factors, prophylaxis, epidemiology, therapy and outcome of GNB in 155 pediatric patients undergoing alloHSCT. The patients after alloHSCT with confi rmed diagnosis of gram-negative sepsis, severe sepsis and septic shock were included in to the study. The diagnoses of septic complications were provided according to the classical ACCP/SCCM criteria and confi rmed with quantitative C-reactive protein (CRP) and semi-quantitative procalcitonin levels. Cultures were provided with BacT/Alert® and Vitek 2® technologies. Results: The incidence of GNB was in 39 patients (25%). GNB developed in 38% on days 30-60 and 34,5% after day ≥100 post alloHSCT. The most common gram-negative pathogens were Kl.pneumoniae 26%, Ps.aeruginosa 26%, Enterobacter cloacae 17%, E.coli 11%, St.maltophilia 8%, Ac.baumanii 6%, Serratia marcescens 3% and Chryseobacterium indologenes 3%. Predisposing risk factors for GNB included disease status, acute and chronic graft-versus-host disease (GvHD), use of systemic steroids. Patients were given prophylactic fl uoroquinolones: resistance to this antibiotic was seen in 38% of isolates. Fever, hypotension, a raised CRP and procalcitonin were common fi ndings at presentation. Initial site of infection was lungs in 38%, intestine in 31%. In 86% of cases patients with GNB have respiratory failure, renal failure-55%, liver impairment-41%, coagulopathy-48%. Septic shock was observed in 11 patients (38%). Mortality from GNB was 52% in the group and 73% in patients with septic shock. The involvement of liver and kidney in multiorgan failure was associated with 100% mortality rate. Introduction: Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Ganciclovir has potent activity against CMV and has been used successfully to treat CMV infection in immunocompromised recipients. However, the suppression of bone marrow function associated with ganciclovir treatment has been of particular concern. We did preemptive treatment of CMV infection with a half-dose of ganciclovir in asymptomatic recipients of HSCT when CMV antigenemia level was under 10/200,000 cells. Patients and methods: A retrospective analysis was done on pediatric patients who underwent HSCT at Seoul National University Children's Hospital between July 2010 and September 2012. All recipients were screened for the presence of CMV in blood samples twice a week from engraftment to at least 180 days after HSCT. The detection of CMV pp65 antigen in leukocytes was used as a diagnostic test to determine the need for preemptive treatment. Patients received a preemptive half-dose of IV ganciclovir (5mg/kg once daily) when CMV antigenemia had been detected in less than 10/200,000 cells. If CMV antigen had been detected in more than or equal to 10/200,000 cells, conventional ganciclovir induction therapy (5mg/kg every 12 hours) was administered. Aim: The aim of this study was to establish a method for assessing viral infection/reactivation after stem cell transplantation (SCT) in children using sugar chain-immobilized gold nano-particles (SGNP), which specifically bind to viruses, and quantitative polymerase chain reaction (qPCR). Method and Patients: Eleven children with a median age of 9 (range 1.6 to 19) were studied. Their diagnoses include 4 acute lymphoblastic leukemia, 2 acute myelogeneous leukemia, 3 myelodysplastic syndrome, and 2 aplastic anemia. Conditioning regimens were total body irradiation-based in 3, reduced intensity stem cell transplantation in 5, busulfan-based in 2 and other in 1. Four and 7 received grafts from related and unrelated donors, respectively. Five were human leukocyte antigen-matched donors and 6 were mismatched donors. Graft-versus-host disease prophylaxis consisted of methotrexate (MTX) + tacrolimus in 9, and MTX + cyclosporine in 2. Saliva, urine, and whole blood were collected weekly after SCT. Whole blood was separated into WBCs and plasma by centrifugation with ficoll. After binding to each virus was confirmed in vitro, sulfated oligosaccharide-immobilized SGNP was used to concentrate viruses, which were adenovirus (ADV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human herpes virus type 6 (HHV-6), and the concentrated viruses were then quantified by qPCR (abbreviated as Nano-PCR).

Result: All 11 patients survived for a median of 4.7 months (1.0 to 9.8) and the study period was 84 days (38 to 142). Five ADV, 8 BKV, 7 CMV, 21, 19, 19 , and 2 viruses were detected in saliva, urine, WBCs and plasma, respectively. In 2 patients who developed CMV antigenemia, before positive antigenemia, Nano-PCR was fi rst positive in saliva and then became positive in WBCs. With preemptive therapy with ganciclovir, after showing negative CMV antigenemia, Nano-PCR became negative in saliva and WBCs. Discussion: Nano-PCR can detect viral infection/reactivation prior to disease development. Since Nano-PCR was more sensitive than CMV antigenemia, we were able to prepare for the development of CMV reactivation prior to engraftment. These results suggest that Nano-PCR is useful for the follow-up of patients who have undergone hematopoietic stem cell transplantation. A. Capobianchi, A. Iori, A. Micozzi, G. Torelli, A. Testi, C. Girmenia, S. Santilli, E. Scalzulli, G. Antonelli, R. Foà, G. Gentile University of Rome "Sapienza" (Rome, IT) Cytomegalovirus (CMV) disease may still develop in some hematopoietic stem cell transplant (HSCT) patients who have a negative pp65-antigenemia (pp65-AG) or undetectable DNA. CMV AG and DNA have been detected in cord blood and bone marrow (BM) CD34+ cells in vitro. We prospectively determined the relationship between the pp65-AG and CMV DNA in peripheral blood leukocytes (PBL) and BM samples pairs, simultaneously collected, from two groups of allogeneic HSCT patients at risk of CMV infection, undergoing BM suppression and with a preceding negative blood CMV DNA or pp65-AG. CMV pp65-AG was detected in 24 of 145 patients (16%) examined (Group I Background: Human herpesvirus (HHV) types 6 and 7 infection occurs in more than 80 percent of the population during childhood and has been documented to be reactivated in patients who undergo hematopoietic stem cell transplantation (HSCT) and may increase morbidity and mortality. Diagnosis is usually made by viral nucleic acid detection by polymerase chain reaction (PCR). Few cases of HHV 6 and 7 infection in children after HSCT in the Asia-Pacifi c region have been documented. We aimed to evaluate the incidence, manifestations and outcomes of HHV infections after pediatric HSCT in our hospital.

Methods: This is a retrospective review of our HSCT patients' clinical record and electronic database over the past 6 years (Jan 2006 -Nov 2012 . Identifi cation of HHV-6 and 7 infection was done using PCR on serum and/or CSF samples. Results: We performed 109 HSCT on 98 children during the period. Ten patients (10.2%) tested positive for HHV-6 (n=6) or HHV-7 (n=4). The median age of the patients was 10.8 years (range: 4-17 years) . Four were males. Underlying diagnoses were acute lymphoblastic leukaemia (n=3), transfusion-dependent thalassemia (n=3), acute myelogenous leukaemia (n=2), juvenile myelomonocytic leukemia (n=1), and medulloblastoma (n=1 Cytomegalovirus (CMV) infection is one of the major complications following allogeneic hematopoietic stem cell transplantation (alloHSCT). The aim of this multicenter retrospective study was to assess the prognosis of CMV reactivation and to analyze risk factors for CMV infection in children after alloHSCT. We retrospectively reviewed CMV infection episodes in 200 consecutive pediatric patients with a median age of 8 years (range: 0.3-19 years) who underwent alloHSCT between January 2011 and May 2012 in three pediatric transplantation centers. Serological studies before HSCT and weekly CMV infection surveillance by quantitative PCR after transplantation were routinely obtained. All patients were given high-dose acyclovir (HD-ACV) prophylaxis and pre-emptive treatment with ganciclovir approach until six months posttransplant. While only one episode was observed in 192 patients, a second episode was developed in 7 and 5 episodes in one. The 6-month cumulative incidence of CMV viremia was 36% (29%-43%) at a median of 36.5 days (range: 4-122 days): 52% (95% confi dence interval 24%-80%) in cord blood recipients (CB), 37% (28%-46%) in marrow (BM) and 31% (17%-44%) using peripheral blood grafts (PBSC), respectively (p>0.05). CMV disease developed in 3 patients (2 colitis, 1 encephalitis). By univariate analysis, risk factors were recipient/donor CMV serostatus (p=0.03), donor type (p<0.001), T-cell depletion (p=0.024), ATG usage (p=0.015) and acute graft versus host disease (aGVHD) (p=0.035). In multivariate analysis, CMV infection (viremia and disease) was signifi cantly in patients with grade II-IV aGVHD (p=0.041) and in those receiving grafts from match unrelated donors (p=0.04). At the end of the fi rst six months after HSCT, overall survival rates were not significant for patients who had CMV reactivation or not (76% vs 78%, respectively). These results show that the rate and prognosis of CMV infection is similar to those reported from developed countries and also that our prevention and management program for CMV in pediatric patient following allogeneic HSCT are adequate. V. Murthy, D. Murray, N. Freeman, S. Paneesha, M. Nikolousis, R. Lovell, B. Kishore Heart of Engalnd NHS Foundation Trust (Birmingham, GB) Obesity is a recognised cause of impaired immune function.

Although the outcome of haematological malignancies has improved with stem cell transplantation, CMV reactivation post transplantation leads to signifi cant morbidity and mortality. The aim of this study was to explore the impact of high BMI on CMV reactivation in patients following allogeneic stem cell transplantation. Objective: To identify the preferential sedimentation location of a number of common microbial cord blood isolates using the Sepax UCB (non HES) protocol. The ANCTC has undertaken this in order to evaluate an appropriate protocol for bacteriology screening. Methods: Six organisms commonly found in cord blood isolates were spiked into pretested cord blood at diff ering concentrations. The blood was processed by Sepax using the routine non HES UCB v306 protocol to ascertain which in fraction the organisms would be preferentially enriched. A 3ml sample from the Buff y coat fraction, Plasma Fraction and RBC fraction was sampled into the appropriate blood culture bottle to ascertain positivity. Concurrently a 0.5 ml sample from each of the fractions was taken and streaked on to agar to verify the purity of the contaminating colony and also to ascertain the microbial concentration in each fraction. Results: The result was a preferential enrichment of microbial contamination in the buff y coat. Although the contamination was often detected in the RBC fraction it was more enriched in the buff y coat leading to the possibility that a low level contamination could be missed during routine testing (missed plasma and RBC tested). Conclusion: Contaminated cords have been transfused with no reported sepsis, no delay in engraftment and no hindrance to the patient's survival. However in these circumstances the individual is treated with a targeted antibiotic therapy alongside the usual broad spectrum prophylaxis antibiotics. There are numerous reported cases of fatal septicaemia as a result of contaminated blood products such as that of a platelet recipient detailed in the 1999 shot report in which a contamination by Staphylococcus Aureus was confi rmed. With this in mind it is conceivable that a cord blood unit contaminated with an organism resistant to the prophylaxis treatment could pose a risk when transplanted into an immunosuppressed patient, despite not having the same growth phase due to the storage the recipient is liable to be more susceptible to a lower infection in the absence of a host defence. It is therefore imperative that high standards are sought in regards to our microbial surveillance as a result a combination of the RBC, Platelet and Buff y coat fractions are sampled into our blood culture system providing a minimum sensitivity (at worst case, i.e. all organisms fractionated into the buff y coat) of 30CFU/ml. (7), H.C. Jang (1) , N.G. Chung (4) Cimminiello, A. Cosentino, G. Brucoli, A. Amendola, I. Attolico, N. Filardi, A. Matturro, D. Vertone, C. Musto, M. Pizzuti, T. Pierri Azienda Ospedaliera San Carlo Potenza (Potenza, IT) Cytomegalovirus(CMV)remains one of the most important pathogens impacting on the outcome in the hematopoietic stem cell S334 transplantation (HSCT) recipients. Oral valganciclovir (VGC) was demonstrated to have an effi cacy that is comparable to intravenous-GCV in CMV-infection. This retrospective study, conducted since october2007, is aimed at collecting information concerning effi cacy and toxicity of VGC in the setting outpatients allogenic-HSCT recipient (allo-HSCT-r) and autologous-HSCT recipients (a-HSCT-r) at time to onset of CMV-viremia reactivation. Data were available on 121 patients, 93a-HSCT-r and 28allo-HSCT-r. Indication for therapy were diagnosed as CMV-viremia with the CMV-DNA load of higher than 3x10(2) copies/ml (polymerase chain reaction, PCR). The total incidence of onset primary CMV infection is 32% (39/121), 28% (26/93) a-HSCT-r and 46% (13/28) allo-HSCT-r at time of 34 days (4-300) respectively 32 days (13-100) for auto-HSCT-r and 41 days (4-300) for allo-HSCT-r. Patients with a positive assay were treated 90% (35/39), 96% (25/26) of a-HSCT-r and 77% (10/13) of allo-HSCT-r, with VGC900 mg p.o. b.i.d. x14 days followed 450mg b.i.d. until at least 7 days after negative test. The median duration of therapy was 21 days (range14-28 days). Preemptive treatment with VGC started with a median time of 42days , with a median CMV-DNA load of 18x10(2) copies/ml (4.24x10 (2)-154x10(2) copies/ml), 20x10(2) copies/ml (4.24x10(2)-140x10 (2) copies/ml) for auto-HSCT-r and 10x10(2) copies/ml (4.68x10 (2)-154 x10(2) copies/ml) for allo-HSCT-r. The rate of response was 100% as confi rmed by negative weekly assay within 28days with PCR assay. The median time to achieve a negative CMV-PCR was 8days (range [7] [8] [9] [10] [11] [12] [13] [14] . A relapse of CMV infection after VGC therapy occurred in 8/35 patients (23%), 3/26 (11%) auto-HSCT-r and 5/9 (55%) allo-HSCT-r. The mean of relapse was 158 days (range 94-367) from transplant, respectively 214 days (range 88-365) for allo-HSCT-r and 265 days (range 88-341)for auto-HSCT-r. Furthermore,the time relapsed between the fi rst and the second CMV reactivation was 170 days (range 47-330), 94 days (range 47-172) for allo-HSCTr, 244 days(range 80-330)for auto-HSCT-r and all of these were treated with the same VGC-schedula. In the safety profi le VGC is generally well tolerated; we observed no signifi cant toxicity, other than moderate neutropenia. Overall, once-daily oral VCG has demonstrated to be a clinically eff ective and well-tolerated therapy for preemptive CMV-viremia in HSCT recipients. Materials and methods. Children and adolescents (160 patients, age 1-21) with ALL and AML after allo-HSCT from both related and unrelated donors were included in the study. Myeloablative (MAC) and reduced intensity conditioning (RIC) was performed in 59% and 41% of patients, respectively. For monitoring of EBV-DNAemia qualitative PCR used weekly from D+1 to D+100. Results: The EBV-DNAemia risk factors were studied on diff erent stages of post allo-HSCT course. The results were subjected to multivariate analysis. On the fi rst month after allo-HSCT (D0-D+30) risk of EBV-DNAemia was signifi cantly higher untill engraftment of donor hematopoietic stem cell (HR 36, 06; 95% CI 10, 68, Er =0, 00001) . The factor related to the decreased risk of EBV-DNAemia was the use BM as a stem cell source (HR 0,2; 95% CI 0,07-0,53, Er =0,001) -in univariant analysis the risk was associated with the number of nuclear cells (NC) in the transplant (HR 1,42; 95% CI 1,01-1,97; Er =0,04), while there was no cor-relation to CD34+ or CD3+ cells contents. The risk was also higher in patients with ALL (HR 2, 22; 95% CI 0, 65, Er =0, 094) . On the third month after allo-HSCT the risk of EBV DNAemia was signifi cantly lower in recipients received RIC (HR 0,19; 95% CI 0,04-0,85; Er =0,03), but had a positive correlation to HLA-mismatch grade (one or two loci) -HR 6,41; 95% CI 1, 28, Er =0, 01 . Multivariate analysis revealed the trend to increase the risk of fatal infectious complications in patients with EBV-DNAemia on the third month after allo-BMT (D+61-D+90): HR 6, 77; 95% CI 0, 7; Er =0, 09. Conclusions: Taking into consideration the found relations between NC count and the risk of early EBV infection (D0-D+30) with no correlation of the risk to CD34+ cells or T-cell con-tents of the graft, the risk could probably be attributed to graft B-cell contents. As the risk of late EBV-DNAemia is associated with MAC, recipients after MAC may need more close monitoring for EBV-LPD signs. In these cases EBV DNAemia could also serve as a sign of delayed immune reconstitution leading to increased risk of infectious complications.

Outcome of allogeneic stem cell transplantation in patients with pre-transplant invasive fungal infection U. Salmenniemi, M. Kauppila, M. Putkonen, T. Salmi, K. Remes, M. Itälä-Remes Turku University Hospital (Turku, FI) Patients with history of invasive infection (IFI) are at high risk of IFI relapse after allogeneic stem cell transplantation (SCT). Since recurrence of IFI may have even higher mortality rate than primary infection the use of secondary antifungal prophylaxis (SAP) in SCT recipients is highly recommended (EGIL 3 grading AII). However, due to lack of randomized studies, there is no consensus on drug selection or treatment duration. (7), liver (2) and both (2) . Voriconaxole (Vori) was the most often used drug in primary treatment. The median duration of antifungal treatment before SCT was 8 mo (5-112 wk) and the IFI status at transplantation was CR (3) and PR (8). All patients received Ambisome (Amb) as SAP during peri-transplant period. After engraftment 8 patients received Vori (alone n=5 or in combination/sequentially with Amb n=3), 2 patients other azoles and 1 patient died before outpatient phase. The median duration of SAP was 18 wk (6-66 wk) . Among the 7 patients alive, 5 patients are still receiving antifungal therapy. With median follow-up time of 7 (1-24) months there were no IFI related deaths and only 2 possible IFI reactivations, 1 occurring after cessation of SAP after 49 weeks of therapy. Conclusions: SAP is eff ective in preventing IFI relapse and allogeneic SCT is feasible also in patients with history of IFI. However, antifungal treatments were lengthy thereby increasing the costs considerably. More data is needed to guide the use of SAP and to improve the cost-eff ectiveness of treatment.

Pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation guided by quantitative real time-PCR A. Banan (1) , M. Ramzi (2) , E. Varnik (1) (

Introduction: Cytomegalovirus (CMV) end-organ disease is a serious and frequent complication afterallo-stem cell transplantation (Allo-SCT).Pre-emptive therapy guided by viral replication is a recent prevention therapy, consisting in treatment if viral replication is detected.The best technique for detection of infection is not defi ned. The PCR-Real time seems to be more sensitive but contradictory information exists on its clinical utility. Material and Method: Prospective study in consecutive Allo-SCT recipients All patients underwent CMV viral load quantifi cation by RT-PCR during six months once a week in the fi rst 100 days and every two weeks there after. Patients received pre-emptive therapy with ganciclovir (5 mg per kg) 15 days, or at least 10 days after a negative quantifi cation.

If the viral load increased above 1000 cop per ml in a symptomatic patients, or with any positive viral load if clinical suspicion existed. For RT-PCR the viral DNA was isolated in plasma and was used as a template for the amplifi cation and quantifi ed. Results: 20 Allo-SCT were performed between June 2010 and May 2012, with a median age 27 years (14-52). 71.2% were from peripheral blood and 63.9% from unrelated donors. The conditioning regimen was myeloablative in 62.4% and 71.6% of recipients were positive for CMV. The incidence of acute GVHD (II-IV grades) was 62.4% and of chronic GVHD 56.8%. The incidence of CMV infection was 70% (n.12) and two patients developed CMV disease ( 10.4%) . No risk factors for CMV infection were identifi ed among infected patients (conditioning regimen, unrelated donor, GVHD prophylaxis, treatment or previous positive serostatus for CMV in recipient or donor. The median viral load in infected patients was 8.10 cop per ml (0-180) and 185 cop per ml (35. 5-346.5) in CMV disease patients (P.NS). The global median day of treatment was 48.5 , being 10 days (10-150) for infected patients and 185 days in CMV disease patients (175-198) (P-0.04).

No CMV Related mortality was observed. Conclusion: RT-PCR is a sensitive and specifi c technique to monitoring CMV viral load after Allo-SCT and clinically useful to guide pre-emptive treatment without increasing incidence of CMV disease nor CMV related mortality.

Human Herpesvirus-6 and GvHD after allogeneic haematopoietic stem cell transplantation R. Greco, F. Lorentino, L. Crucitti, L. Vago, M.T. Lupo Stanghellini, A. Assanelli, M. Carrabba, S. Marktel, M. Bernardi, J. Peccatori, C. Corti, F. Ciceri San Raff aele Scientifi c Institute (Milan, IT) Background: Human herpesvirus 6 (HHV-6) is increasingly recognized as an opportunistic and potentially life-threatening pathogen in recipients of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Reported clinical manifestations of HHV-6 infection in transplanted patients are skin rash, interstitial pneumonia, bone marrow suppression and encephalitis. Moreover, some clinical reports suggest that HHV-6 can facilitate the occurrence of severe clinical complications of allogeneic HSCT, increasing transplant-related mortality. Methods: From January 2009 to November 2012, we retrospectively evaluated 48 consecutive adult patients (median age 50 years) who developed positivity to HHV-6 after allogeneic HSCT for high-risk hematological malignancies. Stem cell donors were family haploidentical (34), HLA identical sibling (6) , unrelated volunteer (5), cord blood (3). The viral load was determined by quantitative PCR in cell-free body fl uids. Results: Acute GvHD was reported in 23 (47%) patients (pts), resulting severe (grade III-IV) in 19 of them (39%). In 18 cases we observed a gut involvement, in 13 a liver and in 13 a skin involvement. All required high dose steroids and mostly additional immunosuppressive treatment lines (2 to 4). Only 7 pts solved the GvHD, while a worsening (13) or a persistence (3) of GvHD were reported in the majority of them. Median time from allogeneic HSCT to HHV-6 reactivation was 33 days and the median absolute count of CD3+ lymphocytes was 466/mcl. In 13 pts HHV-6 was detected in plasma, 5 in the bone marrow, 13 in biopsies (gut, liver) or bronchoalveolar lavage, 3 in cerebrospinal fl uid. In these patients with a concomitant GvHD the clinical manifestations of HHV-6 (fever, skin rash, hepatitis, diarrhoea, encephalitis) were frequently reported, leading to use a specifi c antiviral therapy in the majority of them (foscarnet in 9 or ganciclovir in 5 or both in combination in 3 cases). The mortality rate was relatively high in this population (only 30% of pts were alive). Conclusions: HHV-6 reactivation is associated with high morbidity and mortality in patients who developed acute GvHD after allogeneic HSCT. The regular monitoring of HHV-6 DNA in allogeneic HSCT recipients, using a real-time PCR assay, may be useful for identifying active HHV-6 infection and for the introduction of a pre-emptive treatment, possibly reducing the incidence of the most severe clinical complications. Objective: Our previous research has provided the evidence that an autoreactive immune system can be "reset" into a healthy, tolerant state by immunoablative treatment followed by transplantation of hematopoietic progenitor cells. Nevertheless, disease fl ares may occur in a subset of these patients post-HSCT. Here, we longitudinally analyzed the immune reconstitution of the patients to identify predictive markers for favorable long-term responses. Patients and Methods: Since 1998, 10 patients with refractory SLE received a CD34±selected autologous HSCT after conditioning with ATG and cyclophosphamide as part of a monocentric phase I/II clinical trial. Autoantibody titers were evaluated with ELISA, peripheral T-and B lymphocyte subsets immunophenotyped using multicolor fl ow cytometry. Results: Clinical remission (SLEDAI ≤ 3) could be achieved in all patients, despite immunosuppressive drug withdrawal, associated with disappearance of anti-dsDNA antibodies and marked reduction of protective antibodies in serum. Unfortunately, two patients died due to transplant-related infections. From the remaining eight patients, fi ve patients are in long-term clinical remission for up to 14 years after HSCT, while three patients suff ered a relapse of SLE at 18, 36 and 80 months post-HSCT, respectively. Patients with early relapses (≤ 36 months) had lower baseline complement levels (C3 ≤ 67 mg/dl), showed persistence of antinuclear antibodies, less signifi cant reduction in protective antibody levels and had slower repopulation of CD31+ CD45RA+ thymic-derived CD4+ T cells after HSCT (<100/μl at 18 months) compared to longterm responders. In addition, fl ow cytometric analyses revealed an expansion of peripheral blood plasmablasts and increased coexpression of Siglec-1 on monocytes (as surrogate marker for type-I interferon signature), preceding the clinical fl ares by ~ 6 months. Conclusion: Low baseline complement levels, persistence of antinuclear antibodies and delayed thymic reactivity post-transplantation could be identifi ed as risk factors for development of lupus fl ares after HSCT. Since ATG-mediated cell lysis is complementdependent, we conclude that low serum complement is directly associated with incomplete depletion of immunologic memory cells in these patients and may provide a rationale for complement substitution before the conditioning with ATG. Moreover, lupus fl ares may be predicted individually by fl ow cytometry with plasmablast expansion and recurrence of type-I interferon signature. Objective: Only 70-80% of patients with chronic infl ammatory demyelinating polyneuropathy (CIDP) respond satisfactorily to the established 1st line immunomodulatory treatments. Autologous Hematopoetic Stem Cell Transplantation (AHSCT) has been performed in a few therapy-refractory cases with CIDP. We describe the results of AHSCT in 11 Swedish therapy-refractory CIDP patients with a median follow-up time of 30 months. There were 10 males and one female. The median age at transplantation was 57 years. Method: Data was gathered retrospectively for AHSCT between 2002 and 2012 in patients with CIDP refractory to 1st and 2nd line immunomodulatory treatments. Stem cells were mobilized with Cyklophosphamide(Cy)+G-CSF in 9 and Rituximab+G-CSF in 2 patients.Cy conditioning regimen was administered before AHSCT in 1,Cy+ATG in 6, Melphalan in 1 and BEAM+ATG in 3 cases. Functional disability was measured using the Infl ammatory Neuropathy Cause and Treatment (INCAT) as well as the Rankin scales. Results: The mean INCAT group score within one month prior to HSCT was 6.4 and the Rankin score 4. Total INCAT and Rankin scores improved signifi cantly already within 2-6 months and continued to do so at last follow-up. Mean Compound Muscle Action Potentials (mCMAP) levels measured by electromyography (EMG) of motor nerves improved signifi cantly within 11 months (median) after AHSCT correlating with level of decrease in INCAT scores compared to pretreatment levels. Only two of the 11 patients relapsed 2 and 5 years respectively after AHSCT, requiring retransplanation in one case. All 11 patients maintained remission (drug-free in 6 cases) upon last follow-up. AHSCT was safe but in a short term associated with a risk of CMV and EBV reactivations, but also CMV disease and hemorrhagic cystitis. Conclusion: AHSCT seems to be effi cacious for CIDP, with manageable complication profi le, and should be considered early in patients judged to be treatment-refractory to the established 1st line treatment modalities.

Autologous haematopoietic stem cell transplantation for paediatric patients with multiple sclerosis: outcome and prognosis K. Kirgizov (1) tional immunomodulation after AHSCT. The prognosis for these patients isn't as favorable as for the patients transplanted in highly-infl ammatory relapsing-remitting phase. Conclusion: AHSCT is the eff ective way of autoimmune infl ammation reduction and successful approach for treatment of severe refractory pediatric MS. Well-timed Auto-HSCT can signifi cantly minimize the disability level and improve the outcome of MS. Patients transplanted in secondary-progressive MS have the worst outcome and require the additional observation and treatment.

Target therapy with rituximab and allogeneic haematopoietic stem cell transplantation for paediatric patients with neuromyelitis optica K. Kirgizov (1) Sakellari, D. Mallouri, C. Apostolou, I. Batsis, K. Karypidis, A. Antoniou, C. Smias, P. Kaloyannidis, E. Yannaki, V. Papadimitriou, A. Elias, P. Argyropoulou-Pataka, M. Katsounaros, A. Fassas, A. Anagnostopoulos "George Papanicolaou Hospital" (Thessaloniki, GR) Autologous haematopoietic cell transplantation (AHCT) is considered a treatment option for selected patients (pts) with severe progressive systemic sclerosis (SS) and may induce regression of dermal fi brosis, sustained improvement functional status, stabilization of visceral involvement and lower mortality due to disease progression. We retrospectively analyzed the outcome of 8 pts (6 women, 2 men), 35(30-48) years old, who underwent AHCT for SS in our unit. The pts were transplanted for severe progressive disease post 3(2-7) lines of immunosuppressive treatment, including cyclophosphamide (Cy) pulses in 7/8 pts [total dose 6(2.5-12) g] and at a median (Δ m) time of 4(2-13) years post disease diagnosis. The Δ m modifi ed Rodnan skin score was 32(2-49) out of 51. All pts presented joint, lung and gastrointestinal involvement. Peripheral hematopoietic stem cells were mobilized with Cy 4g/m2 and GCSF without major complications. The conditioning regimen used was Cy 200 mg/kg plus ATG 7.5 mg/kg and pts received 6(3.9-8.65) x 10 6 /kg CD34+ cells. Engraftment was prompt and sustained in all pts, at a Δ m of 10(7-14) days for neutrophils, 9(5-13) for platelets and 7/8 pts were discharged on day +14(13-38). A female pt with severe and rapidly progressive disease, post 7 lines of immunosuppressive treatment, died on day +87 from sepsis and multiorgan failure. In the rest of the pts the complications observed were: pneumothorax during central line catheter placement (1), neutropenic fever (6), mild pulmonary infection (1), BK polyoma virus hemorrhagic cystitis (1), herpes zoster (1), CMV (2) and EBV (4) reactivation. Modifi ed Rodnan skin score was improved post-transplant and was 15 at +3 months (m) and signifi cantly lower 7(2-18) post 32 (14-87) m in 5/7 pts who could proceed to our unit for further follow-up. With a Δ m follow-up 20 (4-87) m, all pts referred improvement or complete remission of dysphagia symptoms and signifi cant improvement of performance status. Respiratory evaluation revealed stable FEV1 and DLCO in 3, improved in 2, asymptomatic mild progression in 1 and clinically symptomatic progression (15m post-transplant) in another pt. Until now 5/7 pts are off further treatment. One female pt was diagnosed with sarcoidosis at +27m and is under corticosteroid treatment. With the limitations of a retrospective study and the small number of pts, AHCT seems to be a valuable treatment in selected pts with SS off ering them a better quality of life.

Autologous haematopoietic stem cell transplantation following high-dose immunosuppressive therapy in neuromyelitis optica H Hägglund (1) , D Bowen (2), G. Kraft (3), A. Wundes (4) , L. Brundin (5), F. Piehl (5) , R. Storb (6) , G. Georges (6) , K. Maravilla (7) Human hereditary C1q defi ciency is associated with development of severe systemic lupus erythematosus (SLE) and bacterial infections. Most complement proteins are produced by the liver. In contrast, C1q is produced by monocytes, which suggests that allogeneic haematopoietic stem cell transplantation (allo-HSCT) may cure these patients.

Here, we report a 9-year-old boy with complete C1q defi ciency and treatment-resistant cerebral SLE, who underwent an unrelated donor allo-HSCT to restore complement function. One month post-transplant, both the levels of monocytes and C1q in the blood were within the normal range, although neutrophil engraftment was delayed (day +35). Multiple enlarged lymph nodes on the neck and in the thorax/abdomen were noted by day +40, and biopsies confi rmed EBV-positive post-transplant lymphoproliferative disorder (PTLD). Fortunately, the PTLD resolved following one dose of rituximab, and two months post-transplant the boy was discharged with normal function of the classical complement pathway. One month later the patient showed signs of graft-versus-host disease (GVHD). A colonoscopy was performed and tissue biopsies showed grade II gastrointestinal GVHD. Although the patient received extensive immunosuppressive treatments including high doses of steroids, extracorporeal photopheresis and mesenchymal stem cells the GVHD never resolved and he passed away in intracerebral haemorrhage and multi-organ failure four months post-transplant.

In conclusion, the present case is probably the fi rst to demonstrate that allo-HSCT restores C1q production in human C1q defi ciency.

We have no indication that the severe GVHD was directly associated with the boys C1q defi ciency, although the outcome may have been aff ected by his low performance status pre-transplant. Future studies are warranted to further investigate the rational for allo-HSCT in human C1q defi ciency. Autologous hematopoietic stem cell transplantation (ASCT) is an emerging therapy for pts with severe autoimmune diseases (AID).

In published trials no attention is usually given to data regarding peripheral recovery following transplant. We analyzed our ASCT in AID pts, making a comparison with a cohort of pts transplanted for neoplastic diseases. Over the last 7 years, 15 pts aff ected by Crohn's disease (CD) and 13 by systemic sclerosis (SS) underwent ASCT. In both groups, conditioning included 200 mg/kg CTX and 7.5 mg/kg rabbit ATG. Pts with CD received unselected and pts with SS received selected HSC. Median number of infused CD34+ cells was 5.23*10 6 /kg (range 2.78-9.54) in CD, and 4.24 (range 3-5) in SS pts; no G-CSF was administered. The data were compared with those of 182 pts undergoing ASCT for hematologic malignancies over 4 years. Median number of infused CD34+ cells was 4.7*10 6 /kg (range 1.8-20) ; all pts received G-CSF. This value was comparable in the 3 groups. In CD, median time to PMN (>500/mcL) and PLT (>50.000/ mcL) recovery were 11 (range 9-14) and 9 (range 0-36) days; median PLT nadir value was 54.000/mcL; 7 pts did not require PLT transfusions. In SS, median time to PMN and PLT recovery were 12 (range 11-14, p<0.025) and 9.5 (range 0-15, p=n.s) days; median PLT nadir value was 29.500/mcL (p<0.001); 4 pts did not require PLT transfusions. In neoplastic pts, median time to PMN and PLT recovery were 10.5 (range 8-19) and 14.5 (range 10-44) days; all pts required at least 1 PLT transfusion. The diff erence between neoplastic and AID pts in PLT recovery was striking; worth of mention, 11 of 28 pts did not require PLT transfusion. This was not at the expense of PMN recovery, only slightly delayed in comparison to neoplastic pts. The use of selected or unselected HSC is the main reason for the diff erences between CD and SS. Our data are in line with those of Oyama (2005), performing ASCT in CD without G-CSF. Conversely, Burt (2011) reported a delayed PLT recovery and increased PLT transfusions in SS pts receiving G-CSF after ASCT, similar to our neoplastic pts. Since the number of infused CD34+ cells was similar, integrity of marrow microenvironment and better harvest due to lack of previous chemotherapy are the main reasons for the diff erent behaviour of neoplastic and nonneoplastic pts. Nevertheless, the role of G-CSF administration should be not overlooked, so raising the questions to whether G-CSF administration is cost eff ective in AID.

Transient improvement of severe and rapidly progressive dysphagia with autologous peripheral blood haematopoietic stem cell transplantation in a patient with long standing dermatomyositis refractory to standard therapy F. Milanetti (1) Soon after HSCT, dysphagia disappeared and PEG could be removed for 18 months. Twelve months after HSCT, infl ammatory oedema on MRI resolved and muscle enzymes normalized. Flowcytometric study showed naïve and regulatory T cell increase and memory T cell and NK reduction, assessing immunological reset after transplantation. However, arm muscle strength worsened and the patient is still wheelchair bound. HSCT seems to work on still active infl ammatory conditions, but it seems less eff ective when degeneration and cumulative damage predominate. In fact, HSCT in this case was eff ective on dysphagia, even though only transiently, likely due to recent infl ammatory involvement of pharyngeal muscles.

Successful autologous stem cell transplantation in a girl with neuropsychiatric systemic lupus erythematosus V. Bordon, P. Verloo, Y. Benoit, S. Verbeek, C. Dhooge Ghent University Hospital (Ghent, BE) Introduction: Neuropsychiatric Systemic Lupus Erythematosus NPSLE)is a rare, chronic auto-immune disorder characterized by either diff use (e.g. encephalopathy, coma, depression and psychosis) or complex presentation (e.g. encephalopathy with stroke or seizure). Disturbances of the cognitive function are a frequent problem. Autologous hematopoietic stem cell transplantation (ASCT) has shown to be an eff ective approach in those patients with SLE who are resistant to standard therapy. Case report: A 15-year old girl was referred with progressive symptoms of fatigue, weight loss and anorexia. These symptoms started at the age of 10 years. The following years symptoms worsened and she developed headaches, depressive thoughts with catatonic as well as obsessive-compulsive and psychotic behaviour with multiple suicidal attempts. Laboratory investigations revealed leuco-and thrombopenia, as well as a positive ANF, with anti-ENA RNP-a, RNP 70-k and RNP-c, suggestive for an auto-immune disorder. MRI of the brain was normal, but EEG was abnormal and the skin biopsy revealed IgG-deposition along the basal membrane. Initial treatment with corticoids and hydroxychloroquine resulted in improvement. However, after three months symptoms worsened and were resistant to subsequent treatment (Corticoids, low dose cyclophosphamide, plasmapheresis and anti-CD20 monoclonal antibodies). Finally, an ASCT according to the EBMT-ASTIL guidelines was performed. PBSC harvest was done after Cyclophosphamide 2X2g/m2).The conditioning regimen consisted of cyclophosphamide 200 mg/kg and ATG 7.5 mg/kg. There were no severe problems with the conditioning regimen. The ASCT resulted in a spectacular improvement of the neuropsychiatric disabilities of this patient.

Discussion: Patients with NPSLE who are refractory to conventional treatment can achieve clinical remission after ASCT. This improvement is due to immunological changes that can not be achieved with other treatments. Patients should be considered for ASCT if a) they are resistant to fi rst line treatment b) there is a high mortality risk due to de NPSLE, in this case suicidal attempts c) ASCT should be performed before irreversible organ damage has occurred.

Iron overload in patients with haematological disorders undergoing allogeneic HSCT: unrevealed implication in diff erent outcomes M. Michallet, M. Sobh, S. Morisset, H. Labussière, M. Detrait, S. Ducastelle, F. Barraco, Y. Chelghoum, A. Cordonnier, R. Cohen, X. Thomas, F. Nicolini, C. Chapuis-Cellier Centre Hospitalier Lyon-Sud (Pierre Benite, FR) The main objective of this study was to determine the impact of serum ferritin level on the different allogeneic HSCT outcomes in adult patients with hematological disorders. We included 158 patients, 100 males and 58 females with a median age of 45 years (18-67) The median serum ferritin level at HSCT was 1327 microg./l (26-14136); 31(20%) patients had a level 26-500, 33 (21%) had a level 500-2500, and 94 (59%) >2500. There were no significant correlation between the different ferritin levels, disease kind and status at HSCT. Twenty two patients received iron chelating agents. The cumulative incidence of acute GVHD ≥ II at 3 months was 14% (11-16.5) with 10.5% (8-13) for grade III and 7% (5-9) for grade IV; the 1 year cumulative incidence of limited and extensive chronic GVHD were 4% (2-6) and 12.4% (9-16) respectively. After a median follow-up of 18 months , the median OS was 25 months (16-NR) with a 2 years probability of 50% (43-59). The median PFS was 13.5 months (9-25) with a 2 years probability of 43% (34-50). The cumulative incidence of relapse at 1 year was 31% (27-34), the TRM rate was 6.5% (4.5-8.5 ) and 20% (17-23.5) at 3 months and 1 year respectively. Multivariate analysis found that ferritin level >500 has a significant impact on OS which is explained by a significant higher TRM for patients with level >2500 and a significant mortality after relapse in patients with level 500-2500 (figure). The analysis on eff ect of iron chelating agents is ongoing and results will be communicated later.

In conclusion, we should give a better attention to iron overload, confer an effi cient follow-up of this parameter and provide a treatment strategy after allo-HSCT especially when its level reaches 500μg/l at transplantation.

Maintenance therapy with decitabine after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and high-risk myelodysplastic syndrome I. Pusic, J. Choi, N. Bernabe, C. Abboud, P. Westervelt, R. Vij, A. Cashen, G. Uy, K. Stockerl-Goldstein, M. Holt, J. DiPersio Washington University School of Medicine (Saint Louis, US) Introduction: Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (alloSCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS Conclusions: Using calcium-phosphate mouth rinse as prophylaxis reduced the incidence of severe mucositis WHO grade III and IV as well as duration of parenteral nutrition. Although oral mucositis still remains a medical challenge, calcium-phosphate rinse allowed almost half the patients to receive an autologous stem cell transplant with BEAM conditioning without having to experience severe mucositis.

Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients J. El-Cheikh, G. Venton, R. Crocchiolo, S. Furst, A. Granata, C. Oudin, C. Faucher, L. Castagna, D. Coso, R. Bouabdallah, P. Berger, N. Vey, P. Ladaique, M. Merlin, C. Chabannon, D. Blaise Institut Paoli Calmettes (Marseille, FR) Objectives: Cytomegalovirus (CMV) infection is a serious complication that may occur in the weeks or months following bone marrow transplantation. However, GANCICLOVIR (GCV) as well as CMV infection itself, includes well-known marrow toxicity, notably neutropenia, that may consequently expose these immunosuppressed patients to life-threatening bacterial and / or fungal infections. The aim of this retrospective study was to identify factors associated with the occurrence of grade III-IV neutropenia among patients receiving preemptive GCV therapy after allogeneic stem cell transplantation (Allo-SCT) at our Institution over the last years. Patients and Methods: We identifi ed 547 consecutive patients transplanted from January 2005 to June 2011 at our Institution. One Hundred ninety patients (35%) presented CMV reactivation. Thirty patients (5%) were excluded from the analysis because they already had neutropenia at the time of reactivation. Finally, 160 (29%) patients were analysed. Results: According to multivariate analysis, at the time of treatment initiation, the risk factors signifi cantly associated with a grade III-IV GCV-related neutropenia included a high viral load (HR=2.68, CI 95%, 1.25-5.737, p = 0.01); ANC over 3000 was a protective factor (HR= 0.26, CI 95 %, p < 0001) while serum creatinine higher than 2 mg/dL was associated with higher GCV-related neutropenia (HR= 2.4, CI 95%, p = 0.002) .

Conclusions: This large analysis revealed three risk factors for GCVrelated neutropenia among patients with CMV reactivation after Allo-SCT; prompt identifi cation of patients at risk when antiviral therapy is started may allow clinicians to adopt adequate preventive measures, thus reducing the morbidity and mortality associated with CMV reactivation.

Severe acute hepatitis following administration of rabbit antithymocyte globulin in reduced-intensity conditioning regimen before allo-SCT. A single centre experience C. Médiavilla, S. Vigouroux, R. Tabrizi, A. Pigneux, N. Milpied Service d'hématologie (Pessac, FR) The liver toxicity of antithymocyte globulin (ATG) in reduced intensity conditioning (RIC) regimen does exist, but its knowledge is limited by the scarcity of available data. To explore the severe acute liver toxicity of ATG in this setting, we undertook a retrospective analysis in our center between Jan 2008 and Apr 2012. During this period, 186 RIC allo were performed with the same regimen of fl udarabine (30 mg/m 2 /day from d-5 to d-1), IV busulfan (0.8 mg/kg x 4/day at d-4 and d-3) and rabbit ATG (Thymoglobulines,® 2.5 mg/kg/day at d-2 and d-1). 27 patients (pts, 14%) developed a severe acute hepatitis (SAH) defi ned by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 10 x ULN shortly after the administration of ATG. Their median age was 57 years . One patient had a chronic C hepatitis before allo while none had a history of B hepatitis. No patient was receiving azoles at the time of hepatitis. No virus was detected in blood by PCR (EBV, CMV, B and C hepatitis). The maximum median levels of AST and ALT were 22 x ULN and 26 x ULN (9-109), respectively. The median time between start of ATG and SAH was 2 days (1) (2) (3) . No patient died of liver failure and the liver function tests improved in all cases with a median time to reach transaminases <5 x ULN and <2 x ULN of 7 days (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and 14 days (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , respectively. The second day of ATG was cancelled in 8 patients when SAH was noted immediately after the 1st day. The prothrombin test was below normal in 15 pts with a median of 40% (19%-68%) but rapidly went back to normal in less than 1 week. No patient developed VOD or acute GVHD of the liver. One patient developed chronic GVHD of the liver 11 months after transplant. With a median follow-up of 20 months , the 2-year OS, EFS, NRM, and relapse incidence were 75% ± 10%, 61% ± 11%, 6% ± 6%, and 32% ± 10%, respectively. The cumulative incidences of acute GVHD II-IV and extensive chronic GVHD were 15% ± 7% and 15% ± 8%, respectively. All these results (survival, NRM, relapse, GVHD) were similar in pts receiving 1 or 2 days of ATG. The incidence of SAH following ATG in RIC regimen is 14%. We report that transaminases rapidly normalized in all patients, that no patient developed severe liver failure, VOD, or acute GVHD of the liver. Our study does not provide any evidence that SAH following ATG might favor NRM and thus adversely aff ect the outcome of RIC allo.

High incidence of post-transplant lymphoproliferative disorder in the last two years, after allogeneic stem cell transplantation with thymoglobulin-based conditioning L. Yañez, M. Gonzales, E. Cuaresma, A. Bermudez, C. Richard, E. Conde, A. Insunza Hospital Marques de Valdecilla (Santander, ES) Introduction: The incidence of post-transplant lymphoproliferative disorder (PTLD) in the setting of allogeneic stem cell transplantation (allo-SCT) is lower than 2% and its risk is strongly associated with T-cell depletion and/or antithymocyte globulin use, and also with unrelated or HLA mismatched grafts, older age at SCT, and multiple transplantations. Thymoglobulin is a rabbit anti-human thymocyte globulin with a high variability in its lymphocytotoxic activity. Moreover, in August 2012, some lots of ATG were withdrawn because one of them, manufactured at the end of 2009, failed a periodic stability test for the molecular size distribution. Objectives: To analyze the incidence of post PTLD in allo-SCT in our center since the year 2000. Patients and methods: Between 2000 and July 2012, 465 allogeneic transplants were performed in our center. They were divided into four periods (1st: 2000-2003: 105 pts, 2nd: 2004-2006: 94 pts, 3rd: 2007-2009: 142 pts and 4th: 2010-2012: 124 pts) . Results: The table shows transplant characteristics. Unrelated donors, fludarabine-based conditioning regimens and bone marrow as stem cell source increased in the latest periods, but there were no differences between the 3rd and 4th periods. Thymoglobulin was used in 92 patients: 1st:10 pts (12%), 2nd:23 pts (26%), 3rd:27 pts (19%), 4th:32 (26%) and total doses were 7.5 or 8 mg/Kg in all periods. The presence of more than 2 risk factors for PTLD was similar between the 3rd and 4th periods (13% vs 15%, p=0.3). With no cases of PTLD in the first 3 periods, 8 patients developed an early PTLD (median 55 days, 45-70) in the 4th period (6.5%). All patients had received Thymoglobulin. They were young (mean age 35 years: 5-59) and had a median of 2 risk factors (1) (2) (3) . They were heterogeneous in diagnosis (acute leukemia 3, aplastic anemia 3, NHL 1 or multiple myeloma 1), stem cell source (BM 3, PB 3, UCB 2) and donor type ( MRD 2, MUD 1, MMUD 5) . Clonality was found in 5 patients (63%) and 4 patients died, being refractory to rituximab ± chemotherapy. Conclusion: We have observed a recent important increase in the incidence of PTLD in our patients, confi ned to those who have received Thymoglobulin in the last two years without changes in our procedure. As 5 of the 8 aff ected patients had received one of the lots that were later withdrawn, we think that more studies are needed to identify other atypical clusters of PTLD and clarify their association with these or other lots.

Hyaluronic acid treatment of post-haematopoietic stem cell transplantation haemorrhagic cystitis M. Piris-Villaespesa, MA. Cabero Becerra, C. Regidor, R. Fores, J. Carballido, JI. Martinez-Salamanca, JA. García-Marco, G. Bautista, I. Krsnik, E. Ojeda, S. Gil, B. Navarro, A. De Laiglesia, JL. Bueno, C. Muñoz, M. Santero, JR. Cabrera Hospital Universitario Puerta de Hierro (Madrid, ES) Introduction: Hemorrhagic cystitis (HC) is recognized as an important complication after haematopoietic stem cell transplantation (HSCT). HC can be divided into early and late onset, being the conditioning regimen toxicity more involved in early HC and virus reactivation (more frequently polyoma BK virus) in late onset HC. Currently there are several treatments but no eff ective prophylaxis or treatment for this disease.

We report the results of the treatment with hyaluronic acid (HA) in ten patients with HC after HSCT. Patients and methods: In period from Jan 2007 till June 2012, 10 patients out of 157 who underwent HSCT at our institution developed HC grade ≥ II. These patients received weekly instillations of 40mg (50ml) intravesical HA and then the catheter was clamped for a minimum of 30 min. Instillation was repeated once weekly until symptoms improved. We defi ne complete response (CR) as disappearance of all symptoms (hematuria, dysuria, etc) and partial response (PR) as persistence of macroscopic hematuria, with disappearance of blood clots and transfusion requirements. Results: We described 10 cases of HC with a median age of 37 years (range 19 -58). The median ANC engraftment was 12 days and 39 days for platelets. Three patients had acute graft versus host disease (aGvHD). The median HC onset was 34 days, 2 patients developed grade IV, 6 grade III and 2 grade II. The median platelet count at onset was 28.5 x 10 6 / l. JC-BK virus were excreted in urine at onset in all patients (see table 1 ). At the beginning, all patients were treated with hyperhydration and blood transfusions. Bladder irrigation was performed for prevention of clots in 6 patients and in one case cidofovir was added. Then, when the initial treatment failed, we proceeded to intravesical instillation of HA. Seven patients had a CR and three patients had a PR. One patient who achieved PR had recurrence of HC 10 days after and fi nally died. In one patient we also proceeded to the infusion of stromal mesenchymal stem cells, achieving a good response. The median response to treatment was 8.4 days (1-35) (see table 2 ). No serious side eff ects were observed. Conclusions: Hyperhydratation and blood transfusions are a commonly accepted treatment but are ineff ective as the sole treatment in most cases. As previously data support Hyaluronic acid instillation is an eff ective and safe treatment and should be the fi rst choice in cases of HC post HSCT.

[P1009]

Low tranplant-related mortality and low graft rejection after related haploidentical stem cell transplantation (HAPLO-SCT) prepared with non-myeloablative conditioning regimen (NMA) and post-transplant cyclophosphamide for advanced lymphoid malignancies S. Fürst, R. Crocchiolo, J. El Cheikh, C. Faucher, L. Castagna, C. Oudin, A. Granata, G. Venton, C. Lemarie, B. Calmels, D. Coso, R. Bouabdallah, A. Stoppa, N. Vey, C. Chabannon, D. Blaise Institut Paoli-Calmettes (Marseille, FR) Introduction: Haplo-SCT has become an alternative transplant option for patients with no HLA identical donor available. However, it is associated with high risk of graft rejection (GR) and severe graft versus host disease (GvHD Conclusion: NMA haplo-SCT with postransplant Cy in pt with advanced lymphoid malignancies is associated with low NRM, low acute GvHD and low GR. However, better disease control in selected pt is needed to overcome early relapse or progression. Even if follow-up is short, PBSC seems to be a promising option to BM as stem cell source.

Enteral-based nutrition is associated with better early outcomes in allogeneic myeloablative haematopoietic stem cell transplantation C.E. Mactier, J. Beckerson, R. Palanicawandar, M. Lasa, R.M. Szydlo, D. Slade, D. Marin, D. Milojkovic, E.J. Kanfer, A. Rahemtulla, J.F. Apperley, J. Pavlu Imperial College London at Hammersmith Hospital (London, GB) Inadequate nutritional intake is an early complication of myeloablative allogeneic stem cell transplantation (SCT) and is associated with increased morbidity and mortality. Current guidelines are inconclusive regarding the optimal route for nutritional support and clinical evidence that enteral nutrition (EN) may reduce nonrelapse mortality (NRM) and the incidence of acute graft-versushost disease (aGVHD) is very limited. We analysed the eff ect of EN versus parenteral nutrition (PN) on NRM and on incidence of aGVHD, particularly of the gut, in 111 consecutive patients undergoing fi rst myeloablative SCT between 2004 and 2011. Their disease stage was categorised according to EBMT criteria: early (50%), intermediate (32%) and late (17%). Conditioning consisted of cyclophosphamide and TBI. Recipients of sibling grafts (n=29) received GvHD prophylaxis with cyclosporine and methotrexate. Additional T-cell depletion with in vivo alemtuzumab was used in recipients of unrelated cells. In patients with inadequate oral intake, nasogastric feeding (NG) was initiated. If NG was declined or not tolerated, parenteral nutrition (PN) was used. According to the feeding route the patients were classifi ed into two groups: 1) PN group (N=48, 43%) with patients receiving ≥ 4 days of PN (median 13 days, range 4-43) and 2) EN group (N=63, 57%) with those who did not receive any artifi cial nutrition support (N=23), those with ≥ 4 days (median 12, 4-43 days) of NG feeding only (N=25), and patients with ≥ 4 days (median 8 days, 4-32) of NG feeding and additional PN (median 11 days, 4-27; N=15). The EN group had lower NRM compared to the PN group in univariate analysis (14% versus 40% at 200 days, p=0.035, fi gure). In multivariate analysis, this survival advantage was confi ned only to those with late stage disease. Incidence of aGVHD grades 3-4 was reduced in the EN group compared to PN group with fi ve (7.8%) versus 12 (25.5%) patients aff ected (p=0.01). EN group also had lower incidence of gut aGVHD (28.1% versus 46.7%, grades 3-4: 1.6% versus 10.6%, p=0.008).

Enteral-based feeding is linked to an improvement in early mortality and reduced incidence of aGVHD, particularly gut disease, following SCT. Further studies are required to better understand this relationship.

Delayed platelet recovery predicts poor transplantation outcome after unmanipulated haploidentical stem cell transplantation Y. Sun, D. Liu, L. Xu, X. Huang Peking Univerisity Institute of Hematology (Beijing, CN) Objects: The signifi cance of delayed platelet recovery in patients received unmanipulated haploidentical stem cell transplantation has not been studied. The present analysis aimed to reveal the relationship between platelet recovery and the transplantation outcome.

Methods: Patients received haplo transplantation between Jan 1, 2007 to Dec 31, 2008 were retrospectively reviewed. They were categorized into 3 groups according to the platelet count on day 30, day 60 and day 90. (1) persistent thrombocytopenia (group A) was defi ned as the platelet never arrived 50×109/l on the three time points; (2) unstable thrombocytopenia (group B): (a) when the platelet count did not recover to a level of 50×109/l by day 30 or day 60,then rebounded to a level of 50×109/l by day 60 or 90, yet did not reach a level over 100×109/l, or (b) when the platelet count recovered to a level over 50×109/l by day 30, yet did not reach a level above 100 ×109/l by day 60 or 90;(3)non-thrombocytopenia (group C) indicated that the platelet count was higher than 100×109/l on day 90. The overall survival (OS), treatment related mortality (TRM) and relapse rate (RR) were compared between 3 groups. Results: A total of 291 consecutive patients were reviewed. Three patients died befored day 28, and all the other 288 patients engrafted. The cumulative incidence of grade III-IV acute graft versus host disease (GVHD) on day 100 was 14.7%, and the cumulative incidence of chronic GVHD on year 3 was 56.4%. The median time of neutrophil engraftment was 13 (9-29) days. And 262 patients were platelet transfusion independent at the last follow-up. Group A, B and C accounted 24.4%, 50.5% and 25.1% respectively. OS in group A, B and C was 38.0%, 69.4% and 80.8% (p<0.001) respectively. TRM in group A, B and C was 53.5%, 17.7% and 1.4% (p<0.001) respectively. And there was no diff erence on relapse rate in 3 groups (p=0.69).

Conclusions: Delayed recovery of platelet count was common after unmanipulated haploidentical stem cell transplantation, and it predicted poor OS and higher TRM.

Infusion of donor peripheral cell harvest for poor graft function after allogeneic stem cell transplantation: a single centre experience Y. Sun, D. Liu, L. Xu, X. Zhang, K. Liu, X. Huang Peking Univerisity Institute of Hematology (Beijing, CN) Objects: Poor graft function (PGF) is a common complication after allogeneic stem cell transplantation, which was associated with high mortality. The effi cacy of donor peripheral cell harvest for PGF was retrospectively analyzed in present study. Methods: The peripheral cell harvest was aphaeresis on the fourth or fi fth day after mobilization with recombinant human granulocyte colony stimulating factor. Hematogical response was assessed at 30 days after infusion. Good response was defi ned as neutrophil > 1.0×109/l without G-CSF support for at least 3 consecutive days, and persistent platelet >20×109/l without transfusion for at least 7 days. Otherwise, poor response was defi ned. Results: Twenty-eight patients with PGF between 2003 to 2012 were infused with donor peripheral cell harvest. There were 21 male and 7 female. The median age was 28 (12-50) years. Of these patients, 12 were primary PGF. The median nucleated cells infused were 2.0 (1.0-5.8) ×108/kg. One patient died of infection within 30 days after infusion, and the other 27 patients were evaluable for hematological response. And 44.4% (12/27) acquired good response. Age (≤/>median=28 years), gender, donor type (matched sibling/mismatched related), additional conditioning prior infusion, time of infusion (≤/>100 day) and number of infused nucleated cell (≤/>median=2.0×108/kg) has no impact on hematological response. However, reponse in primary PGF (3/15, 20%) was signifi cantly lower than secondary PGF (8/12, 75%) (p=0.022). Conclusions: Infusion of donor peripheral cell harvest could be an option for treating poor graft function after allogeneic stem cell transplantation, especially for those patients with secondary PGF.

Hepatic toxicity and VOD after allogeneic stem cell transplantation (SCT): the role of prophylactic defi brotide and application route of busulfan B. Glass, V. Bastubbe, S. Dingeldein, M. Nickelsen, M. Zeis, N. Schmitz Asklepios Klinik St. Georg (Hamburg, DE) Hepatic toxicity and veno-occlusive disease (VOD) are serious early events after allogeneic SCT. A recent meta-analysis revealed an incidence of 12.9% for allogeneic SCT (Copell et al 2010) . Busulfan as part of the conditioning regimen has been identifi ed as an important risk factor for VOD. We investigated whether intravenous (IV) busulfan or the prophylactic use of low-dose defi brotide might result in lower incidences of VOD and hepatic toxicity. From January 2008 to June 2011, 165 consecutive patients received an allogeneic SCT preceded by busulfan-containing conditioning with 2 (n=64) 3 (n=76) or 4 days (n=35) of Busulfan (4 mg/kg BW/day orally or 3.2 mg/kg BW/day i.v., total dose 8 to 16 mg/kg orally). The median patient age was 57 years (18-75 years). Advanced disease (leukemia > CR1, lymphoma at least 2 prior treatment lines) was present in 123 / 165 pts (75%). Ninety-one pts had myeloid neoplasia, 71 had lymphoid malignancy and 3 pts non -malignant disorders. Oral busulfan was given in 133 patients and an i.v. formulation (Busilvex®) was used in 32 pts. Defi brotide prophylaxis (2.5 -7.5 mg/kg/day) was scheduled from day -7 to day +21 in all patients with 3 or 4 days of oral busulfan and was received by 108 pts. The overall incidence of VOD according to Baltimore criteria was very low with only 5/165 pts (3%) developing VOD in this high-risk group of patients. Due to the low incidence of VOD a meaningful risk -factor analysis was not possible. The incidence of hepatic toxicity grade 3 and 4 was 24.4% and 7.3 %, respectively. Grade 4 hepatic toxicity was associated with an extremely poor prognosis with no patient surviving. Grade 4 hepatic toxicity was only seen in patients treated with oral busulfan. Overall, there was a trend to better overall survival in patients given iv busulfan (64.8 % vs 48.7% at 1 year p=0.15885). In patients with four days of busulfan application the diff erence in overall survival was significant (83.3% vs 35.9% at 1 year p=0.2712). However, the number of patients was small in that latter subgroup. We conclude that using oral busulfan at doses of 8 to 16 mg/kg BW with defi brotide prophylaxis or iv busulfan without prophylaxis both result in a low incidence of VOD. When busulfan is administered at full dose (4 days of application, 16 mg (13.2) mg/kg BW) i.v. busulfan might be preferable over oral busulfan.

The Patients with the need of elective ventilation linked to surgical procedures were excluded. Survivors were defi ned as all patients who were extubated and respired spontaneously without need of any support at least 3 weeks. The evaluated parameters were age, duration of ventilation, time from the HSCT, conditioning regimen, the reason of respiratory failure, history of GVHD, intensity of pretreatment, the necessity of reintubation, the need of continuous renal replacement therapy and the presence of neutropenia at the moment of intubation. Results: In total, 99 pts were provided with mechanical ventilation 78% pts died, 22% survived. The survival at 6 months was 13%. Surviving pts did not diff er from dead in age. In pts ventilated prior the day 100 after HSCT the ratio of surviving was 27% against 18% ventilated later. The percentage of pts who died within 24 and 48 hours of ventilation was 14% and 21% respectively. Median of ventilated days was 8 in surviving against 16 in dead. 15% of patients with acute GVHD gr. III and IV survived in contrast to 27% of patients without this complication. In pts with cGVHD it was 7% versus 26%. Patients with reduced intensity conditioning survived in 39% vs 14% with myeloablative. The intensity of pretreatment did not diff er between the two groups. The necessity of re-intubation did not seem to worsen the outcome. Cytomegaloviral pneumonitis and invasive aspergillosis lead nearly always to dead, while patients with non-infectious pneumonitis and disturbances of consciousness survived more frequently. Conclusion: Patients after allogeneic HSCT whose state of health came to the need of mechanical ventilation have considerable unfavourable prognosis, lasting long term after transplantation. However this way of treatment is life-saving procedure for a definite proportion of pts. According to current knowledge it is impossible to predict who will profit from the treatment in the time of intubation and frequently in the course of ventilation as well.

Therapeutic applicability of an algorithm adapted to the risk of BK virus haemorrhagic cystitis in patients undergoing allo-SCT N. Castillo, I. Ruiz, P. Barba, S. Bobillo, J. Montoro, F. Bosch, D. Valcarcel Hospital Vall Hebron (Barcelona, ES) Background: BK virus hemorrhagic cystitis (BKV-HC) is a potential serious complication that increases in incidence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) without established standard treatment. Methods: We retrospectively evaluated the applicability (effi cacy and safety) of a risk-adapted algorithm of treatment in patients with BKV-HC occurred after allo-HSCT. BKV determination was held by RT-PCR techniques. In our algorithm, BK virus viremia was tested in all patients with symptomatic BKV-HC. Patients with positive viremia received systemic cidofovir (SC, 1 mg/kg/day/iv, 3 days/week) and those without viremia, intravesical cidofovir (IVC, 5 mg/kg/week in 60 cc of serum for 1 hour). Failure to IVC was defi ned if symptoms persisted after 2 weeks of therapy. All patients were treated until disappearance of symptoms regardless of viral clearance. Patients who failed to local treatment received SC. Results: 57 consecutive allo-HSCT performed in our centre between September 2009 and April 2012 were included. The median follow-up was 12 months (range 2-31). Nine patients (16%, 60% women) with a median age of 35 years (range 18-62) had HC-BKV after a median of 35 days (range 12-132) post allo-HSCT (n=7 unrelated donor). Most patients received myeloablative conditioning (n=8) including ATG. All patients showed hemorrhagic cystitis grade II-III with symptomatic viruria and viremia was detected in 2 cases. Urine BKV viral load at diagnosis was higher than 2.6 x 109 copies/mL in all cases. Regarding treatment, 6 patients received IVC (median 2 doses, range 1-4) and 3 SC (median 2 doses, range [1] [2] [3] [4] . The response, at 30 and 60 days, was complete in 2 and 4 cases respectively and partial response in 4 and 2 cases, respectively. Two patients were not response evaluable due to they presented a relapse of the underlying disease. One patient presented a HC-BKV relapse 4 weeks after and responded to systemic retreatment. A moderate transient acute renal failure was recorded in 2 out of 3 patients who received SC. IVC was well tolerated with no related toxicity and could be administered on an outpatient basis in 5 out of 6 patients. Conclusions: BKV-HC is common, especially in allo-HSCT recipients from unrelated donor. The application of a treatment algorithm based on the risk has been proven safe and eff ective, with any observed progression of infection in treated IVC patients. These data should be consolidated into a larger number of patients.

Acute cardiac toxicity following mobilization chemotherapy with high-dose cyclophosphamide and etoposide H. Ozkan (1) Results: Of 65 patients, 36 received CY, and 29 received ET as a mobilization regimen. While lymphoma was the major underlying disorder consisting ET group, it was multiple myeloma in CY group (p<0.001). Therefore, median cumulative anthracycline dose was signifi cantly higher in ET group than CY group (p<0.001). Patients consisting ET group was younger than the CY group (p=0.012). NT-proBNP levels were increased in almost all patients, except 2 from CY group in who NT-proBNP levels were decreased compared to base line measures. The mean baseline NT-proBNP levels were not signifi cantly diff erent between the CY and ET group (119.5 vs 149, respectively, p>0.05). A signifi cant diff erence between the median NT-proBNP levels at baseline and at 6 hours after MC was observed for the both group of 63 patients (p<0.001). Furthermore, we noted that change in plasma NT-proBNP levels in ET group was statistically more powerful than the CY group (p=0.001). The reason may be the higher cumulative anthracycline dose in ET group than CY group. 2 patients from the both groups who had antecedent aortic and mitral valve pathologies developed acute congestive heart failure and pulmonary edema during the MC with a peak NT-proBNP levels over 20.000 pgr. Conclusion: Our results suggest that HD CY and ET given as a MC causes very acute cardiac toxicity, and plasma NT-proBNP monitoring seems to be useful for early detection of patients at highrisk for cardiac dysfunction in HSCT.

The impact of pre-transplant hypoalbuminaemia on survival in patients with leukaemia who underwent allogeneic haematopoietic stem cell transplantation (allo-HSCT): a nutritional problem? S. Sivgin, S. Baldane, T. Ozenmis, M. Keklik, L. Kaynar, G. Zararsiz, B. Eser, M. Cetin, A. Unal Erciyes University (Kayseri, TR) Objectives and aim: Serum albumin level is considered a marker for refl ecting the nutritional status in both healthy subjects and patients with malignancies. In this study; we aimed to investigate the association of pre-transplant serum albumin levels with prognosis in patients with leukemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT). Materials and methods: We retrospectively analyzed the data of 102 patients who underwent alloHSCT from 2004 to 2010 in Dedeman Stem Cell Transplantation Hospital, Kayseri, Turkey. A pretransplant serum albumin, D-dimer, creatinin, and fi brinogen levels drawn within 10 days prior to the transplantation were obtained from the patient fi les. All parameters were divided into two groups; patients with normal levels as Group 1 and patients with abnormal levels as Group 2. In our biochemical laboratory devices; the normal range of serum albumin is defi ned as 3. S351 P1020 Rapid reductions in bone mineral density are seen in the fi rst 100 days post-allogeneic stem cell transplant I. Sekhon, D. Kendler, R. Broady Leukemia/BMT Program of BC (Vancouver, CA) Both the underlying hematologic malignancy and stem cell transplant (SCT) procedures may present risks to bone. Given the frequent long-term survival after SCT, protecting bone health in this population is particularly important. Chemotherapy, glucocorticoid therapy, and the acute eff ects of transplanted bone marrow on the bony environment all may contribute to an early and rapid decline in bone mineralization. We studied patients with a variety of hematologic malignancies who underwent SCT between 2011 and 2012. 31 had available both pre-and 100 days post-SCT bone mineral density studies. TThe hematologic diagnoses were AML: 14; ALL: 8; CLL: 2; R AEB: 2; other: 5.

Signifi cant decreases in bone density were seen at both hip and spine sites (spine -0.13 g/cm2, or 4.16%; total hip -0.051 or 5.1%; and femoral neck -0.050 or -8.6%). 18 of the 31 patients were managed with glucocorticoid and similar changes in bone were observed (LS -4.08%; TH -6.99%; FN -7.6%). Patients often had signifi cant weight change over the fi rst 100 days post transplant, however this was not signifi cantly associated with changes in bone mineralization. We conclude that signifi cant declines in bone mineralization both the trabecular and cortical bone sites can be observed in the fi rst 100 days post-allogeneic SCT. These changes appear to be more related to the SCT procedure and potentially the interaction of the transplanted bone marrow with the local bone environment then to medication such as glucocorticoid therapy. This indicates the need for patients to be monitored for bone health subsequent to SCT procedures which would aff ord an opportunity for early intervention for patients at risk of bone loss. Hemorrhagic cystitis (HC) is a major complication in patients undergoing hematopoietic stem cell transplant (HSCT), with a spectrum of manifestations ranging from microscopic hematuria (grade 1) to severe hemorrhage with obstructive renal failure (grade 4). Early bleeding (24-72 hours after transplant) is usually ascribed to toxic eff ects of drugs, while reported predisposing factors for late-occurring cystitis (post-engraftment) include viral infections (polyoma BK virus, cytomegalovirus and adenovirus), allogeneic transplant from matched unrelated donors, graft-versus-host disease (GVHD), thrombocytopenia, coagulopathy, and, fi nally, the conditioning regimens. The aim of this study was to evaluate the risk factors for HC in 121 thalassemia major patients who had undergone allogenic HSCT. In 34 of these the HSC donor was a matched unrelated donor (MUD), while 87 HSCT were from siblings. The conditioning regimen was myeloablative in all patients. Thirty-one were conditioned with tiothepa, treosulfan and fl udarabine, 90, all children (mean age at HSCT 5.6 years), with busulfan and cyclophosphamide. Acute GVHD occurred in 72/121 patients (59%). The GVHD prophylaxis was performed with cyclosporine and methylprednisolone in matched sibling transplants, antithymocyte globulins were added in MUD transplants. HC occurred in 20 patients (16.5%): grade 1 in 3, grade 2 in 5 and grade 3 in the remaining 9. Sixteen subjects (18%) had undergone conditioning regimens with busulfan and cyclophosphamide, 4/31 (13%) tiothepa, treosulfan and fl udarabine (p=0.21). Thirteen HC patients presented concomitant aGVHD whilst 7 did not (p=0.09).

MUD-transplanted patients had an analogue risk to develop HC like the sibling transplanted patients (17.6% vs 16, p=0.8) .

Urine BK virus positivity was seen in 7 patients in whom it was possible to perform quantitative PCR analysis and cidofofovir was used in 6 of these. Hyperhydration was the only treatment employed in all other subjects. In all cases, recovery from HE was successful.

In conclusion, this study confi rms that HE is a frequent complication in HSCT thalassemia patients. Myeloablative conditioning regimen type does not impact HE frequency. The only factor which seems to have any relevance, although it is not of any statistical signifi cance, probably due to the limited number of patients, is acute GVHD and the consequent immunosuppression which increases bladder damage by polioma BK, like other viruses and drugs. Monitoring: all centers reported mucositis data recording on medical record, in 1/6 center accompanied by electronic database recording; WHO scale was commonly used in all centers, 2/6 centers only using a mucositis-related-pain scale. Prevention: 2/6 centers only reported using oral criotherapy (for high dose melphalan); no center commonly used palifermin; oral mouth rinses use in 5/6 (combination of antimicrobial agents and sporadic use of other agents, such as probiotics, electrolytic or barrier solutions). Total parenteral nutrition (TPN), simple or with addition of glutamine or omega acid, in 3/6 centers. Mucositis treatment showed homogeneity: analgesics, NPT, protonic pomp inhibitors and anti-diarrhoeal drugs in 6/6 centers. Missing measures / center were 2, 1 and 0 in 4, 1 and 1 center, respectively. Not-required measures: 1 in each center. Overall, 15 missing or not-required prescriptions were identifi ed: 10 for prevention, 4 for monitoring and 1 for treatment. Conclusions: Heterogeneity level could be addressed as high, intermediate and low for prevention, monitoring and treatment of mucositis, respectively. We will pursue standardization and sharing of prevention, monitoring and treatment protocols, as recommended by the existing guidelines.Full adherence to guidelines would provide: direct cost savings and prophylaxis effi cacy improvement, as well as symptoms burden, rescue therapy and indirect costs reduction. Introduction: In patients with cancer, loss of weight and of active cell mass are prognostic unfavourable. Because little is known about alterations in active body cell mass in patients with hematological malignant diseases, we evaluated weight loss and body composition in patients during and after autologous stem cell transplantation (SCT). Methods: Twenty-six patients were included: Multiple Myeloma (n = 14), Lymphoma (n = 8) and Acute Myeloid Leukemia (n = 4). Body weight was measured at admittance, before SCT and weekly after for three months. Body composition was assessed by the labelled water method at admittance, at discharge and at three months after SCT. Fat free mass (FFM) and fat mass (FM) were calculated from total body water (TBW) assessed by using deuterium-dilution. Combined with the determination of extracellular water (ECW) with bromide-dilution, the intracellular water (ICW) was assessed and used as a measurement for the active body cell mass. Results: Mean weight loss during hospitalization was 3.4% ( Figure I ).

In total, 81% of patients lost weight and 38% were classifi ed as malnourished during hospitalization (> 5% weight loss within the last month), although 62% received parenteral nutrition. One week after discharge, mean weight loss was 6.0%, and 60% of patients was malnourished. From admittance until three months after SCT mean loss was 3.6% (n = 19). compared to baseline: * p ≤ 0.05 ** p ≤ 0.001 *** p ≤ 0.00001 Body mass and FM were signifi cantly reduced at discharge and after three months; median loss of FM was respectively 14.1% (p< 0.01) and 15.4% (p <0.001). FFM was not diff erent between admittance and these time points, but ICW, a marker of active cell mass, was reduced at discharge and at three months. Median loss of ICW during 3 months was 9.1% ( Figure II) . Conclusion: Almost all patients lost weight during hospitalization for autologous SCT with a mean weight loss of 3.4%. Weight decreased further after discharge and nearly recovered after SCT. Loss of body mass seemed to result from loss of fat mass and of active cell mass. Introduction: Toxic epidermal necrolysis (TEN) is a severe skin disorder involving more than 30% of body surface area that rarely may occur after hematopoietic stem cell transplantation(HSCT).Its clinical characteristics included generalized erythema, maculopapular plaques with darkening of the centre, multiple blister formation and large area of very painful epidermal denudation, oral and genital ulcerations and bilateral conjunctivitis. TEN is usually caused by the administration of some drugs, but the association with viral infections or Graft versus Host Disease (GvHD) has been reported. Patients: During the period between 2005 to 2012, 6 children aff ected by TEN occurred after allogeneic HSCT were diagnosed at

[P1028] S355 our centre. TEN was diagnosed 40 days after HSCT (range 27-131) performed for malignant (n=4) and non malignant diseases (n=2). 4 patients received unrelated donor HSCT (bone marrow-BM in 2, peripheral stem cell in 1, and cord blood in 1) and 2 received related donor BM transplant. Conditioning regimens included total body irradiation in 3 pts, busulphan in 2 and treosulphan in 1.Neutrophils' engraftment occurred 19 days after HSCT (range 11-21). 4 pts developed a-GvHD (grade II in 2, grade III in 1, and grade IV in 1) after a median of 18 days after HSCT (range 13-24). Results: The drugs administered before TEN and for its treatment and patients' outcomes are shown in Table 1 . In 2 pts the skin biopsy confi rmed the diagnosis of TEN. In our experience TEN was probably induced by the association of immunological features such as reactions against drugs (like clarithromycin, voriconazole, ciprofl oxacin, allopurinol, micafungin) and severe a-GvHD, viral infections and other comorbidities such as renal insuffi ciency. Treatments of TEN included supportive treatments, and, whether it is possible, the discontinuation of all potential causative agents, high doses of iv immunoglobulin (n=6), reduction of high dosage of steroids (n=2), etanercept (n=3), and plasmaexchange (n=3). Conclusions: Our experience confi rmed that TEN represent a possible severe complications of HSCT. Careful analysis of drugs and clinical features potentially associated to TEN, examination by experienced dermatologist, and skin biopsy could help in diff erential diagnosis with other skin disorders occurred after HSCT as GvHD since therapy is diff erent. Supportive care and nursing, iv immunoglobulin, reduction of steroids represent the management for these critically patients. Objectives: Severe hepatic veno-occlusive disease (VOD) is one of the most frequent causes of early mortality following hematopoietic stem cell transplantation (HSCT), with mortality rate of 30-50%. The initial event in VOD is the injury of sinusoidal endothelial cells and hepatocytes by chemotherapeutic agents. Coagulation cascade and infl ammatory process are activated and there is progressive venular occlusion and subsequent hepatocellular necrosis. Despite numerous investigations on therapeutic agents such as defi brotide, heparin, prostaglandin E1, and tissue-plasminogen activator, there is no proven defi nitive treatment for VOD. In current analysis, the role of AT-III in hepatic VOD treatment was investigated; AT-III has a potent anti-infl ammatory eff ect by interacting with endothelium and prevents further damage to tissues. Methods: A retrospective analysis was done on pediatric patients who received AT-III as VOD treatment after HSCT at Seoul National University Children's Hospital between June 2008 and June 2012. Twenty three transplanted patients (10 autologous and 13 allogeneic HSCT) underwent AT-III treatment after the diagnosis of VOD. They received three doses of 50 unit/kg/dose of AT-III concentrate every 8 hours and then received further doses every 24 hours. Defi brotide, heparin, prostaglandin E1, and tissue-plasminogen activator and ursodeoxycholic acid were administered in some of the patients. Results: Patients underwent HSCT at a median age of 9.2 years old and VOD was diagnosed at median 18 days after transplantation. The median AT-III level at diagnosis was 67%, and after median 10 doses of AT-III, a median AT-III level of 134% was achieved. Overall, median 18 doses were administered during a median period of 16 days. VOD improved in 16 patients (69.6%) and aggravated in 7 patients (30.4%). Overall, 2 patients (8.7%) died of VOD with multi-organ failure. In the improved group, the median AT-III level was 80% (range 46-121%) at diagnosis and 152% (range 50-285%) after median 9 doses of AT-III. In comparison, in the aggravated group, the median AT-III level was 66% (range 56-84%) at diagnosis and 134% (range 66-295%) despite median 11 doses of AT-III. Conclusion: VOD improved in 69.6% of the study population after median 16 days of AT-III treatment. This study shows that AT-III based treatment may be an eff ective strategy for combating VOD after HSCT.

Early muscle mass and physical strength change after haematopoietic stem cell transplantation T. Takekiyo, K. Dozono, T. Mitsuishi, S. Nara, Y. Murayama, A. Kamekou, N. Nakano, M. Tokunaga, T. Makino, A. Kubota, M. Tokunaga, S. Takeuchi, Y. Takatsuka, A. Utsunomiya Imamura bun-in hospital (Kagoshima, JP) Backgrounds: We reported that proximal muscle mass, such as trunk muscle mass, decreased due to low activity which was caused by fever or GVHD after hematopoietic stem cell transplantation (HSCT). There are few reports evaluated at early post-transplantation periods when it is considered that conditioning regimen mainly aff ect the physical function changes. The aim of this study is to analyze muscle mass and physical function changes focused especially within one month after HSCT. Patients and Methods: There were 75 recipients undergone HSCT between February, 2010 and September, 2012 at Imamura Bunin Hospital. Twenty-fi ve patients (M:17,F:8) out of 75, who had agreed on written informed consent, were investigated on physical functions within one month after HSCT. There were cases of 10 allo-HSCT and 15 auto-PBSCT, respectively. Exercise therapies required 20 to 40 minutes per day and performed 5 days a week, started from 2 weeks before HSCT under the supervision of physical therapists. Physical functions were evaluated based on 6 minute walking test (6MWT) and handgrip. Body compositions were evaluated by bioelectrical impedance analysis. We used fever, albumin (Alb) and hemoglobin (Hb) as clinical parameters.

The evaluations were carried out 2 weeks before HSCT and after neutrophil recovery. Results: Median time for evaluation of HSCT was 21 days. Exercises were able to carry out with 94.4% of initially planned patients. As for changes of physical functions before and after, 6MWT was maintained (-1.9%), but handgrip reduced signifi cantly (-5.9%, p<0.01). Change rates of muscle mass were -1.3% of total body, -0.8% of upper extremity, -1.0% of lower extremity and -1.7% of trunk, respectively. Median time of fever due to HSCT was 3 (0-11) days. In a transition of clinical data, Alb (-14.6%), Hb (-8.7%) were signifi cantly reduced after HSCT. Summary and Discussion: Muscle mass and walking ability were maintained during early post-transplantation period by continuing exercise in patients who had received HSCT. It has been reported that about 3 % of lower extremity muscle mass decreased during 7 day strict bed rest even in healthy volunteers. In our study, most of the patients received HSCT suff ered from fever, anemia and poor nutritional condition due to preconditioning regimen related toxicities, nevertheless we continued low-intensity exercise therapy even with these patients. It is suggested that these persistent exercise prevented the decline of muscle mass and physical strength.

R. Maheri Azar (1) Objective: During the treatment process, many hematopoietic stem cell transplants (HSCT) recipients experience and display a wide array of psychosocial disorders including distress, anxiety, and depression. In order to make Stem-Cell Transplantation (SCT) safer and more eff ective, psychological distress of patients must be taken in to account. Patients are facing challenges pre-and post-transplantation. This study attempts to measure and compare the levels of anxiety depression in HSCT patients.

Method and materials: Hundred patients enrolled in the study (63 males and 27 females; range: 18-60 years, 30 AML, 20 MM,18 HD ,2 CML,2 AA ,2 NHD and 2 ALL). Anxiety and depression were evaluated by Hospital Anxiety and Depression Scale (HADS). Questionnaires were fi lled out in four steps; 48 hours after hospitalization, the day before transplantation, two weeks after transplantation and on discharge day. Results: Findings indicated that compared with discharge day , anxiety and depression were more frequent on the day before transplantation .The high prevalence of depression exists in married patients (both p-values <0.001).No evidence of severe anxiety/depression was found in patients. Conclusion: After HSCT, the level of anxiety and depression has been reduced. The fi ndings suggest that other psychological distress should be evaluated in patients. It indicates the importance of psychiatric intervention during the isolation period of patients as well as pre-transplant psychiatric assessment and counseling regarding the procedure .Therapeutic treatment procedure, pharmaceutical and non pharmaceutical treatments should be carried out based on the results obtained from patients under study.

Liver transaminases during the aplastic phase of allogeneic stem cell transplantation K. Jordan (1), P.E. Pontoppidan (2), H. Sengeløv (1) Background: Elevated alanine aminotransferase (ALAT) following allogeneic stem cell transplantation (SCT) is a frequent phenomenon indicating liver aff ection which may lead to severe disease including sinusoidal obstruction syndrome and ultimately acute liver failure. The cause may be multifactorial involving 1) a direct toxic eff ect of the conditioning regimen 2) gastrointestinal (GI) tract toxicity with translocation of bacterial products and release of cytokines 3) infections and 4) side eff ects of the supportive medication.

We studied liver transaminases during the fi rst 4 weeks post-SCT along with mucositis scores and plasma citrulline, a potentially biomarker of GI-toxicity. Patients and methods: 21 patients (10 patients <16 yrs and 11 patients ≥16 yrs) from the National Danish SCT centre were included. Indications for SCT included malignant haematological diseases (n=17) and benign diseases (n=4). Age at SCT was 21.48 years (1.1 years-54.7 years), mean (range)). Results: During the fi rst week post-SCT a signifi cant decline in ALAT levels was observed with a minimum (minALAT) at day +7 of 17 U/l(9-469); median(range) (P=0.001), followed by a reconstitution period resulting in slightly elevated ALAT(maxALAT) at day 20-24 (50 U/l(13-206) (P=0.044)). MinALAT and maxALAT were positively associated correlated (p=0.328, P=0.002). Citrulline levels reached a minimum at day +7 (6 μ M (3-22) ; median (range) (p=0.003). Mucositis scores inversely paralleled citrulline levels peaking at day 7-13 (2 (0-4)).

Overall citrulline levels correlated negatively with mucositis score (p = -0.421, P = 0.005). Overall ALAT levels correlated positively with the levels of citrulline (p = 0.311, P = 0.005). No signifi cant correlations between maxALAT levels and minimum citrulline levels or maximum mucositis scores levels were seen. Conclusion: 1) These preliminary results shows a signifi cant decline in ALAT levels during the fi rst week post-transplant, reaching a minimum at the time of maximum leukopenia and loss of enterocytes, therefore most likely representing a chemotherapy induced metabolic hit on hepatocytes. The possible impact on this on liver aff ection later in the course of SCT deserves further investigation.

2) Our data showed an association between plasma citrullin and the degree of mucositis and elevated transaminase, indicating that further evaluation of citrulline as a marker of GI-toxicity is of interest.

3) ALAT levels appeared not associated with mucositis scores Background: Thrombocytopenia occurs commonly after HSCT and persistent thrombocytopenia has been associated with increased morbidity and mortality. Few studies have looked at the impact of platelet transfusion on clinical outcomes in HSCT while increased use of single donor apheresis platelets (SDAP), alternate platelet dosing and diff erent thresholds for prophylactic transfusions contribute to uncertainty regarding optimal platelet transfusion strategies. In this study, we examined the impact of platelet transfusion on HSCT outcomes and examined the role of SDAP. Methods: Retrospective single centre cohort study was conducted on 522 patients undergoing HSCT between January 2002 and December 2007. Clinical characteristics and transplant-related outcomes were assessed using univariate and multivariate analysis. Subgroup analysis in autologous recipients was performed to examine the impact of SDAP use (not possible in allogeneic group as SDAP used for nearly all transfusions). Results: Mean number of platelet transfusion events before day +60 post-HSCT was 7.5 (95%CI 6.7-8.4) with greater number of events following allogeneic compared with autologous HSCT (p<0.01). Univariate and multivariate analysis confi rmed the number of platelet transfusion events was associated with adverse clinical outcomes, including 100-day non-relapse mortality (p <0. 01), post HSCT length of stay (p<0.01), need for Intensive Care Unit (ICU) admission (p<0. 01) and number of organs aff ected by severe toxicity (p<0.01). Increased platelet transfusion events was associated with prolonged time to platelet engraftment in univariate analysis but was not confi rmed in multivariate analysis. In patients undergoing autologous transplantation, multivariable analysis confi rmed the percentage of transfused platelet products that were SDAP did not correlate with reduced platelet transfusion events, rates of platelet engraftment or other outcomes following HSCT.

Conclusion: HSCT-related toxicity and mortality are associated with increased platelet transfusion events. Whether platelet transfusions improve or worsen transplant outcomes cannot be ascertained in this retrospective study. Despite increasing use of SDAP in HSCT, greater use of SDAP in autologous HSCT was not associated with a reduction in overall platelet transfusion events or with clinical benefit in comparison to pooled random donor platelets in an era of universal leukoreduction. Alternative strategies to reduce platelet transfusion requirements appear necessary.

Posterior reversible encephalopathy syndrome after allogeneic HSCT in children: clinical, radiological fi ndings and management E. Zengin (1), T. Ileri (2), M. Ertem (2), S. Fitöz (2), E. Ünal Ince (2), H. Çakmakli (2), G. Deda (2), E. Aksoy (2) The clinical and laboratory characteristics of the patients are presented in Table 1 and 2, respectively. Antihypertensive and anticonvulsant drugs were added to control hypertension and seizures, respectively. CsA was thought to be the main causative factor of PRES. At the time of the development of PRES, CsA levels were in the therapeutic range in 2 patients except case 1. Two doses of CsA was omitted in case 1 and reduced in case 1 and 2 because of the late presentation, 7 days after it was replaced by tacrolimus in case 2. CsA was discontinued in case 3 and mycophelolate mofetil (MMF) and tacrolimus were initiated 2 and 5 days after the diagnosis, respectively, because of the early presentation of PRES. None of the patients had seizure recurrence and all patients' MRI findings improved. Management of PRES is centered treating the underlying factor. CsA dose reduction or withdrawal allows clinical resolution of symptoms, but symptoms may persist despite these modifications. Alternative treatments should be rapidly considered for these patients with the aim of maintaining an adequate level of immunosuppression.

Replacing CSA with MMF may be inadequate immunosuppression, therefore tacrolimus has been largely proposed as an alternative drug. However, PRES is reported at 1.6% with tacrolimus as well and symptoms may recur on tacrolimus. Although PRES is an uncommon complication for HSCT recipients, it is associated with significant morbidity and mortality if not recognized early. Specific symptoms such as severe headache, hypertension and visual disturbances occurring under use of CSA should be carefully evaluated with MRI.

Acute respiratory distress syndrome related to antithymocyte globulin infusion I. Hilgendorf (1) Anti-thymocyte globulin (ATG) is frequently used for prophylaxis or treatment of graft-versus-host disease in patients undergoing hematopoietic stem cells transplantation (HSCT). ATG-related acute respiratory distress (ARDS) is rarely reported and little is known about the pathophysiological mechanisms. In this report, we describe a 18-year old female patient with pro-B acute lymphoblastic leukaemia who developed ARDS following ATG-administration.

The conditioning for HSCT from a HLA-matched unrelated donor was performed using total body irradiation (12Gy, day -6 to -4), cyclophosphamide (60mg/kg bodyweight (BW), day -3 to -2), ATG (10mg/kg BW, on day -3, and 25mg/kg BW, day -2 and -1).

Eleven hours after start of ATG, the patient complained about strong cough and dyspnoea. Her respiratory rate was 32/min and she developed tachycardia and hypotension requiring the use of noradrenalin. Coarse crepitation's were present on auscultation and chest X-ray demonstrated new bilateral alveolar infi ltrates consistent with pulmonary oedema. The patient required intubation with 100% FiO2-ventilation with 20cm of positive end-expiratory pressure. Ventilation was extended by an interventional lung-assist (ILA) membrane ventilator device. Laboratory investigation of cultured blood, urine and tracheal secrete excluded sepsis as a potential cause of the ARDS.

Since the symptoms we observed were consistent with transfusion-related acute lung injury (TRALI), which is usually induced by antibodies directed against the human neutrophil alloantigens, we investigated the presence of neutrophils-activating antibodies in ATG using the gold standard, the granulocyte aggregation test (GAT). In GAT; strong activation of neutrophils was observed after adding ATG (titration 1:128). Interestingly, an increase of neutrophils count was observed in the patient in parallel to ATG-infusion indicating that ATG activated these neutrophils and induced ARDS in similar way to what is typically observed in TRALI. The patient died due to severe ARDS 43 days after HSCT.

To the best of our knowledge, this is the fi rst report on ATG-related ARDS in HSCT-recipients. Although the clinical manifestation and the results of the in vitro experimental investigations suggest that ATG was the causal agent of ARDS, further in vivo studies are required to defi nitively prove that ARDS was secondary to ATG. However, clinicians should be aware of the potential risk of ARDS after administration of ATG. Pneumatosis intestinalis (PI) is referred to gas cysts in the bowel wall (either the small or the large intestine). In newborns, PI is considered diagnostic for necrotizing enterocolitis, and the gas is produced by bacteria in the bowel wall. In adults it is associated with numerous conditions, ranging from benign to life threatening (bowel ischemia, infarction, necrotizing enterocolitis, neutropenic colitis, volvulus, sepsis, etc.). The overall incidence of PI in the general population has been reported to be 0.03% based on an autopsy series. As a radiological sign, PI can be seen on abdominal radiographs and CT is the most sensitive imaging test for identifi cation of PI. We identifi ed a group of patients post allo-HSCT that were diagnosed with PI. None of these events occurred during neutropenia and most of the patients were barely symptomatic or asymptomatic. In symptomatic patients, PI was mostly associated with acute GI GVHD. Overt perforation was excluded in all patients and all were managed conservatively with temporary nothing per os regime along with local and systemic antibiotics. Under conservative management, PI subsided gradually in all cases. None of the patients was in need for surgery and the prognosis was excellent. We assume that post allo-HSCT PI is secondary to mucosal disruption caused by subtle form of erosions that may be secondary to clinical or subclinical GI GVHD, viruses or medications. We conclude that post allogeneic HSCT PI is a benign process that can be conservatively managed with excellent prognosis. Introduction: Mucositis is a pathological process where the mucous is aff ected, the broad of the aff ected area can go from infl ammation to ulcers, in the gastrointestinal tract (GI) from the mouth to the anus. Several studies have showend that patients that received bone marrow transplantation (BMT), almost 75% had mucositis as a side eff ect after the BMT in diff erent grades. Topic FEC-GM has being used to disminish the severity and duration of the mucositis promoting migration and proliferation of endothelial cells. Objective: We want to evaluate the effi cacy of topic FEC-GM in a mouth wash presentation to diminish the duration and the severity of mucositis en BMT patients. We conclude in our study that mucositis incidence was minor of the published, because our patients receive FEC-GM as an early therapy once a grade 1 mucositis was detected with a recover days of 6.7. We also conclude that our patients did not required intravenously nutrition therefore less hospitalized time, comorbidities and costs. Objectives: High-dose chemotherapy with stem cell rescue (autotransplant) became a well established consolidation procedure in several solid tumor protocols for pediatric cancer patients. Peritransplant toxicity includes main organ parameters, but its infl uence on basic electrolytes is yet to be determined. We followed and compared sodium (Na), potassium (K), phosphorous (P), magnesium and total bilirubin (T. Introduction: Sweet's syndrome, also known as acute febrile neutrophilic dermatosis, is characterized by fever, neutrophilia, erythematous and tender skin lesions (papules, nodules, and plaques), that typically show a diff use infi ltrate consisting predominantly of mature neutrophils in histopathology. This syndrome is often associated with several conditions, such as malignancy, autoimmune disease, infections and drug-induced. Herein we report a 15 year old boy that presented with fever and skin lesions consistent with Sweet's syndrome after autologous stem cell transplantation (SCT) for relapse acute myeloblastic leukemia (AML). Case report: We present the case of a 15-year-old boy with the diagnosis of relapse AML who was undergoing autologous SCT with granulocyte colony-stimulating factor (G-CSF) mobilization 15 μg/kg/day yielded maximum CD34+ count of 1.5 x 10 CD34+ cells/kg after complete remmision. On day + 10 he developed persistent fever and severe neutropenia despite broad-spectrum antibiotic and G-CSF therapy. Times to neutrophil and platelet engraftment were 14 and 25 days, respectively. All culture results were negative. His bone marrow studies on day 21 demonstrated a reactive bone marrow in regenerative phase. Histopathologic fi ndings of a skin biopsy showed a mature neutrophilic infi ltrate besides fever and skin papular lesions that met the criteria of Sweet's syndrome on day 24. His fever and skin fi ndings resolved following treatment with methlyprednisolone (2 mg/kg/day, tapered over 6 weeks). He has been well without any signs of recurrence for 6 months after SCT. Conclusions: The literature contains only one case of G-CSF associated Sweet's syndrome in a child after autologous SCT for acute nonlymphoblastic leukemia that responded to steroid therapy. The appropriate diagnosis is of great clinical importance because G-CSF induced Sweet's syndrome is reversible with cessation of the drug and administration of glucocorticosteroids.

Introduction and Aim: In the present study, we presented an ATM attack developed after total body irradiation (TBI) as allogeneic stem cell transplantation conditioning regimen in an acute lymphoblastic lymphoma (ALL) case, as it hasn't been found in literature so far. Case: An 18-years old man was presented with fatigue, loss of appetite and abdominal distension at 2004, when he was 10 years old. Ph (+) chronic, stable phase CML diagnosis was made by peripheral blood smear and bone marrow evaluations including morphological and genetic studies. After cytoreduction by hydroxyurea, he was given 1 x 260 mg/m2 imatinib therapy At 2010, dasatinib 1 x 70 mg plus BFM (Berlin, Frankfurt, Munster) chemotherapy was given to Ph (+) patient with CALLA (+) pre-B ALL. Allogeneic stem cell transplantation (ASCT) decision was taken for patient who had bone marrow remission following remission induction and consolidation therapies and 10/10 fullcompatible non-related donor. According to ASCT preparation protocol, TBI (2 Gy, twice daily for 3 days; overall dose 12 Gy), followed by 60 mg/kg/day over 2 days cyclophosphamide regime were planned; however, he reported that he couldn't move his arms on the day 3 of TBI therapy. 3/5 weakness was detected in both upper extremities in neurologic examination, as being more prominent in distal. No pathological refl ex was detected. Deep tendon refl exes were hypoactive at upper extremities, but there was no sensorial defect. Thus, TBI was discontinued and 1 mg/kg steroid therapy was initiated. On the cervical MRI, there were T1weighted isointense and T2-weighted hyperintense pathological signal changes, which begins at C2 level, involves all cervical spinal cord and extends to thoracic segments and expansion of spinal cord. By these fi ndings, diagnosis of ATM was made. No abnormal fi nding was detected in viral, bacteriological and autoimmune evaluations; in addition, no growth was found in culture tests. Result and Discussion: Known adverse eff ects of TBI include nausea, vomiting, sweating and irritability as well as renal dysfunction, interstitial pneumonia, lung injury, cataract, osteosarcoma and cystitis in rare cases; no case of myelitis has been reported. Treatment aims etiology; however, steroid therapy is recommended in idiopathic cases. This case is important, as it is the fi rst reported ATM case after TBI as allogeneic stem cell transplantation conditioning regimen.

Idiopathic hyperammonaemia after haematopoetic stem cell transplantation: a case report A.

Yesilipek (1) Idiopathic hyperammonemia (IHA) is characterized by a sudden increase in plasma ammonia levels in the absence of any identifi able causes which mostly results in intractable coma and high mortality. It has been reported in some patients after receiving intensive chemotherapy for hematological malignancy or hematopoetic stem cell transplantation (HSCT). Although there is no reported absolute association of IHA with a specifi c drug, cytarabine, daunomycin, cyclophosphamide, vincristine, amsacrine, etoposide, asparaginase, busulfan, methotraxate, vinorelbine, topotecan, melphalan, 5-Fluorouracil and cisplatin were used in the reported IHA cases. We describe a case of a patient with Fanconi anemia that developed acute idiopathic hyperammonemia after the preparative regimen for HSCT.The underlying mechanism for the development of idiopathic hyperammonaemia following bone marrow transplantation remains uncertain, but an acquired defect of urea synthesis after chemoterapy remains a plausible explanation.

In HSCT patients, a newly diagnosed mental confusion should be entitled to suspect from idiopathic hyperammonemia and despite unexpected level of insuffi ciency, hemofi ltration should start immediately. Background: Autoimmune haemolytic anaemia (AIHA) is a recognized complication of haematopoietic stem cell transplantation (HSCT), and is often refractory to treatment and carries a high mortality. To improve understanding of this complication, we analyzed allogeneic HSCT patients in our institution for the prevalence of post-transplant AIHA, its risk factors, treatment response, and mortality. Methods: AIHA was identifi ed by positive direct anti-globulin test (DAT), and biochemical markers of haemolysis (raised serum lactate dehydrogenase, reduced haptoglobin or spherocytes on blood fi lm appearance). We also assessed for clinically signifi cant AIHA defi ned as ≥ 2 g/dL drop in haemoglobin. DAT positivity due to red cell allo-antibodies were excluded from AIHA diagnosis. Red cell allo-antibody was identifi ed if the antigen corresponded to a mis-matched blood group between donor/recipient, or the absence of such antigen in both donor/recipient. Cases with positive DAT prior to HSCT were removed from analysis. Serological analysis revealed greater prevalence of red cell alloantibodies in AIHA versus non-AIHA patients (55.6% vs 3.8%, p<0.0001). 8 patients (44%) responded to treatment for AIHA. Allcause mortality in patients with post-transplant AIHA was 55% (n = 10), with 39% (n=7) one-year mortality from diagnosis of AIHA. Conclusion: We report the prevalence of AIHA following HSCT as 3.2% in the largest study of its kind. AIHA was associated with receiving HSCT from VUD, but not associated with using Alemzutumab in the conditioning regimen. We also observed an increased prevalence of red cell allo-antibodies in patients with AIHA. This may refl ect increased transfusions received by these patients, but also raises the possibility of a global immune dysregulation which predispose to both AIHA and allo-immunization following HSCT. Overall, the patients with AIHA showed variable response to treatment and often have a poor prognosis.

BU group (p<0.001, p=0.04 and p=0.03 respectively), whereas alopecia was common (25.8%, p<0.001). We observed a trend towards fewer second tumours but this lessening did not reach statistical signifi cance. Impaired gonadal function was found in 48.1% of patients in the BU group and 53.9% in the TBI group. Multivariate analyses ( (1), J. Barry (2) , D. Turner (2) , V. Robertson (2) , H. Newlands (2) , P. Flanagan (3), T Haque (4) Objective: Exposure to genotoxic chemotherapeutic agents and radiation may induce persistent genetic damage in patients received hematopoietic cell transplantation (HCT). We report chromosomal instability of bone marrow (BM) and/or skin fi broblasts, BM of relapsed or secondary leukemia and solid tumors from patients received HCT 49 days -25 years after HCT. Methods: We performed standard cytogenetic analysis in BM of relapsed or secondary leukemia (n=10), solid tumor (n=4) and BM and/or skin fi broblasts from 38 subjects, including short-term (49-463 days, n=18) and long-term (2-25 years, n=14) HCT survivors (two autologous and 29 allogeneic HCT patients). Of our 31 patients (2 had second transplant), 16 received high-dose irradiation (6.5-12Gy), 12 received low-dose irradiation (3-6Gy) and 5 had non-irradiation regimen. Controls included BM and/or skin fi broblasts from 11 subjects before HCT patients. The metaphase counts ranged 9 to 20 (20 cells were analyzed in 27 out of 38 subjects). Chimerism of fi broblasts was assayed using STR and/or XY-chromosomal analysis.

Results: Chimerism of all fi broblasts was 100% recipient type, and fi broblasts from 11 subjects before HCT patients showed normal karyotypes. Clonal and random non-clonal chromosomal cytogenetic aberrations were observed in fi broblasts from 17 and 29 subjects, respectively. Only 5 subjects of fi broblasts after HCT showed normal karyotypes. In fi broblasts, the frequency of chromosomal instability was signifi cantly higher in the patients received highdose irradiation, but was not associated with the sampling time.

Six BM of relapsed leukemia after HCT and one BM of secondary leukemia had gross chromosomal rearrangements. Two BM of donor type leukemia and MDS showed normal karyotypes. Karyotypes of the four solid tumors after HCT (Epulis, fi broma, pheochromocytoma and meningioma) revealed complex clonal and random non-clonal chromosomal aberrations although they were all benign at pathological analysis. Conclusion: Our data show that chromosomal instability is frequent in both somatic and tumor cells after HCT, particularly in patients received high-dose irradiation and may be implicated in the development of second malignancies.

Self-management in long-term survivors after allogeneic haematopoietic stem cell transplantation: a cross-sectional multicentre study M. Kirsch (1) (10-21) years. Fourteen pregnancies occurred following natural or induced conception in 11 and 3 cases respectively. Three pregnancies resulted in early termination because of tubal pregnancy in 1 patient and because of 2 elective abortions. Pregnancy-related complications included preeclampsia in 1 patient, severe anemia requiring transfusion support in 1, and uterine hemorrhage in 1. Twelve live births were delivered after cesarean section in all cases following a median gestation of 37 weeks (36-38). APGAR scores were 9 to 10 at 5 minutes after birth in 11 infants and 6 in one baby due to distress respiratory syndrome. The median birth weight and height was 2.800 Kg (1.990 -3.600) and 49 cm (44 -53) respectively. These 12 infants currently survive from 1 to 11 years with normal growth. Ten of them had no congenital abnormality whereas 2 were aff ected by TM. MALE PATIENTS: age of the 3 male patients was 10, 17 and 24 at time of HCT, whereas the median time from HCT to fi rst partner pregnancy was 14, 19, and 3 years respectively. Nine pregnancies occurred following natural conception in all cases. One of 9 pregnancies resulted in early termination because of elective abortion. No pregnancy-related complication occurred. Eight live births were delivered after uncomplicated cesarean section in one case and vaginal delivery in the remaining 7 cases following a median gestation of 38 weeks (37-40). APGAR score was 10 at 5 minutes after birth in 8 cases and 9 in 1 case. The median birth weight and height was 3.300 Kg (3.200 -3.500 ) and 50 cm (49 -52) respectively. These 8 infants currently survive from 2 to 18 years with normal growth. This study demonstrates that fertility is maintained in some patients with TM following HCT and that pregnancy is likely to have a successful outcome in most cases.

Decline of NIH lung function score at one-year after allogeneic haematopoietic cell transplantation is related to severe chronic GVHD and CMV reactivation YY. Cho (1) , SK. Sohn (2) , JH. Moon (2) , YR. Do (3), YJ. Lee (2) In addition, the patients with early decline of FEV1 more than 10% at 3 months compared to baseline showed a higher incidence of cGVHD during follow-up (p=0.016). Conclusion: Patients who had extensive cGVHD or CMV infection had a higher possibility of late pulmonary dysfunction and decline of FEV1 at 3 months of transplantation refl ected the development of cGVHD.

[P1050]

induced a negative iron balance in 84% of pt. A rise in Hemoglobin (Hb) with 62% of total upsurge in the fi rst 3 months was seen (Fig.2) . Median exposure to DEF was 330 days with a median compliance of >80%. Yet, adverse events (AEs) lead to DEF adjustment/ temporary interruption in 65 pt with creatinine elevation being a major cause. 13.6% of AEs were suspected to be drug related and occasionally resulted in drug withdrawal [gastrointestinal (n=5), skin (n=3), elevated transaminases (n=2) and creatinine (n=2)]. AEs were dose-related with 7.5mg/kg/d being tolerated. Conclusions: After HCT, A negative iron balance could be induced by low dose DEF. Our data imply that DEF eliminates non-transferrin bound iron fi rst which may explain the early Hb rise. Expression of hepcidin from donor leukocytes (with paracrine/autocrine actions) and recipient liver might prevent increased ferroportin-mediated iron export from recipient macrophages thereby protecting body organs. The lack of impact of the mainly heterozygote HFE mutations is not surprising considering that it is the recipient hepatocytic but not donor macrophage Hfe that plays the key role in iron metabolism.

Depression and anxiety before allogeneic haematopoietic cell transplantation A. Barata (1), K. Philips (2), B. Small (3), P. Jacobsen (2), J. Pidala (2), C. Anasetti (4) Conclusion: More than half of the patients had evidence of peripheral airway dysfunction as estimated by LCI 3-10 years after paediatric HSCT, which however, appeared to be unrelated to cGvHD criteria and respiratory symptoms and only weakly correlated to standard PFT parameters. Prospective studies are needed to investigate LCI as a diagnostic tool for early detection of cGvHD related lung disease, and are currently performed in our centre. Background: Hematopoietic stem cell transplantation (HSCT) is increasingly used as a treatment for a variety of malignant and non-malignant conditions. With improvements in conditioning regimens and post-transplant care, more HSCT recipients are becoming long-term survivors and are thus at risk of long-term complications. Iron overload is common after HSCT. It is associated with chronic liver disease, increased rates of infection and may also aff ect survival in this population. In other clinical settings such as hereditary hemochromatosis and transfusional iron overload states such as thalassemia, the reduction of iron stores by phlebotomy or chelation has been unequivocally demonstrated to reduce both morbidity and mortality. Objectives: The main objective of this study was to establish the feasibility and effi cacy of phlebotomy to reduce total body iron in HSCT recipients. Methods: We enrolled patients who were at least 60 days following an autologous or allogeneic HSCT with a serum ferritin of 1000 μg/L or greater. Patients underwent phlebotomy of 500 mL of whole blood for 12 procedures. Iron stores were measured serially in each patient by serum ferritin and magnetic resonance imaging (MRI) measurement of hepatic iron. Hepatic iron was determined by using multiple gradient echo sequences and liver to muscle intensity ratio. This was related to hepatic iron concentration using previously correlated MRI signal to biopsy proven ratios. Results: 22 patients were enrolled and 16 patients were able to complete the series of 12 planned phlebotomies. The reasons for inability to complete all 12 treatments were relapse (n=1), the development of extensive graft-versus-host disease (n=1), noncompliance (n=2) and intolerance (n=2). At baseline, the mean ferritin was 1855.9 μg/L and 900.6 μg/L at 12 months (p=0.0007). The mean MRI hepatic iron concentration at baseline was 220 μmol/g and 148.1 μmol/g at 12 months (p<0.0001).

Conclusions: Phlebotomy is a feasible method to remove excess iron in HSCT patients with most patients demonstrating the ability to complete all planned phlebotomies. Phlebotomy was demonstrated to be eff ective at reducing iron stores with statistically signifi cant reductions in mean ferritin and mean MRI hepatic iron concentration. Given the positive results in this study, we plan to undertake a larger study to determine the eff ect on morbidity and mortality in this patient population. The overall incidence of SN was 4,9% and it was higher in the AUTO-HSCT than in the ALLO-HSCT (6,6% versus 3,2%). The median time since HSCT to diagnostic of SN was 4,1 years. Hematologic SN developed earlier than solid SN, 3,9 and 9,1 years after HSCT respectively (p < 0,001). The most frequent locations among solid SN were gastrointestinal tract: 11, genitourinary: 9, respiratory: 9, gynecological: 6 and central nervous system: 3. Conditioning regimen with TBI was associated more frequently with development of solid SN (p = 0,07). Hematologic SN were myelodysplastic syndrome: 20, post-transplant lymphoproliferative disease: 9, acute myeloblastic leukemia: 5 and non-Hodgkin´s lymphoma: 5. Eight of them (21%) received a second HSCT as treatment (ALLO: 7, AUTO: 1). The overall mortality rate related with SN was 61% with a median survival time of 15,6 months after the SN was diagnosed. Conclusions: Our serie confi rm that the incidence of SN after HSCT is low but it has an important impact in the long-term mortality of these patients. They are more frequent in AUTO-HSCT than in ALLO-HSCT. Solid SN appear later and are more common than hematologic SN. TBI previous to HSCT seems to be more associated with solid than hematologic SN. The aim of the study was to determine the cumulative incidence of second malignancies among patients with Hodgkin Lymphoma (HL) and non-Hodgkin Lymphoma (NHL) who were treated with autologous hematopoietic stem cell transplantation (ASCT) following modifi ed BEAM regimen at our department. We also intended to defi ne the potential risk factors for the occurrence of second neoplasms after ASCT. The cumulative incidence of second malignancy was calculated by controlling for death from any reason other than second malignancy as a competing risk. We evaluated the long-term outcomes after ASCT in 268 patients, median age 33 years (range 17-61 years), with HL (n=167) and NHL (n=101), who were treated with autotransplant following modifi ed BEAM regimen (BCNU 300mg/m 2 , etoposid 800mg/m 2 , cytarabine 6000mg/m 2 , melphalan 140mg/m 2 and dexamethasone 168mg/m 2 ) between 1992 and 2011. The patients received a median of 2 chemotherapy lines (range 1-5) before ASCT. MOPP-type chemotherapy were given to 8% and radiotherapy to 40% of patients prior to ASCT. The median follow-up of the living patients was 66 (12-242) months. The 5-year OS and PFS for all patients were 74% and 66%, respectively. Eighteen patients died from transplant-related causes within 100 days of ASCT, corresponding to early TRM of 6.7%. Second malignancies occurred in 9 of the 268 patients, including 5 MDS/AML, 1 ALL, 1 NHL, and 2 solid tumors (bladder cancer and thyroid cancer). The second neoplasms developed at a median of 6.8 years (range 0.4-15) from ASCT. The 10-year and 14-year cumulative incidence of developing a second malignancy was 7% (95%CI 3-14) and [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , respectively. In univariate analysis, age at transplant (<45 vs ≥45 years, p=0.001) and pre-transplant MOPP-type chemotherapy (p=0.062) were the only factors associated with the occurrence of a second neoplasm. In contrast, sex, the number of prior chemotherapy lines, radiotherapy, and the disease status at ASCT were not predictive for the development of a second neoplasm. In multivariate analysis, age at transplant (HR=11.7; p=0.002) and pre-transplant MOPP-type chemotherapy (HR=6.1; p=0.016), remained signifi cant for the development of a second malignancy.

In conclusion, our results indicate that age of the patient and the type of pre-transplant chemotherapy contribute to the risk of the development of a second neoplasm after ASCT in patients with lymphoma. We believe that expanding the published experience may be useful in cancer prevention in this setting.

longitudinal real-life data from a single centre P. Cetkovsky (1), J. Jarkovsky (2) Background: Acquired defi ciencies of clotting factors as a consequence of auto antibodies are rare conditions but lead to complex treatment approaches with high morbidity and mortality. The most common such condition is acquired FVIII defi ciency, while others are described only in a small group of patients. The treatment is directed towards bleeding control with activated recombinant factor VII (rFVIIa) and towards long term eradication of autoantibodies using immune suppression. FIX and FXI defi ciency are rare and described in patients with hematologic malignancies and autoimmune diseases. In the hematopoietic SCT setting, only acquired FVII defi ciency was described to date. Children with haemoglobinopathies undergoing HSCT are not exposed to total body irradiation but have their own specifi c endocrine issues, especially pubertal and growth delay related to iron toxicity. Experience is growing in HSCT in patients with haemoglobinopathies worldwide, but data on endocrine lateeff ects is scanty. Aims: To evaluate the endocrine late-eff ects seen in children with β-thalassaemia major (β-thal) and sickle cell disease (SCD) post HSCT focusing on gonadal, growth and thyroid eff ects. S374 with β-thal(mean height SDS -1.32) pre-HSCT. There was no signifi cant change in height SDS during follow-up. Only 1 male(βthal) had severe growth failure with a low IGF-1 but a normal GH stimulation test. He responded well to empirical GH. Conclusion: Hormonal evidence of gonadal failure is more common post-HSCT in females than males. Growth and thyroid adverse eff ects are rare. Children with haemoglobinopathy seem to have a decreased burden of endocrine late-eff ects post-HSCT compared with oncology patients. 

We report on granulomatous infl ammation occurring in 4 patients during long-term follow up of hematopoietic stem cell transplantation (HSCT) for severe combined immune defi ciency related to IL2RG mutations (n=3) or Artemis defi ciency (n=1). All patients received HSCT from an haplo-identical donor without conditioning regimen (n= 3) or conditioned with cyclophosphamide (n= 1). Median age at HSCT was 4.5 months (2 to 6.5 months). Early immune reconstitution (1 and 2 years post HSCT) was good in 3 patients (CD4 > 600/mm 3 ) and poor in one while none of these patients had B cell reconstitution. CD4 T cells and naïve CD4 T cells counts (when documented) declined in all patients (median CD4 count 340/mm3 5 years post HSCT). Onset of granulomatous disease occurred 5 to 25 years post HSCT (median 5.5 years). The fi rst organs involved were the liver (n=2), skin (n=2) and digestive tract (n=1). Duration of follow up for granulomatous disease was 3.75 years (1 to 16 years). All patients except one (follow up 1 year) displayed progressive multisystemic involvement (recurrent fever (n= 3), lungs (n= 3), digestive tract (n= 2)). Immunohistochemical studies showed non necrotic epithelioid granuloma with lymphocytic infi ltrate made predominantly of CD3+CD8+ T cells was observed in the skin (n=3). Liver biopsies showed portal infl ammation with CD8+ cells (n=4). Broad microbiologic investigations were negative in all cases. Circulating CD8 lymphocytosis (mainly eff ector memory) was documented concomitantly in 2 patients. Treatment is challenging. In our patients, several lines of immunosuppressive drugs as steroids (n=3), ciclosporine (n=2), azathioprine (n=1), anti-TNFα monoclonal antibodies (n=3), rapamycine (n=1), interferon α(n=1), hydroxychloroquine (n=1), thalidomide (n=1) showed limited improvement. One patient died after retransplantation from an HLA matched unrelated donor performed late in the course of granulomatous infl ammation. In patients with poor immune reconstitution, cytotoxic immunosuppressive drugs have to be used with caution. Early intervention with retransplantation or gene therapy should be discussed, as long-term outcome of these complications is uncertain.

A secondary pulmonary alveolar proteinosis occuring late after allogeneic haematopoietic stem cell transplantation cured by the combination of whole lung lavage and rituximab F. Paul, C. Exbrayat, N. Fegueux, P. Ceballos, I. Serre, T. Vincent, G. Boursier, A. Bourdin Universitary Hospital Montpellier (Montpellier, FR) Pulmonary alveolar proteinosis (PAP) is a rare lung aff ection characterized by the intra-alveolar accumulation of PAS-positive surfactant, resulting from a defi ciency in graulocyte-macrophage colony stimulating factor (GM-CSF) signaling pathway. Secondary PAP is an unusual pulmonary complication after allogenic hematopoietic stem cell transplant (allo-HSCT). The mechanism is not yet elucidaded, especially those occuring out of aplasia. Whole Lung Lavage (WLL), the standard of care of PAP, is an invasive procedure. So, GM-CSF and Rituximab have been used to treat patients with idiopathic PAP, who have anti-GM-CSF autoantibodies. Their eff ects on secondary PAP are not known. We here report the fi rst case of secondary PAP post-alloHSCT cured through treatment with WLL and Rituximab. This combination seems synergystic and may constitute a therapeutic option. A 35-year-old man with a smoking history was diagnosed in 2007 with acute myeloid leukemia (AML). After induction and consolidation chemotherapy, he underwent an allo-HSCT from a matched related donor after a myeloablative conditioning while in fi rst complete remission. Graft versus Host Disease (GvHD) prophylaxis consisted of methotrexate and ciclosporine. The neutrophil recovery occurred on day 22 post-alloHSCT. In 2008, he developed acute digestive GvHD with multiple exacerbations requiring the introduction of corticosteroids. The immunosuppression was complicated by many infections including sepsic shocks evoking bacterial translocation, invasive pulmonary aspergillosis and EBV reactivation treated by Rituximab.

In 2009, the patient received Rituximab for a stage 4 acute digestive GvHD. He also had a severe dyspnea investigated by spirometry revealing a restrictive syndrome and a reduced diff using capacity. A chest computed tomography scan showed a crazy paving, a typical feature of PAP and the broncho-alveaolar lavage (BAL) was suggestive of PAP. The anti-GM-CSF antibodies were negative. After initial improvement following two WLL, the patient had a respiratory failure with increased crazy paving treated with Rituximab. Two months later, without major clinical improvement and with a persistant crazy paving, a transbronchial biopsy confi rmed the diagnosis of PAP and the BAL found less abundant PAS-positive material. An association of Rituximab and two WLL led to a clinical recovery in one month. Cure of PAP was histologically confi rmed in 2010. On december 2012, the patient was still in complete remission for AML with chronic GvHD and no recurrence of PAP.

The 3.7-11.9 ) months, respectively ( Figure 1 ). Conclusion: The general features of SPM seemed be diff erent from that of general population data in which thyroid cancer, stomach cancer and colon cancers were quite common. It seemed that the incidence of SPM could be diff erent from that of cancers in general population. We need to provide clear guideline for the prevention or early detection of SPM.

Physician activity in a multi-professional clinic for long-term survivors of stem cell transplantation N. Salooja, J. Apperley, J. Goldman, J. Todd Hammersmith Hospital (London, GB) As the success of SCT leads to increasing numbers of very longterm survivors, more attention is being given to non-haematological sequelae and requirements for follow-up. It is not clear whether multi-professional clinics are necessary or whether community based follow up using protocolised guidance would suffi ce. In our transplant centre we have a combined haematology-endocrine consultant led clinical service once a month for patients surviving more than 10 years after SCT. Although the clinic is protocolised it is our impression that these patients have complex medical problems and the majority benefi t from expert physician input at annual follow up. We have collected data on all patients attending our service over a 3-month period to evaluate the prevalence of chronic and active medical problems benefi tting from physician input. 24 patients (11 female) were seen a median of 20 years post SCT (range 10-33 years). The median age at follow up was 52y (range 23-77). Diagnoses were CML (18) ALL (2) AML (2) AA (1) Thal (1) Infertility is common following HSCT as a result of the chemoradiotherapy given as pre-transplant conditioning. Although radiation is potentially toxic to both the sperm producing Sertoli cells

S377 and testosterone producing leydig cells of the testes the latter are less sensitive to radiation, Following total body irradiation testosterone production is usually normal. In patients surviving more than 10 years, however, we have noted development of testosterone defi ciency in some patients. This can be associated with sexual dysfunction, decreased bone mineral density and decreased longevity. In this study we have investigated the prevalence of low testosterone levels in very long term survivors of haemopoietic SCT. Clinical and biochemical records were reviewed from 45 consecutive male patients attending a dedicated haematology/endocrinology follow up clinic. Testosterone, SHBG and LH levels are measured annually in these patients. The median transplant to follow up time was 15.9 years (range 8-33 years). All had received TBI/cyclophosphamide conditioning with a median dose of 12 Gy (range 10-14Gy). 30 patients had been treated for CML and 15 patients were treated for acute leukaemia. 19 patients were identifi ed with testosterone levels below the normal range a median of 13.9 years (range 7-25 years) after SCT. In 9/19 cases borderline low testosterone levels occurred in asymptomatic patients with normal bone density and LH levels were normal. These patients continue to be monitored. 2/19 multiply relapsed patients treated for acute leukemia had hypogonadotrophic hypogonadism and were taking testosterone replacement. 8/19 patients had developed low testosterone with raised LH and had commenced testosterone replacement. We conclude that standard doses of TBI can cause testosterone defi ciency with evidence of leydig cell dysfunction in long-term survivors. Furthermore, new cases continue to occur more than 20 years after SCT. Annual surveillance is therefore required to identify this important complication of HSCT.

Molecular evidence for repertoire-skewing of T large granular lymphocyte proliferations after allogeneic haematopoietic stem cell transplantation: report of two cases A. Papalexandri (1) We present two cases with benign oligoclonal expansion of CD3+ Large Granular Lymphocytes (LGLs) causing transient myelosupression in a context of successive episodes of herpesvirus reactivation after allogeneic hematopoetic transplantation (allo-HSCT). They both developed a highly restricted T cell receptor β chain (TRB) gene repertoire with common gene usage in the predominant clonotypes, implicating antigen involvement in their development. #1: A 27 year-old female was treated for CMV reactivation on day +45 after allo-HCT. Grade III neutropenia was noted, persisting for 5 months. After the recovery of hematopoiesis, EBV reactivation led to pre-emptive therapy with Rituximab and mild neutropenia developed, lasting for 7 months. Bone marrow (BM) aspiration revealed a hypocellular bone marrow. #2: A 14-year-old male presented with CMV gastritis on day +30 after allo-HCT, succeeded by grade III neutropenia for seven months. Five months later, EBV reactivation was treated with Rituximab and soon grade IV neutropenia was identifi ed. Examination of the BM aspirate revealed a hypercellular BM with hyperplastic myeloid series and shift to the left. In both cases further virologic and serologic screening was negative. Peripheral blood (PB) lymphocyte subpopulation analysis with fl ow cytometry revealed: i) inverted ratio of CD4/ CD8 lymphocytes, ii) absolute increase (>1.0 x 109/l) of CD3+/ CD8+ lymphocytes and iii) increased (>30%) CD3+/CD8+/CD57+ lymphocytes. T-cell receptor β chain gene repertoire analysis was conducted i) after the CMV reactivation and ii) after the EBV reactivation episodes, respectively, and revealed: Case #1 Six clusters with 3 dominant clonotypes: (a) TRBV10-2/TRBD1/TRBJ2-7, 19.5%, (b) TRB27/TRBD2/TRBJ1-5, 9.7%, (c) TRBV6-5/TRBD1/TRBJ1-5, 36.6%. Diff erent clonotypes were identifi ed at diff erent timepoints. Case #2 Three clusters: (a) TRBV2/TRBD2/TRBJ1-5, 29.4%, (b) TRB27/TRBD1/TRBJ1-6, 29.4%, (c) TRBV6-5/TRBD1/TRBJ2-7, 27.4%. Clonotypes (a) and (b) were detected in both timepoints.

In conclusion, in both cases oligoclonal myelosupressive T-LGL expansions with remarkable skewing and similarities of the TRB gene repertoire (i.e. high frequency of the TRBV6-5 gene) developed after successive viral infections prompting speculations about (super)antigen involvement in the selection and expansion of cytotoxic T cells and supporting a dynamic T cell response against auto-and exo-antigens as the initial event in T-LGL lymphoproliferation. Autologous hematopoietic stem cell transplantation (AHSCT) in severe Autoimmune Diseases (AD) has led to AD remission in many patients with prior severe and refractory disease, of whom many were young women with strong desire of pregnancy if the AD could be halted. Since 1996, data analysis from EBMT registry has shown improved survival and quality of life of AD patients after AHSCT. However, in this population ovarian and uterine functions may be compromised by the underlying AD and HSCT with potential impact on fertility.

We therefore conducted a retrospective study to describe onset and outcome of pregnancy in adult female patients aged 18 or older transplanted with autologous HSCT for AD from 1994 to 2012, whose data were reported to the EBMT database. The centers were invited to participate to this study and a specifi c questionnaire designed to collect additional data was sent to all centers with eligible patients. Of 39 responding centers: 5 reported pregnancy cases, 28 reported no cases and 6 refused to participate. There were 588 HSCT for Autoimmune Diseases performed in this population. The median age at transplantation was 35 (range 18-50) years. So far there are 5 reported patients who became pregnant after autologous HSCT for AD (2 patients with multiple sclerosis, 2 patients with systemic sclerosis and 1 patient with rheumatoid arthritis). There were 8 reported pregnancies, of which 7 resulted in live births and one lead to natural abortion. The conception was mostly natural (6 natural conceptions and 2 assisted conceptions). The mean duration of pregnancy was 39 weeks. The mean birth weight of children was 3200 g. There were no abnormalities reported in the delivered children observed in the follow up observation of mean 83 months. The exacerbation of underlying autoimmune disorder during and after pregnancy was reported in 1 patient. This data shows that pregnancy is feasible in women who underwent autologous HSCT for prior autoimmune diseases. The outcome of pregnancy in this population of patients is generally good. The low percentage of women who become pregnant after AHSCT could in part be explained by the age at transplantation. The exacerbation of underlying autoimmune disorder is possible, however due to the paucity of recorded cases, it is still impossible to draw any conclusion whether it could be connected with pregnancy.

36. 5 (19-66) , with 67% male. Out of 116 patients eligible for the study, 89 patients received HSCT in CR2. Salvage therapy before HSCT included ATO, with or without ATRA, in most patients (83%). Eighty-nine per cent of patients with available information were in molecular CR at time of HSCT (52/54 of autoHSCT, 22/29 of alloHSCT). Median time from diagnosis to transplant was 34 months , and from relapse to transplant 6.5 months (2.5-16) . Regarding alloHSCT, donor consisted of an HLA identical sibling in 25 patients and peripheral blood was the stem-cell source in 21 procedures. Conditioning regimen was myeloablative in 27 patients receiving alloHSCT, and did not include radiotherapy in most cases (22/32 alloHSCT, 52/57 autoHSCT) . After a median follow-up of 46 mos. , outcome after alloHSCT and autoHSCT was comparable, with a 5-year OS, LFS and relapse incidence of 62±10% vs. 67±8%, 56±10% vs. 59±8%, and 31±9% vs. 34±8%, respectively. Despite a trend to an inferior NRM after autoHSCT (vs. alloHSCT) was observed (5±4% vs. 13±6%, p=0.13), this difference did not achieve statistical signifi cance. Of note, out of 7 patients who underwent alloHSCT with detectable MRD prior to transplant, 6 patients were alive and disease-free at last followup (median, 50 mos., 32-81). In summary, the outcome of patients with relapsed APL who receive an autologous HSCT as consolidation strategy is relatively favorable, provided that a molecular response prior to the procedure is achieved. On the other hand, alloHSCT might remain as an alternative for patients failing to achieve a molecular response after salvage therapy. In multivariate analysis, the uCBT was found to be an independent factor providing lower RI (HR: 0.3, 95%CI: 0.11-0.82, p=0.02) but higher NRM (HR: 4.16; 95%CI: 1.46-11.9, p=0.008) leading to comparable survivals between both types of graft Conclusion: Despite better prognosis factors for pts of Auto group, results from this large study suggest that uCBT provide better disease control than auto-SCT in CR2 AML pts in the absence of a suitable donor. However, this disease control advantage after uCBT is counterbalanced by a higher NRM, highlighting the need for novel approaches aiming to decrease treatment related mortality after uCBT.

Equivalent outcome between siblings, unrelated donors and cord blood after reduced intensity allogeneic haematopoietic cell transplantation for patients older than 50 years with acute myeloid leukaemia in complete remission R. Peff ault de Latour (1) (Figure 1 ). The use of TBI-containing regimen was associated with a non-signifi cant, but worse OS in recipients of MRD and URD grafts (HR 1.8, p=0.11) . Outcome was similar between the 3 centers. These data suggest similar outcome using SIB, URD or UCB in pts >50 years with AML in CR. Poor cytogenetic risk was the dominant prognostic factor. Until prospective studies are completed, this study supports the recommendation to consider SIB, URD or UCB for HCT for pts with older AML in CR. We analyzed outcome of 239 patients with refractory AML who received sequential chemotherapy including fl udarabine, cytarabine and amsacrine, followed by reduced intensity conditioning (RIC) and allogeneic hematopoietic stem cell transplantation (HSCT). Busulfan (Bu) conditioning was given to 73 patients with or without cyclophosphamide (Cy, 80-120 mg/kg). We wanted to compare outcome using Bu with those treated with Cy and 4 Gy total body irradiation (Cy-TBI) which was given to 166 patients. Median age was 62 and 51 years and median year of transplant was 2009 and 2008 in the two groups, respectively (p<0.0001). The proportion of patients with primary induction failure vs. 1st or 2nd relapse, did not diff er signifi cantly in the Bu and Cy-TBI groups. CR rate post-transplant, engraftment, acute and chronic GVHD were similar between the two groups. One-year non-relapse mortality (NRM), relapse incidence (RI), survival and leukemia-free survival (LFS) for the entire cohort was 18±3%, 49±3%, 47±4% and 33±4%. The Bu and Cy-TBI groups did not diff er regarding outcome. For instance, LFS at one year was 32±6% and 33±4% in the two groups, respectively.

Recipients of unrelated grafts had a lower probability of relapse (Hazards ratio (HR)=0.64; p=0.02) and better LFS (HR=0.67; p=0.02) compared to recipients of HLA-identical sibling HSCT. The prognosis of patients with acute leukemia (AL) relapsing after allogeneic stem cell transplantation (alloSCT) is dismisal. A 2nd alloSCT can potentially improve survival, but only a selected group of patients is likely to benefi t from this approach. Two large retrospective EBMT and CIBMTR registry based studies showed that disease status, TBI and age at the 2nd allograft, and the interval between 1st alloSCT and relapse signifi cantly correlated with a better LFS and OS at 3 years. However, no longer follow-up data on 2nd alloSCT are available.

In order to evaluate prognostic factors with a 10-year follow-up, we retrospective analyzed EBMT registry data from 286 patients receiving a 2nd myeloablative alloSCT for AL relapse between 1985 and 2000. Median age was 30 years (18-61), 58% had a diagnosis of Acute Myeloid Leukemia, 42% of Acute Lymphoblastic Leukemia; source of stem cells was bone marrow (BM) in 51%, and, peripheral blood (PB) in 49% of the patients; 18% of the patients received TBI. At 2nd alloSCT, 39% of the patients were in CR1, 27% in CR2, 12% in ≥CR3, and 61% had active disease. With a median follow-up of 11.3 years (1.2-23), 10-year OS and LFS were 10±2% and 7±2% respectively; relapse incidence (RI) and non-relapse mortality (NRM) at 10 years were 58±3% and 35±3%. ). An interval from 1st to 2nd alloSCT >10 months was also associated with better OS (HR 1.88) and LFS (HR 1.89), lower RI (HR 0.54) and lower NRM (HR 0.59). TBI was associated with lower RI (HR 0.53), better LFS (HR 1.68) and OS (HR 1.76). The use of PB as opposed to BM had a positive eff ect on NRM and was inversely correlated with RI. Considering the main adverse factors (no CR, no TBI at 2nd alloSCT, interval between 1st to 2nd alloSCT <10 months), patients without any adverse factor showed a 10-year OS and LFS of 44±10% and 27±9%, respectively, whereas the 10-year OS/ LFS was 6±2%/4±1% among patients having ≥ 1 adverse factor (p<0.0001; Figure 1 ). Based on the longest follow-up reported so far for 2nd alloSCT in AL, this retrospective analysis was able to identify a subset of patients with long-term benefi t from a 2nd alloSCT. Prognostic factors available at time of 2nd alloSCT can be used for clinical decisions. We retrospectively analyzed 1013 non-M3 AML patients undergoing ASCT in 72 GITMO centers up to December 2008; 531 were male and 482 female, with a median age of 47 years (range 2-78); conditioning regimens included Busulfan in 553 (55%) or other drug not including Busulfan in 312 (31%); 92 (9%) received TBI; in 56 (5%) conditioning was unknown. The 5 years Overall Survival (OS) and Leukemia Free Survival (LFS) in the whole population were 47% and 39% respectively. Among these patients 866 (85%) received ASCT in CR1, 63 in CR2 and the remaining with advanced disease (>CR2). According to the main cytogenetics and molecular markers (Foran JM, Hematology 2010, 47-55, Educational book), the 866 patients transplanted in CR1, have been categorized in 4 groups: group A, including 138 patients with favourable karyotype (K)/molecular markers: (t(8;21)(q22;q22); inv(16)(p13q22)/ t(16;16)(p13;q22); normal K with CEBPA or NPM1 mutant with FLT3-ITD-; group B: 147 patients with adverse K/molecular markers including: complex K (>3 abnormalities); inv(3)(q21q26)/ t(3;3)(q21;q26); -5,-5q,-7,-7q, other 11q23 abn, inv(3)(q21q26.2), t(3;3)(q21q26.2), t (6;9), t(9;22), abn(17p); FLT3-ITD+, in absence of favorable K; group C: 311 patients with cytogenetics abnormalities not encompassed in group A or B: (+8; t(3;5), t(9;11)(p22q23); other K abnormalities; absence of NPM1 mutation or FLT3-ITD; and group D, including 270 patients with normal K and unknown molecular markers. With a median F-U of 989 days (range 14-7543), the 5 years OS was 65% in group A; 44% in group B; 48% in group C and 51% in group D, with signifi cant diff erences between the groups A vs B, A vs C and A vs D (Fig. 1a) . LFS was 54% in group A; 35% in group B, 38% in group C and 44% in group D respectively, with signifi cant diff erences between the groups A vs B, A vs C, A vs D, B vs D, C vs D (Fig. 1b) . These data confi rm that the outcome of AML patients transplanted in CR1 is aff ected by cytogenetics and molecular factors; the patients of the groups A and D showed the best outcome; in patients of group B we observed an unexpected 35% 5 years LFS, without statistical diff erence, compared to group C while patients with normal K and unknown molecular markers showed a better outcome. Our results confi rm that ASCT in CR1 remains a suitable option in AML patients with normal-intermediate K. Many patients with Acute Myeloid Leukemia (AML) relapse due to persistence of low numbers of residual leukemia cells that are undetectable by conventional cytomorphologic criteria. Achieving complete remission is often insuffi cient to predict long-term remission. The leukemia cell population undetectable by morphologic methods has been defi ned as a minimal residual disease (MRD).

Our objective was to determine the impact of MRD by any technique in adult patients with AML in morphologic fi rst (CR1) and second complete remission (CR2) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). Material and Methods: We performed a retrospective study of patients admitted to the Department of Medicine Hematological Malignancy/Stem Cell Transplant Unit at UCLA between 2000 and 2011. For detecting of MRD we used multiparametric fl ow cytometry, cytogenetics and fl uorescent in situ hybridization. Any level of residual disease was considered MRD-positive.

[P1086]

S383 Results: There were 64 patients eligible for the study of 160 patients transplanted over ten years. Patients with MRD had a consistently worse outcome over those without MRD, with 3-years leukemia-free survival (LFS) and overall survival (OS) of 15% vs. 58.0% (HR = 2.7; 95% CI: 1.4-5.3; p<0.0035 Background: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a potentially curative treatment for a variety of hematologic malignancies and nonmalignant hematologic disorders. In this retrospective, single center study we evaluated safety and effi cacy of haploidentical allo-HSCT compared to those of HLA-matched allo-HSCT in patients with acute leukemia. Methods: A total of 94 acute leukemia patients who underwent allo-HSCT between June 2010 and November 2012 were reviewed. Characteristics of patients are summarized in Table- 1. All patients received Cyclophosphamide (Cy) 50 mg/kg i.v. on days +3 and +4. Pharmacologic prophylaxis of GvHD with cyclosporine-A (Cy-A) and mycophenolate mofetil (MMF) was not initiated until day +5 to avoid blocking Cy-induced tolerance. All patients received Cy-A which was initiated at a dose of 400 mg/day, and then adjusted according to the plasma levels. If there was no GvHD, it was tapered off by day +180. In addition to Cy-A, all haploidentical

S384 allo-HSCT recipients received MMF until day +35 at a dose of 1 gr/day. Results: There were no signifi cant diff erences in patient characteristics between the groups except a higher median number of stem cells infused in haploidentical group (p=0.002). The median follow-up was 194 days for haploidentical group and 210 days for HLA-matched group. 98% of the patients engrafted. The median time to neutrophil engraftment and also time to thrombocyte engraftment was signifi cantly longer in the haploidentical group compared to the HLA-matched group. The incidence of acute GvHD ≥ 2 was 56% in haploidentical group and 19% in HLAmatched group (p=0.001). The incidence of documented viral infections was signifi cantly higher in haploidentical group compared to HLA-matched group (42% vs 11%, respectively, p=0.001).

The relapse rate and as well as overall mortality rate was not signifi cantly diff erent between the two groups. Outcomes according to type of HSCT were summarized in Table-2 . Conclusion: Our results suggest that haploidentical allo-HSCT is a safe alternative treatment modality in patients with acute leukemia who lack HLA-matched siblings. The major problems are seems to be viral infections and acute GvHD. Future challenges remain in improving post-transplant immune reconstitution and fi nding the best approach to reduce the incidence and severity of GvHD and infections, while preserving graft-versus-leukemia eff ect to prevent the recurrence of the underlying disease.

High AUC intensity with once-daily IV BuCy2 as myeloablative conditioning regimen prior to HSCT for adult AML patients in fi rst complete remission F. Suarez (1) Background: Busilvex (Bu) followed by Cyclophosphamide (Cy) is a standard conditioning therapy used prior to Allogeneic HSCT. Moreover, relapse rate in AML CR1 patients remains a matter of concern, being as high as 25%. Therefore, we hypothesized that Area Under the Curve (AUC) intensifi cation may reduce the relapse incidence for high-risk patients. Primary objective: To target the upper range of the Bu therapeutic window (i.e.: AUC = 4400 -6000 μmol/L.min) from a once daily BuCy2 regimen. Methods and patients: This prospective phase II study included 30 (9 females, 21 males) CR1 AML patients (26 de novo AML, 4 secondary AML). All patients received a once-daily 3.2 mg/kg dose of Busilvex on day 1 of conditioning, with dose adjustment from day 2 to day 4 in order to target the middle of the defi ned therapeutic area (AUC = 5200 μmol/L.min). The total dose of Cy was 120 mg/kg. GVHD prophylaxis included ciclosporine, methotrexate, and ATG in case of unrelated donors. Median age: 43.5 years (19. 3-55.5) . Median time interval from the diagnosis to HSCT: 5.6 months (2.5-9); 20 patients were transplanted with a matched

S385 sibling donor and 10 with MUD; 13 patients received BM and 17 PBSC. Results: The median observed AUC was 4837 μmol/L.min at day 1 and 5297, 5709, 5395 μmol/L.min for the following adjusted doses. The inter-individual coeffi cient of variation of AUCs decreased from 29% at day 1 to 16%, 18% and 21% at days 2, 3 and 4, respectively. Based on the cumulated AUC over the 4 days, 27 out of 30 patients (90%) achieved the targeted therapeutic window. The median follow-up was 7.65 months (3.4-12.05 ). All patients engrafted: the median time to reach neutrophil and platelet engraftment was 17.5 (11-35) and 14 (8-49) days, respectively. The median duration of hospitalization post-HSCT was 25.5 days (14-75). At day +100, 2 cases of VOD occurred, one mild, one severe, both resolved. No death from organ toxicities occurred at 3 months. Overall, 25 patients were alive at last follow up. Two patients died of relapse and 3 of non-relapse. The cumulative incidence of relapse at one year was 16.9% [95% CI 14-20].

Conclusions: This study confi rms that once-daily IV BuCy2 with AUC intensifi cation is feasible, without major safety concerns, and is potentially an eff ective regimen in high risk AML. The incidence of acute myeloid leukemia (AML) increases with age, but outcomes for elderly patients are known to remain worse. Intensive chemotherapy (CTx) and hematopoietic stem cell transplantation (HSCT) is associated with poor outcome with high therapy related mortality. Whereas, several studies showed advantage of low dose CTx or HSCT with reduced intensity conditioning (RIC).

We tried to fi nd the better way to manage elderly AML focusing into HSCT and low dose ARA-C (LDARA) maintenance. We've treated elderly AML (≥60yrs) with risk-adapted strategies according to age, comorbidity and performance by eastern cooperative oncology group (ECOG). While 158 with advanced ECOG, age and comorbidity were planned to conservative care, we initiated several treatments (Tx) in 256 from '02 to '11. 85 (age≤65 or ECOG 0-1) were treated with standard anthracycline+ARA-C(3+7), 86 (age>65 or ≤65 with ECOG>1 'without' comorbidity) were with intermediate dose CTx, 63 (same as prior 'with' comorbidity) were with LDARA(20mg/m 2 )+Etoposide(VP16, po100mg) for 14d and the last 22 were with LDARA+VP16 less than 14d due to higher comorbidity. 148 (57.8%) achieved complete remission (CR) and 142 got post-CR Tx. 41 with available donors were treated with allo-HSCT with RIC mostly, 13 were with auto-HSCT, 58 were with intermediate dose ARA-C (IDARA) consolidation, and 30 were with LDARA+VP16 for 10d up to 6 cycles.

As an induction regimen, CR rates of standard, intermediate and LDARA+VP16 were 71.8%, 60.5% and 50.8%. Each group included 96.5%, 64% and 26.4% of patients with ECOG 0-1 and the age was higher in LDARA+VP16 (67.2yrs, p<0.001). As a post-CR Tx, 3 groups were compared; Group 1, allo-HSCT (n=41); Group 2, auto-HSCT or IDARA consolidation (n=71); Group 3, LDARA+VP16 (n=30). Group 1 showed the best OS (2yrs 64%, med 46.1mo) and DFS (2yrs 55%) and Group 2 showed the worst OS (2yrs 28%, med 16.1mo) and DFS (2yrs 24%, med 8.9mo). Group 3 showed intermediate OS (2yrs 43%, med 23.5mo) and DFS (2 yrs 28%, med 11.8mo). Multivariate analysis showed the worst OS (HR=2.342, p = 0.007) and DFS (HR=3.173, p < 0.001) in Group 2, but Group1 and 3 showed no signifi cant diff erences. In subgroup analysis of ECOG>1, Group 3 showed superior OS than Group 2 (p = 0.049).

For elderly AML, this study showed we are supposed to initiate risk adapted CTx actively. After CR, if donor is available, allo-HSCT should be considered. If patients' performances are poor, LDARA+VP16 maintenance can be a good choice for prolongation of survival outcomes.

[P1090]

of 20 days (13-27) with full donor chimerism, with a 30-day CI of 96±0.1%. The CI of III-IV grade A-GVHD was 13±0.3%. The CI of extensive C-GVHD for 40 evaluable patients was 14±0.5%. At a median follow-up of 2 years (0.1-5 yrs), the CI of TRM and relapse was 24±0.4% and 38±1%, respectively. For all 48 patients, the 1-and 5-yr probability of OS was 67±7% and 49±9%, respectively and that of DFS was 59±7% and 44±8%. For the 40 patients transplanted in CR1 and CR2, these probabilities were, respectively, 71±7% and 54±9% for OS, 65±8% and 51±9% for DFS. Twentynine patients in remission were conditioned with TBF-MAC regimen and the 5-yr probability of OS and DFS was 63±11% and 55±10%, respectively. The 3-yr OS and DFS of 11 patients in remission, 9 of whom aged >55 yrs (55-66) and prepared with the TBF-RIC regimen, were 44±15% and 45±15%, respectively. Conclusions: This transplant procedure not requiring expensive laboratory tools and advanced expertise in cell manipulation can be widespread extended to all transplant Centers and could be off ered as alternative option to high-risk AML patients lacking an HLA identical sibling and on urgency to be transplanted. Introduction: Diagnostic karyotype is the most signifi cant prognostic factor in AML patients and provides the framework for current risk-stratifi ed treatment approaches. The aim of our study was to use this score for outcome prediction after HSCT in fi rst complete remission. Methods: We studied 167 AML patients with a median age of 26 years (range:2-63 yrs) who underwent HSCT in fi rst CR at Hematology, Oncology and Stem Cell Transplantation Research center. The median follow-up was 14 months (2-89 months Introduction: Although the role of autologous stem cell transplantation(ASCT) in the treatment of AML is controversial. It was still recommended as consolidation therapy for selective patients due to low TRM and potential anti-leukemia advantage. The relapse is main treatment failure. The current cohort study evaluated effi cacy of ASCT based on minimal residual disease (MRD) for patients with favorable-and intermediate-risk AML. Methods: Patients with de novel AML in favorable and intermediate-risk group younger than 60 years were eligible. Peripheral blood stem cell (PBSC) harvesting was started if patients achieved CR1 and MRD level was less than 0.1% after 1 to 2 courses of induction therapy(3+7) and at least 2-coursrs of consolidation therapy including high-doses Ara-C. MRD was monitored using real-time PCR (RT-PCR) to quantify the RUNX1/RUNX1T1,CBFB-MYH11 transcript level and NPM1 mutation. 

Use of granulocyte colony-stimulating factor to promote engraftment after autologous stem cell transplantation for acute myelocytic leukaemia is not associated with increased relapse incidence: a report from the Acute Granulocyte colony-stimulating factor (G-CSF) is widely used to accelerate neutrophil recovery after autologous hematopoietic stem cell transplantation (autoHSCT). However, its application in acute myeloid leukemia (AML) is controversial as leukemic blasts may express G-CSF receptors interacting with the cytokine. Hence, there may be concern about increased risk of relapse and reduced leukemia-free survival (LFS) when using G-CSF after autoHSCT in a setting of AML. The goal of our study was to verify this hypothesis based on a retrospective analysis of a large cohort of patients reported to the EBMT registry. Adults with AML (excluding acute promyelocytic leukemia) treated with autoHSCT in fi rst complete remission between 1994-2010 were included in the analysis. Among 2093 subjects 972 Background: AlloSCT is a well-established therapy for patients with intermediate/high risk AML /MDS. The outcome of patients relapsing after alloSCT is dismal, but promising results have been achieved in an imminent relapse. The main obstacle has been that sensitive MRD-markers are not frequently available. Another potential method to predict relapse early for timely decision of pre-emptive immunotherapy is monitoring of chimerism. We hypothesized that targeting 100% donor chimerism measured by specifi c techniques in patients with ultra-high risk, viz AML with primary induction failure or blastic MDS with very poor cytogenetics, could result in a lower relapse risk. Methods: Microsatellite (short tandem repeat, STR) technique and a new chimerism analysis system (Abbott AlleleSEQR), based on quantitative PCR, were used to detect residual recipient-derived cells. Samples for STR-PCR were collected from bone marrow CD34-positive precursor fraction in addition to whole blood. More sensitive alleleSEQR was tested from peripheral blood. Posttransplant immunomodulation included LD-azacitidine, combined with escalated DLI on demand, in parallel with a rapid withdrawal of immunosuppression starting at week 7. Sequential conditioning according to Schmid et al (2006) , with minor modifi cations, was used as a preparative regimen. Immunosuppression consisted of ATG 5mg/kg, short methotrexate, and calcineurin inhibitor or mTOR inhibitor everolimus. Results: In this first pilot phase of the study, 10 patients were treated (AML n=7, blastic MDS n=3). One patient relapsed early, and two patients are too early to be evaluated (follow-up less than 6 months). Other seven patients, with a minimum follow-up of 6 months, are in continuing MRD-negative CR. In this small but homogeneous patient cohort, a relapse rate was 12.5%, TRM was 0%, and consequently OS was 87.5%. Full donor chimerism (100%), assessed by sensitive techniques, was achieved in all patients. All patients developed grade >2 acute GVHD which was resolved in all cases. Four patients (50%) developed mild/moderate chronic GVHD, and one patient is still on immunosuppression due to limited GVHD after followup of 18 months. Conclusion: In conclusion, sensitive methods tracking small amounts of residual recipient-derived cells after alloSCT seem to be useful for timely decision of pre-emptive prevention of posttransplant relapse in patients with high-risk AML and MDS. However, more data are needed before defi nitive conclusions can be made. Figure 1A ) & event-free survival (EFS; P=.03; Figure 1B) 27.3%, p=0.0035). Transplant-related mortality (TRM) was 6.9% in the entire cohort; in the group of patients that received bone marrow stem cells it was higher (10.2%) compared to the group that received peripheral stem cells (4.3%).

[P1102]

[P1102]

S393 Analysis according to cytogenetic risk groups was done, and as expected, patients with high-risk disease treated with autologous HSCT did very poorly. Patients with intermediate-and low-risk disease did well, achieving 5-year overall survival of 49.7% and 60.6%, respectively. Patients with FLT3 internal tandem duplication had also signifi cantly lower overall (25.9% vs. 59.2% at 5 y; p=0.0369) and disease-free survival (14.8% vs. 54.2% at 5 y; p=0.0128).

In conclusion, our results of autologous transplantation in AML patients are comparable to other published results. Our data suggests autologous HSCT remains a very good option in postremission treatment of AML patients with intermediate-and low-risk disease, but not FLT3 positive patients.

Combination of fl udarabine, amsacrine and cytarabine followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in 60 patients with high-risk acute myeloid leukaemia M. Krejci (1) Background: Sequential use of chemotherapy and reduced-intensity conditioning (RIC) with allogeneic stem cell transplantation (SCT) has been proposed to improve the treatment outcomes in patients (pts) with high-risk acute myeloid leukemia (AML). Here we present our experience in cohort of 60 AML pts. Methods: Patients fulfi lled at least one of following criteria: primary induction failure after 2 or more cycles of chemotherapy (n=9); fi rst early relaps after a remission duration of fewer than 6 months (n=15); relapse refractory to salvage combination therapy containing high-dose AraC (n=11); second or subsequent relaps (n=15); and presence of unfavorable cytogenetic (n=10). Fludarabine (30 mg/m2), cytarabine (2 g/m2), and amsacrine (100 mg/m2) for 4 days (FLAMSA) were used for cytoreduction. After 3 days of rest, RIC consisting of 4 Gy TBI, anti-thymocyte globulin (ATG-Fresenius) 10-20 mg/kg/day for 3 days, and cyclophosphamide 40-60 mg/kg/day for 2 days followed. Prophylactic donor lymphocyte transfusions (pDLT) were given from day +120 in pts who were free of immunosupressive medication for at least 30 days without developing GvHD. Median age was 51 years. Types of donors and used grafts were as follows: HLA identical sibling, n=14; unrelated donor, n=46; PBSCs, n=56; BM, n=4. Results: The median time of neutrophil engraftment (above 0.5x10E9/L) was 17 days, 51 pts engrafted, 9 pts died in aplazia to day +30. Incidence of acute GvHD was evaluated in 51 pts: 47% (24/51) of pts had GvHD (grade I+II in 15 pts, grade III in 9 pts). Incidence of chronic GvHD was evaluated in 44 pts, 55% (24/44) of pts had GvHD (limited in 17 pts, extensive in 7 pts). The cumulative incidence of non-relapse mortality (NRM) at 1 year and 3 years was 25% (15/60) and 28% (17/60) . The other most frequent toxicities were grade III/IV infections according to common toxicity criteria in 43 of 51 pts and gastrointestinal toxicity (grade III in 15 of 51 pts). Complete remission was achieved in 47 of 51 pts (93%), progression was present in 4 pts (7%). Relapse of AML occurred in 18 pts. With the median follow-up of 37 months from SCT(range 10-69), the entire cohort had 1-year and 3-year overall survival rates of 45% and 42%, respectively. Progression-free survival rates at these time points were 38% and 33%, respectively. Conclusion: The FLAMSA-RIC protocol can be recommended for treatment suitable high-risk AML pts with a chance of long-term survival for over 40% of these pts.

Allogeneic stem cell transplantation in patients with acute myeloid leukaemia: a report from the Austrian Stem Cell Transplantation Registry (ASCTR) A. Boehm (1), W. Rabitsch (2) , HT Greinix (2), P. Kalhs (2) , M. Mitterbauer (2) , A. Schulenburg (2) , S. Woehrer (2) , N. Worel (2) , D. Strunk (3), W. Linkesch (3), C. Urban (3), W. Schwinger (3), C. Peters (4) , G. Gastl (5) , D. Nachbaur (5) , B. Kircher (5) , J. Clausen (6) , J. Auberger (6) Aim: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potent cure for acute lymphoblastic leukemia (ALL). Reduced intensity conditioning regimens (RIC) are used to overcome HSCT-related drug toxicity. The study assesses the role of this regimen. Methods: Newly diagnosed ALL cases who candidate HSCT with full HLA matched sibling after obtain informed consent received reduced induction chemotherapy (Vincristine/Dexamethasone) and underwent early HSCT after disease stabilization within 15-30 days without intention to achieve CR. The comparison group was patients who received conventional chemotherapy followed by HSCT. Both group received busulfan/cyclophosphamide as conditioning regimen before peripheral blood source. Results: Totally, 80 patients were assessed, twenty eight patients in the study group and 52 patients in the comparison group. S399 and 61.4% (SE: 7.6%) in case and comparison groups, respectively (p=0.809). Death occurred in 8(35.7%) of cases (causes: relapse, GvHD) and 17(36.5%) of comparison group (causes: GvHD, relapse). Conclusion: Reduced induction followed by early transplantation without consolidation is not inferior then routine HSCT. Due to small size of patients and short time of follow-up a study with more cases and long time follow-up is recommended. A randomized study can reveal, if there is, the benefi t of this modality in ALL treatment. . There was no signifi cant diff erence in leukemia free survival (p=0.59), overall survival (p=0.577). Conclusion: Our results show that there is no diff erence for allogenic HCT results, when patients received or not received consolidation chemotherapy. Confi rmation of this preliminary data need more cases and longer time. Allogeneic stem cell transplantation (SCT) is successfully applied in treatment of paediatric patients with refractory B-lineage acute lymphoblastic leukaemia (ALL). However, relapse is still the major cause of death post-transplant and correlates signifi cantly with persistent minimal residual disease (MRD) prior to or after SCT. In order to reduce or clear MRD and, thus, preventing relapse in high-risk patients pre-and post-transplant, immunotherapy using a third-generation CD19-specifi c monoclonal antibody (mAb) is deployed in an ongoing compassionate use program at our institution. Through its improved capability to recruit FcγRIIIA bearing eff ector cells, this Fc-optimized chimerized CD19-specifi c mAb (4G7SDIE) mediates enhanced antibody-dependent cellular cytotoxicity (ADCC) by NK cells. The CD19 antigen is commonly expressed in paediatric leukaemias as it is continuously and stably expressed on all stages of B lineage diff erentiation and therefore a suitable target for immunotherapy. 6 paediatric patients with refractory B-lineage ALL and detectable MRD received a mean number of 12 infusions. In 5/6 patients infusions were applied prior to SCT. In 3/6 patients leukaemic load was reduced for ≥ 1 log and in 1/6 patients MRD was eradicated by 4G7SDIE. 2/6 patients relapsed, 4/6 patients are in remission (17-468 days) . Taken together a response could be documented in 4/6 patients. Concomitant in vitro studies with donor-derived PBMCs of patients (n=8/9) in 2 h-cytotoxicity assays showed that NK cells exerted insuffi cient lysis of primary B-lineage ALL blasts or paediatric pre B-ALL cell line MHH-CALL-4 (mean specifi c lysis: 6.1% / 4.4 %). However, lysis could be increased by 18.5 % and 18.9 % by adding 1 μg/ml 4G7SDIE (n=19; p=0.0024 / n=13; p=0.0018) or by 9.7% and 24.4 % by adding autologous patient serum taken 1 day after antibody treatment (n=21; p=0.0068 / n=15; p=0.0002). Serum titers of biologically active 4G7SDIE in patient serum samples were analyzed by a fl ow cytometry-based method and saturating and ADCC relevant serum titers of 4G7SDIE were detectable 13 days after antibody infusion. In conclusion, promising antileukaemic eff ects have been observed in vitro and in vivo in this compassionate use program. However, a further clinical trial will be necessary to investigate the capability of this therapeutic antibody to reduce relapse rates.

First experiences with SPECTRA OPTIA® in therapeutic leucodepletion M. Reti, R. Rasonyi, A. Fodor, V. Goda, T. Masszi St.Istvan and St.Laszlo Hospital (Budapest, HU) Introduction: Hyperleukocytosis is a rare but life-threatening condition. About 30-50 leukodepletions (LD) are performed yearly due to this indication in our center. Effi cient and fast white blood cell (WBC) depletion using older generation of cell separators needs high skill and is not without risk. Recently, an automated, separate leukodepletion (LD) program was developed for Spectra Optia: -automated interface management -possibility of giving fl uid substitution (FS) with automatic control of fl uid balance (FC) were incorporated as main new features into the system. Since December of 2011 till now, 21 LD procedures were done with this instrument. The aim of this study: We analyzed our fi rst experience with Optia in LD. Patients and methods: There were 9 patients (pts ) with acute leukemia (AL) and 9 pts with chronic leukemia (CL) (see the table). The following protocol was used: The indications of LD in our center: -Acute leukemia: hyperviscosity syndrome (HS) and/or blast cell count > 100 G/l -Chronic myeloid leukemia: HS or WBC count > 300 G/L or blast cell count >100 G/l -Chronic lymphoid leukemia: HS or WBC count > 500 G/l (>200 G/l, before rituximab) Our anticoagulation (AC) protocol: (low citrate toxicity allowing high speed procedure) -HAES steril-10% + ACDA (ratio: 1:1) + 2500 IU heparin/1 liter AC (unless in DIC) -AC : whole blood (WB) ratio = 1:9 -1:10 (setting of Qac: 2,4 ml/ total blood volume (TBV)/min) As red blood cell transfusion (RBC) sharply increases WB viscosity, it was given only during or after LD, never before. Fresh frozen plasma (FFP) was transfused, only if indicated. WB cell counts were checked at regular intervals. Buff y coat (BC) was collected in 1-5 fractions. Results: The results are summarized in the table (median values, range in brackets) and the graph. The LD was very well tolerated in all cases: 8 pts needed transfusion during the procedure and 7 were given only saline/albumin FS (AL: saline / albumine: 2, RBC: 2, FFP: 4; CL: saline / albumine: 5, FFP: 2). The treatment was highly effi cient in both, AL and CL respectively, with similar results. Our data prove the interface stability during LD (not shown). The automatic FC functioned very well, even at extreme circumstances (BC volume > pt's TBV). There was no serious side eff ect. Conclusion: Due to the high WBC, low PLT collection effi ciencies and the safety of automatic FC, Optia may be the 1st choice instrument for LD at present.

Fludarabine-melphalan as reduced-intensity conditioning for allogeneic stem cell transplantation in AML beyond complete remission: 10-year single centre experience M. Karas, K. Steinerova, T. Svoboda, D. Lysak, S. Vokurka, V. Vozobulova, P. Jindra Charles University Hospital (Pilsen, CZ) Background: According to published data reduced-intensity transplantation (RIT) in patients (pts) with AML beyond complete remission (CR) is associated with lower progression-free survival (PFS) and overall survival (OS) due to high risk of relapse. But elderly pts or pts with comorbidities can rarely benefi t from myeloablative conditioning because of high risk of transplant-related mortality (TRM). To evaluate the potential role of RIT for pts with AML beyond CR we retrospectively analysed the outcome of such pts undergoing RIT in our centre in last 10 years.

[P1117]

[P1117] S401 Patients and methods: Since 2002 39 pts with median of age 58 years (range, 22-66 years) with AML beyond CR underwent RIT (19 pts were in the 1st or 2nd untreated relapse, 9 pts had chemotherapy-resistant disease, 11 pts had untreated secondary AML following an antecendent hematologic disorder). All pts had more than 5% blasts in the bone marrow (BM) with the median of BM blast 20% (range,6-75%), 28% of pts had blasts in peripheral blood and 5% of pts had extramedullary manifestation of AML. Donors were in 33% HLA identical related, 58% HLA matched unrelated and 9% HLA mismatched unrelated. The source of stem cells was peripheral blood with the median of infused CD 34+cells 6, 3x10 6 /kg (range,1, 8-13, 8x10 6 /kg). The conditioning regimen consisted of fl udarabine (30 mg/m 2 for 4 days) and melphalan (140mg/ m 2 for 1 day). CsA and methotrexate (10mg/m 2 at day +1, +3, +6) were used as GVHD prophylaxis. After day +30 in pts without GVHD, CsA was tapered over a period of 4 weeks. Results: all pts except one patient engrafted and achieved CR at day +30. Among 38 evaluable pts 19 (50%) of them developed acute GVHD (18%grade III-IV). Among 34 evaluable pts 19 (56%) of them developed chronic GVHD (26%extensive). With median follow-up 52 months (range,12-126 months) 15 pts (38%) are alive (13 pts in continuing CR), 12 pts (31%) relapsed and 10 of them died. 2 relapsed pts achieved subsequent CR lasting 28 and 68 months. 14 pts (36%) died due to TRM, 5 (13%) of them till day +100. The probabilities of 5-years PFS and OS are 35% and 40%. Conclusion: despite smaller number of evaluated pts and retrospective type of analysis our data suggest that fl udarabine and melphalan conditioning shows excellent early disease control and in association with early withdrawal of immunosuppresion can achieved continuing long-term CR with acceptable TRM and GVHD incidence in pts with AML beyond CR not eligible for myeloablative conditioning. Objective: Acute lymphoblastic leukaemia (ALL) is the most common malignancy in childhood. Although about 80% of the paediatric patients can successfully be treated by standard therapy, especially the high risk patients are severely endangered in developing a relapse with a dismal prognosis. Somatic mutations in cancer are not only a hallmark of the disease, but can also lead to novel mutated peptide ligands presented by the MHC molecules of the transformed cell. These neoantigens are the ideal T cell target and thereby vaccine in theory, since neither tolerance mechanisms nor autoimmune reactions would interfere with the positive outcome of the therapy. However, they are mostly patient individual, limiting the possibilities of an off -the-shelf vaccine. Therefore we were establishing a patient individual ALL specifi c peptide vaccination strategy combining next generation sequencing (NGS) of the whole exome and the transcriptome of the patients' tumor and normal tissue with in silico epitope prediction for the patients' individual HLA type. Methods: Whole exome sequencing of seven c-ALL patients' leukemia and fi broblast (control tissue) DNA was performed. ALL specifi c single nucleotide variants (SNVs) as well as Insertions and Deletions (InDels) were identifi ed using a comparative bioinformatics pipeline. The transcriptome of the patients' ALL blasts was analyzed by next generation RNA sequencing and the expression of the mutations was determined. Putative epitopes containing the mutated sequences were predicted specifi cally for the patients HLA type using SYFPEITHI, NetMHC and NetMHCpan. Results: The analysis of the tumor specifi c mutanome of seven pediatric c-ALL patients revealed on average 31 cancer specifi c nonsynonymous mutations (SNVs and InDels) per patient. Out of these, an average of about 30 patient individual MHC class I epitope candidates was predicted. Several already described cancer genes, as well as genes linked to leukaemia like JAK2, TP53 or PTPN11 were somatically mutated in the patient's blast. However, the detected mutations but also the aff ected genes were highly individual among the patients, as only in three genes alterations were determined in two and three patients respectively. The results underline the high potential of an actively individualized vaccination approach in these patients.

Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukaemia: 12 years' follow-up data J. Park (1) , Y. Kim (2) , Y. Ko (2) , K. Kim (2) , C. Jung (2) , H. Lee (3) (1) We previously published data that suggested that induction of an autologous graft-versus-host disease (GVHD) has an anti-leukemic eff ect, consequently increasing the survival rate of patients who undergo autologous peripheral blood stem cell transplantation (PBSCT). Here we report the long term follow up data regarding the overall survival (OS) and disease free survival (DFS). In total, 22 acute myeloid leukemia patients with favorable and intermediate cytogenetic risk, in their fi rst complete remission, were administered cyclosporine c.i.v. from day 0 to day +28 at a dose of 3.0 mg/~kg per day and interferon-γ (IFN-γ ) at 0.025 mg/~m2 s.c. every other day from day +14 to day +42 following autologous PBSCT. Natural-killer (NK) -cell activity assays and skin biopsies were performed. Engraftment was successful in all patients at a median of 13 days without any signifi cant additional toxicity. Histologically confi rmed that cutaneous GVHD had developed in 12 patients, and NK-cell activity was signifi cantly augmented after the autologous PBSCT in those patients (P=0.03). After a median follow-up duration of 153.6 months (range, 122.3-188.8), the 3-year DFS and OS rates were 68.2% and 72.7%, respectively, and the 5-year DFS and OS rates were 63.6% and 73%, respectively. They were without signifi cant correlation with GVHD status or augmentation of NK-cell activity. The median OS was unreached yet. Fourteen patients (63 % ) are still alive without relapse or other related disease, nor were there secondary malignancies. This data suggests that the administration of cyclosporine and IFN-γ following autologous PBSCT improves OS and DFS, which may be attributable to the antileukemic eff ect, although no diff erence in survival rates could be demonstrated between cutaneous GVHD-positive and -negative groups.

Results of salvage therapy with ARA-C and gemtuzumab ozogamicin in post-Allo-SCT high risk AML patients M. Koren-Michowitz, H. Maayan, R. Yerushalmi, N. Shem-Tov, A. Avigdor, A. Shimoni, A. Nagler Chaim Sheba Medical Center (Ramat Gan, IL) AML relapse after Allo-SCT is associated with a poor outcome. Therapy in pts relapsing early after SCT is further limited by the fear for an increased toxicity. GO was introduced into therapy of CD33 positive AML pts as a targeted therapy with limited extramedullary toxicity profi le. We hypothesized that in pts with AML relapsing early after an Allo-SCT, combination of GO with single agent chemotherapy will result in disease control for a sufficient amount of time to allow a trial of GvL induction. Therapy consisted of ARA-C (1 gr/m 2 days 1-4) followed by GO, 9 mg/m 2 (day 5) and was supported by donor stem cells, when available. In the abscence of GVHD, responding pts where eligible for DLI or a second Allo-SCT. 16 pts (F=10 M=6), median age 52 years (range 26-63) are included in this analysis. Most (14/16) were previously transplanted for a high risk AML (secondary AML-6, unfavorable cytogenetics-5, FLT3-ITD-3); disease status at SCT were CR1 (n=8), who were got complete remission (0.336±0.147) and nromal control (0.218±0.125)( p < 0.01) . The expression RUNX2 in HOX11+ cell lines was signifi cantly lower than HOX11-cell lines, and the expression level of RUNX2 in the HOX11+ T-ALL patients (0.581 ± 0.257) was signifi cantly lower than HOX11-T-ALL patients (0.835 ± 0.317). The relationship between RUNX2 and HOX11 mRNA expression level was a negative correlation. The methyIation rate of the promoter CpG isIands of RUNX2 gene in HOX11+ T-ALL (78.9%) was signifi cantly higher than HOX11-ALL (36.8%) (P<0.01). The expression levels of RUNX2 gene was negatively correlated with the methylation of CpG island in it's promoter region in T-ALL. Conclusion: HOX11 is a negative regulator of RUNX2 gene and the expression of RUNX2 is downregnlated or even lost by promoter methylation in T-ALL, which demonstrate a better event-free survival and a marked trend for longer overall survival for TLX1-high T-ALLs. The expression and methylation level of RUNX2 gene may have some signifi cance in evaluating the curative eff ect of T-ALL patients. The abnomal expression of RUNX2 might be a prognostic marker in T-ALL patients.

Sequential chemotherapy plus allogeneic haematopoetic stem cell transplantation: is it a good alternative as salvage treatment for heavily pretreated patients with leukaemia? P. Topcuoglu, G.C. Seval, O. Arslan, O. Ilhan, H. Akan, M. Beksac, G. Gurman, M. Ozcan Ankara University (Ankara, TR) Aim: The aim of this retrospective single-centre study was to examine the allogenic HSCT results based on FLAMSA cytoreductive therapy followed by a reduced intensity or myeloablative conditioning regimen.

[P1125]

Unique helper T-cell subsets in acute and chronic skin graftversus-host disease in paediatrics measured using a novel noninvasive methodology P. Khandelwal (1) Introduction: The exact functional subset of T cells responsible for organ specifi c GVHD remains elusive. While cytokine profi les are useful markers to defi ne T cell subsets, plasma cytokines may not reveal the distinct cytokine milieu in a GVHD target organ. We present cytokine profi les from the skin of children with acute and chronic skin GVHD to implicate the T helper subset responsible for its pathophysiology. A novel methodology of obtaining skin samples noninvasively using an epidermal skin patch called D Squame (CuDerm, Dallas, TX) was used. Methods: D-squame skin sampling discs were placed on the forearm/wrist of 13 pediatric patients (ages 0.25 years-14 years) for 2 minutes and removed. Samples were obtained from the involved area of the forearm/wrist in acute skin GVHD and from visually and palpably involved and uninvolved skin in chronic GVHD. This procedure was painless and safe even for young infants. Superficial keratinocytes were sampled by the fully cured medical grade polyacrylate ester adhesive on the disc. Cytokines were extracted from the sampling discs using a buff er made of phosphate buffered saline and 0.25 molar saline and analyzed using a 38 plex human cytokine Milliplex MAP magnetic bead panel (EMD Millipore Corp, Billerica, MA). Patients were divided into 4 groups; acute skin GVHD (n=5), chronic skin GVHD (n=2), no GVHD (n=2) and healthy pediatric controls (n=4).

Results: In acute GVHD, mean IL8 levels were elevated when compared to patients without GVHD and to healthy controls. IL8, also known as CXCL8, probably acts as a signal for recruitment of macrophages to site of infl ammation. Mean IL17a was higher in patients with GVHD, suggesting recruitment of Th17 cells into the skin during acute GVHD. In patients with chronic GVHD, mean IL8 and IL2 was higher in involved skin as compared to uninvolved skin of the same patients and to healthy controls. Values of IFN γ were found to be elevated in chronic GVHD, suggesting a Th1 response. Conclusions: This skin-sampling disc allows for direct quantifi cation of a GVHD target organ cytokine profi le, which carries greater impact in terms of providing novel insight into mechanisms for acute and chronic skin GVHD .Elevated IL17a suggests a Th17 response in acute skin GVHD, while elevation of IFN γ in chronic GVHD suggests a Th1 response.

[P1127] P1130 Role of monocytes, S100 proteins and Hsp90 in pathogenesis of graft-versus-host disease after allogeneic haematopoetic cell transplantation K. Reinhardt (1) Objectives: Graft-versus-host disease (GvHD) is one of the major live threatening complications of allogeneic hematopoietic cell transplantation (HCT). Th17 cells have been shown to play an important role in the pathogenesis of GvHD. The aim of this study was to investigate the infl uence of monocytes and their interaction with proinfl ammatory S100 proteins and 90kDa heat shock protein (Hsp90) on the induction of Th17 cells in patients with GvHD. Methods: CD4+ T cells from healthy donors were co-cultured with monocytes from patients with or without GvHD or healthy donors in the presence of anti-CD3 monoclonal antibody for 5 days on various time points prior and after allogeneic HCT. Optionally, monocytes were additionally stimulated with S100 proteins. For inhibition of Hsp90, monocytes were incubated with 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) for 16 hours before co-culturing with CD4+ T cells. After 5 days, cells were stimulated for 5 hours with PMA and ionomycin in the presence of monensin. For fl ow cytometric analysis, cells were harvested, stained for cell surface markers, fi xed, permeabilized, and stained with anti-IL17 antibody. For determining the concentration of S100 proteins in the stool of patients Enzyme Linked Immunosorbent Assays (ELISA) were carried out. Results: Monocytes from patients with acute and chronic skin or gut GvHD induce signifi cant higher percentages of Th17 cells compared to monocytes of healthy donors or patients without GvHD (p<0.0001). Inhibition of Hsp90 in monocytes resulted in a signifi cant decrease in Th17 cells pointing towards an important role of Hsp90 in GvHD. Additionally, induction of Th17 cells could be further enhanced by stimulation of monocytes with either S100 A8, S100 A9 or S100 A8/A9. Furthermore, the concentration of S100A12 was increased in the stool of patients with gut GvHD compared to patients without GvHD. Conclusion: Our fi ndings suggest that monocytes may play a major role in the pathogenesis of GvHD by triggering the induction of Th17 cells. S100 A8, S100 A9 and S100A8/9 could further enhance monocyte-induced Th17 cell development. Hsp90 might be an important regulator in monocyte-induced development of Th17 cells and might therefore be a therapeutic target for GvHD.

[P1129] P1131 GVHD inhibition and GVT augmentation in multi-donor transplantation (MDT) is Tregs-associated Z. Yekhtina, M.Y, Shapira Hadassah -Hebrew University Medical Cen (Jerusalem, IL) Introduction: we previously showed that multi-donor transplantation (MDT) in a murine breast cancer model suppresses GVHD while augmenting the GVT eff ect. Here we aimed to assess whether the GVT augmentation is present in a diff erent tumor model and by what mechanism is the GVHD suppressed. Methods: Following total body irradiation of 7.5 Gy on day -1, T-cell repleted bone marrows from C57BL/6, C3H alone or together (MDT) were transplanted into BALB/c mice. The recipient mice were also injected with IV 104 cells B-169 melanoma cells. We followed the development of GVHD, melanoma metastases and Tregs level in the recipient mice. Results: Again, we found that MDT composed by C57BL/6 and C3H cells transplanted into BALB/c resulted with signifi cantly suppress GVHD (measured by the Cooke grading system; p<0.01) as compare to those transplanted from C57BL/6 or C3H alone. The number of lung metastases at +30d was signifi cantly lower (p<0.001) with MDT as compared to all controls (BALB/c, C57BL/6 or C3H transplanted alone; fi gure 1). All splenic Tregs in the MDT group originated from the C57BL/6 donors. The Tregs level was signifi cantly higher in the MDT group (p<0.0002 in MDT vs. C57BL/6, p<0.02 MDT vs. C3H; fi gure 2). Conclusion: We conclude that MDT's anti tumor eff ect is present with various tumors. Despite the transplantation of 2 donors simultaneously, splenic Tregs were composed only by C57BL/6 cells and were signifi cantly increased as compared to single donor transplantation. This may explain the suppression of GVHD, but the increased GVT is yet to be elucidated.

Infl uence of microRNA expression in graft-versus-host disease after allogeneic transplantation M. Koldehoff , C. Maniera, N.K. Steckel, M. Kekec, D.W. Beelen, A.H. Elmaagacli University of Duisburg-Essen (Essen, DE) Background: MicroRNAs (miRNAs) are a family of 19-24 nucleotide noncoding RNAs, which aff ect the regulation of gene expression in eukaryotic cells by binding to a 3´-untranslated region which target messenger RNAs. MiRNAs plays important roles in many cellular processes such as development, stem cell division, apoptosis and cancer. We profi led miRNAs expressed on patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). Methods: Here we analyzed in a retrospective study 258 patients (pts) for miRNAs expression in whole blood that underwent allogeneic HSCT and analyzed their outcome. MiRNA expressions were performed by miRNA-specifi c real time RT-PCR. Results: In this cohort 84 pts received grafts from HLA-identical siblings (32%), 126 pts from matched (49%) and 48 pts from mismatched (19%) unrelated donors. Transplantat consisted of unmanipulated peripheral blood stem cells (n=228, 88%) or bone marrow (n=30, 12%) . Of all pts, 59 (23%) had relapsed and 25 (10%) died of October 2012. There was no signifi cant correlation between miRNA expressions from siblings and unrelated donors. For miRNA-181, we found a moderate up-regulation in mismatched unrelated donors versus matched donors (489 vs. 330%, p<0.06). Analysis of each miRNAs for relapse or TRM showed no statistically diff erences. Among all pts, 208 (81%) developed acute GVHD (86 pts had an aGvHD of grade ≥2). There was a signifi cant diff erences between low level of miRNA-146 (519 ± 507% vs. 799 ± 1308%; p<0.04), and high level of miRNA-let7 (665 ± 422% vs. 535 ± 332%, p<0.04) of pts with aGvHD ≥ 2. In pts with severe aGVHD (grade >3) comparing all other aGvHD pts., we found a high signifi cant reductions of miRNA-146 (308% vs. 723%, p<0.0001), and miRNA-21 (506% vs. 2358%, p<0.02). In regard to chronic GvHD, we found a downregulation of miRNA-let7 expressions in pts with severe cGVHD (498% vs. 639%, p<0.03) comparing other cGVHD. The probability of severe aGvHD with low level of miRNA-146 (< 387%, p<0.001) is 21 ± 7% versus 7 ± 4% with higher levels of miRNA-146 levels. However, an estimate for death in remission or overall survival was not signifi cantly associated with miRNAs. Conclusions: These results suggest that pts with diff erent expression of miRNA-146, miRNA-21 and miRNA-let7 confi rms a relevant association of the development of aGVHD and miRNA profi lings could be an early indicator of severe acute GvHD.

Th17-mediated immunity and associations with NOD2/ CARD15 mutations in acute GvHD after haematopoietic stem cell transplantation A. Klimczak (1), E. Jaskula (1), A. Lange (2) (1)Institute of Immunology and Experimental Therapy Polish Academy of Sciences (Wroclaw, PL); (2) Institute of Immunology and Experimental Therapy Polish Academy of Sciences and Lower Silesian Center for Cellular Transplantation and National Bone Marrow Donor Registry (Wroclaw, PL) Objectives: Damage of the gastrointestinal tract during the acute phase of GvHD plays a major role in the amplifi cation of this systemic disease after hematopoietic stem cell transplantation (HSCT). The role of genetic background and eff ector cells migration into the target tissues is currently investigated in the pathobiology of aGvHD. Methods: A total of 219 patients were evaluated for the presence of NOD2/CARD15 gene mutation using single nucleotide polymorphism technique (SNP) by assessing polymorphism of SNP8, SNP12 and SNP13.Thirty fi ve gastrointestinal biopsies taken from patients with clinical symptoms of aGvHD were analyzed by immunocytochemical staining for the presence of cellular infi ltrates (CD3, CD4, CD8, CD138) including detection of IL-17, FOXP3. Results: The NOD2/CARD15 gene mutation was assessed in 11% of HSCT recipients, in 13% of HSCT donors and in 5.5% when both donor and recipient have gene mutated. The cumulative incidence of transplant-related mortality was 64% when recipient (p=0.021; log-rang test) and 35% when donor were aff ected with NOD2/CARD15 gene mutation (NS) compared to patients without NOD2/CARD15 gene mutation. If the mutation involved both recipient and donor this proportion increases to 75% (p=0.016; log-rang test). NOD2/CARD15 gene mutation was also associated with susceptibility to severe GvHD grade III-IV and this aff ected 36% of patients when both recipient and donor were involved compared to 25% when recipient and 29% when donor have NOD2/CARD15 gene mutated and 16% without gene mutation. In all biopsies gut epithelium was damaged by cellular infi ltrates composed predominantly with CD8+ T-cells and proportion of IL-17 producing cells. When donor and recipient were carrier NOD2/ CARD15 gene mutation severe lesions in the gut epithelium were associated with abundant infi ltration of IL-17+ cells compared of the ones without gene mutation. Conclusions: NOD2/CARD15 gene mutation is associated with severity of intestinal aGvHD. Patients aff ected with NOD2/CARD15 gene mutation have worse prognosis for posttransplant outcome and survival compared to these without gene mutation. Supported by the National Centre for Research and Development grant N R13 0082 06.

A. Klimczak (1), K. Suchnicki (2) , M. Sedzimirska (2) , E. Jaskula (1) Objectives: Chronic graft-versus-host-disease (cGvHD) especially in the extensive form impairs the quality of life and makes people disable to continue normal activity due to infl ammatory lesions in the skin and mucous. In this study we focused on the presence of IL-17+ cells in aff ected tissues in association with clinical manifestations and NOD2/CARD15 gene mutation. Methods: Thirty six biopsies were taken from 20 pts with cGvHD lesions after PBPC (n=18) or BMT (n=2) from sibling (n=12) or matched unrelated donors (n=8). Conditioning regimen (myeloablative -6 pts or reduced intensity conditioning -14 pts) included ATG -15 pts and Campath -3 patients. Skin was involved in all cases (poikiloderma and/or scleroderma-like lesions). 14 out of 20 pts had oral mucosa lesions and resulted in impairment of feeding and painful ulcerations. Gastric and intestinal mucosa lesions resulted in vomits and diarrhea in 5 cases. Biopsy specimens: skin (n=24), gastrointestinal tract (n=7) and oral mucosa (n=5) were analyzed for the composition of cellular infi ltrates (CD3, CD4, CD8, CD138) including detection of IL-17, FOXP3 and CCR6 positive cells. Co-expression of CCR6+/IL-17+ and IL-17+/CD138+ were verifi ed by double immunostaining. NOD2/CARD15 gene mutation was assessed by single nucleotide polymorphism (SNP) of SNP8, SNP12 and SNP13 using LightCycler 480 instrument.

Results: (i) CD8+ prevailed over CD4+ lymphocytes in all oral and gut mucosa biopsies and in 18/24 skin biopsies. (ii) IL-17+ cells were seen in both mucosa (12/12) and skin biopsies (23/24) but in the mucosa they were signifi cantly more numerous compared to skin 10/12 vs 11/13 (p=0.04) with a median value >10 cells in 5 HPF. (iii) IL-17+ cells infi ltrating the gut mucosa tissue were more frequently CD138+ whereas in the skin IL-17+ cells often coexpressed CCR6+ (iv) FoxP3+ cells were rarely present at the tissue site but if seen their abundant presence was associated with mild clinical activity.

(v) NOD2/CARD15 gene mutation in patient and/or donor aff ected 7/20 cases (35%) and was associated with moderate and severe cGvHD manifestation (6/7) especially in patients when oral mucosa were aff ected (5/7 vs 9/13). Conclusions: Activity of IL-17+ cells in the skin is supported by traffi cking receptor CCR6+, but in the gut by CD138+ cells, and is associated with the infl ammatory process in a course of cGVHD. NOD2/CARD15 gene mutations are associated with severity of cGvHD and oral mucosa lesions. Graft-versus-leukemia (GVL) eff ects are considered to play a major role in the maintenance of remission after allogeneic hematopoietic stem cell transplantation (HSCT). These eff ects are believed to be mediated by functional tumor-associated antigen (TAA)specifi c donor-derived T cells, although the clear evidence of functional TAA-specifi c T cells has not been demonstrated so far. Wilms tumor protein-1 (WT1) is one of the most intensively investigated TAAs in the fi eld of cancer immunotherapy. Therefore, we synthesized 5 peptides derived from WT1 which were selected as a candidate of peptide for HLA A*24:02 by the prediction algorithm SYFPEITH, and these peptides were screened using interferon (IFN)-g intracellular cytokine staining (ICS) to identify immunogenic peptides and the presence of functional TAA-specifi c T cells with peripheral blood mononuclear cells from 60 patients after allogeneic HSCT. Eighteen patients out of 38 patients (47%) with HLA A*02:01 and none without HLA A*02:01 had positive results in ICS, irrespective of the presence of HLA A*24:02. There was no correlation between the presence of WT1-specifi c T cells and the incidence of acute or chronic graft-versus-host disease (GVHD). The median frequency of positive WT1-specifi c T cells and CMV pp65 495-503-specifi c T cells was 0.76% (range 0.07%-6.48%) and 1.00% (range 0.06%-9.95%), respectively. There was no signifi cant diff erence between the frequency of WT1-specifi c T cells and that of CMV pp65 495-503-specifi c T cells (P=0.794), even though the functional avidity of WT1 peptide was far less than that of CMV pp65 495-503 peptide as demonstrated by serial peptide dilution assays. The majority of WT1-specifi c T cells was CD107a positive (median 72%; range 50-93%) with mainly eff ector phenotype. IFNg induction by WT1 peptide and CMV pp65 495-503 peptide was also detectable using ELISPOT assays. Longitudinal analysis demonstrated the persistence of WT1-specifi c T cells in 2 patients and these WT1-specifi c T cells had the same restricted T cell receptor Vb at diff erent time points. Expanded WT1-specifi c T cells lysed peptide-loaded T2 cells in a dose-dependent manner. These T cells also lysed WT1+HLA A2+ acute myeloid leukemia cell lines (THP-1 and ML-2), but not WT1-HLA A2+ lymphoma cell line (DG75).

In conclusion, functional WT1-specifi c T cells were detected after allogeneic HSCT without complicated ex vivo manipulation. Lack of correlation between WT1-specifi c T cells and GVHD suggests the possibility to separate GVL from GVHD.

In vitro activity of new proteasome and immunoproteasome inhibitors on dendritic cell maturation A.S. Al-Homsi, Z. Lai, T.S. Roy, N. Kouttab Roger Williams Medical Center (Providence, US) Owed to its inhibiting activity on dendritic cells (DC), bortezomib (Bor), a reversible proteasome inhibitor, is being incorporated in graft versus host disease (GvHD) prevention regimens with promising results. We aimed to examine the activity of new proteasome inhibitors individually and in combinations on DC maturation. Carfi lzomib and oprozomib are active on both the constitutive proteasome and immunoproteasome. PR-825 has more potent activity on the β5 subunit of proteasome and ONX 0914 and PR-924 on LMP7 subunit of immunoproteasome. DC from blood of healthy volunteer donors were isolated using a negative selection procedure, treated (2 10?5) with the subject drug(s) for 1-4 hours (depending on the drug tested) at 37oC. After 3 washings with cell media, the cells were stimulated with lipopolysaccharide (LPS) for 18 h at 37oC followed by a fi nal large volume wash. The cells were then harvested and incubated with fl uorescent conjugated antibodies to DC maturation markers (DC-SIGN, CCR7, CD40, CD54, CD80, CD83, and CD86) and fl ow cytometry analysis was performed. Experiments were run in triplicate or quadruplicate and the results were compared to control and Bor (10 nM, 4 h) utilizing unpaired two-sided t-test. Carfi lzomib (30 nM, 1 h) and PR-924 (1000 nM, 1 h) were superior to control in suppressing the expression of all markers. Oprozomib (100 and 300 nM, 1 h) was superior to the control for 6 and 7 markers. ONX 0914 (200 nM, 1h) and PR-825 (125 nM, 1 h) were superior to control for 6 and 1 markers respectively. Furthermore, oprozomib at 100 nM was equal to Bor for 6 markers and at 300 nM was superior for 3 markers. The combinations of ONX 0914 and PR-825 and of PR-924 and PR-825 at the above concentrations were superior to control for 5 and 6 markers respectively. While ONX 0914 and PR-825 were inferior to Bor for 4 and 6 markers, the combination was equal to Bor for 6 markers. PR-924 alone was inferior to Bor for 5 markers but equal to Bor for all markers when combined with PR-825. In summary, we have demonstrated that some new molecules are active and inhibit DC maturation to variable degrees and that targeting the constitutive proteasome and immunoproteasome simultaneously is needed for optimal activity on DC. Confi rmatory studies with mixed lymphocyte reaction and quantitative RT-PCR of IκB are being conducted and the results will be presented.

Genomic risk factors and biomarkers as predictors of GVHD after haematopoietic stem cell transplantation K.F. Pearce (1) (4), U. Holtick (5) , C. Scheid (5) , G. Socie (6) , H. Greinix (7) Introduction: In this study we propose a risk score to predict acute and/or chronic GvHD utilising clinical and genetic/biomarker variables. Methods Selected clinical variables were initially summed and an association was found between clinical risk score and outcome. Further potential genetic/biomarker predictors were additionally evaluated with a view to establishing if sensitivity and specifi city could be improved. Results: In a cohort consisting of 442 HLA-matched sibling patient and donor pairs where the transplants were non T cell depleted, a strong association existed between clinical risk score and both the incidence of acute GvHD II-IV and chronic GvHD. Further investigation revealed that the donor IL10 haplotype ATA/ACC (rs1800872, rs1800871 and rs1800896), donor glucocorticoid receptor haplotype (rs6198, rs33389 and rs33388) ACA and recipient IL 10-592 SNP Any A (rs1800872) improved the goodness of fi t when viewed in association with the clinical risk score for acute GvHD II-IV; no such genetic factors were found when modelling chronic GvHD but donor IL 4 Any T (rs2243250) did show a strong univariate association. It was established that the association between outcome and clinical risk score was still strong in a full cohort comprising of T cell replete and depleted patients (HLA matched siblings and unrelated donors). However, the association between the genetic factors and outcome was weaker. Specifi c biomarkers (CXCL10, CXCL11, IL-33 and BAFF) were therefore assessed as alternatives to genetic factors in a smaller cohort. It was found that BAFF (recorded at 14 days post transplant) was an additional predictor for acute GvHD II-IV and, when added to a model containing the clinical risk score, sensitivity improved from 64% to 86% and specifi city from 69% to 81% (N=30). Conclusion: Preliminary analysis has demonstrated that a statistical model can be constructed to predict occurrence of acute GvHD II-IV and chronic GvHD using clinical factors. Genetic factors could improve the goodness of fi t of a model when viewed alongside a clinical risk score, however, we were unable to confi rm the result in a second cohort. As an alternative to genetic factors, biomarkers could, however, be used as additional predictors. Further work is under way to validate the results in independent cohorts.

A. Al-Homsi, Z. Lai, T. Roy, P. Welch, M. AlMalki, N. Kouttab, M. Curtis, R. Junghans Roger Williams Medical Center (Providence, US) Bortezomib (Bor) inhibits dendritic cell (DC) maturation in part by blocking the nuclear factor-κ B (NF-κ B) pathway. In normal T cell, NF-κ B translocation into the nucleus occurs only in stimulated, not resting cells, allowing for development of immune tolerance. Cyclophosphamide (Cy) kills also alloreactive proliferating T cells while sparing resting cells. Hence, the combination of Bor and Cy seems attractive for prevention of graft versus host disease (GvHD). Blood samples from 6 patients enrolled in an institutional review board-approved phase I feasibility trial were collected at specifi c time points. Bor was given on day 0, 6 hours after transplant and on day +4 at an escalating dose from 0.7 to 1.3 mg/m 2 . Cy was given on days +3 and +4 at a fi xed dose of 50 mg/kg. The control subjects were transplanted during the same period and received mycophenolate mefotil and cyclosporine for prevention of GvHD. All patients received the same supportive care according to established protocols. Pan DC were isolated by negative selection from samples obtained on day 0 before transplant, +1, +4, and +7. CD4 cells were isolated by positive selection from samples obtained on days +7, +14, and +21. DC from days 0, +1, +4, and +7 were stimulated with lipopolysaccharide for 18 hours, stained with fl uorescent conjugated antibodies to DC maturation markers CD40, CD54, CD80, CD83, DC-SIGN, and CCR7, and then analyzed by fl ow cytometry. Autologous DC-CD4 mixed lymphocyte reaction was performed using DC from day 0 as stimulator and CD4 cells from days +7, +14, and +21 as responders. Bromodeoxyuridine (BrDU) incorporation was measured after 4 days of incubation with fl uorescent anti-BrDU antibody using fl ow cytometry. An adequate number of DC was not obtained in every instance to perform all the planned experiments. The results were analyzed using t-test. In comparison to the control group, the expression of all DC markers on days +1, +4, and +7 and the incorporation of BrDU on days +7, +14, and +21 were statistically signifi cantly decreased in the study group in comparison to the control group in all tested samples. The expression of all markers was also signifi cantly decreased in the study group on days +1, +4, and +7, in comparison to samples obtained on day 0. Taken together, our data suggest that post transplant Bor and Cy eff ectively inhibit DC maturation in response to immunogenic stimulation and impair T cell priming and proliferation and that their eff ect was detectable to at least up to 21 days.

CEBPA gene mutants involved in the etiological mechanisms of donor cell leukaemia play distinct roles in blockage of C/EBP-α function H. Xiao, L. Wang, C. Wang, L. Zhang, S. Fu, Y. Wang, H. Huang Zhejiang University School of Medicine (Hangzhou, CN) Objectives: CCAAT/enhancer-binding protein-α (C/EBP-α/CEBPA) is mutated in approximately 8% of acute myeloid leukemia (AML) and, has been received as a predictive marker of outcome in patients with normal karyotype. Furthermore, we have provided the fi rst report of multiple mutations of CEBPA contributing to the transformation of donor cells to the leukemic phenotype after allogeneic hematopoietic stem cell transplantation (H Xiao, Blood 2011; 117: 5257-5260) . Despite murine models provide the functional consequences of C/EBP-α in human hematopoiesis and how diff erent mutations contribute to abrogate the protein function have received less attention. Methods: In our previous research, we have identifi ed 3 diff erent CEBPA gene mutants forms involved in donor cell leukemia, which disrupted 3 major functional domains of C/EBP-α respectively. The patient and his donor-sister both harbored the N-terminal germline mutation (584-589dup disrupting the TAD2 domain of protein). Susceptible donor hematopoietic cells evolved to overt AML by developing two somatic CEBPA mutations, the N-terminal mutation (247dupC causing overproduction of truncated 30-KDa isoform (p30) lacking the TAD1 domain) and the C-terminal mutation (914-916dup disrupting the bZIP domain), in the patient's microenvironment. We used these 3 mutants forms, as well as CEBPA wide type to subclone into pLenti6.3-MSC vector. Eight leukemia cell lines, mouse myeloid progenitor cell line 32Dcl3 and human and mouse hematopoietic stem/ progenitor cells were transduced by diff erent mutants forms. C/EBP-α functions including antileukemia eff ect, cell cycle arrest and granulocyte diff erentiation were analyzed. Results: (1) Three C/EBP-α protein mutants showed an increased cytoplasmic localization, diff erent from nuclear localization of wide type. (2) The N-terminal germ-line mutation retains the function of inducing apoptosis in leukemia cells, however, blockage the eff ect of cell cycle arrest of C/EBP-α. (3) The C-terminal mutation and p30 abrogate the eff ect of inducing apoptosis, furthermore the C-terminal mutation inhibited G-CSF-induced diff erentiation of 32Dcl3 cells into mature neutrophiles. (4) Three mutants forms all impair the ability of colony-forming of hematopoietic stem cell. Conclusions: Our data provide clues to support that the N-terminal mutation of CEBPA works as a class I mutation while the C-terminal mutation works as a class II mutation in inducing leukemia.

Serum superoxide dismutase levels in allogeneic stem cell transplantation B. Kircher, P. Schumacher, D. Nachbaur Medical University Innsbruck (Innsbruck, AT) Oxidative stress resulting from the increased production of free radicals and reactive oxygen species due to chemotherapy and/ or radiotherapy is a suspected mechanism leading to organ damage after hematopoietic stem cell transplantation (HSCT). The content of reactive oxygen species is balanced by antioxidative systems, which include enzymes such as catalase and superoxide dismutase (SOD), however, studies investigating the enzymes' impact on outcome after HSCT are limited. Therefore, we have analyzed the Cu-Zn SOD levels of 42 patients with hematological malignancies undergoing allogeneic HSCT from HLA-matched family and unrelated donors. Cu-Zn SOD levels were measured in serum at various time points before and after HSCT and were expressed as median levels ± standard error. The probability of overall survival was estimated using the Kaplan-Meier method and the incidence of developing acute graft-versus-host disease (GvHD) was analyzed by cumulative incidence.

Statistical signifi cance was determined using the Wilcoxon Rank-Sum and the log-rank test. Serum Cu-Zn SOD levels determined on days -4/-5 before HSCT were signifi cantly higher (36,74 ± 13,11 ng/ml) than those of 18 healthy normal controls (14,46 ± 0,60 ng/ml; p<0.0001) indicating enhanced repair mechanisms present in leukemia patients already during chemotherapy. The median Cu-Zn SOD levels at the time of acute GvHD were 41,62 ± 18,88 ng/ml. If the serum level on days -4/-5 before HSCT were higher than 42 ng/ml, the cumulative incidence of developing acute GvHD was 72,73 ± 13,43% whereas the cumulative incidence for acute GvHD of patients with lower pretransplant serum levels was 50,00 ± 11,18%. In accordance, patients with higher levels (42 ng/ml) on days -4/-5 before HSCT had a lower survival rate than patients with lower pretransplant levels. At day 200, patients with higher levels on days -4/-5 before HSCT had a survival of 90,00 ± 6,71% in contrast to 51,95 ± 15,69% of patients with pretransplant levels lower than 42 ng/ml. After HSCT Cu-Zn SOD levels did not signifi cantly change in the whole study cohort.

In conclusion, pretransplant Cu-Zn SOD levels are higher than Cu-Zn SOD levels of normal controls and are indicative for the development of acute GvHD and a poorer survival during the fi rst year of HSCT. It is clear, however, that larger patient cohorts and analysis of further antioxidative enzymes are needed in order to elucidate antioxidative processes and their relationship to outcome after HSCT.

Adiponectin and resistin levels correlate with graftversus-host disease and relapse after haematopoetic cell transplantation: a prospective study O. Robak, Z. Kuzmina, A. Winkler, P. Kalhs, W. Rabitsch, S. Knapp, H.T. Greinix Medical University of Vienna (Vienna, AT) Introduction: Graft-versus-host disease (GVHD) and relapse of malignant disease have remained challenges of hematopoietic cell transplantation (HCT) impacting on patients' survival and quality of life. Adiponectin (APN) and Resistin (RES) are adipocytokines produced by visceral fat tissue. Whereas APN predominantly exerts anti-infl ammatory eff ects and is an important regulator of infl ammatory responses, RES acts as a pro-infl ammatory agent and poses a major link between obesity, insulin resistance, diabetes and certain systemic autoimmune diseases associated with chronic infl ammation. Patients and Methods: Between November 2008 and August 2010 we prospectively measured serum concentrations of APN, RES and other infl ammatory markers such as fi bronectin (FNC), serum amyloid A (SAA) and haptoglobin (HPT) by ELISA collected from patients after autologous (n=12) or allogeneic HCT (n=28) on admission (7 days prior HCT), on the day of transplantation (T0), during aplasia, on the day of engraftment defi ned by a granulocyte count >0.5 G/l, 4 weeks after HCT, 3 to 6 months, and 6 to 12 months after HCT, respectively. Results: In patients with acute GVHD grades II-IV signifi cantly higher APN levels (23.4 vs 9.6, p=0.04) and APN/body mass index (BMI) ratios (1 vs 0.4, p=0.01) and decreased SAA (31 vs 145, p=0.04) were observed prior to onset of acute GVHD. Patients dying with relapse of malignant disease had signifi cantly lower APN levels (8.2 vs 30.4, p=0.0075) and APN/BMI ratios (0.3 vs 1.1, p=0.004) before HCT compared to patients surviving without relapse. After day 10 RES levels (8.6 vs 4.1, p=0.01) were significantly higher in patients dying of relapse compared to ones alive without recurrence of malignant disease. Decreased HPT levels at the time of engraftment (62 vs 163, p=0.003) as well as increased RES levels (8.6 vs 14, p=0.012) from day 0 until 6 months after HCT were signifi cantly associated with later deaths. Conclusion: Adipocytokines and other infl ammatory markers could be predictive for occurrence of acute GVHD, relapse and mortality of patients undergoing HCT. Larger patient cohorts are warranted to confi rm preliminary results.

Graft-versus-leukaemia eff ect in HLA-mismatched allogeneic stem cell transplantations for acute leukaemias and advanced myelodysplasias M. Stadler, L. Hambach, S. Immenschuh, F. Thol, E. Dammann, W. Kühnau, E. Mischak-Weissinger, S. Buchholz, M. Eder, J. Krauter, A. Ganser Hannover Medical School (Hannover, DE) Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) from HLA-mismatched donors exposes recipients to an increased risk for graft-versus-host disease (GvHD). However, it is unknown whether this improves or impedes the graft-versusleukemia (GvL) eff ect required to control malignancies at high relapse risk. Patients: To address this question, we retrospectively evaluated two cohorts of high risk patients experiencing strong GvHD/GvL reactions: (1) 300 patients transplanted for acute leukemias (AL) and advanced myelodysplasias (MDS) from 2006 through 2011 (90 percent at high relapse risk), and (2) 107 recipients of donor lymphocyte infusions (DLI) for relapsing AL and advanced MDS between 1996 and 2011. For both cohorts, information on HLA-A, -B, -C, -DRB1, and -DQB1 alleles were available in both recipients and donors. Results: In the fi rst cohort (300 AL/MDS patients after alloHSCT, 2006-2011), we found a trend towards a disadvantage in diseasefree survival (DFS) at 5 years for 70 mismatched compared to 230 fully matched transplants (34% versus 49%, p = 0.072), whereas overall survival (OS), relapse incidence (RI) and treatment related mortality (TRM) were not signifi cantly diff erent. Focussing onto the subgroup with severe graft-versus-host disease (acute GvHD grades II to IV or extensive chronic GvHD; n = 89), 24 patients after mismatched transplants had signifi cantly worse relapse incidence (39% versus 14%, p = 0.042), 5-year-DFS (24% versus 54%, p= 0.003), and 5-year-OS (29% versus 56%, p= 0.009), as compared to 65 fully matched transplant recipients, whereas only a trend was seen for TRM (59% versus 38%, p = 0.059). Conversely, in patients with less severe (n = 95) or without any GvHD (n = 101), there was no diff erence in OS, DFS, RI or TRM between fully matched and mismatched transplants. In the second cohort (107 AL/MDS recipients of therapeutic DLI, 1996-2011), a landmark analysis starting from the fi rst DLI demonstrated a trend to inferior 5-year-OS for 25 mismatched as compared to 82 fully matched DLI recipients (9% versus 25%, p= 0.085). Loss of mismatch has recently been proposed as a relapse mechanism in haploidentical transplantation. However, when we examined uniparental disomy in mismatched DLI patients by HLA retyping at relapse, we found a loss of mismatch in only four out of 25 patients (16%). Conclusion: HLA-mismatches seem to compromise GvL after alloSCT for high risk AL and MDS.

Characterization of mixed and full donor chimeras post reduced-intensity fl udarabine, melphalan, alemtuzamab conditioned peripheral blood haematopoietic stem cell transplantation F.A.M Kinsella (1) , J.E Croudace (1), C.F Inman (1), S. Nagra (2) , J. Nunnick (2) , E. Nikolousis (3), R. Malladi (2) , M. Griffi ths (4), C. Craddock (2) Mixed chimerism (MC), the presence of residual recipient and donor derived haematopoietic cells, can be observed in patients following reduced intensity conditioned allogeneic stem cell transplantation (RIC-SCT) for haematological malignancy. Whilst some studies reported MC to be a risk factor for disease relapse, others have observed that persistent stable MC does not correlate with relapse, suggesting that durable graft versus tumour eff ects (GvT) can exist without achieving full donor chimerism (FC). In addition, many studies associate MC with robust immune tolerance, suffi cient to sustain solid organ transplantation without the need for supplementary immunosuppression. Such tolerance is thought to involve central and peripheral processes, but the mechanisms regulating immune tolerance and alloreactivity in MC remain unclear. We identifi ed patients with stable mixed and full donor chimerism following RIC-SCT and studied the phenotype and function of peripheral blood T cells. The only signifi cant clinical diff erence between the two cohorts was an increased incidence of aGvHD in the FC population, which has been observed in other studies. Flow cytometric analysis showed that T cell number in MC patients was twice that of FC patients, whilst the number of naïve cells increased 4 times. The highest T cell number was seen in patients in whom MC was selectively observed in the T cell compartment. This supports a theory that continued interactions between donor DC and both donor and host T cells are of importance maintaining MC. To assess the function of FC and MC T cells, they were cultured in vitro with PHA or recipient (host) APC derived pre-transplant. Diff erences between FC and MC responses to host APC in vitro were only observed early post transplant where a signifi cantly lower proportion of MC CD4+25-T cells were present post culture. In this scenario, MC CD4+25-T cell cytokine production was suppressed, consistent with the induction of an adaptive tolerance. However, CD4+25-T cells derived from MC late post transplant were present at higher proportions than the same cohort derived early post transplant, and produced more IL-10 in particular. In corollary, CD4+25+ T cells derived from MC late post transplant produced less IFNg and IL-10. Overall, these fi ndings are consistent with a proposed theory that tolerance to host is not reliant upon dominant peripheral mechanisms (which would require antigen educated regulatory T cells), but is ensured by adaptive and later central tolerogenic mechanisms.

Tryptophan catabolism attenuates alloreactivity of donor T cells by inhibiting dendritic cell activation W. Lee (1) Objectives: Indoleamine 2,3-dioxygenase (IDO) is an intracellular enzyme that catalyzes the fi rst and rate-limiting step in tryptophan catabolism. Generation of tryptophan metabolites by IDO is an eff ective mechanism in IDO-mediated T cell suppression. Our previous study reported that exogenous administration of 3-hydroxyanthranilic acid , the most potent metabolite, into the allogeneic bone marrow transplanted mice reduced acute graft-versus-host disease (GVHD) lethality by inhibition of alloreactive T cell expansion . In addition to aff ecting donor T cells, we investigated whether 3-HAA indirectly suppresses alloreactivity of donor T cells through inhibiting dendritic cell (DCs) activation. Methods: We generated bone marrow-derived DCs and treated them with various concentration of 3-HAA for 6 hrs before LPS stimulation. Phenotype of the cell for maturation was analyzed by fl ow cytometry. Cytokine levels were measured in the cell culture supernatants using Flex-Set analysis. Allo-stimulatory capacity of BMDCs was measured on allogenenic mixture-lymphocyte reaction (MLR).

systematically every 2 weeks. Before each Eculizumab infusion, clinical and biological data were systematically collected. Concomitantly, CH50 (Mayer technique), C3d deposition on red blood cells, C3 and C4 circulating levels were also studied. Complete C5 blockage was defi ned by a CH50 activity ≤10% (as for pts with hereditary complete C5 defi ciency). Before starting eculizumab, 21 pts were transfusion-dependent with a mean of 7 red blood cell (RBC) transfusions per year and 9 pts had a signifi cant PNHrelated complication (9 thrombosis and 7 with a previous history of aplastic anemia). During the study period, 6 pts received at least one transfusion (mean of 3 RBC transfusions per year) and 1 patient presented a deep vein thrombosis. CH50 measurements (412 samples; median 19 per patient; range, 4 to 31) showed substantial variability for most pts ( Figure 1A ). Residual CH50 activity (>10%) was signifi cantly associated with higher LDH levels (p=0.002) and reticulocyte counts in the 14 patients with pure hemolytic PNH (p=0.038). C3 and C4 circulating levels were in the normal range during the study period in all but one patient (pts#15, Fig. 1B) , who carry a complement factor H (CFH) mutation, leading to a quantitative Factor H defi ciency. Systematic screening was positive for 2 other pts (CFH, pts#1; C3 mutation, pts#14). Type III PNH red blood cell C3d deposition (assessed in all but 1 patient; 277 samples; median 14 per patient; range, 2 to 21) was found in all pts evaluated during the study period (Fig. 1C) , with no correlation with clinical or biological signs of hemolysis. Our results confi rm the excellent overall response of hemolytic PNH pts to eculizumab. Unblocked CH50 activity, refl ecting the residual C5 activity, was signifi cantly associated with residual intravascular hemolysis and may be of particular interest in the management of PNH patients under Ecuizumab. We also identifi ed mutations in C3 and factor H genes suggesting new unknown pathophysiological insights in this disease.

Detection of leukocytes lacking HLA-A alleles by fl ow cytometry predicts a response to immunosuppressive therapy in patients with acquired aplastic anaemia H. Maruyama, T. Katagiri, K. Hosokawa, C. Saito, H. Yamazaki, S. Nakao Kanazawa University Graduate School of Medical Science (Kanazawa, JP) Background: Leukocytes with copy number-neutral loss of heterozygosity of the HLA haplotype due to uniparental disomy in the short arm of chromosome 6 (6pUPD) are detectable in 13%

S416 of patients with acquired aplastic anemia (AA) and are thought to refl ect the involvement of cytotoxic T lymphocytes specifi c to autoantigens presented by particular HLA class I antigens on hematopoietic stem cells in the pathogenesis of AA (Katagiri, et al. Blood, 2011) . Although the detection of 6pUPD by the SNP array may be useful for predicting a response to immunosuppressive therapy (IST) in AA patients, the assay cannot be performed promptly enough to use the results to choose the optimal therapy for newly diagnosed patients and may not be suffi ciently sensitive to detect small populations of 6pUPD(+) cells. The effi cacy of detecting leukocytes lacking HLA-A alleles using fl ow cytometry as a SNP array substitute was examined to overcome these problems. Patients and methods: HLA-A alleles of 114 (28 newly diagnosed and 86 pretreated) patients with AA were determined and the HLA-A allelic expression by leukocytes of the patients that were found to be heterozygous for the HLA-A allele were assessed using fl ow cytometry with monoclonal antibodies specifi c to A24, A2, A26, and A31. Results: 68 (59.6%) patients were assessable for the presence of HLA-A allele-lacking leukocytes due to their heterozygosity in two of the four alleles. Leukocytes lacking one of the two HLA-A alleles were detected in 6 (46.5%) newly-diagnosed and 19 (34.5%) pretreated patients with 3.9%-61.1% (median 8.4%) and 10.3%-99.4% (median 54.2%) of total granulocytes, respectively. The percentages of HLA-A allele-lacking monocytes derived from cryopreserved mononuclear cells were similar to those of HLA-A allele lacking granulocytes in each patient. Of the 23 patients with HLA-A allele lacking leukocytes, 9 and 14 were treated with antithymocyte globulin plus cyclosporine or cyclosporine alone. The response rates to each therapy were 88.9% and 78.6%, respectively. Conclusion: Flow cytometry using commercially available monoclonal antibodies specifi c to HLA-A alleles enabled the detection of as few as 3% of leukocytes lacking HLA-A alleles in 21.9% of patients with newly diagnosed AA. Rapid typing of HLA-A alleles followed by screening of granulocytes or cryopreserved monocytes for the presence of HLA-A allele-lacking cells may be useful for predicting a response to IST in patients with AA heterozygous for the HLA-A allele.

Haematopoietic stem cell transplantation for secondary myeloid malignancy after immunosuppressive therapy in patients with aplastic anaemia A. Yoshimi (1), B. Strahm (1) , M. Führer (2) , C. Niemeyer (1) (1)University of Freiburg (Freiburg, DE) ; (2)Dr. von Haunersches Kinderspital, University of Munich (Munich, DE) Introduction: Previous reports show that 2-16% of patients with aplastic anemia (AA) following immunosuppressive therapy (IST) develop secondary myelodysplastic syndrome /acute myeloid leukemia (2nd MDS/AML). However, there is limited data on the outcome of hematopoietic stem cell transplantation (HSCT) in these patients. We report here the outcome of HSCT in 19 German patients with 2nd MDS/AML following AA, who were registered to the SAA-94 and/or EWOG-MDS 96/06 studies. Patients and methods: The diagnosis of 2nd MDS/AML was made in 21 patients (03/1995-11/2009 ) at a median of 2.9 years (0.5-13.0 years) after the diagnosis of AA. Excluding 2 patients given intensive chemotherapy only, the remaining 19 transplanted patients were included in this analysis. The median age at diagnosis of 2nd MDS/AML (9 refractory cytopenia(RC), 5 RAEB, 2 RAEBt and 3 AML) was 13.1 (3.3-26.2) years. Eight patients had a normal karyotype, 10 patients -7 and 1 patient +19. HSCT was performed at a median of 5.3 (0.4-26) months after diagnosis of 2nd MDS/AML. Donor was a matched sibling donor in 2 patients, a mismatched family member in 2 patients and an unrelated donor in 15 patients. Stem cell source was BM in 7 patients and peripheral blood in 12 patients. The preparative regimen consisted of busulfan, cyclophosphamide and melphalan (BU/CY/MEL) in 13 patients and other combinations in 6 patients. Graft-versus-host disease (GVHD) prophylaxis was cyclosporin A and methotrexate in most patients. Results: All patients engrafted (med. 15 days). Grade II-IV and III-IV acute GVHD was observed in 9 and 7 patients, respectively. Eight of 13 evaluable patients developed chronic GVHD (3 limited, 5 extensive) . Overall survival at 6 years after HSCT was 50.1 % with no diff erence according to karyotype (-7 vs. others; 47% vs. 53 %), morphological subtype (RC vs. others; 44% vs. 54 %) or conditioning regimen (BU/CY/MEL vs. others 46% vs. 63%). Cause of death was relapse of MDS in one patient and transplant related mortality (TRM) in 9 patients. Conclusion: The outcome of HSCT in patients with 2nd MDS/AML following AA was unfavorable. The major problem was a high rate of TRM. Based on the high TRM and the occurrence of 2nd MDS/ AML it can be speculated that some of these patients have an underlying congenital bone marrow failure. The outcome may be possibly improved by earlier indication of HSCT and by a reduced toxicity regimen.

Favourable outcome of patients with 13q deletion and severe aplastic anaemia A. Holbro (1) Objective: The prognostic signifi cance of cytogenetic abnormalities in aplastic anemia (AA) are controversial. Del(13q) has been reported to occur in patients with MDS and other hematologic malignancies. Additionally, cases of patients with bone marrow failure syndrome with del(13q), who showed good response to immunosuppressive therapy have been reported. Methods: We retrospectively analyzed outcome of patients diagnosed as AA with del(13q) at our institution. Results: For 86/353 (24%) patients cytogenetic analysis at any time during the disease course was available. We identifi ed six patients (7%) with del(13q). Table 1 shows patients characteristics. Median age at diagnosis was 50.5 years (range: 22-71 years), half were male. One patient was diagnosed with very severe AA, three patients with severe AA and two with AA. Del(13q) was detected at diagnosis in four patients. One patient (UPN 936) had a normal karyotype at diagnosis and developed del(13q) after a fi rst course of antithymocyte globuline (ATG), and cyclosporine A (CYA). Two years later this patient relapsed and received a second course of ATG and CYA with disappearance of the del(13q) clone. She reached a partial response (PR) and remains under immunosuppression with CYA, free of transfusions 86 months after last ATG. One patient diagnosed in 1987 with SAA (UPN 410) was treated with ATG in 1990, cytogenetics at diagnosis were not available. She reached a complete response with persisting macrocytic anemia. Del(13q) was documented 10 years after ATG. She remained hematologically stable for 276 months until her death in a car accident. In two patients, del(13q) was no longer detectable at last follow-up. All patients except one are still alive after a median follow-up of 105 months (range: 84-276 months). None of the patients showed progression to acute myeloid leukemia or MDS. Conclusion: Patients with bone marrow failure without dysplasia and isolated del(13q) should be classifi ed as AA and treated accordingly as they represent a subgroup of patients with favorable outcome.

Mixed chimerism seems to improve survival of children with aplastic anaemia after allogeneic haematopoietic stem cell transplantation: preliminary report K. Drabko, M. Ussowicz, A. Pieczonka, J. Gozdzik, R. Debski, M. Lejman, M. Choma, A. Zaucha-Prazmo, B. Wojcik, J. Wachowiak, A. Cybicka, M. Wysocki, J 

Aim of the study was to evaluate the role of mixed chimerism in outcome of children with the aplastic anemia after allogeneic haematopoietic stem cell transplantation (alloHSCT). One hundred patients, diagnosed as having aplastic anemia and underwent alloHSCT were identifi ed in 5 Polish Pediatric HSCT centers, between 2005 and 2011. There were 74 children with severe aplastic anemia, 17 with Fanconi anemia and 9 with Blackfan-Diamond anemia. Median age of the patients at diagnosis was 9, 5 years and median age at HSCT was 11 years. Donors were siblings in 32 cases whereas 65 children were transplanted from match unrelated donor and 3 from mismatched donors. Source of stem cells were bone marrow stem cells in 49 patients, peripheral blood stem cells in 47, cord blood in 2 and in 2 children combined stem cell sources were used. The most common conditioning regiments were : fl udarabin, cyclophosphamide and ATG (29 pts) and cyclophosphamide and ATG (23 pts). GvHD prophylaxis consisted of CsA and MTX in majority of patients (80%). Median time from diagnosis to HSCT was 10 months. To the fi nal analysis we included 74 patients who survived at least 3 months after HSCT and having at least 3 assessment of chimerism within fi rst 2 years post transplantation. Qualitative chimerism was evaluated in all centers in peripheral blood, using variable number of tandem repeats (VNTR) PCR method. We considered as full donor chimerism patients with less than 1% of recipient cells (DC) and as mixed chimera (MC) those having more than 1% of recipient cells in two consecutive evaluation. Median follow-up was 3 years. Overall survival of whole group was 0,8. Twenty eight of seventy four evaluable patient were found to be MC, forty fi ve DC and one autologous recovery was noted. Survival of patients with MC was signifi cantly better than those with DC -0,96 vs 0,79 respectively (p=0,04). No statistically significant diff erence in survival was found between children with DC and MC in respect to diagnosis, donor type or stem cell source. Only one patient with MC died from infection whereas 9 patients with DC died of complication: 5 GvHD, 2 toxicities, 1 infection and 1 PTLD. None patient with MC lost their graft and experienced aplasia relapse. We concluded that in our material mixed chimerism in children with the aplastic anemia may improve survival probably due to less severe transplant related complications. However follow up of the study population is short and data requires further confirmation.

In aplastic anaemia, immunosuppression with purine analogues leads to good engraftment rates of grafts immunodepleted with alemtuzumab N. Novitzky, V. Thomas, C. du Toit University of Cape Town (Cape Town, ZA) Introduction: Immunodepletion with alemtuzumab is an eff ective method to prevent graft vs. host disease but may be associated with graft failure. We tested the eff ectiveness of a purine analogue based reduced intensity conditioning combination in patients with marrow aplasia. Patients and Methods: Patients with severe marrow aplasia who had tissue compatible siblings were conditioned with fl udarabine 30 mg/m2 for 5 days and cyclophosphamide 120 mg/kg. Stem cells from HLA identical sibling donors were mobilized with fi lgrastim and the harvested blood concentrates incubated ex vivo with alemtuzumab. Following graft infusion patients received therapeutic levels of cyclosporine until day 90. Chimerism studies were performed by standard cytogenetic, FISH and STRs at 3 months after transplantation and thereafter when graft failure was suspected. Primary objective was to study the proportion of patients achieving engraftment and overall survival. Secondary

S418 objectives were rate of graft vs. host disease, post-transplant infections and graft failure. Results: Thirty three patients received 36 cytokine mobilized blood stem cell transplants and were studied. Median CD34+ cell infused was 5.38 x106/kg. All patients engrafted at a median of 12 days. Four patients had delayed graft failure at 3, 6, 7 and 7 months and required re transplantation (n=3) or donor lymphocyte infusion (n=2) to re-establish full donor chimerism or for the treatment of pure red cell aplasia unresponsive to immunosuppression. One patient had graft failure at 7 months and died of neutropenic sepsis before referral to our unit. At 3 months chimerism studies showed >90% donor cells in each case. At median of 2302 days thirty two (97%) patients survive transfusion free with normal blood parameters. Conclusions: We confi rm that the combination of purine analogue and cyclophosphamide is adequate for engraftment of a graft that was immunodepleted with alemtuzumab. This strategy is associated with excellent outcomes. However patients should continue being closely followed up for the fi rst year as delayed graft failure remains a problem.

Fludarabine, cyclophosphamide and ATG, with or without low doses of total body irradiation for unrelated donor transplants in children with severe aplastic anaemia. Long-term follow up from a single centre experience F. Vendemini, P. Gasperini, R. Masetti, D. Zama, C. Di Leo, M. Franzoni, A. Prete, A. Pession Sant'Orsola-Malpighi Hospital, University of Bologna (Bologna, IT) Objectives: Hematopoietic stem cell transplantation from unrelated donor (UD-HSCT) has become a frequent therapeutic alternative in children diagnosed with severe aplastic anemia (SAA), due to the low rate response to immunosuppressive therapy (IST) along with the frequent absence of a matched sibling donor (MSD). In UD-HSCT setting, treatment-related mortality, graft versus host disease (GVHD) and graft rejection have been major cause of treatment failure. We report the long-term outcome of 10 children with SAA undergone to UD-HSCT after reduced intensity conditioning (RIC) regimen based on Fludarabine (FLU), Cyclophosphamide (CY) and ATG. Methods: Between 1997 and 2010, 10 pts (4 M), median age 10 (range 5-18) ys, underwent HSCT from UD for SAA after failure to repsond to IST. RIC regimen consisted of FLU 30 mg/sqm/day X 4, CY 300 mg/mq/day X 4, ATG 3.75 mg/kg X 3 in 9/10 cases. Low dose Total Body Irradiation (200 cGy) was added in 2 pts>14 ys. GVHD prophylaxis consisted of Cyclosporine (5 mg/kg/die iv on day -1, 3 mg/kg/die iv from day 0, 6-10 mg/kg/die orally for at least 6 months) and short term Methotrexate. Monitoring of chimerism (complete, CC or mixed, MC), was performed on BM samples by using short tandem repeat (STR)-PCR analysis starting from the day of neutrophils (PMN) engraftment and then every 3 months. Results: The median interval from diagnosis to HSCT was 24 months (range 7-46). HSCs source was bone marrow (BM) in 8 pts and peripheral blood in 2. 6/10 donors were full matched, 4/10 were mis-matched in 1 or more loci. The median number of infused BM nucleated cells was 5.7x10 8 /kg and 7x10 6 /kg CD34+ PBSC. PMN and platelets engrafment was reached in all pts after a median time of 14 and 23 days, respectively. One pt experienced secondary graft failure with autologous reconstruction. aGVHD occurred in 2 pts (20%, 1 grade II and 1 grade IV); 4 pts (40%) developed limited chronic GVHD. After a mean follow up of 7.9 ys (range 2-15.9), 9/10 pts are alive and disease free: amongst them 8/9 showed CC. The patient with secondary graft failure is alive and transfusion independent: BM samples show MC with autologous prevalence. One patient died because of grade IV aGVHD. Conclusion: UD-HSCT is an eff ective and low toxic treatment for children with SAA: the long term outcomes following UD-HSCT are similar to those obtained in MSD setting. Careful selection of HLA matched UD, RIC regimen and chimerism monitoring by STR analysis have improved the outcome of UD-HSCT.

HLA haploidentical stem cell transplantation for children with aplastic anaemia in urgent need of stem cell transplantation Y. Takahashi, N. Kawashima, A. Narita, H. Sakaguchi, S. Doisaki, H. Muramatsu, K. Nakanishi, A. Hama, S. Kojima Nagoya University Graduate School of Medicine (Nagoya, JP) Background: For children who urgently need stem cell transplantation (SCT), a human leukocyte antigen (HLA) haploidentical family donor could be considered as one of alternative donor sources because it's 1) easy to fi nd the donor in parents, 2) fast to engraft and 3) possible to use donor cell derived cell therapies such as virus specifi c cytotoxic T lymphocytes (CTLs) and mesenchymal stromal cells (MSCs). We analyzed children with aplastic anemia (AA) who underwent HLA haploidentical SCT for an urgent need of SCT. Materials and Methods: Four children with AA underwent unmanipulated HLA haploidentical SCT in urgent need of SCT in our center. Bone marrow taransplantation (BMT) was conducted on day0 and G-CSF mobilized peripheral blood stem cells (PBSC) were infused on day6 to boost numbers of stem cells. GVHD prophylaxis consisted of tacrolimus and short term MTX while antithymocyte globulin (ATG) were given at 10mg/kg prior to BMT and at 5mg/kg one day before PBSCT. Patients received a conditioning treatment consisting of fl udarabine 30 mg/m2 i.v. x 4 days, melphalan 70 mg/m2 i.v. x 2 day and total body irradiation 5Gy in two fractions. Results: The reasons of urgent SCT were very severe aplastic anemia with a neutrophil count of zero cells/mm3 with infections in two patients and graft failure after fi rst SCT in other two patients. The ages of the patients were 5, 10, 15 and 15 years old. Donors were two fathers, one mother and one brother. HLA disparity between patients and donors were all 2/6 HLA (HLA-A, B and DRB1) mismatched at antigen level. All patients engrafted and the duration of neutropenia (ANC <500) was 15, 21, 25 and 29 days respectively. Two patients developed acute GVHD grade II and III. One received infl iximab for steroid refractory GVHD. One patient developed extensive chronic GVHD. CMV reactivations were observed in all four patients and ganciclovir and/or foscavir were given. EBV reactivations were observed in one patients and the patient were treated by rituximab. The follow-up time was 6, 41, 76 and 103 months. All patients are alive. Discussion: Unmanipulated haploidentical SCT was useful option for children with aplastic anemia who don't have HLA matched related donor and need urgent SCT.

Detection of paroxysmal nocturnal haemoglobinuria clone in aplastic anaemia patients at diff erent stages of disease and treatment Z. Fidarova (1) , E. Mikhailova (1), S. Lugovskaia (2) , E. Naumova (2) Objective: To detect the presence of Paroxysmal Nocturnal Hemoglobinuria (PNH) clone in de novo aplastic anemia (AA) patients, during the immunosuppressive therapy (IST) (1 to 24 months), in remission and in relapsed AA. Methods: 62 AA patients have been included into the study. Median age -24 years (from 16 till 64 years). All 62 patients were divided into 4 groups. The 1st one included de novo AA patients (n=23); the 2nd group included AA patients, who had undergone the IST(n=14); 3d group -in remission (n=16); and 4th group-relapsed AA patients (n=9). Peripheral blood samples were analyzed with monoclonal antibodies CD45, CD15, CD64, CD235a, GPI-antibodies CD59, CD14, CD24 and FLAER. Results: The PNH clone was found in 38 patients (61%), in whom minor clone was found in 8 patients and in 30 patients the clone size does not exceed 1%. In the 1st group PNH clone was detect in 12 of 23 (52%), 4 of them were positive for a minor clone. Median (Me) clone size on the Red Blood Cells (RBC) was 0,9% (0,1-1,5%), Background: Although most of HL patients are cured with fi rst line conventional chemotherapy/radiotherapy or autologous transplantation (HDC) continue to relapse and can be treated by ALLO after nonmyeloablative/reduced intensity conditioning regimens (NMA/RIC). For these advanced patients, however, the relapse rate is still high after ALLO. The aim of this study was to describe the outcome of HL patients relapsing after ALLO in a single institution. Patients and methods: Since 1999, 55 HL patients were treated by ALLO in our institution. All patients received NMA/RIC regimens. Inclusion criteria were relapse after HDC, refractoriness to salvage chemotherapy in a program with HDC followed by ALLO. Diff erent NMA/RIC has been used (table 1). Treatment choice after relapse was made by treating physician mainly based on previous therapies and relapse characteristics (limited vs extensive) Results: Patient characteristics are shown in Table 1 . 21 (31%) out of 53 patients relapsed or progressed after ALLO. All but one patient were treated, because of poor performance status. Main patient characteristics and therapies were reported in Table 2 . The median time to relapse was 4 months (range 1-13). The response rate was high after each CT lines because was 44% after fi rst line, 30% after the second, and 40% after the third. DLI ± radiotherapy seemed to be the more eff ective therapy, probably linked to the fact that patients treated by RT had a less extensive relapse. The 1y OS, PFS, and relapse incidence were 65%, 27%, and 73%, respectively. The median PFS was 5 months and the median OS was 13 months. Conclusions: This retrospective analysis showed that survival for patients relapsing or progressing after ALLO is quite high, as patients continued to respond to therapy. However, treatment have to be prolonged because frequent relapses. In this cohort of patients, we did not used brentuximab vedotin. S. Takeuchi, N. Nakano, A. Kubota, M. Tokunaga, Y. Takatsuka, K. Yonekura, A. Utsunomiya Imamura Bun-in Hospital (Kagoshima, JP) Background: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive hematological malignancy and so allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasingly used as a curative option. However, 3-year overall survival rate is low with approximately 30% and incidence of non-relapse mortality is so high. Therefore, it is necessary to consider its indication. Here we clarify the relation between pre-transplant prognostic indexes and overall survival (OS) after allo-HSCT in our single institute located in endemic area of ATLL.

Is autologous stem cell transplantation feasible in solid organ transplant recipients with non-Hodgkin's lymphoma? E. Jantunen, M. Pyörälä, T. Kuittinen, P. Mäntymaa, E. Koljonen, O. Kuittinen, H. Kuitunen, T. Nousiainen Kuopio University Hospital (Kuopio, FI) Introduction: Solid organ recipients have chronic immunosuppression and are at increased risk for development of post-transplant lymphoproliferative disorder (PTLD) frequently associated with Ebstein-Barr virus. Early PTLDs are treated with reduction of immunosuppression and rituximab but true lymphomas are clinically aggressive. Limited data is available on feasibility of ASCT in treatment of lymphomas in solid organ recipients. Patients and treatments: In 2009-2012 fi ve patients with posttransplant lymphomas were included into high-dose therapy protocol. All were males with a median age of 47 years (range 19-55). Two patients had received renal transplantation, two a combined

S422 renal and liver transplantation, and one a cardiac transplantation. Two patients had received two renal allografts. The median time from the most recent solid organ transplant to the diagnosis of lymphoma was 10 years (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . The histology included diffuse large B-cell lymphoma in four patients and plasmablastic lymphoma in one patient. The tumour was EBV-positive in three patients and two patients had EB-viremia at the time of diagnosis. All patients received a combination chemotherapy and rituximab. One patient was included into high-dose therapy protocol at the time of the fi rst relapse and four other patients due to initial poor prognostic features/poor response to therapy; one of these patients showed a clear progression prior to high-dose therapy. Blood stem cells were mobilized with chemotherapy plus G-CSF. Three out of fi ve patients needed plerixafor to augment mobilization. With median of two aphereses a median of 2.7 CD34+ cells/kg (1.8-4.1) were collected. Four patients received BEAM followed by stem cell graft infusion plus pegfi lgrastim. One patient died due to septic shock and multiorgan failure on d +13, another patient shortly after stem cell collection due to rapidly progressive disease. Three patients are alive and well 1, 2 and 26 months from ASCT. Conclusions: Lymphomas appearing late after solid organ transplantation appear to behave aggressively and are diffi cult to treat. Perhaps based on chronic immunosuppression these patients have more problems with standard-dose chemotherapy and may perhaps also have more problems with high-dose therapy. Many of these patients appear to be poor stem cell mobilizers. More experience is clearly needed to optimize treatment of these patients. (1) It is now clearly established that cure or control of the underlying malignancy is not necessarily accompanied by full restoration of quality of life (QoL) in long-term survivors. Thus, information about QoL in long-term lymphoma survivors is worthwhile. We aimed to examine QoL in lymphoma patients in complete remission after AHSCT at long-term follow-up and provide comparison with population norms. A total of 34 lymphoma patients (Stage IIA-IVB) with the follow-up period more than 12 months were enrolled in the study: non-Hodgkin's lymphoma -18; Hodgkin's lymphoma -16. Mean age -37 years old, SD-11.2; male/female -17/17. All the patients were in complete remission after AHSCT. Median follow-up was 19.5 months (range 15-54 months). QoL was assessed using generic questionnaire SF-36. To compare patient population with normative data the sample from population norm (PN) data base adjusted to age and gender (n=72) was used. Distribution of patients according to the grades of QoL impairment was analyzed: no QoL impairment (Integral QoL index similar to the one in normative population sample), mild (25% decrease from a PN), moderate (25-50% decrease), severe (50-75% decrease) and critical (>75% decrease). For comparisons t-test for independent samples or Mann-Whitney test was used. QoL parameters in lymphoma patients in complete remission were similar to the ones in population norms for the majority of scales: role-physical functioning -72.1 vs 78.5, bodily pain -87.8 vs 79.7, general health -65.1 vs 65.4, vitality -66.6 vs 68.3, social functioning -85.7 vs 77.8, role-emotional functioning -72.5 vs 74.1 and mental health -71.4 vs 65.8. Physical functioning scale was significantly lower in patients as compared to PN: 81.5 vs 92.2 (P<0,05). The majority of patients had no QoL impairment (24 patients); 1 patient -mild QoL impairment, 4 -moderate QoL impairment; 4 -severe QoL impairment; and 1 -critical QoL impairment.

In conclusion, lymphoma survivors in complete remission at the follow-up of more than 1 year after AHSCT had QoL parameters similar to normative data except decreased physical functioning. The vast majority of patients exhibited either no or mild to moderate QoL impairment. At the same time 15% of patients have either severe or critical QoL impairment. Careful examination of longterm lymphoma survivors after AHSCT is needed to improve treatment outcomes in this patient population.

Early response by 18F-fl uorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsed/refractory Hodgkin's lymphoma (HL) patients (pts) could predict the outcome after high dose chemotherapy (HDC) S. Bramanti (1) Background: HDC is the gold standard in HL relapsing/refractory after fi rst line chemotherapy (CT). Pre-HDC FDG-PET can predict the outcome. Few data have been reported about the value of an interim FDG-PET during salvage CT. In a previous small cohort of patients, we suggested that PET2 was predictive of outcome, independently from PET4. In the present analysis, we aimed to confi rm these results in a more consistent number of patients. Patients and Methods: From March 2003 to July 2011, 67 pts with relapsed/refractory HL received 4 courses of IGEV (ifosfamide, gemcitabine, and vinorelbine) and HDC. FDG-PET was performed at relapse/progression, after the 2nd (PET2) and 4th (PET4) salvage CT. The progression free survival (PFS) and Overall survival (OS) were calculated. Univariate and multivariate analysis were performed. Results: Median age was 33 years. 31 pts (49%) were refractory after fi rst line treatment and 32 (51%) were relapsed. Pts characteristics were reported in table 1. The overall response rate after IGEV was 74% (n= 47). With a median follow up of 46 months, for the whole population the 3-years (3-ys) PFS and OS were 70% and 79% (fi g 1). 3-ys PFS was 52% and 84% for pts with positive (pos) and negative (neg) PET2 respectively (p=0.008). 3-ys OS was 60% and 94% for pts with pos and neg PET2 (p=0.002). Considering only 47 chemosensitive pts after IGEV, the 3-ys PFS was 86% and 50% for patients CR and PR-PET2 (p= 0.005). 3-ys OS was 96% and 70% for CR and PR-PET2 (p= 0.011). In multivariate analysis, PET2 and PET4 signifi cantly infl uenced the PFS (p= 0.01). Conclusions: This retrospective multicenter study confi rms that interim PET after 2 courses of salvage chemotherapy can predict the outcome after HDC in HL pts. Moreover in the setting of chemosensitive pts PR identifi ed a group of patients with a poorer prognosis compared to CR. and presence or absence of B symptoms(66% vs 38%), HR=8.1(2.24 29.0), p-value=0.001). CI of DS-death for 0, vs 1-2 factors was 36% vs 65% (P=0.04). Table shows the confi dence interval with upper and lower limits (UL) (LL) and p-value. Conclusion: In patients with primary refractory DLBCL, presence of B symptoms and no prior use of rituximab are negative prognostic factors. Patients with higher scores have higher risk of treatment failure and are potential candidate for newer therapies.

High-dose therapy and autologous stem cell transplantation in Hodgkin's disease. The value of pre-transplant PET/TC assessment S. Capria, A. Polino, S. Mallano, F. De Angelis, S. Panfi lio, A. Piciocchi, C. Stefanizzi, S.M. Trisolini, R. Foà, G. Meloni Sapienza University (Rome, IT) Clinical management of advanced Hodgkin's disease (HD) currently involves the use of high-dose therapy followed by autologous stem cell transplantation (ASCT). PET/CT imaging is becoming the standard tool to assess treatment response before ASCT and recent data suggest a high negative predictive value of this procedure. Aim of the study was to analyze retrospectively the value of pre-ASCT PET/TC in poor risk HD patients consecutively autografted at our Institution since 2002, focusing in particular on the prognostic signifi cance of the presence of measurable disease pre-ASCT in PET negative patients. A cohort of 83 patients with a median age of 29 years (12-61) was analyzed. The M/F ratio was 45/38. Poor risk disease was defi ned as sensitive relapse (23 pts), response to 2nd line treatment (28 pts), more advanced disease (>2 lines of treatment, refractory relapse) (32 pts). The median number of chemotherapy lines received was 3 (2) (3) (4) . Bulky disease at diagnosis was present in 53% (44/83) of patients, while extranodal disease at baseline or at relapse was detected in 33% (28/83). In 36 cases, pre-tranplant PET/TC was positive and in 47 it was negative. Within the latter group, 19/47 patients had measurable disease (≥4cm). The conditioning regimen varied during the years: BEAM was the treatment of choice until 2011 (74 pts); thereafter, Carmustine was replaced by Bendamustine 400 mg/m2 (3 pts) and Fotemustine 300 mg/m2 (6 pts). The two-year projected Kaplan-Meyer estimate of overall survival (OS) of the whole population was 87% (95% CI: 78-97), and pre-ASCT PET evaluation had no infl uence on OS (p: 0.2). The two-year projected progression-free-survival (PFS) was 73% overall (95% CI:63-83). Pre-ASCT PET negativity was the only factor infl uencing PFS both in univariate (85% vs 58%; p: 0.002) and multivariate analysis including in the model disease status, lines of treatment, bulky disease and extranodal involvement as covariates. Within PET negative patients, the presence of residual measurable disease was not associated with a worse outcome (p: 0.71). In our series, pre-transplant negative 18FDG-PET identifi ed patients with a better outcome and was a useful prognostic factor, independently of disease status before ASCT. Patients undergoing transplant with a persistent PET positivity still have a worse prognosis and for them alternative therapeutic strategies combined with ASCT should be considered.

Autologous stem cell transplantation in patients with ALKperipheral T-cell lymphoma: feasibility of fi rst-line autoSCT and effi cacy of salvage strategies after relapse. A single centre intent-to-treat analysis S Rohlfi ng, S. Dietrich, M. Witzens-Harig, U. Hegenbart, S. Schönland, T. Luft, A.D. Ho, P. Dreger University of Heidelberg (Heidelberg, DE) The role of autologous stem cell transplantation (autoSCT) as consolidating treatment for peripheral T cell lymphoma (PTCL) is unsettled. The aim of this retrospective single center analysis was to investigate the feasibility and effi cacy of autoSCT in the upfront setting by intent-to-treat, and to study salvage strategies in case of relapse. Eligibility criteria: all patients with PTCL aged 18-70 years, diagnosed from 2002 through 2011. Results: 106 patients could be identifi ed. 7 were not treated, 1 was lost to follow up, 4 died within the fi rst month and 17 patients had ALK+ PTCL. These groups were excluded from further analysis. Of the remaining 77 patients, diagnosis was ALCL ALK-in 21, AITL in 16, EATCL in 10, and other PTCL in 30. Disregarding 15 patients whose initial treatment was performed externally, 1st-line autoSCT was not intended in 19 patients due to comorbidity, refusal, or unknown reasons (non-ITT), while intent-totransplant (ITT) was documented in 43 patients. Of these, 22 were autografted, whereas 19 (44%) could not proceeded to autoSCT usually due to progression, toxicity or refusal. By multivariate analysis adjusting for age, IPI and PTCL subtype, ITT vs non-ITT was not associated with signifi cant benefi ts for progression-free survival (PFS) and overall survival (OS). Altogether, 58 (75%) of all 77 patients relapsed. Median OS after PTCL recurrence was only 10 months with no signifi cant impact of the time interval from 1st-line therapy to relapse, but higher IPI and age as well as subtype EATCL had a negative infl uence on the OS after relapse. increased uptake (SUV<3.5). A homogenous pattern with normal FDG distribution and absence of focally increased uptake was also considered as negative. Active disease was considered when the defi nition of controlled disease was not fulfi lled. Results: Eighteen patients (55%) had controlled disease before transplantation. With a median follow up of 9 months (IQL 5-34), the median OS of patients with active disease is 7.5 months (IC 95% 4.7-10.3) and it has not been reached in patients with controlled disease (p<0.001). At 2 years OS is 23% and 78% respectively (p<0.001). Nine patients did not respond and 5 patients relapsed after transplantation. In patients with previous active disease, the probability of relapse at two years is 100%, while it is lower than 20% in patients with controlled disease. PFS at 2 years is 15% and 78% respectively (p<0.001). Conclusion: In our experience, disease status evaluated by PET before reduced intensity allogeneic SCT is strongly predictive of outcome in patients with lymphoma. Patients with active disease have long-term dismal results and should follow a diff erent strategy.

High-dose chemotherapy with autologous stem cell transplantation in the treatment of patients with diff use large B-cell lymphoma with bone marrow involvement A. Gavrilina, E. Zvonkov, G. Gabeeva, K. Morozova, A. Sidorova, A. Bariakh, I. Vorobyev, K. Mangasarova, G. Gemdjian, K. Kravchenko, U. Magomedova, V. Savchenko National Research Center for Hematology (Moscow, RU) Background: Bone marrow involvement occurs in 10-20% of cases of diff use large B-cell lymphoma (DLBCL). According to its morphological characteristics bone marrow involvement can be concordant (CBM) or discordant(DBM). DLBCL with bone marrow involvement (BM) is characterized by aggressive course and poor response to standard chemotherapy (CT), and the worst results were obtained from the group of patients with CBM: 5-yrs OS rate of less than 10%. Application of the modifi ed NHL-BFM-90 program in treatment of DLBCL BM patients(pts) resulted in only partial remission. In these cases it seems reasonable to apply consolidating high-dose sequential chemotherapy(sHDT) with autologous stem cells transplantation (ASCT). Aim: To evaluate the effi cacy of the mNHL-BFM-90 program with sHDT with ASCT in the treatment of patients with DLBCL BM. Patients and Methods: Since Feb 2005 14 untreated DLBCL BM pts (median age 43(23-57), the M/F ratio 3,67; IPI: IH 50%, H 50%; bone marrow involvement: CBM 36%, DBM 64%) were enrolled in the mNHL-BFM-90 with sHDT with ASCT treatment program. All pts underwent 4 courses of CT mNHL-BFM-90 blocks A and C. After 4 courses the pts continued receiving treatment according to the sHDT scheme, including 2 DHAP courses and 3 high-dose courses with the mobilization and collection of hematopoietic stem cells (HSC): cyclophosphamide 8 g day 1, methotrexate 16 g and vincristine 2 mg day 15, etoposide 1 g q 12 hrs days 21-24. With enough CD 34+ cells collected the BEAM conditioning and the ASCT were carried out. Out of 14 pts included in the study, full therapy scheme was implemented in 6(43%) pts (arm 1). There had not been enough HSC collected from the remaining 8(57%) pts and therefore the ASCT was not carried out (arm 2). In arm 2, in case the complete remission (CR) was achieved only after sHDT, one additional Dexa-BEAM course was carried out (4 pts). The other 2 arm pts completed the therapy after the sHDT (4 pts). Results: A median follow-up is 44 months (19-95). All 14 pts achieved CR. There were 2(14%) pts with the early recurrence: 1 with CBM and 1 with DBM. One case of recurrence was registered in each arm. CR is maintained in 4 out of 5 patients with CBM. The 5-year OS and RFS were 79% and 85%, respectively. Conclusions: For the fi rst time the application of the primaryintensive mNHL-BFM-90 program with the sHDT with ASCT in the treatment of DLBCL BM pts, including pts with CBM, demonstrated high effi cacy.

HSP105 inhibition hampers the growth of human aggressive B-cell non-Hodgkin lymphoma by counteracting key oncogenic pathways R. Zappasodi (1) We have now set out to clarify whether and how HSP105 can contribute to the malignant phenotype in these diseases. Methods and Results: Towards this goal, we stably silenced HSP105 expression in the Namalwa aggressive lymphoma model by using a lentiviral vector carrying a specifi c pre-microRNA sequence in frame with the green fl uorescent protein (GFP) gene under the P1200 Predictors of response and survival in patients of chronic graft-versus-host disease treated with extracorporeal photopheresis: a single centre experience of 219 patients A Garg, R Whittle, F Hammerton, A Alfred, P Taylor Rotherham Hospital Foundation Trust (Rotherham, GB) Introduction: Extracorporeal photopheresis (ECP) has been widely used as a second line therapy for treatment of chronic graft versus host disease (cGVHD) with recognized effi cacy as a steroid sparing intervention. However the factors aff ecting the outcome of patients treated by ECP is still under investigation. We report our experience of the patients who were treated with ECP at the Rotherham Hospital Foundation Trust from 1996-2012. Methods: Single centre, retrospective cohort study based on the data in the unit's ECP database. 219 consecutive patients were included who were steroid dependent, steroid refractory or intolerant to them. We recorded the baseline features including gender, age, type of transplant, sex of the donor, performance status, steroid dose, bilirubin level, platelet count, ECP duration, number of immunosuppressive agents, type of cGVHD and overall severity of GVHD (NIH classifi cation).The individual organ scores were also recorded. The response was measured at 3months, 6 months, 1 year and 2 years. Patients who showed ≥ 50% improvement in organ score and/or ≥ 50% reduction in steroid dose were classifi ed as responders. All the others were in the non responder group. Results: There was superior overall survival for the patients in the responder group as compared to the non responders (Table 1 ). In Univariate Cox regression analysis, signifi cant factors of survival included platelet count ≤100 (HR 2.671, CI 1.653-4.315, p<0.001), bilirubin level ≤2mg/dl (HR 0.345, p<0 .001), steroid dose at the start of ECP ≤0.5 mg/kg (HR 0.464, CI 0.289-0.745, p<0.001) and the duration of ECP with an increase in survival with the increased duration (HR 0.979, CI 0.973-0.985, p<0.001).Other factors including female gender, male donors, good performance status, less immunosuppressive agents, less severe GVHD score were predictive of better survival, but did not reach statistical signifi cance. There was improvement in the response rates with the duration of ECP. The response rates improved from 78% at 3 months to 90.2% at 2 years. (Fig 1) . Conclusion: This study suggests that there are no obvious predictors of response to ECP, but prolonged ECP appears to be

S442 necessary for optimal therapeutic aff ect which improves the overall survival.

Extracorporeal photopheresis for treatment of GvHD after donor lymphocyte infusion C Del Fante (1) , L Scudeller (1), G Viarengo (1), M Cervio (1), L. Castagna (2) , C Perotti (1) (1)Fondazione IRCCS Policlinico S.Matteo (Pavia, IT); (2)Istituti Clinici Humanitas (Rozzano, Milan, IT) Objectives: Donor lymphocyte infusion (DLI) is often used after allo-SCT for treating diff erent oncohaematologic diseases to exploit the graft-versus-tumor eff ect in pts receiving T-celldepleted grafts, early after relapse or as a prophylactic strategy of relapse. However, more than 1/3 of patients develop acute and/or chronic GvHD and need an increase of immunosuppressive therapy (IST) thus entailing higher risk of disease relapse. Extracorporeal photochemotherapy (ECP) is a cell therapy, used to treat GVHD after allo-SCT. We here detail the results of 11 pts with chronic GvHD (NIH classifi cation) after DLI, treated with ECP with the aim of reducing or avoiding the need for IST. Methods: ECP consists in mononuclear cell collection, their UV-A irradiation in presence of 8-methoxypsoralen and reinfusion of the cells to the pts. The ECP treatment schedule consisted of three rounds of two procedures per week, three rounds of two procedures every other week, and fi nally two procedures every month until clinical improvement and/or IST tapering. Description of the whole cohort has been recently published (Transfusion 2012; 529:2007-15) . Results: Out of 102 patients treated with ECP at our Centre for chronic GvHD, 11 (10.8%) had received DLI. Of these, 7 (63.6%) were males. ECP was second line treatment for 3 (27.3%) pts and third line for 8 (72.7%) pts. Table 1 details pts' characteristics at ECP initiation. 8 (72.7%) pts showed a satisfactory response to ECP: 3 (27.3%) were complete responders, 5 (45.4%) partial responders; 2 (18.2%) minimal responders and 1 (9.1%) no responder. Rate of response was 2.6 (95%CI 1. 2 -5.6, p-value=0.02 ) higher than the rest of our cohort. 3 pts (27.3%) died (1 for disease relapse and 2 for infection). Of the 7 pts with steroid at baseline, 5(71.4%) discontinued steroid at the last ECP; other IST was tapered in 6 (54.5%) pts ( Table 2) . Conclusion: ECP proved to be eff ective in treating patients with GVHD after DLI. Compared to the whole cohort, these patients had a higher chance of complete or partial response; most patient could taper or even suspend IST even if ECP represented third line treatment for most patients. If these results will be confi rmed, ECP could be proposed as fi rst line treatment to reduce cGVHD severity in patients receiving DLI.

Evaluation of an intensifi ed structured physiotherapy programme for patients with chronic skin and musculoskeletal graft-versus-host disease D. Benz (1) Background: Chronic Graft-versus-host disease (cGvHD) involving the skin, joints or fascia may lead to restriction in movement, pain and hence disability. Physiotherapy is often prescribed, albeit prospective evaluation of physiotherapy programs for these patients is largely lacking. Methods: All consecutive patients diagnosed with cGvHD manifestations involving the joints and fascia and/or the skin with deep sclerotic features or impaired mobility (skin organ Score 3) were asked to participate in the Basel prospective physiotherapy cohort study. Initial assessment was performed in a standardized way by an experienced trained rheumatologist and a physiotherapist. The assessment included GvHD skin score, muscle strength, range of motion and self-reported health assessment measured by S-HAQ, a validated instrument in scleroderma patients. Aspects of quality of life were measured by SF-36. Patients were planned to receive a 12 months course of 2 intense sessions every week of physiotherapy and ergotherapy if deemed to be necessary. The following techniques were applied and modifi ed according to patients needs: Isotonic muscle exercise, stretching, deep facial massage and ergotherapeutic techniques if hands or face were involved. For those patients not able to come twice a week to Basel local physiotherapists were instructed by a written letter. All patients will be/were reassessed at 6 and 12 months. Results: So far 11 patients (6 female) were included. Diagnoses were AML in 5, CML in 3, ALL, HD and PCM in 1 each. Median time interval between HSCT and inclusion was 5.8 years (4) (5) (6) (7) (8) (9) (10) (11) (12) , global scoring of cGvHD was severe in 9 patients and moderate and mild in 1 each. All but 1 patient had systemic immunosuppressive therapy. Median age at inclusion was 52 years (32-68), six months assessment has been completed for 6 patients. Preliminary

Surrogate markers of iron stores and hepcidin under deferasirox in patients with iron overload after allogeneic haematopoietic cell transplantation (HCT): results from the DE02 trial

O. Leismann (3), G. Bug (4), N. Kröger (5), U. Platzbecker (6), M. Stadler

DE) Data suggest that transfusional iron could persist and retain its negative impact on survival after allogeneic HCT. In this context, trials to the impact of the oral chelator deferasirox (DEF) on iron homeostasis are lacking. Data from the multi-center DE02 trial are presented. Patients and methods: DEF was given over 52 weeks with a starting dose of 10 mg/kg/d (later dose adjustments were performed based on safety) to 76 non-thalassemic recipients of HCT [47 male, 29 female (median age 56 years)] with a history of >20 units of transfusions and a serum ferritin (SF) ≤1000ng/ml. HFE-genotype was analyzed post-HCT. Urinary hepcidin was measured every 3 months by a SELDI-TOF mass spectrometer-based assay (Altamura et al

)Acute Leukaemia Working Party

Sce Maladies du Sang

Background: A broad spectrum of molecular aberrations has been identifi ed in cytogenetically normal acute myeloid leukaemia (CN-AML). However, the prognostic relevance is still unclear for the majority of observations. In contrast, NPM1mut and FLT3-ITD allowed the defi nition of molecular subgroups, associated with leukaemia-free survival (LFS) both after chemotherapy and alloSCT. Hence, the genotype is frequently used to defi ne the indication for alloSCT in CR1. Its infl uence on overall survival (OS) has not yet been evaluated. Methods: An EBMT registry-based analysis included adults with CN-AML, alloSCT in CR1 between

Results: 366 patients (median age: 49.5, [18.0-70.6] years; 49% males, 54% with MRD, median follow-up 14 months) were included. 2-year OS and LFS for the entire cohort were 69±3% and 62±3%, CRI and NRM were 23±2% and 14±2%. Whereas NPM1mut had no infl uence on outcome, FLT3-ITD was associated with increased RI (p=0.0004), decreased LFS (p=0.004) and OS (p=0.0007). Table 1 shows results at 2 years from alloSCT, according to molecular subgroups

Mohty on behalf of the Acute Leukemia Working Party Despite the favorable outcome of patients with acute promyelocytic leukemia (APL) treated with ATRA-based therapy, a proportion of these patients, between 10-20%, experience a relapse. Most of relapsed APL patients will achieve a second complete response (CR2) with arsenic trioxide (ATO), but the optimal consolidation strategy for these patients (repeated courses of ATO, autologous or allogeneic hematopoietic stem cell transplantation -HSCT-) remains uncertain. The outcome of HSCT for APL in EBMT centers was addressed in previous studies (Mandelli F, 1994; Sanz MA, 2007), but more recent information, in the era of generalized use of ATO as salvage therapy, is lacking. In this context, we analyzed the outcome of patients with a cytogenetic and/or molecularly confi rmed APL who received HSCT (autoHSCT n=57, alloHSCT=32) for relapsed APL during the period 2004-2009. Median age was were treated with G-CSF after autoHSCT starting no later than on day +7 while remaining 1121 ones did not receive cytokines to support neutrophil recovery. Bone marrow (BM) and peripheral blood (PB) was used as a source of stem cells in 454 (22%) and 1693 (78%) cases, respectively. Conditioning regimen was based on TBI in 402 (19%) patients. Detailed patient characteristics are listed in Table 1. With the median follow-up of 8 years the probability of LFS at 5 years in the BM-autoHSCT group was 51% (±3%) for patients receiving post-transplant G-CSF and 48% (±3%) for those not treated with G-CSF, p=0.73

Their infl uence on OS and RR post alloSCT is unclear. Objectives: To retrospectively investigate the eff ect of cytogenetics at diagnosis on OS and RR of patients transplanted with AML in fi rst (CR1, n=126) and second complete remission (CR2, n=70), as well as the eff ects of age, conditioning intensity, donor type and CMV status

MDS) have poor outcomes with conventional chemotherapy. The only curative treatment is allogeneic hematopoietic cell transplantation (HCT)

Outcomes in our patients were assessed for these factors: age > 35 years; poor-risk cytogenetics; t-AML not in remission or advanced t-MDS; and donor other than an HLA-identical sibling or a partially or well-matched URD. One-year disease free survival for our subjects with 0-1, 2, or 3-4 of these risk factors was 56%, 38%, and 14%, respectively (P = 0.03), but OS was not diff erent (P=0.219). However, pre-transplant KPS ≤ 80; intermediate or poor cytogenetics; and URD mismatched or other relative donor impacted with one-year OS for subjects with none

KPS was more predictive for OS than age. s-AML had improved OS compared to t-AML and t-MDS patients. These data suggest exploration of prognostic factors for secondary AML

Allogeneic SCT (alloSCT) is associated with a benefi cial graft versus leukemia response mediated by donor T cells. However, graft versus host disease (GvHD) results in substantial non-relapse mortality (NRM) and long-term morbidity. T-cell depletion (TCD) of the graft reduces the severity of GvHD, but is associated with an increased relapse rate post alloSCT. Therefore, we developed a strategy with TCD-alloSCT following a myeloablative conditioning for patients with ALL in fi rst complete-remission (CR1) for temporary control of the disease, and early sequential donor lymphocyte infusion (DLI) in order to induce a successful GvL response. Study design: Twenty-fi ve adult patients with ALL (median age at alloSCT: 38 years, range 19-54; 10 Ph+ALL) were eligible for treatment with myeloablative TCD-alloSCT in CR1

Active GvHD was defi ned as acute GvHD grade ≥ 2 or chronic GvHD requiring systemic immunosuppression, between 3 and 6 months after alloSCT. Patients with a sibling donor or unre

Overall, 1-year cumulative incidences of grade 2 and grade 3 acute GvHD were 28% (95%CI 10-46%) and 8% (95%CI 0-19%), respectively. Only 17% required systemic immunosuppression for GvHD at one year after alloSCT. With a median follow-up after TCD-alloSCT of 50 months, the two-year survival probability was 68% (95%CI 49-87%). Two-year cumulative incidences of NRM and relapse were 20% (95%CI 4-36%) and 16% (95%CI 1-31%), respectively. There was no significant diff erence in survival between patients with a sibling donor or an unrelated donor (p=0.78, Figure 1a)

Median time from diagnosis to transplantation was 7 (range: 1-54) months. Acute graft-versushost disease developed in 24% (N=23), whereas chronic graft-versus-host disease (GvHD) in 27% (n=26) of the patients. Neutrophil engraftment occurred in median 15 (range: 8-33) days, whereas thrombocyte engraftment in median 12 (range: 7-24) days. Of the patients, recurrence was observed in 65% (n=62), while 45% (n=43) were survived. There was no signifi cant diff erence between TBI+Cy and Bu+Cy groups in terms of gender, donor status, time from diagnosis to transplantation, disease status at transplantation, acute or chronic GvHD, thrombocyte engraftment and transplantation-related mortality rate (p>0.05). There were signifi cant diff erences between two study arms in terms of age, Ph chromosome positivity, neutrophil engrafment and mortality (p<0.05). Median follow-up was 24 (range: 3-107) months. Post-transplantation median overall survival (OS) was found as 29 months. Median event-free survival (EFS) was 9 months

In univariate and multivariate analysis, it was found that high OS and EFS were signifi cantly correlated to TBI+Cy conditioning regime and lack of transplantation-related mortality (p<0.05). Conclusion: TBI+Cy conditioning regime was found to be superior than Bu+Cy regime in patients with ALL underwent to AHSCT regarding both OS and EFS

F. Testa (1), C. Frairia (1), F. Ferrando (1), M. Festuccia (1), L. Brunello (1), A. Evangelista (2), M. Boccadoro (1), U. Vitolo (1), G. Ciccone (2), M. Falda (1), F. Marmont

AML relapse occurred at a median of 104 days (range 15-623) after SCT. ARA-C/GO therapy was supported with donor stem cells in 8/16 pts and was relatively well tolerated. One pt died in aplasia 2 in day +2 due to sepsis resulting in 6% induction mortality. Non-hematological treatment toxicity included VOD (n=4) and mucositis (n=4), all of low grade

In pts surviving induction, death occurred due to relapse (n=10) or severe GVHD (n=5). Median EFS and OS were 76 and 133 days, respectively in the entire cohort. There was a trend for longer median EFS in responding pts (97 vs. 16 days, p=0.09), while median OS was not signifi cantly diff

/GO combination is a valid option for salvage therapy in AML pts relapsing after an Allo-SCT and is relatively well tolerated. Although responses are usually of a short duration, they may allow immunologic manipulation in the absence of an already established signifi cant GVHD

Mentkevich Institute of pediatric oncology

Here we present our results of haploidentical non T depleted HSCT from family donors in children with very high risk AML. Study group included 14 pts with advanced AML: slow responders in CR1 -2pts, CR>1 -6pts, active disease -4pts, secondary AML in CR -2pts. The median age of pts was 8(2 -18) years. All pts received Flu 180mg/m 2 + hATG 40mg/kg containing RIC with Busulfan 8 mg/kg or Treosulfan 30-36 g/m2 as alkylating agent. Toxicity of conditioning regimen was defi nitely mild. Pts received non-T-depleted grafts after in vitro incubation with vincristine and methylprednisolone. aGVHD prophylaxis consisted of CSA or tacrolimus and low-dose Mtx. Hematologic recovery WBC >1x109/ l, PLT>20x109/l occurred in all but one pt at an average on d+11. One pt transplanted in DP died of infection before WBC recovery. Acute GVHD > II occurred in one pt (IV=0)

Allogeneic haematopoietic stem cell transplantation in adult acute lymphoblastic leukaemia: the CIC-813 experience

Ciceri San Raff aele Scientifi c Institute (Milan, IT) Background: Hematopoietic stem cell transplantation (HSCT) from an allogeneic donor is the main curative option for adult patients (pts) with high-risk acute lymphoblastic leukemia (ALL)

We off ered also alternative donors to allow prompt HSCT, mainly in refractory cases; 17 pts (22%) received graft from an HLA identical sibling, 18 pts (24%) from an unrelated donor, 37 (49%) from an haploidentical donor and 4 (5%) from umbilical cord blood. Conditioning regiments were manly at reduced intensity (RIC 63 pts, 83%) and in few cases fully myeloablative (MAC 13 pts 17%)

Every eff ort should be directed to promptly recognize patients at high risk and off er them a transplant as soon as possible, while also off ering alternative donors in a strategic decision-making algorithm. P1124 Hypermethylation of CpG island in promoter region of RUNX2 gene in HOX11+ acute T-lymphoblastic leukaemia

Methods: The methylation pattem in pmmoter region of RUNX2 gene was detected with Bisulfi te sequencing PCR, DNA methylation immunoprecipitation technique and promoter oligonucleotide microarray analysis and the expression levels of RUNX2 mRNA was detected with RT-PCR in T-ALL cell lines as well as in 75 clinic bone marrow samples including 38 de novo T-ALL patients, 29 complete remission T-ALL patients and 8 normal samples. Results: There were high expression of RUNX2 gene in T-ALL cell lines and T-ALL patients. The expression level of RUNX2 in de novo T-ALL patients (0.672±0.386) were signifi cantly higher than those Patients: Between 2007 and 2012, a total of 20 patients (17 de novo or secondary AML, 2 ALL, 1 Mantle cell lymphoma; all with active refractory disease) were treated with the FLAMSA (fl udarabine, amsacrine, and cytarabine) followed by a reduced intensity regimen (n=19) or myeloablative regimen (n=1) (Table 1). The median age was 41 years (range 28-48.5 ys ); three patients were females and 17 males. In our cohort, three patients underwent the second allo-HSCT due to relapse of acute myeloid leukemia. Donors were HLA-identical siblings in 11 and unrelated donors in 10 patients. The allograft source was peripheral blood stem cells in 17 patients; two patient received cord blood and one patient received bone marrow. Results: Twelve patients reached complete remission (CR)

DE) Introduction: We have earlier reported from retrospectively performed studies that the occurrence of a CMV-reactivation after transplant has infl uence on the risk for relapse in patients with AML and NHL. Here we report the fi rst results of a prospectively performed observational study about the occurrence of a CMVreactivation after T cell repleted allogeneic hematopoietic stem cell transplantation (alloSCT) on the risk for leukemic relapse in patients with AML (Registration Trial DRKS00004300). Patients and Method: Between

In conclusion, the first results of this prospective study shows also a tendency for an independent effect of early CMV replication on the leukemic relapse risk in patients with AML after transplant. Biology of GvHD and relapse P1127 Gene variants of CTLA4 advantageously infl uence outcome of patients after transplant: results of a prospective study of 48 gene variants A

At donor side, we found that the rate of one-year NRM was associated adversely with the detection of wild-type of CTLA4 (42% vs 10%, p=0.02), and AA gene variants of GSTP1 at 313 (9% vs 24%,p=0,05). OS was better in patients transplanted from donors with gene variants of CTLA4 (73% vs 49%, p=0,048). Conclusion: In accordance to our earlier reported retrospective studies LTA, FA670 and VEGF405 gene variants signifi cantly, and gene variants of IL10, IL23R and CYP1B1 tends to result to infl uence the occurrence of severe aGVHD grade 3-4 in this study, too, whereas NOD2 had no infl uence on the occurrence of GVHD here. NRM was infl uenced from gene variants of CTLA4 and FAS670 as reported also earlier

P1129 High pre-transplant serum nitrate levels predict risk of acute steroid-refractory GVHD in the absence of statins S. Dietrich (1)

Diff erences in nitrate serum levels did not correlate with tumour necrosis factor (TNF) serum levels or expression of iNOS or TNF-a in blood cells. Statins mediate endothelial cell protective eff ects; however, GVHD rates or NRM in the whole patients' cohort were not signifi cantly aff ected by statins. Still, patients with high pre-transplant nitrate levels had signifi cantly reduced rates of refractory GVHD when pravastatin was taken from the time of transplantation

Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal Graft-versus-Host Disease Haematologica

Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft-versus-Host Disease and Response to Steroid Treatment

Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system

Serum cytokine levels early post-allogeneic haematopoietic stem cell transplant are predictors of GvHD and survival R. Danby (1)

Quantitation of pro-and anti-infl ammatory cytokines early post-HSCT may therefore be useful for predicting transplant related events. In this study, the serum levels of TNF-α, TGF-β 1, IL-10 and IL-7 were measured on days zero and 14 post-allogeneic HSCT from 56 patients (median age 49 years (18-66)). 44 patients (79%) received reduced intensity conditioning and 33 HSCT (59%) used an unrelated donor

During the fi rst 14 days post-HSCT, there was a signifi cant increase in the levels of TNF-α, IL-10 and IL-7

However, there was no signifi cant change in the level of TGF-β 1 (14420pg/ml (4940-71560) v 13641pg/ml

The one year CI of NIH moderate/severe chronic GvHD was 28% (14-43%) (median onset 198 days (145-320)). One year non-relapse mortality (NRM) and overall survival (OS) were 15% (6-26%) and 69% (56-86%) respectively. There were no deaths before day 14. In multivariate analysis, low levels (below the median) of TGF-β 1 and IL-7 on day 14 were independently associated with increased risk of grade II-IV acute GvHD (HR 3.4 (1.3-8.6), P=0.01) and moderate/severe chronic GvHD

Results: 3-HAA treatment reduced the expression of CD40, CD80, CD86, and I-A on DCs stimulated with LPS. IL-2 and IL-6 production were also signifi cantly reduced. In addition, 3-HAA decreased the ability of DC to stimulate allogeneic T cells in MLR assays

males, 4 females) with SAA and a median age of 14 years (3-37) underwent allo-HSCT using Flu-Mel-rATG RIC: Flu 150mg/m 2 , Mel 140mg/m 2 , prednisone and variable dose of rATG -8 mg/kg for 10/10 allele HLA matching, 10 mg/kg for 8/10 and 9/10 matched donor/recipient pairs. Cyclosporine and mycophenolate mofetil were used for GVHD prophylaxis. Data was analyzed with SPSS. Results: Median follow-up was 693 days (5-1951)

Total of 3 deaths: intracranial bleeding at D+5, aGVHD at D+78, sepsis at D+139. OS: 76.9%, with a trend to lower mortality of patients treated with 10mg/kg of ATG (p = 0.077). Discussion: The use of Flu-Mel-rATG RIC in unrelated donor allo-HSCT in patients with SAA allowed 100% engraftment, absence of graft rejection and relapse, and an OS of 76.9% at 2 years. Despite HLA mismatch in 10/13 patients, there were no signifi cant diff erences in the incidence of acute or chronic GVHD compared to 10/10 allele matched donor/recipient pairs. P1147 Complement assessment in patients with paroxysmal nocturnal haemoglobinuria treated by eculizumab R

)Hôpital HEGP

It worth to note, that after allo-BMT (n=2) PNH clone disappeared. Conclusion: we did not fi nd any diff erences in the frequencies of PNH clone in AA patients at diff erent stages of disease and treatment

Lymphoma P1156 Outcome of Hodgkin's lymphoma (HL) patients relapsing after allogeneic stem cell transplantation

We analyzed the relation between pre-transplant prognostic indexes such as the HCT-specifi c comorbidity index (HCT-CI), the European Group for Blood and Marrow Transplantation (EBMT) score, the prognostic index for acute-and lymphoma-type adult T-cell leukemia/lymphoma (ATL-PI) and OS after allo-HSCT retrospectively. Results: In 70 patients (40 male, 30 female), median age was 51.5 (range: 32-65) years. Performance status (PS) at HSCT was 0-1 in 59 patients and 2 in 11 patients. Disease status at HSCT was 19 complete remission (CR) and 51 non-CR (14 partial remission (PR), 10 stable disease (SD), 27 progressive disease (PD)). Forty-two patients received bone marrow transplantation (BMT), 20 peripheral blood stem cell transplantation (PBSCT)

for PTCL) on EFS or any other endpoint. Similar results were seen when the analysis was broken down to specifi c conditioning regimens (TT-CY vs BUbased). MEL-and TREO-based regimens did not show a signifi cant diff erence compared to BU for any endpoint. Conclusions: This study did not identify signifi cant outcome differences between the four conditioning regimen types tested. However, the limitations inherent to registry analyses have to be considered. In particular, conclusions on diff erential regimen toxicity apart from NRM will require additional, ideally prospective studies. P1159 Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients V. Varmavuo (1)

); (5)Mikkeli Central Hospital

The median follow-up time from autologous stem cell transplantation (ASCT) was 491 days (range 5-1100 days) in the plerixafor group and 630 days (range 91-1245 days) in the control group (p=0.087). The median haemoglobin level was signifi cantly higher in the control group at the +3 months from ASCT but no other signifi cant diff erences were observed at +1, +3, +6, +12 month time points in the counts of haemoglobin, leukocytes, neutrophils, lymphocytes or platelets. Progression-free survival (PFS) and overall survival (OS) analyses are presented in Figures 1 and 2. Conclusions: Recovery from ASCT and outcome after ASCT seem to be comparable in lymphoma patients whether they have received plerixafor or not to mobilize stem cells

P1163 Improved outcome after allogeneic stem cell transplantation (SCT) as compared to non-allogeneic SCT therapies in patients with high risk peripheral T-cell lymphomas in fi rst response M. Robles (1), L. Ysabert (2), S. Vigouroux

Bouabdallah (1)

were reviewed. Cutaneous T-cell lymphomas and ALK-positive ALCL, patients with IPI score at diagnosis of 0/1, patients relapsing within 3 months after the 1st response and thus ineligible for allo-SCT were excluded. The primary objective was to compare the outcome of allo-SCT as compared to non-allogeneic SCT therapies in these pts with high-risk PTCL in 1st response. 33 patients were included (16 in the allo-group, 17 in the non allogroup). In the allo group, conditioning regimes were of reduced intensity (n=12) or myeloablative (n=4). The sources of stem cells were PB (n=13), BM (n=2) or cord blood (n=1). Donors were matched related (n=7), matched unrelated (n=6), mismatched unrelated (n=2)

The median ages at diagnosis were 54 years vs 59 years

With a median follow-up of 34 months (8-74) after the 1st response, in the allo vs no-allo groups, the 2-year OS (fi g.1) were 87% vs 49% respectively (p= 0.06); the 2-year EFS (fi g. 2) were 81% vs 33% respectively (p = 0.007). In the allo and no-allo with high-risk PTCL (IPI ≥2) might benefi t from allo-SCT in 1st response in comparison with non-allogeneic SCT therapies

Median follow-up 33 months. Etoposide + solumedrol + high dose Ara-C and cisplatinum (ESHAP) was used as salvage chemotherapy in 93%, of these, 38% had rituximab added to it. Twenty-one (50%) patients never had rituximab, others had R-CHOP then ESHAP 12%, CHOP then R-ESHAP 19%, R-CHOP then R-ESHAP 19% (total R-ESHAP 38%). For disease-specifi c event (DS-event), persistent, progressive or relapsed disease were considered as an event. The predictive risk factors for DS-event model were no rituximab ever used vs rituximab used at any time and presence or absence of B symptoms, cumulative incidence (CI) and hazard ratios associated with no rituximab ever used vs rituximab used was (57% vs 33%), HR=2.7(1.09, 6.48),p-value=0.03) and for presence or absence of B symptoms (73% vs 37%), HR=3.9(1.66 ,9.00),p-value=0.001. CI of DS-event 0,vs 1-2 risk factors was 38% vs 67% (P=0.04) respectively. Same risk factors were signifi cant for DS-death. CI and hazard ratios for no rituximab ever used vs rituximab used was

P1171 Allogeneic stem cell transplantation in patients with de novo diff use large B-cell lymphoma relapsed or progressed after autologous stem cell transplantation: a Korea-Japan collaborative study

The risk factors for OS were Eastern Cooperative Oncology Group performance status (PS) 2 (HR 33.34; p=0.005) and chemo-refractory disease at alloSCT (HR 5.24; p=0.024). TRM was associated with prior chemotherapy lines ≥5 (p=0.042), chemo-refractory disease at alloSCT (p=0.009), and poor PS (p<0.001). Donor lymphocyte infusion (DLI) was performed in 4 pts who had persistent or relapsed disease after alloSCT. After a median 1.5 (range, 1-6) cycles of DLI, 1 pt achieved CR. Conclusions: AlloSCT showed considerable effi cacy in pts with de novo DLBCL relapsed or progressed after autoSCT. Our results suggest that alloSCT should be considered if pts have fewer lines of prior chemotherapy, chemo-sensitive disease, and good PS. P1172 Relapsed DLBCL patient pretransplant PET result predicts curability after autologous stem cell transplantation P

Pre transplant PET CT results were chategorized positive, negative and uncertain by nuclear medicine consultant. 19/51 (37%) were positive, 6/51 uncertain, and 26/51 negative before ASCT. Only 3/18 PET positive patients turned to PET negative (1 patient died) after ASCT. All of the 6 patients with uncertain PET CT cathegory achived PET CT negativity. At 24 months OS was 92 %for PET CT negative and 55% for PET CT positive patients (p=0,003), and DFS was 88% for PET negative and 20 % for PET positive patients (p=0,001) ASCT was a higly eff ective consolidation therapy for PET CT negative patient population with a good chance of being cured. For pretansplant PET CT positive patients ASCT did not add much benefi t but toxicity. Pretransplant PET CT is a valid and important examination to assess chemosensitivity

P1173 Allogeneic stem cell transplantation in Hodgkin's lymphoma in the Czech Republic: positive eff ect of DLI in the treatment of relapse V. Valkova (1), L. Raida (2), K. Steinerova (3), P. Zak (4), M. Krejci (5), P. Sedlacek (6), M. Trneny

Chemosensitivity status before ASCT is a known prognostic factor, and has been conventionally assessed with computed tomography (CT). Recently, 18-fl uorodeoxyglucose positron emission tomography (PET) has been introduced for evaluation of chemosensitivity before ASCT. We retrospectively evaluated the role of pre-ASCT PET and CT scan in 54 HL pts treated at two Italian haematological institutions

median age was 33 years (range 14-62) at diagnosis and 36 years (range 19-62) at ASCT

Median number of chemotherapy lines before ASCT was 2 (range 2-5). ASCT was performed because of relapse in 20 pts (median time to relapse 41 months, range 3-90 months) while the remaining 34 pts underwent ASCT for refractory disease after induction therapy; this category included pts with a positive PET after two cycles of ABVD. Conditioning regimen was BEAM in all pts but one

Overall survival (OS) and time-to-progression (TTP) at fi ve years were 77% and 71%, respectively. Both pre-ASCT CT and PET status were signifi cant for TTP (p=0.029 and p=0.000, respectively); 5-years TTP was 88% in PET negative pts and 42% in PET positive pts; according to pre-ASCT CT status, 5 years TTP was 76% in pts who obtained at least a PR at CT scan and 50% in the remaining pts. The positive predictive value (PPV) and negative predictive value (NPV) of pre-ASCT PET for TTP were 58% and 88%, respectively, while PPV and NPV of pre-ASCT CT for TTP were 50% and 77%. Multivariate analysis showed pre-ASCT PET as the only prognostic factor for TTP. Our study confi rms the prognostic signifi cance of pre-transplantation PET in HL pts undergoing ASCT; diff erent treatments (including autologous-allogeneic tandem transplant or chemotherapy with non-cross resistant drugs) have been suggested to improve clinical outcome in this setting, and prospective trials are needed to evaluate the possible benefi cial role of such approaches. P1176 High-dose chemotherapy and autologous stem cell transplantation for relapsed and refractory B non-Hodgkin's lymphoma: long term follow-up and interim evaluation of Bone Marrow Transplant Centers of Tuscany

We are here presenting the interim experience of the three Bone Marrow Transplant Centers of Tuscany, Italy in the effi cacy of HD-ASCT for relapsed and refractory NHL patients. Data are updated at the time of submission and one Center's data are actually under evaluation

203/155; NHL subtype: high grade (DLBCL, MCL, follicular lymphoma grade 3, Burkitt lymphoma) 74.7%, low grade (follicular lymphoma grade 1-2, MZL, SLL, CLL)

Ann Arbour stage at diagnoses: 4.7% stage I, 21.3% stage II, 12.6% stage III, 61.4% stage IV

Pts received high dose chemotherapy (BEAM 40.2%, ICE 26.3%, CYVBP 1.7% or MITO/L-PAM 31.8%) as conditioning regimen

6%) in a PR and 40 (11.2%) with refractory disease. 352 pts are evaluable for response with 1.7% transplant related mortality (6 patients died for infection)

In 15.1% of pre HD-ASCT CR pts we observed a lost of previous response with worsening of disease status after HD-ASCT, while 72 of 113 PR (63.7%) converted to a CR with HD-ASCT. High grade NHL pts (268) status pre HD-ASCT was 146 (54.5%) CR, 89 (33.2%) PR and 33 (12.3%) RD. 267 pts were evaluable for response: 185 CR (69.3%)

At the same median follow-up, 15.2% of pts died because of disease, 22% at 10 years, with an OS projection of 75.1% at 15 years (fi gure 1). DFS and OS for high grade and low grade subset are reported in fi gure 2. To conclude this retrospective evaluation with a long term followup observation confi rms the potential role of HD-ASCT in provid

158 patients were treated in Bone Marrow Transplant Centers of Tuscany with HD-ASCT. Available patients characteristics are as here reported: median age 32

81/77; Hodgkin lymphoma subtype: nodular sclerosing77

Ann Arbour stage at diagnoses: 60.9% stage II, 25.7% stage III, 14.3% stage IV; median number of previous chemotherapy lines 2 (range 1-4). Patients received high dose chemotherapy

9%) in a PR and 65 (41.1%) with refractory disease. 155 patients are evaluable for response with 1.9% transplant related mortality (2 patients died for infection, 1 for cardiac event before restaging)

At a median follow-up of 3 years (range 1 months -18 years), 27.3% of patients relapsed with a PFS projection of 61.5% at more than 5 years (fi gure 1)

To conclude this retrospective evaluation with a long term followup observation, confi rms the potential role of HD-ASCT in providing a long PFS and OS in patients with relapsed or refractory Hodgkin lymphoma

pts after AutoHSCT are still alive. In this description we analyzed the results of AutoHCT performed between

Patients were treated with one of the following lines of therapy: ABVD, BEACOPP, ESHAP, radiotherapy. Then pts were qualifi ed to AutoHCT using conditioning: BEAM -12pts, BEAM+Procarbasine -31pts, CBV-10 pts, IGEV-3 pts. Peripheral blood stem cells were mobilized after IVE (Ifosfamid 3g/m 2 iv in 1-3d, Etoposide 200mg/m 2 iv in 1-3d , Epirubicine 50mg/m 2 in 1d) and G-CSF (10ug/kg/d, from +5 day after chemotherapy till the last day of mobilization) in all cases. The pts collected sufficient for AutoHCT the number of CD34+ cells. The median number of transplanted CD34+ cells was

Early complications after AutoHCT were mainly: infection

Etoposide and Epirubicine chemotherapy for mobilization gives satisfactory result in long-term follow up for high risk Hodgkin Lymphoma patients

TARC was increasing in one patient who had a weakly positive PET at a previous disease site and returned <1000pg/mL when PET became negative after cyclosporine withdrawal. In 4 patients who relapsed after alloSCT TARC increased progressively (median fold increase: 5,2) before PET scan became positive. Considering TARC values done on the day of PET scans, the ROC curve showed that the cut off value of 1500 pg/mL had a sensitivity and specifi city of 86% and 91%, respectively. Conclusions: Serum TARC level correlated with HL tumor burden as detected by PET scan. Patients with disease after alloSCT had elevated TARC levels compared to those in CR. TARC monitoring may be able to predict PET positivity, thus potentially allowing immune manipulation before clinical relapse. Chronic GvHD P1190 Impact of NIH global scoring system of chronic graftversus

Among them, 317 patients were reclassifi ed to have classic cGVHD (n=144, 41.6%) and overlap syndrome (n=173, 50.0%) by the NCC. Twenty nine patients (8.4%) were reclassifi ed as lateonset/recurrent acute GVHD. Out of 317 patients diagnosed to have a classic chronic GVHD and overlap syndrome, the severity scores at the onset of cGVHD were as follows: mild (n=137, 43.2%), moderate (n=134, 42.3%) and severe (n=46, 14.5%), while more moderate and severe cGVHD was noted when severity

When comparing the NCC classifi cations, the 5-yr CIR rates were 11.7±0.9%, 19.3±1.4%, and 9.6±2.2% at onset (p=0.129) and 11.7±0.9%, 19.3±1.4%, and 9.6±2.2% at peak (p=0.203) for the mild, moderate, and severe groups, respectively. Conclusion: The incidence of relapse was not diff erent among the NIH severity groups at onset and peak. The explanation for these results is that the NCC severity groups all had similar graft-versus-leukemia (GVL) eff ects, yet the higher incidence of treatmentrelated mortality in the severe group led to worse outcomes. P1191 Evidence for expansion of CD21-negative B-cells with an exhausted phenotype in patients with active chronic GVHD A

US) months of ECP treatment, where available. Groups were matched for factors reported to

Griskevicius Vilnius University Hospital Santariskiu Klinikos (Vilnius, LT) Objectives: Extracorporeal photopheresis (ECP) has been used for the treatment of Graft versus host disease (GVHD) with encouraging results. Many centers use an "off -line" ECP technique and different apheresis devices for mononuclear cell (MNC) collection. The optimal collection step should produce highly MNC-enriched product with minimal hematocrit (Hct) to avoid negative eff ects on UV-A absorption. GVHD patients are known to have low cell counts, thus making apheresis procedure challenging. Therefore it is important to evaluate quality of collection with diff erent devices. Methods: ECP was performed using an "off -line" regimen (Cobe Spectra (CS) or Spectra Optia MNC Version 5 (SO) (TerumoBCT, USA) for MNC collection + Puva Combi Light). Data of apheresis records (pre-apheresis counts, processing parameters and apheresis product counts) were analysed to compare collection efficiency of both devices. Results: The total of 142 records for SO and 239 records for CS were analysed

University Hospital Regensburg (Regensburg, DE) Chronic graft-versus-host disease (cGVHD) after allogeneic haematopoietic stem cell transplantation (alloHSCT) still causes signifi cant mortality. We analysed lymphocyte reconstitution after alloHSCT aiming to identify predictive cellular marker for the development of cGVHD

All mean cell counts are presented as x10E6/ml including standard deviation, signifi cance was defi ned as p<.05. Results: Pts with de novo cGVHD had signifi cantly higher absolute counts of CD3+CD4+CD8-T cells including CD4+CD45RA-memory type T cells (22.3, ±13.2; 16.2; ±10, respectively) compared to pts with quiescent cGVHD (8.1, ±6.3; 5.0, ±3.9) and pts who never developed cGVHD

±0.02) compared to pts who never developed cGVHD (0.009, ±0.009) were detected. B cell (CD19+) counts including naïve B cells (CD19+CD27-) were signifi cantly increased in pts who developed de novo cGVHD

We investigated whether percentages (%) and absolute numbers of 2 T-reg phenotypes were altered post-ECP, and examined how this correlated with skin disease response and the ability to taper steroids. Methods: Absolute numbers and % of CD4+, CD4+CD25+FOXP3+, and CD4+CD25+FOXP3+CD127dim/-T cells were evaluated using fl ow cytometry in adult patients with cGvHD treated by ECP for a minimum of 3 months (m). ECP was performed on 2 consecutive days (a cycle) every 2 weeks for 3 m, then a cycle every month. The median % change in cell numbers from pre-ECP to month

Dramatic increases (>100%) in CD4+CD25+FOXP3+ and CD4+CD25+FOXP3+CD127dim/-cells were observed at 6 m post-ECP, which was over and above the increase expected due to an enhanced lymphocyte count. T-reg numbers were further elevated at 12 m. The median % of CD4+ cells in healthy controls (49.8%) was approximately twice that of cGVHD patients pre-ECP (22.8%), and at all time points post-ECP (maximum of 25.5% at 3 m). Increases in absolute numbers of each T-reg phenotype correlated with a greater likelihood of achieving a response in skin disease, but not with steroid tapering. Conclusion: T-regs increased in the majority of patients after 3 m of ECP, with the greatest median %increase in number of cells occurring at 12 m post-ECP. Greater % increases in T-regs (especially CD4+CD25+FOXP3+ cells) from pre-ECP numbers are associated with a better response in skin disease

Extracorporeal photopheresis (ECP) has objective activity in the treatment of both forms steroid-refractory GVHD pts. The aim was evaluate the eff ectiveness of the ECP method, determine risk factors and improving predictors of treatment response of refractory forms acute and chronic GVHD. Patients and methods. 83 pts after allo-HSCT, 34 with aGVHD and 49 with cGVHD. The age: 2-55 y.o. (m-22). HSCT details: 47 pts had unrelated donors, 19 pts -related, 17 pts -haploidentical. GVHD prophylaxis includes CsA -45 pts, Tx -38 pts. Treatment aGVHD was: combination CsA/Tx basic GVHD therapy and steroids (2 mg/ kg) as a fi rst line, MAB as a second. For therapy cGVHD steroids (1 mg/kg) were used as a fi rst line, imatinib, MMF or MAB as a second. ECP combined with fi rst or second line therapy. Results: Response to therapy was observed in 23 pts (67%) with aGVHD and in 37 cases with cGVHD (77%). Factors aff ecting the achievement of response were severity of GVHD: II grade aGVHD vs III, IV -100 vs 47%, (p=0,005); «moderate GVHD» vs «severe chronic» -93 vs 71%, (p=0,02), normal level of thrombocytes (cGVHD: 82 vs 57%, p=0,04) and adult vs adolescents (aGVHD: 89 vs 54%, p=0,04, cGVHD: 85 vs 57%, p=0,06). Probability of overall survival (OS) at 3 years was 45% for aGVHD, and 70% for cGVHD. Factors aff ecting to OS were achievement of response (60 vs 12%, p=0,00 for aGVHD

It shows the best results in cases of II grade aGVHD and moderate cGVHD in adult and children with normal level of thrombocytes. ECP can be use as a second line aGVHD treatment. For pts with cGVHD, better results are documented in combination of ECP and IST-agents. P1204 The eff ect of low-energy laser therapy on oral chronic graftversus-host disease

Oral cGVHD was defi ned as presence of one of the diagnostic or distinctive features of oral GvHD such as lichen planus-like changes, hyperkeratotic plaques, mucoceles, mucosal atrophy, pseudomembranes, or ulcers recommended by NIH consensus. Low-energy laser therapy (LeLT) was given to the 10 pts during systemic therapy to provide better local control of oral cGvHD. Results: 10 pts (5 acute leukemias, 3 myeloma, 2 OMF) were screened and treated for oral GvHD with LeLT. The median age at transplant was 48.9 (range, 20-65) years. In this cohort 5 pts received grafts from HLA-identical siblings (50%), 5 pts from matched (50%) unrelated donors. All transplantats consisted of unmanipulated peripheral blood stem cells

All centers used single bedded rooms with HEPA fi lters. Visitor policy during neutropenic phase and the use of gowns, masks or gloves when examining patients varied among centers. MRSA/VRE screen & use of low bacterial diet was applied in 65% & 82% respectively. Antibacterial prophylaxis is employed in 58% (Auto-SCT) & 60% (Allo-SCT) of centers. Drug choice varied (cotrimoxazole, ciprofl oxacin, levofl oxacin, piperacillin-tazobactam); 60% of centers used penicillin prophylaxis in GVHD patients. PCP prophylaxis is applied in 58% (Auto-SCT) and 87% (Allo-SCT) of centers; cotrimoxazole is usually used. Antiviral prophylaxis with acyclovir or, less commonly, valacyclovir is used in 70% (Auto-SCT) & 93% (Allo-SCT) of centers

Cyclosporine/methotrexate is the most commonly used GVHD prophylaxis in myeloablative Allo-SCT (93%)

Preemptive anti CMV therapy is used in 86% of centers, while 7% used routine CMV prophylaxis;7% had no specifi c CMV management policy. Conclusion: consistency was observed in areas of pre-SCT work up, use of single rooms HEPA fi lters and GVHD prophylaxis. Heterogeneity is observed in other practice aspects including other isolation measures, antimicrobial prophylaxis, VOD prophylaxis, GCSF use and treatment of steroid refractory GVHD. P1225 Opinion survey for peripheral blood stem cell donors and patients C

Long-term health status and quality of life of childhood leukaemia survivors who received haematopoietic stem cell transplantation after busulfan or total body irradiation. An LEA study F. Bernard (1) , P. Auquier (2) , I. Herrmann (1) , A. Contet (3) , M. Poiree (4) , F. Demeocq (5) , D. Plantaz (6) , V. Barlogis (1) , J. Berbis (7) , N. Sirvent (8) , J. Kanold (9) , P. Chastagner (9), H. Chambost (1) , G. Michel (1) (1)La Timone Children's Hospital (Marseille, FR) ; (2) University Hospital of marseille (Marseille, FR) ; (3) Brabois children 's Hospital (Vandoeuvre les Nancy, FR) ; (4) L'Archet II Hospital (Nice, FR); (5) University Hospital of Clermont-Ferrand (Clermont-Ferrand, FR) ; (6) University Hospital of Grenoble (Grenoble, FR); (7) University Hospital of marseille (Marseille, FR); (8)Arnaud de Villeneuve Hospital (Montpellier, FR); (9) University Hospital of Clermont-Ferrand (Clermont-Ferrand, FR) ; (9)Brabois children's Hospital (Vandoeuvre les Nancy, FR) The purpose of this multicentre study was to compare the longterm impact of a preparative regimen with either busulfan (BU) or total body irradiation (TBI) on health status and quality of life in childhood acute leukaemia survivors treated with haematopoietic stem cell transplantation (HSCT). 240 patients were included. 66 had received BU, while 174 had received TBI. Mean follow-up from HSCT was 10.9 years. Late eff ects were assessed and reported by physicians. Multivariate analyses were performed to assess the occurrence of late eff ects according to conditioning regimen when adjusting for gender, age at HSCT, CNS irradiation, leukaemia type and time from HSCT to last visit. Quality of life was evaluated in 130 adults using SF-36 questionnaires and multivariate analyses were performed to assess the infl uence of conditioning regimen. The scores obtained were also compared to the French reference scores for age and sex. Patients developed fewer late complications after BU (2.35 vs 3.01, p=0 .03) while the risk to present with at least one complication was equivalent in both groups (87.9% after BU and 93.1% after TBI, p=0.68). Univariate analyses revealed that adverse eff ects on height were signifi cantly less common after a BU-based conditioning regimen (27.3% of patients vs 49.4 in the TBI group, p<0.01). Cataract, hypothyroidism and iron overload were also signifi cantly less frequent in the Although the numbers are small, we can conclude that the prevalence of thyroid antibodies is higher in these patients than in the normal population and that the presence of antibodies is associated with a high chance (50%) of developing hypothyroidism. Hypothyroidism was common, however, irrespective of thyroid antibody status and new cases continue to occur more than 20 years after SCT. This highlights the need for indefi nite surveillance in all patients regardless of antibody status.

Non-malignant late complications after allogeneic haematopoietic stem cell transplantation (allo-HSCT); Korean experience C. Jung, S. Park, J. Jang, K. Kim, S. Lee, W. Chang, J. Hong, C. Ki, H. Jung, J. Lee, S. Lim Samsung Medical Center (Seoul, KR) Introduction: With steadily growing number of long term survivors after allogeneic transplantation (allo-HSCT), late physiologic side eff ects are also increasingly reported in these patients. However, the incidence and the risk factors for post transplant late complications were rarely reported so far. Methods: Medical records of 634 post transplant long term survivors from 3 institutes in Seoul, Korea were retrospectively reviewed. Long term survivors were defi ned as those who were still alive at least 2 year after allo-HSCT. Results: The median age was 37 and AML was the most common disease (39.9%). Sibling donor was common (64.5%), and PB was more frequently used as a stem cell source (PB=51.5%; BM=48.6%). ATG was used in 33.3% of patients, 10.3% received TBI, and RIC transplantation comprised 35.6%. Acute GVHD and chronic GVHD occurred in 26.5% and 57.6% of patients. Among the endocrine dysfunction, hypothyroidism, gonadal failure, and adrenal insufficiency were observed with an incidence of 1.4%, 95.9% and 2.2%. In multivariate analysis, only TBI attained statistical signifi cance for hypothyroidism (HR=7.1) and adrenal insuffi ciency (HR=9.7). BO/BOS was the most common pulmonary complication (7%) and then the BOOP (2%) and interstitial pneumonitis (1%). PB source and cGHVD were the risk factors for lung complications in multivariate analysis (PB, HR=2.3; cGHVD, HR=7.9). Osteoporosis and avascular necrosis (AVN) were observed in 4.1% and 3.9% of patients. Female sex, age ≥40, and cGHVD were the signifi cant risk factors for osteoporosis in multivariate analysis with a HR of 9.6, 4.9 and 7.2, respectively. No use of ATG had signifi cance for AVN in univariate analysis but not in multivariate analysis. Among the long term survivors, 6.2% of patients experienced cataract; age ≥40, PB source, no use of ATG and cGHVD were signifi cant in univariate analysis, of which, only age ≥40 was signifi cant in multivariate analysis (HR=5.5). Nephropathy was observed in 7.4%, and male sex was the risk factor with a HR of 2.3. Cardiovascular diseases involving cardiomyopathy, CHF, arrhythmia and pericarditis were reported from 1.4% of patients, and unrelated donor was the risk factor in multivariate analysis (HR=12.1). Conclusion: This retrospective data showing the incidence and risk factors for late physiologic side eff ects could serve as a basis for optimal approach in long term survivors after allogeneic HSCT.

Late onset granulomatous infl ammation occurring in long-term outcome of patients treated by haplo-identical haematopoietic stem cell transplantation for severe combined immune defi ciency G. Cros, B. Neven, F. Suarez, D. Moshous, N. Brousse, J. Bruneau, C. Picard, O. Hermine, M. Cavazzana-Calvo, S. Blanche, A. Fischer Hôpital Necker-Enfant Malades (Paris, FR) Granulomatous infl ammation can occur in patients with primary T cell immune defi ciency. It has been previously reported in patients with hypomorphic Recombination Activating Gene mutations, Ataxia-Telangiectasia, Common Variable Immuno Defi ciency and Cartilage Hair Hypoplasia.

The role of allogeneic haematopoietic cell transplantation in patients > 50 years with acute lymphoblastic leukaemia (ALL). A donor-no donor comparison based on the PETHEMA protocols P. Barba, R. Martino, D. Martinez-Cuadrón, A. Esquirol, P. Fernandez, J. Gonzalez, F. Fernandez-Avilés, R. Guardia, R.F Duarte, J. Hernandez-Rivas, E. Abella, P. Montesino, J 

The role of allogeneic hematopoietic cell transplantation (allo-HCT) for older patients with ALL has been studied in recent years, mostly from registry-based studies. This perspective, although informative, is inherently biased by studying only transplanted patients. We report herein the outcomes of ALL patients aged 50-70 years prospectively included and treated following consecutive PETH-EMA protocols (1999 -2010 . HCT was recommended for patients with Philadelphia + ALL and for slow responders. All patients who underwent HLA typing were considered as being HCT candidates (intention-to-treat approach). A total of 110 patients were eligible with a median age of 59 years (range 50-70) and a median follow-up for survivors of 51 months (range . Most common cytogenetics were t(9;22) (19%) and normal karyotype (19%) . HLA typing (HCT candidates) was performed in 55 (50%) patients. HCT candidates were younger (57 vs 62 years, p<0.001) and were more likely to be included in conventional protocols rather than in elderly/unfi t protocols (90% vs 67%, p=0.01). Among HCT candidates, 34 (61%) patients had an HLA identical sibling (donor group). Demographic and disease characteristics were similar to the no donor group (n=21, 39%). Eventually, 25 patients (45% of HCT candidates) underwent an allo-HCT, 21 with a fl udarabinebased reduced intensity conditioning and 4 with cyclophosphamide-TBI. Cyclosporine A with mycophenolate mophetil or short course methotrexate were used for GVHD prophylaxis. The complete remission (CR) rate was 83%, while 4-year overall survival (OS), leukemia free survival (LFS) and relapse risk (RR) for all patients were 28% (95%CI 23-32), 27% (95%CI [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] and 53% (95%CI 46-59), respectively. In multivariate analysis the only factor associated with lower LFS was not achieving CR after induction therapy (p<0.001). The lack of an HLA identical sibling did not aff ect LFS (Fig.1) , OS (p=0.7) or RR (p=0.8). Among patients who achieved CR, those receiving an allo-HCT had higher LFS , p=0.06) and lower RR ], p=0.01) than non-HCT patients. 4-year cumulative incidence of non-relapse mortality and any grade of acute and chronic GVHD were 41%, 52% and 56%, respectively. In conclusion, only 50% of patients with ALL aged 50-70 years are considered potential candidates for HCT by their physicians. Although HCT is capable of achieving long-term remissions, having a related HLA identical donor is not associated with improved outcome in this population.

The role of allogeneic haematopoietic cell transplantation in patients with primary refractory AML J. Finke, H. Bertz, R. Marks, R. Wäsch, M. Waterhouse, R. Zeiser Freiburg University Medical Hospital (Freiburg, DE) Clinical trials in AML focus on patients achieving CR and most transplant centers require CR prior allogeneic transplantation, assuming that prognosis for patients transplanted with active disease is dismal. However, with older age the percentage of patients primary refractory to chemotherapy increases and without allogeneic transplantation the prognosis of these patients is fatal.Here we report on our 20 year long experience with 187 patients, (median age 57 years, 20-77) transplanted with primary refractory AML from related (n=61) or unrelated (n=126) donors. All patients failed prior chemotherapy and presented with median number of leukemic blasts in the marrow of 43% and in peripheral blood of 6%. Conditioning was mainly standard ablative Busulfan/ Cyclophosphamid based up to the age of 50 years and Fludarabin/ BCNU/ Melphalan in older or frail patients. GvHD prophylaxis was cyclosporin based with anti T-cell antibodies in unrelated or in elderly sibling transplants. PBSC was the preferred graft source. Of all evaluable patients only 7 did not achieve CR after transplantation. Median overall survival was 411 days with 35% patients surviving after 3 years and 20% patients being alive with a survival plateau 7 to 20 years after allotransplant. 133 patients died from relapse (n=87) or non relapse associated (n=50), mainly infections. Conclusion: Allogeneic hematopoietic cell transplantation in primary refractory AML resulted in cure for 20% of the patients. Early donor search at initial diagnosis, adequate conditioning combined with PBSC and GVHD strategies including anti T-cell antibodies in patients with high risk off er cure in every 5th patient. Novel AML targeting drugs pre and post allotransplant as well as better antiinfections strategies in recent years are likely to improve these S387 results. Therapeutic nihilism for primary refractory AML patients is not warranted.

R. Arnold (1) , T. Terwey (1) , P. Hemmati (1) , I. Blau (1) , O. Penack (1) , C. Jehn (1) , G. Vuong (1) , B. Doerken (1) , B. Ostendorf (1) , I. Na (1) , G. Massenkeil (2) (1)University Hospital Charité (Berlin, DE) ; (2) Klinikum Gütersloh (Gütersloh, DE) In the German Multicenter ALL Studies (GMALL) patients (pts) with prae-T or mature T-ALL are high risk pts and candidates for allogeneic stem cell transplantation (allo SCT) in fi rst complete remission (CR1). Beyond CR1 all T-ALL pts are candidates for allo SCT. Here we report the SCT data of a single center. 12/1995 to 12/2011 51 T-ALL pts underwent allo SCT, median age 31 years . 24 pts had prae-T-ALL, mature T-ALL (n=9), thymic T-ALL (n=17), unclassifi ed T-ALL (n=1). Stage of disease was CR1 in 28 pts (21 pts had prae-T or mature T-ALL, 7 pts with thymic ALL had leukocytes > 100.000 at diagnosis (1) , complex karyotype (1), delayed response (2) or molecular persistence/relapse (3) and were regarded as high risk. 23 pts were transplanted in CR2 or CR3 (8 and 3 pts) or with active disease (primary refractory n=2, 1. relapse n=9, 2. relapse n=1). Conditioning regimens were 12 Gy TBI + Cyclophosphamide or VP 16 (n=46), 8 Gy TBI (n=1) and FLU/BU in pts with contraindications against TBI (n = 4). Stem cell donors were related in 16 pts (HLA id. siblings n=13, mismatched family donors n=3) and unrelated in 35 pts (HLA id. in 29, mismatched in 6 pts) . ATG as GvHD prophylaxis was given in mismatched donor transplantation and from 2006 onwards in all unrelated SCT. Results: 19/51 pts are alive in CR, 1/19 pts after 2nd SCT after relapse. Median follow up of the surviving pts is 69 months . 32/51 pts are dead. Causes of death were leukemia in 14/32 pts and transplant related mortality (TRM), e.g. GvHD ± infection in 18/32 pts.Probability of survival (PoS) at 5 yrs for the whole group is 0.41. For all pts transplanted in CR1 (n=28) PoS at 5 yrs is 0.57 and for pts with prae-T and mature T-ALL (n=21) is 0.43, for pts transplanted beyond CR1 PoS at 5 yrs is 0.23. For pts with CR2 and CR3 or with active disease PoS at 5 yrs was not diff erent (0.24 vs. 0.22). The TRM was high (prob. at 5 years) in pts with CR1 0.27 and in pts > CR1 0.48. Prob. of relapse at 5 years was 0.28 for pts in CR1 and 0.56 in pts > CR1. In conclusion: In high risk T-ALL allo SCT is a curative therapy. The survival rate could be improved after 2005, when high resolution typing was done and ATG was given to all unrelated transplant recipients besides improved supportive care.

Specifi c stratifi cation model predicts relapse incidence and outcome of patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation: a 12-year monocentric retrospective analysis R. Devillier, R. Crocchiolo, J. El-cheikh, A. Etienne, T. Prebet, C. Oudin, A. Granata, S. Fürst, A. Charbonnier, S. Harbi, J. Rey, C. Chabannon, N. Vey, D. Blaise Institut Paoli Calmettes (Marseille, FR) Allogeneic stem cell transplantation (Allo-SCT) remains the main curative treatment for most cases of acute myeloid leukemia (AML). In the past decade, the development of reduced-toxicityconditioning regimens has decreased the transplantation-related morbidity and mortality. However, relapse after Allo-SCT remains a major issue and occurs in about 30% of patients transplanted for AML. To identify predictive factors of poor outcome after All-SCT in the specifi c setting of AML is a key issue to stratify patients and to develop specifi c risk-adapted strategies. To assess factors infl uencing relapse incidence (RI), we retrospectively analyzed 263 consecutive patients with AML who underwent Allo-SCT at the Institut Paoli Calmettes from 2000 to 2012. Median age was 50 . Matched related donor, unrelated donor, cord blood unit and haploidentical donor were used in 145 (55%), 73 (28%),

S388 41 (16%) and 4 (1%) patients respectively. RIC was used in 196 patients (75%). 223 patients (85%) were transplanted in complete remission (CR). Karyotype was favorable (FK), intermediate (IK) and unfavorable (UK) in 26 (10%), 160 (62%) and 72 (28%) patients respectively. Among 70/160 IK patients with FLT3 mutational status available, 26/70 (37%) carried a FLT3-ITD. Median follow up was 37 months . We identifi ed in univariate analyses that no CR at the time of Allo-SCT, UK and FLT3-ITD (in IK patients) were associated with high RI. No diff erence was found between patients who received RIC or myeloablative regimens. To assess a stratifi cation model with these relevant adverse factors, we performed a step by step partitioning analysis on 186 patients (77 patients excluded for missing FLT3 status or cytogenetic; referred patients or treated before 2006) and found 3 risk groups ( Figure  1 ): Very high risk (VHR, n=40) (patients in no CR at the time of Allo-SCT); High risk (HR, n=79) (patients with UK or IK FLT3-ITD, transplanted in CR); Standard risk (SR, n=67) (patients with IK FLT3-WT or FK, transplanted in CR). RI at 2 years was 17%, 38% and 53% in the SR, HR and VHR respectively (p<0.001) ( Figure 2 ). This translated in survival stratifi cation with 2-year progression-free survival of 68%, 41% and 27% (p<0.001) and 2-year overall survival of 75%, 52% and 33% (p<0.001) in SR, HR and VHR respectively. We conclude that this AML-specifi c stratifi cation model predicts RI and survival after Allo-SCT. It could be useful to conduct risk-adapted strategy in further trials. Validation analyses on an independent cohort are ongoing.

Early blast clearance after the fi rst course of induction chemotherapy predicts favourable outcome in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation in CR1 P. Hemmati (1) , T. Terwey (1) , P. le Coutre (1), L. Vuoung (1), G. Massenkeil (2) , B. Dörken (1), R. Arnold (1) (1)Charite Universitätsmedizin Berlin (Berlin, DE); (2)Klinikum Gütersloh (Gütersloh, DE) Purpose: Failure to achieve early blast clearance (i.e. at day +16) following the fi rst course of induction chemotherapy is an important predictor for long-term disease control in patients (pts) with acute myeloid leukemia (AML). Here, we investigated the impact of early blast clearance on the overall outcome of patients (pts) with AML undergoing alloSCT in fi rst complete remission (CR1) after either reduced intensity conditioning (RIC) or standard myeloablative conditioning (MAC). Patients and Methods: We retrospectively analyzed 169 pts (median age 47 (range: 17-69) years) with AML who underwent alloSCT in CR1 from a matched-related (82 pts, 49%) or an unrelated donor (85 pts, 51%) at our center between 1994 and 2011. Cytogenetic risk was either favorable (6 pts, 4%), intermediate (104 pts, 62%), or poor (47 pts, 27%). Prior to alloSCT all pts were treated in a German multicenter AML trial and received at least two courses of induction chemotherapy, i.e. either standard "7+3" or a "high-dose Ara-C" containing regimen (Ara-C 1-3 g/m2). In 98 pts (58%) early blast clearance was achieved, whereas 71 pts (42%) entered remission after a subsequent induction course. In 146 pts (86%) peripheral blood stem cells (PBSCs) were used, whereas 23 pts (14%) received bone marrow (BM). Conditioning consisted of standard myeloablative conditioning (6x2 Gy TBI and 2x60 mg/m2 CY) in 81 pts (48%), whereas 86 pts (52%) received reduced intensity conditioning (BU 2x4 mg/kg, FLU 6x30 mg/m2, ATG 4x10 mg/kg). Results: After a median follow-up of 45 (range: months, 91 pts (54%) are alive and in CR. Causes of death were relapse in 38 pts (22%) or NRM in 33 pts (19%). At 1, 3 or 5 years projected overall survival (OS) was 72±6%, 58±6%, or 54±8% for all pts. Probability of relapse or non-relapse mortality (NRM) at 1, 3, and 5 years was 20±10% (20±11%), 31±12% (20±11%), and 34±12% (20±11%). Pts who achieved early blast clearance as compared to pts who failed to do so (p=0.09), disease-free survival (DFS) and probability of relapse diff ered signifi cantly between the two groups at 3 years (77±8% vs 55±14%) or 5 years (75%±9% vs 52%±14%) (p=0.02). There was no signifi cant diff erence in NRM. Likewise, there was no statistically signifi cant diff erence between pts conditioned with either MAC or RIC. Conclusions: Early blast clearance following the fi rst course of induction chemotherapy predicts a very favorable outcome in pts with AML undergoing alloSCT in CR1.

Uniform chemotherapy-based conditioning regimen and GVHD prophylaxis in haploidentical, unmanipulated bone marrow transplantation for patients with high-risk acute myeloid leukaemia R. Cerretti (1), S. Santarone (2) , A. Picardi (1) , G. De Angelis (1), L. Cudillo (1) , P. Bavaro (2) , P. Olioso (2) Introduction: For patients with high-risk AML a family donor represents the ideal source of hematopoietic stem cells for transplant. Herein, we report results of unmanipulated, G-CSF primed, haploidentical BMT in high-risk AML patients lacking an HLA identical sibling. Materials and methods: Between January 2006 and October 2012, 48 patients (median age: 44 yrs, range 5-66) with high-risk AML (CR1=29; CR2=11; advanced stage=8) underwent BMT from haploidentical donor in 2 transplant Centers (Rome: n=32; Pescara: n=16). For patients grafted in CR1, AML was refractory (n=8), secondary (n=9), with cytogenetic-molecular high-risk characteristics (n=10) or MRD positive after consolidation (n=2). All patients were prepared with a myeloablative (MAC) or a reduced intensity (RIC) conditioning regimen consisting of Thiotepa at days -7 and -6 i.v. Busulfan combined with Fludarabine at days -5, -4 and -3 (TBF-MAC: n=33). In the TBF-RIC (n=15), one dose of Thiotepa and one dose of Busulfan were omitted. All patients received an identical GvHD prophylaxis. Donors were primed with G-CSF at 4 mcg/Kg/ day for 7 days. BM was infused unmanipulated. Results: The median number of CD34+ and CD3+ cells infused was 2 (0.7-11) and 30 (9-170)x10 6 /Kg, respectively. Two patients died early after transplant and engraftment was reached at a median Results: The probability of OS and DFS at 3 years after HSCT were 40.1% and 38%, respectively. Table1 shows the result of risk factor analysis for OS and DFS among all 65 patients. In univariate analysis, hematological status (CR and non CR), the days from the diagnosis to the transplant, the number of WBC at diagnosis were the factors to infl uence OS and DFS. In multivariate analysis, the factor to infl uence OS and DFS was gender and hematological status. By the uni-and multivariate analysis, the hematological status was only associated with unfavorable OS. We analyzed the risk factor for OS and DFS among 51 patients with CR. In univariate analysis, the number of WBC at diagnosis was the factors to infl uence OS and DFS. In multivariate analysis, the factor to infl uence OS and DFS was gender, the number of WBC at diagnosis and the source of stem cells. Twenty one patients relapsed after HSCT with a median of 207 days (range : 19-1324 days). The estimated cumulative incidence of relapse at 3 years was 39.4%. Patients with CR showed lower relapse rate (34.2%) compared with patients with non CR (62.7%) at 5 years. The treatment after the relapse was chemotherapy with TKI : 7 patients, without TKI:13 patients, respectively. Four patients received the second HSCT. Two patients survived and 19 patients died. Among 19 patients, the main cause of the death was recurrence (15 patients).

Risk factors for relapse in acute leukaemia after allogeneic stem cell transplantation. A single centre experience M. Engström (1) , P. Svenberg (1) , P. Ljungman (2) , M. Uhlin (3) In this single center study we evaluated risk factors for relapse in 476 patients with acute leukemia undergoing HSCT between 1995 and 2012. AML was the underlying diagnosis in 295 patients and 181 had ALL. Median age of the patients was 33 (0.5-69) years. HLA-identical sibling donor (SIB ) was used in 173 patients, matched unrelated donor (MUD) in 237 and mismatched graft (MM) in 66 patients. The conditioning regimen was myeloablative in 381 patients and reduced intensity conditioning (RIC) in 95 patients. GVHD prophylaxis consisted of CsA +MTX in the majority of patients. Transplant related mortality (TRM) at one year was 15%. Acute GVHD grades I-II was diagnosed in 281(59%) patients and 37(8%) had grades III-IV. Chronic GVHD (cGVHD) was diagnosed in 150(35%) patients. Leukemia relapse occurred in 176 patients (37%), hematological relapse in 156 and molecular in 20 patients. In patients with early disease relapse was diagnosed in 32% compared to 44% in patients with late disease (p=0.01). In patients with grade I aGVHD relapse incidence was 38%, grade II 30% and grade III-IV 12% (p<0.001). The risk of relapse was 25% compared to 46% in patients with or without cGVHD (p<0.001). The overall survival (OS) was 74% in patients without relapse and 77% in patients with molecular relapse compared to 22% in patients with hematological relapse (p<0.001). Patients with a SIB donor had a relapse-free survival (RFS) of 59%, 42% for MUD and 26% for patients with MM donor (p<0.001). RFS was 53% for patients with aGVHD grade I compared to 29% in patients with aGVHD grade III at 5 years. Patients with a blood stream infection (BSI) had an overall survival of 40% at 5 years compared to 64% for those without a BSI (p<0.001). In multivariate analysis for relapse late disease (p<0.01) and RIC (p=0.025) were associated with an increased risk and chronic (p<0.001) and acute GVHD (p=0.006) with a decreased risk. For survival early disease (p<0.001), cGVHD (p<0.001) and no BSI (p<0.001) were associated with a prolonged survival and aGVHD grades III-IV with a decreased survival (p<0.001).In conclusion, acute and chronic GVHD was signifi cantly correlated to less relapse whereas late disease and the use of RIC signifi cantly increased the risk. Interestingly patients with molecular relapse showed a comparable survival to patients without relapse. Early disease, cGVHD and no BSI was signifi cantly correlated to improved survival and severe GVHD with a decreased survival.

Allogeneic stem cell transplantation in secondary myeloid malignancies: single institute experience G. Perets Avraham (1), G. Meyers (2) , A. Lemieux (2) , R.T Maziarz (2) (1)Soroka University Medical Center (Beer-Sheva, IL); (2)Oregon Health and Science University (Portland, US) Objectives: Secondary AML evolving from MDS (s-AML), therapy related acute myeloid leukemia (t-AML) and myelodysplastic

Allografting is curative in acute myeloid leukemia (AML). Aim of the study: To evaluate outcomes in newly diagnosed patients, younger than 66, who achieved complete remission (CR) after induction/consolidation therapy at the Divisions of Hematology at Città della Salute e della Scienza, Università di Torino, Torino, Italy, between 2000 were consecutively diagnosed and stratifi ed by risk as follows: low risk included presence of t(8;21), inv(16)/t(16;16); high risk features included WBC>50.000/uL at diagnosis, secondary leukemia, presence of extramedullary AML, complex karyotype, chromosomal monosomy, no remission after induction, and FLT3/ MLL mutations (since 2004). Intermediate risk included patients who did not meet either low or high risk criteria. Moreover, the standard risk group included low+intermediate risk patients. Patients were treated according to Center guidelines or on clinical trials active at the time of diagnosis. All high risk patients were considered for an allograft since diagnosis Results After induction/consolidation, 229/302 patients (76%) achieved complete remission: 16/229 (7%) were at low, 54/229 (24%) at intermediate, and 159/229 (69%) at high risk respectively. Eighty/159 (50%) high risk patients received an allograft as 1st line treatment; 56% from a HLA-matched sibling, 42% from an unrelated donor and 2% received a haplo-identical transplant. Seventy-nine/159 (50%) did not receive an allograft primarily because of failure to fi nd a suitable donor either sibling or unrelated. At median follow-ups of 53 months from induction therapy and 49 months from achieving CR, 5-year overall survival (OS) and 5-year event free survival (EFS) of the entire patient cohort were 45% and 35% respectively. By risk category, standard risk patients showed a 5-year OS of 56% and high risk patients of 40% (p=0.008). Five-year EFS was 37 and 34% in standard and high risk patients respectively (p=0.194). High risk patients who underwent an allograft up-front showed a 5-year OS of 53% and showed a statistically signifi cant advantage as compared with those who did not receive a transplant (p=0.018). Conclusion: Allografting plays a pivotal role in OS and EFS for high risk acute myeloid leukemia. The lack of a donor is associated with bad clinical outcomes. Prospective clinical trials designed to evaluate the use of more readily available donors such as haploidentical siblings or parents are needed.

Allogeneic stem cell transplantation is a treatment of choice for selected adolescents and young adults with acute lymphoblastic leukaemia: our experience D. Stamatovic, M. Elez, B. Balint, O. Tarabar, S. Marjanovic, Z. Tatomirovic, M. Strnad, O. Tasic Radic, M. Malesevic, Lj. Tukic Military Medical Academy (Belgrade, RS) Background: Several factors such as patient age, immunophenotype and clinical, cytogenetic and molecular features of the disease are predictors for treatment outcome in patients (pts) with acute lymphoblastic leukemia (ALL). Adolescents and young adults with ALL still have lower rates of survival than younger children. Majority of reports published so far indicate that these pts have a better outcome when treated with pediatric, rather than adult therapeutic protocols. Role of allogeneic stem cell transplantation (SCT) in fi rst complete remission (CR) in this particular cohort of pts is still controversial. Aim: Analysis of treatment outcome in adolescents and young adults aged 15 to 30 years with newly diagnosed ALL who were treated in our adult hematology department either with conventional approach or allogeneic SCT. Patients and methods: Since 1989 till 2012. a total of 90 pts, male/ female 58/32, aged 15 to 30 (average age 20), with newly diagnosed ALL were treated with adult chemotherapy protocol and allogeneic SCT. In the postremission setting, pts were divided in two gruops: with "donor" (40 pts) in whom we have performed allogeneic SCT in CR1 from idenstical sibling and with "no donor" (50 pts) who were treated with conventional maintenance therapy. With respect to disease risk parameters (standard vs. high risk), age (15-18 vs. 19-30) , white blood count (>30x109/l vs. <30x109/ l), time to achieve remission (below 28 days vs. above 28 days) groups "donor" vs. "no donor" did not diff er. Results: For the whole cohort, the remission rate was 91,4%, iduction failure 8,6%, early deaths 3,4% and relapse rate 55,1%. After a median observation time of 9 years the overall survival (OS) and event-free survival (EFS) of pts who were treated with allogeneic SCT in CR1 were superior in comparisson to pts who were treated with conventional therapy (OS 43,2% vs. 25,3%, p < 0.05; DFS 54,1% vs.28,7%, p < 0.05). Relapse incidence was signifi cantly lower in the group of pts with allogeneic SCT (32,1% vs 67,3%, p < 0.05). Signifi cantly better OS had pts with initial lower white blood count and those who have achieved remission in the fi rst 28 days. In this cohort of pts age had no impact on the results. Conclusion: Allogeneic SCT in CR1 is superior treatment option for adolescents and young adults with ALL in comparisson to conventional adult chemotherapy protocol, but further investigation, especially in the new target agents era is needed.

Prognostic impact of minimal residual disease analysis by fl ow cytometry in patients with acute myeloid leukaemia before and after allogeneic haemopoietic stem cell transplantation M. Bastos Oreiro, A. Perez Corral, C. Pascual Izquierdo, C. Martinez Laperche, M. Kwon, J. Gayoso, I. Buño, D. Serrano, J. Anguita, J.L. Diez-Martin Hospital General Universitario Gregorio Marañon (Madrid, ES) Aim: To study the prognosis impact of minimal residual disease (MRD) analysis by fl ow cytometry (FC) for the follow-up of patients (pts) with acute myeloid leukemia (AML) before and after allogeneic haemopoietic stem cell transplantation (SCT). Methods: From January 2008 to August 2011 all ps with a diagnosis of AML who underwent allo-SCT were analyzed. MRD was studied at bone marrow (BM) by 4-color multiparametric FC with a Cytomics FC.500 fl ow cytometer. FC was performed at the pretransplant moment and at months 1, 3, 6, 12 and 24 after SCT. The CXP acquisition program was used for acquisition with a gating strategy and INFINICYT software (Cytognos) was used for data analysis. We also collected information about molecular techniques (WT1, NPM) karyotype and chimerism. Regarding FC, only pts who had 2 or more leukemic aberrant phenotypes (LAIPs) at the time of diagnosis were analyzed. MRD was considered negative when it was lower than 0.1%. The relationship between MRD, and clinical evolution was described. Results: 35 pts were included; features are described in table 1. 28 of the pts had LAIPs at diagnosis, (5 missing data at diagnosis and 2 had no LAIPs). Of the 28 pts: 13 pts had less than 3 LAIPs, 13 had 4 or 5 LAIPs, and 2 had 5 or more LAIPs; 19 pts (68%) went to transplant with MRD-and 9 (32%) with MRD+. Patients MRDby FC who underwent transplantation had lower rates of relapse (12% vs 48%) and better survival (15% vs. 46%) one year posttransplant (p: ≤0.05) compared with patients with MRD+. One year after transplant 2 pts had MRD+ and 17 MRD-(9 losses), for a cut value of 0.1, the area under the ROC curve for FC to predict relapse was 0.85 (IC: 0.61-1). Of 11 pts (1 missing by persistent MRD+) with MRD+: 6 were detected by FC and molecular techniques at the same time and 2 were detected by FC fi rst. In Paroxysmal Nocturnal Hemoglobinuria (PNH) is an acquired hemolytic anemia which is eff ectively controlled with eculizumab. We hypothesized residual intravascular hemolysis under treatment may be due to incomplete C5 blockage. From October 2010 to February 2012, 22 pts (7 male, median age 42 years range 21 to 72) with hemolytic PNH treated with eculizumab (900 mg intravenously every 14±2 days) were prospectively followed 22 patients proceeded to salvage allografting, 7 of these with refractory disease prior to alloSCT. With a follow-up of 34 months (14-95), 12 allografted patients live disease-free, translating into a PFS of 61% at 3 years after alloSCT. In contrast, all 7 patients who received a salvage autoSCT relapsed and died, and only 3 of the 29 patients not eligible for SCT salvage survived, none of them with sustained disease control (Fig) . Conclusions: In patients with ALK-PTCL scheduled for primary autoSCT, transplantation is feasible only in a limited fraction of patients. A signifi cant benefi t of 1st-line autoSCT over non-transplant induction remains to be shown. More than two thirds of all patients will fail after 1st-line treatment and have a very poor outlook if salvage alloSCT cannot be performed.

Long-term follow-up of reduced intensity allogeneic haematopoietic stem cell transplantation in follicular lymphoma S. Meireles, R. Branca, C. Pinho Vaz, F. Campilho, M. Rosales, S. Roncon, A. Campos Instituto Português de Oncologia do Porto FG, E.P.E. (Porto, PT) Background: Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation (RIC-HSCT) has been used in refractory or relapsed follicular lymphoma (FL) as an alternative to myeloablative transplantation. Disease status at HSCT is an important factor that has emerged as a predictor of outcome. The aim of this study was to describe our experience with RIC-HSCT in refractory or relapsed FL and to identify predictive factors for the outcome. Material and methods: Retrospective analysis of patients (pts) with refractory or relapsed FL submitted to RIC-HSCT from September 2000 until October 2010. Progression-free survival (PFS) and overall survival (OS) were performed by Kaplan-Meier method. Predictive factors of relapse/progression and prognostic factors in PFS and OS were identifi ed by chi-square and log rank tests. Results: Thirty-two pts were submitted to RIC-HSCT. Median age was 48 years old [33;62] and 60% were male. At diagnosis, 62% of pts were in stage IV and 60% had extra-nodal disease. At HSCT, 31% had performed > 2 therapy lines and 53% of pts were in complete remission (CR). Median time from diagnosis to HSCT was 35 months [14;174]. All pts received grafts from an HLA-identical sibling and the conditioning regimen was fl udarabine and busulfan. Median CD34 dose was 6 x10 6 /Kg [2;12] . Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine and mycophenolate mofetil. Incidence of acute and chronic GvHD was 19% and 59% respectively. After HSCT, CR was possible in 72% of pts. Five pts had progressive disease (PD) and one relapsed. Four pts received donor lymphocyte infusion (PD: 3; loss of chimerism: 1).With a median follow-up of 60 months [21;135] , 20 pts are alive and without evidence of disease. Four pts died (extensive-type chronic GVHD: 2; PD: 2). A secondary neoplasm occurred in one patient (squamous cell carcinoma of the lip, 9 years after HSCT). The estimated 5-year and 10-year PFS and OS are 79% and 85% respectively. CR at the time of HSCT and after allografting were identifi ed as factors with impact on relapse/progression, PFS and OS (p<0.05). There was a trend to a better OS in pts submitted to rituximab therapy before HSCT, although without statistical signifi cance (p=0.06). Conclusion: Our data confi rm that RIC-HSCT has the potential to induce long term remissions and eventually cure some pts with refractory or relapsed FL. CR at the time and after HSCT was an important predictive factor for the outcome.

Feasibility and early outcome of clofarabine induction followed by allogeneic transplant using haploidentical donors in relapsed/refractory lymphoma J. Tischer (1), S. Fritsch (1) , D. Prevalsek (1) , N. Engel (1) , T. Herold (1) , C. Schulz (1), A.K. Zoellner (1) , V. Buecklein (1) , R. Reibke (1) , W. Hill (1), G. Ledderose (1) , M. Dreyling (1) , A. Hausmann (2) (1)LMU-Klinikum der Universität München -Großhadern (Munich, DE) ; DE) Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a valuable treatment option for patients (pts) with advanced or refractory aggressive lymphoma. However, outcome in non-remission pts is still poor. Therefore, we set out to evaluate the feasibility of a protocol using the concept of sequential therapy with clofarabine as induction chemotherapy followed by haploidentical HSCT. Methods: Since March 2010 ten adult pts (6 male, median age: 56 years) with MCL (n=5), transformed CLL (n=2) or DLCL (n=3) were included. All pts were classifi ed as high risk according to the age-adjusted IPI. Four pts were primary refractory and 6 pts had relapsed after autologous HSCT. The mean number of prior chemotherapy regimens was fi ve. After a rituximab (n=8) or ofatumumab (n=2) containing salvage chemotherapy prior to HSCT a partial remission (PR) or stable disease was achieved in 3 and 2 pts, respectively. Five pts had progressive disease. Chemotherapy with clofarabine (5x30 mg/m2 IV) was followed -after three days of rest-by a reduced intensity conditioning (RIC) regimen consisting of fl udarabin/cyclophosphamide (Flu/Cy) plus either melphalan 110 mg/m2 IV (n=9) or TBI 2 Gy (n=1). High-dose Cy post-transplant was applied for post-grafting immuno-suppression. Results: Neutrophil and platelet engraftment was achieved in 9/10 and 8/10 pts within a median of 21 and 31 days. No primary graft rejection and only one early death were observed. Complete remission (n=4) and PR (n=3) could be induced by day +100 in 7/10 pts. Full donor chimerism by day +100 was achieved in 7/10 pts. After a median follow up of 6 month (range 3-27) the cumulative incidence of non-relapse mortality at day +100 was 10%. Rate of grade II-IV acute GvHD was 40%. Exceptionally mild chronic GVHD was seen in 4 pts. Three pts died from infection (n=1), toxicity (n=1) or relapse (n=1). Accordingly, overall survival and progression free survival after one year from haploidentical transplantation were both 70%. Regimen related grade III-IV toxicity (non-hematologic) was reported in 5/10 pts with mucositis and transient elevation of transaminases as the most common seen toxicities. Conclusion: Haploidentical HSCT following initial induction with clofarabine, RIC and high-dose Cy post-transplant is feasible with an acceptable toxicity profi le in patients with relapsed/refractory aggressive lymphoma. Our preliminary results are promising, but long-term results are required.

Allogeneic stem cell transplantation for lymphoma: role of conditioning with treosulfan and fl udarabine R. Niittyvuopio, J. Heiskanen, V. Lindstrom, E. Juvonen, A. Nihtinen, H. Uotinen, T. Ruutu, L. Volin Helsinki University Central Hospital (Helsinki, FI) The use of allogeneic stem cell transplantation (SCT) in lymphoma has been limited by high transplant-related mortality (TRM) in heavily pre-treated patients. However, the potentially curative graft-versus-lymphoma eff ect is well established, and TRM can be reduced with less toxic conditioning. We report our single centre experience of 35 patients treated with allogeneic SCT using treosulfan-based conditioning since the year 2001, showing low TRM and a good relapse-free survival (RFS). The median age of the patients was 47 (range 19-63) years. The diagnoses were mantle cell lymphoma 9, Hodgkin's disease 8, follicular lymphoma 7, diffuse large B-cell lymphoma 6, T-cell lymphoma 3, Waldenstrom's disease 1, and small B-cell lymphoma 1. The conditioning consisted of treosulfan 42 g/m 2 (10 patients) or 30 -36 g/m 2 (25 patients)We present the analysis of allogeneic stem cell transplantation (allo-SCT) in Hodgkin´s lymphoma which summarizes the results of all transplant centers in the Czech Republic. In the period from june 1998 to june 2011, overall 45 patients (pts) were transplanted; 23 men / 22 women, median age was 31.5 years (range; 10.5-56.2) . As a graft, PBPC were used in 37 (82%) pts, thirty-six (80%) pts were transplanted after RIC, thirty-one pts (70%) were transplanted from an unrelated donor. Thirty-nine pts (87%) were previously treated with autologous transplant. At time of allo-SCT, twenty-one (47%) pts had chemoresistant disease. The median time from diagnosis to allo-SCT was 44 months ( range; 14-144), the majority (93%) of allo-SCT were performed after 2000. Median follow-up was 17 months (range; 1-125) for all patients and 70 months (range;14-125) for survivors. All but one patient engrafted, the median time to neutrophils engraftment was 15 days (range; 8-31). Acute GVHD grade 1-2 developed in 7 cases, grade 3-4 in 7 cases. Overall incidence was 33%. Thirty-seven patients could be evaluated for chronic GVHD and its incidence was 49% (18 patients; eight had extensive and ten had limited form). Twenty-fi ve (56%) patients relapsed after a median time of 13 months (range; 3-50), ten out of them were treated with DLI. At the last follow-up, fi fteen pts (33%) were alive, thirty pts (67%) died: seven (16%) of NRM and 23 (51%) of disease progression. Estimated 3-and 5-years OS and PFS were 42% and 30% and 23% and 16%, respectively. Median survival was 22 months. Cumulative incidence of NRM was 7%, 21% and 21% at 100 days, 3 years and 5 years resp. Cumulative incidence of relapse at 1 year, 3 years and 5 years was 32%, 69% and 79% resp. OS after relapse was signifi cantly better for pts receiving DLI (median survival 29 vs 6,5 months, p= 0.048), moreover OS of relapsed pts treated with DLI was comparable with pts who never relapsed. Conclusion: Despite the fact that this is an unfavourable prognostic group of heavily pretreated patients, a third of them are longterm survivors. Undoubtedly, the main problem of allo-SCT failure is disease recurrence. Optimal timing, and the eff ort to achieve maximum of GVL eff ect using DLI provide the possibilities of further improvement of allo-SCT outcomes. The study was supported by IGA of the Czech Ministry of Health -grant No. NT 11299.

Granulocyte-colony stimulating factors (G-CSFs) are commonly used to accelerate bone marrow recovery and reduce the duration of severe neutropenia after chemotherapy. Some metaanalysis demonstrate that pegylated fi lgrastim is more eff ective than fi lgrastim in reducing chemotherapy induced neutropenia. The aim of this study was to evaluate the impact of pegfi lgrastim (PEG-G-CSF) administration on haematopoietic reconstitution and supportive care in patients with lymphoproliferative malignancies after autologous peripheral stem cell transplantation (autoPBSCT). We analyzed 139 patients including 61 with multiple myeloma, 38 with Hodgkin's lymphoma and 40 with non-Hodgkin's lymohoma. Patients received a single 6 mg dose of PEG-G-CSF on day +1 after transplantation (n=39) or fi lgrastim (n=70) at a dose 5 μg/kg/d on day +1 posttransplant and continued to an absolute neutrophil count (ANC)>1,5x109/L. The median consumption of fi lgrastim vials a 0,3 mg was 19 (range 1-30). The control group consisted of 30 patients who did not receive G-CSF. The median time to ANC>0,5x109/L was signifi cantly shorter in PEG-G-CSF group than in the control group (10 vs 15 days, p<0,0001) and also between patients receiving fi lgrastim and control (11 vs 15, p<0,0001). We did not fi nd diff erences in time to ANC recovery between PEG-G-CSF and fi lgrastim groups. There was also diff erence in the median time to platelet engraftment (PLT>20 x 109/L), which was signifi cantly shorter in control compared to groups receiving fi lgrastim (12 vs 13 days, p=0,04). The median number of platelet transfusions in PEG-G-CSF, fi lgrastim and control group was 12 vs 15 vs 5 units, respectively. The diff erence was signifi cant between PEG-G-CSF and control (p=0,001) and between fi lgrastim and control (p=0,001). No statistical diff erences in the number of red blood cells transfusions and duration of febrile neutropenia were seen between all groups. The length of hospitalization was signifi cantly shorter in patients receiving PEG-G-CSF compared to fi lgrastim (30 vs 37 days, p<0,0001) but longer relative to control group (30 vs 28 days, p=0,047). PEG-G-CSF signifi cantly reduce the duration of severe neutropenia but has no impact on the time of hospitalization in patients with lymphoproliferative malignancies after autoPBSCT. According to the median number of G-CSF vials used, PEG-G-CSF administration may be more cost eff ective compared to fi lgrastim (1 vs 19 vials). Our study support some previous observations that use of G-CSF can delay platelets recovery. (1) Hematologic malignancy currently represents the main indication for HSCT. Clearly, autologous and allogeneic HSCT are established therapies in many of hematologic malignancies. High dose therapy (HDT) supported by autologous HSCT are the preferred choice for relapsed/refractory Hodgkin lymphoma. Between Jan 2004 and Nov 2011, 68 patients with diagnosis of Hodgkin's lymphoma (HD) underwent autologous peripheral blood stem cell transplantation in our center in Shiraz University of with medical sciences. Patients were treated by intensive chemotherapy followed by reinfusion of non-cryopreserved autologous stem cells. The pretransplant conditioning chemotherapy regimen was CEAM (lomustin150-200mg/m2, etoposide 1000mg/ m2, cytarabine 1000-1200mg/m2 and melphalan 140mg/m2). All apheresis products were kept in a conventional blood bank refrigerator at 4°C for 3 days before infusion. During 7 years 68 patients with relapsed or refractory HD, underwent autologous peripheral blood stem cell transplantation. Median age of patients was 28 years (range; 16-50). The median time to platelet count > 20×109/L was 15 days (range; 9-35). The median time to ANC > 0.5×109/L was 12 days (range; 8-27). All patients have engrafted and there were not graft failure in this study group. 100 days transplant related mortality rate was 2.9%. The mean number of MNCs collected and transfused was 3.8 × 108/kg (range, 1.9 × 108-9 × 108/kg). All patients in our study showed hematopoietic engraftment after receiving the CEAM conditioning regimen, with neutrophil and platelet recovery times comparable to those reported for most carmustine-based regimens.Our data refl ects the important role of HDT followed by HSCT in improvement of outcome for a Hodgkin's lymphoma patients of in our center. We concluded high dose therapy with this modifi ed conditioning regimen rescued with non-cryopreserved auto SCT is safe and eff ective method that is feasible in our patients. The eff ectiveness of high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) as a frontline treatment in peripheral T cell lymphomas (PTCLs) is still unclear. We retrospectively investigated the clinical outcomes of HDT/ASCT as an intensifying frontline treatment in 31 patients with newly diagnosed PTCLs. The conditioning regimen of HDT/ASCT consisted of busulfan, cyclophosphamide, and etoposide (BuCyE). At diagnosis, fi ve (16.1%) patients were classifi ed as high risk according to the prognostic index for PTCL (PIT). The disease status of the patients before HDT/ASCT consisted of 23 patients (74.2%) with complete response (CR) and eight patients (25.8%) with partial response (PR). Six (75%) out of eight patients with PR at pretransplantation were improved in terms of the response to CR after HDT/ASCT. At a median follow-up of 32.4 months, the three-year probability of overall survival (OS) and progression-free survival (PFS) was 64.5 ± 8.6%. Transplant-related mortality occurred in three patients (9.7%), due to septic shock, hemorrhage and delayed pneumonia respectively. Bone marrow involvement of PTCL at diagnosis was a poor prognostic factor for OS. In conclusion, frontline HDT/ASCT with a conditioning regimen of BuCyE may be an eff ective and tolerable intensifying therapeutic option to improve outcomes in patients with PTCLs.

Disease status evaluated by PET before allogeneic reduced-intensity stem cell transplantation in patients with lymphoma is a strong predictor of overall and progression-free survival G. Martin, L. Yañez, A. Bermudez, C. Richard, E. Conde, A. Insunza Hospital Marques de Valdecilla (Santander, ES) Introduction: Allogeneic stem cell transplantation (SCT) is an alternative therapy for patients with relapsed lymphoma, but the role of positron emission tomography (PET) scanning before allogeneic SCT is uncertain. Objective: To investigate whether disease status evaluated by PET before reduced intensity allogeneic SCT predicted outcome. Patients and Methods: We retrospectively analyzed 33 patients transplanted between 2004 and June 2012. Twenty-two were male and median age was 46 years (IQL, 36-55). The diagnoses were Hodgkin lymphoma (n=15), diff use large B-cell lymphoma (n=5), follicular lymphoma (n=3), transformed follicular lymphoma (n=3), mantle cell lymphoma (n=3), peripheral T-cell lymphoma (n=3) and angioimmunoblastic lymphoma (n=1). Eighteen patients underwent HLA-matched sibling donor transplantation, 8 matched unrelated donor transplantation, 6 mismatched unrelated donor transplantation and 1 haploidentical transplantation. Except in 3 patients, fl udarabine (160 mg/m2) and melfalan (70 mg/m2) was used as the conditioning regimen. Controlled disease was defi ned by a negative PET or a unique area of weakly human cytomegalovirus immediate early promoter. FACS-sorted and cloned GFP+ cells displayed a constitutive and specifi c downregulation of HSP105, as the expression of the two major molecular chaperones, HSP90 and HSP70, was not aff ected. Despite no increase in cell death, the two best-silenced clones showed a signifi cant reduction in their in vitro proliferation rate due to a signifi cant extension in their doubling time (P= 0.04, < 0.001, and P= 0.03, 0.001). Accordingly, the tumour-forming capability of these clones, subcutaneously injected into severe combined immunodefi cient mice, was signifi cantly hampered compared with that of the MOCK-infected cells (P= 0.0009, 0.019), to the point of the complete loss of tumorigenicity when 10 4 HSP105silenced cells were inoculated (Fig 1) . Western blot analysis of 6 silenced clones showed that BCL-6 and c-Myc were both downmodulated in function of HSP105 knockdown levels. In two diff erent aggressive B-NHL cell lines, HSP105 co-immunoprecipitated with BCL-6 and c-Myc, suggesting that it may favour the stabilization of these oncoproteins. Along this line, immunohistochemistry analysis of 50 primary human aggressive B-NHLs revealed that HSP105 expression is signifi cantly higher in c-Myc+ Burkitt's (P= 0.0264) or BCL-6+ diff use large B-cell lymphomas (P= 0.0068) than in other aggressive histotypes that do not overexpress these oncoproteins. In addition, we found a signifi cant positive correlation between HSP105 and BCL-6 expression in these cases (Pearson r= 0.8537, P< 0.0001). Conclusions: Overall, these results point to HSP105 as a per se non-oncogenic molecule that can contributes to lymphomagenesis by fostering the expression of key oncoproteins. They equally provide the rationale for developing HSP105 inhibitors as a new strategy to improve the treatment of aggressive B-NHLs.

High-dose chemotherapy and autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma: long term follow-up and interim evaluation of bone marrow transplant centres of Tuscany, Italy

High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) is an accepted therapy for most patients with relapsed Hodgkin lymphoma that is not controlled by conventional multiagent chemotherapy and can result in long-term progression-free survival (PFS) in a signifi cant proportion of patients. We are presenting the interim experience of the three Bone Marrow Transplant Centers of Tuscany, Italy (University of Florence, University of Pisa and University of Siena) in the effi cacy of HD-ASCT for relapsed and refractory Hodgkin lymphoma patients. Data are updated at the time of submission and Siena's data are actually under evaluation.[P1181]

High-dose chemotherapy BEAM followed by autologous peripheral stem cell transplantation in Hodgkin's lymphoma in chemo-sensitive relapse: no signifi cant diff erence in longterm outcome for patients autotransplanted in fi rst relapse or subsequent relapses A. Ibrahim (1), M. El-Saifi (2), G. Nsouli (2), R. Jalloul (2) , N. Droubi (2) , F. Farhat (2) , M. Haydar (2) , I. Chehadeh (2) , W. Mokaddem (2), H. Sadek (2) High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is considered the gold standard of care for patients (pts) with Hodgkin's lymphoma (HL) in chemosensitive relapse. In spite of this consideration, the pts autotransplanted after multiple relapses have poorer long-term outcome than those autotransplanted after a fi rst chemo-sensitive relapse. Between June, 2000 and June 2011, 35 consecutive pts with HL in chemo-sensitive relapse underwent ASCT. Median age at ASCT was 33 years (y) (18-57). There were 26 males and 9 females. All the pts received a fi rst line chemotherapy (CT) which was combined to radiotherapy in 15 pts. First line CT was ABVD in 33 pts, BEA-COPP in one patient (pt), and MOPP in one pt. Among the 35 pts, 27 underwent ASCT in fi rst chemo-sensitive relapse (2ndCR/PR) after one line of salvage CT which was ICE in 25 pts and DHAP in 2pts. Eight pts underwent ASCT after subsequent chemosensitive relapses including 7 after 2 relapses (in 3rd CR/PR) and one after 3 relapses (in 4th PR). High-dose CT consisted in BEAM protocol (carmustine, etoposide, cytarabine, melphalan). Source of transplant was peripheral stem cells in all the pts. Median follow-up was 40 months. Overall survival (OS) and disease-free survival (DFS) rates at 10y were 60% and 57%, respectively. There was no signifi cant diff erence in DFS and OS at 10y between the two groups of pts undergoing ASCT after a fi rst and subsequent sensitive relapses. Disease-free survival rates at 10y were 55.4% and 55.6% for pts autotransplanted in fi rst and subsequent sensitive relapses, respectively (p=0.933) (fi g 1), and OS rates at 10y were 58% and 66%, respectively (p=0.51)(fi g2).This study conducted in a developing country showed that if ASCT for HL in sensitive relapse is not feasible after the fi rst relapse for non medical reason, it could be performed after subsequent sensitive relapses with no diff erence in long-term outcome.

Autologous stem cell transplantation for primary refractory and relapsed Hodgkin's lymphoma patients sensitive to salvage therapy: necessity of obtaining complete remission before autologous transplant for signifi cantly better longterm outcomes A. Ibrahim, M. El-Saifi , O. Chamdine, G. Nsouli, J. Makdissi, R. Jalloul, L. Khayat, M. Haïdar, S. Faddoul, F. Kamar, T. Jisr, A. Mugharbil Makassed Hospital (Beirut, LB) Between January, 2000 and December, 2011, 53 consecutive patients (pts) with Hodgkin's lymphoma (HL) sensitive to salvage therapy after a primary refractory status (18pts) or after relapse (35 pts) underwent high-dose chemotherapy (HDCT) BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem cell transplantation (ASCT). Median age at ASCT was 33 years (y) (18-57). There were 35 males and 18 females. Among the 18 S434 primary refractory pts, 14 received ABVD alone and 4 pts ABVD combined to radiation therapy (RP), as primary therapy. Fourteen pts responded after one line and 4 pts needed ≥ 2 lines of salvage therapy to respond. Ten of the 18 pts were autotransplanted in complete remission (CR) and 8 pts in partial remission (PR). Among the 35 pts autotransplanted in sensitive relapse, 20 pts received, as primary therapy, chemotherapy alone (ABVD: 19 pts, BEACOPP: 1 pt), and 15pts received chemotherapy (ABVD: 14 pts, MOPP: 1pt) combined to RP. Of these 35 pts, 21 were autotransplanted in CR and 14 pts in PR. Among the all 53 pts, 31 underwent ASCT in CR and 22 pts in PR. Evaluation of response to salvage therapy before ASCT was performed by PET scan in 32 pts. Source of stem cells were peripheral blood in 51 pts and bone marrow in 2 pts. With a median follow-up of 36 months (m) , overall survival (OS) and disease-free survival (DFS) rates at 10y were 62% and 58%, respectively, for the 53 pts. Concerning the 18 pts with primary refractory disease, OS and DFS rates at 10y were 60% and 59%, respectively. Concerning the 35 pts with sensitive relapse, OS and DFS rates at 10y were 60% and 57%, respectively. There was a signifi cant diff erence in long-term outcome between the two groups of pts autotransplanted in CR and those autotransplanted in PR. Overall survival rates at 10y for the pts autotransplanted in CR versus in PR were 86% and 31%, respectively (p< 0.001). Disease-free survival rates at 10y for the pts autotransplanted in CR versus in PR were 76.5% and 28%, respectively (p< 0.001). (4), S. Kim (5), J. Kim (6) , B. Park (7) The addition of rituximab to CHOP has resulted in signifi cant improvement in the overall survival (OS) of CD20+ diff use large B cell lymphoma (DLBCL). However, OS and progression-free survival (PFS) in patients with high-intermediate or high IPI DLBCL was not satisfactory, and the upfront autologous stem cell transplantation (ASCT) was reported to improve the survival in these patients subset. Therefore, we retrospectively evaluated the survival rates in patients with DLBCL with CD20+, who were treated with R-CHOP followed by ASCT. We analyzed 48 DLBCL patients who underwent an ASCT, reported to the Korean Blood and Marrow Transplant Registry between 2005 and 2011 by 12 centers. The patients treated with the upfront ASCT had either stage II with bulky disease (4.2%) or stage III/IV disease (95.8%). Patients characteristics at diagnosis: median age, 48 years(range, 23-66); male, 60.4%; high LDH, 77.1%; high-intermediate or high risk by IPI score and age-adjusted IPI score, 64.6% and 79.2%, respectively. Patients characteristics at the time of ASCT: 81.3% of patients received ≥6 cycles of R-CHOP; response to R-CHOP, 77.1% CR and 22.9% PR; 12.5% of patients received involved fi eld radiotherapy prior to ASCT for bulky disease or residual lymphoma; median time from diagnosis to ASCT was 7.85 months (range, 4.4-16.1) . Median CD34+ cell count infused for ASCT was 5.0x106/kg (range, 1.10-50.47). Median time to ANC ≥500/μL and platelet ≥20,000/μL without platelet transfusion were 12 days (range, 8-25) and 18 days(range, 2-559) posttransplant, respectively. One patient died from transplantation, and lymphoma relapsed after ASCT in 11 patients. Median followup period from diagnosis was 37.4 months (range, 6.3-88.5). 3-year estimates of PFS, OS and relapse from diagnosis were 72.6±6.8%, 82.7±6.0% and 25.8±6.8%, respectively. 5-year estimates of PFS, OS and relapse from diagnosis were 72.6±6,8%, 74.4±9.5% and 25.8±6.8%, respectively. 3-year estimates of PFS and OS according to IPI score were not signifi cantly diff erent among 4 risk groups (P=0.688 and P=0.949, respectively). 3-year estimates of PFS and OS according to aaIPI score were not signifi cantly diff erent among 4 risk groups, either (P=0.890 and P=0.417, respectively). The upfront ASCT following R-CHOP induction therapy may improve survival for patients with advanced high risk DLBCL. Prospective evaluation of the treatment outcome of R-CHOP followed by ASCT is warranted for high risk DLBCL on a large scale. Background: Diff use large B-cell lymphomas (DLBCL) account approximately 30% of non-Hodgkin lymphomas (NHL). Their curse is aggressive but the cure is the only option that we should look for. The role of high-dose therapy followed by autologous stem cell transplantation (HDT/ASCT) in fi rst complete remission (CR1) is not clearly established, although several groups propose this alternative in young and fi t patients (pt) with intermediate/high or high risk features. We show our experience about HDT/ASCT in a cohort of DLBCL pt in our hospital. Patients and methods: We analyzed retrospectively 61 consecutive adult pt with DLBCL transplanted for a period of 16 years (y), (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . They had a median age of 49 y [18-69 y]. Thirty-six pt were transplanted in CR1, 12 pt in second or more complete remission (CR2), 10 pt in partial remission (PR) and 3 pt in refractory or progressive disease (Rf/Pg). Pt were risk-stratifi ed using International Prognosis Index (IPI). There were 26 extranodal DLBCL (42%), and 20 pt (32,8%) did not received rituximab-based therapies before HDT/ASCT. All of conditioning therapies were non-radiotherapy contained (i.e. BEAC and BEAM). Results: After a median follow-up time of near 5 y, median overall survival (OS) and relapse-free survival (RFS) was not reached. Nineteen pt (31%) dead: relapsed or progressive lymphoma in 13 pt (21%), transplant-related mortality (TRM) in 1 (1,6%) and other causes in 5. We did not observe signifi cant diff erences in OS or RFS rate considering regimens before ASCT (rituximab-contained therapies or not), site (nodal or extranodal), or response before ASCT (CR1 or PR/CR2) ( Figure 1 ). In addition, OS rate were higher considering IPI (low/intermediate-low or intermediate-high/high, p=0,021). Four pt were diagnosed of epithelial neoplasm in a median time after ASCT of 4,5 y [2-13y].

Discussion: Our results are based in a series from a single centre during long-term follow-up. HDT/ASCT in DLBCL is a non-toxic proceeding with low TRM in this series. ASCT in CR2 pt showed the same OS and RFS rates than CR1, so these results suggest that proceeding might be delayed until then. Otherwise, no signifi cant diff erences were observed in RFS rates between pt with lower or higher IPI. We think that pt with lower IPI showed other risk fi gures, as bulky disease, relapsed lymphoma or higher purely extranodal lymphoma rate. These reasons were considered in clinical decisions to indicate HDT/ASCT in front-line therapy in these pt.

Prognostic factors, clinical outcome and survival of patients with relapsed or refractory Hodgkin's lymphoma after autologous stem cell transplantation F. Gaudio, D. Pastore, M. Delia, T. Perrone, P. Curci, F.E. Laddaga, G. Specchia University of Bari (Bari, IT) No standard treatment exists for relapsed or refractory classical Hodgkin lymphoma (cHL) following autologous stem cell transplant (ASCT) failure, and prognosis is poor. The natural history of recurrent HL in this setting ranges from a rapidly progressive to a more indolent course. We performed a retrospective analysis of 25 adult patients (15 females/10 males) with cHL relapse/progression after ASCT in order to analyze prognostic factors, response rate and survival. Disease status at transplant was complete remission in 7 patients (28%), sensitive disease in 14 (56%), and refractory disease in 4 (16 %). Median time from ASCT to relapse was 7 months (range 0.5-72), and 44% of the patients relapsed <6 months after ASCT; 12 patients (48%) had stage 3-4 at relapse/progression. Forty percent of the patients had B symptoms, 8% bulky disease and 56% extranodal involvement. Treatment following relapse/progression consisted of the standard BEACOPP regimen in 11 patients (44%), 2nd ASCT in 5 (20%), and Bendamustine in 9 (36%). Results: Overall response rate was 64%, including 36% complete remission and 28% partial response. Thirty-four percent experienced progression and 12% had stable disease. No diff erence in response rate was found between the three treatment regimens. Factors aff ecting the response were: refractory disease, early relapse (<6 months) and more than 3 previous chemotherapy lines. Seven patients (5 in complete remission and 2 in partial remission), underwent non myeloablative allogeneic stem cell transplant (NMT) and 6 of them are still in complete remission at a median follow-up of 11 months (range 3-60). After a median follow-up of 39 months (range 1-80), PFS at 3 years from relapse/progression after ASCT was 18% and OS was 40%. To date, 15 patients (60%) are alive, nine (29%) still in complete remission (67% of them underwent NMT). All patients treated with BEACOPP and with 2nd ASCT experienced hematologic toxicity (WHO 3-4) and two deaths occurred due to septic shock. In patients treated with bendamustine, drugrelated toxicity WHO 3-4 grade was documented in 2/9 (22%) of patients, with no toxic death. Conclusions: Patients with cHL who fail ASCT have a very poor prognosis and the ultimate goal of treatment should be to refer them for NMT. New agents, including monoclonal antibody are useful in order to reduce disease burden before allo-SCT. Hodgkin lymphoma (HLy) is one of the frequently and potentially curable hematological neoplasm, most patients (pts) are curable with chemo -and radiotherapy but the rests achieve only partial remission or have relapse after treatment. High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AutoHCT) can off er the chance to obtain long-term survival for some patients with refractory form of HLy. In Department of Hematology and BMT Medical University of Silesia until November 2012, 390 AutoHCT in HLy patients were performed. Most of Chronic graft versus host disease (cGvHD) remains a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). A number of pre-clinical and clinical studies support a role for B cell involvement in the pathogenesis of cGvHD. A unique population of CD21-CD20hiCD27-B cells with features of exhaustion was recently described in patients with chronic HIV viremia. In this study we describe a similar population of CD21-B cells in the peripheral blood of cGVHD patients. Using multicolor fl ow cytometry we performed an extensive analysis of B phenotype and function in 16 patients with active cGvHD compared to 14 age-matched HSCT recipients without clinical evidence of cGVHD and 11 healthy controls. Chronic GvHD patients had signifi cantly higher frequencies of CD21-B cells in the PB compared with patients without cGvHD and HC (median 12.2% vs. 2.12% vs. 3%; p<0.01). Multi-parameter fl ow cytometry revealed that the majority of these cells were CD10-CD27-CD21 CD20hi, reminiscent of the recently described exhausted B cells in HIV patients with chronic viremia. We did not observe increased transitional (CD24hi-CD38hi-CD19+) or immature B cells (CD10+CD21-CD27-CD19+) in cGvHD patients compared with patients with no cGVHD (median transitional 3.4% vs. 6.3%; p=0.08) and [median immature (out of total CD21-B cells) 3.15 vs.9.34%; p=0.045)]. As reported in chronic HIV viremia, expanded CD21-B cells in cGVHD patients also expressed higher inhibitory receptors namely FCRL4, CD22 and CD85J, chemokine receptors CD11c, CXCR3 and lower CD62L and CCR7 compared with naïve (CD27-CD21+CD19+) and classical memory (CD27+CD21+CD19+) B cells. Moreover, B cells in patients with cGVHD had a lower proliferative potential following B-cell receptor crosslinking compared with B cells from patients with no GvHD or HC, a feature of exhaustion associated with high expression of inhibitory receptors. The frequencies of CD21-B cell were predictive for the severity of cGVHD with an OR for severe, moderate and mild cGVHD of 1.31 (p=0.001), 1.22 (p=0.005) and 1.17 (p=0.02) respectively. In multivariate analysis, previous history of aGvHD (p=0.01) and CD21-B cell frequencies > 5% (p=0.001) were the only variables found to be independently associated with cGVHD. These data suggest that CD21-B cells may play a role in the pathogenesis of cGVHD and could be used as as a marker of disease severity.

Prognostic factors for survival of graft-versus-host disease occurring later than 100 days after allogeneic stem cell transplantation F. Ayuk, T. Zabelina, R. Veit, L. Bussmann, C. Wolschke, H. Lellek, U. Bacher, A.R. Zander, N. Kröger University Medical Center Hamburg (Hamburg, DE) Introduction: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality after allogeneic stem cell transplantation (allo-SCT). Only few studies addressing survival of patients who developed cGVHD used the recently introduced NIH consensus criteria. Methods: We retrospectively analysed 495 consecutive adult patients who underwent allo-SCT at our center between 2005 and 2009. GVHD occurring ≥ 100 days after allo-SCT was classifi ed as late acute or chronic GvHD. cGVHD was retrospectively categorized according to NIH consensus criteria and considered progressive onset if diagnosed ≤ 2 weeks of end of steroid treatment for aGVHD or quiescent onset if diagnosed > 2 weeks after end of steroid treatment for aGVHD. GVHD was categorized as overlap syndrome if cGVHD and acute gastrointestinal GVHD were present. Survival was estimated from time of diagnosis of cGVHD. Results: In all 412 patients were evaluable for GVHD ≥ 100 days after allo-SCT of whom 179 (43%) developed no GVHD, 32 (8%) developed late acute GVHD, 182 (44%) classic cGVHD and 19 (5%) overlap syndrome. Of the 201 patients with cGVHD 66 (33%) were categorized de novo onset, 123 (61%) quiescent onset and 12 (6%) progressive onset. Late acute GVHD was associated with worse 3 yr. survival (38%) compared to classic cGVHD (73%) and overlap syndrome (76%) p < 0.001. In patients with cGVHD platelet counts less than 100.000/ul at time of cGVHD diagnosis was associated with worse 3 year survival 51% vs. 80% (p< 0.001). 3 year survival according to NIH overall stage was 58% for severe, 69% for moderate and 79% for mild cGVHD (p= 0.174). After excluding patients with myeloma, low IgG level at diagnosis also negatively impacted survival with 3 year survival rates of 74% for normal, 79% for decreased and 47% (7 months) for increased IgG level (p= 0.04). In multivariate analysis only platelet counts at diagnosis (RR = 3.24; 95% CI = 1.81-5.80; p< 0.001) and patient age (RR = 1.03; 95% CI = 1.01-1.06; p= 0.01) signifi cantly impacted survival of patients with cGVHD. Conclusion: Our results confi rm the negative prognostic impact of low platelet counts and late acute GVHD and indicate that these are still the parameters with strongest impact and highest consistency even in the era of the NIH classifi cation. We suggest a prognostic role of serum IgG level that merits further investigation. S438 P1193 Successful use of autologous platelet rich plasma (PRP) in the management of ocular chronic graft-versus-host disease (GVHD) F. Zallio (1) Purpose: Allogeneic (allo)-SCT represents a potentially curative treatment option for many hematological malignancies; the widespread use of this procedure has, however, a number of important limitations. Ocular chronic graft-versus-host disease (cGVHD) is one of the most frequent complications after allo-SCT and is often associated with signifi cant morbidity and reduced quality of life. The main therapeutic aim in the management of ocular cGVHD is the treatment of infl ammation and dryness in order to decrease patients' symptoms and to maintain ocular integrity and function. Unfortunately conventional medical treatments, represented by systemic immunosuppressive and local therapies (mainly artifi cial tears and corticosteroids), off er unsatisfactory results. Methods: We investigated the safety and effi cacy of autologous platelet rich plasma (PRP) to treat ocular cGVHD unresponsive to standard medications. From 2007 to 2012 we treated with PRP eye drops 18 patients who underwent to allogeneic SCT and aff ected by ocular GVHD refractory to local steroid therapy. PRP eye drops were used six times/day for one year. PRP eye drops are prepared under laminar fl ow hood, in sterile single dose, stored at -20°C. Patients were evaluated through subjective (symptoms pointed out in a self-assessment questionnaire) and objective tests (Schirmer test, FBUT, BVA, anterior segment score, fl uorescein score, lissamine score) by the same ophthalmologist at time 0, 30, 180 and 365. Results: Patients were defi ned as "responders" if they had showed at least one sign: at 30 days 86% and 57% of the patients had an improvement of symptoms (S) and ocular signs (T), respectively and 0% had corneal damage; these response was kept on throughout the treatment period: in fact after one year of treatment 86% and 43% continued to have an amelioration of their symptoms (S) and ocular signs (T), respectively, while 7% had corneal damage. Conclusions: Therapy with autologous PRP eye drops is easy to use, safe and low cost; this procedure shows an improvement of symptoms and corneal damage already since 30 days of treatment, with a progressive improvement in quality of life and return to daily activities; in addition it is worthwhile to demonstrate that the effi cacy is maintained throughout the year of treatment. Therefore autologous PRP eye drops could represent a valid alternative option to conventional therapy in the management of ocular cGVHD. Introduction: Graft-versus-host disease (GVHD) is the leading complication of allogeneic hematopoietic stem cell transplantation (HSCT) and causes signifi cant morbidity and mortality. CD4+ T-cells play a critical role in mediating GVHD, and much eff ort has been devoted to studying the eff ect of CD4+ T-cells during the pathophysiology process of GVHD. Even though just accounting for 5% of the total CD4+ T-cell population, the most promising candidates are naturally occurring CD4+CD25+ regulatory T cells (Tregs), which are one of the regulators of immune responses. TH17 is a newly identifi ed T-cell lineage that secretes IL-17, a proinfl ammatory cytokine. However, the functional role of TH17 cells in the development of GVHD has not been well characterized in humans. The aim of our study was to characterize the expression of Treg (FOXP3) and TH17-related (RORγt) genes in peripheral blood of patients undergoing HSCT and correlate them with the development of GVHD in allogeneic HSCT.Patients and Methods: Samples were collected from the peripheral blood of 50 patients before and after HSCT and at the time of GVHD onset. Thirty patients were diagnosed as acute leukemia/myelodysplastic syndrome, eleven as chronic myeloid leukemia and ten with lymphomas. Seven healthy donors were used as controls. All patients received an HLA-identical related donor graft.Expression of FOXP3 and RORγt were assessed by Real-Time quantitative PCR (qPCR) using the 7500 Fast Real Time PCR System (Applied Biosystems), by Taqman method. Results: Median age for the 50 analyzed patients was 36 years-old (range: 17-60), 52% were female. 50% had GVHD, with an average onset of 39 days after HSCT for acute GVHD (range: 12-93) and 182 days for chronic . No signifi cant association was observed between FOXP3 expression and patients with or without GVHD. On the other hand, RORγt showed significantly higher expression in patients with chronic GVHD compared to samples before HSCT (p<0.0001), without GVHD (p<0.0001) and acute GVHD (p=0.0006). Both FOXP3 and RORγt showed signifi cant statistical decreased expression in patients compared to healthy controls, except for RORγt expression in patients with chronic GVHD (p=NS). Conclusion: RORγt showed signifi cantly higher expression in patients with chronic GVHD compared to samples before HSCT, without GVHD and acute GVHD, suggesting that a proinfl ammatory state is involved in chronic GVHD pathophysiology.

Comparison of the Cellex™ and UVAR XTS™ closed system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease R. Whittle, H. Denney, M. Foster, T. Maher, R. Goodgrove, C. Swift, L. Robertson, F. Hammerton, J. Mayo, A. Alfred, P.C. Taylor Rotherham General Hospital (Rotherham, GB) Introduction: In 2008, Rotherham Foundation Trust became the fi rst UK hospital to utilise the Therakos Cellex TM integrated extracorporeal photopheresis (ECP) system for the treatment of chronic Graft versus-Host Disease (cGvHD). The device was designed to supersede the UVAR XTS TM , introduced in 1998. The newer device off ers simultaneous blood collection and return via continuous fl ow modality resulting in reduced extracorporeal volumes compared to single-needle confi guration. We and others have reported diff erences in the leucocyte harvests generated by the 2 devices. To examine whether the introduction of the Cel-lex™ device has impacted on clinical and steroid dose response we compared patients treated with either device. Methods: cGvHD patients treated either exclusively with the Cellex (n=50) or the XTS device (n=51) for a minimum period of 6 months, were included. Clinical assessment of organ involvement and then response was taken prior to ECP start and at 3,6 and 12 rates in our cohort. However, the Cellex device may off er shorter median in-treatment time for patients due to continuous fl ow technology.

The Impact of lung chronic GVHD on survival after cord blood transplantation S. Kato (1) Chronic graft-versus-host disease (cGVHD) is major cause of mortality and impairs patient's quality of life after allogeneic stem cell transplantation. Especially, the prognosis of patients suff ered from lung cGVHD is poor. Although incidence and severity of cGVHD after cord blood transplantation (CBT) is lower than those after bone marrow transplantation, impact of cGVHD on survival has not been analyzed enough in CBT. We have investigated the eff ects of cGVHD on outcomes of CBT. One-hundred-eighty adult patients with various hematological diseases underwent CBT after myeloablative conditioning containing 12Gy total body irradiation in the Institute of Medical Science, University of Tokyo between August 1998 and August 2012. Among them, we have analyzed 153 patients who survived more than 100 days after CBT. Eighty-six patients (56%) were categorized as standard risk (CR1,CR2,CML-CP,NHLCR-u,MDS-RA, MDS-RCMD, AA) and 67 (44%) were high risk(others)in disease status. All patients received single cord blood unit and acute GVHD prophylaxis with cyclosporine plus short-term methotrexate . Median age was 41(range:18-55years, median weight was 57(37-104) kg, median numbers of cryopreserved nucleated and CD34 positive cells were 2.5(1.3-3.7)×107/kg and 0.9(0.2-7.8)×105/kg, respectively. Variables considered in statistical analyses were age,weight,disease risk,total nucleated and CD34 positive cell dose, positivity of CMV, sex ,ABO and HLA mismatches.The impact of cGVHD was assessed as a time-dependent covariate using Cox models. Median follow up period of survivors (N=124) was 80(3-174) months after transplant.Cumulative incidence of extended type cGVHD (extGVHD) and lung cGVHD at 5 years after CBT were 34 (95% confi dence interval [CI], 26-41)and 20(95%CI, 13-26)%, respectively. The 5years probabilities of overall survival of patients with/without extGVHD and with/without lung GVHD were 73 (95% CI, 57-84) %/85 (95% CI, 75-91) % (p<0.05) and 67 (95% CI, 44-82) %/84 (95% CI, 76-90) % (p<0.05). The cumulative incidences of relapse between patients with/ without extGVHD or those of lung GVHD were similar. However, the 5-years cumulative incidences of non-relapse mortality (NRM) was higher in patients with both extGVHD [1 (0-3) %vs 18 (7-30)%; P<0.05] and lung GVHD [3 (0-5) % vs 25 (8-43)%; P<0.01]. It is suggested that patients developing lung GVHD had significantly poor survival due to increasing NRM. This is the fi rst analysis evaluating the impact of lung GVHD on patients after CBT. derived MP levels. However there was no signifi cant diff erence in plasma levels of MPs in patients with and without chronic GVHD. In a previous study by Pihusch R et al patients with chronic GVHD demonstrated seven fold increased levels of circulating platelet derived MPs. In that report blood samples were analysed when patients showed signs of chronic GVHD, however our patients were already on immunosupressive treatment for chronic GVHD. Infl ammatuary activity of chronic GVHD which might have been supressed by immunosupppressive treatment might explain the contoversial results. Acknowledgements: This study was supported by the research grant from the Turkish Society of Hematology. Objective: To analize BO as a severe complication of allo-SCT in order to identify risk factors, response to specifi c treatment and overall survival. Material And Methods: Retrospective study in 439 patients who have undergone allo-SCT between 2002 and 2012 in our centre. From the 350 analizable ones for chronic GVHD,41 were diagnosed of BO (11,7%): probable BO when they only showed clinical, radiologic and spirometric characteristics (19 patients), and proven BO if they also met histological criteria (22 patients). The median age at SCT was 52 and 22/19 were men/ women. Allo-SCT was related in 22 patients and unrelated in the other 19, with a missmatched donor in 10 cases (24%). Conditioning regimen was ablative in 28(68%), including radiotherapy in 7 cases, and 6 patients had undergone a SCT before. GVHD prophilaxis was based on calcioneurin inhibitors (Ciclosporine in 88%), with Methrotexate in 21patients and Micofenolate in 18.ATG was employed in 6 cases. Stem cell source was peripheral blood in 10 (24%). >grade1 acute GVHD was observed in 26 patients (63%), and 23 were good responders to corticosteroids (15CR and 8PR). Extensive chronic GVHD, basically mucocutaneous, was observed in 35 patients (85%) before the onset of BO. Median time from allo-SCT to chronic GVHD was 9 months and, from the 15 patients (37%) with pulmonary tests, the median FEV1 decrease was 35% [0-69]. Median time from chronic GVHD to BO was 2 months [0-31]. All patients were treated with bronchodilators and corticosteroids: 9 (22%) at high doses, and 21 (51%) in combination with another immunosupressor. 15 patients (37%) needed outpatient oxygen support. Results: Estimated overall survival (OS) was 56% at 2 years and 47% at 5 years,with a median follow-up of 19 months [8-115] from the diagnosis of BO. 22 patients are alive by now (54%), half of them without treatment and with ECOG0. 19 patients died, 12 of them (63%) because of BO. We found signifi cant diff erences in 2 variables: need of treatment (OS if independent: 100% at 2 years, and if dependent: 39%, p<0.001) and time to develop BO (OS if < 1 year: 48% at 2 years and if > 1year: 77%, p=0.008). Conclusions: BO related to GVHD involves high mortality in our series. Early BO onset and high dose corticosteroids/ immunosuppressive therapy seem to decrease the OS. Pulmonary tests could help with an earlier diagnosis of BO.

Background: Extracorporeal photopheresis (ECP) is recognised as a second-line treatment option for chronic graft-versus-host disease (GvHD). There are few reports of the eff ect of ECP on patients' quality of life. Objective: To prospectively assess the impact of ECP on healthrelated quality of life in patients with chronic GvHD using two validated questionnaires. Methods: We report a single-centre prospective study of patients undergoing fortnightly ECP. Response was assessed after 6 months of treatment using National Institutes for Health scoring criteria and reduction in immunosuppression. Patients completed a formal assessment of quality of life at baseline and after six months of treatment using the chronic GvHD symptom scale (cGvHD SS) and dermatology life quality index (DLQI). Results: Eighteen patients (8 male, 10 female) completed the cGvHD SS at baseline and after six months of ECP. 14 patients had received a transplant from an unrelated donor and 4 from a sibling donor. 15 patients had moderate GvHD and 3 had severe GvHD. 15 had classic chronic GvHD, 2 had overlap syndrome and 1 had developed GvHD post donor lymphocyte infusions. 14 patients had cutaneous GvHD. Other organs involved were: mouth (9), liver (4), ocular (9), gastrointestinal tract (3), lung (2), musculoskeletal (4), gynaecological (1). Ten patients were receiving 2 immunosuppressive drugs at start of ECP, 4 were receiving one drug, 3 were receiving 3 drugs and one patient was not receiving any immunosuppression. Baseline cGvHD SS scores ranged from 8/120 to 64/120 with a median score of 38/120. 17/18 (94%) showed an improvement in scores. The mean cGvHD SS was signifi cantly lower after 6 months of ECP (22 compared to 36, p=0.012). Sixteen patients completed the DLQI at both time points. Baseline scores ranged from 0/30 to 15/30 with a median of 7/30. The mean score was signifi cantly lower after 6 months of ECP treatment (3.4 compared to 6.9, p=0.009). 13/18 (72%) patients had a partial clinical response and 1 had a complete response. Two patients had a mixed response, one a minimal response and one patient had progressive disease. All the patients who had a complete or partial response had an improvement in both scores except for one. 9/15 (60%) patients receiving steroid therapy at baseline had a > 50% dose reduction. Conclusion: ECP may lead to an improvement in quality of life in patients with GvHD in addition to clinical response and reduction of immunosuppression.

The chronic GVHD Symptom Bother Scale, known as the Lee cGVHD Scale is a patient reported instrument developed and validated in English to measure symptoms and functional losses in patients with chronic GVHD. Lee cGVHD Scale includes 30 questions with 7 subscale containing 2 to 7 symptoms items representing domains of skin, mouth, respiratory system, gastro intestinal system, energy and pshychological status. This study objectives include translate S445 and validate the Lee cGVHD Scale in Portuguese among Brazilian patients with chronic GVHD and to assess the correlation with other quality of life (QoL) instruments. Inclusion criteria was adult patients with chronic GVHD diagnosed according to the 2005 NIH consensus criteria. Exclusion criteria included inability to answer the questionnaires, less than six months of life expectancy due to co-morbidity or relapse of primary disease. The study was approved by the institutional review board of all participating centers and all patients signed an Informed Consent for the study. Methods: A cross-sectional multicenter study was conducted by the Brazil-Seattle chronic GVHD Consortium (Grupo de Estudos da Doença do Enxerto versus Hospedeiro Crônica Brasil-Seattle, GeDECHc Brasil-Seattle) between April 2011 to August 2012. Methodology used to translate into Portuguese and validate Lee cGVHD instrument was according to the American Association of Orthopedic Surgeons (AAOS) Outcome Committee guideline. All patients answered the Brazilian version of the Lee cGVHD Scale questionnaire and also completed two QoL questionnaires: the Medical Outcomes Study Short Form 36 (SF-36) and the Functional Assessment of Chronic Illness Therapy with Bone Marrow Transplant subscale (FACT-BMT). Spearman's correlation coeffi cient was used to measure construct validity. Reliability was assessed using Cronbach's α and intraclass correlation coeffi cients. Results: A total of 47 patients from fi ve Brazilian Institutions participated in this study. The cohort median age was 48 years (23-69) and 29 (61.7%) were male. Lee cGVHD Scale reliability was adequate (Cronbach's α 0.62-0.83). Spearman's correlations between similar dominium's of Lee cGVHD Scale, SF-36 and FACT-BMT were moderate and high, as expected. Brazilian Portuguese version of Lee chronic GVHD Scale is valid, reliable, and may add value to assess treatment response and quality of life in clinical trials of patients with chronic GVHD in Brazil.

Background: Tacrolimus is an established immunosuppressant for the prevention and treatment of graft-versus-host disease (GvHD). The aim of this study was to determine the effi cacy and safety in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients converted from continuous infusion tacrolimus (TAC cont. IV) or twice-daily tacrolimus (TAC BID) to once-daily prolonged release of tacrolimus formation (TAC OD). Patients and Methods: We have retrospectively analyzed the records of 51 adult patients who underwent allo-HSCT and have treated with TAC OD in our hospital before December 2011. The dose conversion ratio between TAC cont. IV and TAC OD was 1:5, TAC BID and TAC OD was 1:1. Tacrolimus trough level has checked day0 and day7. Laboratory parameters (total cholesterol, triglyceride, fasting blood sugar, brain natriuretic peptide, estimated glomerular filtration rate) and adverse events were assessed. Results: The underlying disease was Acute myeloid leukemia (AML) in 11 patients, Myelodysplastic syndrome (MDS) in 13, MDS overt AML in 10, Acute lymphoblastic leukemia in 8, Malignant lymphoma in 7, Adult T-cell leukemia/lymphoma in 2. The conditioning regimen was myeloablative regimen in 26 and non-myeloablative in 25. The donor source was sibling-donor in 16, unrelated-donor in 31, cord blood in 4. In all patients, tacrolimus was started at 0.02mg/kg/day as continuous infusion from day -1 or -3. All patients were combined with short-methotrexate and 2 patients with anti-thymocyte globulin. After engraftment, 11 patients were first changed to TAC OD from TAC cont. IV, and 40 patients to TAC BID and changed to TAC OD from TAC BID at the TAC concentration stable. GvHD status when converted to TAC OD was no sign of GvHD in 24, and acute or chronic GvHD in 27. After one week, TAC concentrations were lower in 20 patients (7 patients from TAC cont. IV) and higher in 9 patients when compared with baseline. By changing TAC BID to TAC OD, there were only 3 patients to GvHD got worse, but TAC cont. IV, 5patients got worse. All laboratory parameters were not significantly different. Adverse events were consistent with the safety profile known from previous studies with TAC BID. In 32 patients, chronic GvHD has been improved gradually during treated with TAC OD, but in 5 patients, lung GvHD has not improved. Conclusion: Conversion to TAC OD is eff ective and safe, enhances immunosuppressant adherence and should be accompanied by a close tacrolimus level monitoring during the initial period.

Introduction: Hematopoietic stem cell transplantation is a curative treatment for many hematological disorders. Chronic graft-versushost disease (GVHD) is a serious complication that appears in 20-70% of the patients. There are some described cases of patients with nephrotic syndrome after bone marrow transplantation(BMT) as an expression of GVHD.The objective of our study is to analyze patients with allogenic BMT who developed a glomerular pathology as an expression of GVHD. Material and methods: We analyzed all patients who underwent allogenic BMT in our hospital from October 1995 to June 2011 who developed a glomerular pathology after the transplant. Chronic GVHD was defi ned in patients who survived >100 days after allogenic BMT.The diff erent clinical and analytical variables of patients with chronic kidney GVHD were studied. Results: Five hundred and ten allogenic BMT patients were analyzed. The age range was 1-69 years old ( Table 1 ). The prevalence of chronic kidney GVHD was 0.784%. All patients with renal GVHD, were patients with BMT of peripheral blood, identical HLA. GVHD prophylaxis was administered with methotrexate and ciclosporin, and in 1 patient, this treatment was replaced by tacrolimus due to neurological toxicity. Chronic kidney GVHD appeared after removal of the GVHD prophylaxis with proteinuria levels of 2.65-15.46 g/day secondary to membranous glomerulonephritis, focal segmental glomerulonephritis and lupic nephropathy class III. After the start of the immunosuppressant treatment with corticoids in all patients and anti-calcineurin drugs in 3 patients,complete remission was achieved.In 3 patients under complete remission, recurrence of the glomerular pathology was observed when the immunosuppressant therapy was removed, which led to the re-introduction of the treatment. Conclusions: Chronic GVHD with renal involvement is a rare entity associated to the removal of immunosuppressant therapy which usually appears with proteinuria. Membranous glomerulonephritis is the most common histology. It can be useful to monitor proteinuria levels in these patients.-In our population,we identifi ed the following risk factors for GVHD of the kidney: donor/recipient gender disparity, positive results for CMV, peripheral blood BMT, and the presence of previous acute or chronic GVHD.-Complete remission was achieved in all cases of chronic GVHD of the kidney, but some outbreaks appeared after removal of the immunosuppressant therapy. We must consider a diff erent therapeutic approach for glomerular pathology secondary to chronic GVHD.

Purpose: Montpellier University Hospital performs therapeutic apheresis since 1978. In 2011, 1217 procedures were performed with 40% plasma exchanges (TPE), 32% extracorporeal photopheresis (ECP), 16% Stem cells collection and lymphocyte collection.[P1210] S447 Two Spectra (Terumo BCT), one Com.Tec (Fresenius) and one Optia (Terumo BCT) are currently used. We evaluated the Amicus Separator (Fenwal) as an alternate platform to collect lymphocytes for off line ECP. The objective was to assess procedure performance, safety and compatibility with off -line technique. Methods: A total of 21 procedures to collect Mononuclear cells (MNC) for ECP were evaluated between June and August 2012 in patients with GVHD (14), cutaneous T-cell lymphomas (4), lichen planus (2), systemic lupus erythematosus (1). One total blood volume was targeted to process. Maximum whole blood fl ow rate was 60 ml/min. The software version was 4.3. The procedure settings were MNC off set 1.5ml, RBC off set 5.0 ml, plasma fl ush 8ml, WB per cycle 2000ml for patient with WBC count < 5 x 10E9/l and 1400ml for patient with WBC count > 5 x 10E9/l. The illumination procedure post collection was performed after addition of 8-MOP (Macopharma) using a UVA PIT System device (Med Tech Solution). The 21 Amicus procedures were compared with historical data for Spectra (N=260), Optia (N=174) and Com.Tec (N=198). The performance was evaluated based on 1) lymphocyte collection yield and purity; 2) patient PLT depletion; 3) procedure time (reinfusion included) and 4) adverse events during the collection procedure. Results: The average blood volume treated was 1.02 for Amicus, 1.04 for Spectra, 0.95 Optia and 0.95 for Com.Tec. Yield and purity of collected products are presented in table 1. Adverse events with Amicus were mild. No citrate related reaction was observed. Conclusions: Monocytes and lymphocytes collection effi ciency with Amicus was satisfactory and comparable to other platforms with signifi cantly lower platelet depletion from the patient. Yield and purity of the Amicus collected product are predictable and show less variability than with Optia. The full automation of the Amicus machine was well appreciated by the operators who keep the opportunity to adjust parameters during the procedure.

Treatment and outcome of bronchiolitis obliterans syndrome following allogeneic haematopoietic stem cell transplantation S. Fritsch (1) 

Bronchiolitis obliterans syndrome (BOS) is a late pulmonary complication after allogeneic stem cell transplantation and is associated with signifi cant morbidity and mortality. Unfortunately diagnosis and treatment of BOS still remain diffi cult. Extracorporeal photopheresis (ECP) has shown effi cacy in treatment of chronic graft versus host disease (cGvHD) as well as BOS. According to the National Institute of Health (NIH) Consensus Criteria for diagnosis of BOS after allogeneic stem cell transplantation 26 patients (pts) at our centre were diagnosed with BOS between 2003 and 2012. All patients (median age 52 years) were treated by corticosteroids including inhalative application forms. 19 patients (73%) additionally received ECP treatment for a minimum of 3 months. Improvement of pulmonary function, clinical symptoms and outcome were analyzed. The donors were HLA identical siblings in 8 patients, HLA-mismatched siblings in 2 patients, HLAcompatible unrelated donors in 11 patients and unrelated donors with one HLA-mismatch in 5 patients. 6 Patients presented with de novo cGvHD, 6 with quiescent and 14 with progressive cGvHD. Manifestation of BOS, diagnosed by the NIH criteria for diagnosis of BOS, was in median detected at day 343 after transplantation (range day 126-1679). FEV1 and FEV1/FVC as parameters of pulmonary function were monitored continuously during treatment. At diagnosis of BOS FEV1/FVC was less than 50% in 4 pts, less than 60% in 8 pts and between 60% and 70% in 14 pts. 3 patients showed a FEV1 of less than 35% predicted, 9 between 36% and 50% and 14 between 51% and 75%. Improvement of lung function was defi ned as 10% increase of FEV1. Response to treatment measured by pulmonary function tests was observed in 10 of 26 pts (38,5%) and clinical response in 12 pts (46,2%). Overall survival (OS) after a follow up between 280 and 3469 days was 65,4% and median OS was 958 days. Additional treatment with ECP had no positive impact on survival: OS was 58% in the ECP group compared to 86% in the other group. Cause of death was progressive BOS and GvHD in 7 patients, relapse of leukemia in one and unknown in one patient. BOS and cGvHD were confi rmed as life threatening complications after allogeneic stem cell transplantation. In our patient cohort additional treatment with ECP for BOS did not improve survival. To evaluate the eff ect of ECP in BOS treatment further studies should be performed. E. Jakob, A. Knoll, K. Brandauer, B. Dobner, G. Auff arth, P. Dreger, U. Hegenbart, F. Mackensen University of Heidelberg (Heidelberg, DE) Purpose: Ocular Graft-versus-Host-Disease (oGvHD) is a frequent sequelae after hematopoietic stem cell transplantation (HSCT).

S448 We hypothesized that a decrease of goblet cells in the conjunctival epithelium can serve as a predictive marker for an emerging oGvHD. To assess goblet cell density we compared the more invasive impression cytology (IC) with the less invasive in vivo confocal microscopy (IVCM). Methods: Patients who were listed for HSCT were examined before and 100 days after the transplantation. The examination included a questionnaire, slit lamp examination, Schirmer Test II, impression cytology and confocal microscopy of the conjunctiva with the Heidelberg Retina Tomograph with the Rostock Cornea Modul attachment (HRT-RCM). At least three specimen/pictures of each patient were assessed for goblet cell density and means were calculated. Approval of the Ethical Review Board Heidelberg and informed consent was obtained. Results: 44 patients were included (mean age 56 years). 18 patients were not re-examined after HSCT (4 died, 2 were pre fi nal, 2 were not transplanted, 10 repeatedly cancelled their follow-up examination due to poor health). Mean time to follow-up examination was 147 days after HSCT. Goblet cell density before and after HSCT of all patients with evaluable pre-and post HSCT -examination was 52.6±7.5 vs. 43.9±4.1 cells/mm2 (Mean±SEM, p=0.46, n=8, wilcoxon's signed rank) assessed with IC and 62.7±3.4 vs 61.6 ±4.3 Zellen/mm2 (p=0.8, n=24) assessed with IVCM. 8 healthy subjects were examined via IVCM as control (mean age 38 years), mean goblet cell density was 74.8 ± 4.3 cells/mm 2 . Conclusions: IVCM showed goblet cell numbers in similar magnitude to the standard method IC, we therefore conclude that IVCM can also reliably be used. Conjunctival goblet cells did not show a signifi cant decrease after HSCT. The time interval to follow-up examination may have been too short as most patients still were on immunosuppressants and only 2 had signs of oGvHD. Patients who present with oGvHD symptoms will be re-examined for goblet cell density in our clinic.

Low-dose methotrexate for treatment of severe and overlap chronic graft-versus-host disease G. Levati, R. Greco, E. Sala, E. Guggiari, S. Malato, S. Marktel, M.G. Carrabba, S. Claudiani, M. Marcatti, F. Lunghi, A. Assanelli, M. Bernardi, J. Peccatori, C. Corti, F. Ciceri, M. Lupo-Stanghellini San Raff aele Scientifi c Institute (Milan, IT) Background: Graft-versus-Host-Disease (GvHD) is a serious complication after allogeneic stem cell transplantation: frequent cause of late morbidity and non-relapse-mortality. Steroids are the treatment of choice to control GvHD manifestation, but for steroid-refractory GvHD alternative options are of need. In view of the anti-infl ammatory and antiproliferative properties and its successful use in patients (pts) with autoimmune disorders, low dose methotrexate (MTX) is an option mainly for skin and oral manifestations of cGVHD. Methods: We describe here the data from a retrospective study in our transplanted pts in order to assess the effi cacy of MTX in GvHD therapy. Pts were treated between Jan-2011 and Oct-2012. Results: Overall 13 pts with GvHD were treated with a starting dose of 7.5 mg/m2 weekly of MTX. Only 1 pt was treated for acute GvHD but the drug was discontinued after 2 weeks due to pancitopenia and worsening of liver function. Pts characteristics are reported in table 1, of note 11 pts had a severe chGvHD and 7 an overlap chGvHD. Three out of 13 pts had to discontinue therapy with MTX (median 2 administration) due to the onset of hepatic toxicity (grade II-III). Nine pts were able to receive a proper treatment for a median time of 9 months (range 2-20). All of them had skin involvement, 7 eye and 5 notes of scleroderma or fasciitis. After the introduction of MTX 5 pts completely resolved skin GvHD, 2 had major response, 1 partial response (reduction of sclerodermic features and reduction of Rodnam score from 19 to 5.5), 1 pt is so far stable after 2 months of treatment. In our records scleroderma/fasciitis improved with MTX in 4/5 pts, one pt shows stabilization -table 2a.At the start of MTX 6 pts were assuming steroid-therapy with a mean dosage of 0.25mg/kg/day; 3 pts succeeded in discontinuing the therapy with prednisone and the other 3 encountered a substantial reduction of the steroid dosage -table 2b. Furthermore, all pts were also receiving several lines of immunosuppressive treatment (IST): 7/9 pts reduced the IST during therapy with MTX, no case of strengthening of IST. Discussion: A global evaluation of all 9 pts shows an improvement of the chGvHD in the totality of them. As previously reported, lowdose MTX show good tolerance and easy manageability. Longterm use seems feasible. So far, from our data, we can state that MTX seems an eff ective choice as steroid-sparing agent in severe chGvHD and, of interest, in overlap chGvHD therapy.

Long-term follow up of allogeneic PBSC transplantation in B-thalassemia major, with a low incidence of chronic GVHD: a single centre experience of 118 patients G. Fathy, A. El-Haddad, M. Abdel-Mooti, R. Abd El Fattah, O. Fahmy, H. Mahmoud Nasser institute hospital for research&treatment (Cairo, EG) Background: Allogeneic HSCT is the only curative approach for patients with B-Thalassemia Major (BTM). Compared to PBSCs, BM is the preferred source of engraftment with an expected lower incidence of cGVHD. Aims: Back in 1997, when we started our transplant program at Nasser Institute (Cairo, Egypt), the vast majority of our patients, including those with BTM, recieved PBSCs; and we published some of our encouraging results regarding engraftment, GVHD incidence & outcome (HK Mahmoud et al. Bone Marrow Transplant. 1999; 24:355) . Thus, in this single arm in this single arm prospective study, we investigated the same approach on a wider b-thalassemia patient scale, with a much longer follow up to, eventually, evaluate the incidence & severity of cGVHD, as well as EFS & OS (Primary end points). Patients & methods: In the time period between November 1997 and March 2010, 118 BTM patients received allogeneic HLA-Matched sibling PBSCT at the BMT unit of Nasser institute, Cairo, Egypt. Mean age of patients was 5.6(Range=15 months -18 years). The regimen consisted of Bu at a total dose of 16 mg/Kg, a total Cy dose of 120mg/kg and a total ATG dose of 110 mg/Kg.Cyclosporine & Methotrexate were used for GVHD prophylaxis.Results: The mean number of infused CD34+ve cells was 7.2 x 106 /kg recipient weight. All patients engrafted promptly at a median of 17 days for neutrophils and 19 days for platelets. The total incidence of cGVHD was 9% ,while that of grade 2-4 acute GVHD was 3.3%. Incidence of primary graft failure did not exceed 6. At a follow up period of up to 13 years (median 7.9 years), OS&EFS were 89 %, with 70% of patients having complete chimerism and 19% stable mixed chimerism, all of whom are transfusion independent. Conclusion: Allografting BTM patients using PBSCs instead of BM, is a signifi cantly easier & safer approach for the donor, with promising outcome regarding engraftment, DFS & OS. Finally, Our results showed signifi cantly lower incidence of cGVHD, compared to that reported with BM stem cells. Introduction: Interest in defi ning the role of immunomodulation of graft versus host disease (GVHD) by ultraviolet radiation has recently increased, since systemic immunosuppression (IS) is associated with high morbidity and mortality. We have been using at our institution three modalities of phototherapy -PUVA (psor-S450 alen+ ultraviolet A), UVBNB (ultraviolet B narrow band) and extracorporeal photopheresis (ECP) -to treat diff erent manifestations of cutaneous GVHD for the last 22 years. Objective: Report the applicability, indications and benefi cial eff ects of each phototherapy modality in the treatment of GVHD in a single institution. Methods: Puvatherapy was used in 55 patients to treat lichen planus like and sclerodermic chronic GVHD(cGVHD) with no visceral involvement. UVBNB was used in 15 patients for vitiligo, limited lichen planus like cGVHD, those with psoralen intolerance and children. ECP was reserved to treat 36 patients with extensive sclerodermic, fasciíte cGVHD, systemic cGVHD and 11 patients with acute GVHD (grade III and IV) as second or third line therapy. It was not feasible to evaluate median time of sessions until an answer or time for reducing IS, because there was great heterogeneity of disease severity and systemic treatment adopted.Results: From the 55 patients treated with PUVA, 23(42%) achieved complete response, 16(29%) partial response, 9(16,3%) no response and 7(12,7%) were too early to evaluate (in treatment). Immunosuppression was withdrawn in 27 patients and reduced in 12. Three patients treated with UVBNB achieved complete response, 8 partial response, 2 no response and 2 were still under treatment. In 7 patients, IS was suspended and in 4 reduced. FEC was performed in 36 cGVHD steroid refractory patients. Eight (22%) achieved complete response and 19(53%) partial response with global response in 75%. Immunossupression was withdrawn in 3 and reduced in 24. Among the 11 acute GVHD patients submitted to FEC, 6(54.5%) responded well. Conclusion: PUVA and UVBNB is a topical direct therapy and should be considered in patients in whom the increase of systemic IS leads to high risk of infection or interference with the graft-versus-tumor effect. ECP is indicated to patients not responsive to corticosteroids, those with IS toxicity or those who need early withdrawal of IS (high risk of relapse of malignant disease). Phototherapy modalities are safe, effective and should be individualized for the type of cutaneous GVHD. Introduction and objectives: Chronic graft versus host disease (GVHD) of the lung, also known as bronchiolitis obliterans syndrome (BOS), is a serious complication after hematopoietic stem cell transplantation (HSCT). Therapy of BOS includes topical treatment and systemic treatment with corticosteroids and immunosuppressive therapy. However, when medical treatment fails, lung transplantation (LTX) may be indicated as the ultimate treatment option. Methods: We searched our institutional data base for lung and bone marrow transplantation and three patients were found with an history of both procedure performed. We collected demographic and outcome data about transplant procedures. Results: Between 1998 and 2005, 3 patients (2 females and 1 male), with a median age of 24 years (range 21-49), underwent alloHSCT because of myelodisplastic syndrome, B-precursor acute lymphoblastic leukemia and multiple myeloma. In all cases, donors were HLA identical siblings while the cell source was the bone marrow for one patient and the peripheral blood for the other two. No patient presented acute GVHD and in all cases a de novo chronic GVHD developed and, eventually, respiratory failure. LTX was needed after a median time of 4 years (range 3-9) from HSCT. Bilateral LTX was performed in 2 out of 3 patients, cardiopulmonary bypass in 2 and only one of them required tracheostomy (before LTX). All patients are alive and in hematological complete remission after a median follow-up of 5 years (range 4-6) from LTX. One of them developed acute lung rejection 2 years after LTX that was successfully treated with high dose steroids even though the late follow up was also complicated by chronic rejection. At last follow up his pulmonary function tests (PFTs) by spirometry show a severe reduction of the diff using capacity of the lung for carbon monoxide (DLCO) and severe restrictive and obstructive changes of the lung volumes. This patient is currently being considered for a second LTX. The other two patients are leading an active life, are currently maintained on immunosuppressive therapy with tacrolimus, everolimus and prednisone and their PFTs show normal or middle reduction of DLCO and lung volumes with stable values over time. Conclusion: Our data indicate that lung transplantation may represent an eff ective treatment option of BOS with remarkable improvement of the quality of life. In selected good prognosis HSCT patients, lung transplantation should not be unnecessarily delayed or refused. (1) Extracorporeal Photopheresis (ECP) represents an innovative therapeutical option, however data supporting the efficacy are limited. Methods: 42 months after double-lung transplantation due to cystic fi brosis a patient presented himself with BOS grade 3 with a vital capacity (VC) of 5,100 ml (BOS grade 1: VC of 5,940 ml) and a forced expiratory volume in one second (FEV1) of 2,120 ml (BOS grade 1: FEV1 of 4,930 ml). He showed a progressive decline in lung function despite a triple drug therapy with steroids, FK506 and mycophenolate mofetil. At our unit he was treated with two ECPs per week for 8 weeks, later at lower frequency. Multi-color fl ow cytometry was performed for naive T-cells, CD45RA+ eff ector T cells (T EMRA), memory T-cells and FoxP3+ regulatory T-cells (Treg), NK-cells, NKT-cells and BAFF-R+ B-cells. Results: 12 weeks after the start of ECP treatment no further decline of lung function with a VC of 5,070 ml and a FEV1 of 2,160 ml was measured by spirometry. In addition, the lung function improved to a VC of 5,360 ml and to a FEV1 of 2,410 ml 15 weeks later. The frequency of regulatory T cells of all CD4+ T cells increased over the time of ECP treatment from 1.2% before ECP to 6.7% after 106 days of treatment. The frequency of CD8+ eff ector T cells was reduced from 58.8% to 36.6% and of T(EM) from 10.4% to 3.2% over the time of ECP treatment, while naïve T cells increased from 27.8% to 55.6%. The B cell population presented with a very low percentage of < 2.6% over the time of therapy. The NK cell population presented with a low regular percentage of around 10% of all lymphocytes over the time of therapy, as well as NK-T cells of around 0.7% of all lymphocytes. Conclusion: ECP treatment was well tolerated and no severe infectious disease complications occurred during the therapy. Through ECP the lung function improved. Immunologically, the frequency of eff ector T cells thought to be responsible for the allograft rejection were reduced and the frequency of the regulatory T cells hampering the eff ector T cells increased. S451 Therefore, ECP therapy is an immunologically interesting and clinically promising therapeutic option for patients suff ering from allograft rejection.

Sclerodermatous graft-versus-host disease successfully treated with water-fi ltered infrared A (wIRA) radiation: improved wound healing, regained range of motion and pain alleviation C.L. Marks, H. Schumann University Hospital Freiburg (Freiburg, DE) Chronic graft-versus-host disease (GvHD) as a major post-transplant complication is responsible for increased morbidity after allogeneic hematopoietic stem cell transplantation (HSCT). Skin is the most common organ involved by chronic GvHD (cGvHD). In patients with sclerodermatous GvHD treatment of chronic wounds is challenging. Water-fi ltered infrared A (wIRA) radiation can improve the healing of acute and chronic wounds by increasing tissue temperature, oxygen partial pressure and perfusion.Here we present an impressive case report of a 52-year-old patient after allogenic HSCT for acute lymphoblastic leukemia in December 2007 who was treated later on with wIRA because of his numerous very badly-healing wounds on sclerodermatous skin due to chronic cutaneous GvHD. In 10/2008 he presented with his first symptoms of cutaneous GvHD: initially inflammatory signs changing into multifocal sclerodermatous lesions leading to restriction of motion and loss of function. Next to diverse immunosuppressive systemic therapy and physiotherapy the patient underwent extracorporeal photopheresis since 5/09 and had UV-A1 phototherapy in 11/2009. He experienced slight improvement, but no striking success by these treatment modalities. In January 2010 numerous painful ulcerations developed on the sclerodermatous skin, especially on shoulder, neck and head. The wounds measured up to 6 x 5 cm and were up to 5mm deep and purulent. Every week numerous new skin lesions developed-altogether around 30 smaller wounds. Local therapy with antiseptic agents like octenidine, fucidic acid and diverse wound dressings did not improve the situation. In 3/2010 we started wIRA. The patient was advised to perform this therapeutic procedure at home for at least 4-5 times a week for 30 minutes for each affected localisation. Only two weeks later we could observe considerably pain alleviation with substantially less need for analgesics. In addition, reduction of wound size could be observed and the patient regained range of motion. Only three months after, he showed a 50% improvement concerning wound size, after one more month he showed complete healing. Since then he no more developed any wounds on the shoulder/neck/head area. The patient is still performing wIRA twice a week with continuing improvement of his mobility. In conclusion wIRA is a promising therapy option for bad healing wounds in sclerodermatous GvHD.

Revisions to ISBT 128 nomenclature for cellular therapy I. Slaper-Cortenbach, P. Distler, P. Ashford on behalf of the Cellular Therapy Coding and Labeling Advisory Group ISBT 128 terminology has been widely adopted by cellular therapy facilities globally and its use has been an accreditation requirement by AABB, FACT and JACIE for several years. Accredited facilities are now required to put in place an implementation plan for the full use of ISBT 128 coding and labeling in addition to terminology, and many facilities are moving forward with this implementation. Responding to regulator concern about the use of TC ("therapeutic cell") terminology, the Cellular Therapy Coding and Labeling Advisory Group (CTCLAG) re-evaluated existing terminology. As a result of this review, a revision of the terminology was drafted to eliminate the "TC" class designation and to create a more consistent format for cellular therapy class terms. The revised terminology also takes into consideration consistency with nomenclature used for tissue products. Changes will not aff ect HPC terminology which represents about 65% of ISBT 128 product description codes. For class names that will change, not all nomenclature changes will result in a change to the ISBT 128 product description code ("S" code). While accepting that changing terminology will create rework for facilities that have implemented ISBT 128 and delay for those in the process of implementation, it is felt the revised terminology provides a strong foundation for consistent nomenclature as new products are developed and addresses regulatory concerns. An appropriate timescale for implementation of the revised terminology will be developed. This presentation will describe the revised terminology and explain the reasoning supporting the changes.

Cooperative programme for standard operating procedures and document preparation for JACIE accreditation. Advantages and disadvantages D. Sotiropoulos (1) (1) (

The establishment of a Quality Management System (QMS) according to FACT -JACIE standards in a BMT center is a very laborious project. Involvement of all personnel implicated in collection, processing and clinical procedures is absolutely necessary. Involvement includes strategic scheduling of QMS development, writing of SOPs and documents, and implementation of the system. Collaboration between diff erent centers could have advantages and disadvantages. We present the experience of such collaboration in our country. The four major BMT centers of the country had an agreement to collaborate in the establishment of a common QMS and apply for JACIE accreditation. The goal was all the centers to be able to communicate and collaborate in a more efficient way. Centers were located in three different cities. A common strategy was applied. A team of QM specialists was hired to work for the common project. Doctors, nurses, technicians and the QM specialists attended JACIE courses for center preparation. Writing of SOPs and documents was shared between the centers. The duration of the task from the beginning to the fi rst application for JACIE accreditation was four years. The development of the system lasted three years. SOPs and documents written by one center were distributed to the other centers for adjustments according to each center's demands. The total cost was estimated to be 30% lower compared to individual projects for each center separately. The cost was covered by a donation. In contrast, the separation of the tasks and the implication of more than one center were time-consuming. Delay of writing of SOPs in one center could aff ect the whole system. The development of the system is estimated to have lasted 50% more than the expected time. Two of the centers have already applied for JACIE accreditation. Overall, the major benefi t was that doctors, nurses and technicians from diff erent centers collaborated and shared knowledge and experience for a common task. (1), J. Baran (1) (1)Polish Stem Cell Bank (Warsaw, PL); PL) Introduction: Umbilical Cord Blood (UCB) is a widely used alternative to bone marrow and a mobilized peripheral blood source of transplantable hematopoietic stem cells in treatment of various disorders. Nowadays, two basic models of UCB banking exist: public (allogeneic donations from volunteers donors) and private (parents deciding to store UCB units in case of need by the donor-child or his/her family). In many countries public UCB banking is not developed, mainly due to insufficient funds. The Polish Stem Cell Bank (PBKM S.A.) decided to start UCB banking for public use in April 2011. In the autumn of the same year some public resources were raised (POLGRAFT -Program for Transplantation Medicine Development). In this paper we present the results of public UCB banking at our company. Materials and methods: Donations were collected from donors, after they mothers had given informed consent. The UCB were transported to the PBKM S.A. After preliminary assessment and qualifi cation, the UCB were processed by volume reduction and red blood cells depletion, followed by controlled-rate cryopreservation in the presence of 10% DMSO as a cryoprotectant. Units were stored in the vapour phase of liquid nitrogen at the monitored temperature of below -150 °C. The following assay were performed: total nucleated cell number (TNC), CD34+ cell, nucleated red blood cell, viability, as well as blood group, microbial culture, the presence of infectious agents, and HLA typing using molecular methods (PCR-SSP) at low resolution level (loci HLA-A,B and DR). Obtained HLA data were transferred to the database of the Polish Central Potential Unrelated Bone Marrow Donor and Cord Blood Registry and published on Bone Marrow Donor Worldwide websites, making them accessible for physicians all over the world. Results: After two years of UCB banking for public use, we have collected over 900 UCB units. 65% of collected UCB units were qualifi ed for processing, and fi nally more than 400 units were reported. The mean fi nal TNC count and CD34+ count were 101 x 10 7 and 3.2 x 10 6 respectively. Conclusions: The PBKM S.A. is a good model of combined public/ private umbilical cord blood banking. In 2 years, more than 400 UCB units were registered. The costs of these units were covered equally by public resources of POLGRAFT and the PBKM S.A. The quality of UCB units banked for public and private purposes revealed the same quality features, despite the diff erences in the processing for long-term storage.

HSCT practice variation among EMBMT centres in EMRO region W. Rasheed (1), A. Ghavamzadeh (2), R. Hamladji (3) , T. Ben Othman (4), A. Seraihy (1), , A. Elhaddad (6) , A. Alabdulaaly (7), D. Dennison (8), A. Ibrahim (9) , A. Bazarbachi (10) , M. Bekadja (11), S. Mohamed (1), S. Adil (12), P. Ahmed (13), S. Benchekroun (14) , M. Ramzi (15) , M. Jarrar (16), F. Hussain (1), A. Hamidieh (2) , M. Aljurf (1) (1)King Faisal Specialist Hospital and Research Centre (Riyadh, SA) ; (2) Introduction: The Blood Bank of Cantabria (BSTC) participates in the Hematopoietic Stem Cell Transplantation(HSCT) program of Marqués de Valdecilla University Hospital (HUMV), in the collection, manipulation, cryopreservation, distribution and infusion areas. The number of HCST made in the last fi ve years was 380, of these, 146(38%) were peripheral blood stem cells (PBSC). Since november 2010, both centres are accredited by Comité Conjunto de Acreditación(CCA:JACIE+CAT+ONT) for HCST activity. Aim: Knowing the degree of satisfaction of our clients, in this case, PBSC patients and donors, to be able to detect attitudes or incorrect cares by staff of BSTC during the collection and to be able to resolve them, in order to meet with our policy of continuous improvement. Material And Methods: Since june 2009, every patient and PBSC donor received, just after collection end, one opinion survey with 6 questions about issues like "information", "cares", "security" and "privacy" provided by staff of BSTC during apheresis processes. The fi ve possible answers vary from "very unfavourable(VU)" to "very favourable (VF)". The survey was delivered in stamped envelops intended to answer anonymously. Results: The percentage of opinion surveys answered was 47%(65/139). Of total valid answers (390), 83%(322) were "VF" and 15%(58) "favourable(F)". Only 2%(8) and 0.5%(2) were valued as "correct(C)" and "unfavourable(U)" respectively. There were no "UF" answers. Related to the specifi c issues, more favourable were "attention" and "security"(VF: 92%), followed by "information"(VF: 80%). "Privacy" was the issue than achieved "VF" in fewer times(VF: 71%). Conclusions: The opinion surveys are useful tools that allow easily know the satisfaction degree of the users on important issues as attention and security provided to apheresis patients and donors, allowing recognise the weakest points, to establish corrective or improvement actions.

Ambulatory care: the way forward? S. Anandram, S. Krishnan, V. Banumukala, J. Haughton, S. Liebersbach, N. Marsden, C. Kallmeyer, G. Cook, M. Gilleece The Leeds Teaching Hospitals NHS Trust (Leeds, GB) Conditioning incorporated fl udarabine in 55/65 patients & was given for the fi rst 3 days of conditioning as a single cytotoxic agent. CMV reactivation risk was high in 9(14%), intermediate in 27(41.5%) & low risk in 29 (44.5%) There were a total of 90 readmission episodes of which 21 (23.3%) were due to CMV reactivation requiring ganciclovir which in our unit requires in-patient admission. The median number & duration of admissions/patient for CMV reactivation were 1(0-2) & 15 days respectively. CMV reactivation associated total number of inpatient bed days was 534. The other reasons for readmission were sepsis, 30 (33.4%); graft versus host disease, 13(14.5%); relapse, 6(6.5%) & others, 20(22.3%). Conclusion: 85% of patients received fl udarabine based conditioning. When administered as a single agent this may potentially be given in an ambulatory care setting, with resultant cost savings. CMV reactivation accounts for at least 23% of readmissions post-AlloHSCT with median duration >2w. Ganciclovir is fi rstline therapy for CMV reactivation & may be safely delivered as ambulatory care with potential cost reductions & improved patient experience. This may provide better quality of life for patients.

Single centre pharmacoeconomic analysis of palifermin in autologous stem cell transplantation H.R. Johnson, A. Nooka, J. Kaufman, C. Flowers, A. Langston, M. Graiser, T. Plummer, S. Lonial, E. Waller Winship Cancer Institute (Atlanta, US) Background: Randomized clinical trials have shown palifermin reduces the incidence and severity of oral mucositis, TPN use, and use of opioid analgesics in patients with hematological malignancies receiving TBI-based conditioning regimens and autologous stem cell transplant (ASCT). However, similar outcomes data for patients receiving non-TBI conditioning is inconclusive. Our objective was to determine whether resource utilization including length of stay (LOS), analgesic use, and total transplant costs were diff erent between patients who received palifermin and those who did not in the setting of ASCT following non-TBI based conditioning. Methods: Patient data was retrospectively obtained on 829 patients with multiple myeloma (MM) or lymphoma (LY) who received ASCT following non-TBI based conditioning regimens between 1/02 and 12/10. Patients were stratifi ed by diagnosis and multiple linear regression controlled for other diff erences in baseline characteristics between the two groups (age, gender, ethnicity, and conditioning regimen). Results: 598 patients were in the palifermin-treated group (P) and 231 in the control group (C). There were 508 MM pts (389 P; 119 C) and 321 LY pts (209 P; 112 C). MM pts were conditioned with Melphalan and LY pts were conditioned with BEAM (28 P; 6 C), Bu/Cy or Bu/Cy/etoposide (174 P; 106 C), or Melphalan (7 P; 0 C). Two year survival did not diff er between P and C groups. Mean LOS was not signifi cantly diff erent between those who received palifermin and those who did not [MM: 18.7 days (P) vs. 19.1(C); LY: 23.0 (P) vs. 22 .8 (C)]. A sub-set analysis matching 24 C pts with 72 P pts (based upon diagnosis, conditioning regimen, age, and race) found no signifi cant diff erence between the P versus C groups on mean duration of PCA use (0.81 days vs. 0.88 days), mean duration of all analgesic use (8 days vs. 6 days), total PCA dose per day morphine equivalent (58.95 mg vs. 57.39 mg), or total dose of morphine equivalents (634 mg vs. 518 mg). Also, mean total charges incurred for the transplant hospitalization were not signifi cantly diff erent comparing the P vs. C groups, after adjusting for infl ation ($139K (P) vs. $135K (C); P=0.5). Conclusion: In patients receiving non-TBI conditioning regimens and ASCT, palifermin does not signifi cantly decrease length of stay, analgesic use, or total costs associated with ASCT. More detailed quality-of-life endpoints are needed to support palifermin use in the setting of non-TBI conditioning and ASCT. S454 P1228 Economic analysis of autologous haematopoietic stem transplantation in the treatment of early type 1 diabetes E. Snarski (1) , D. Szmurlo (2) , K. Halaburda (1) 

Introduction: Autologous haematopoietic stem cell transplantation is an emerging treatment option in early diabetes type 1. The cost of transplantation raises the question to how this treatment modality compares economically with standard insulin therapy. So far this question was not addressed for this population of patients and there is only a scarce data for HSCT in autoimmune diseases Aims of the study: We analysed the cost eff ectiveness of autologous hematopoietic stem cell transplantation when compared to the standard insulin therapy. Methods: The retrospective analysis of the medical records of patients with early diabetes type 1 treated with autologous hematopoietic transplantation and patients with diabetes type 1 treated with insulin was performed. Then the CORE model was used for economic analysis. The CORE model is a tool that allows simulation of diabetes type 1 outcome and complications. Simulation with patient data was performed to obtain the QALY and ICER values of the treatment based on observation of patients after transplantation. Results: Series of scenarios using the real patient data were tested with CORE model. The QALY increased in all scenarios. The worst case scenarios assumed that after HSCT full doses of insulin were to be taken by patients and eff ect on HbA1c disappeared after given period of time. In that case if the observed diff erence in HbA1c between transplanted and not transplanted patients could be preserved over 10 years the ICER of the treatment would be still below the threshold value. In the more optimistic scenarios that included patients achieving remission and reduction of doses of insulin in the post transplantation period with the eff ect on HbA1c the ICER was under the threshold values in shorter time frame. Conclusion: Autologous hematopoietic stem cell transplantation in early diabetes type 1 leads to improvement in QALY and in preliminary analysis show cost-eff ectiveness of HSCT versus standard insulin therapy if the eff ect of the treatment on HbA1c is sustained over few years. The ICER values will be positively aff ected by the reduction of doses of insulin after HSCT and increase of use of expensive long term analogues of insulin in the population of patients with diabetes type 1.

Outpatient-based autologous stem cell transplantation is a safe and eff ective strategy: a single centre experience M. Robinson, M. Lawes Norfolk and Norwich University Hospital Foundation Trust (Norfolk, GB) Traditionally the inpatient stay for those undergoing Autologous Peripheral Blood Stem Cell Transplant (ASCT) is from initiation of conditioning chemoradiotherapy until evidence of bone marrow recovery. Given that blood products are given frequently in our outpatient department and severe neutropenia is not an immediate complication of the procedure, we have designed an outpatient based transplant protocol that allows early discharge. After conditioning and stem-cell re-infusion, patients can be discharged on day +1 if they have (i) an adequate oral intake and require no IV fl uids or medication (ii) have no clinical evidence of infection (iii) access to adequate social support which would allow immediate transport to hospital if required. Prophylactic antimicrobials were given to patients as standard, as well as emergency contact details. Supportive GCSF was not given. Follow up occurred via the specialist nurse-led day unit, three times per week for blood product support and central line care. Patients would be readmitted at any time in their recovery phase if there was evidence of infection or other complications requiring IV therapy. We retrospectively reviewed 124 patients who underwent ASCT following this protocol. The median time for marrow recovery for all patients (defi ned as a neutrophil count of >0.5x109/L) was 14 days . The majority (83.2%) required readmission for treatment of infection. A small group (8.8%) required no inpatient care; the remainder were required to remain as inpatients throughout the entire recovery period as they failed to meet the discharge criteria. After readmission, a median of only seven days (IQR 10-14) was spent as an inpatient in the recovery phase of their transplant. Following our protocol suggests that an average of 7 days in-patient care (IQR 3-12) is saved in comparison to waiting for evidence of marrow recovery before discharge. There was no transplant related mortality from any patient in this cohort, however one death occurred within 100 days due to early disease relapse. Our data suggests that outpatient based ASCT is safe and may benefi t the majority of patients undergoing the procedure. We also suggest it signifi cantly reduces the length of time that patients are required to remain in hospital following stem cell re-infusion. This may confer benefi ts in terms of psychological and nutritional support for those undergoing the procedure and produce institutional savings with regards to cost and bed occupancy. Results of alloHSCT from HLA-identical siblings performed between 2004-2008 for adults with ALL in CR1 were analyzed. Among 983 individuals treated in 27 European countries the median age was 35 (18-55) years and the interval from diagnosis to alloHSCT -158 (42-831) days. TBI was used for conditioning in 820 (83%) cases and peripheral blood was a source of stem cells in 656 (67%) cases. The following factors were studied for their impact on outcome: current HCE, HCE as % of gross domestic product, public HCE, private HCE, no. of physicians, nurses and pharmacists per population, no. of teams per country area and population, HDI and center activity (no. of alloHSCT for ALL in a study period). All variables were categorized by medians. In a univariate analysis the probability of leukemia-free survival (LFS) was positively infl uenced by current HCE > median (p=0.003), public HCE (p=0.002), higher number of nurses/population (p=0.002) and higher center activity (p=0.04). The incidence of relapse(RI) was decreased for current HCE > median (p=0.001) and higher number of nurses/population (p=0.0001). The incidence of non-relapse mortality (NRM) was reduced for HDI > median (p=0.02) while increased for higher number of teams per population (p=0.03). A tendency was found for increased NRM in centers with lower activity (p=0.06). In a multivariate analysis, adjusted for other potential prognostic factors (age, type of conditioning, CR duration, source of stem cells, donor/recipient gender), current HCE >median was associated with reduced risk of treatment failure (HR = 0.78, 95%CI = 0.62-0.97, p=0.03) and reduced risk of relapse (HR = 0.67, 95%CI = 0.5-0.89, p=0.006). Other variables could not be included in the model due to strong internal correlations. We conclude that health care expenditure and related economic factors infl uence results of alloHSCT for adults with ALL. The outcome may also be related to the distribution of transplant centers and the team experience. Our fi ndings may be useful for creating future strategies of transplant development at national levels as well as for interpretation of results of clinical analyses in the fi eld of alloHSCT. S455 P1231 CryoStem: establishment of a national thematic collection of biological samples pre-and post-allogeneic haematopoietic stem cell transplantation for the study of graft-versus-host disease R. Peff ault de Latour (1), C. Fournel (2) , C. Fontenille (3) , B. Calmels (4) (1) 

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is the only curative treatment for many patients with hematological disease. Unfortunately, the transplanted immune system may reacts against the recipient, inducing Graft-versus-Host Disease (GvHD). GvHD is the leading cause of treatment related mortality and morbidity following HSCT. Risk factors, human pathophysiology as well as response to immunosuppressive therapy are still largely unknown. CryoStem has been created to federate all French HSCT unit to be able to collect and store a large number of pre-and post-HSCT samples to study GvHD. The French Society for Stem Cell Transplantation and Cell Therapy (SFGM-TC) is the project promoter. CryoStem already brings together 21 HSCT Units and 14 Biological Resources Centers that will contribute to a networked, prospective, longitudinal and standardized HSCT samples collection with a concomitant well documented clinical database. CryoStem has been selected and funded to the extent of 5,5 millions € over a period of 9 years by the French Government's Investissements d'Avenir program. Patients sampling is scheduled before and after HSCT, depending on the occurrence or not of acute and/or chronic GvHD. Three types of pre-analytical products are processed and stored, according to standardized techniques: viable cells in DMSO, dried cell pellets and plasma. Samples and clinical data are anonymized and centralized in CryoStem-dedicated web-based database application. National projects are the only way to acquire the high number of samples needed for statistically signifi cant results in a reasonable time line. CryoStem thus expect to draw more than 5000 HSCT samples per year. The fi rst partner center is open and includes patients since july 2012. The other centers will open shortly on the whole French territory. Currently, about one hundred patients and related donors have been included within two centers in no more than 3 months. CryoStem represents a fundamental step toward progress in GvHD research. Cryostem will allow collaborative studies between leading French and international research organizations and foster technology transfer with potential industrial players in the near futur.

A combination of lean working practices and Therakos™ Cellex® identify substantial effi ciency enhancements and a 63% productivity gain B. Linic (1) Introduction: Lean is a methodology that considers the expenditure of resources for any goal other than the creation of value to be wasteful. Value, in this context, is defined as an attribute which adds benefit to the patient. Process improvement strategies based on Lean solutions can cut costs, dramatically reduce processing times and free up valuable staff to undertake more productive work. Such gains can be directly translated into availability of extra capacity and improved patient care. Lean brings a fundamental change in working practices and the thinking behind them. It is an attitude of mind which constantly seeks to challenge and refine every aspect of working life. Study: The Dermatology Day Care Centre at St. Thomas's Hospital provides Extracorporeal Photophoresis (ECP) for patients presenting with Graft-versus-host disease (GvHD) and Cutaneous T-Cell

S456 Lymphoma (CTCL). The challenge faced in 2013 is to substantially increase the number of patients receiving ECP with no increase in staff costs. Lean tools were used to assess capacity constraints, design layout, and patient scheduling to reduce process wastage and patient waiting lists. Observations were made of variations in key parameters of the patient journey including; arrival to start delay, pre-observations, treatment times and post-observations. Data was collected from 133 ECP treatments and a statistical analysis was performed. The assessment included a review of both process and equipment and how personnel integrated within the work processes. Results: A lack of standardisation in the process resulted in substantial variation in all of the parameters assessed as illustrated below. Bottle-necks and inefficiencies were identified throughout the patient journey resulting in valuable time and capacity not being utilised efficiently. The implementation of Lean working practices, in combination with the Therakos™ Cellex® instrument, resulted in substantial efficiency and productivity gains with capacity being more fully utilised. The number of daily treatments can be increased in a two-phase approach from an average of 6 per day to 12 and then to 18 with the same number of nurses. Conclusions: Implementation of these new practices means that the number of treatments performed per annum can be increased by 63% and the department can move to a six and then a four day treatment week, compared to seven days previously. The elimination of weekend working would release funds for extra treatments.

An effi ciency study comparing Open System and Therakos™ Cellex® for extracorporeal photophoresis procedures G. Adorno (1) (1), F. Docimo (1) , A. Zizzari (1) , H. Klein (2) , P.M. Button (2) (1)RTN -Policlinico Tor Vergata (Rome, IT); (2)ProcEx Solutions Ltd. (London, GB) Introduction: The Department of Transfusion Medicine at the Policlinico-Tor-Vergata in Rome provides Extra Corporeal Photophoresis (ECP) for patients presenting with acute and chronic Graft-versus-host disease (GvHD), Cutaneous T-Cell Lymphoma (CTCL) and various dermatological disorders. The centre performs approximately 450 treatments per annum utilising a 5 day treatment week. Currently two processes are used for ECP; Open System (collection of buff y coat with a blood cell separator and irradiation with an external irradiator system) and Therakos Cellex (Closed System). The department desires to move all treatments to the Therakos Cellex system utilising a 2 day treatment week (currently 5 days/week) with minimal changes in cost compared to the current condition. Study: Data was collected and statistically analysed from a total of 149 routine ECP treatments performed in the period July to November 2012 (Open=75, Cellex=74). Parameters assessed included; patient arrival to start delay, pre-observations, treatment times and post-observations. Results: Therakos Cellex off ers a reduction in overall procedural times from 221 to 145 minutes with ECP treatment times reduced from a mean of 192 to 115 minutes: Treating all 447 patients on Therakos Cellex compared to all patients on Open System releases an annual capacity of 76 doctor days and 47 bed days. Conclusions: The Assessment concluded that the Therakos Cellex system off ered substantial improvements in patient treatment times improving patient Quality of Life and substantially increases capacity for more patient treatments with the same number of staff . Improvements in patient safety are off ered with the Therakos system due to the security of the closed system methodology. Activity Based Costing illustrated that a change from the current treatment regime to performing all treatments on Therakos Cellex (n=447), incorporating the application of Lean principles, added a small increase in actual cost (4.4%). A comparison of performing all 447 procedures on either system means a gain of 76 FTE days together with 47 bed days when using Therakos Cellex compared to Open System. By performing all treatments on Therakos Cellex

S457 the department is able to perform all ECP procedures 2 days/ week (currently 5 days) allowing other activities, such as stem cell collection, to be performed on the remaining 3 days/week.

A. Syrigou (1) , D. Zacharaki (1) , E. Matthaiou (2) , C. Smias (1) , M. Ganidou (1) , I. Sakellari (1) , D. Sotiropoulos (1), A. Anagnostopoulos (1) (1)George Papanikolaou Hospital (Thessaloniki, GR); (2)Aristotle University of Thessaloniki (Thessaloniki, GR) Objectives: The BMT Unit and the Post-Transplant Unit (PTU) of Hematology Clinics are major consumers of blood products: red blood cells (RBCs), platelets (PLTs) and fresh frozen plasma (FFP). We estimated the total consumption of blood products in the 328 patient admissions to the BMT Unit and the PTU of our Hospital for 2011. We tried to identify the parameters aff ecting the consumption needs of blood products in both Units. Methods: We evaluated all patients' admissions in relation to the following parameters: days of hospitalization, diagnosis, disease status, transplantation type, conditioning and number of RBCs, PLTs and FFPs consumed. All measurements of blood products follow the rule: Mean blood product unit (MBPU) consumption per day= [Number of blood product units consumed/Total days of hospitalization] x 100. Statistical analysis was performed. Results: 328 admissions corresponded to 4291 hospitalization days. MBPU in the BMT unit were 13. 5 RBCs, 18.2 PLTs, and 15.6 FFPs versus 19.9 RBCs, 26.3 PLTs and 50.6 FFPs in the PTU. Allo-transplanted patients had the highest consumption of RBCs and PLTs vs autoand allo-RIC-transplanted (Kruskal-Wallis test, p<0.001), whereas allo-RIC had the highest consumption of FFPs (p=0.045). No statistically signifi cant diff erence was shown between MBPU of lymphomas and multiple myelomas in the BMT Unit (Mann-Whitney test). Again, no signifi cant diff erence was recorded between MBPU of Hodgkin and NHL in the BMT Unit (Mann-Whitney test). In the PTU, the type of transplantation aff ected the consumption of RBCs (auto: 8.2%, allo: 91.8%, p<0.001) and FFPs (auto: 7.1%, allo: 92.9%, p=0.002, Mann-Whitney test). In the PTU AML patients consumed more RBCs and PLTs, but less FFPs compared to ALL patients (no stat. signifi cant diff erence, Mann-Whitney test). Conclusion: In this study we identifi ed which groups of hematological patients undergoing BMT and which types of diseases require most blood product units in order to minimize the amount of units given to recipients. Such a survey can serve as a tool to estimate in advance the mean annual needs of the BMT Unit and PTU patients and coordinate accordingly the Blood Bank's donations.

Cost analysis of allogeneic haematopoietic stem cell transplantation C. Martínez-Múgica, C. Alarcón, A.J. González, C. Pardo, M. Alaguero, A.P. González, P. Palomo, R. Fernández, S. González, C. Rayón, C. Vallejo University Central Hospital of Asturias (Oviedo, ES) Objective: to evaluate the pharmacy costs of the allogeneic hematopoietic stem cell transplantation (allo-HSCT). Materials and methods: all patients who underwent allo-HSCT due to hematological diseases at the Hematopoietic Transplant Unit of University Central Hospital of Asturias (Spain) between February 2008 and October 2012 were included in this study. The period analyzed is from the moment of admission to hospital for HSCT to discharge from hospital. Total charges for the hospitalization were obtained from medical charts and from the Pharmacy-dispensing software. Medications included: preparative regimens, immunosuppressive therapy, prophylactic treatments and drugs for comorbidities and complications. Fluid therapy was not included.Total costs were calculated using laboratory sale prices (without taxes). Results: a total of 116 patients were transplanted during the period of the study. Characteristics of the series of patients and procedures are shown in table 1. The median hospitalization stay was 33 days (range 8-69), during which 338 different pharmaceutical specialities were prescribed. Nineteen of those specialities accounted for 80% of costs, including thymo globulin (16 % of total prescription cost), busulphan (11 %), voriconazole (6 %) and non-specific immunoglobulins (5 %). The breakdown analysis of drug cost by therapeutic groups showed that group J (anti-infectives for systemic use) was the most expensive category, accounting for 30,9 % of the total cost, followed by group L (anti-neoplastic and immunomodulating agents), accounting for 30,5 % of the total cost. The total median and average costs per patient were 7.722,5 € and 10.108,8 €, respectively (range: 1.438-61.805 €) . Costs of unrelated donor and family donor transplants were similar, while UCBT was more expensive (figure 1). Conclusions: our fi ndings show that allo-HSCT for patients with hematological diseases is a cost-eff ective choice. These fi ndings provide useful information regarding costs of allo-HSCT to physicians, highlighting the challenge faced in the effi cient management of therapeutic resources. S458 P1236 Filgrastim XM02 (Tevagrastim) after autologous stem cell transplantation (ASCT): favourable cost-effi cacy eff ect in comparison with lenograstim A. Gardellini, F. Gigli, A. Babic, G. Andreola, D. Radice, G. Martinelli, D. Laszlo European Institute of Oncology (Milan, IT) Granulocyte colony-stimulating factors (G-CSF), filgrastim and lenograstim, are recognized to be useful in accelerating engraftment after ASCT. Studies comparing the efficacy of filgrastim and lenograstim demonstrated no difference in this setting. Recently, several forms of biosimilar non-glycosylated G-CSF have been approved by the EMA, with limited published data supporting the clinical equivalence in peripheral blood stem cell mobilization and recovery after ASCT. With the aim to compare the cost-effective strategy in the use of G-CSF after ASCT, we retrospectively evaluated 32 patients cosecutively treated at IEO with biosimilar filgrastim XMO2 (Tevagrastim) and 26 with lenograstim between November 2010 and December 2011. Median age, sex, diagnosis, conditioning regimen and median number of CD34+ reinfused were similar in the two groups. All patients received G-CSG (biosimilar or lenograstim) at the dosage of 5mcg/Kg/day subcoutaneously from day +5 to absolute neutrophil count (ANC) of 1500/mm3 for three consecutive days. Engraftment was defined as ANC > 500/mmc and platelets count > 20.000/mmc. Results: median days to ANC engraftment was 11 days (range 10 -11) for filgrastim XM02 group and 12 days (range 10 -12) for lenograstim group (p 0.055). As for platelets recovery, median days was 12 in both groups with a range of 7-22 for filgrastim XM02 group and 9 -30 for lenograstim group. Median number of G-CSF vials used was 9.5 for Tevagrastim and 10.5 for lenograstim, reflecting a mean estimated cost of about 556.1 (± 20.0) euros for Tevagrastim versus 932.2 (± 54.4) euros for lenograstim (p < 0.001). Median days of febrile neutropenia was 1.5 (range 0 -5) and 1 (range 0 -10) for filgrastim XM02 and lenograstim respectively. With a median follow-up of 14 months (range 3 -23) no adverse event related to the use of XM02 filgrastim was recorded. With the growing importance of managing limited healthcare resources, biosimilar G-CSFs may represent a cost-effective strategy; for this reason, clinical results confirming the efficacy of biosimilar G-CSF in any indications as the reference filgrastim are needed. To our knowledge, this is the first experience comparing biosimilar G-CSF to lenograstim after ASCT. In our experience filgrastim XM02 and lenograstim showed comparable efficacy to shorten the period of neutro penia after cytoreduction and ASCT with a favourable cost-effect profile for filgrastim XM02.